"text","relation"
"Agents that have only begun to undergo clinical evaluation include <e1>CI-1033</e1>, an irreversible pan-<e2>erbB</e2> tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).","Downregulator"
"Agents that have only begun to undergo clinical evaluation include <e1>CI-1033</e1>, an irreversible pan-erbB <e2>tyrosine kinase</e2> inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).","Downregulator"
"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine <e2>kinase</e2> inhibitor, and <e1>PKI166</e1> and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).","Downregulator"
"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and <e1>PKI166</e1> and GW572016, both examples of dual kinase inhibitors (inhibiting <e2>epidermal growth factor receptor</e2> and Her2).","Downregulator"
"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and <e1>PKI166</e1> and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and <e2>Her2</e2>).","Downregulator"
"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine <e2>kinase</e2> inhibitor, and PKI166 and <e1>GW572016</e1>, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).","Downregulator"
"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and <e1>GW572016</e1>, both examples of dual kinase inhibitors (inhibiting <e2>epidermal growth factor receptor</e2> and Her2).","Downregulator"
"Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and <e1>GW572016</e1>, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and <e2>Her2</e2>).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules <e1>gefitinib</e1> (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (<e1>Iressa</e1>, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, <e1>ZD1839</e1>) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and <e1>erlotinib</e1> (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (<e1>Tarceva</e1>, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, <e1>OSI-774</e1>), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as <e1>cetuximab</e1> (IMC-225, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (<e1>IMC-225</e1>, Erbitux).","Downregulator"
"<e2>Epidermal growth factor receptor</e2> inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, <e1>Erbitux</e1>).","Downregulator"
"<e1>Alprenolol</e1> and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of <e2>beta-adrenoceptor</e2> blockade.","Downregulator"
"Alprenolol and <e1>BAAM</e1> at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of <e2>beta-adrenoceptor</e2> blockade.","Downregulator"
"Alprenolol and BAAM also caused surmountable antagonism of <e1>isoprenaline</e1> responses, and this <e2>beta 1-adrenoceptor</e2> antagonism was slowly reversible.","Agonist"
"Alprenolol and bromoacetyl<e1>alprenolol</e1>menthane are competitive slowly reversible antagonists at the <e2>beta 1-adrenoceptor</e2>s of rat left atria.","Antagonist"
"Alprenolol and <e1>BAAM</e1> also caused surmountable antagonism of isoprenaline responses, and this <e2>beta 1-adrenoceptor</e2> antagonism was slowly reversible.","Antagonist"
"<e1>Alprenolol</e1> and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the <e2>beta 1-adrenoceptors</e2> of rat left atria.","Antagonist"
"Alprenolol and <e1>bromoacetylalprenololmenthane</e1> are competitive slowly reversible antagonists at the <e2>beta 1-adrenoceptors</e2> of rat left atria.","Antagonist"
"<e1>Alprenolol</e1> and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the <e2>beta 1-adrenoceptor</e2>s of rat left atria.","Antagonist"
"Alprenolol and <e1>BAAM</e1> also caused surmountable antagonism of isoprenaline responses, and this <e2>beta 1-adrenoceptor</e2> antagonism was slowly reversible.","Antagonist"
"Apolipoprotein E was chemically bound via linkers to <e1>loperamide</e1>-loaded <e2>HSA</e2>-NP.","Part_of"
"<e2>Apolipoprotein E</e2> was chemically bound via linkers to <e1>loperamide</e1>-loaded HSA-NP.","Regulator"
"As part of an effort to discover orally active reversible inhibitors of <e2>MetAP2</e2>, a series of <e1>anthranilic acid sulfonamides</e1> with micromolar affinities for human MetAP2 were identified using affinity selection by mass spectrometry (ASMS) screening.","Regulator"
"As part of an effort to discover orally active reversible inhibitors of MetAP2, a series of <e1>anthranilic acid sulfonamides</e1> with micromolar affinities for <e2>human MetAP2</e2> were identified using affinity selection by mass spectrometry (ASMS) screening.","Regulator"
"Discovery and optimization of <e1>anthranilic acid sulfonamides</e1> as inhibitors of <e2>methionine aminopeptidase-2</e2>: a structural basis for the reduction of albumin binding.","Regulator"
"Discovery and optimization of <e1>anthranilic acid sulfonamides</e1> as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of <e2>albumin</e2> binding.","Downregulator"
"We have expressed and characterized recombinant, <e1>N</e1>-terminally His-tagged <e2>human adenine phosphoribosyltransferase</e2>.","Part_of"
"<e2>Adenine phosphoribosyltransferase</e2> plays a role in purine salvage by catalyzing the direct conversion of adenine to <e1>adenosine monophosphate</e1>.","Substrate"
"<e2>Adenine phosphoribosyltransferase</e2> plays a role in purine salvage by catalyzing the direct conversion of <e1>adenine</e1> to adenosine monophosphate.","Substrate"
"BACKGROUND: Since the introduction of the first <e2>cholinesterase</e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, <e1>donepezil</e1>, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.","Downregulator"
"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, <e1>donepezil</e1>, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase</e2>.","Downregulator"
"BACKGROUND: Since the introduction of the first <e2>cholinesterase</e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, <e1>galantamine</e1> and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.","Downregulator"
"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, <e1>galantamine</e1> and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase</e2>.","Downregulator"
"BACKGROUND: Since the introduction of the first <e2>cholinesterase</e2> inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and <e1>rivastigmine</e1>, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.","Downregulator"
"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and <e1>rivastigmine</e1>, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase</e2>.","Downregulator"
"BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of <e1>acetylcholine</e1>, an important neurotransmitter associated with memory, by blocking the enzyme <e2>acetylcholinesterase</e2>.","Substrate"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (<e2>Kir6.2</e2>/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Not"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/<e2>SUR2A</e2>, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Not"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (<e2>Kir6.2</e2>/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Not"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/<e2>SUR2B</e2>) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Not"
"Binding experiments on mitiglinide, nateglinide, and repaglinide to <e2>SUR1</e2> expressed in COS-1 cells revealed that they inhibit the binding of <e1>[3H]glibenclamide</e1> to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.","Regulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Regulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Regulator"
"In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <e1>nateglinide</e1>.","Regulator"
"In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <e1>nateglinide</e1>.","Regulator"
"Binding experiments on mitiglinide, nateglinide, and <e1>repaglinide</e1> to <e2>SUR1</e2> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.","Regulator"
"Binding experiments on mitiglinide, nateglinide, and <e1>repaglinide</e1> to <e2>SUR1</e2> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.","Regulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Regulator"
"In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <e1>nateglinide</e1>.","Regulator"
"Binding experiments on mitiglinide, nateglinide, and <e1>repaglinide</e1> to <e2>SUR1</e2> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.","Regulator"
"Binding experiments on mitiglinide, nateglinide, and repaglinide to <e2>SUR1</e2> expressed in COS-1 cells revealed that they inhibit the binding of [3H]<e1>glibenclamide</e1> to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding site.","Regulator"
"The <e2>insulin</e2> responses to <e1>glucose</e1>, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment.","Regulator"
"The effects of <e1>mitiglinide</e1> (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and <e2>insulin</e2> secretion: comparison with the sulfonylureas and nateglinide.","Regulator"
"The <e2>insulin</e2> responses to glucose, mitiglinide, <e1>tolbutamide</e1>, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment.","Regulator"
"The <e2>insulin</e2> responses to glucose, mitiglinide, tolbutamide, and <e1>glibenclamide</e1> in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment.","Regulator"
"The effects of <e1>mitiglinide</e1> (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and <e2>insulin</e2> secretion: comparison with the sulfonylureas and nateglinide.","Regulator"
"The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and <e2>insulin</e2> secretion: comparison with the sulfonylureas and <e1>nateglinide</e1>.","Regulator"
"The <e2>insulin</e2> responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or <e1>repaglinide</e1> treatment were comparable to those after chronic tolbutamide and glibenclamide treatment.","Regulator"
"The <e2>insulin</e2> responses to glucose, mitiglinide, <e1>tolbutamide</e1>, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment.","Regulator"
"The <e2>insulin</e2> responses to glucose, mitiglinide, tolbutamide, and <e1>glibenclamide</e1> in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment.","Regulator"
"These results indicate that, similar to the <e1>sulfonylureas</e1>, mitiglinide is highly specific to the <e2>Kir6.2</e2>/SUR1 complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug.","Regulator"
"These results indicate that, similar to the <e1>sulfonylureas</e1>, mitiglinide is highly specific to the Kir6.2/<e2>SUR1</e2> complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug.","Regulator"
"These results indicate that, similar to the <e1>sulfonylureas</e1>, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell <e2>K(ATP) channel</e2>, and suggest that mitiglinide may be a clinically useful anti-diabetic drug.","Regulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Regulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned <e2>K(ATP) channel</e2>s (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Regulator"
"The effects of <e1>mitiglinide</e1> (KAD-1229), a new anti-diabetic drug, on <e2>ATP-sensitive K+ channels</e2> and insulin secretion: comparison with the sulfonylureas and nateglinide.","Regulator"
"The effects of <e1>mitiglinide</e1> (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and <e2>insulin</e2> secretion: comparison with the sulfonylureas and nateglinide.","Regulator"
"The effects of mitiglinide (<e1>KAD-1229</e1>), a new anti-diabetic drug, on <e2>ATP-sensitive K+ channels</e2> and insulin secretion: comparison with the sulfonylureas and nateglinide.","Regulator"
"The effects of mitiglinide (<e1>KAD-1229</e1>), a new anti-diabetic drug, on ATP-sensitive K+ channels and <e2>insulin</e2> secretion: comparison with the sulfonylureas and nateglinide.","Regulator"
"The effects of mitiglinide (<e1>KAD-1229</e1>), a new anti-diabetic drug, on ATP-sensitive K+ channels and <e2>insulin</e2> secretion: comparison with the sulfonylureas and nateglinide.","Upregulator"
"<e1>Mitiglinide</e1> (KAD-1229), a new anti-diabetic drug, is thought to stimulate <e2>insulin</e2> secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells.","Upregulator"
"Mitiglinide (<e1>KAD-1229</e1>), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the <e2>ATP-sensitive K+ (K(ATP)) channels</e2> in pancreatic beta-cells.","Downregulator"
"<e1>Mitiglinide</e1> (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the <e2>ATP-sensitive K+ (K(ATP)) channels</e2> in pancreatic beta-cells.","Downregulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (<e2>Kir6.2</e2>/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Downregulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned K(ATP) channels (Kir6.2/<e2>SUR1</e2>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Downregulator"
"<e1>Nateglinide</e1> inhibits <e2>Kir6.2</e2>/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).","Downregulator"
"<e1>Nateglinide</e1> inhibits Kir6.2/<e2>SUR1</e2> and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).","Downregulator"
"<e1>Nateglinide</e1> inhibits <e2>Kir6.2</e2>/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).","Downregulator"
"<e1>Nateglinide</e1> inhibits Kir6.2/SUR1 and Kir6.2/<e2>SUR2B</e2> channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).","Downregulator"
"<e1>Nateglinide</e1> inhibits <e2>Kir6.2</e2>/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM).","Downregulator"
"<e1>Nateglinide</e1> inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/<e2>SUR2A</e2> channels at high concentrations (1 microM).","Downregulator"
"In this study, we examined the effects of <e1>mitiglinide</e1> on various cloned <e2>K(ATP) channel</e2>s (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide.","Agonist"
"Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly <e1>telmisartan</e1>, are partial agonists at <e2>peroxisome proliferator-activated receptor-γ</e2>.","Agonist"
"Although generally highly specific for <e2>angiotensin II type 1 receptors</e2>, some ARBs, particularly <e1>telmisartan</e1>, are partial agonists at peroxisome proliferator-activated receptor-γ.","Antagonist"
"Direct-acting <e2>CB1</e2> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and <e1>AM4054</e1> [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of <e1>WIN 55,212</e1> antagonized by the <e2>CB2</e2> antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].","Agonist"
"Direct-acting <e2>CB1</e2> agonists, including <e1>Δ(9)-tetrahydrocannabinol</e1>, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"Direct-acting <e2>CB1</e2> agonists, including Δ(9)-tetrahydrocannabinol, <e1>WIN 55,212</e1> [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"Direct-acting <e2>CB1</e2> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [<e1>R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate</e1>], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"Direct-acting <e2>CB1</e2> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], <e1>AM2389</e1> [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"Direct-acting <e2>CB1</e2> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [<e1>9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol</e1>], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"Direct-acting <e2>CB1</e2> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and <e1>AM4054</e1> [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"Direct-acting <e2>CB1</e2> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [<e1>9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol</e1>], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia.","Agonist"
"Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <e2>CB2</e2> agonist <e1>AM1241</e1> [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.","Agonist"
"Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <e2>CB2</e2> agonist AM1241 [<e1>1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole</e1>], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.","Agonist"
"Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <e2>CB2</e2> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor <e1>AM404</e1>, and the CB antagonist rimonabant did not have diuretic effects.","Agonist"
"In further studies, the diuretic effects of the <e2>CB1</e2> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with <e1>rimonabant</e1>, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].","Antagonist"
"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the <e2>vanilloid receptor type I</e2> antagonist <e1>capsazepine</e1>, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].","Antagonist"
"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <e2>CB2</e2> antagonist <e1>AM630</e1> [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)].","Antagonist"
"In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the <e2>CB2</e2> antagonist AM630 [<e1>(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)</e1>].","Antagonist"
"Rheumatoid synovial cells expressed <e2>PPARgamma</e2> mRNA, and the PPARgamma ligands <e1>15-deoxy-Delta(12,14)-prostaglandin J(2)</e1> and troglitazone reduced the proliferation and induced apoptosis in synovial cells.","Regulator"
"Rheumatoid synovial cells expressed <e2>PPARgamma</e2> mRNA, and the PPARgamma ligands <e1>15-deoxy-Delta(12,14)-prostaglandin J(2)</e1> and troglitazone reduced the proliferation and induced apoptosis in synovial cells.","Regulator"
"Rheumatoid synovial cells expressed <e2>PPARgamma</e2> mRNA, and the PPARgamma ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and <e1>troglitazone</e1> reduced the proliferation and induced apoptosis in synovial cells.","Regulator"
"Rheumatoid synovial cells expressed <e2>PPARgamma</e2> mRNA, and the PPARgamma ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and <e1>troglitazone</e1> reduced the proliferation and induced apoptosis in synovial cells.","Regulator"
"<e1>N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide</e1> (NS-398), a selective <e2>cyclooxygenase-2</e2> inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.","Downregulator"
"N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (<e1>NS-398</e1>), a selective <e2>cyclooxygenase-2</e2> inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.","Downregulator"
"The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of <e2>MEN1</e2> that results in a replacement of <e1>lysine</e1> by glutamic acid.","Part_of"
"The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of <e2>MEN1</e2> that results in a replacement of lysine by <e1>glutamic acid</e1>.","Part_of"
"Mutation of arginine 228 to <e1>lysine</e1> enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (<e2>Glc-T</e2> activity), albeit at only 0.3% efficiency.","Part_of"
"Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound <e2>beta4Gal-T1</e2> reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain <e1>carboxylate</e1> group of Glu317.","Part_of"
"The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain <e1>carboxylate</e1> group of Glu317, accounting for the enzyme's low <e2>Glc-T</e2> activity.","Part_of"
"Mutation of arginine 228 to <e1>lysine</e1> enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e2>Gal-T1</e2>) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Part_of"
"Mutation of arginine 228 to <e1>lysine</e1> enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (<e2>Glc-T</e2> activity), albeit at only 0.3% efficiency.","Part_of"
"Mutation of arginine 228 to <e1>lysine</e1> enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e2>Gal-T</e2>1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Part_of"
"Mutation of <e1>arginine</e1> 228 to lysine enhances the glucosyltransferase activity of <e2>bovine beta-1,4-galactosyltransferase I</e2>.
Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Part_of"
"Mutation of arginine 228 to <e1>lysine</e1> enhances the glucosyltransferase activity of <e2>bovine beta-1,4-galactosyltransferase I</e2>.
Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Part_of"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (<e2>beta4Gal-T1</e2>) normally transfers Gal from <e1>UDP-Gal</e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Regulator"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (<e2>beta4Gal-T1</e2>) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from <e1>UDP-Glc</e1> to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Regulator"
"The crystal structure of <e2>R228K</e2>-Gal-T1 complexed with LA, <e1>UDP-Gal</e1>, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type.","Regulator"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e2>Gal-T1</e2>) normally transfers Gal from <e1>UDP-Gal</e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Regulator"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e2>Gal-T1</e2>) normally transfers Gal from UDP-Gal to GlcNAc in the presence of <e1>Mn(2+)</e1> ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Regulator"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e1>Gal</e1>-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (<e2>Gal-T</e2> activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Regulator"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e2>Gal-T</e2>1) normally transfers Gal from <e1>UDP-Gal</e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Regulator"
"The orientation of the <e1>O4 hydroxyl of glucose</e1> causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low <e2>Glc-T</e2> activity.","Regulator"
"Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4<e2>Gal-T</e2>1 reveals that the <e1>O4 hydroxyl</e1> group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317.","Regulator"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e2>Gal-T</e2>1) normally transfers Gal from <e1>UDP-Gal</e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Regulator"
"Mutation of arginine 228 to <e1>lysine</e1> enhances the <e2>glucosyltransferase</e2> activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Upregulator"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from <e1>UDP-Glc</e1> to GlcNAc (<e2>Glc-T</e2> activity), albeit at only 0.3% efficiency.","Substrate"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
<e2>Beta-1,4-galactosyltransferase I</e2> (beta4Gal-T1) normally transfers Gal from <e1>UDP-Gal</e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Substrate"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (beta4<e2>Gal-T</e2>1) normally transfers Gal from <e1>UDP-Gal</e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Substrate"
"Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I.
Beta-1,4-galactosyltransferase I (<e2>beta4Gal-T1</e2>) normally transfers Gal from <e1>UDP-Gal</e1> to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.","Substrate"
"Discovery of novel <e1>2-hydroxydiarylamide</e1> derivatives as <e2>TMPRSS4</e2> inhibitors.","Downregulator"
"In this study, a novel series of <e1>2-hydroxydiarylamide</e1> derivatives were synthesized and evaluated for inhibiting TMPRSS4 <e2>serine protease</e2> activity and suppressing cancer cell invasion.","Downregulator"
"Discovery of novel <e1>2-hydroxydiarylamide</e1> derivatives as <e2>TMPRSS4</e2> inhibitors.","Downregulator"
"In the presence of alphaAR blockade, concentration-response curves for <e1>isoproterenol</e1>, norepinephrine, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Regulator"
"In the presence of alphaAR blockade, concentration-response curves for isoproterenol, <e1>norepinephrine</e1>, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Regulator"
"In the presence of alphaAR blockade, concentration-response curves for isoproterenol, nor<e1>epinephrine</e1>, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Regulator"
"In the presence of alphaAR blockade, concentration-response curves for <e1>isoproterenol</e1>, norepinephrine, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Regulator"
"In the presence of alphaAR blockade, concentration-response curves for isoproterenol, <e1>norepinephrine</e1>, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Regulator"
"In the presence of alphaAR blockade, concentration-response curves for isoproterenol, nor<e1>epinephrine</e1>, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Regulator"
"In higher cortical structures such as the hippocampus, <e1>norepinephrine</e1>, via <e2>beta adrenergic receptor</e2> (AR) activation, has been shown to reinforce the cognitive processes of attention and memory.","Regulator"
"In higher cortical structures such as the hippocampus, <e1>norepinephrine</e1>, via beta adrenergic receptor (<e2>AR</e2>) activation, has been shown to reinforce the cognitive processes of attention and memory.","Regulator"
"In contrast, the selective <e2>beta2AR</e2> antagonists ICI-118,551 and butoxamine inhibited <e1>isoproterenol</e1>-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).","Agonist"
"In the presence of alphaAR blockade, concentration-response curves for <e1>isoproterenol</e1>, norepinephrine, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Agonist"
"The selective <e2>betaAR</e2> agonist <e1>isoproterenol</e1> caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.","Agonist"
"In the presence of alphaAR blockade, concentration-response curves for <e1>isoproterenol</e1>, norepinephrine, and epinephrine suggested that a <e2>beta1AR</e2> was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine.","Agonist"
"In contrast, the selective <e2>beta2AR</e2> antagonists ICI-118,551 and <e1>butoxamine</e1> inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).","Antagonist"
"The selective <e2>beta1AR</e2> antagonists <e1>atenolol</e1> and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.","Antagonist"
"The selective <e2>beta1AR</e2> antagonists atenolol and <e1>metoprolol</e1> blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.","Antagonist"
"In contrast, the selective <e2>beta2AR</e2> antagonists <e1>ICI-118,551</e1> and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).","Antagonist"
"<e2>P2Y(2) receptor</e2> agonist <e1>INS37217</e1> enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.","Agonist"
"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, <e1>topiramate</e1> at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by <e2>kainate receptors</e2> containing the GluR5 subunit.","Downregulator"
"Selective antagonism of <e2>GluR5</e2> kainate-receptor-mediated synaptic currents by <e1>topiramate</e1> in rat basolateral amygdala neurons.","Downregulator"
"<e1>Topiramate</e1> also partially depressed predominantly <e2>AMPA-receptor</e2>-mediated EPSCs, but with lower efficacy.","Downregulator"
"Selective antagonism of <e2>GluR5</e2> kainate-receptor-mediated synaptic currents by <e1>topiramate</e1> in rat basolateral amygdala neurons.","Downregulator"
"In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, <e1>topiramate</e1> at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by <e2>kainate receptors</e2> containing the GluR5 subunit.","Downregulator"
"Selective antagonism of <e2>GluR5</e2> kainate-receptor-mediated synaptic currents by <e1>topiramate</e1> in rat basolateral amygdala neurons.","Antagonist"
"Selective antagonism of GluR5 <e2>kainate-receptor</e2>-mediated synaptic currents by <e1>topiramate</e1> in rat basolateral amygdala neurons.","Antagonist"
"The inhibitor binds at the base of the active site gorge of <e2>TcAChE</e2>, interacting with both the choline-binding site (<e1>Trp</e1>-84) and the acyl-binding pocket (Phe-288, Phe-290).","Part_of"
"The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the <e2>choline-binding site</e2> (<e1>Trp</e1>-84) and the acyl-binding pocket (Phe-288, Phe-290).","Part_of"
"The inhibitor binds at the base of the active site gorge of <e2>TcAChE</e2>, interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket (<e1>Phe</e1>-288, Phe-290).","Part_of"
"The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the <e2>acyl-binding pocket</e2> (<e1>Phe</e1>-288, Phe-290).","Part_of"
"The inhibitor binds at the base of the active site gorge of <e2>TcAChE</e2>, interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket (<e1>Phe</e1>-288, Phe-290).","Part_of"
"The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the <e2>acyl-binding pocket</e2> (<e1>Phe</e1>-288, Phe-290).","Part_of"
"Structure of <e2>acetylcholinesterase</e2> complexed with <e1>(-)-galanthamine</e1> at 2.3 A resolution.","Regulator"
"Methyl transfer in glycine N-<e1>methyl</e1>transferase.","Substrate"
"Density functional theory calculations using the hybrid functional B3LYP have been performed to study the <e1>methyl</e1> transfer step in glycine N-methyltransferase (<e2>GNMT</e2>).","Substrate"
"The starting point for the calculations is the recent X-ray crystal structure of <e2>GNMT</e2> complexed with <e1>SAM</e1> and acetate.","Substrate"
"A great deal of information has now accumulated pertaining to the mechanisms by which <e2>nuclear receptors</e2>, such as the <e1>androgen</e1> receptor, modulate the activity of responsive genes.","Modulator"
"In addition to studies focused on the mechanisms of <e2>nuclear receptor</e2> function, additional work has illuminated the mechanism by which <e1>androgens</e1> are metabolized in selected tissues.","Modulator"
"Dasatinib (BMS-354825) inhibits <e2>KIT</e2>D816V, an <e1>imatinib</e1>-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Not"
"Dasatinib (BMS-354825) inhibits KIT<e2>D816V</e2>, an <e1>imatinib</e1>-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Not"
"Dasatinib (BMS-354825) inhibits <e2>KIT</e2>D816V, an <e1>imatinib</e1>-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Not"
"Dasatinib (BMS-354825) inhibits KIT<e2>D816V</e2>, an <e1>imatinib</e1>-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Not"
"Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple <e1>imatinib</e1>-resistant <e2>BCR</e2>-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).","Not"
"Dasatinib (BMS-354825) is a novel orally bioavailable SRC/<e2>ABL</e2> inhibitor that has activity against multiple <e1>imatinib</e1>-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).","Not"
"Dasatinib (BMS-354825) inhibits <e2>KIT</e2>D816V, an <e1>imatinib</e1>-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Regulator"
"Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the <e2>KIT activation loop</e2> to which <e1>imatinib</e1> binds, but it is not predicted to impair binding of KIT by dasatinib.","Regulator"
"Dasatinib (BMS-354825) inhibits <e2>KIT</e2>D816V, an <e1>imatinib</e1>-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Regulator"
"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib</e1> against both wild-type <e2>KIT</e2> and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.","Regulator"
"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib</e1> against both wild-type <e2>KIT</e2> and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.","Regulator"
"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib</e1> against both wild-type <e2>KIT</e2> and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.","Downregulator"
"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib</e1> against both wild-type <e2>KIT</e2> and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.","Downregulator"
"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib</e1> against both wild-type KIT and the KIT<e2>D816V</e2> mutation in the nanomolar range in in vitro and cell-based kinase assays.","Downregulator"
"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib</e1> against both wild-type <e2>KIT</e2> and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.","Downregulator"
"In this study, we demonstrate significant inhibitory activity of <e1>dasatinib</e1> against both wild-type KIT and the KIT<e2>D816V</e2> mutation in the nanomolar range in in vitro and cell-based kinase assays.","Downregulator"
"<e1>Dasatinib</e1> (BMS-354825) inhibits <e2>KIT</e2>D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Downregulator"
"<e1>Dasatinib</e1> (BMS-354825) inhibits KIT<e2>D816V</e2>, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Downregulator"
"Dasatinib (<e1>BMS-354825</e1>) inhibits KIT<e2>D816V</e2>, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","Downregulator"
"<e1>Dasatinib</e1> (BMS-354825) is a novel orally bioavailable <e2>SRC</e2>/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).","Downregulator"
"<e1>Dasatinib</e1> (BMS-354825) is a novel orally bioavailable SRC/<e2>ABL</e2> inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).","Downregulator"
"Dasatinib (<e1>BMS-354825</e1>) is a novel orally bioavailable <e2>SRC</e2>/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).","Downregulator"
"Dasatinib (<e1>BMS-354825</e1>) is a novel orally bioavailable SRC/<e2>ABL</e2> inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).","Downregulator"
"The results reinforce previous assumptions that <e1>dopamine</e1> may interact with eicosanoid metabolism by means of D(2) receptor activation, and implicate an involvement of <e2>cPLA(2)</e2> and COX-2 in this effect.","Regulator"
"The results reinforce previous assumptions that <e1>dopamine</e1> may interact with eicosanoid metabolism by means of D(2) receptor activation, and implicate an involvement of cPLA(2) and <e2>COX-2</e2> in this effect.","Regulator"
"We have earlier demonstrated that <e1>dopamine</e1> stimulates the liberation of the prostaglandin E(2) (PGE(2)) precursor, arachidonic acid, in Chinese hamster ovary cells transfected with the rat dopamine <e2>D(2) receptor</e2> (long isoform), also without concomitant administration of a Ca(2+)-releasing agent [Nilsson et al., Br J Pharmacol 1998;124:1651-8].","Upregulator"
"It was also antagonized by the non-specific <e2>cyclooxygenase</e2> (COX) inhibitor, <e1>indomethacin</e1>, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate.","Downregulator"
"It was also antagonized by the non-specific cyclooxygenase (<e2>COX</e2>) inhibitor, <e1>indomethacin</e1>, and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate.","Downregulator"
"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective <e2>COX-2</e2> inhibitor, <e1>NS-398</e1>, but not by the specific COX-1 inhibitor, valeryl salicylate.","Downregulator"
"It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific <e2>COX-1</e2> inhibitor, <e1>valeryl salicylate</e1>.","Downregulator"
"Both the non-specific <e2>phospholipase A(2)</e2> inhibitor, <e1>quinacrine</e1>, and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective.","Downregulator"
"The effect was counteracted by the <e2>D(2)</e2> antagonist <e1>eticlopride</e1>, pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA.","Antagonist"
"Dopamine D(2) receptor-induced <e2>COX-2</e2>-mediated production of <e1>prostaglandin E(2)</e1> in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.","Substrate"
"At a substrate concentration of 20 µM, the most active <e1>HFC</e1> glucuronidation catalysts were <e2>UGT1A1</e2>0 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","Not"
"The activities of UGTs 1A3, 1A8, 1A9, 2B4 and 2B7 were low, whereas UGT1A1 and <e2>UGT2B17</e2> exhibited no <e1>HFC</e1> glucuronidation activity.","Not"
"At a substrate concentration of 20 µM, the most active <e1>HFC</e1> glucuronidation catalysts were <e2>UGT1A10</e2> followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","Substrate"
"At a substrate concentration of 20 µM, the most active <e1>HFC</e1> glucuronidation catalysts were UGT1A10 followed by <e2>UGT1A6</e2> >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","Substrate"
"At a substrate concentration of 20 µM, the most active <e1>HFC</e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 ><e2>UGT1A7</e2> >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","Substrate"
"At a substrate concentration of 20 µM, the most active <e1>HFC</e1> glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 ><e2>UGT2A1</e2>, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","Substrate"
"At a substrate concentration of 20 µM, the most active <e1>HFC</e1> glucuronidation catalysts were UGT1A10 followed by <e2>UGT1A6</e2> >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","Substrate"
"We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (<e1>HFC</e1>) for several <e2>UGTs</e2>.","Substrate"
"A high throughput assay for the glucuronidation of <e1>7-hydroxy-4-trifluoromethylcoumarin</e1> by recombinant <e2>human UDP-glucuronosyltransferases</e2> and liver microsomes.","Substrate"
"We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (<e1>HFC</e1>) for several <e2>UGTs</e2>.","Substrate"
"At a substrate concentration of 20 µM, the most active <e1>HFC</e1> glucuronidation catalysts were UGT1A10 followed by <e2>UGT1A6</e2> >UGT1A7 >UGT2A1, whereas at 300 µM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.","Substrate"
"<e1>UDP</e1>-glucuronosyltransferases (<e2>UGTs</e2>) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics.","Substrate"
"<e2>UGT1A6</e2> exhibited a significantly higher Vmax and Km values toward both HFC and <e1>UDP</e1>-glucuronic acid than the other UGTs.","Substrate"
"UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<e1>glucuronic acid</e1> than the other <e2>UGTs</e2>.","Substrate"
"<e2>UGT1A6</e2> exhibited a significantly higher Vmax and Km values toward both HFC and UDP-<e1>glucuronic acid</e1> than the other UGTs.","Substrate"
"We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of <e1>7-hydroxy-4-trifluoromethylcoumarin</e1> (HFC) for several <e2>UGTs</e2>.","Substrate"
"We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (<e1>HFC</e1>) for several <e2>UGTs</e2>.","Substrate"
"We have used this method to screen 11 recombinant <e2>human UGTs</e2> for <e1>HFC</e1> glucuronidation activity and studied the reaction kinetics with the most active enzymes.","Substrate"
"OBJECTIVE: In the present study, the effects of systemic injection of the newly synthesized <e2>H3R</e2> antagonist ST1283 on ethanol (<e1>EtOH</e1>) voluntary intake and EtOH-conditioned reward in mice have been investigated.","Regulator"
"This inhibition was blocked when mice were pretreated with the selective <e2>H3R</e2> agonist <e1>R-(alpha)-methyl-histamine</e1> (10 mg/kg).","Agonist"
"These results suggest that <e1>clomipramine</e1> induces hyperglycemia in mice by blocking the <e2>5-HT(2B )</e2>and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.","Downregulator"
"These results suggest that <e1>clomipramine</e1> induces hyperglycemia in mice by blocking the 5-HT(2B )and/or <e2>5-HT(2C)</e2> receptors, which results in facilitation of adrenaline release.","Downregulator"
"The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the <e2>5-HT(1A/1B)-receptor</e2> antagonist <e1>(-)-propranolol</e1> and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.","Antagonist"
"The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the <e2>5-HT(3/4)-receptor</e2> antagonist <e1>tropisetron</e1> did not affect it.","Antagonist"
"The <e2>5-HT(2B/2C)-receptor</e2> antagonist <e1>SB 206553</e1> facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.","Antagonist"
"The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the <e2>5-HT(2A)</e2>-receptor antagonist <e1>ketanserin</e1> was without effect.","Antagonist"
"The 5-HT(1/2/5/7)-receptor antagonist methysergide and the <e2>5-HT(2A/2B/2C)-receptor</e2> antagonist <e1>LY 53857</e1> enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.","Antagonist"
"Here we show that <e2>TRF2</e2> specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the <e1>lysine</e1> residue at position 293 of TRF2.","Part_of"
"<e1>Phosphatidylserine</e1> (PtdSer) is made in mammalian cells by two <e2>PtdSer synthases</e2>, PSS1 and PSS2.","Substrate"
"<e1>Phosphatidylserine</e1> (PtdSer) is made in mammalian cells by two PtdSer synthases, <e2>PSS1</e2> and PSS2.","Substrate"
"<e1>Phosphatidylserine</e1> (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and <e2>PSS2</e2>.","Substrate"
"Phosphatidylserine (<e1>PtdSer</e1>) is made in mammalian cells by two PtdSer synthases, <e2>PSS1</e2> and PSS2.","Substrate"
"Phosphatidylserine (<e1>PtdSer</e1>) is made in mammalian cells by two PtdSer synthases, PSS1 and <e2>PSS2</e2>.","Substrate"
"<e1>I3A</e1> was unable to cause the same extent of association of the <e2>C1b domain</e2> of PKC-delta with lipids, compared with PMA or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.","Not"
"<e2>PKC-delta</e2> in particular showed a different pattern of translocation in response to <e1>I3A</e1> and PMA.","Not"
"<e1>I3A</e1> bound to <e2>PKC-alpha</e2> in the presence of phosphatidylserine with high affinity; however, under these assay conditions, little PKC isoform selectivity was observed.","Regulator"
"Here, we report the initial characterization of <e1>I3A</e1> as a protein kinase C (<e2>PKC</e2>) ligand.","Regulator"
"I3A bound to <e2>PKC-alpha</e2> in the presence of <e1>phosphatidylserine</e1> with high affinity; however, under these assay conditions, little PKC isoform selectivity was observed.","Regulator"
"Here, we report the initial characterization of <e1>I3A</e1> as a protein kinase C (<e2>PKC</e2>) ligand.","Regulator"
"<e2>PKC</e2> isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (<e1>PMA</e1>) in WEHI-231, HOP-92, and Colo-205 cells.","Regulator"
"<e2>PKC-delta</e2> in particular showed a different pattern of translocation in response to <e1>I3A</e1> and PMA.","Regulator"
"<e2>PKC-delta</e2> in particular showed a different pattern of translocation in response to I3A and <e1>PMA</e1>.","Regulator"
"I3A was unable to cause the same extent of association of the <e2>C1b domain</e2> of PKC-delta with lipids, compared with <e1>PMA</e1> or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.","Regulator"
"<e2>PKC-delta</e2> in particular showed a different pattern of translocation in response to I3A and <e1>PMA</e1>.","Regulator"
"I3A was unable to cause the same extent of association of the <e2>C1b domain</e2> of PKC-delta with lipids, compared with PMA or the physiological regulator <e1>diacylglycerol</e1>, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.","Regulator"
"I3A was unable to cause the same extent of association of the C1b domain of <e2>PKC-delta</e2> with lipids, compared with PMA or the physiological regulator <e1>diacylglycerol</e1>, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.","Regulator"
"Characterization of the interaction of ingenol 3-angelate with <e2>protein kinase C</e2>.
Ingenol 3-angelate (<e1>I3A</e1>) is one of the active ingredients in Euphorbia peplus, which has been used in traditional medicine.","Regulator"
"Here, we report the initial characterization of <e1>I3A</e1> as a protein kinase C (<e2>PKC</e2>) ligand.","Regulator"
"Characterization of the interaction of <e1>ingenol 3-angelate</e1> with <e2>protein kinase C</e2>.
Ingenol 3-angelate (I3A) is one of the active ingredients in Euphorbia peplus, which has been used in traditional medicine.","Regulator"
"<e1>I3A</e1> bound to <e2>PKC-alpha</e2> in the presence of phosphatidylserine with high affinity; however, under these assay conditions, little PKC isoform selectivity was observed.","Upregulator"
"The in vitro kinase activity of <e2>PKC-alpha</e2> induced by I3A was lower than that induced by <e1>PMA</e1>.","Upregulator"
"<e1>I3A</e1> induced a higher level of secretion of the inflammatory cytokine <e2>interleukin 6</e2> compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.","Upregulator"
"<e1>I3A</e1> induced a higher level of secretion of the inflammatory <e2>cytokine</e2> interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.","Upregulator"
"I3A induced a higher level of secretion of the inflammatory cytokine <e2>interleukin 6</e2> compared with <e1>PMA</e1> in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.","Upregulator"
"I3A induced a higher level of secretion of the inflammatory <e2>cytokine</e2> interleukin 6 compared with <e1>PMA</e1> in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.","Upregulator"
"Here, we report the initial characterization of <e1>I3A</e1> as a protein kinase C (<e2>PKC</e2>) ligand.","Downregulator"
"<e2>PKC</e2> isoforms did show different sensitivity and selectivity for down-regulation by I3A and <e1>phorbol 12-myristate 13-acetate</e1> (PMA) in WEHI-231, HOP-92, and Colo-205 cells.","Downregulator"
"<e2>PKC</e2> isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (<e1>PMA</e1>) in WEHI-231, HOP-92, and Colo-205 cells.","Downregulator"
"<e2>Type I deiodinase</e2>, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by <e1>TCPP</e1>, while TDCPP induced CYP3A37 and CYP2H1.","Upregulator"
"Type I deiodinase, <e2>liver fatty-acid binding protein</e2> and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by <e1>TCPP</e1>, while TDCPP induced CYP3A37 and CYP2H1.","Upregulator"
"Type I deiodinase, liver fatty-acid binding protein and <e2>cytochrome P450 (CYP) 3A37</e2> mRNA levels were significantly induced by <e1>TCPP</e1>, while TDCPP induced CYP3A37 and CYP2H1.","Upregulator"
"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while <e1>TDCPP</e1> induced <e2>CYP3A37</e2> and CYP2H1.","Upregulator"
"Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while <e1>TDCPP</e1> induced CYP3A37 and <e2>CYP2H1</e2>.","Upregulator"
"The results suggested that both the <e1>EtOAc</e1> extract and berberine were able to activate <e2>PPARα/β/γ</e2>, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.","Agonist"
"The results suggested that both the EtOAc extract and <e1>berberine</e1> were able to activate <e2>PPARα/β/γ</e2>, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.","Agonist"
"The results suggested that both the EtOAc extract and <e1>berberine</e1> were able to activate <e2>PPARα/β/γ</e2>, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.","Agonist"
"The results suggested that both the EtOAc extract and <e1>berberine</e1> were able to activate PPARα/β/γ, and Rhizoma Coptis contains potential natural agonists of <e2>PPARs</e2> besides berberine.","Agonist"
"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific <e2>renin</e2>-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor <e1>remikiren</e1> could be predicted from pretreatment renal vascular tone.","Downregulator"
"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-<e2>angiotensin</e2>-aldosterone system (RAAS) blockade by renin-inhibitor <e1>remikiren</e1> could be predicted from pretreatment renal vascular tone.","Downregulator"
"This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific <e2>renin</e2>-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor <e1>remikiren</e1> could be predicted from pretreatment renal vascular tone.","Downregulator"
"<e2>TREK-1</e2> currents are insensitive to pharmacological agents that block TWIK-1 activity such as <e1>quinine</e1> and quinidine.","Not"
"<e2>TREK-1</e2> currents are insensitive to pharmacological agents that block TWIK-1 activity such as quinine and <e1>quinidine</e1>.","Not"
"Despite a low <e1>amino acid</e1> identity between <e2>TWIK-1</e2> and TREK-1 (approximately 28%), both channel proteins share the same overall structural arrangement consisting of two pore-forming domains and four transmembrane segments (TMS).","Part_of"
"Despite a low <e1>amino acid</e1> identity between TWIK-1 and <e2>TREK-1</e2> (approximately 28%), both channel proteins share the same overall structural arrangement consisting of two pore-forming domains and four transmembrane segments (TMS).","Part_of"
"Here we report the structural and functional properties of <e2>TREK-1</e2>, a mammalian TWIK-1-related <e1>K+</e1> channel.","Regulator"
"Extensive inhibitions of <e2>TREK-1</e2> activity are observed after activation of protein kinases A and C. TREK-1 currents are sensitive to extracellular K+ and <e1>Na+</e1>.","Regulator"
"TREK-1 currents are insensitive to pharmacological agents that block <e2>TWIK-1</e2> activity such as <e1>quinine</e1> and quinidine.","Downregulator"
"TREK-1 currents are insensitive to pharmacological agents that block <e2>TWIK-1</e2> activity such as quinine and <e1>quinidine</e1>.","Downregulator"
"Dopamine <e2>D2 receptor</e2> occupancy by <e1>risperidone</e1>: implications for the timing and magnitude of clinical response.","Regulator"
"The objective of the study is to investigate whether <e2>dopamine D2 receptor</e2> occupancy by <e1>risperidone</e1> and plasma levels over time can account for therapeutic efficacy and the latency period to response.","Regulator"
"<e2>Dopamine D2 receptor</e2> occupancy by <e1>risperidone</e1>: implications for the timing and magnitude of clinical response.","Regulator"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptor</e2>s in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of <e1>isoprenaline</e1> and CGP 12177A (in the presence of 1 microm propranolol).","Not"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptors</e2> in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of isoprenaline and <e1>CGP 12177A</e1> (in the presence of 1 microm propranolol).","Regulator"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptors</e2> in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of isoprenaline and CGP 12177A (in the presence of 1 microm <e1>propranolol</e1>).","Regulator"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptor</e2>s in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of <e1>isoprenaline</e1> and CGP 12177A (in the presence of 1 microm propranolol).","Regulator"
"Overexpression of <e2>beta 1-adrenoceptors</e2> in adult rat ventricular myocytes enhances <e1>CGP 12177A</e1> cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology.","Regulator"
"This study demonstrates enhanced cardiostimulation by <e1>CGP 12177A</e1> (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a <e2>Gs</e2>/cAMP signalling pathway.","Regulator"
"This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of <e1>propranolol</e1>) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a <e2>Gs</e2>/cAMP signalling pathway.","Regulator"
"This study demonstrates enhanced cardiostimulation by CGP 12177A (in the presence of propranolol) in rat ventricular myocytes overexpressing beta(1)-adrenoceptors, mediated by a <e2>Gs</e2>/<e1>cAMP</e1> signalling pathway.","Regulator"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptors</e2> in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of <e1>isoprenaline</e1> and CGP 12177A (in the presence of 1 microm propranolol).","Regulator"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptors</e2> in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of isoprenaline and <e1>CGP 12177A</e1> (in the presence of 1 microm propranolol).","Regulator"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptors</e2> in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of isoprenaline and CGP 12177A (in the presence of 1 microm <e1>propranolol</e1>).","Regulator"
"Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances <e1>CGP 12177A</e1> cardiostimulation: implications for 'putative' <e2>beta 4-adrenoceptor</e2> pharmacology.","Regulator"
"<e1>CGP 12177A</e1> mediates cardiostimulation by activation of the 'putative' <e2>beta(4)-adrenoceptor</e2>; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect.","Upregulator"
"We have adenovirally overexpressed <e2>beta(1)-adrenoceptors</e2> in isolated, cultured adult rat ventricular cardiomyocytes and observed the inotropic potency of isoprenaline and CGP 12177A (in the presence of 1 microm <e1>propranolol</e1>).","Upregulator"
"<e1>CGP 12177A</e1> mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the <e2>beta(1)-adrenoceptor</e2> gene abolishes this effect.","Upregulator"
"<e1>(125)I-Cyanopindolol</e1> saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in <e2>beta(1)-adrenoceptors</e2>.","Upregulator"
"<e1>(3)H-CGP 12177A</e1> saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of <e2>beta(1)-adrenoceptors</e2>.","Upregulator"
"<e1>CGP 12177A</e1> mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the <e2>beta(1)-adrenoceptor</e2> gene abolishes this effect.","Upregulator"
"In contrast, in the presence of <e1>Ca</e1> UFH accelerated the inhibition of <e2>factor Xa</e2> by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.","Downregulator"
"In contrast, in the presence of <e1>Ca</e1> UFH accelerated the inhibition of factor Xa by <e2>antithrombin</e2> 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.","Downregulator"
"Further insights into the effect of <e1>quinidine</e1> in short QT syndrome caused by a mutation in <e2>HERG</e2>.","Regulator"
"Further insights into the effect of <e1>quinidine</e1> in short QT syndrome caused by a mutation in <e2>HERG</e2>.","Regulator"
"INTRODUCTION: The principal aim of this study was to assess the efficacy of <e1>quinidine</e1> in suppressing <e2>IKr</e2> in vitro and in modulating the rate dependence of the QT interval in the ""SQT1"" form of the short QT syndrome.","Downregulator"
"INTRODUCTION: The principal aim of this study was to assess the efficacy of <e1>quinidine</e1> in suppressing <e2>IKr</e2> in vitro and in modulating the rate dependence of the QT interval in the ""SQT1"" form of the short QT syndrome.","Downregulator"
"Our results indicate that Salix extract 1520L inhibits <e2>COX-2</e2>-mediated <e1>PGE2</e1> release through compounds other than salicin or salicylate.","Substrate"
"The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (<e1>PGE2</e1>) reflecting <e2>cyclooxygenase (COX)-2</e2>-mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively.","Substrate"
"<e2>Follicle-stimulating hormone</e2> (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex <e1>steroids</e1> and gametes.","Substrate"
"Follicle-stimulating hormone (<e2>FSH</e2>), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex <e1>steroids</e1> and gametes.","Substrate"
"Humans with <e2>FSH beta</e2> gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex <e1>steroid</e1> production occur in both types of mutations.","Substrate"
"Antipsychotic profile of <e1>rolipram</e1>: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (<e2>PDE4B</e2>) enzyme.","Regulator"
"Antipsychotic profile of <e1>rolipram</e1>: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (<e2>PDE4B</e2>) enzyme.","Regulator"
"Antipsychotic profile of <e1>rolipram</e1>: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (<e2>PDE4</e2>B) enzyme.","Downregulator"
"These results suggest that <e2>PDE4B</e2> mediates the antipsychotic effects of rolipram in CAR and that the PDE4B-regulated <e1>cyclic adenosine monophosphate</e1> signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.","Substrate"
"<e2>Cat-1</e2>, the transporter for the essential <e1>amino acids</e1>, arginine and lysine, is one of the up-regulated genes.","Substrate"
"<e2>Cat-1</e2>, the transporter for the essential amino acids, <e1>arginine</e1> and lysine, is one of the up-regulated genes.","Substrate"
"<e2>Cat-1</e2>, the transporter for the essential amino acids, arginine and <e1>lysine</e1>, is one of the up-regulated genes.","Substrate"
"RESULTS: Fractionated bulb extracts and the two isolated <e1>steroidal glycoalkaloids</e1> (1) and (2) induced NO production and <e2>TGF-β receptor I</e2> mRNA expression in fibroblast cell culture.","Upregulator"
"On the basis of data obtained in rabbits, the imidazoline receptor ligand <e1>rilmenidine</e1> has been suggested to decrease blood pressure in humans by activating central <e2>alpha(2A)-adrenoceptors</e2>.","Not"
"In addition, a partial nucleotide and <e1>amino acid</e1> sequence of the <e2>rabbit alpha(2A)-adrenoceptor</e2> (a region known to substantially influence the pharmacological characteristics of the alpha(2)-adrenoceptor) revealed marked differences between the rabbit and the human alpha(2A)-adrenoceptor.","Part_of"
"On the basis of data obtained in rabbits, the <e2>imidazoline receptor</e2> ligand <e1>rilmenidine</e1> has been suggested to decrease blood pressure in humans by activating central alpha(2A)-adrenoceptors.","Regulator"
"The antagonistic property of <e1>rilmenidine</e1> at human alpha(2A)-adrenoceptors indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably <e2>I(1)-imidazoline receptors</e2>, are probably involved.","Regulator"
"On the basis of data obtained in rabbits, the imidazoline receptor ligand <e1>rilmenidine</e1> has been suggested to decrease blood pressure in humans by activating central <e2>alpha(2A)-adrenoceptors</e2>.","Upregulator"
"On the basis of data obtained in rabbits, the imidazoline receptor ligand <e1>rilmenidine</e1> has been suggested to decrease blood pressure in humans by activating central <e2>alpha(2A)-adrenoceptors</e2>.","Upregulator"
"Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of <e2>alpha(2)-adrenoceptor</e2> agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the alpha(2)-adrenoceptor-mediated inhibition induced by <e1>moxonidine</e1>.","Downregulator"
"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <e2>alpha(2A)-autoreceptors</e2>, at which, however, both rilmenidine and <e1>oxymetazoline</e1> exhibit different properties (antagonism and agonism, respectively).","Agonist"
"In the rabbit pulmonary artery, <e1>rilmenidine</e1> and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors</e2>, sharing this property with rauwolscine, phentolamine, and idazoxan.","Antagonist"
"In the rabbit pulmonary artery, rilmenidine and <e1>oxymetazoline</e1> are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors</e2>, sharing this property with rauwolscine, phentolamine, and idazoxan.","Antagonist"
"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors</e2>, sharing this property with <e1>rauwolscine</e1>, phentolamine, and idazoxan.","Antagonist"
"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors</e2>, sharing this property with rauwolscine, <e1>phentolamine</e1>, and idazoxan.","Antagonist"
"In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the <e2>alpha(2)-autoreceptors</e2>, sharing this property with rauwolscine, phentolamine, and <e1>idazoxan</e1>.","Antagonist"
"The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with <e2>alpha(2A)-autoreceptors</e2>, at which, however, both <e1>rilmenidine</e1> and oxymetazoline exhibit different properties (antagonism and agonism, respectively).","Antagonist"
"A prerequisite for this hypothesis was the unproved assumption that rabbit and <e2>human alpha(2A)-adrenoceptors</e2> are equally activated by <e1>rilmenidine</e1>.","Antagonist"
"<e1>Cetrorelix</e1> completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the <e2>GnRH-R</e2> mRNA, during both the infantile and the juvenile periods.","Downregulator"
"<e1>Cetrorelix</e1> also abolished the developmental rise of the <e2>gonadotropin beta</e2> subunit mRNAs during the two periods of the study.","Downregulator"
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor</e2> antagonists <e1>terfenadine</e1>, astemizole, loratadine, and acrivastine are reviewed.","Antagonist"
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor</e2> antagonists terfenadine, <e1>astemizole</e1>, loratadine, and acrivastine are reviewed.","Antagonist"
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor</e2> antagonists terfenadine, astemizole, <e1>loratadine</e1>, and acrivastine are reviewed.","Antagonist"
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor</e2> antagonists terfenadine, astemizole, loratadine, and <e1>acrivastine</e1> are reviewed.","Antagonist"
"<e1>Terfenadine</e1> and astemizole are chemically unrelated to <e2>histamine H1-receptor</e2> antagonists such as diphenhydramine and chlorpheniramine.","Antagonist"
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating <e2>histamine H1-receptor</e2> antagonists terfenadine, <e1>astemizole</e1>, loratadine, and acrivastine are reviewed.","Antagonist"
"Terfenadine and astemizole are chemically unrelated to <e2>histamine H1-receptor</e2> antagonists such as <e1>diphenhydramine</e1> and chlorpheniramine.","Antagonist"
"Terfenadine and astemizole are chemically unrelated to <e2>histamine H1-receptor</e2> antagonists such as diphenhydramine and <e1>chlorpheniramine</e1>.","Antagonist"
"In addition, <e1>prunetin</e1> inhibits NF-κB-dependent inflammatory responses by modulating <e2>IκB kinase</e2> (IKK)-inhibitor κBα (IκBα)-NF-κB signaling.","Regulator"
"In addition, <e1>prunetin</e1> inhibits NF-κB-dependent inflammatory responses by modulating IκB kinase (<e2>IKK</e2>)-inhibitor κBα (IκBα)-NF-κB signaling.","Regulator"
"In addition, <e1>prunetin</e1> inhibits NF-κB-dependent inflammatory responses by modulating IκB kinase (IKK)-<e2>inhibitor κBα</e2> (IκBα)-NF-κB signaling.","Regulator"
"In addition, <e1>prunetin</e1> inhibits NF-κB-dependent inflammatory responses by modulating IκB kinase (IKK)-inhibitor κBα (<e2>IκBα</e2>)-NF-κB signaling.","Regulator"
"Anti-inflammatory effect of <e1>prunetin</e1> via the suppression of <e2>NF-κB</e2> pathway.","Regulator"
"Promoter assay revealed that <e1>prunetin</e1> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of <e2>iNOS</e2> and COX-2 at the transcriptional level.","Downregulator"
"Promoter assay revealed that <e1>prunetin</e1> inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and <e2>COX-2</e2> at the transcriptional level.","Downregulator"
"Consistent with these results, <e1>prunetin</e1> significantly reduced serum levels of inflammatory <e2>cytokines</e2> and mortality in mice challenged with lipopolysaccharide.","Downregulator"
"Anti-inflammatory effect of <e1>prunetin</e1> via the suppression of <e2>NF-κB</e2> pathway.","Downregulator"
"Anti-inflammatory effect of <e1>prunetin</e1> via the suppression of <e2>NF-κB</e2> pathway.","Downregulator"
"G6PC2: A Negative Regulator of Basal <e1>Glucose</e1>-Stimulated <e2>Insulin</e2> Secretion.","Upregulator"
"Genome-wide association studies (GWAS) have linked polymorphisms in G6PC2 with variations in FBG and body fat, although not <e2>insulin</e2> sensitivity or <e1>glucose</e1> tolerance.","Upregulator"
"These data suggest that <e2>G6pc2</e2> represents a novel, negative regulator of basal GSIS that acts by hydrolyzing <e1>glucose-6-phosphate</e1>, thereby reducing glycolytic flux.","Substrate"
"Using the mTOR inhibitor <e1>PP242</e1>, we found that TGFβ-induced both early and sustained activation of TORC1 and TORC2 was necessary for <e2>deptor</e2> suppression.","Upregulator"
"Using the <e2>mTOR</e2> inhibitor <e1>PP242,</e1> we found that TGFβ-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.","Downregulator"
"METHODS: <e1>(+/-)-Modafinil</e1> and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in <e2>human dopamine transporter</e2> (DAT) wild-type and mutants with altered conformational equilibria.","Regulator"
"METHODS: <e1>(+/-)-Modafinil</e1> and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>DAT</e2>) wild-type and mutants with altered conformational equilibria.","Regulator"
"METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and <e1>[(3)H]WIN 35428</e1> binding in <e2>human dopamine transporter</e2> (DAT) wild-type and mutants with altered conformational equilibria.","Regulator"
"METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (DA) uptake and <e1>[(3)H]WIN 35428</e1> binding in human dopamine transporter (<e2>DAT</e2>) wild-type and mutants with altered conformational equilibria.","Regulator"
"RESULTS: (+/-)-, R-, and S-modafinil bind to the <e2>DAT</e2> and inhibit DA uptake less potently than cocaine, with <e1>R-modafinil</e1> having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"<e1>R-modafinil</e1> was significantly less potent in the DAT <e2>Y156F</e2> mutant compared with wild-type DAT, whereas S-modafinil was affected less.","Regulator"
"RESULTS: (+/-)-, R-, and S-modafinil bind to the <e2>DAT</e2> and inhibit DA uptake less potently than cocaine, with <e1>R-modafinil</e1> having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"RESULTS: <e1>(+/-)-, R-, and S-modafinil</e1> bind to the <e2>DAT</e2> and inhibit DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"RESULTS: (+/-)-, R-, and S-modafinil bind to the <e2>DAT</e2> and inhibit DA uptake less potently than <e1>cocaine</e1>, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"RESULTS: (+/-)-, R-, and S-modafinil bind to the <e2>DAT</e2> and inhibit DA uptake less potently than cocaine, with <e1>R-modafinil</e1> having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"RESULTS: (+/-)-, R-, and <e1>S-modafinil</e1> bind to the <e2>DAT</e2> and inhibit DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"R-modafinil was significantly less potent in the DAT <e2>Y156F</e2> mutant compared with wild-type DAT, whereas <e1>S-modafinil</e1> was affected less.","Regulator"
"RESULTS: (+/-)-, R-, and <e1>S-modafinil</e1> bind to the <e2>DAT</e2> and inhibit DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"Studies with the <e2>Y335A</e2> DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than <e1>cocaine</e1>, which was further supported by [2-(trimethylammonium)ethyl]-methanethiosulfonate reactivity on the DAT E2C I159C.","Regulator"
"RESULTS: (+/-)-, R-, and S-modafinil bind to the <e2>DAT</e2> and inhibit DA uptake less potently than <e1>cocaine</e1>, with R-modafinil having approximately threefold higher affinity than its S-enantiomer.","Regulator"
"Studies with the Y335A <e2>DAT</e2> mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by <e1>[2-(trimethylammonium)ethyl]-methanethiosulfonate</e1> reactivity on the DAT E2C I159C.","Regulator"
"Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by <e1>[2-(trimethylammonium)ethyl]-methanethiosulfonate</e1> reactivity on the DAT <e2>E2C</e2> I159C.","Regulator"
"Studies with the Y335A DAT mutant showed that the R- and S-enantiomers tolerated the inward-facing conformation better than cocaine, which was further supported by <e1>[2-(trimethylammonium)ethyl]-methanethiosulfonate</e1> reactivity on the DAT E2C <e2>I159C</e2>.","Regulator"
"METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <e1>[(3)H] dopamine</e1> (DA) uptake and [(3)H]WIN 35428 binding in <e2>human dopamine transporter</e2> (DAT) wild-type and mutants with altered conformational equilibria.","Substrate"
"METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of <e1>[(3)H] dopamine</e1> (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>DAT</e2>) wild-type and mutants with altered conformational equilibria.","Substrate"
"METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<e1>DA</e1>) uptake and [(3)H]WIN 35428 binding in <e2>human dopamine transporter</e2> (DAT) wild-type and mutants with altered conformational equilibria.","Substrate"
"METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<e1>DA</e1>) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>DAT</e2>) wild-type and mutants with altered conformational equilibria.","Substrate"
"METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine (<e1>DA</e1>) uptake and [(3)H]WIN 35428 binding in human dopamine transporter (<e2>DAT</e2>) wild-type and mutants with altered conformational equilibria.","Substrate"
"A significant decrease in HLA-DR expression was observed in the AP and fractionated <e1>procyanidin</e1>-treated cells in the presence of ovalbumin (OVA), but no effect on <e2>CD86</e2> expression was observed.","Not"
"Furthermore, the up-regulation of <e2>IL-12</e2> and TNF-α was found in the <e1>procyanidin</e1> trimers-treated cells in the presence of OVA.","Upregulator"
"Furthermore, the up-regulation of IL-12 and <e2>TNF-α</e2> was found in the <e1>procyanidin</e1> trimers-treated cells in the presence of OVA.","Upregulator"
"Apple <e1>polyphenols</e1> suppress antigen presentation of <e2>ovalbumin</e2> by THP-1-derived dendritic cells.","Downregulator"
"A significant decrease in <e2>HLA-DR</e2> expression was observed in the AP and fractionated <e1>procyanidin</e1>-treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed.","Downregulator"
"<e1>AOH</e1> treatment also induced abnormal <e2>Aurora B</e2> bridges, suggesting that cytokinesis was interfered within cells undergoing karyokinesis.","Regulator"
"A major part of this processing requires endoproteolytic cleavage at specific pairs of basic <e1>amino acid</e1> residues, an event necessary for the maturation of a variety of important biologically active proteins, such as <e2>insulin</e2> and nerve growth factor.","Part_of"
"A major part of this processing requires endoproteolytic cleavage at specific pairs of basic <e1>amino acid</e1> residues, an event necessary for the maturation of a variety of important biologically active proteins, such as insulin and <e2>nerve growth factor</e2>.","Part_of"
"To confirm molecular recognition of <e1>tinzaparin</e1> by <e2>VLA-4</e2>, a surface acoustic wave-biosensor was applied.","Regulator"
"<e1>Tinzaparin</e1> binds to <e2>VLA-4</e2> with affinity in the low micromolar range (4.61 x 10(-6) M), which clearly indicates specific molecular recognition.","Regulator"
"To confirm molecular recognition of <e1>tinzaparin</e1> by <e2>VLA-4</e2>, a surface acoustic wave-biosensor was applied.","Regulator"
"Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/<e1>Cys</e1>(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Furthermore, a combinatory mutation (<e1>Pro</e1>(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in <e2>EL3</e2> and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"Furthermore, a combinatory mutation (<e1>Pro</e1>(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in <e2>EL3</e2> and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-<e1>Ser</e1>(7.33) motif to Ser-Glu-Pro in <e2>EL3</e2> and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to <e1>Ser-Glu-Pro</e1> in <e2>EL3</e2> and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and <e1>Leu</e1>(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of <e2>rat GnRHR</e2>) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and <e1>Leu</e1>(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of <e2>rat GnRHR</e2>) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), Leu(7.43), <e1>Ala</e1>(7.46), and Pro(7.47) to those of <e2>rat GnRHR</e2>) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"Furthermore, a combinatory mutation (<e1>Pro</e1>(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of <e2>rat GnRHR</e2>) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.","Part_of"
"[Trp(7)]GnRH-I and [Trp(8)]GnRH-I but not [His(5)]GnRH-I exhibit a higher potency in activating wild-type gmGnRHR-2 than native GnRH-I, indicating that <e1>amino acids</e1> at positions 7 and 8 of <e2>GnRHs</e2> are more important than position 5 for differential recognition by type I and type II GnRHRs.","Part_of"
"Point-mutation studies indicate that four <e1>amino acids</e1>, Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Point-mutation studies indicate that four amino acids, <e1>Leu</e1>/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Point-mutation studies indicate that four amino acids, Leu/<e1>Phe</e1>(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Point-mutation studies indicate that four amino acids, <e1>Leu</e1>/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Point-mutation studies indicate that four amino acids, Leu/<e1>Phe</e1>(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), <e1>Ala</e1>/Pro(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/<e1>Pro</e1>(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/<e1>Pro</e1>(7.46), and Pro/Cys(7.47) in <e2>TMH7</e2> are critical for ligand selectivity as well as receptor conformation.","Part_of"
"Both the phosphotriesterase and <e1>physostigmine</e1> treatments protected the brain <e2>AChE</e2> activities measured 24 h after sarin exposure.","Regulator"
"Both the phosphotriesterase and physostigmine treatments protected the brain <e2>AChE</e2> activities measured 24 h after <e1>sarin</e1> exposure.","Regulator"
"Both the phosphotriesterase and physostigmine treatments protected the brain <e2>AChE</e2> activities measured 24 h after <e1>sarin</e1> exposure.","Downregulator"
"The acute toxicity of <e1>organophosphorus</e1> (OP) compounds in mammals is due to their irreversible inhibition of <e2>acetylcholinesterase</e2> (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.","Downregulator"
"The acute toxicity of <e1>organophosphorus</e1> (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (<e2>AChE</e2>) in the nervous system, which leads to increased synaptic acetylcholine levels.","Downregulator"
"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of <e1>acetylcholine</e1>sterase (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.","Substrate"
"The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of <e1>acetylcholine</e1>sterase (<e2>AChE</e2>) in the nervous system, which leads to increased synaptic acetylcholine levels.","Substrate"
"The <e2>CYP3A4</e2> activity could be induced 2-fold by <e1>rifampicin</e1>, whereas CYP2C9 activity remained equally high.","Upregulator"
"The CYP3A4 activity could be induced 2-fold by <e1>rifampicin</e1>, whereas <e2>CYP2C9</e2> activity remained equally high.","Upregulator"
"The modification of the inhibitor scaffold of 1 and 2 from a <e1>dihydroquinolinone</e1> core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent <e2>KAT II</e2> inhibitors with excellent physicochemical properties.","Downregulator"
"The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a <e1>tetrahydropyrazolopyridinone</e1> core led to discovery of a new series of potent <e2>KAT II</e2> inhibitors with excellent physicochemical properties.","Downregulator"
"PF-04859989 as a template for structure-based drug design: identification of new <e1>pyrazole</e1> series of irreversible <e2>KAT II</e2> inhibitors with improved lipophilic efficiency.","Downregulator"
"<e1>PF-04859989</e1> as a template for structure-based drug design: identification of new pyrazole series of irreversible <e2>KAT II</e2> inhibitors with improved lipophilic efficiency.","Downregulator"
"PF-04859989 as a template for structure-based drug design: identification of new <e1>pyrazole</e1> series of irreversible <e2>KAT II</e2> inhibitors with improved lipophilic efficiency.","Downregulator"
"Differential inhibition of <e1>[3H]-oxotremorine-M</e1> and [3H]-quinuclinidyl benzilate binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"Differential inhibition of <e1>[3H]-oxotremorine-M</e1> and [3H]-quinuclinidyl benzilate binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"Differential inhibition of <e1>[3H]-oxotremorine-M</e1> and [3H]-quinuclinidyl benzilate binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"Differential inhibition of <e1>[3H]-oxotremorine-M</e1> and [3H]-quinuclinidyl benzilate binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"Differential inhibition of [3H]-oxotremorine-M and <e1>[3H]-quinuclinidyl benzilate</e1> binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"Differential inhibition of <e1>[3H]-oxotremorine-M</e1> and [3H]-quinuclinidyl benzilate binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"Differential inhibition of [3H]-oxotremorine-M and <e1>[3H]-quinuclinidyl benzilate</e1> binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"Differential inhibition of <e1>[3H]-oxotremorine-M</e1> and [3H]-quinuclinidyl benzilate binding to <e2>muscarinic receptors</e2> in rat brain membranes with acetylcholinesterase inhibitors.","Regulator"
"The capacity of acetylcholinesterase inhibitors, with the exception of tacrine and ambenonium, to displace bound [3H]-oxotremorine-M in preference to <e1>[3H]quinuclinidyl benzilate</e1> predicts that the former compounds could act as potential agonists at <e2>muscarinic receptors</e2>.","Regulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=<e1>pyridostigmine</e1>=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=<e1>pyridostigmine</e1>=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> <e1>edrophonium</e1>=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> <e1>edrophonium</e1>=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=<e1>galanthamine</e1>>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=<e1>galanthamine</e1>>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine><e1>desoxypeganine</e1>) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine><e1>desoxypeganine</e1>) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase</e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine><e1>parathion</e1>>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.","Downregulator"
"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase</e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine><e1>parathion</e1>>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.","Downregulator"
"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase</e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion><e1>gramine</e1>) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.","Downregulator"
"Moreover, the rank order for potency in inhibiting <e2>acetylcholinesterase</e2> (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion><e1>gramine</e1>) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=<e1>tacrine</e1>>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (<e1>ambenonium</e1>>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (<e1>ambenonium</e1>>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (<e1>ambenonium</e1>>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium><e1>neostigmine</e1>=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium><e1>neostigmine</e1>=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine><e1>physostigmine</e1>> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine><e1>physostigmine</e1>> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=<e1>tacrine</e1>>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"A series of compounds, representative of the principal classes of <e2>acetylcholinesterase</e2> inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=<e1>tacrine</e1>>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.","Downregulator"
"DISCUSSION: These results are consistent with previous studies that found that: (1) <e2>pyridoxal kinase</e2> had a very low activity in children with autism and (2) pyridoxal 5 phosphate (<e1>PLP</e1>) levels are unusually low in children with autism.","Substrate"
"CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired <e2>pyridoxal kinase</e2> for the conversion of <e1>pyridoxine</e1> and pyridoxal to PLP.","Substrate"
"DISCUSSION: These results are consistent with previous studies that found that: (1) <e1>pyridoxal</e1> kinase had a very low activity in children with autism and (2) pyridoxal 5 phosphate (PLP) levels are unusually low in children with autism.","Substrate"
"β-Amyloid aggregation results showed that all compounds exhibited remarkable <e2>Aβ</e2> fibril aggregation inhibition activity with a nearly similar potential as the reference compound <e1>rifampicin</e1>, which makes them promising anti-Alzheimer drug candidates.","Downregulator"
"To develop new drugs for treatment of Alzheimer's disease, a group of <e1>N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones</e1> was designed, synthesized and tested for their ability to inhibit <e2>acetylcholinesterase</e2>, butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).","Downregulator"
"To develop new drugs for treatment of Alzheimer's disease, a group of <e1>N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones</e1> was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, <e2>butyrylcholinesterase</e2> and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).","Downregulator"
"Synthesis, molecular modeling and evaluation of novel <e1>N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone</e1> derivatives as dual inhibitors for <e2>cholinesterases</e2> and Aβ aggregation.","Downregulator"
"Synthesis, molecular modeling and evaluation of novel <e1>N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone</e1> derivatives as dual inhibitors for cholinesterases and <e2>Aβ</e2> aggregation.","Downregulator"
"<e1>Testosterone</e1> (TEST) had the fastest translocation rate for the <e2>hAR</e2> of 0.0525 min(-1).","Regulator"
"Testosterone (<e1>TEST</e1>) had the fastest translocation rate for the <e2>hAR</e2> of 0.0525 min(-1).","Regulator"
"The rates of <e2>hAR</e2> transport for the exogenous steroids methyltrienelone (MET), nandrolone (<e1>NAN</e1>), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.","Regulator"
"The rates of <e2>hAR</e2> transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and <e1>oxandrolone</e1> (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.","Regulator"
"The rates of <e2>hAR</e2> transport for the exogenous steroids methyltrienelone (MET), nandrolone (NAN), and oxandrolone (<e1>OXA</e1>) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.","Regulator"
"The other endogenous steroids, androstenedione (ANE) and dihydro<e1>testosterone</e1> (DHT), had considerably lower <e2>hAR</e2> transport rates.","Regulator"
"Effect of anabolic-androgenic <e1>steroids</e1> and glucocorticoids on the kinetics of <e2>hAR</e2> and hGR nucleocytoplasmic translocation.","Regulator"
"The other endogenous steroids, androstenedione (<e1>ANE</e1>) and dihydrotestosterone (DHT), had considerably lower <e2>hAR</e2> transport rates.","Regulator"
"The other endogenous steroids, androstenedione (ANE) and dihydrotestosterone (<e1>DHT</e1>), had considerably lower <e2>hAR</e2> transport rates.","Regulator"
"Effect of anabolic-androgenic <e1>steroids</e1> and glucocorticoids on the kinetics of hAR and <e2>hGR</e2> nucleocytoplasmic translocation.","Regulator"
"Effect of anabolic-androgenic <e1>steroids</e1> and glucocorticoids on the kinetics of <e2>hAR</e2> and hGR nucleocytoplasmic translocation.","Regulator"
"The other endogenous steroids, <e1>androstenedione</e1> (ANE) and dihydrotestosterone (DHT), had considerably lower <e2>hAR</e2> transport rates.","Regulator"
"The other endogenous steroids, androstenedione (<e1>ANE</e1>) and dihydrotestosterone (DHT), had considerably lower <e2>hAR</e2> transport rates.","Regulator"
"The other endogenous steroids, androstenedione (ANE) and <e1>dihydrotestosterone</e1> (DHT), had considerably lower <e2>hAR</e2> transport rates.","Regulator"
"The other endogenous steroids, androstenedione (ANE) and dihydrotestosterone (<e1>DHT</e1>), had considerably lower <e2>hAR</e2> transport rates.","Regulator"
"Effect of anabolic-androgenic <e1>steroids</e1> and glucocorticoids on the kinetics of <e2>hAR</e2> and hGR nucleocytoplasmic translocation.","Regulator"
"The rates of <e2>hAR</e2> transport for the exogenous steroids <e1>methyltrienelone</e1> (MET), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.","Regulator"
"The rates of <e2>hAR</e2> transport for the exogenous steroids methyltrienelone (<e1>MET</e1>), nandrolone (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.","Regulator"
"The rates of <e2>hAR</e2> transport for the exogenous steroids methyltrienelone (MET), <e1>nandrolone</e1> (NAN), and oxandrolone (OXA) are lower than that of testosterone and similar to those of the endogenous steroids ANE and DHT.","Regulator"
"Effect of anabolic-androgenic <e1>steroids</e1> and glucocorticoids on the kinetics of <e2>hAR</e2> and hGR nucleocytoplasmic translocation.","Upregulator"
"<e1>Licofelone</e1> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, <e2>monocyte chemoattractant protein-1</e2> (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.","Downregulator"
"<e1>Licofelone</e1> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (<e2>MCP-1</e2>) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.","Downregulator"
"<e1>Licofelone</e1> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of <e2>nuclear factor-kappaB</e2> in rabbit atheroma.","Downregulator"
"We examined the anti-inflammatory effect of <e1>licofelone</e1> on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of <e2>COX-2</e2>, rofecoxib.","Downregulator"
"Moreover, <e1>licofelone</e1> inhibited COX-2 and <e2>5-LOX</e2> protein expression in vascular lesions.","Downregulator"
"<e1>Rofecoxib</e1> only diminished <e2>COX-2</e2> protein expression and MCP-1 gene expression in vascular atheroma.","Downregulator"
"<e1>Rofecoxib</e1> only diminished COX-2 protein expression and <e2>MCP-1</e2> gene expression in vascular atheroma.","Downregulator"
"We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of <e2>COX-2</e2>, <e1>rofecoxib</e1>.","Downregulator"
"<e1>Licofelone</e1>, a balanced inhibitor of <e2>cyclooxygenase</e2> and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.","Downregulator"
"<e1>Licofelone</e1>, a balanced inhibitor of cyclooxygenase and <e2>5-lipoxygenase</e2>, reduces inflammation in a rabbit model of atherosclerosis.","Downregulator"
"<e1>Licofelone</e1>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to <e2>cycloxygenase-1</e2> blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.","Downregulator"
"<e1>Licofelone</e1>, a balanced inhibitor of cyclooxygenase and <e2>5-lipoxygenase</e2>, reduces inflammation in a rabbit model of atherosclerosis.","Downregulator"
"<e1>Licofelone</e1>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (<e2>LOX</e2>) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.","Downregulator"
"<e1>Licofelone</e1>, a balanced inhibitor of <e2>cyclooxygenase</e2> and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.","Downregulator"
"<e1>Licofelone</e1>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (<e2>COX</e2>) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.","Downregulator"
"<e1>Licofelone</e1> almost abolished <e2>5-LOX</e2> activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.","Downregulator"
"Licofelone almost abolished <e2>5-LOX</e2> activity by inhibiting <e1>leukotriene B4</e1> generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.","Substrate"
"Licofelone almost abolished <e2>5-LOX</e2> activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet <e1>thromboxane B2</e1> production from whole blood.","Substrate"
"No influence of moderate hepatic impairment on the pharmacokinetics of <e1>lumiracoxib</e1>, an oral <e2>COX-2</e2> selective inhibitor.","Downregulator"
"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel <e2>cyclooxygenase-2</e2> (COX-2) selective inhibitor <e1>lumiracoxib</e1> (Prexige), so that dose recommendations for clinical use can be provided.","Downregulator"
"No influence of moderate hepatic impairment on the pharmacokinetics of <e1>lumiracoxib</e1>, an oral <e2>COX-2</e2> selective inhibitor.","Downregulator"
"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel <e2>cyclooxygenase-2</e2> (COX-2) selective inhibitor lumiracoxib (<e1>Prexige</e1>), so that dose recommendations for clinical use can be provided.","Downregulator"
"The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (<e2>COX-2</e2>) selective inhibitor lumiracoxib (<e1>Prexige</e1>), so that dose recommendations for clinical use can be provided.","Downregulator"
"The present study was designed to test the hypothesis that <e1>alcohol</e1> alters global DNA methylation, and modulates expression of the <e2>DNA methyltransferases</e2> (DNMTs) and various methyl CpG-binding proteins.","Regulator"
"The present study was designed to test the hypothesis that <e1>alcohol</e1> alters global DNA methylation, and modulates expression of the DNA methyltransferases (<e2>DNMTs</e2>) and various methyl CpG-binding proteins.","Regulator"
"The present study was designed to test the hypothesis that <e1>alcohol</e1> alters global DNA methylation, and modulates expression of the DNA methyltransferases (DNMTs) and various methyl <e2>CpG-binding proteins</e2>.","Regulator"
"<e1>Alcohol</e1> modulates expression of <e2>DNA methyltranferases</e2> and methyl CpG-/CpG domain-binding proteins in murine embryonic fibroblasts.","Regulator"
"<e1>Alcohol</e1> modulates expression of DNA methyltranferases and <e2>methyl CpG-/CpG domain-binding proteins</e2> in murine embryonic fibroblasts.","Regulator"
"In addition, <e1>ethanol</e1> induced degradation of <e2>DNA methyltransferases</e2> (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.","Downregulator"
"In addition, <e1>ethanol</e1> induced degradation of DNA methyltransferases (<e2>DNMT-</e2>1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.","Downregulator"
"In addition, <e1>ethanol</e1> induced degradation of DNA methyltransferases (DNMT-1, <e2>DNMT-3a</e2>, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.","Downregulator"
"In addition, <e1>ethanol</e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and <e2>DNMT-3b</e2>), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.","Downregulator"
"In addition, <e1>ethanol</e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the <e2>methyl CpG-binding proteins</e2> (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.","Downregulator"
"In addition, <e1>ethanol</e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (<e2>MeCP-2</e2>, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway.","Downregulator"
"In addition, <e1>ethanol</e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, <e2>MBD-2</e2> and MBD-3), in MEF cells by the proteasomal pathway.","Downregulator"
"In addition, <e1>ethanol</e1> induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and <e2>MBD-3</e2>), in MEF cells by the proteasomal pathway.","Downregulator"
"Cosinor analysis indicated no diurnal rhythm of <e2>Pparγ</e2> expression in the livers of diabetic <e1>STZ</e1> or Iddm rats or in those of insulin-substituted Iddm rats.","Not"
"We investigated the diurnal expression of <e2>clock</e2> genes and clock-controlled genes (CCGs) in 3-hour intervals for a 24-h period in the livers of male <e1>streptozotocin</e1> (STZ)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with insulin.","Regulator"
"We investigated the diurnal expression of clock genes and <e2>clock-controlled genes</e2> (CCGs) in 3-hour intervals for a 24-h period in the livers of male <e1>streptozotocin</e1> (STZ)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with insulin.","Regulator"
"We investigated the diurnal expression of clock genes and clock-controlled genes (<e2>CCGs</e2>) in 3-hour intervals for a 24-h period in the livers of male <e1>streptozotocin</e1> (STZ)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with insulin.","Regulator"
"We investigated the diurnal expression of <e2>clock</e2> genes and clock-controlled genes (CCGs) in 3-hour intervals for a 24-h period in the livers of male streptozotocin (<e1>STZ</e1>)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with insulin.","Regulator"
"We investigated the diurnal expression of clock genes and <e2>clock-controlled genes</e2> (CCGs) in 3-hour intervals for a 24-h period in the livers of male streptozotocin (<e1>STZ</e1>)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with insulin.","Regulator"
"We investigated the diurnal expression of clock genes and clock-controlled genes (<e2>CCGs</e2>) in 3-hour intervals for a 24-h period in the livers of male streptozotocin (<e1>STZ</e1>)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with insulin.","Regulator"
"We investigated the diurnal expression of <e2>clock</e2> genes and clock-controlled genes (CCGs) in 3-hour intervals for a 24-h period in the livers of male streptozotocin (<e1>STZ</e1>)-treated rats, male spontaneous type 1 diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with insulin.","Regulator"
"<e2>Clock</e2> Gene Expression in the Liver of <e1>Streptozotocin</e1>-induced and Spontaneous Type 1 Diabetic Rats.","Regulator"
"The effects of two reversible, predominantly monoamine oxidase-A (<e2>MAO-A</e2>) inhibitors, <e1>moclobemide</e1> (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.","Downregulator"
"The effects of two reversible, predominantly monoamine oxidase-A (<e2>MAO-A</e2>) inhibitors, moclobemide (150 mg three times daily) and <e1>toloxatone</e1> (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.","Downregulator"
"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>monoamine oxidase-A</e2> inhibitors <e1>moclobemide</e1> and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.","Downregulator"
"Comparison of the <e2>monoamine oxidase</e2> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors <e1>moclobemide</e1> and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.","Downregulator"
"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>monoamine oxidase-A</e2> inhibitors <e1>moclobemide</e1> and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.","Downregulator"
"Comparison of the <e2>monoamine oxidase</e2> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and <e1>toloxatone</e1>, and assessment of their effect on psychometric performance in healthy subjects.","Downregulator"
"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>monoamine oxidase-A</e2> inhibitors moclobemide and <e1>toloxatone</e1>, and assessment of their effect on psychometric performance in healthy subjects.","Downregulator"
"Comparison of the monoamine oxidase inhibiting properties of two reversible and selective <e2>monoamine oxidase-A</e2> inhibitors moclobemide and <e1>toloxatone</e1>, and assessment of their effect on psychometric performance in healthy subjects.","Downregulator"
"Previously, we have found that <e1>BRN-103</e1>, a nicotinamide derivative, inhibits vascular endothelial growth factor (<e2>VEGF</e2>)-mediated angiogenesis signaling in human endothelial cells.","Downregulator"
"Previously, we have found that <e1>BRN-103</e1>, a nicotinamide derivative, inhibits <e2>vascular endothelial growth factor</e2> (VEGF)-mediated angiogenesis signaling in human endothelial cells.","Downregulator"
"Previously, we have found that BRN-103, a <e1>nicotinamide</e1> derivative, inhibits vascular endothelial growth factor (<e2>VEGF</e2>)-mediated angiogenesis signaling in human endothelial cells.","Downregulator"
"Previously, we have found that BRN-103, a <e1>nicotinamide</e1> derivative, inhibits <e2>vascular endothelial growth factor</e2> (VEGF)-mediated angiogenesis signaling in human endothelial cells.","Downregulator"
"Furthermore, <e1>BRN-250</e1> inhibited the <e2>VEGF</e2>-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.","Downregulator"
"Furthermore, <e1>BRN-250</e1> inhibited the VEGF-induced phosphorylation and intracellular <e2>tyrosine kinase</e2> activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.","Downregulator"
"Furthermore, <e1>BRN-250</e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of <e2>VEGF receptor 2</e2> (VEGFR2) and the activation of its downstream AKT pathway.","Downregulator"
"Furthermore, <e1>BRN-250</e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (<e2>VEGFR2</e2>) and the activation of its downstream AKT pathway.","Downregulator"
"Furthermore, <e1>BRN-250</e1> inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream <e2>AKT</e2> pathway.","Downregulator"
"We have examined the effects of the synthetic matrix <e2>metalloproteinase</e2> inhibitor, <e1>batimastat</e1> (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.","Regulator"
"We have examined the effects of the synthetic matrix <e2>metalloproteinase</e2> inhibitor, batimastat (<e1>BB-94</e1>) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.","Regulator"
"We have examined the effects of the synthetic matrix <e2>metalloproteinase</e2> inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, <e1>captopril</e1>, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.","Regulator"
"Both <e1>BB-94</e1> and captopril also prevented substrate degradation by <e2>gelatinase A and B</e2> released in conditioned medium by cultured cells.","Downregulator"
"Inhibition of <e2>gelatinase A</e2> (MMP-2) by batimastat and <e1>captopril</e1> reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.","Downregulator"
"We have examined the effects of the synthetic <e2>matrix metalloproteinase</e2> inhibitor, <e1>batimastat</e1> (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.","Downregulator"
"We have examined the effects of the synthetic <e2>matrix metalloproteinase</e2> inhibitor, batimastat (<e1>BB-94</e1>) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.","Downregulator"
"Inhibition of <e2>gelatinase A</e2> (MMP-2) by <e1>batimastat</e1> and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.","Downregulator"
"Inhibition of gelatinase A (<e2>MMP-2</e2>) by <e1>batimastat</e1> and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.","Downregulator"
"Inhibition of <e2>gelatinase A</e2> (MMP-2) by batimastat and <e1>captopril</e1> reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.","Downregulator"
"Inhibition of gelatinase A (<e2>MMP-2</e2>) by batimastat and <e1>captopril</e1> reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.","Downregulator"
"We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the <e2>angiotensin-converting enzyme</e2> inhibitor, <e1>captopril</e1>, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.","Downregulator"
"Methionine synthase reductase (<e2>MTRR</e2>) is an enzyme involved in the conversion of Hcy to <e1>methionine</e1>.","Substrate"
"<e2>Methionine synthase reductase</e2> (MTRR) is an enzyme involved in the conversion of Hcy to <e1>methionine</e1>.","Substrate"
"Methionine synthase reductase (<e2>MTRR</e2>) is an enzyme involved in the conversion of <e1>Hcy</e1> to methionine.","Substrate"
"<e2>Methionine synthase reductase</e2> (MTRR) is an enzyme involved in the conversion of <e1>Hcy</e1> to methionine.","Substrate"
"<e2>GPxs</e2> reduce hydroperoxides to the corresponding <e1>alcohols</e1> by means of glutathione (GSH).","Substrate"
"<e1>TCDD</e1> decreased the expression of the <e2>glucose transporter</e2>, SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.","Downregulator"
"<e1>TCDD</e1> decreased the expression of the glucose transporter, <e2>SLC2A1</e2>, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.","Downregulator"
"Mitochondrial <e2>glutathione (GSH) reductase</e2> activity and the GSH/glutathione disulfide ratio were decreased by <e1>TCDD</e1>, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide.","Downregulator"
"Second, <e1>probucol</e1>, an antiatherogenic compound reported to be an inactivator of <e2>ABCA1</e2> reduced hepatic alpha-tocopherol secretion.","Downregulator"
"First, addition of <e2>apolipoprotein A-I</e2> (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased <e1>alpha-tocopherol</e1> secretion in a dose-dependent manner.","Substrate"
"First, addition of apolipoprotein A-I (<e2>apoA-I</e2>), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased <e1>alpha-tocopherol</e1> secretion in a dose-dependent manner.","Substrate"
"<e2>ATP-binding cassette transporter A1</e2> is involved in hepatic <e1>alpha-tocopherol</e1> secretion.","Substrate"
"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (<e2>ABCA1</e2>)-secreted lipids, increased <e1>alpha-tocopherol</e1> secretion in a dose-dependent manner.","Substrate"
"<e2>ATP-binding cassette transporter A1</e2> is involved in hepatic <e1>alpha-tocopherol</e1> secretion.","Substrate"
"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (<e2>ABCA1</e2>)-secreted lipids, increased <e1>alpha-tocopherol</e1> secretion in a dose-dependent manner.","Substrate"
"First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (<e2>ABCA1</e2>)-secreted lipids, increased <e1>alpha-tocopherol</e1> secretion in a dose-dependent manner.","Substrate"
"alpha-Tocopherol transfer protein (<e2>alpha-TTP</e2>), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>alpha-tocopherol</e1> level by mediating the secretion of alpha-tocopherol by the liver.","Substrate"
"<e2>alpha-Tocopherol transfer protein</e2> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>alpha-tocopherol</e1> level by mediating the secretion of alpha-tocopherol by the liver.","Substrate"
"alpha-Tocopherol transfer protein (<e2>alpha-TTP</e2>), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>alpha-tocopherol</e1> level by mediating the secretion of alpha-tocopherol by the liver.","Substrate"
"<e2>alpha-Tocopherol transfer protein</e2> (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma <e1>alpha-tocopherol</e1> level by mediating the secretion of alpha-tocopherol by the liver.","Substrate"
"Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which microcystins but not <e1>nodularins</e1> permanently modify their <e2>protein phosphatase</e2> targets by covalent addition to an active site cysteine residue.","Not"
"Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which microcystins but not nodularins permanently modify their <e2>protein phosphatase</e2> targets by covalent addition to an active site <e1>cysteine</e1> residue.","Part_of"
"We have elucidated the crystal structures of the cyanotoxins, motuporin (<e1>nodularin-V</e1>) and dihydromicrocystin-LA bound to <e2>human protein phosphatase-1c (gamma isoform)</e2>.","Regulator"
"We have elucidated the crystal structures of the cyanotoxins, motuporin (nodularin-V) and <e1>dihydromicrocystin-LA</e1> bound to <e2>human protein phosphatase-1c (gamma isoform)</e2>.","Regulator"
"Crystal structures of <e2>protein phosphatase-1</e2> bound to <e1>motuporin</e1> and dihydromicrocystin-LA: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.","Regulator"
"Crystal structures of <e2>protein phosphatase-1</e2> bound to motuporin and <e1>dihydromicrocystin-LA</e1>: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.","Regulator"
"Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which <e1>microcystins</e1> but not nodularins permanently modify their <e2>protein phosphatase</e2> targets by covalent addition to an active site cysteine residue.","Regulator"
"Crystal structures of <e2>protein phosphatase-1</e2> bound to motuporin and dihydro<e1>microcystin</e1>-LA: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.","Regulator"
"A previous crystal structure of a <e1>microcystin</e1> bound to the catalytic subunit of protein phosphatase-1 (<e2>PP-1c</e2>) showed distinct changes in the active site region when compared with protein phosphatase-1 structures bound to other toxins.","Regulator"
"We have elucidated the crystal structures of the cyanotoxins, <e1>motuporin</e1> (nodularin-V) and dihydromicrocystin-LA bound to <e2>human protein phosphatase-1c (gamma isoform)</e2>.","Regulator"
"<e2>dSERT1</e2> shows little transport of other <e1>monoamines</e1> and is Na+ and Cl- dependent.","Not"
"A <e1>cocaine</e1>-sensitive <e2>Drosophila serotonin transporter</e2>: cloning, expression, and electrophysiological characterization.","Regulator"
"<e2>dSERT1</e2> shows little transport of other monoamines and is <e1>Na+</e1> and Cl- dependent.","Regulator"
"<e2>dSERT1</e2> shows little transport of other monoamines and is Na+ and <e1>Cl-</e1> dependent.","Regulator"
"A <e1>cocaine</e1>-sensitive, high-affinity Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter cDNA, denoted <e2>dSERT1</e2>, was isolated and characterized in oocytes.","Regulator"
"A <e1>cocaine</e1>-sensitive, high-affinity <e2>Drosophila serotonin (5-hydroxytryptamine; 5HT) transporter</e2> cDNA, denoted dSERT1, was isolated and characterized in oocytes.","Regulator"
"The atypical neuroleptics <e1>remoxipride</e1>, clozapine, perlapine, seroquel, and melperone had low affinity for the dopamine <e2>D2 receptor</e2> (radioligand-independent dissociation constants of 30 to 90 nM).","Regulator"
"The atypical neuroleptics remoxipride, <e1>clozapine</e1>, perlapine, seroquel, and melperone had low affinity for the dopamine <e2>D2 receptor</e2> (radioligand-independent dissociation constants of 30 to 90 nM).","Regulator"
"The atypical neuroleptics remoxipride, clozapine, <e1>perlapine</e1>, seroquel, and melperone had low affinity for the dopamine <e2>D2 receptor</e2> (radioligand-independent dissociation constants of 30 to 90 nM).","Regulator"
"The atypical neuroleptics remoxipride, clozapine, perlapine, <e1>seroquel</e1>, and melperone had low affinity for the dopamine <e2>D2 receptor</e2> (radioligand-independent dissociation constants of 30 to 90 nM).","Regulator"
"The atypical neuroleptics remoxipride, clozapine, perlapine, seroquel, and <e1>melperone</e1> had low affinity for the dopamine <e2>D2 receptor</e2> (radioligand-independent dissociation constants of 30 to 90 nM).","Regulator"
"Atypical neuroleptics have low affinity for <e1>dopamine</e1> D2 receptors or are selective for D4 receptors.","Regulator"
"For example, <e1>clozapine</e1> revealed a radioligand-independent value of 1.6 nM at the <e2>dopamine D4 receptor</e2>, agreeing with the value directly measured with [3H]-clozapine at D4.","Regulator"
"For example, clozapine revealed a radioligand-independent value of 1.6 nM at the dopamine <e2>D4</e2> receptor, agreeing with the value directly measured with <e1>[3H]-clozapine</e1> at D4.","Regulator"
"However, because <e1>clozapine</e1> competes with endogenous dopamine, the in vivo concentration of clozapine (to occupy <e2>dopamine D4 receptors</e2>) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.","Regulator"
"However, because clozapine competes with endogenous <e1>dopamine</e1>, the in vivo concentration of clozapine (to occupy <e2>dopamine D4 receptors</e2>) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.","Regulator"
"However, because <e1>clozapine</e1> competes with endogenous dopamine, the in vivo concentration of clozapine (to occupy <e2>dopamine D4 receptors</e2>) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.","Regulator"
"<e1>2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid</e1> (1) is a potent AMPA receptor agonist with moderate affinity for native <e2>kainic acid (KA) receptors</e2>, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.","Regulator"
"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas <e1>(S)-E-4-(2,2-dimethylpropylidene)glutamic acid</e1> (3) show high affinity for the <e2>GluR5</e2> subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.","Regulator"
"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas <e1>(S)-E-4-(2,2-dimethylpropylidene)glutamic acid</e1> (3) show high affinity for the GluR5 subtype of <e2>KA receptors</e2> and much lower affinity for the GluR2 subtype of AMPA receptors.","Regulator"
"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas <e1>(S)-E-4-(2,2-dimethylpropylidene)glutamic acid</e1> (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the <e2>GluR2</e2> subtype of AMPA receptors.","Regulator"
"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas <e1>(S)-E-4-(2,2-dimethylpropylidene)glutamic acid</e1> (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of <e2>AMPA receptors</e2>.","Regulator"
"Synthesis and in vitro pharmacology at <e1>AMPA</e1> and kainate preferring <e2>glutamate receptors</e2> of 4-heteroarylmethylidene glutamate analogues.","Regulator"
"Synthesis and in vitro pharmacology at AMPA and <e1>kainate</e1> preferring <e2>glutamate receptors</e2> of 4-heteroarylmethylidene glutamate analogues.","Regulator"
"Synthesis and in vitro pharmacology at AMPA and kainate preferring <e2>glutamate receptors</e2> of <e1>4-heteroarylmethylidene glutamate</e1> analogues.","Regulator"
"2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent <e1>AMPA</e1> receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the <e2>GluR5</e2> subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.","Regulator"
"4a was shown to be a potent GluR5 agonist and a high affinity ligand and to indiscriminately bind to the <e1>AMPA</e1> receptor subtypes <e2>GluR1-4</e2> with lower affinities.","Regulator"
"<e1>2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid</e1> (1) is a potent <e2>AMPA receptor</e2> agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.","Agonist"
"In addition, <e1>cysteinyl leukotrienes</e1> per se failed to upregulate the <e2>IL-5</e2> production.","Not"
"BACKGROUND: <e1>Pranlukast</e1>, a cysteinyl leukotriene receptor 1 (<e2>CysLTR1</e2>) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.","Regulator"
"<e1>Pranlukast</e1>-induced inhibition of <e2>IL-5</e2> mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status.","Downregulator"
"The aim of this study was to determine the mechanism of <e1>pranlukast</e1>-induced interleukin-5 (<e2>IL-5</e2>) inhibition in allergic inflammation.","Downregulator"
"<e1>Pranlukast</e1>, a leukotriene receptor antagonist, inhibits <e2>interleukin-5</e2> production via a mechanism distinct from leukotriene receptor antagonism.","Downregulator"
"The aim of this study was to determine the mechanism of <e1>pranlukast</e1>-induced interleukin-5 (<e2>IL-5</e2>) inhibition in allergic inflammation.","Downregulator"
"The aim of this study was to determine the mechanism of <e1>pranlukast</e1>-induced <e2>interleukin-5</e2> (IL-5) inhibition in allergic inflammation.","Downregulator"
"The aim of this study was to determine the mechanism of <e1>pranlukast</e1>-induced interleukin-5 (<e2>IL-5</e2>) inhibition in allergic inflammation.","Downregulator"
"<e1>Pranlukast</e1>, a <e2>leukotriene receptor</e2> antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.","Antagonist"
"<e1>Pranlukast</e1>, a <e2>leukotriene receptor</e2> antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.","Antagonist"
"BACKGROUND: <e1>Pranlukast</e1>, a <e2>cysteinyl leukotriene receptor 1</e2> (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.","Antagonist"
"BACKGROUND: <e1>Pranlukast</e1>, a cysteinyl leukotriene receptor 1 (<e2>CysLTR1</e2>) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.","Antagonist"
"CONCLUSION: Our results indicate that <e1>pranlukast</e1> inhibits IL-5 synthesis via a mechanism distinct from <e2>CysLTR1</e2> antagonism.","Antagonist"
"Due to its central role in the formation and stabilization of a thrombus, the <e2>P2Y12</e2> receptor is a well-established target of antithrombotic drugs like <e1>ticlopidine</e1> or clopidogrel, which have proved efficacy in many clinical trials and experimental models of thrombosis.","Regulator"
"Due to its central role in the formation and stabilization of a thrombus, the <e2>P2Y12</e2> receptor is a well-established target of antithrombotic drugs like ticlopidine or <e1>clopidogrel</e1>, which have proved efficacy in many clinical trials and experimental models of thrombosis.","Regulator"
"Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and <e2>ENT2</e2>, it was found that <e1>troglitazone</e1> inhibited ENT1 but had no effect on ENT2.","Not"
"The present study studied the effects of three <e1>thiazolidinediones</e1>, troglitazone, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Not"
"The effect of <e1>troglitazone</e1> on ENT1 was <e2>PPAR(gamma)</e2>-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1.","Not"
"<e1>Thiazolidinediones</e1> are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the <e2>peroxisome proliferator-activated receptor gamma</e2> (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.","Regulator"
"<e1>Thiazolidinediones</e1> are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (<e2>PPAR(gamma)</e2>) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.","Regulator"
"Although incubating HASMCs for 48h with thiazolidinediones had no effect on <e2>ENT1</e2> mRNA and protein levels, troglitazone acutely inhibited [3H]adenosine uptake and <e1>[3H]NBMPR</e1> binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.","Regulator"
"The present study studied the effects of three thiazolidinediones, <e1>troglitazone</e1>, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Regulator"
"Although incubating HASMCs for 48h with thiazolidinediones had no effect on <e2>ENT1</e2> mRNA and protein levels, troglitazone acutely inhibited <e1>[3H]adenosine</e1> uptake and [3H]NBMPR binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.","Regulator"
"The present study studied the effects of three thiazolidinediones, <e1>troglitazone</e1>, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Regulator"
"Effect of <e1>thiazolidinediones</e1> on <e2>equilibrative nucleoside transporter-1</e2> in human aortic smooth muscle cells.","Regulator"
"<e1>Thiazolidinediones</e1> are a new class of anti-diabetic agents which increase <e2>insulin</e2> sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.","Upregulator"
"<e1>Thiazolidinediones</e1> are a new class of anti-diabetic agents which increase <e2>insulin</e2> sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.","Upregulator"
"The present study studied the effects of three thiazolidinediones, <e1>troglitazone</e1>, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Downregulator"
"The present study studied the effects of three thiazolidinediones, <e1>troglitazone</e1>, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Downregulator"
"The present study studied the effects of three thiazolidinediones, <e1>troglitazone</e1>, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Downregulator"
"The present study studied the effects of three thiazolidinediones, <e1>troglitazone</e1>, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Downregulator"
"The present study studied the effects of three thiazolidinediones, <e1>troglitazone</e1>, pioglitazone and ciglitazone, on <e2>ENT1</e2> in the human aortic smooth muscle cells (HASMCs).","Downregulator"
"We also show that an intronic polymorphism in the <e2>SCN1A</e2> gene shows significant association with maximum doses in regular usage of both <e1>carbamazepine</e1> and phenytoin (P = 0.0051 and P = 0.014, respectively).","Regulator"
"We also show that an intronic polymorphism in the <e2>SCN1A</e2> gene shows significant association with maximum doses in regular usage of both carbamazepine and <e1>phenytoin</e1> (P = 0.0051 and P = 0.014, respectively).","Regulator"
"We report that a known functional polymorphism in <e2>CYP2C9</e2> is highly associated with the maximum dose of <e1>phenytoin</e1> (P = 0.0066).","Regulator"
"<e1>Phenytoin</e1> is principally metabolized by <e2>CYP2C9</e2>, and both are probable substrates of the drug transporter P-glycoprotein.","Substrate"
"<e1>Phenytoin</e1> is principally metabolized by CYP2C9, and both are probable substrates of the <e2>drug transporter</e2> P-glycoprotein.","Substrate"
"<e1>Phenytoin</e1> is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter <e2>P-glycoprotein</e2>.","Substrate"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Regulator"
"To evaluate whether <e1>fisetin</e1> regulates mTORC1 signaling, we investigated the phosphorylation and <e2>kinase</e2> activity of the 70-kDa ribosomal protein S6 kinase 1 (S6K1) and mTORC1 in 3T3-L1 preadipocytes.","Regulator"
"To evaluate whether <e1>fisetin</e1> regulates mTORC1 signaling, we investigated the phosphorylation and kinase activity of the <e2>70-kDa ribosomal protein S6 kinase 1</e2> (S6K1) and mTORC1 in 3T3-L1 preadipocytes.","Regulator"
"To evaluate whether <e1>fisetin</e1> regulates mTORC1 signaling, we investigated the phosphorylation and kinase activity of the 70-kDa ribosomal protein S6 kinase 1 (<e2>S6K1</e2>) and mTORC1 in 3T3-L1 preadipocytes.","Regulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Regulator"
"To evaluate whether <e1>fisetin</e1> regulates mTORC1 signaling, we investigated the phosphorylation and kinase activity of the 70-kDa ribosomal protein S6 kinase 1 (<e2>S6K1</e2>) and mTORC1 in 3T3-L1 preadipocytes.","Regulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTOR</e2>C1), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Regulator"
"To further our understanding of how <e1>fisetin</e1> negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and <e2>Akt</e2> in fisetin-treated TSC2-knockdown cells.","Regulator"
"<e1>Fisetin</e1> regulates obesity by targeting <e2>mTORC1</e2> signaling.","Regulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTOR</e2>C1), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Regulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Regulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of <e2>mammalian target of rapamycin complex 1</e2> (mTORC1), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Regulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Regulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Downregulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTOR</e2>C1), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Downregulator"
"To further our understanding of how <e1>fisetin</e1> negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and <e2>Akt</e2> in fisetin-treated TSC2-knockdown cells.","Downregulator"
"To evaluate whether <e1>fisetin</e1> regulates mTORC1 signaling, we investigated the phosphorylation and kinase activity of the 70-kDa ribosomal protein S6 kinase 1 (<e2>S6K1</e2>) and mTORC1 in 3T3-L1 preadipocytes.","Downregulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Downregulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Downregulator"
"<e1>Fisetin</e1> treatment of preadipocytes reduced the phosphorylation of <e2>S6K1</e2> and mTORC1 in a time- and concentration-dependent manner.","Downregulator"
"<e1>Fisetin</e1> regulates obesity by targeting <e2>mTORC1</e2> signaling.","Downregulator"
"In this study, we have demonstrated that <e1>fisetin</e1> prevents diet-induced obesity through regulation of the signaling of mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), a central mediator of cellular growth, cellular proliferation and lipid biosynthesis.","Downregulator"
"To further our understanding of how <e1>fisetin</e1> negatively regulates mTORC1 signaling, we analyzed the phosphorylation of S6K1, mTOR and <e2>Akt</e2> in fisetin-treated TSC2-knockdown cells.","Downregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and <e2>kinase</e2> activities 24 h after a 2-h exposure.","Upregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in <e2>cyclin E</e2> and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","Upregulator"
"Cyclin E-<e2>cdk2</e2> activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor <e1>Tomudex</e1>.","Upregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and <e2>kinase</e2> activities 24 h after a 2-h exposure.","Upregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in <e2>cyclin E</e2> and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","Upregulator"
"Cyclin E-<e2>cdk2</e2> activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor <e1>Tomudex</e1>.","Upregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in <e2>cyclin E</e2> and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","Upregulator"
"Cyclin E-<e2>cdk2</e2> activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor <e1>Tomudex</e1>.","Upregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in <e2>cyclin E</e2> and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","Upregulator"
"Cyclin E-<e2>cdk2</e2> activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor <e1>Tomudex</e1>.","Upregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in <e2>p27(kip1)</e2> expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","Downregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in <e2>p27(kip1)</e2> expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","Downregulator"
"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the <e2>thymidylate synthase</e2> inhibitor <e1>Tomudex</e1>.","Downregulator"
"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the <e2>thymidylate synthase</e2> inhibitor <e1>Tomudex</e1>.","Downregulator"
"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the <e2>thymidylate synthase</e2> inhibitor <e1>Tomudex</e1>.","Downregulator"
"<e1>Tomudex</e1> treatment resulted in the decrease in p27(kip1) expression, with an increase in <e2>cyclin E</e2> and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.","Downregulator"
"Cyclin E-<e2>cdk2</e2> activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor <e1>Tomudex</e1>.","Downregulator"
"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the <e2>thymidylate synthase</e2> inhibitor <e1>Tomudex</e1>.","Downregulator"
"Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the <e2>thymidylate synthase</e2> inhibitor <e1>Tomudex</e1>.","Downregulator"
"Excess lipids in peripheral tissues - skeletal muscle, liver and adipose tissue - may attenuate insulin signaling through the protein kinase B (AKt) pathway and up-regulate protein <e1>tyrosine</e1> phosphatase 1B (<e2>PTP1B</e2>), a negative regulator of insulin signaling.","Part_of"
"Unsaturated FFAs increased DAGs, TAGs and <e2>PTP1B</e2> expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at <e1>serine</e1> (Ser) 50, Ser 398 and tyrosine 152.","Part_of"
"Unsaturated FFAs increased DAGs, TAGs and <e2>PTP1B</e2> expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (<e1>Ser</e1>) 50, Ser 398 and tyrosine 152.","Part_of"
"Unsaturated FFAs increased DAGs, TAGs and <e2>PTP1B</e2> expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (<e1>Ser</e1>) 50, Ser 398 and tyrosine 152.","Part_of"
"Unsaturated FFAs increased DAGs, TAGs and <e2>PTP1B</e2> expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (<e1>Ser</e1>) 50, Ser 398 and tyrosine 152.","Part_of"
"Unsaturated FFAs increased DAGs, TAGs and <e2>PTP1B</e2> expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (<e1>Ser</e1>) 50, Ser 398 and tyrosine 152.","Part_of"
"Unsaturated FFAs increased DAGs, TAGs and <e2>PTP1B</e2> expression significantly, but cells remained insulin sensitive as assessed by robust AKt and PTP1B phosphorylation at serine (<e1>Ser</e1>) 50, Ser 398 and tyrosine 152.","Part_of"
"We studied accumulation of lipid metabolites [<e1>triglycerides</e1> (TAGs), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (<e1>TAGs</e1>), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), <e1>diglycerides</e1> (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (<e1>DAGs</e1>)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (DAGs)] and <e1>ceramides</e1> in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [<e1>triglycerides</e1> (TAGs), diglycerides (DAGs)] and ceramides in relation to <e2>insulin</e2> signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [<e1>triglycerides</e1> (TAGs), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (<e1>TAGs</e1>), diglycerides (DAGs)] and ceramides in relation to <e2>insulin</e2> signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (<e1>TAGs</e1>), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), <e1>diglycerides</e1> (DAGs)] and ceramides in relation to <e2>insulin</e2> signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), <e1>diglycerides</e1> (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (<e1>DAGs</e1>)] and ceramides in relation to <e2>insulin</e2> signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (<e1>DAGs</e1>)] and ceramides in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (DAGs)] and <e1>ceramides</e1> in relation to <e2>insulin</e2> signaling and expression and phosphorylation of PTP1B by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (DAGs)] and <e1>ceramides</e1> in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Regulator"
"Saturated <e1>palmitic and stearic acids</e1> increased ceramides, up-regulated <e2>PTP1B</e2>, and had AKt and PTP1B phosphorylation at Ser 50 impaired.","Upregulator"
"Saturated <e1>palmitic and stearic acids</e1> increased ceramides, up-regulated PTP1B, and had <e2>AKt</e2> and PTP1B phosphorylation at Ser 50 impaired.","Upregulator"
"Saturated <e1>palmitic and stearic acids</e1> increased ceramides, up-regulated <e2>PTP1B</e2>, and had AKt and PTP1B phosphorylation at Ser 50 impaired.","Upregulator"
"Cells were also evaluated in the presence of <e1>wortmannin</e1>, an inhibitor of phosphatidylinositol 3-kinases and thus <e2>AKt</e2> (0-100 nM).","Downregulator"
"Saturated palmitic and stearic acids increased <e1>ceramides</e1>, up-regulated PTP1B, and had <e2>AKt</e2> and PTP1B phosphorylation at Ser 50 impaired.","Downregulator"
"Cells were also evaluated in the presence of <e1>wortmannin</e1>, an inhibitor of <e2>phosphatidylinositol 3-kinases</e2> and thus AKt (0-100 nM).","Downregulator"
"We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (DAGs)] and <e1>ceramides</e1> in relation to insulin signaling and expression and phosphorylation of <e2>PTP1B</e2> by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 μM).","Downregulator"
"Indoleamine 2,3-dioxygenase (<e2>IDO</e2>), a <e1>tryptophan</e1> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.","Substrate"
"<e2>Indoleamine 2,3-dioxygenase</e2> (IDO), a <e1>tryptophan</e1> catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.","Substrate"
"Endothelial dysfunction induced by <e2>SIRT1</e2> inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor <e1>apocynin</e1> or superoxide dismutase.","Regulator"
"Inhibition of <e2>SIRT1</e2> significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by <e1>resveratrol</e1>.","Regulator"
"Inhibition of <e2>SIRT1</e2> significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by <e1>resveratrol</e1>.","Upregulator"
"SIRT1 co-precipitated with PPARα and <e1>nicotinamide</e1> increased the acetylation of the PPARα coactivator <e2>PGC-1α</e2>, which was suppressed by resveratrol.","Upregulator"
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced <e2>NADPH oxidase</e2> activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by <e1>resveratrol</e1>.","Downregulator"
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits <e2>p22(phox)</e2> and NOX4, which were prevented by <e1>resveratrol</e1>.","Downregulator"
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and <e2>NOX4</e2>, which were prevented by <e1>resveratrol</e1>.","Downregulator"
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced <e2>NADPH oxidase</e2> activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by <e1>resveratrol</e1>.","Downregulator"
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits <e2>p22(phox)</e2> and NOX4, which were prevented by <e1>resveratrol</e1>.","Downregulator"
"Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and <e2>NOX4</e2>, which were prevented by <e1>resveratrol</e1>.","Downregulator"
"To determine whether dysregulation of <e2>SIRT1</e2> promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (<e1>nicotinamide</e1>, sirtinol, EX527) in aorta segments isolated from young Wistar rats.","Downregulator"
"To determine whether dysregulation of <e2>SIRT1</e2> promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, <e1>sirtinol</e1>, EX527) in aorta segments isolated from young Wistar rats.","Downregulator"
"To determine whether dysregulation of <e2>SIRT1</e2> promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, <e1>EX527</e1>) in aorta segments isolated from young Wistar rats.","Downregulator"
"Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the <e2>NADPH oxidase</e2> inhibitor <e1>apocynin</e1> or superoxide dismutase.","Downregulator"
"SIRT1 co-precipitated with PPARα and nicotinamide increased the acetylation of the PPARα coactivator <e2>PGC-1α</e2>, which was suppressed by <e1>resveratrol</e1>.","Downregulator"
"To determine whether dysregulation of SIRT1 promotes <e2>NADPH oxidase</e2>-dependent production of reactive <e1>oxygen</e1> species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats.","Substrate"
"Endothelial dysfunction induced by <e2>SIRT1</e2> inhibition was prevented by treatment of the vessels with the NADPH oxidase inhibitor apocynin or <e1>superoxide</e1> dismutase.","Substrate"
"Correlations between matrices made it possible to conclude that EROD activity in PBL should be considered as a sensitive, convenient and non-destructive approach for (i) evaluating EROD activity in liver, which was found to represent 98% of the observed EROD activities in the three tested matrices and (ii) evaluating oral exposure of homogeneous groups of farm animals (race, diet) to <e2>CYP</e2> inducing PAH and <e1>PHH</e1>.","Regulator"
"<e2>EROD</e2> activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to <e1>polycyclic aromatic hydrocarbons</e1>.","Upregulator"
"Little is known in terms of multi-matrix <e2>cytochrome P450</e2> activity induction under repeated oral exposure to planar <e1>halogenated and polycyclic aromatic hydrocarbons</e1> (PHH, PAH).","Upregulator"
"Little is known in terms of multi-matrix <e2>cytochrome P450</e2> activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, <e1>PAH</e1>).","Upregulator"
"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor <e1>manumycin A</e1> caused elevation of <e2>ApoA-I</e2> secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.","Upregulator"
"Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor <e1>manumycin A</e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing <e2>hApoA-I</e2> and cholesterol ester transfer protein transgenes.","Upregulator"
"Repression of <e2>farnesyltransferase</e2> (FNTA) by siRNA and the enzyme inhibitor <e1>manumycin A</e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.","Downregulator"
"Repression of farnesyltransferase (<e2>FNTA</e2>) by siRNA and the enzyme inhibitor <e1>manumycin A</e1> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.","Downregulator"
"The potent and selective third-generation <e2>aromatase</e2> inhibitors anastrozole, <e1>letrozole</e1> and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.","Downregulator"
"<e1>Anastrozole</e1> and letrozole are both non-steroidal <e2>aromatase</e2> inhibitors that compete with the substrate for binding to the enzyme active site.","Downregulator"
"The potent and selective third-generation <e2>aromatase</e2> inhibitors anastrozole, <e1>letrozole</e1> and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.","Downregulator"
"The potent and selective third-generation <e2>aromatase</e2> inhibitors <e1>anastrozole</e1>, letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.","Downregulator"
"<e1>Estrogens</e1> are biosynthesised from androgens by the <e2>CYP450</e2> enzyme complex called aromatase.","Substrate"
"<e1>Estrogens</e1> are biosynthesised from androgens by the CYP450 enzyme complex called <e2>aromatase</e2>.","Substrate"
"In breast cancer, intratumoural <e2>aromatase</e2> is the source for local <e1>estrogen</e1> production in the tissue.","Substrate"
"Estrogens are biosynthesised from <e1>androgens</e1> by the CYP450 enzyme complex called <e2>aromatase</e2>.","Substrate"
"Identification and synthesis of <e1>N-(thiophen-2-yl) benzamide</e1> derivatives as <e2>BRAF</e2>(V600E) inhibitors.","Downregulator"
"Identification and synthesis of <e1>N-(thiophen-2-yl) benzamide</e1> derivatives as BRAF(<e2>V600E</e2>) inhibitors.","Downregulator"
"Identification and synthesis of <e1>N-(thiophen-2-yl) benzamide</e1> derivatives as <e2>BRAF</e2>(V600E) inhibitors.","Downregulator"
"Identification and synthesis of <e1>N-(thiophen-2-yl) benzamide</e1> derivatives as BRAF(<e2>V600E</e2>) inhibitors.","Downregulator"
"We begin by capturing <e2>RISC</e2> using a complementary <e1>2'-O-methyl</e1> oligonucleotide tethered to beads.","Regulator"
"<e1>Fluoride</e1> treatment also increased phosphorylation of JNK and ERK, but not <e2>p38</e2>, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.","Not"
"Exposure of cells to 4mM <e1>NaF</e1> for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of <e2>Bax</e2> to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.","Regulator"
"Exposure of cells to 4mM <e1>NaF</e1> for 24h induced caspase-3 activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of <e2>cytochrome c</e2> from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.","Regulator"
"<e1>Sodium fluoride</e1> induces apoptosis in odontoblasts via a <e2>JNK</e2>-dependent mechanism.","Regulator"
"Taken together, these findings suggest that <e1>NaF</e1> induces apoptosis in OLC odontoblasts through a <e2>JNK</e2>-dependent mitochondrial pathway.","Regulator"
"Exposure of cells to 4mM <e1>NaF</e1> for 24h induced <e2>caspase-3</e2> activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.","Upregulator"
"<e1>Fluoride</e1> treatment also increased phosphorylation of <e2>JNK</e2> and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.","Upregulator"
"<e1>Fluoride</e1> treatment also increased phosphorylation of JNK and <e2>ERK</e2>, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.","Upregulator"
"Furthermore, the <e2>Panx1</e2> channel blockers <e1>carbenoxolone</e1> and Probenecid were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed.","Downregulator"
"Furthermore, the <e2>Panx1</e2> channel blockers carbenoxolone and <e1>Probenecid</e1> were less effective in inhibiting Panx1 currents when Kvbeta3 was co-expressed.","Downregulator"
"<e1>(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one</e1> (KCA-1490) exhibits moderate dual <e2>PDE3/4</e2>-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent.","Downregulator"
"(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (<e1>KCA-1490</e1>) exhibits moderate dual <e2>PDE3/4</e2>-inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent.","Downregulator"
"<e1>N</e1>-alkylation of the pyridazinone ring markedly enhances potency against <e2>PDE4</e2> but suppresses PDE3 inhibition.","Downregulator"
"<e1>N</e1>-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses <e2>PDE3</e2> inhibition.","Downregulator"
"N-alkylation of the <e1>pyridazinone</e1> ring markedly enhances potency against <e2>PDE4</e2> but suppresses PDE3 inhibition.","Downregulator"
"N-alkylation of the <e1>pyridazinone</e1> ring markedly enhances potency against PDE4 but suppresses <e2>PDE3</e2> inhibition.","Downregulator"
"Addition of a <e1>6-aryl-4,5-dihydropyridazin-3(2H)-one</e1> extension to the N-alkyl group facilitates both enhancement of <e2>PDE4</e2>-inhibitory activity and restoration of potent PDE3 inhibition.","Downregulator"
"Addition of a <e1>6-aryl-4,5-dihydropyridazin-3(2H)-one</e1> extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent <e2>PDE3</e2> inhibition.","Downregulator"
"<e1>N</e1>-alkylation of the pyridazinone ring markedly enhances potency against <e2>PDE4</e2> but suppresses PDE3 inhibition.","Downregulator"
"<e1>N</e1>-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses <e2>PDE3</e2> inhibition.","Downregulator"
"The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X-ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a <e1>phenylalanine</e1> from the conserved <e2>FxxA interaction motif</e2> found in BRCA2.","Part_of"
"The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X-ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a <e1>phenylalanine</e1> from the conserved FxxA interaction motif found in <e2>BRCA2</e2>.","Part_of"
"Given that <e2>FRD</e2>, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (<e1>morantel</e1>, oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.","Downregulator"
"Given that <e2>FRD</e2>, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, <e1>oxantel</e1> and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.","Downregulator"
"Given that <e2>FRD</e2>, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, oxantel and <e1>thiabendazole</e1>), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.","Downregulator"
"Fumarate reductase (<e2>FRD</e2>) is the key enzyme in <e1>fumarate</e1> respiration induced by anaerobic growth of bacteria.","Substrate"
"<e2>Fumarate reductase</e2> (FRD) is the key enzyme in <e1>fumarate</e1> respiration induced by anaerobic growth of bacteria.","Substrate"
"The frdA gene coding for subunit A of FRD, and two control genes, <e2>copA</e2> and copP associated with the export of <e1>copper</e1> out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.","Substrate"
"The frdA gene coding for subunit A of FRD, and two control genes, copA and <e2>copP</e2> associated with the export of <e1>copper</e1> out of H. pylori, were inactivated by insertion of the chloramphenicol acetyltransferase cassette into these individual genes.","Substrate"
"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the <e1>tetrahydrobiopterin</e1> (BH4), the obligate cofactor for <e2>TPH</e2>.","Cofactor"
"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (<e1>BH4</e1>), the obligate cofactor for <e2>TPH</e2>.","Cofactor"
"To begin to examine whether these changes are mediated by alterations in gene expression for <e2>tryptophan hydroxylase</e2> (TPH), the rate-limiting enzyme in <e1>5-HT</e1> biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR).","Substrate"
"To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase (<e2>TPH</e2>), the rate-limiting enzyme in <e1>5-HT</e1> biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR).","Substrate"
"In contrast, there was little change in mRNA levels for <e2>GTP cyclohydrolase I</e2> (GTPCH), the rate limiting enzyme in synthesis of the <e1>tetrahydrobiopterin</e1> (BH4), the obligate cofactor for TPH.","Substrate"
"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (<e2>GTPCH</e2>), the rate limiting enzyme in synthesis of the <e1>tetrahydrobiopterin</e1> (BH4), the obligate cofactor for TPH.","Substrate"
"In contrast, there was little change in mRNA levels for <e2>GTP cyclohydrolase I</e2> (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (<e1>BH4</e1>), the obligate cofactor for TPH.","Substrate"
"In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (<e2>GTPCH</e2>), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (<e1>BH4</e1>), the obligate cofactor for TPH.","Substrate"
"In relation to <e1>zinc</e1> bioavailability, <e2>α-CPPs</e2>, β-CPPs, α(s1)-CN(64-74)4P and β-CN(1-25)4P increased zinc uptake.","Substrate"
"In relation to <e1>zinc</e1> bioavailability, α-CPPs, <e2>β-CPPs</e2>, α(s1)-CN(64-74)4P and β-CN(1-25)4P increased zinc uptake.","Substrate"
"A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (β-CN(1-25)4P, <e2>α(s1)-CN</e2>(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and <e1>zinc</e1> bioavailability (retention, transport and uptake of zinc) in Caco-2 cells.","Substrate"
"A study has been made of the influence of two pools of caseinophosphopeptides (CPPs) obtained from α(s)- and β-casein (CN) fractions, and of three specific CPPs (<e2>β-CN</e2>(1-25)4P, α(s1)-CN(64-74)4P and α(s2)-CN(1-19)4P), on iron bioavailability (ferritin synthesis) and <e1>zinc</e1> bioavailability (retention, transport and uptake of zinc) in Caco-2 cells.","Substrate"
"These illnesses are a result of <e1>saxitoxin</e1>'s ability to bind to the <e2>voltage-gated sodium channel</e2>, blocking the passage of nerve impulses and leading to death via respiratory paralysis.","Regulator"
"Recent advances in <e1>saxitoxin</e1> research are discussed, including the molecular biology of toxin synthesis, new protein targets, association with <e2>metal-binding motifs</e2> and methods of detection.","Regulator"
"Pulmonary delivery of an aerosolized recombinant human butyryl<e2>cholinesterase</e2> pretreatment protects against aerosolized <e1>paraoxon</e1> in macaques.","Upregulator"
"Key marker of diabetes in cells is the <e2>insulin dependent glucose transporter-4</e2> (Glut-4) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and <e1>palmatine</e1>, respectively.","Regulator"
"Key marker of diabetes in cells is the insulin dependent glucose transporter-4 (<e2>Glut-4</e2>) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and <e1>palmatine</e1>, respectively.","Regulator"
"Key marker of diabetes in cells is the <e2>insulin</e2> dependent glucose transporter-4 (Glut-4) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and <e1>palmatine</e1>, respectively.","Regulator"
"Key marker of diabetes in cells is the insulin dependent <e1>glucose</e1> transporter-4 (<e2>Glut-4</e2>) which also responds to exogenous chemicals, and is over expressed up to 5- and 4-fold, by Tinospora cordifolia and palmatine, respectively.","Substrate"
"These two antibodies recognize closely spaced epitopes on the 55 kD chain of the <e2>IL-2 R</e2>. IL-2 R expression was examined on peripheral blood small lymphocytes in three groups of patients who received: <e1>(A) cyclosporine</e1> CsA and prednisone for baseline immunosuppression (n = 9); (B) anti-Tac with CsA and prednisone as baseline immunosuppression (n = 12); and (C) anti-Tac with azathioprine and prednisone as baseline immunosuppression (n = 5).","Regulator"
"These two antibodies recognize closely spaced epitopes on the 55 kD chain of the <e2>IL-2 R</e2>. IL-2 R expression was examined on peripheral blood small lymphocytes in three groups of patients who received: (A) cyclosporine <e1>CsA</e1> and prednisone for baseline immunosuppression (n = 9); (B) anti-Tac with CsA and prednisone as baseline immunosuppression (n = 12); and (C) anti-Tac with azathioprine and prednisone as baseline immunosuppression (n = 5).","Regulator"
"These two antibodies recognize closely spaced epitopes on the 55 kD chain of the <e2>IL-2 R</e2>. IL-2 R expression was examined on peripheral blood small lymphocytes in three groups of patients who received: (A) cyclosporine CsA and <e1>prednisone</e1> for baseline immunosuppression (n = 9); (B) anti-Tac with CsA and prednisone as baseline immunosuppression (n = 12); and (C) anti-Tac with azathioprine and prednisone as baseline immunosuppression (n = 5).","Regulator"
"These two antibodies recognize closely spaced epitopes on the 55 kD chain of the <e2>IL-2 R</e2>. IL-2 R expression was examined on peripheral blood small lymphocytes in three groups of patients who received: (A) cyclosporine <e1>CsA</e1> and prednisone for baseline immunosuppression (n = 9); (B) anti-Tac with CsA and prednisone as baseline immunosuppression (n = 12); and (C) anti-Tac with azathioprine and prednisone as baseline immunosuppression (n = 5).","Regulator"
"These two antibodies recognize closely spaced epitopes on the 55 kD chain of the <e2>IL-2 R</e2>. IL-2 R expression was examined on peripheral blood small lymphocytes in three groups of patients who received: (A) cyclosporine CsA and <e1>prednisone</e1> for baseline immunosuppression (n = 9); (B) anti-Tac with CsA and prednisone as baseline immunosuppression (n = 12); and (C) anti-Tac with azathioprine and prednisone as baseline immunosuppression (n = 5).","Regulator"
"These two antibodies recognize closely spaced epitopes on the 55 kD chain of the <e2>IL-2 R</e2>. IL-2 R expression was examined on peripheral blood small lymphocytes in three groups of patients who received: (A) cyclosporine CsA and prednisone for baseline immunosuppression (n = 9); (B) anti-Tac with CsA and prednisone as baseline immunosuppression (n = 12); and (C) anti-Tac with <e1>azathioprine</e1> and prednisone as baseline immunosuppression (n = 5).","Regulator"
"These two antibodies recognize closely spaced epitopes on the 55 kD chain of the <e2>IL-2 R</e2>. IL-2 R expression was examined on peripheral blood small lymphocytes in three groups of patients who received: (A) cyclosporine CsA and <e1>prednisone</e1> for baseline immunosuppression (n = 9); (B) anti-Tac with CsA and prednisone as baseline immunosuppression (n = 12); and (C) anti-Tac with azathioprine and prednisone as baseline immunosuppression (n = 5).","Regulator"
"Both the <e2>5 alpha-reductase</e2> inhibitor <e1>finasteride</e1> and alpha 1-adrenoceptor antagonists (e.g.","Downregulator"
"Central <e2>5-HT3</e2> receptor stimulation by <e1>m-CPBG</e1> increases blood glucose in rats.","Regulator"
"Central <e2>5-HT3</e2> receptor stimulation by <e1>m-CPBG</e1> increases blood glucose in rats.","Upregulator"
"Central <e2>5-HT3</e2> receptor stimulation by <e1>m-CPBG</e1> increases blood glucose in rats.","Agonist"
"Central <e2>5-HT3</e2> receptor stimulation by <e1>m-CPBG</e1> increases blood glucose in rats.","Agonist"
"Guided by the <e2>acetylcholinesterase</e2> inhibiting activity, the <e1>bisindole alkaloid</e1> 3'-R/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory.","Downregulator"
"Guided by the <e2>acetylcholinesterase</e2> inhibiting activity, the bisindole alkaloid <e1>3'-R/S-hydroxyvoacamine</e1> was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory.","Downregulator"
"<e1>3'-R/S-Hydroxyvoacamine</e1>, a potent <e2>acetylcholinesterase</e2> inhibitor from Tabernaemontana divaricata.","Downregulator"
"In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of <e1>tunicamycin</e1>, higher fold change of <e2>TCF7L2</e2> and VEGFA mRNA levels were observed in rs7903146-TT cells than that in rs7903146-CC cells (P = 0.02 for TCF7L2; P = 0.004 for VEGFA), suggesting ER stress plays a role in PDR pathogenesis.","Regulator"
"In lymphoblastoid cells induced to undergo endoplasmic reticulum (ER) stress by treatment of <e1>tunicamycin</e1>, higher fold change of TCF7L2 and <e2>VEGFA</e2> mRNA levels were observed in rs7903146-TT cells than that in rs7903146-CC cells (P = 0.02 for TCF7L2; P = 0.004 for VEGFA), suggesting ER stress plays a role in PDR pathogenesis.","Regulator"
"<e1>α-Amino-α´-Halomethylketones</e1>: Synthetic Methodologies and Pharmaceutical Applications as <e2>Serine and Cysteine Protease</e2> Inhibitors.","Downregulator"
"Introduction: 5-Lipoxygenase (<e2>5-LO</e2>) is a crucial enzyme of the <e1>arachidonic acid</e1> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.","Substrate"
"Introduction: <e2>5-Lipoxygenase</e2> (5-LO) is a crucial enzyme of the <e1>arachidonic acid</e1> (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.","Substrate"
"These variants are expected to encode either a full length (<e2>OATP2B1-FL</e2>) or shortened protein lacking 22 <e1>N</e1>-terminus amino acids (OATP2B-Short).","Part_of"
"These variants are expected to encode either a full length (OATP2B1-FL) or shortened protein lacking 22 <e1>N</e1>-terminus amino acids (<e2>OATP2B-Short</e2>).","Part_of"
"These variants are expected to encode either a full length (<e2>OATP2B1-FL</e2>) or shortened protein lacking 22 N-terminus <e1>amino acids</e1> (OATP2B-Short).","Part_of"
"These variants are expected to encode either a full length (<e2>OATP2B1</e2>-FL) or shortened protein lacking 22 <e1>N</e1>-terminus amino acids (OATP2B-Short).","Part_of"
"Using a transient heterologous cell expression system, we find that the transport activities of the <e2>short OATP2B1</e2> variant towards substrates <e1>estrone sulfate</e1> and rosuvastatin are similar to the well-characterized full length variant.","Substrate"
"Using a transient heterologous cell expression system, we find that the transport activities of the <e2>short OATP2B1</e2> variant towards substrates estrone sulfate and <e1>rosuvastatin</e1> are similar to the well-characterized full length variant.","Substrate"
"While the neurobiological basis for the therapeutic activity of <e1>memantine</e1> is not fully understood, the drug is not a <e2>cholinesterase</e2> inhibitor and, therefore, acts differently from current AD therapies.","Not"
"<e1>Memantine</e1> can interact with a variety of <e2>ligand-gated ion channels</e2>.","Regulator"
"However, <e2>NMDA receptors</e2> appear to be a key target of <e1>memantine</e1> at therapeutic concentrations.","Regulator"
"Moreover, recent in vitro studies suggest that <e1>memantine</e1> abrogates <e2>beta-amyloid</e2> (Abeta) toxicity and possibly inhibits Abeta production.","Downregulator"
"Moreover, recent in vitro studies suggest that <e1>memantine</e1> abrogates beta-amyloid (<e2>Abeta</e2>) toxicity and possibly inhibits Abeta production.","Downregulator"
"Moreover, recent in vitro studies suggest that <e1>memantine</e1> abrogates beta-amyloid (<e2>Abeta</e2>) toxicity and possibly inhibits Abeta production.","Downregulator"
"However, <e2>NMDA receptors</e2> appear to be a key target of <e1>memantine</e1> at therapeutic concentrations.","Downregulator"
"However, <e2>NMDA receptor</e2>s appear to be a key target of <e1>memantine</e1> at therapeutic concentrations.","Downregulator"
"<e1>Memantine</e1> is an uncompetitive (channel blocking) <e2>NMDA receptor</e2> antagonist.","Antagonist"
"However, <e2>NMDA receptor</e2>s appear to be a key target of <e1>memantine</e1> at therapeutic concentrations.","Antagonist"
"However, <e2>NMDA receptor</e2>s appear to be a key target of <e1>memantine</e1> at therapeutic concentrations.","Antagonist"
"OBJECTIVETo describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in <e2>insulin</e2> sensitivity with <e1>thiazolidinediones</e1> and changes in renal threshold with sodium glucose transporter (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments.","Regulator"
"OBJECTIVETo describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with <e1>thiazolidinediones</e1> and changes in renal threshold with <e2>sodium glucose transporter</e2> (SGLT2) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments.","Regulator"
"OBJECTIVETo describe and make available an interactive, 24-variable homeostasis model assessment (iHOMA2) that extends the HOMA2 model, enabling the modeling of physiology and treatment effects, to present equations of the HOMA2 and iHOMA2 models, and to exemplify iHOMA2 in two widely differing scenarios: changes in insulin sensitivity with <e1>thiazolidinediones</e1> and changes in renal threshold with sodium glucose transporter (<e2>SGLT2</e2>) inhibition.RESEARCH DESIGN AND METHODSiHOMA2 enables a user of the available software to examine and modify the mathematical functions describing the organs and tissues involved in the glucose and hormonal compartments.","Regulator"
"The concomitantly administered effects of <e1>rifampicin</e1> on other drugs can result in their altered metabolism or transportation that are metabolised by <e2>cytochromes P450</e2> or transported by p-glycoprotein in the gastrointestinal tract and liver.","Regulator"
"In general, <e1>rifampicin</e1> can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, <e2>glucuronosyltransferases</e2> and p-glycoprotein activities.","Regulator"
"The concomitantly administered effects of <e1>rifampicin</e1> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by <e2>p-glycoprotein</e2> in the gastrointestinal tract and liver.","Regulator"
"In general, <e1>rifampicin</e1> can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, <e2>glucuronosyltransferases</e2> and p-glycoprotein activities.","Regulator"
"The concomitantly administered effects of <e1>rifampicin</e1> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by <e2>p-glycoprotein</e2> in the gastrointestinal tract and liver.","Regulator"
"The concomitantly administered effects of <e1>rifampicin</e1> on other drugs can result in their altered metabolism or transportation that are metabolised by <e2>cytochromes P450</e2> or transported by p-glycoprotein in the gastrointestinal tract and liver.","Regulator"
"Roles of <e1>rifampicin</e1> in drug-drug interactions: underlying molecular mechanisms involving the <e2>nuclear pregnane X receptor</e2>.","Regulator"
"Roles of <e1>rifampicin</e1> in drug-drug interactions: underlying molecular mechanisms involving the <e2>nuclear pregnane X receptor</e2>.","Upregulator"
"Roles of <e1>rifampicin</e1> in drug-drug interactions: underlying molecular mechanisms involving the <e2>nuclear pregnane X receptor</e2>.","Agonist"
"The concomitantly administered effects of <e1>rifampicin</e1> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by <e2>p-glycoprotein</e2> in the gastrointestinal tract and liver.","Substrate"
"The concomitantly administered effects of <e1>rifampicin</e1> on other drugs can result in their altered metabolism or transportation that are metabolised by <e2>cytochromes P450</e2> or transported by p-glycoprotein in the gastrointestinal tract and liver.","Substrate"
"A few compounds, <e1>17alpha-methyltestosterone</e1> (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the <e2>AR</e2> was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.","Regulator"
"A few compounds, 17alpha-methyltestosterone (<e1>17alpha-MT</e1>), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the <e2>AR</e2> was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.","Regulator"
"A few compounds, 17alpha-methyltestosterone (17alpha-MT), <e1>vinclozolin</e1> and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the <e2>AR</e2> was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.","Regulator"
"A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and <e1>linuron</e1>, were studied using a real world scenario, i.e., assuming that their interaction with the <e2>AR</e2> was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening.","Regulator"
"Experimental studies performed for characterizing the inhibitory mechanism indicate that <e2>GSK-3β</e2> inhibition by palinurin cannot be competed out by <e1>ATP</e1> nor peptide substrate.","Not"
"We describe here the isolation and biochemical characterization of the marine natural <e1>sesquiterpene</e1> palinurin as a <e2>GSK-3β</e2> inhibitor.","Downregulator"
"We describe here the isolation and biochemical characterization of the marine natural sesquiterpene <e1>palinurin</e1> as a <e2>GSK-3β</e2> inhibitor.","Downregulator"
"We describe here the isolation and biochemical characterization of the marine natural sesquiterpene <e1>palinurin</e1> as a <e2>GSK-3β</e2> inhibitor.","Downregulator"
"We describe here the isolation and biochemical characterization of the marine natural sesquiterpene <e1>palinurin</e1> as a <e2>GSK-3β</e2> inhibitor.","Downregulator"
"Evidence for a new binding mode to <e2>GSK-3</e2>: allosteric regulation by the marine compound <e1>palinurin</e1>.","Modulator"
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of <e2>p21</e2>(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib</e1>(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Upregulator"
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(<e2>WAF1</e2>/CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib</e1>(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Upregulator"
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/<e2>CIP1</e2>) and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib</e1>(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Upregulator"
"Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of <e2>cyclinB1</e2>, since these effects were prevented by <e1>rofecoxib</e1>(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Downregulator"
"Platelet-induced <e2>COX-2</e2>-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by <e1>rofecoxib</e1>(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Downregulator"
"<e2>Cyclooxygenase(COX)-2</e2>-derived <e1>prostanoids</e1> can influence several processes that are linked to carcinogenesis.","Substrate"
"Platelet-induced <e2>COX-2</e2>-dependent <e1>PGE2</e1> synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2.","Substrate"
"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either <e2>5-HT(1A)</e2> receptors by <e1>WAY100635</e1>, or 5-HT(2A/2C) receptors by ritanserin.","Downregulator"
"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or <e2>5-HT(2A/2C)</e2> receptors by <e1>ritanserin</e1>.","Downregulator"
"Previous studies demonstrated that the <e2>Group III mGlu receptor</e2>-selective orthosteric agonist, <e1>LSP1-2111</e1> produced anxiolytic- but not antidepressant-like effects upon peripheral administration.","Agonist"
"The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the <e2>benzodiazepine receptor</e2> antagonist <e1>flumazenil</e1> (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.","Antagonist"
"Anxiolytic- but not antidepressant-like activity of <e1>Lu AF21934</e1>, a novel, selective positive allosteric modulator of the <e2>mGlu₄</e2> receptor.","Modulator"
"Herein, we report the pharmacological actions of <e1>Lu AF21934</e1>, a novel, selective, and brain-penetrant positive allosteric modulator (PAM) of the <e2>mGlu(4)</e2> receptor in the stress-induced hyperthermia (SIH), four-plate, marble-burying and Vogel's conflict tests.","Modulator"
"Cocrystal structures of <e2>PDE5</e2> catalytic (C) domain with inhibitors reveal a hydrogen bond and hydrophobic interactions with <e1>Tyr</e1>-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5</e2> catalytic (C) domain with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with <e1>Gln</e1>-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5</e2> catalytic (C) domain with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by <e1>Phe</e1>-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5 catalytic (C) domain</e2> with inhibitors reveal a hydrogen bond and hydrophobic interactions with <e1>Tyr</e1>-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5 catalytic (C) domain</e2> with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with <e1>Gln</e1>-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5 catalytic (C) domain</e2> with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by <e1>Phe</e1>-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5 catalytic (C) domain</e2> with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and <e1>Val</e1>-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5 catalytic (C) domain</e2> with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with <e1>His</e1>-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5 catalytic (C) domain</e2> with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, <e1>Leu</e1>-765, and Phe-786 [Sung et al.","Part_of"
"Cocrystal structures of <e2>PDE5 catalytic (C) domain</e2> with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by <e1>Phe</e1>-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.","Part_of"
"Critical <e1>amino acids</e1> in <e2>phosphodiesterase-5</e2> catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.","Part_of"
"Affinity of <e2>V782A</e2> for cGMP, <e1>vardenafil</e1>, sildenafil, tadalafil, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.","Regulator"
"Affinity of <e2>V782A</e2> for cGMP, vardenafil, <e1>sildenafil</e1>, tadalafil, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.","Regulator"
"Affinity of <e2>V782A</e2> for cGMP, vardenafil, sildenafil, <e1>tadalafil</e1>, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.","Regulator"
"Affinity of <e2>V782A</e2> for cGMP, vardenafil, sildenafil, tadalafil, or <e1>IBMX</e1> was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.","Regulator"
"Change in affinity for <e1>cGMP</e1>, vardenafil, sildenafil, or IBMX in <e2>Y612F</e2>, H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for <e1>cGMP</e1>, vardenafil, sildenafil, or IBMX in Y612F, <e2>H613A</e2>, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for <e1>cGMP</e1>, vardenafil, sildenafil, or IBMX in Y612F, H613A, <e2>L765A</e2>, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for <e1>cGMP</e1>, vardenafil, sildenafil, or IBMX in Y612F, H613A, L765A, or <e2>F786A</e2> was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, <e1>vardenafil</e1>, sildenafil, or IBMX in <e2>Y612F</e2>, H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, <e1>vardenafil</e1>, sildenafil, or IBMX in Y612F, <e2>H613A</e2>, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, <e1>vardenafil</e1>, sildenafil, or IBMX in Y612F, H613A, <e2>L765A</e2>, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, <e1>vardenafil</e1>, sildenafil, or IBMX in Y612F, H613A, L765A, or <e2>F786A</e2> was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, <e1>sildenafil</e1>, or IBMX in <e2>Y612F</e2>, H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, <e1>sildenafil</e1>, or IBMX in Y612F, <e2>H613A</e2>, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, <e1>sildenafil</e1>, or IBMX in Y612F, H613A, <e2>L765A</e2>, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, <e1>sildenafil</e1>, or IBMX in Y612F, H613A, L765A, or <e2>F786A</e2> was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, sildenafil, or <e1>IBMX</e1> in <e2>Y612F</e2>, H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, sildenafil, or <e1>IBMX</e1> in Y612F, <e2>H613A</e2>, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, sildenafil, or <e1>IBMX</e1> in Y612F, H613A, <e2>L765A</e2>, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, sildenafil, or <e1>IBMX</e1> in Y612F, H613A, L765A, or <e2>F786A</e2> was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, sildenafil, or IBMX in Y612F, <e2>H613A</e2>, L765A, or F786A was less, but affinity of H613A or F786A for <e1>tadalafil</e1> was weakened 37- and 17-fold, respectively.","Regulator"
"Change in affinity for cGMP, vardenafil, sildenafil, or IBMX in Y612F, H613A, L765A, or <e2>F786A</e2> was less, but affinity of H613A or F786A for <e1>tadalafil</e1> was weakened 37- and 17-fold, respectively.","Regulator"
"The molecular bases for phosphodiesterase 5 (<e2>PDE5</e2>) catalytic-site affinity for cyclic guanosine monophosphate (<e1>cGMP</e1>) and potency of inhibitors are poorly understood.","Regulator"
"The molecular bases for phosphodiesterase 5 (<e2>PDE5</e2>) catalytic-site affinity for cyclic guanosine monophosphate (<e1>cGMP</e1>) and potency of inhibitors are poorly understood.","Regulator"
"Catalytic-site affinities for <e1>cGMP</e1>, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for <e2>Y612A</e2>; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for <e1>cGMP</e1>, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>Q817A</e2>; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for <e1>cGMP</e1>, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for <e2>F820A</e2>.","Regulator"
"Catalytic-site affinities for cGMP, <e1>vardenafil</e1>, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for <e2>Y612A</e2>; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, <e1>vardenafil</e1>, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>Q817A</e2>; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, <e1>vardenafil</e1>, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for <e2>F820A</e2>.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, <e1>sildenafil</e1>, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for <e2>Y612A</e2>; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, <e1>sildenafil</e1>, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>Q817A</e2>; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, <e1>sildenafil</e1>, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for <e2>F820A</e2>.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, <e1>tadalafil</e1>, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for <e2>Y612A</e2>; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, <e1>tadalafil</e1>, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for <e2>F820A</e2>.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or <e1>3-isobutyl-1-methylxanthine</e1> (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for <e2>Y612A</e2>; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or <e1>3-isobutyl-1-methylxanthine</e1> (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>Q817A</e2>; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or <e1>3-isobutyl-1-methylxanthine</e1> (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for <e2>F820A</e2>.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (<e1>IBMX</e1>) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for <e2>Y612A</e2>; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (<e1>IBMX</e1>) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>Q817A</e2>; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (<e1>IBMX</e1>) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for <e2>F820A</e2>.","Regulator"
"The molecular bases for <e2>phosphodiesterase 5</e2> (PDE5) catalytic-site affinity for <e1>cyclic guanosine monophosphate</e1> (cGMP) and potency of inhibitors are poorly understood.","Regulator"
"The molecular bases for phosphodiesterase 5 (<e2>PDE5</e2>) catalytic-site affinity for <e1>cyclic guanosine monophosphate</e1> (cGMP) and potency of inhibitors are poorly understood.","Regulator"
"The molecular bases for <e2>phosphodiesterase 5</e2> (PDE5) catalytic-site affinity for cyclic guanosine monophosphate (<e1>cGMP</e1>) and potency of inhibitors are poorly understood.","Regulator"
"The molecular bases for phosphodiesterase 5 (<e2>PDE5</e2>) catalytic-site affinity for cyclic guanosine monophosphate (<e1>cGMP</e1>) and potency of inhibitors are poorly understood.","Regulator"
"Critical amino acids in <e2>phosphodiesterase-5</e2> catalytic site that provide for high-affinity interaction with <e1>cyclic guanosine monophosphate</e1> and inhibitors.","Regulator"
"Affinity of <e2>V782A</e2> for <e1>cGMP</e1>, vardenafil, sildenafil, tadalafil, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.","Regulator"
"Catalytic-site affinities for cGMP, vardenafil, sildenafil, <e1>tadalafil</e1>, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for <e2>Q817A</e2>; and 59-, 448-, 71-, 137-, and 93-fold for F820A.","Substrate"
"The activation of the complement cascade, a cornerstone of the innate immune response, produces a number of small (74-77 <e1>amino acid</e1>) fragments, originally termed <e2>anaphylatoxins</e2>, that are potent chemoattractants and secretagogues that act on a wide variety of cell types.","Part_of"
"<e1>Allicin</e1> treatment showed reduced production of pro-inflammatory cytokines and NO and increased <e2>HO-1</e2> activity.","Upregulator"
"<e1>Allicin</e1> treatment showed reduced production of pro-inflammatory <e2>cytokines</e2> and NO and increased HO-1 activity.","Downregulator"
"Recently, it has been shown that the activation of particular <e2>T2R</e2> bitter taste receptors is partially involved with the bitter aftertaste sensation of <e1>saccharin</e1> and acesulfame-K. To more fully understand the biology behind these phenomena we have addressed the question of whether AS could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals.","Upregulator"
"Recently, it has been shown that the activation of particular <e2>T2R</e2> bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and <e1>acesulfame-K</e1>. To more fully understand the biology behind these phenomena we have addressed the question of whether AS could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals.","Upregulator"
"We also found that <e2>TRPV1</e2> receptors are activated by <e1>CuSO(4)</e1>, ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation.","Upregulator"
"We also found that <e2>TRPV1</e2> receptors are activated by CuSO(4), <e1>ZnSO(4)</e1>, and FeSO(4), three salts known to produce a metallic taste sensation.","Upregulator"
"We also found that <e2>TRPV1</e2> receptors are activated by CuSO(4), ZnSO(4), and <e1>FeSO(4)</e1>, three salts known to produce a metallic taste sensation.","Upregulator"
"<e1>2-Arylpropionic</e1> <e2>CXC chemokine receptor 1</e2> (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.","Regulator"
"<e1>2-Arylpropionic</e1> CXC chemokine receptor 1 (<e2>CXCR1</e2>) ligands as novel noncompetitive CXCL8 inhibitors.","Regulator"
"<e1>(R)-Ketoprofen</e1> (1) was previously reported to be a potent and specific noncompetitive inhibitor of <e2>CXCL8</e2>-induced human PMNs chemotaxis.","Downregulator"
"<e1>2-Arylpropionic</e1> CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive <e2>CXCL8</e2> inhibitors.","Downregulator"
"Role of organic cation/carnitine transporter 1 in uptake of <e1>phenformin</e1> and inhibitory effect on <e2>complex I</e2> respiration in mitochondria.","Downregulator"
"Role of organic cation/carnitine transporter 1 in uptake of <e1>phenformin</e1> and inhibitory effect on <e2>complex I</e2> respiration in mitochondria.","Downregulator"
"<e1>Phenformin</e1> causes lactic acidosis in clinical situations due to inhibition of <e2>mitochondrial respiratory chain complex I</e2>.","Downregulator"
"Role of organic cation/carnitine transporter 1 in uptake of <e1>phenformin</e1> and inhibitory effect on <e2>complex I</e2> respiration in mitochondria.","Downregulator"
"Role of organic cation/carnitine transporter 1 in uptake of <e1>phenformin</e1> and inhibitory effect on <e2>complex I</e2> respiration in mitochondria.","Downregulator"
"Role of organic cation/carnitine transporter 1 in uptake of <e1>phenformin</e1> and inhibitory effect on <e2>complex I</e2> respiration in mitochondria.","Downregulator"
"Role of <e2>organic cation/carnitine transporter 1</e2> in uptake of <e1>phenformin</e1> and inhibitory effect on complex I respiration in mitochondria.","Substrate"
"Similar characteristics were also observed for uptake of TEA; however, uptake of <e1>phenformin</e1> into mitochondria of organic cation/carnitine transporter 1 (<e2>OCTN1</e2>) knockout mice was lower than that in wild-type mice, whereas uptake of TEA was comparable between the two strains, suggesting the involvement of distinct transport mechanisms for these two cations in mitochondria.","Substrate"
"Synthesis and biological evaluation of <e1>xanthine</e1> derivatives on <e2>dipeptidyl peptidase 4</e2>.","Downregulator"
"A series of <e1>xanthine</e1> derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (<e2>DPP-4</e2>) for the treatment of type 2 diabetes.","Downregulator"
"Synthesis and biological evaluation of <e1>xanthine</e1> derivatives on <e2>dipeptidyl peptidase 4</e2>.","Downregulator"
"A series of <e1>xanthine</e1> derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (<e2>DPP-4</e2>) for the treatment of type 2 diabetes.","Downregulator"
"5-HT1B receptors, alpha2A/2C- and, to a lesser extent, <e2>alpha1-adrenoceptors</e2> mediate the external carotid vasoconstriction to <e1>ergotamine</e1> in vagosympathectomised dogs.","Regulator"
"<e2>5-HT1B</e2> receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to <e1>ergotamine</e1> in vagosympathectomised dogs.","Regulator"
"It has previously been suggested that <e1>ergotamine</e1> produces external carotid vasoconstriction in vagosympathectomised dogs via <e2>5-HT1B/1D</e2> receptors and alpha2-adrenoceptors.","Regulator"
"It has previously been suggested that <e1>ergotamine</e1> produces external carotid vasoconstriction in vagosympathectomised dogs via 5-HT1B/1D receptors and <e2>alpha2-adrenoceptors</e2>.","Regulator"
"<e2>5-HT1B</e2> receptors, alpha2A/2C- and, to a lesser extent, alpha1-adrenoceptors mediate the external carotid vasoconstriction to <e1>ergotamine</e1> in vagosympathectomised dogs.","Regulator"
"5-HT1B receptors, alpha2A/2C- and, to a lesser extent, <e2>alpha1-adrenoceptors</e2> mediate the external carotid vasoconstriction to <e1>ergotamine</e1> in vagosympathectomised dogs.","Regulator"
"bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists <e1>SB224289</e1> (300 microg/kg; <e2>5-HT1B</e2>), BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).","Antagonist"
"bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B), <e1>BRL15572</e1> (300 microg/kg; <e2>5-HT1D</e2>), rauwolscine (300 microg/kg; alpha2), SB224289 + BRL15572 (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C).","Antagonist"
"In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the <e2>dopamine D2</e2> agonist <e1>apomorphine</e1>; however, it is not clear whether both findings share the same biological basis.","Agonist"
"Functional and biochemical studies indicated that <e1>TES</e1> signaling involved activity of the <e2>phosphoinositide 3 (PI3) kinase</e2>-protein kinase B (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation.","Regulator"
"Functional and biochemical studies indicated that <e1>TES</e1> signaling involved activity of the phosphoinositide 3 (PI3) kinase-<e2>protein kinase B</e2> (Akt) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation.","Regulator"
"Functional and biochemical studies indicated that <e1>TES</e1> signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (<e2>Akt</e2>) cascade initiated by activation of the androgen receptor and culminated in enhanced production of cGMP and microvascular vasodilation.","Regulator"
"Functional and biochemical studies indicated that <e1>TES</e1> signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the <e2>androgen receptor</e2> and culminated in enhanced production of cGMP and microvascular vasodilation.","Upregulator"
"As predicted, TES enhanced the production of both <e1>peroxynitrite</e1> precursors (i.e., superoxide and nitic oxide), and <e2>xanthine oxidase</e2> was identified as the likely source of TES-stimulated superoxide production.","Substrate"
"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., <e1>superoxide</e1> and nitic oxide), and <e2>xanthine oxidase</e2> was identified as the likely source of TES-stimulated superoxide production.","Substrate"
"These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from <e2>xanthine oxidase</e2>-generated superoxide and <e1>NO</e1>.","Substrate"
"As predicted, <e1>TES</e1> enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and <e2>xanthine oxidase</e2> was identified as the likely source of TES-stimulated superoxide production.","Substrate"
"As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., <e1>superoxide</e1> and nitic oxide), and <e2>xanthine oxidase</e2> was identified as the likely source of TES-stimulated superoxide production.","Substrate"
"D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the '<e1>glycine</e1>' site of the <e2>N-methyl-D-aspartate (NMDA)-type receptors</e2>.","Part_of"
"<e1>D-Serine</e1> was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the <e2>N-methyl-D-aspartate (NMDA)-type receptors</e2>.","Agonist"
"Racemization of serine is catalyzed by <e2>serine racemase</e2>, a <e1>pyridoxal 5'-phosphate</e1>-dependent enzyme expressed mainly in brain and liver.","Cofactor"
"<e2>Mouse brain serine racemase</e2> catalyzes specific elimination of L-serine to <e1>pyruvate</e1>.","Substrate"
"<e2>Mouse brain serine racemase</e2> catalyzes specific elimination of <e1>L-serine</e1> to pyruvate.","Substrate"
"Mouse brain <e1>serine</e1> racemase catalyzes specific elimination of L-serine to pyruvate.","Substrate"
"In addition to the <e1>N</e1>-terminal and <e2>Src homology 2 domains</e2> that mediate these interactions, SOCS proteins contain a C-terminal SOCS box.","Part_of"
"In addition to the N-terminal and Src homology 2 domains that mediate these interactions, SO<e1>C</e1>S proteins contain a C-terminal <e2>SOCS box</e2>.","Part_of"
"Pharmacogenetic analysis of two genes, the <e1>warfarin</e1> metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 <e2>VKORC1</e2>, confirmed their influence on warfarin maintenance dose.","Regulator"
"<e1>Warfarin</e1> dose and the pharmacogenomics of <e2>CYP2C9</e2> and VKORC1 - rationale and perspectives.","Regulator"
"<e1>Warfarin</e1> dose and the pharmacogenomics of CYP2C9 and <e2>VKORC1</e2> - rationale and perspectives.","Regulator"
"Pharmacogenetic analysis of two genes, the <e1>warfarin</e1> metabolic enzyme CYP2C9 and warfarin target enzyme, <e2>vitamin K epoxide reductase complex 1</e2> VKORC1, confirmed their influence on warfarin maintenance dose.","Regulator"
"Pharmacogenetic analysis of two genes, the <e1>warfarin</e1> metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 <e2>VKORC1</e2>, confirmed their influence on warfarin maintenance dose.","Regulator"
"Pharmacogenetic analysis of two genes, the <e1>warfarin</e1> metabolic enzyme <e2>CYP2C9</e2> and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.","Substrate"
"Pharmacogenetic analysis of two genes, the <e1>warfarin</e1> metabolic enzyme <e2>CYP2C9</e2> and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.","Substrate"
"Pharmacogenetic analysis of two genes, the <e1>warfarin</e1> metabolic enzyme <e2>CYP2C9</e2> and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.","Substrate"
"To further characterize the inhibitory mechanisms of <e1>PSE</e1> at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic <e2>NF-kappaB inhibitory protein</e2>, IkappaBalpha or the DNA-binding activity.","Not"
"To further characterize the inhibitory mechanisms of <e1>PSE</e1> at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, <e2>IkappaBalpha</e2> or the DNA-binding activity.","Not"
"To further characterize the inhibitory mechanisms of <e1>PSE</e1> at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (<e2>NFAT</e2>), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.","Not"
"In addition, PSE inhibited the transcriptional activity of <e2>NFAT</e2> without interfering with the <e1>calcium</e1>-induced NFAT dephosphorylation event, which represents the major signaling pathway for its activation.","Upregulator"
"We found that <e1>PSE</e1> inhibits interleukin-2 (IL-2) and <e2>tumor necrosis factor (TNF) alpha</e2>-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.","Upregulator"
"We found that <e1>PSE</e1> inhibits <e2>interleukin-2</e2> (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.","Downregulator"
"We found that <e1>PSE</e1> inhibits interleukin-2 (<e2>IL-2</e2>) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.","Downregulator"
"To further characterize the inhibitory mechanisms of <e1>PSE</e1> at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (<e2>NF-kappaB</e2>), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.","Downregulator"
"<e1>Pseudoephedrine</e1> inhibits T-cell activation by targeting <e2>NF-kappaB</e2>, NFAT and AP-1 signaling pathways.","Downregulator"
"<e1>Pseudoephedrine</e1> inhibits T-cell activation by targeting NF-kappaB, <e2>NFAT</e2> and AP-1 signaling pathways.","Downregulator"
"<e1>Pseudoephedrine</e1> inhibits T-cell activation by targeting NF-kappaB, NFAT and <e2>AP-1</e2> signaling pathways.","Downregulator"
"However, phosphorylation of the <e2>p65</e2>/RelA subunit was clearly inhibited by <e1>PSE</e1> in stimulated cells.","Downregulator"
"However, phosphorylation of the p65/<e2>RelA</e2> subunit was clearly inhibited by <e1>PSE</e1> in stimulated cells.","Downregulator"
"To further characterize the inhibitory mechanisms of <e1>PSE</e1> at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (<e2>NFAT</e2>), and activator protein-1 (AP-1) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.","Downregulator"
"NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that <e1>PSE</e1> inhibited both <e2>JNK</e2> activation and AP-1 transcriptional activity.","Downregulator"
"To further characterize the inhibitory mechanisms of <e1>PSE</e1> at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and activator protein-1 (<e2>AP-1</e2>) transcription factors and found that PSE inhibited NF-kappaB-dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic NF-kappaB inhibitory protein, IkappaBalpha or the DNA-binding activity.","Downregulator"
"Here we have investigated the contribution of the nitric oxide and <e2>cyclooxygenase</e2> (COX) pathways to the activity of <e1>DEC</e1> against B. malayi microfilariae in mice.","Regulator"
"Here we have investigated the contribution of the nitric oxide and cyclooxygenase (<e2>COX</e2>) pathways to the activity of <e1>DEC</e1> against B. malayi microfilariae in mice.","Regulator"
"Western blot analysis was used to determine any effect of <e1>DEC</e1> on the production of COX and inducible <e2>nitric-oxide synthase</e2> (iNOS) proteins.","Regulator"
"To investigate a role for inducible nitric oxide in <e1>DEC</e1>'s activity, DEC and ivermectin were administered to microfilaraemic <e2>iNOS</e2>-/- mice and their background strain (129/SV).","Regulator"
"<e1>Diethylcarbamazine</e1> activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the <e2>cyclooxygenase</e2> pathway.","Regulator"
"<e1>Diethylcarbamazine</e1> activity against Brugia malayi microfilariae is dependent on <e2>inducible nitric-oxide synthase</e2> and the cyclooxygenase pathway.","Regulator"
"Pre-treatment of animals with <e1>dexamethasone</e1> or indomethacin reduced DEC's efficacy by almost 90% or 56%, respectively, supporting a role for the arachidonic acid and <e2>cyclooxygenase</e2> pathways in vivo.","Regulator"
"Pre-treatment of animals with dexamethasone or <e1>indomethacin</e1> reduced DEC's efficacy by almost 90% or 56%, respectively, supporting a role for the arachidonic acid and <e2>cyclooxygenase</e2> pathways in vivo.","Regulator"
"Furthermore, experiments showed that treatment with <e1>DEC</e1> results in a reduction in the amount of <e2>COX-1</e2> protein in peritoneal exudate cells.","Downregulator"
"<e1>N</e1>tp and Ctp, synthetic peptides based on the N- and C-terminal sequences of <e2>K(IR)</e2>6.0, respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels.","Part_of"
"<e1>N</e1>tp and Ctp, synthetic peptides based on the N- and C-terminal sequences of <e2>K(IR)</e2>6.0, respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels.","Part_of"
"<e1>N</e1>tp and Ctp, synthetic peptides based on the N- and C-terminal sequences of <e2>K(IR)6.0</e2>, respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels.","Part_of"
"Ntp and <e1>C</e1>tp, synthetic peptides based on the N- and C-terminal sequences of <e2>K(IR)6.0</e2>, respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels.","Part_of"
"<e1>N</e1>tp and Ctp, synthetic peptides based on the N- and C-terminal sequences of <e2>K(IR)6.0</e2>, respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels.","Part_of"
"SUR-dependent modulation of KATP channels by an <e1>N</e1>-terminal <e2>KIR6.2</e2> peptide.","Part_of"
"<e1>N</e1>tp and Ctp, synthetic peptides based on the N- and C-terminal sequences of <e2>K(IR)</e2>6.0, respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels.","Part_of"
"The L0 linker has been reported to be required for glibenclamide binding, and <e2>DeltaNK(IR)6.2</e2>/SUR1 channels exhibit reduced labeling of K(IR) with <e1>(125)I-azidoglibenclamide</e1>, implying that the K(IR) N terminus and L0 of SUR1 are in proximity.","Regulator"
"The L0 linker has been reported to be required for glibenclamide binding, and DeltaNK(IR)6.2/<e2>SUR1</e2> channels exhibit reduced labeling of K(IR) with <e1>(125)I-azidoglibenclamide</e1>, implying that the K(IR) N terminus and L0 of SUR1 are in proximity.","Regulator"
"The L0 linker has been reported to be required for glibenclamide binding, and DeltaN<e2>K(IR)</e2>6.2/SUR1 channels exhibit reduced labeling of K(IR) with <e1>(125)I-azidoglibenclamide</e1>, implying that the K(IR) N terminus and L0 of SUR1 are in proximity.","Regulator"
"Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity <e1>sulfonylurea</e1> binding with <e2>K(ATP)</e2> pore closure.","Regulator"
"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the <e1>ATP</e1> inhibition of <e2>K(IR)6.2</e2>/SUR1, but had no effect on homomeric K(IR)6.2 channels.","Downregulator"
"Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the <e1>ATP</e1> inhibition of K(IR)6.2/<e2>SUR1</e2>, but had no effect on homomeric K(IR)6.2 channels.","Downregulator"
"These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(<e1>ATP</e1>) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+).","Downregulator"
"<e2>Monocarboxylate transporters</e2> (MCTs) are proton-linked membrane carriers involved in the transport of <e1>monocarboxylates</e1> such as lactate, pyruvate, as well as ketone bodies.","Substrate"
"Monocarboxylate transporters (<e2>MCTs</e2>) are proton-linked membrane carriers involved in the transport of <e1>monocarboxylates</e1> such as lactate, pyruvate, as well as ketone bodies.","Substrate"
"<e2>Monocarboxylate transporters</e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as <e1>lactate</e1>, pyruvate, as well as ketone bodies.","Substrate"
"Monocarboxylate transporters (<e2>MCTs</e2>) are proton-linked membrane carriers involved in the transport of monocarboxylates such as <e1>lactate</e1>, pyruvate, as well as ketone bodies.","Substrate"
"<e2>Monocarboxylate transporters</e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <e1>pyruvate</e1>, as well as ketone bodies.","Substrate"
"Monocarboxylate transporters (<e2>MCTs</e2>) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, <e1>pyruvate</e1>, as well as ketone bodies.","Substrate"
"<e2>Monocarboxylate transporters</e2> (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <e1>ketone</e1> bodies.","Substrate"
"Monocarboxylate transporters (<e2>MCTs</e2>) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as <e1>ketone</e1> bodies.","Substrate"
"Interestingly, part of <e2>MCT2</e2> immunoreactivity is located at postsynaptic sites, suggesting a particular role of <e1>monocarboxylates</e1> and their transporters in synaptic transmission.","Substrate"
"<e1>LY541850</e1> was claimed from <e2>human mGlu receptors</e2> expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and mGlu3 antagonist.","Regulator"
"Differentiating the roles of <e2>mGlu2</e2> and mGlu3 receptors using <e1>LY541850</e1>, an mGlu2 agonist/mGlu3 antagonist.","Agonist"
"Differentiating the roles of <e2>mGlu2</e2> and mGlu3 receptors using <e1>LY541850</e1>, an mGlu2 agonist/mGlu3 antagonist.","Agonist"
"Differentiating the roles of <e2>mGlu2</e2> and mGlu3 receptors using <e1>LY541850</e1>, an mGlu2 agonist/mGlu3 antagonist.","Agonist"
"Differentiating the roles of mGlu2 and <e2>mGlu3</e2> receptors using <e1>LY541850</e1>, an mGlu2 agonist/mGlu3 antagonist.","Antagonist"
"Differentiating the roles of mGlu2 and <e2>mGlu3</e2> receptors using <e1>LY541850</e1>, an mGlu2 agonist/mGlu3 antagonist.","Antagonist"
"Differentiating the roles of mGlu2 and <e2>mGlu3</e2> receptors using <e1>LY541850</e1>, an mGlu2 agonist/mGlu3 antagonist.","Antagonist"
"However, due to the very high affinity of <e2>CBG</e2> for <e1>corticosterone</e1> at 4 C, this slight contamination resulted in significant alterations in the apparent affinity of steroids competing for aldosterone-binding sites.","Regulator"
"Characterization of <e2>rat brain aldosterone receptors</e2> reveals high affinity for <e1>corticosterone</e1>.","Regulator"
"Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of <e1>steroid</e1> binding similar to that of the kidney <e2>mineralocorticoid receptor</e2> (aldosterone greater than desoxycorticosterone greater than corticosterone).","Regulator"
"Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of steroid binding similar to that of the kidney <e2>mineralocorticoid receptor</e2> (<e1>aldosterone</e1> greater than desoxycorticosterone greater than corticosterone).","Regulator"
"Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of steroid binding similar to that of the kidney <e2>mineralocorticoid receptor</e2> (aldosterone greater than <e1>desoxycorticosterone</e1> greater than corticosterone).","Regulator"
"Selective precipitation of cytosol receptors with 36% <e1>(NH4)2SO4</e1> reduced <e2>CBG</e2> concentrations to negligible levels.","Downregulator"
"<e2>SSTR2</e2> and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both <e1>octreotide</e1> and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5.","Regulator"
"SSTR2 and <e2>SSTR5</e2> are usually expressed in GH-secreting pituitary tumors, and both <e1>octreotide</e1> and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5.","Regulator"
"<e2>SSTR2</e2> and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and <e1>lanreotide</e1> bind preferentially to SSTR2 and, to a lesser extent, to SSTR5.","Regulator"
"SSTR2 and <e2>SSTR5</e2> are usually expressed in GH-secreting pituitary tumors, and both octreotide and <e1>lanreotide</e1> bind preferentially to SSTR2 and, to a lesser extent, to SSTR5.","Regulator"
"The activity of the human nasal mucosa microsomes was inhibited by <e1>8-methoxypsoralen</e1>, a known <e2>CYP2A</e2> inhibitor.","Downregulator"
"<e2>Acetylcholinesterase</e2> (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by <e1>oximes</e1> due to dealkylation of the soman-enzyme complex.","Upregulator"
"Acetylcholinesterase (<e2>AChE</e2>) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by <e1>oximes</e1> due to dealkylation of the soman-enzyme complex.","Upregulator"
"Acetylcholinesterase (<e2>AChE</e2>) inhibited by the organophosphate <e1>soman</e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"<e2>Acetylcholinesterase</e2> (AChE) inhibited by the <e1>organophosphate</e1> soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"Acetylcholinesterase (<e2>AChE</e2>) inhibited by the <e1>organophosphate</e1> soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"<e2>Acetylcholinesterase</e2> (AChE) inhibited by the organophosphate <e1>soman</e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"Acetylcholinesterase (<e2>AChE</e2>) inhibited by the organophosphate <e1>soman</e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"<e2>Acetylcholinesterase</e2> (AChE) inhibited by the organophosphate soman (<e1>1,2,2-trimethyl-propylmethylphosphonofluoridate</e1>) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"Acetylcholinesterase (<e2>AChE</e2>) inhibited by the organophosphate soman (<e1>1,2,2-trimethyl-propylmethylphosphonofluoridate</e1>) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of <e1>soman</e1>-inhibited <e2>human acetylcholinesterase</e2> in vitro.","Downregulator"
"Acetylcholinesterase (<e2>AChE</e2>) inhibited by the organophosphate <e1>soman</e1> (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.","Downregulator"
"In the current studies, we show that two different classes (<e1>ATP</e1>-sensitive and -insensitive) of <e2>TOP2</e2> poisons can be identified based on their differential sensitivity to the ATP-bound conformation of TOP2.","Regulator"
"Third, using <e1>ciprofloxacin</e1> competition assay, <e2>TOP2</e2>-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive poisons was shown to be antagonized by ciprofloxacin.","Regulator"
"Third, using <e1>ciprofloxacin</e1> competition assay, <e2>TOP2</e2>-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive poisons was shown to be antagonized by ciprofloxacin.","Regulator"
"In the current studies, we show that two different classes (<e1>ATP</e1>-sensitive and -insensitive) of <e2>TOP2</e2> poisons can be identified based on their differential sensitivity to the ATP-bound conformation of TOP2.","Regulator"
"In the current studies, we show that two different classes (<e1>ATP</e1>-sensitive and -insensitive) of <e2>TOP2</e2> poisons can be identified based on their differential sensitivity to the ATP-bound conformation of TOP2.","Regulator"
"In the current studies, we show that two different classes (<e1>ATP</e1>-sensitive and -insensitive) of <e2>TOP2</e2> poisons can be identified based on their differential sensitivity to the ATP-bound conformation of TOP2.","Regulator"
"In addition, <e1>ADP</e1> was shown to strongly antagonize <e2>TOP2</e2>-mediated DNA cleavage induced by ATP-sensitive but not ATP-insensitive TOP2 poisons.","Regulator"
"In the current studies, we show that two different classes (<e1>ATP</e1>-sensitive and -insensitive) of <e2>TOP2</e2> poisons can be identified based on their differential sensitivity to the ATP-bound conformation of TOP2.","Upregulator"
"Second, C427A mutant human TOP2alpha, which exhibits reduced <e1>ATP</e1>ase activity, was shown to exhibit cross-resistance to all ATP-sensitive but not ATP-insensitive TOP2 poisons.","Downregulator"
"<e1>doxorubicin</e1>, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"<e1>doxorubicin</e1>, etoposide, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"doxorubicin, <e1>etoposide</e1>, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"doxorubicin, <e1>etoposide</e1>, mitoxantrone, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"doxorubicin, etoposide, <e1>mitoxantrone</e1>, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"doxorubicin, etoposide, <e1>mitoxantrone</e1>, and 4'-(9-acridinylamino)methanesulfon-m-anisidide) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"doxorubicin, etoposide, mitoxantrone, and <e1>4'-(9-acridinylamino)methanesulfon-m-anisidide</e1>) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"doxorubicin, etoposide, mitoxantrone, and <e1>4'-(9-acridinylamino)methanesulfon-m-anisidide</e1>) was 30-100-fold stimulated, whereas DNA cleavage induced by ATP-insensitive <e2>TOP2</e2> poisons (e.g.","Downregulator"
"Activation of <e2>ALDH2</e2> with <e1>ethanol</e1> attenuates diabetes induced myocardial injury in rats.","Upregulator"
"Activation of <e2>ALDH2</e2> with <e1>ethanol</e1> attenuates diabetes induced myocardial injury in rats.","Upregulator"
"This study assessed changes in myocardial <e2>ALDH2</e2> expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (<e1>EtOH</e1>).","Upregulator"
"Compared with DM8W group, <e2>SOD</e2> and ALDH2 in <e1>EtOH</e1>+DM8W group was increased, MDA was decreased.","Upregulator"
"This study assessed changes in myocardial <e2>ALDH2</e2> expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (<e1>EtOH</e1>).","Upregulator"
"<e2>HbA1c</e2> level in DM12W group was higher than in DM4W group, HbA1c level in <e1>EtOH</e1>+DM8W group was lower than in DM8W group.","Downregulator"
"<e2>Quinone oxidoreductase 2</e2> (QR2) purified from human red blood cells was recently shown to be a potential target of the <e1>quinoline</e1> antimalarial compounds [Graves et al., (2002) Mol.","Regulator"
"Quinone oxidoreductase 2 (<e2>QR2</e2>) purified from human red blood cells was recently shown to be a potential target of the <e1>quinoline</e1> antimalarial compounds [Graves et al., (2002) Mol.","Regulator"
"To investigate the mechanism and consequences of inhibition of <e2>QR2</e2> by the <e1>quinolines</e1> further, we have used steady-state and transient-state kinetics to define the mechanism of QR2.","Downregulator"
"To investigate the mechanism and consequences of inhibition of <e2>QR2</e2> by the <e1>quinolines</e1> further, we have used steady-state and transient-state kinetics to define the mechanism of QR2.","Downregulator"
"Kinetic mechanism of <e2>quinone oxidoreductase 2</e2> and its inhibition by the antimalarial <e1>quinolines</e1>.","Downregulator"
"To investigate the mechanism and consequences of inhibition of <e2>QR2</e2> by the <e1>quinolines</e1> further, we have used steady-state and transient-state kinetics to define the mechanism of QR2.","Downregulator"
"<e2>QR2</e2> catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or <e1>N-ribosylated nicotinamides</e1>.","Substrate"
"<e2>QR2</e2> catalyzes the two-electron reduction of <e1>menadione</e1> via the oxidation of N-alkylated or N-ribosylated nicotinamides.","Substrate"
"<e2>QR2</e2> catalyzes the two-electron reduction of menadione via the oxidation of <e1>N-alkylated</e1> or N-ribosylated nicotinamides.","Substrate"
"Results: Our results demonstrate that treatment with <e1>LBH589</e1> leads to <e2>NIS</e2> RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors.","Upregulator"
"Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the <e2>histone deacetylase</e2> inhibitor <e1>LBH589</e1>.","Downregulator"
"This study is aimed at delineating <e1>harmaline</e1> and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Downregulator"
"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>MAO-A</e2>) inhibitor <e1>harmaline</e1> (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.","Downregulator"
"This study is aimed at delineating <e1>harmaline</e1> and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Downregulator"
"This study is aimed at delineating <e1>harmaline</e1> and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Downregulator"
"Our recent study has demonstrated that coadministration of <e2>monoamine oxidase A</e2> (MAO-A) inhibitor <e1>harmaline</e1> (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.","Downregulator"
"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>MAO-A</e2>) inhibitor <e1>harmaline</e1> (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.","Downregulator"
"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>MAO-A</e2>) inhibitor <e1>harmaline</e1> (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.","Downregulator"
"Pharmacokinetic Interactions between <e2>Monoamine Oxidase A</e2> Inhibitor <e1>Harmaline</e1> and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.","Downregulator"
"This study is aimed at delineating <e1>harmaline</e1> and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Downregulator"
"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>MAO-A</e2>) inhibitor <e1>harmaline</e1> (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.","Downregulator"
"This study is aimed at delineating <e1>harmaline</e1> and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Downregulator"
"This study is aimed at delineating <e1>harmaline</e1> and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Downregulator"
"This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce <e1>bufotenine</e1>.","Substrate"
"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>MAO-A</e2>) inhibitor harmaline (5 mg/kg) increases systemic exposure to <e1>5-MeO-DMT</e1> (2 mg/kg) and active metabolite bufotenine.","Substrate"
"This study is aimed at delineating harmaline and <e1>5-MeO-DMT</e1> pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Substrate"
"This study is aimed at delineating harmaline and <e1>5-MeO-DMT</e1> pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Substrate"
"This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce <e1>bufotenine</e1>.","Substrate"
"Our recent study has demonstrated that coadministration of monoamine oxidase A (<e2>MAO-A</e2>) inhibitor harmaline (5 mg/kg) increases systemic exposure to <e1>5-MeO-DMT</e1> (2 mg/kg) and active metabolite bufotenine.","Substrate"
"This study is aimed at delineating harmaline and <e1>5-MeO-DMT</e1> pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Substrate"
"This study is aimed at delineating harmaline and <e1>5-MeO-DMT</e1> pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of <e2>CYP2D6</e2> that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine.","Substrate"
"RESULTS: In an animal study with <e1>(129)I</e1>-labeled <e2>EPO</e2> in Han-Wistar rats, an increase of (129)I-EPO is observed after dose administration.","Part_of"
"The potent <e2>histamine H(1)-receptor</e2> antagonist <e1>cetirizine</e1> (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.","Antagonist"
"The potent <e2>histamine H(1)-receptor</e2> antagonist cetirizine (<e1>Zyrtec</e1>) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine.","Antagonist"
"The potent <e2>histamine H(1)-receptor</e2> antagonist cetirizine (Zyrtec) is a racemic mixture of <e1>levocetirizine</e1> (now available under the trademark Xyzal and dextrocetirizine.","Antagonist"
"Compared pharmacological characteristics in humans of racemic <e1>cetirizine</e1> and levocetirizine, two <e2>histamine H1-receptor</e2> antagonists.","Antagonist"
"Compared pharmacological characteristics in humans of racemic cetirizine and <e1>levocetirizine</e1>, two <e2>histamine H1-receptor</e2> antagonists.","Antagonist"
"The potent <e2>histamine H(1)-receptor</e2> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark <e1>Xyzal</e1> and dextrocetirizine.","Antagonist"
"The potent <e2>histamine H(1)-receptor</e2> antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and <e1>dextrocetirizine</e1>.","Antagonist"
"A new inhibitor of <e2>VEGF receptor tyrosine kinases</e2>, <e1>vegfrecine</e1> (1), was isolated from the culture broth of Streptomyces sp.","Downregulator"
"<e1>Vegfrecine</e1>, an Inhibitor of <e2>VEGF Receptor Tyrosine Kinases</e2> Isolated from the Culture Broth of Streptomyces sp.","Downregulator"
"The narrow substrate specificity prevents interaction of drugs with dicarboxylate-like structure with hNaDC-3 and ensures sufficient support of the proximal tubule cells with <e1>alpha-ketoglutarate</e1> for anion secretion via <e2>organic anion transporter 1 or 3</e2>.","Regulator"
"As opposed to the rat and flounder orthologs, <e2>hNaDC-3</e2> was hardly inhibited by <e1>lithium</e1> concentrations up to 5 mM.","Downregulator"
"Effects of inhibition of urokinase-type plasminogen activator (<e2>u-PA</e2>) by <e1>amiloride</e1> in the cornea and tear fluid of eyes irradiated with UVB.","Downregulator"
"Effects of inhibition of urokinase-type plasminogen activator (<e2>u-PA</e2>) by <e1>amiloride</e1> in the cornea and tear fluid of eyes irradiated with UVB.","Downregulator"
"Effects of inhibition of urokinase-type plasminogen activator (<e2>u-PA</e2>) by <e1>amiloride</e1> in the cornea and tear fluid of eyes irradiated with UVB.","Downregulator"
"Effects of inhibition of urokinase-type plasminogen activator (<e2>u-PA</e2>) by <e1>amiloride</e1> in the cornea and tear fluid of eyes irradiated with UVB.","Downregulator"
"Effects of inhibition of <e2>urokinase-type plasminogen activator</e2> (u-PA) by <e1>amiloride</e1> in the cornea and tear fluid of eyes irradiated with UVB.","Downregulator"
"Effects of inhibition of urokinase-type plasminogen activator (<e2>u-PA</e2>) by <e1>amiloride</e1> in the cornea and tear fluid of eyes irradiated with UVB.","Downregulator"
"Therefore, comparative histochemical and biochemical studies of <e2>u-PA</e2> and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate <e1>Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin</e1>.","Substrate"
"Circulating <e2>POMC</e2> peptide concentrations were unaffected, suggesting that the rapid <e1>corticosteroid</e1> inhibitory effect specifically targeted ACTH secretion from pituitary corticotrophs.","Not"
"<e1>Prednisolone</e1> fast feedback was only reduced by glucocorticoid receptor antagonist pretreatment and not by <e2>mineralocorticoid receptor</e2> antagonism, suggesting a glucocorticoid receptor-mediated pathway.","Not"
"<e1>Prednisolone</e1> fast feedback was only reduced by <e2>glucocorticoid receptor</e2> antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a glucocorticoid receptor-mediated pathway.","Regulator"
"<e1>Prednisolone</e1> fast feedback was only reduced by <e2>glucocorticoid receptor</e2> antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a glucocorticoid receptor-mediated pathway.","Regulator"
"We have investigated in normal human male subjects the importance, site of action, and receptor-mediated processes involved in rapid basal <e1>corticosteroid</e1> feedback and its interaction with <e2>corticotrophin releasing hormone</e2> (CRH) drive.","Regulator"
"We have investigated in normal human male subjects the importance, site of action, and receptor-mediated processes involved in rapid basal <e1>corticosteroid</e1> feedback and its interaction with corticotrophin releasing hormone (<e2>CRH</e2>) drive.","Regulator"
"<e1>Prednisolone</e1> also inhibited ACTH and cortisol secretion in response to exogenous <e2>CRH</e2> stimulation, inferring rapid feedback inhibition at the anterior pituitary.","Downregulator"
"Prednisolone also inhibited ACTH and <e1>cortisol</e1> secretion in response to exogenous <e2>CRH</e2> stimulation, inferring rapid feedback inhibition at the anterior pituitary.","Substrate"
"A structure-activity relationship (SAR) study of the c-<e2>Myc</e2> (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by <e1>arginine</e1> residues - was executed in order to determine its pharmacophore.","Part_of"
"A structure-activity relationship (SAR) study of the <e2>c-Myc</e2> (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by <e1>arginine</e1> residues - was executed in order to determine its pharmacophore.","Part_of"
"A structure-activity relationship (SAR) study of the c-<e2>Myc</e2> (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by <e1>arginine</e1> residues - was executed in order to determine its pharmacophore.","Part_of"
"Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the <e2>Myc</e2>-Max heterodimer, <e1>JY-3-094</e1> demonstrated excellent selectivity over Max-Max homodimers, with no apparent effect at 100 μM.","Regulator"
"Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the Myc-<e2>Max</e2> heterodimer, <e1>JY-3-094</e1> demonstrated excellent selectivity over Max-Max homodimers, with no apparent effect at 100 μM.","Regulator"
"Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the Myc-<e2>Max</e2> heterodimer, <e1>JY-3-094</e1> demonstrated excellent selectivity over Max-Max homodimers, with no apparent effect at 100 μM.","Regulator"
"Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the Myc-<e2>Max</e2> heterodimer, <e1>JY-3-094</e1> demonstrated excellent selectivity over Max-Max homodimers, with no apparent effect at 100 μM.","Regulator"
"Pharmacophore identification of c-<e2>Myc</e2> inhibitor <e1>10074-G5</e1>.","Regulator"
"A structure-activity relationship (SAR) study of the c-<e2>Myc</e2> (Myc) inhibitor 10074-G5 (<e1>N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine</e1>, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.","Regulator"
"Pharmacophore identification of <e2>c-Myc</e2> inhibitor <e1>10074-G5</e1>.","Downregulator"
"Around five times as potent as the lead with an IC(50) of 33 μM for disruption of the <e2>Myc</e2>-Max heterodimer, <e1>JY-3-094</e1> demonstrated excellent selectivity over Max-Max homodimers, with no apparent effect at 100 μM.","Downregulator"
"Pharmacophore identification of <e2>c-Myc</e2> inhibitor <e1>10074-G5</e1>.","Downregulator"
"Pharmacophore identification of c-<e2>Myc</e2> inhibitor <e1>10074-G5</e1>.","Downregulator"
"A structure-activity relationship (SAR) study of the <e2>c-Myc</e2> (Myc) inhibitor 10074-G5 (<e1>N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine</e1>, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.","Downregulator"
"A structure-activity relationship (SAR) study of the c-<e2>Myc</e2> (Myc) inhibitor 10074-G5 (<e1>N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine</e1>, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.","Downregulator"
"<e1>Miglustat</e1>, a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits <e2>glucosylceramide synthase</e2>, which catalyses the first committed step in glycosphingolipid synthesis.","Downregulator"
"<e1>Safrole-2',3'-oxide</e1> induces atherosclerotic plaque vulnerability in <e2>apolipoprotein E</e2>-knockout mice.","Regulator"
"In this study, we investigated <e1>SFO</e1>-induced atherosclerotic plaque vulnerability (possibility of rupture) in apolipoprotein E-knockout (<e2>apoE</e2>(-/-)) mice.","Regulator"
"In this study, we investigated <e1>SFO</e1>-induced atherosclerotic plaque vulnerability (possibility of rupture) in apolipoprotein E-knockout (<e2>apoE</e2>(-/-)) mice.","Regulator"
"In this study, we investigated <e1>SFO</e1>-induced atherosclerotic plaque vulnerability (possibility of rupture) in <e2>apolipoprotein E</e2>-knockout (apoE(-/-)) mice.","Regulator"
"In this study, we investigated <e1>SFO</e1>-induced atherosclerotic plaque vulnerability (possibility of rupture) in apolipoprotein E-knockout (<e2>apoE</e2>(-/-)) mice.","Regulator"
"Furthermore, compared with control groups, the plaque endothelium level of <e2>p75(NTR)</e2> was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by <e1>SFO</e1>-HD.","Upregulator"
"Meanwhile, the serum level of KC (a functional homolog of <e2>IL-8</e2> and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in <e1>SFO</e1>-HD treated group.","Upregulator"
"Furthermore, compared with control groups, the plaque endothelium level of <e2>p75(NTR)</e2> was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by <e1>SFO</e1>-HD.","Upregulator"
"Furthermore, compared with control groups, the plaque endothelium level of <e2>p75(NTR)</e2> was 3-fold increased and the liver level of p75(NTR) was 17.4-fold increased by <e1>SFO</e1>-HD.","Upregulator"
"Meanwhile, the serum level of KC (a functional homolog of <e2>IL-8</e2> and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in <e1>SFO</e1>-HD treated group.","Upregulator"
"Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory <e2>alpha chemokine</e2> in mice) in apoE(-/-) mice was up to 357pg/ml in <e1>SFO</e1>-HD treated group.","Upregulator"
"Because gastric <e2>AADC</e2> and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or <e1>benserazide</e1>), and inhibitors of COMT will also enter clinical use.","Downregulator"
"Because gastric <e2>AADC</e2> and COMT degrade levodopa, the drug is given with inhibitors of AADC (<e1>carbidopa</e1> or benserazide), and inhibitors of COMT will also enter clinical use.","Downregulator"
"<e1>Levodopa</e1> is absorbed in the small bowel and is rapidly catabolized by <e2>aromatic-L-amino-acid decarboxylase</e2> (AADC) and catechol-O-methyltransferase (COMT).","Substrate"
"<e1>Levodopa</e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (<e2>AADC</e2>) and catechol-O-methyltransferase (COMT).","Substrate"
"<e1>Levodopa</e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and <e2>catechol-O-methyltransferase</e2> (COMT).","Substrate"
"<e1>Levodopa</e1> is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (<e2>COMT</e2>).","Substrate"
"Because gastric <e2>AADC</e2> and COMT degrade <e1>levodopa</e1>, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.","Substrate"
"Because gastric AADC and <e2>COMT</e2> degrade <e1>levodopa</e1>, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.","Substrate"
"Rats were fed experimental diets containing SPI or <e2>casein</e2> as a <e1>nitrogen</e1> source.","Substrate"
"The inhibition of <e2>aminopeptidase</e2> activity in the presence of <e1>bestatin</e1> and puromycin inhibitors was also investigated.","Downregulator"
"The inhibition of <e2>aminopeptidase</e2> activity in the presence of bestatin and <e1>puromycin</e1> inhibitors was also investigated.","Downregulator"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of <e1>L-arginine</e1> for <e2>aminopeptidase B</e2>.","Substrate"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: <e1>4-methoxy-2-naphthylamide</e1> of L-alanine for <e2>aminopeptidase N</e2>, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.","Substrate"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of <e1>L-alanine</e1> for <e2>aminopeptidase N</e2>, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.","Substrate"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: <e1>4-methoxy-2-naphthylamide</e1> of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for <e2>leucine aminopeptidase</e2>, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.","Substrate"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of <e1>L-leucine</e1> for <e2>leucine aminopeptidase</e2>, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.","Substrate"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: <e1>4-methoxy-2-naphthylamide</e1> of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for <e2>aminopeptidase A</e2> and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.","Substrate"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of <e1>L-glutamic acid</e1> for <e2>aminopeptidase A</e2> and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.","Substrate"
"Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: <e1>4-methoxy-2-naphthylamide</e1> of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for <e2>aminopeptidase B</e2>.","Substrate"
"Incubation of purified <e2>Pin1</e2> with HNE followed by MALDI-TOF/TOF mass spectrometry resulted in detection of Michael adducts at the active site residues <e1>His</e1>-157 and Cys-113.","Part_of"
"Incubation of purified <e2>Pin1</e2> with HNE followed by MALDI-TOF/TOF mass spectrometry resulted in detection of Michael adducts at the active site residues His-157 and <e1>Cys</e1>-113.","Part_of"
"Incubation of purified <e2>Pin1</e2> with HNE followed by MALDI-TOF/TOF mass spectrometry resulted in detection of Michael adducts at the active site residues His-157 and <e1>Cys</e1>-113.","Part_of"
"Here, we demonstrate that <e2>peptidyl-prolyl cis/trans-isomerase A1</e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to <e1>HNE</e1> modification.","Regulator"
"Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<e2>Pin1</e2>), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to <e1>HNE</e1> modification.","Regulator"
"<e2>Pin1</e2> was adducted in MDA-MB-231 breast cancer cells treated with <e1>8-alkynyl-HNE</e1> as judged by click chemistry conjugation with biotin followed by streptavidin-based pulldown and Western blotting with anti-Pin1 antibody.","Regulator"
"Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<e2>Pin1</e2>), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to <e1>HNE</e1> modification.","Regulator"
"Recent studies indicate that <e2>Pin1</e2> is an important molecular target for the chemopreventive effects of green tea <e1>polyphenols</e1>.","Regulator"
"Here, we demonstrate that <e2>peptidyl-prolyl cis/trans-isomerase A1</e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of <e1>pSer</e1>/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.","Substrate"
"Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<e2>Pin1</e2>), an enzyme that catalyzes the conversion of the peptide bond of <e1>pSer</e1>/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.","Substrate"
"Here, we demonstrate that <e2>peptidyl-prolyl cis/trans-isomerase A1</e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/<e1>pThr</e1>-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.","Substrate"
"Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<e2>Pin1</e2>), an enzyme that catalyzes the conversion of the peptide bond of pSer/<e1>pThr</e1>-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.","Substrate"
"Here, we demonstrate that <e2>peptidyl-prolyl cis/trans-isomerase A1</e2> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-<e1>Pro</e1> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.","Substrate"
"Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<e2>Pin1</e2>), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-<e1>Pro</e1> moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.","Substrate"
"<e1>Ethanol</e1> withdrawal significantly increased the packing density of <e2>GS</e2>- and GFAP-IR astrocytes in the PLC of P rats as compared with P rats with continuous access to ethanol.","Regulator"
"<e1>Ethanol</e1> withdrawal significantly increased the packing density of GS- and <e2>GFAP</e2>-IR astrocytes in the PLC of P rats as compared with P rats with continuous access to ethanol.","Regulator"
"However, it is unclear if withdrawal from free-choice <e1>ethanol</e1> drinking causes changes in the numbers of astrocytes expressing <e2>GS</e2> or the cytoskeletal protein of astrocytes glial fibrillary acidic protein (GFAP).","Regulator"
"However, it is unclear if withdrawal from free-choice <e1>ethanol</e1> drinking causes changes in the numbers of astrocytes expressing <e2>GS</e2> or the cytoskeletal protein of astrocytes glial fibrillary acidic protein (GFAP).","Regulator"
"However, it is unclear if withdrawal from free-choice <e1>ethanol</e1> drinking causes changes in the numbers of astrocytes expressing GS or the cytoskeletal protein of astrocytes glial fibrillary acidic protein (<e2>GFAP</e2>).","Regulator"
"Withdrawal from free-choice <e1>ethanol</e1> consumption results in increased packing density of <e2>glutamine synthetase</e2>-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.","Upregulator"
"Withdrawal from free-choice ethanol consumption results in increased packing density of <e1>glutamine</e1> synthetase-immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats.","Substrate"
"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to <e1>glutamine</e1> through the enzyme glutamine synthetase (<e2>GS</e2>).","Substrate"
"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <e1>glutamate</e1> and its conversion to glutamine through the enzyme <e2>glutamine synthetase</e2> (GS).","Substrate"
"Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released <e1>glutamate</e1> and its conversion to glutamine through the enzyme glutamine synthetase (<e2>GS</e2>).","Substrate"
"<e1>Rufinamide</e1> attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes <e2>voltage-gated sodium channel</e2> inactivated state.","Regulator"
"Knockdown of <e2>COL8A2</e2> blocked enhancement in the early stage of cell adhesion by <e1>atRA</e1> treatment.","Regulator"
"<e1>All-trans retinoic acid</e1> protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating <e2>collagen 8A2</e2>.","Upregulator"
"The protein exhibited modest <e1>H(2)O(2)</e1>-dependent <e2>peroxidase</e2> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).","Upregulator"
"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase</e2> activities with <e1>guaiacol</e1>, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).","Substrate"
"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase</e2> activities with guaiacol, <e1>potassium iodide</e1>, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).","Substrate"
"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase</e2> activities with guaiacol, potassium iodide, and <e1>2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid</e1> (ABTS).","Substrate"
"The protein exhibited modest H(2)O(2)-dependent <e2>peroxidase</e2> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (<e1>ABTS</e1>).","Substrate"
"Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and <e1>8Br-cAMP</e1> treatment through two <e2>SF-1</e2> binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.","Regulator"
"Luciferase reporter assays showed that transcription of <e2>FDX1</e2> was synergistically activated by the NR5A family and <e1>8Br-cAMP</e1> treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.","Upregulator"
"Luciferase reporter assays showed that transcription of <e2>FDX1</e2> was synergistically activated by the NR5A family and 8Br-<e1>cAMP</e1> treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.","Upregulator"
"Ferredoxin 1 (<e2>FDX1</e2>; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid</e1> hormone synthesis in mammalian tissues.","Substrate"
"Ferredoxin 1 (FDX1; <e2>adrenodoxin</e2>) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid</e1> hormone synthesis in mammalian tissues.","Substrate"
"<e2>Ferredoxin 1</e2> (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid</e1> hormone synthesis in mammalian tissues.","Substrate"
"Ferredoxin 1 (<e2>FDX1</e2>; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid hormone</e1> synthesis in mammalian tissues.","Substrate"
"Ferredoxin 1 (FDX1; <e2>adrenodoxin</e2>) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid hormone</e1> synthesis in mammalian tissues.","Substrate"
"<e2>Ferredoxin 1</e2> (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid hormone</e1> synthesis in mammalian tissues.","Substrate"
"Ferredoxin 1 (<e2>FDX1</e2>; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including <e1>steroid</e1> hormone synthesis in mammalian tissues.","Substrate"
"In the liver of rats given <e1>flutamide</e1> as initiating agent at the dose of 500 mg/kg/week for 6 successive weeks, <e2>gamma-glutamyltraspeptidase</e2>-positive foci were detected only in 3 of 10 rats.","Upregulator"
"<e1>Flutamide</e1>, an effective competitive inhibitor of the <e2>androgen receptor</e2> used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes.","Downregulator"
"<e2>Cycloxygenase-2</e2> (COX-2)-derived <e1>prostaglandin E2</e1> (PGE2) has been shown to be important in esophageal tumorigenesis.","Substrate"
"Cycloxygenase-2 (<e2>COX-2</e2>)-derived <e1>prostaglandin E2</e1> (PGE2) has been shown to be important in esophageal tumorigenesis.","Substrate"
"Knockdown of <e2>mPGES1</e2> by mPGES1 small interfering RNA (siRNA) blocked acid-induced increase in <e1>PGE2</e1> production and thymidine incorporation.","Substrate"
"<e2>Cycloxygenase-2</e2> (COX-2)-derived prostaglandin E2 (<e1>PGE2</e1>) has been shown to be important in esophageal tumorigenesis.","Substrate"
"Cycloxygenase-2 (<e2>COX-2</e2>)-derived prostaglandin E2 (<e1>PGE2</e1>) has been shown to be important in esophageal tumorigenesis.","Substrate"
"Cycloxygenase-2 (<e2>COX-2</e2>)-derived prostaglandin E2 (<e1>PGE2</e1>) has been shown to be important in esophageal tumorigenesis.","Substrate"
"In addition, <e1>butein</e1>-dependent <e2>HO-1</e2> expression was required for the inhibition of H2O2-induced cell death and ROS generation.","Regulator"
"<e1>Butein</e1> protects human dental pulp cells from hydrogen peroxide-induced oxidative toxicity via Nrf2 pathway-dependent <e2>heme oxygenase-1</e2> expressions.","Regulator"
"<e1>Butein</e1> protects human dental pulp cells from hydrogen peroxide-induced oxidative toxicity via <e2>Nrf2</e2> pathway-dependent heme oxygenase-1 expressions.","Regulator"
"Treatment of HDP cells with a c-Jun NH2-terminal kinase (<e2>JNK</e2>) inhibitor also reduced <e1>butein</e1>-induced HO-1 expression, and butein treatment led to increased JNK phosphorylation.","Upregulator"
"<e1>Butein</e1> protects human dental pulp cells from hydrogen peroxide-induced oxidative toxicity via Nrf2 pathway-dependent <e2>heme oxygenase-1</e2> expressions.","Upregulator"
"<e1>Butein</e1> also increased heme oxygenase-1 (<e2>HO-1</e2>) protein expression and HO activity.","Upregulator"
"Furthermore, <e1>butein</e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of <e2>antioxidant response elements</e2> (AREs).","Upregulator"
"Furthermore, <e1>butein</e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (<e2>AREs</e2>).","Upregulator"
"Furthermore, <e1>butein</e1> treatment caused nuclear accumulation of <e2>nuclear factor-E2-related factor 2</e2> (Nrf2) and increased the promoter activity of antioxidant response elements (AREs).","Upregulator"
"Furthermore, <e1>butein</e1> treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (<e2>Nrf2</e2>) and increased the promoter activity of antioxidant response elements (AREs).","Upregulator"
"In addition, <e1>butein</e1>-dependent <e2>HO-1</e2> expression was required for the inhibition of H2O2-induced cell death and ROS generation.","Upregulator"
"<e1>Butein</e1> also increased heme oxygenase-1 (<e2>HO</e2>-1) protein expression and HO activity.","Upregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact <e2>bovine pancreatic ribonuclease A</e2> (RNase A) and its <e1>proline</e1>-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Part_of"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its <e1>proline</e1>-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Part_of"
"The refolding kinetics of guanidine-denatured disulfide-intact <e2>bovine pancreatic ribonuclease A</e2> (RNase A) and its proline-42-to-<e1>alanine</e1> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Part_of"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-<e1>alanine</e1> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Part_of"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>Pro42Ala</e2>) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Regulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Regulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>Pro42Ala</e2>) have been studied by monitoring <e1>tyrosine</e1> burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Regulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring <e1>tyrosine</e1> burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Regulator"
"Folding pathway of guanidine-denatured <e1>disulfide</e1>-intact wild-type and mutant <e2>bovine pancreatic ribonuclease A</e2>.","Regulator"
"Folding pathway of guanidine-denatured <e1>disulfide</e1>-intact wild-type and mutant <e2>bovine pancreatic ribonuclease A</e2>.","Regulator"
"The refolding kinetics of guanidine-denatured <e1>disulfide</e1>-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Regulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring <e1>tyrosine</e1> burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.","Regulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Regulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its <e2>proline-42-to-alanine</e2> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate</e1> (2'CMP) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>Pro42Ala</e2>) have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate</e1> (2'CMP) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact <e2>bovine pancreatic ribonuclease A</e2> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate</e1> (2'CMP) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and <e1>2'-cytidine monophosphate</e1> (2'CMP) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its <e2>proline-42-to-alanine</e2> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<e2>Pro42Ala</e2>) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact <e2>bovine pancreatic ribonuclease A</e2> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Downregulator"
"The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<e2>RNase A</e2>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (<e1>2'CMP</e1>) inhibitor binding.","Downregulator"
"<e1>Cortisol</e1> and IFNT stimulated endometrial <e2>HSD11B1</e2> expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.","Upregulator"
"<e1>Cortisol</e1> and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial <e2>PTGS2</e2> activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.","Upregulator"
"<e1>Cortisol</e1> and IFNT stimulated endometrial <e2>HSD11B1</e2> expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.","Upregulator"
"In study 1, cyclic ewes received vehicle, cortisol, <e1>PF 915275</e1> (PF; a selective inhibitor of <e2>HSD11B1</e2>), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.","Downregulator"
"In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, <e1>meloxicam</e1> (a selective inhibitor of <e2>PTGS2</e2>), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.","Downregulator"
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>cortisol</e1> via hydroxysteroid (11-β) dehydrogenase 1 (<e2>HSD11B1</e2>).","Substrate"
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce <e1>prostaglandins</e1> (PG) via <e2>PG synthase 2</e2> (PTGS2) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1).","Substrate"
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce <e1>prostaglandins</e1> (PG) via PG synthase 2 (<e2>PTGS2</e2>) and cortisol via hydroxysteroid (11-β) dehydrogenase 1 (HSD11B1).","Substrate"
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>cortisol</e1> via hydroxysteroid (11-β) dehydrogenase 1 (<e2>HSD11B1</e2>).","Substrate"
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>cortisol</e1> via <e2>hydroxysteroid (11-β) dehydrogenase 1</e2> (HSD11B1).","Substrate"
"During early pregnancy in sheep, the elongating conceptus secretes interferon-τ (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and <e1>cortisol</e1> via hydroxysteroid (11-β) dehydrogenase 1 (<e2>HSD11B1</e2>).","Substrate"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the <e2>5-HT1A</e2> receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites <e1>(+/-)-pindolol</e1> (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Regulator"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and <e2>5-HT1B</e2> binding sites <e1>(+/-)-pindolol</e1> (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Regulator"
"It is concluded that <e1>D-1997</e1> contracts the canine basilar artery by stimulating <e2>5-HT1-like receptors</e2> unrelated to either the 5-HT1A or 5-HT1B receptor subtypes.","Upregulator"
"The effects of <e1>D-1997</e1> in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the <e2>5-HT1A</e2> receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Upregulator"
"The effects of <e1>D-1997</e1> in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and <e2>5-HT1B</e2> binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Upregulator"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the <e2>beta-adrenoceptor</e2> blocker with high affinity for 5-HT1A and 5-HT1B binding sites <e1>(+/-)-pindolol</e1> (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Downregulator"
"<e1>2-(2-Aminoethyl)-quinoline</e1> (D-1997): a novel agonist at <e2>5-hydroxytryptamine1-like receptors</e2> in the canine basilar artery.","Agonist"
"2-(2-Aminoethyl)-quinoline (<e1>D-1997</e1>): a novel agonist at <e2>5-hydroxytryptamine1-like receptors</e2> in the canine basilar artery.","Agonist"
"In contrast, the <e1>D-1997</e1>-induced responses were potently and concentration-dependently antagonized by the mixed <e2>5-HT1-like</e2> and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).","Agonist"
"The effects of <e1>D-1997</e1> in the basilar artery were not modified by incubation with either the <e2>5-HT2 receptor</e2> antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Agonist"
"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed <e2>5-HT1-like</e2> and 5-HT2 receptor antagonist <e1>methiothepin</e1> (0.01-1 microM).","Antagonist"
"In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and <e2>5-HT2 receptor</e2> antagonist <e1>methiothepin</e1> (0.01-1 microM).","Antagonist"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the <e2>5-HT2 receptor</e2> antagonist <e1>ketanserin</e1> (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Antagonist"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the <e2>5-HT3</e2> and 5-HT4 receptor antagonist ICS205930 (<e1>tropisetron</e1>; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Antagonist"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and <e2>5-HT4</e2> receptor antagonist ICS205930 (<e1>tropisetron</e1>; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Antagonist"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the <e2>5-HT1A</e2> receptor antagonist <e1>spiroxatrine</e1> (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).","Antagonist"
"The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the <e2>alpha 1-adrenoceptor</e2> antagonist <e1>prazosin</e1> (0.01-1 microM).","Antagonist"
"Moreover, VK2-2,3 epoxide, an intracellular metabolite of VK2, was shown to covalently bind to the <e1>cysteine</e1>-166 residue of <e2>Bak</e2>.","Part_of"
"<e1>Vitamin K2</e1> covalently binds to <e2>Bak</e2> and induces Bak-mediated apoptosis.","Regulator"
"<e1>Vitamin K2</e1> covalently binds to <e2>Bak</e2> and induces Bak-mediated apoptosis.","Regulator"
"Here, we identified Bcl-2 antagonist killer 1 (<e2>Bak</e2>) as a molecular target of <e1>VK2</e1>-induced apoptosis.","Regulator"
"Moreover, <e1>VK2-2,3 epoxide</e1>, an intracellular metabolite of VK2, was shown to covalently bind to the cysteine-166 residue of <e2>Bak</e2>.","Regulator"
"Here, we identified Bcl-2 antagonist killer 1 (<e2>Bak</e2>) as a molecular target of <e1>VK2</e1>-induced apoptosis.","Regulator"
"Here, we identified Bcl-2 antagonist killer 1 (<e2>Bak</e2>) as a molecular target of <e1>VK2</e1>-induced apoptosis.","Regulator"
"Here, we identified Bcl-2 antagonist killer 1 (<e2>Bak</e2>) as a molecular target of <e1>VK2</e1>-induced apoptosis.","Regulator"
"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for <e1>VK2</e1>-induced <e2>cytochrome c</e2> (cyt c) release and cell death.","Upregulator"
"Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for <e1>VK2</e1>-induced cytochrome c (<e2>cyt c</e2>) release and cell death.","Upregulator"
"These results show that the robust effects of <e1>TCDD</e1> on the mRNA expression of <e2>Snrpn</e2>, Peg3 and Igf2r genes in the sperm and of Igf2r in the muscle and liver are unrelated to changes in methylation in their respective genes.","Regulator"
"These results show that the robust effects of <e1>TCDD</e1> on the mRNA expression of Snrpn, <e2>Peg3</e2> and Igf2r genes in the sperm and of Igf2r in the muscle and liver are unrelated to changes in methylation in their respective genes.","Regulator"
"In muscle and liver, <e1>TCDD</e1> (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of <e2>Igf2r</e2>.","Regulator"
"In muscle and liver, <e1>TCDD</e1> (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of <e2>Igf2r</e2>.","Regulator"
"In muscle and liver, <e1>TCDD</e1> (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of <e2>Igf2r</e2>.","Downregulator"
"We have used a combination of <e2>alpha-synuclein</e2> and free radical mediated toxicity in a dopaminergic cell line to provide a model of nigral toxicity in order to investigate the potential molecular mechanisms that mediate <e1>rasagiline</e1> protection.","Regulator"
"We demonstrate that <e1>rasagiline</e1> protects against cell death induced by the combination of free radicals generated by paraquat and either wild-type or <e2>A53T</e2> mutant alpha-synuclein over-expression.","Regulator"
"We have used a combination of <e2>alpha-synuclein</e2> and free radical mediated toxicity in a dopaminergic cell line to provide a model of nigral toxicity in order to investigate the potential molecular mechanisms that mediate <e1>rasagiline</e1> protection.","Regulator"
"<e1>Rasagiline</e1> protects against <e2>alpha-synuclein</e2> induced sensitivity to oxidative stress in dopaminergic cells.","Regulator"
"<e1>Rasagiline</e1> is a propargylamine and irreversible <e2>monoamine oxidase (MAO) B</e2> inhibitor used for the treatment of Parkinson's disease (PD).","Downregulator"
"Rasagiline is a <e1>propargylamine</e1> and irreversible <e2>monoamine oxidase (MAO) B</e2> inhibitor used for the treatment of Parkinson's disease (PD).","Downregulator"
"<e1>Tolvaptan</e1> is a selective arginine vasopressin (<e2>AVP</e2>) V(2) receptor blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.","Regulator"
"Prolonged use of <e1>tolvaptan</e1> leads to increased endogenous levels of AVP and perhaps over-stimulation of <e2>V(1A) receptors</e2>.","Upregulator"
"Prolonged use of <e1>tolvaptan</e1> leads to increased endogenous levels of <e2>AVP</e2> and perhaps over-stimulation of V(1A) receptors.","Upregulator"
"<e1>Tolvaptan</e1> is a selective <e2>arginine vasopressin (AVP) V(2) receptor</e2> blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia.","Downregulator"
"In addition, <e1>tolvaptan</e1> is metabolized by the <e2>CYP3A4</e2> system; thus physicians should be aware of the potential for increased interactions with other medications.","Substrate"
"Peptidergic neurones accumulate amines via an unusual uptake process, designated Transport-P. <e1>[(3)H]-prazosin</e1> binds to <e2>alpha(1) adrenoceptors</e2> on these cells and is displaceable by unlabelled prazosin in concentrations up to 10(-7) M. However, at greater concentrations of prazosin, there is a paradoxical accumulation of [(3)H]-prazosin which we have attributed to Transport-P. Uptake of prazosin via Transport-P is detectable at 10(-10) M prazosin concentration, is linear up to 10(-7) M and at greater concentrations becomes non-linear.","Regulator"
"In COS cells transfected with <e2>alpha(1b) adrenoceptor</e2> cDNA and in DDT(1) MF-2 cells which express native alpha(1B) adrenoceptors, <e1>[(3)H]-prazosin</e1> was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.","Regulator"
"In COS cells transfected with alpha(1b) adrenoceptor cDNA and in DDT(1) MF-2 cells which express native <e2>alpha(1B) adrenoceptors</e2>, <e1>[(3)H]-prazosin</e1> was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.","Regulator"
"In COS cells transfected with <e2>alpha(1b) adrenoceptor</e2> cDNA and in DDT(1) MF-2 cells which express native alpha(1B) adrenoceptors, [(3)H]-<e1>prazosin</e1> was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.","Regulator"
"In COS cells transfected with alpha(1b) adrenoceptor cDNA and in DDT(1) MF-2 cells which express native <e2>alpha(1B) adrenoceptors</e2>, [(3)H]-<e1>prazosin</e1> was displaced by unlabelled prazosin in a normal equilibrium process, with no prazosin paradox in concentrations up to 10(-6) M. In DDT(1) MF-2 cells, [(3)H]-prazosin was displaced likewise by a series of alpha(1) adrenergic agonists, none of which increased the binding of [(3)H]-prazosin.","Regulator"
"Peptidergic neurones accumulate amines via an unusual uptake process, designated Transport-P. <e1>[(3)H]-prazosin</e1> binds to <e2>alpha(1)</e2> adrenoceptors on these cells and is displaceable by unlabelled prazosin in concentrations up to 10(-7) M. However, at greater concentrations of prazosin, there is a paradoxical accumulation of [(3)H]-prazosin which we have attributed to Transport-P. Uptake of prazosin via Transport-P is detectable at 10(-10) M prazosin concentration, is linear up to 10(-7) M and at greater concentrations becomes non-linear.","Regulator"
"Peptidergic neurones accumulate amines via an unusual uptake process, designated Transport-P. <e1>[(3)H]-prazosin</e1> binds to <e2>alpha(1)</e2> adrenoceptors on these cells and is displaceable by unlabelled prazosin in concentrations up to 10(-7) M. However, at greater concentrations of prazosin, there is a paradoxical accumulation of [(3)H]-prazosin which we have attributed to Transport-P. Uptake of prazosin via Transport-P is detectable at 10(-10) M prazosin concentration, is linear up to 10(-7) M and at greater concentrations becomes non-linear.","Regulator"
"Peptidergic neurones accumulate amines via an unusual uptake process, designated Transport-P. [(3)H]-<e1>prazosin</e1> binds to <e2>alpha(1) adrenoceptors</e2> on these cells and is displaceable by unlabelled prazosin in concentrations up to 10(-7) M. However, at greater concentrations of prazosin, there is a paradoxical accumulation of [(3)H]-prazosin which we have attributed to Transport-P. Uptake of prazosin via Transport-P is detectable at 10(-10) M prazosin concentration, is linear up to 10(-7) M and at greater concentrations becomes non-linear.","Regulator"
"<e1>Fisetin</e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma <e2>insulin</e2>.","Upregulator"
"<e1>Fisetin</e1> treatment showed a significant decline in the levels of blood glucose, <e2>glycosylated hemoglobin</e2> (HbA1c), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.","Downregulator"
"<e1>Fisetin</e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (<e2>HbA1c</e2>), NF-kB p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.","Downregulator"
"<e1>Fisetin</e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), <e2>NF-kB</e2> p65 unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.","Downregulator"
"<e1>Fisetin</e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB <e2>p65</e2> unit (in pancreas) and IL-1β (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.","Downregulator"
"<e1>Fisetin</e1> treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and <e2>IL-1β</e2> (plasma), serum nitric oxide (NO) with an elevation in plasma insulin.","Downregulator"
"The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the <e2>estrogen receptor</e2> and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and <e1>monohydroxytamoxifen</e1> in the ovariectomized mouse and immature rat.","Regulator"
"The aim of the study was to determine whether the dihydroxylated antiestrogen <e1>LY117018</e1>, with a high affinity for the <e2>estrogen receptor</e2> and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat.","Regulator"
"The aim of the study was to determine whether the dihydroxylated antiestrogen <e1>LY117018</e1>, with a high affinity for the <e2>estrogen receptor</e2> and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat.","Regulator"
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>glucose</e1> environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -<e2>extracelluar signal-regulated kinase</e2> (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.","Regulator"
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>glucose</e1> environment enhanced IL-8 production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (<e2>ERK</e2>) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.","Regulator"
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>glucose</e1> environment enhanced IL-8 production via <e2>epidermal growth factor receptor</e2> (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.","Regulator"
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>glucose</e1> environment enhanced IL-8 production via epidermal growth factor receptor (<e2>EGFR</e2>) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.","Regulator"
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>glucose</e1> environment enhanced <e2>IL-8</e2> production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.","Upregulator"
"Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<e1>glucose</e1> environment enhanced <e2>IL-8</e2> production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.","Upregulator"
"High-<e1>glucose</e1> environment enhanced oxidative stress and increased <e2>interleukin-8</e2> secretion from keratinocytes: New insights on impaired diabetic wound healing.","Upregulator"
"Effects of <e1>2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine</e1> (PhIP) on histopathology, oxidative stress, and expression of <e2>c-fos</e2>, c-jun and p16 in rat stomachs.","Regulator"
"Effects of <e1>2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine</e1> (PhIP) on histopathology, oxidative stress, and expression of c-fos, <e2>c-jun</e2> and p16 in rat stomachs.","Regulator"
"Effects of <e1>2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine</e1> (PhIP) on histopathology, oxidative stress, and expression of c-fos, c-jun and <e2>p16</e2> in rat stomachs.","Regulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of <e2>c-fos</e2>, c-jun and p16 in rat stomachs.","Regulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of c-fos, <e2>c-jun</e2> and p16 in rat stomachs.","Regulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of c-fos, c-jun and <e2>p16</e2> in rat stomachs.","Regulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of <e2>c-fos</e2>, c-jun and p16 in rat stomachs.","Upregulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of c-fos, <e2>c-jun</e2> and p16 in rat stomachs.","Upregulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of c-fos, <e2>c-jun</e2> and p16 in rat stomachs.","Upregulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of <e2>c-fos</e2>, c-jun and p16 in rat stomachs.","Upregulator"
"The results showed that (1) 15mg/kg body weight <e1>PhIP</e1> induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased <e2>catalase</e2> (CAT) activity compared with the control.","Upregulator"
"The results showed that (1) 15mg/kg body weight <e1>PhIP</e1> induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (<e2>CAT</e2>) activity compared with the control.","Upregulator"
"The results showed that (1) 15mg/kg body weight <e1>PhIP</e1> induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased <e2>superoxide dismutase</e2> (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.","Downregulator"
"The results showed that (1) 15mg/kg body weight <e1>PhIP</e1> induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (<e2>SOD</e2>) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.","Downregulator"
"The results showed that (1) 15mg/kg body weight <e1>PhIP</e1> induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and <e2>glutathioneperoxidase</e2> (GPx) activities, while increased catalase (CAT) activity compared with the control.","Downregulator"
"The results showed that (1) 15mg/kg body weight <e1>PhIP</e1> induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (<e2>GPx</e2>) activities, while increased catalase (CAT) activity compared with the control.","Downregulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of c-fos, c-jun and <e2>p16</e2> in rat stomachs.","Downregulator"
"Effects of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (<e1>PhIP</e1>) on histopathology, oxidative stress, and expression of c-fos, c-jun and <e2>p16</e2> in rat stomachs.","Downregulator"
"An intermediate <e1>GTX2,3-aldehyde</e1> was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-<e2>bovine serum albumin</e2> (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.","Regulator"
"An intermediate <e1>GTX2,3-aldehyde</e1> was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (<e2>BSA</e2>) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.","Regulator"
"An intermediate <e1>GTX2,3-aldehyde</e1> was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- <e2>keyhole limpet hemocyanin</e2> (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.","Regulator"
"An intermediate <e1>GTX2,3-aldehyde</e1> was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (<e2>KLH</e2>) were then prepared by cross-linking the intermediate with BSA or KLH.","Regulator"
"Ever since the discovery that (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4) is a cofactor of <e1>NO</e1>S, its function has been the object of intense research and occasional controversy.","Not"
"the <e2>NOS</e2>-catalyzed oxidation of <e1>NADPH</e1> in the absence of substrate or pterin that does not result in NO production.","Regulator"
"Ever since the discovery that (6R)-5,6,7,8-tetrahydro-L-biopterin (<e1>BH4</e1>) is a cofactor of <e2>NOS</e2>, its function has been the object of intense research and occasional controversy.","Regulator"
"Ever since the discovery that (6R)-5,6,7,8-tetrahydro-L-biopterin (<e1>BH4</e1>) is a cofactor of <e2>NOS</e2>, its function has been the object of intense research and occasional controversy.","Regulator"
"Finally, we illustrate how <e1>BH4</e1> might transform the NOS dimer into an efficient <e2>S-nitrosoglutathione synthase</e2>,and briefly touch on some more speculative aspects of the role of BH4 in NO synthesis.","Regulator"
"Ever since the discovery that <e1>(6R)-5,6,7,8-tetrahydro-L-biopterin</e1> (BH4) is a cofactor of <e2>NOS</e2>, its function has been the object of intense research and occasional controversy.","Cofactor"
"Ever since the discovery that (6R)-5,6,7,8-tetrahydro-L-biopterin (<e1>BH4</e1>) is a cofactor of <e2>NOS</e2>, its function has been the object of intense research and occasional controversy.","Cofactor"
"Ever since the discovery that (6R)-5,6,7,8-tetrahydro-L-biopterin (<e1>BH4</e1>) is a cofactor of <e2>NOS</e2>, its function has been the object of intense research and occasional controversy.","Cofactor"
"Ever since the discovery that (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4) is a cofactor of <e1>NO</e1>S, its function has been the object of intense research and occasional controversy.","Substrate"
"The inhibitory effects of iloprost on <e2>tissue factor</e2> expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and dibutyryl cyclic AMP but not <e1>dibutyryl cyclic GMP</e1>.","Not"
"Iloprost was the most potent: 50% inhibition occurred at 5 nM, a concentration close to the reported dissociation constant for <e1>iloprost</e1> binding to the platelet <e2>prostacyclin receptor</e2>.","Regulator"
"Iloprost was the most potent: 50% inhibition occurred at 5 nM, a concentration close to the reported dissociation constant for iloprost binding to the platelet <e1>prostacyclin</e1> receptor.","Regulator"
"An orally active analogue, <e1>cicaprost</e1>, was equally effective against endotoxin-induced <e2>tissue factor</e2> expression.","Regulator"
"Prostacyclin analogues inhibit <e2>tissue factor</e2> expression in the human monocytic cell line THP-1 via a <e1>cyclic AMP</e1>-dependent mechanism.","Regulator"
"Prostacyclin analogues inhibit <e2>tissue factor</e2> expression in the human monocytic cell line THP-1 via a <e1>cyclic AMP</e1>-dependent mechanism.","Downregulator"
"The present studies were undertaken to determine whether stable analogues of <e1>prostacyclin</e1>, a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit <e2>tissue factor</e2> expression by human monocytic cells.","Downregulator"
"The present studies were undertaken to determine whether stable analogues of <e1>prostacyclin</e1>, a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit <e2>tissue factor</e2> expression by human monocytic cells.","Downregulator"
"Preincubation for 30 minutes with <e1>iloprost</e1>, ciprostene, and carbacyclin led to a dose-dependent inhibition of <e2>tissue factor</e2> expression induced by all three challenging agents.","Downregulator"
"Preincubation for 30 minutes with iloprost, <e1>ciprostene</e1>, and carbacyclin led to a dose-dependent inhibition of <e2>tissue factor</e2> expression induced by all three challenging agents.","Downregulator"
"Preincubation for 30 minutes with iloprost, ciprostene, and <e1>carbacyclin</e1> led to a dose-dependent inhibition of <e2>tissue factor</e2> expression induced by all three challenging agents.","Downregulator"
"<e1>Prostacyclin</e1> analogues inhibit <e2>tissue factor</e2> expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.","Downregulator"
"This effect was potentiated by <e1>isobutylmethylxanthine</e1>, an inhibitor of <e2>phosphodiesterase</e2>.","Downregulator"
"The inhibitory effects of iloprost on <e2>tissue factor</e2> expression were also potentiated by <e1>isobutylmethylxanthine</e1> and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.","Downregulator"
"The inhibitory effects of iloprost on <e2>tissue factor</e2> expression were also potentiated by isobutylmethylxanthine and mimicked by <e1>forskolin</e1> and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.","Downregulator"
"The inhibitory effects of iloprost on <e2>tissue factor</e2> expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and d<e1>ibutyryl cyclic AMP</e1> but not dibutyryl cyclic GMP.","Downregulator"
"Histone de<e1>acetyl</e1>ase 3 (Hdac3) is a nuclear enzyme that removes acetyl groups from lysine residues in <e2>histones</e2> and other proteins to epigenetically regulate gene expression.","Part_of"
"Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes acetyl groups from <e1>lysine</e1> residues in <e2>histones</e2> and other proteins to epigenetically regulate gene expression.","Part_of"
"In six tumors, TP was more intense that <e2>DPD</e2>, suggesting <e1>capecitabine</e1> sensitivity.","Not"
"<e1>5-FU</e1> interferes with DNA synthesis by blocking thymidylate synthase (<e2>TS</e2>) but is inactivated by dihydropyrimidine dehydrogenase (DPD).","Regulator"
"<e1>5-FU</e1> interferes with DNA synthesis by blocking <e2>thymidylate synthase</e2> (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).","Downregulator"
"<e1>5-FU</e1> interferes with DNA synthesis by blocking thymidylate synthase (<e2>TS</e2>) but is inactivated by dihydropyrimidine dehydrogenase (DPD).","Downregulator"
"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to <e1>5-fluorouracil</e1> (5-FU) by thymidine phosphorylase (<e2>TP</e2>) inside target tissues.","Substrate"
"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to <e1>5-fluorouracil</e1> (5-FU) by <e2>thymidine phosphorylase</e2> (TP) inside target tissues.","Substrate"
"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<e1>5-FU</e1>) by thymidine phosphorylase (<e2>TP</e2>) inside target tissues.","Substrate"
"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<e1>5-FU</e1>) by <e2>thymidine phosphorylase</e2> (TP) inside target tissues.","Substrate"
"PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (<e1>5-FU</e1>) by thymidine phosphorylase (<e2>TP</e2>) inside target tissues.","Substrate"
"<e1>5-FU</e1> interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (<e2>DPD</e2>).","Substrate"
"PURPOSE: The <e1>fluoropyrimidine carbamate</e1> (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<e2>TP</e2>) inside target tissues.","Substrate"
"PURPOSE: The <e1>fluoropyrimidine carbamate</e1> (capecitabine) is converted to 5-fluorouracil (5-FU) by <e2>thymidine phosphorylase</e2> (TP) inside target tissues.","Substrate"
"PURPOSE: The fluoropyrimidine carbamate (<e1>capecitabine</e1>) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (<e2>TP</e2>) inside target tissues.","Substrate"
"PURPOSE: The fluoropyrimidine carbamate (<e1>capecitabine</e1>) is converted to 5-fluorouracil (5-FU) by <e2>thymidine phosphorylase</e2> (TP) inside target tissues.","Substrate"
"<e1>Indomethacin</e1> abolished the inhibitory effect of acetazolamide on <e2>CA I</e2> and CA II.","Upregulator"
"<e1>Indomethacin</e1> abolished the inhibitory effect of acetazolamide on CA I and <e2>CA II</e2>.","Upregulator"
"Histamine and <e1>Ca</e1> added to NSAIDs amplified the activating effect of the latter on <e2>CA II</e2>.","Upregulator"
"Association of PGE2 or <e1>acetazolamide</e1> to NSAIDs reduced NSAID-induced activation of <e2>CA I</e2> and CA II.","Downregulator"
"Association of PGE2 or <e1>acetazolamide</e1> to NSAIDs reduced NSAID-induced activation of CA I and <e2>CA II</e2>.","Downregulator"
"Association of PGE2 or <e1>acetazolamide</e1> to NSAIDs reduced NSAID-induced activation of <e2>CA I</e2> and CA II.","Downregulator"
"Association of PGE2 or <e1>acetazolamide</e1> to NSAIDs reduced NSAID-induced activation of CA I and <e2>CA II</e2>.","Downregulator"
"Previous studies by this research team proved that vasodilating <e1>prostaglandins</e1> (PGs) E1, E2 and I2 inhibit <e2>carbonic anhydrase</e2> (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.","Downregulator"
"Previous studies by this research team proved that vasodilating <e1>prostaglandins</e1> (PGs) E1, E2 and I2 inhibit carbonic anhydrase (<e2>CA</e2>) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.","Downregulator"
"Previous studies by this research team proved that vasodilating prostaglandins (<e1>PGs</e1>) E1, E2 and I2 inhibit <e2>carbonic anhydrase</e2> (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.","Downregulator"
"Previous studies by this research team proved that vasodilating prostaglandins (<e1>PGs</e1>) E1, E2 and I2 inhibit carbonic anhydrase (<e2>CA</e2>) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.","Downregulator"
"AIMS: To compare the effects of <e1>nabumetone</e1> and meloxicam, two cyclo-oxygenase-2 (<e2>COX-2</e2>) preferential nonsteroidal anti-inflammatory drugs (NSAIDs), on platelet COX-1 activity and platelet function.","Downregulator"
"<e2>COX-1</e2> inhibition was measured as percentage inhibition of serum <e1>TXB2</e1> generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100.","Substrate"
"Treatment with <e1>diclofenac</e1> resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated <e2>caspase-3</e2> after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.","Upregulator"
"Treatment with <e1>diclofenac</e1> resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated <e2>caspase</e2>-3 after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.","Upregulator"
"Correlation between activation of <e2>PPARγ</e2> and resistin downregulation in a mouse adipocyte cell line by a series of <e1>thiazolidinediones</e1>.","Upregulator"
"Correlation between activation of PPARγ and <e2>resistin</e2> downregulation in a mouse adipocyte cell line by a series of <e1>thiazolidinediones</e1>.","Downregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (<e1>sulforaphane</e1>, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Regulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (<e1>sulforaphane</e1>, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (<e1>sulforaphane</e1>, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (sulforaphane, <e1>tert-butylhydroquinone</e1>, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (sulforaphane, <e1>tert-butylhydroquinone</e1>, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, <e1>cinnamic aldehyde</e1>, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, <e1>cinnamic aldehyde</e1>, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>hydrogen peroxide</e1>) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>hydrogen peroxide</e1>) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported <e2>NRF2</e2> target genes in response to NRF2 inducers (<e1>sulforaphane</e1>, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (<e1>sulforaphane</e1>, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the <e2>aldo-keto reductase (AKR) 1C1</e2> is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, <e1>tert-butylhydroquinone</e1>, cinnamic aldehyde, and hydrogen peroxide) showed that the <e2>aldo-keto reductase (AKR) 1C1</e2> is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, <e1>cinnamic aldehyde</e1>, and hydrogen peroxide) showed that the <e2>aldo-keto reductase (AKR) 1C1</e2> is highly inducible by all treatments.","Upregulator"
"Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and <e1>hydrogen peroxide</e1>) showed that the <e2>aldo-keto reductase (AKR) 1C1</e2> is highly inducible by all treatments.","Upregulator"
"The treatment of U937 cells with NRF2 inducers including <e1>sulforaphane</e1> effectively elevated the expression of <e2>AKR1B1, 1B10, 1C1, 1C2, and 1C3</e2>.","Upregulator"
"Whereas, the levels of both the basal and <e1>sulforaphane</e1>-inducible expression of <e2>AKR1C1</e2> were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells.","Upregulator"
"Cellular mechanisms of insulin resistance: role of stress-regulated <e1>serine</e1> kinases and insulin receptor substrates (<e2>IRS</e2>) serine phosphorylation.","Part_of"
"<e2>Insulin receptor substrates</e2> (IRS) <e1>serine</e1> phosphorylation is a time-controlled physiological feedback mechanism in insulin signaling that is hijacked by metabolic and inflammatory stresses to promote insulin resistance.","Part_of"
"Cellular mechanisms of insulin resistance: role of stress-regulated <e1>serine</e1> kinases and insulin receptor substrates (<e2>IRS</e2>) serine phosphorylation.","Part_of"
"Cellular mechanisms of insulin resistance: role of stress-regulated <e1>serine</e1> kinases and insulin receptor substrates (<e2>IRS</e2>) serine phosphorylation.","Part_of"
"Cellular mechanisms of insulin resistance: role of stress-regulated <e1>serine</e1> kinases and <e2>insulin receptor substrates</e2> (IRS) serine phosphorylation.","Part_of"
"<e2>Endothelial NO synthase</e2> expression was increased by cilazapril but not by <e1>losartan</e1>.","Not"
"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by <e1>losartan</e1> and cilazapril treatments, whereas no changes in the expression of <e2>rat ACE</e2> and AT1A receptor genes were observed.","Not"
"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by <e1>losartan</e1> and cilazapril treatments, whereas no changes in the expression of rat ACE and <e2>AT1A</e2> receptor genes were observed.","Not"
"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and <e1>cilazapril</e1> treatments, whereas no changes in the expression of <e2>rat ACE</e2> and AT1A receptor genes were observed.","Not"
"Human and rat renin and angiotensinogen genes were downregulated in dTGR and were increased by losartan and <e1>cilazapril</e1> treatments, whereas no changes in the expression of rat ACE and <e2>AT1A</e2> receptor genes were observed.","Not"
"<e2>Endothelial NO synthase</e2> expression was increased by <e1>cilazapril</e1> but not by losartan.","Upregulator"
"<e2>Human and rat renin</e2> and angiotensinogen genes were downregulated in dTGR and were increased by <e1>losartan</e1> and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.","Upregulator"
"Human and rat renin and <e2>angiotensinogen</e2> genes were downregulated in dTGR and were increased by <e1>losartan</e1> and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.","Upregulator"
"<e2>Human and rat renin</e2> and angiotensinogen genes were downregulated in dTGR and were increased by losartan and <e1>cilazapril</e1> treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.","Upregulator"
"Human and rat renin and <e2>angiotensinogen</e2> genes were downregulated in dTGR and were increased by losartan and <e1>cilazapril</e1> treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.","Upregulator"
"<e1>Angiotensin</e1>-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with <e2>human renin</e2> and angiotensinogen genes.","Cofactor"
"<e1>Angiotensin</e1>-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and <e2>angiotensinogen</e2> genes.","Cofactor"
"A novel SCN5A arrhythmia mutation, <e2>M1766L</e2>, with expression defect rescued by <e1>mexiletine</e1>.","Regulator"
"A novel <e2>SCN5A</e2> arrhythmia mutation, M1766L, with expression defect rescued by <e1>mexiletine</e1>.","Regulator"
"RESULTS: The <e2>M1766L</e2> mutation caused a significant decrease in the <e1>sodium</e1> channel expression.","Upregulator"
"<e1>OMT</e1> showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of <e2>Bcl-2</e2> family.","Upregulator"
"<e1>OMT</e1> showed partial protection in the cortical neurons via down-regulation of NR2B containing <e2>NMDA receptors</e2> and up-regulation of Bcl-2 family.","Downregulator"
"Western blot analysis revealed that <e1>OMT</e1> decreased the expression of <e2>Bax</e2> and repaired the balance of pro- and anti-apoptotic proteins.","Downregulator"
"Furthermore, <e1>OMT</e1> significantly reversed the up-regulation of <e2>NR2B</e2> and inhibited the calcium overload in the cultured neurons after challenging the NMDA.","Downregulator"
"Furthermore, <e1>OMT</e1> significantly reversed the up-regulation of <e2>NR2B</e2> and inhibited the calcium overload in the cultured neurons after challenging the NMDA.","Downregulator"
"<e1>Emodin-6-O-β-D-glucoside</e1> inhibits <e2>HMGB1</e2>-induced inflammatory responses in vitro and in vivo.","Downregulator"
"<e1>Ramelteon</e1> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin <e2>MT(1)</e2>/MT(2) receptor agonist.","Agonist"
"<e1>Ramelteon</e1> (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/<e2>MT(2)</e2> receptor agonist.","Agonist"
"Unlike the sedative hypnotics that target GABA(A) receptor complexes, <e1>ramelteon</e1> is a chronohypnotic that acts on the melatonin <e2>MT(1)</e2> and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's ""master clock.""","Agonist"
"Unlike the sedative hypnotics that target GABA(A) receptor complexes, <e1>ramelteon</e1> is a chronohypnotic that acts on the melatonin MT(1) and <e2>MT(2)</e2> receptors, which are primarily located in the suprachiasmatic nucleus, the body's ""master clock.""","Agonist"
"Pharmacology of <e1>ramelteon</e1>, a selective <e2>MT1</e2>/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.","Agonist"
"Pharmacology of <e1>ramelteon</e1>, a selective MT1/<e2>MT2</e2> receptor agonist: a novel therapeutic drug for sleep disorders.","Agonist"
"<e1>Am80</e1> inhibited VEGF-induced phosphorylation of <e2>VEGF receptor</e2>.","Downregulator"
"<e1>Am80</e1> slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by <e2>VEGF</e2>.","Downregulator"
"<e1>Am80</e1> slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by <e2>VEGF</e2>.","Downregulator"
"<e1>Am80</e1> slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by <e2>VEGF</e2>.","Downregulator"
"<e1>Felodipine</e1> and nicardipine have similar affinities for 60-kDa <e2>CaMPDE</e2> isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by dihydropyridine Ca2+-channel blockers.","Regulator"
"We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and <e1>nicardipine</e1> on <e2>CaMPDE</e2>.","Regulator"
"We have examined the effect of dihydropyridine <e2>Ca2+-channel</e2> blockers <e1>felodipine</e1> and nicardipine on CaMPDE.","Downregulator"
"We have examined the effect of dihydropyridine <e2>Ca2+-channel</e2> blockers felodipine and <e1>nicardipine</e1> on CaMPDE.","Downregulator"
"The results suggest that the 63-kDa (<e2>PDE 1B1</e2>) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by <e1>felodipine</e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.","Downregulator"
"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (<e2>PDE 1A2</e2>) CaMPDE isozymes are inhibited by <e1>felodipine</e1> and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.","Downregulator"
"We have examined the effect of dihydropyridine Ca2+-channel blockers <e1>felodipine</e1> and nicardipine on <e2>CaMPDE</e2>.","Downregulator"
"The results suggest that the 63-kDa (<e2>PDE 1B1</e2>) and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and <e1>nicardipine</e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.","Downregulator"
"The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (<e2>PDE 1A2</e2>) CaMPDE isozymes are inhibited by felodipine and <e1>nicardipine</e1> by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other.","Downregulator"
"We have examined the effect of dihydropyridine Ca2+-channel blockers felodipine and <e1>nicardipine</e1> on <e2>CaMPDE</e2>.","Downregulator"
"We have examined the effect of <e1>dihydropyridine</e1> Ca2+-channel blockers felodipine and nicardipine on <e2>CaMPDE</e2>.","Downregulator"
"We have examined the effect of <e1>dihydropyridine</e1> <e2>Ca2+-channel</e2> blockers felodipine and nicardipine on CaMPDE.","Downregulator"
"We have examined the effect of <e1>dihydropyridine</e1> <e2>Ca2+-channel</e2> blockers felodipine and nicardipine on CaMPDE.","Downregulator"
"Several inhibitors of <e2>Lp-PLA(2)</e2> have been described, including <e1>darapladib</e1>, which is currently in phase 3 clinical development for the treatment of atherosclerosis.","Downregulator"
"Several inhibitors of <e2>Lp-PLA(2)</e2> have been described, including <e1>darapladib</e1>, which is currently in phase 3 clinical development for the treatment of atherosclerosis.","Downregulator"
"We show that both darapladib and a novel class of structurally distinct <e1>carbamate</e1> inhibitors inactivate <e2>Lp-PLA(2)</e2> in mouse tissues and human cell lines with high selectivity.","Downregulator"
"Sepracor in the US is developing ar<e1>formoterol</e1> [R,R-formoterol], a single isomer form of the <e2>beta(2)-adrenoceptor</e2> agonist formoterol [eformoterol].","Agonist"
"Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the <e2>beta(2)-adrenoceptor</e2> agonist formoterol [<e1>eformoterol</e1>].","Agonist"
"Nitric oxide products of <e1>VP-16</e1> displayed significantly diminished <e2>topoisomerase II</e2>-dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells.","Downregulator"
"Triacsin C, a competitive inhibitor of both <e2>ACS</e2>1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified <e1>triacsin</e1>-sensitive ACS is present in mitochondria.","Regulator"
"Re-feeding normal chow or a high <e1>sucrose</e1> diet for 24 h after a 48-h fast increased both <e2>ACS1</e2> and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies.","Upregulator"
"Re-feeding normal chow or a high <e1>sucrose</e1> diet for 24 h after a 48-h fast increased both ACS1 and <e2>ACS4</e2> protein expression 1.5-2.0-fold, consistent with inhibition studies.","Upregulator"
"Consistent with these locations, <e1>N-ethylmaleimide</e1>, an inhibitor of <e2>ACS4</e2>, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.","Downregulator"
"Consistent with these locations, <e1>N-ethylmaleimide</e1>, an inhibitor of <e2>ACS</e2>4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.","Downregulator"
"<e1>Troglitazone</e1>, a second <e2>ACS4</e2> inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM.","Downregulator"
"<e1>Troglitazone</e1>, a second <e2>ACS</e2>4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM.","Downregulator"
"<e1>Triacsin C</e1>, a competitive inhibitor of both <e2>ACS1</e2> and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.","Downregulator"
"<e1>Triacsin C</e1>, a competitive inhibitor of both ACS1 and <e2>ACS4</e2>, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.","Downregulator"
"<e1>Triacsin C</e1>, a competitive inhibitor of both <e2>ACS</e2>1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.","Downregulator"
"These results suggest that <e2>ACS1</e2> and ACS4 may be linked to <e1>triacylglycerol</e1> synthesis.","Substrate"
"These results suggest that ACS1 and <e2>ACS4</e2> may be linked to <e1>triacylglycerol</e1> synthesis.","Substrate"
"The tyrosine kinase inhibitor <e1>ZD1839</e1> (""Iressa"") inhibits <e2>HER2</e2>-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Regulator"
"The <e2>tyrosine kinase</e2> inhibitor <e1>ZD1839</e1> (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Downregulator"
"<e1>ZD1839</e1> (""Iressa""), a quinazoline tyrosine kinase inhibitor selective for the <e2>EGFR</e2>, has shown good activity in preclinical studies and in the early phase of clinical trials.","Downregulator"
"The <e2>tyrosine kinase</e2> inhibitor ZD1839 (""<e1>Iressa</e1>"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Downregulator"
"ZD1839 (""<e1>Iressa</e1>""), a quinazoline tyrosine kinase inhibitor selective for the <e2>EGFR</e2>, has shown good activity in preclinical studies and in the early phase of clinical trials.","Downregulator"
"The <e2>tyrosine kinase</e2> inhibitor <e1>ZD1839</e1> (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Downregulator"
"The tyrosine kinase inhibitor <e1>ZD1839</e1> (""Iressa"") inhibits <e2>HER2</e2>-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Downregulator"
"The tyrosine kinase inhibitor ZD1839 (""<e1>Iressa</e1>"") inhibits <e2>HER2</e2>-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Downregulator"
"The <e2>tyrosine kinase</e2> inhibitor ZD1839 (""<e1>Iressa</e1>"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Downregulator"
"The tyrosine kinase inhibitor ZD1839 (""<e1>Iressa</e1>"") inhibits <e2>HER2</e2>-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Downregulator"
"The <e1>tyrosine</e1> kinase inhibitor ZD1839 (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Substrate"
"The <e1>tyrosine</e1> kinase inhibitor ZD1839 (""Iressa"") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.","Substrate"
"ZD1839 (""Iressa""), a <e1>quinazoline tyrosine</e1> kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.","Substrate"
"Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with <e1>phosphatidylinositol</e1> 3-kinase, and down-regulation of Akt activity.","Substrate"
"[Pharmacological effects of a <e2>mu-opioid receptor</e2> antagonist <e1>naltrexone</e1> on alcohol dependence].","Antagonist"
"[Pharmacological effects of a <e2>mu-opioid receptor</e2> antagonist <e1>naltrexone</e1> on alcohol dependence].","Antagonist"
"RATIONALE: There is substantial evidence that <e1>lisuride</e1> can produce effects linked to <e2>5-HT(1A)</e2> receptor occupancy.","Regulator"
"RATIONALE: There is substantial evidence that <e1>lisuride</e1> can produce effects linked to <e2>5-HT(1A)</e2> receptor occupancy.","Regulator"
"Nevertheless, this action has generally been ignored in the mechanism of action of <e1>lisuride</e1>, in favor of an exclusive role for <e2>dopamine receptors</e2> in considering its antiparkinsonian effects, or an exclusive role of 5-HT(2A/2C) receptor activation in hallucinogenesis.","Regulator"
"RATIONALE: There is substantial evidence that <e1>lisuride</e1> can produce effects linked to <e2>5-HT(1A)</e2> receptor occupancy.","Regulator"
"<e1>Lisuride</e1> produced a significant dose-related increase in flat body posture, forepaw treading, and lower-lip retraction which reflect a modulation of behavior by action at central <e2>5-HT(1A)</e2> receptors.","Regulator"
"RESULTS: In drug discrimination studies, lisuride fully mimicked the <e2>5-HT(1A)</e2> agonist <e1>LY 293284</e1>, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.","Agonist"
"RATIONALE: There is substantial evidence that <e1>lisuride</e1> can produce effects linked to <e2>5-HT(1A)</e2> receptor occupancy.","Agonist"
"RESULTS: In drug discrimination studies, lisuride fully mimicked the <e2>5-HT(1A)</e2> agonist <e1>LY 293284</e1>, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.","Agonist"
"Only pMPPI [<e1>4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride</e1>], a selective <e2>5-HT(1A)</e2> antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.","Antagonist"
"To eliminate the interaction of <e1>bupropion</e1> with <e2>DAT</e2> or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer.","Downregulator"
"To eliminate the interaction of <e1>bupropion</e1> with DAT or <e2>NET</e2>, nomifensine or desipramine, respectively, was included in the superfusion buffer.","Downregulator"
"Recently, <e1>bupropion</e1> has been reported to noncompetitively inhibit alpha3beta2, alpha3beta4, and alpha4beta2 nicotinic acetylcholine receptors (<e2>nAChR</e2>s) expressed in Xenopus oocytes or established cell lines.","Downregulator"
"<e1>Bupropion</e1>, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (<e2>DAT</e2> and NET, respectively).","Downregulator"
"<e1>Bupropion</e1>, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and <e2>NET</e2>, respectively).","Downregulator"
"To eliminate the interaction of <e1>bupropion</e1> with <e2>DAT</e2> or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer.","Downregulator"
"To eliminate the interaction of <e1>bupropion</e1> with DAT or <e2>NET</e2>, nomifensine or desipramine, respectively, was included in the superfusion buffer.","Downregulator"
"The present results indicated that <e1>N</e1>-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of <e2>caspase-9</e2> and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.","Upregulator"
"The present results indicated that <e1>N</e1>-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and <e2>caspase-3</e2>, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.","Upregulator"
"The present results indicated that N-<e1>BPs</e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of <e2>caspase-9</e2> and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.","Upregulator"
"The present results indicated that N-<e1>BPs</e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and <e2>caspase-3</e2>, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.","Upregulator"
"<e1>Nitrogen</e1>-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>Bim</e2>-mediated activation of the intrinsic apoptotic pathway.","Upregulator"
"Nitrogen-containing <e1>bisphosphonates</e1> induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>Bim</e2>-mediated activation of the intrinsic apoptotic pathway.","Upregulator"
"<e1>N</e1>itrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>Bim</e2>-mediated activation of the intrinsic apoptotic pathway.","Upregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced <e2>Bim</e2> expression.","Upregulator"
"<e1>N</e1>itrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and <e2>Bim</e2>-mediated activation of the intrinsic apoptotic pathway.","Upregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced <e2>Bim</e2> expression.","Upregulator"
"Furthermore, <e1>N</e1>-BPs decreased the levels of <e2>phosphorylated extracellular signal-regulated kinase</e2> (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, <e1>N</e1>-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>ERK</e2>) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, <e1>N</e1>-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>mTOR</e2> via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of <e2>phosphorylated extracellular signal-regulated kinase</e2> (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>ERK</e2>) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>mTOR</e2> via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"<e1>N</e1>itrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of <e2>Ras</e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of <e2>Ras</e2> prenylation and enhanced Bim expression.","Downregulator"
"<e1>N</e1>itrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of <e2>Ras</e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.","Downregulator"
"The present results indicated that <e1>N</e1>-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/<e2>MEK</e2>/ERK and Ras/mTOR pathways.","Downregulator"
"Furthermore, <e1>N</e1>-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>ERK</e2>) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"<e1>N</e1>itrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of <e2>Ras</e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.","Downregulator"
"Furthermore, <e1>N</e1>-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>mTOR</e2> via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of <e2>Ras</e2> prenylation and enhanced Bim expression.","Downregulator"
"The present results indicated that N-<e1>BPs</e1> induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/<e2>MEK</e2>/ERK and Ras/mTOR pathways.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (<e2>ERK</e2>) and mTOR via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of <e2>Ras</e2> prenylation and enhanced Bim expression.","Downregulator"
"Furthermore, N-<e1>BPs</e1> decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and <e2>mTOR</e2> via suppression of Ras prenylation and enhanced Bim expression.","Downregulator"
"<e1>Nitrogen</e1>-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of <e2>Ras</e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.","Downregulator"
"Nitrogen-containing <e1>bisphosphonates</e1> induce apoptosis of hematopoietic tumor cells via inhibition of <e2>Ras</e2> signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.","Downregulator"
"<e1>Nitrogen</e1>-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins</e2>.","Downregulator"
"Nitrogen-containing <e1>bisphosphonates</e1> (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins</e2>.","Downregulator"
"<e1>N</e1>itrogen-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins</e2>.","Downregulator"
"Nitrogen-containing bisphosphonates (N-<e1>BPs</e1>) induce apoptosis in tumor cells by inhibiting the prenylation of small <e2>G-proteins</e2>.","Downregulator"
"The present study investigated the role of calcium/calmodulin-dependent <e1>serine</e1> protein kinase CASK in interacting and controlling <e2>P2X3</e2> receptor expression and function in mouse trigeminal ganglia.","Part_of"
"The reduction of <e2>P2X3</e2> expression levels was reversed by the proteasomal inhibitor <e1>MG-132</e1>.","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of <e2>Cdx2</e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).","Regulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of Cdx2 and <e2>MUC2</e2> in normal rat gastric epithelial cells (RGM-1 cells).","Regulator"
"The effects of CDCA and <e1>GW4064</e1> on expression of <e2>Cdx2</e2> and MUC2 were abolished by guggulsterone.","Regulator"
"The effects of CDCA and <e1>GW4064</e1> on expression of Cdx2 and <e2>MUC2</e2> were abolished by guggulsterone.","Regulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the <e1>chenodeoxycholic acid</e1> (CDCA)-induced expression of <e2>Cdx2</e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the <e1>chenodeoxycholic acid</e1> (CDCA)-induced expression of Cdx2 and <e2>MUC2</e2> in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of <e2>Cdx2</e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of Cdx2 and <e2>MUC2</e2> in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of <e2>Cdx2</e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of Cdx2 and <e2>MUC2</e2> in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of <e2>Cdx2</e2> and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of Cdx2 and <e2>MUC2</e2> in normal rat gastric epithelial cells (RGM-1 cells).","Upregulator"
"The effects of CDCA and GW4064 on expression of <e2>Cdx2</e2> and MUC2 were abolished by <e1>guggulsterone</e1>.","Downregulator"
"The effects of CDCA and GW4064 on expression of Cdx2 and <e2>MUC2</e2> were abolished by <e1>guggulsterone</e1>.","Downregulator"
"We investigated the involvement of the farnesoid X receptor (<e2>FXR</e2>), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<e1>CDCA</e1>)-induced expression of Cdx2 and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).","Agonist"
"RGM-1 cells were treated with CDCA or <e1>GW4064</e1>, an <e2>FXR</e2> agonist, in the presence or absence of guggulsterone, an FXR antagonist.","Agonist"
"RGM-1 cells were treated with CDCA or GW4064, an <e2>FXR</e2> agonist, in the presence or absence of <e1>guggulsterone</e1>, an FXR antagonist.","Antagonist"
"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of <e1>[(125)I] RTI-55</e1> at HEK-<e2>hDAT</e2>, HEK-hSERT, and HEK-hNET cells.","Regulator"
"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of <e1>[(125)I] RTI-55</e1> at HEK-hDAT, HEK-<e2>hSERT</e2>, and HEK-hNET cells.","Regulator"
"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and NE and inhibit binding of <e1>[(125)I] RTI-55</e1> at HEK-hDAT, HEK-hSERT, and HEK-<e2>hNET</e2> cells.","Regulator"
"The <e1>4',7,8-trichloro</e1> analogue (38) of mazindol was the most potent and selective ligand for HEK-<e2>hDAT</e2> cells (DAT K(i) = 1.1 nM; SERT/DAT = 1283 and NET/DAT = 38).","Regulator"
"The <e1>4',7,8-trichloro</e1> analogue (38) of mazindol was the most potent and selective ligand for HEK-h<e2>DAT</e2> cells (DAT K(i) = 1.1 nM; SERT/DAT = 1283 and NET/DAT = 38).","Regulator"
"The <e1>4',7,8-trichloro</e1> analogue (38) of mazindol was the most potent and selective ligand for HEK-hDAT cells (DAT K(i) = 1.1 nM; <e2>SERT</e2>/DAT = 1283 and NET/DAT = 38).","Regulator"
"The <e1>4',7,8-trichloro</e1> analogue (38) of mazindol was the most potent and selective ligand for HEK-h<e2>DAT</e2> cells (DAT K(i) = 1.1 nM; SERT/DAT = 1283 and NET/DAT = 38).","Regulator"
"The <e1>4',7,8-trichloro</e1> analogue (38) of mazindol was the most potent and selective ligand for HEK-hDAT cells (DAT K(i) = 1.1 nM; SERT/DAT = 1283 and <e2>NET</e2>/DAT = 38).","Regulator"
"The <e1>4',7,8-trichloro</e1> analogue (38) of mazindol was the most potent and selective ligand for HEK-h<e2>DAT</e2> cells (DAT K(i) = 1.1 nM; SERT/DAT = 1283 and NET/DAT = 38).","Regulator"
"Mazindane (26) was found to be a pro-drug, oxidizing (5-H --> 5-OH) to <e1>mazindol</e1> on rat striatal membranes and HEK-<e2>hDAT</e2> cells.","Regulator"
"A series of <e1>mazindol</e1> (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"The 4',7,8-trichloro analogue (38) of <e1>mazindol</e1> was the most potent and selective ligand for HEK-hDAT cells (DAT K(i) = 1.1 nM; <e2>SERT</e2>/DAT = 1283 and NET/DAT = 38).","Regulator"
"A series of <e1>mazindol</e1> (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"The 4',7,8-trichloro analogue (38) of <e1>mazindol</e1> was the most potent and selective ligand for HEK-hDAT cells (DAT K(i) = 1.1 nM; SERT/DAT = 1283 and <e2>NET</e2>/DAT = 38).","Regulator"
"A series of <e1>mazindol</e1> (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of <e1>mazindol</e1> (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the <e2>dopamine transporter</e2> (DAT) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of <e1>mazindol</e1> (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant <e1>aryl</e1> group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the <e2>dopamine transporter</e2> (DAT) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant <e1>aryl</e1> group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the <e1>benzo</e1> ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the <e2>dopamine transporter</e2> (DAT) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the <e1>benzo</e1> ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, <e1>methoxy</e1>, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the <e2>dopamine transporter</e2> (DAT) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, <e1>methoxy</e1>, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and <e1>alkyl</e1> groups replacing the hydroxyl group were synthesized, and their binding affinities at the <e2>dopamine transporter</e2> (DAT) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and <e1>alkyl</e1> groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the <e1>hydroxyl</e1> group were synthesized, and their binding affinities at the <e2>dopamine transporter</e2> (DAT) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the <e1>hydroxyl</e1> group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and <e1>homomazindol</e1> (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the <e2>dopamine transporter</e2> (DAT) on rat or guinea pig striatal membranes were determined.","Regulator"
"A series of mazindol (2) and <e1>homomazindol</e1> (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the dopamine transporter (<e2>DAT</e2>) on rat or guinea pig striatal membranes were determined.","Regulator"
"<e1>Mazindol</e1> analogues as potential inhibitors of the <e2>cocaine binding site</e2> at the dopamine transporter.","Downregulator"
"<e1>Mazindol</e1> analogues as potential inhibitors of the cocaine binding site at the <e2>dopamine transporter</e2>.","Downregulator"
"Several active analogues were also evaluated for their ability to block uptake of DA, <e1>5-HT</e1>, and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-<e2>hSERT</e2>, and HEK-hNET cells.","Substrate"
"Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and <e1>NE</e1> and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-<e2>hNET</e2> cells.","Substrate"
"Mazindol analogues as potential inhibitors of the cocaine binding site at the <e1>dopamine</e1> transporter.","Substrate"
"Several active analogues were also evaluated for their ability to block uptake of <e1>DA</e1>, 5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-<e2>hDAT</e2>, HEK-hSERT, and HEK-hNET cells.","Substrate"
"<e1>Glyphosate</e1> affects aromatic amino acid biosynthesis by inhibiting <e2>5-enolpyruvylshikimate-3-phosphate synthase</e2> (EPSPS).","Downregulator"
"<e1>Glyphosate</e1> affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase (<e2>EPSPS</e2>).","Downregulator"
"<e1>Glufosinate</e1> inhibits <e2>glutamine synthetase</e2> and blocks biosynthesis of glutamine.","Downregulator"
"Glufosinate inhibits <e1>glutamine</e1> synthetase and blocks biosynthesis of glutamine.","Substrate"
"Fasting plasma glucose (FPG), fasting plasma insulin, <e1>C</e1>-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL.","Part_of"
"Mechanisms of Glucose Lowering of <e2>Dipeptidyl Peptidase-4</e2> Inhibitor <e1>Sitagliptin</e1> When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.","Downregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Regulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, <e2>Cyp1a2</e2>, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Regulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, Cyp1a2, or <e2>Cyp1b1</e2> mRNA, protein, or catalytic activity levels.","Regulator"
"Modulation of cytochrome P450 1 (<e2>Cyp1</e2>) by <e1>vanadium</e1> in hepatic tissue and isolated hepatocyte of C57BL/6 mice.","Regulator"
"The objective of the current study was to investigate the effect of vanadium (<e1>V(5+)</e1>) on <e2>Cyp1</e2> expression and activity in C57BL/6 mice liver and isolated hepatocytes.","Regulator"
"Modulation of <e2>cytochrome P450 1</e2> (Cyp1) by <e1>vanadium</e1> in hepatic tissue and isolated hepatocyte of C57BL/6 mice.","Regulator"
"Modulation of cytochrome P450 1 (<e2>Cyp1</e2>) by <e1>vanadium</e1> in hepatic tissue and isolated hepatocyte of C57BL/6 mice.","Regulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Regulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, <e2>Cyp1a2</e2>, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, Cyp1a2, or <e2>Cyp1b1</e2> mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, <e2>Cyp1a2</e2>, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, Cyp1a2, or <e2>Cyp1b1</e2> mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, <e2>Cyp1a2</e2>, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, Cyp1a2, or <e2>Cyp1b1</e2> mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, <e2>Cyp1a2</e2>, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, Cyp1a2, or <e2>Cyp1b1</e2> mRNA, protein, or catalytic activity levels.","Upregulator"
"<e1>V(5+)</e1> also increased <e2>serum hemoglobin</e2> (Hb) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with Hb alone or in the presence of TCDD, there was an increase in the AhR-dependent luciferase activity.","Upregulator"
"<e1>V(5+)</e1> also increased serum hemoglobin (<e2>Hb</e2>) levels in animals treated for 24 h. Upon treatment of isolated hepatocytes with Hb alone or in the presence of TCDD, there was an increase in the AhR-dependent luciferase activity.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"Furthermore, V(5+) significantly inhibited the <e1>TCDD</e1>-induced <e2>AhR</e2>-dependent luciferase activity.","Upregulator"
"Furthermore, V(5+) significantly inhibited the <e1>TCDD</e1>-induced <e2>AhR</e2>-dependent luciferase activity.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, <e2>Cyp1a2</e2>, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with V(5+) (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter Cyp1a1, Cyp1a2, or <e2>Cyp1b1</e2> mRNA, protein, or catalytic activity levels.","Upregulator"
"For this purpose, C57BL6 mice were injected intraperitoneally with <e1>V(5+)</e1> (5 mg/kg) in the absence and presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (15 μg/kg) for 6 and 24 h. Furthermore, isolated hepatocytes from C57BL6 mice were treated with V(5+) (5, 10, and 20 μM) in the absence and presence of TCDD (1 nM) for 3, 6, 12, and 24 h. In vivo, V(5+) alone did not significantly alter <e2>Cyp1a1</e2>, Cyp1a2, or Cyp1b1 mRNA, protein, or catalytic activity levels.","Downregulator"
"Furthermore, <e1>V(5+)</e1> significantly inhibited the TCDD-induced <e2>AhR</e2>-dependent luciferase activity.","Downregulator"
"<e1>GCS</e1> therapy results in reduced mRNA expression of interleukin-4 (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of <e2>IFN-gamma</e2>.","Not"
"Interestingly, two categories of clones were distinguished based on the effects of <e1>GCS</e1> on <e2>IL-2</e2> production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Regulator"
"Interestingly, two categories of clones were distinguished based on the effects of <e1>GCS</e1> on IL-2 production and <e2>IL-2R alpha</e2> expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Regulator"
"Interestingly, two categories of clones were distinguished based on the effects of GCS on <e2>IL-2</e2> production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers <e1>DEX</e1> blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Regulator"
"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and <e2>IL-2R alpha</e2> expression and proliferation; 1) In low IL-2 producers <e1>DEX</e1> blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Upregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>IFN-gamma</e2> in all 20 clones tested.","Upregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of <e2>IL-4</e2>, IL-5 and IFN-gamma in all 20 clones tested.","Upregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of <e2>IL-4</e2>, IL-5 and IFN-gamma in all 20 clones tested.","Downregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of IL-4, <e2>IL-5</e2> and IFN-gamma in all 20 clones tested.","Downregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>IFN-gamma</e2> in all 20 clones tested.","Downregulator"
"<e1>GCS</e1> therapy results in reduced mRNA expression of <e2>interleukin-4</e2> (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.","Downregulator"
"<e1>GCS</e1> therapy results in reduced mRNA expression of interleukin-4 (<e2>IL-4</e2>) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.","Downregulator"
"<e1>GCS</e1> therapy results in reduced mRNA expression of interleukin-4 (IL-4) and <e2>IL-5</e2> in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.","Downregulator"
"Interestingly, two categories of clones were distinguished based on the effects of GCS on <e2>IL-2</e2> production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers <e1>DEX</e1> blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Downregulator"
"Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and <e2>IL-2R alpha</e2> expression and proliferation; 1) In low IL-2 producers <e1>DEX</e1> blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Downregulator"
"Interestingly, two categories of clones were distinguished based on the effects of GCS on <e2>IL-2</e2> production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers <e1>DEX</e1> blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.","Downregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of <e2>IL-4</e2>, IL-5 and IFN-gamma in all 20 clones tested.","Downregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of IL-4, <e2>IL-5</e2> and IFN-gamma in all 20 clones tested.","Downregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>IFN-gamma</e2> in all 20 clones tested.","Downregulator"
"<e1>Dexamethasone</e1> (DEX) inhibited the anti-CD3-induced production of <e2>IL-4</e2>, IL-5 and IFN-gamma in all 20 clones tested.","Downregulator"
"<e1>Dexamethasone</e1> (DEX) inhibited the anti-CD3-induced production of IL-4, <e2>IL-5</e2> and IFN-gamma in all 20 clones tested.","Downregulator"
"<e1>Dexamethasone</e1> (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and <e2>IFN-gamma</e2> in all 20 clones tested.","Downregulator"
"Dexamethasone (<e1>DEX</e1>) inhibited the anti-<e2>CD3</e2>-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested.","Downregulator"
"In vitro studies with blood-derived T cells, however, show inhibition of all three <e2>cytokines</e2> by <e1>GCS</e1>.","Downregulator"
"<e1>Dexamethasone</e1> (DEX) inhibited the anti-<e2>CD3</e2>-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested.","Downregulator"
"In the present study, we identified <e1>amprenavir</e1>, a widely used HIV PI, as a potent <e2>PXR</e2>-selective agonist.","Not"
"In the present study, we identified <e1>amprenavir</e1>, a widely used HIV PI, as a potent <e2>PXR</e2>-selective agonist.","Regulator"
"<e1>Amprenavir</e1> efficiently activated <e2>PXR</e2> and induced PXR target gene expression in vitro and in vivo.","Upregulator"
"<e1>Amprenavir</e1> efficiently activated <e2>PXR</e2> and induced PXR target gene expression in vitro and in vivo.","Upregulator"
"<e1>Amprenavir</e1> efficiently activated <e2>PXR</e2> and induced PXR target gene expression in vitro and in vivo.","Upregulator"
"Pregnane X Receptor Mediates Dyslipidemia Induced by the <e2>HIV Protease</e2> Inhibitor <e1>Amprenavir</e1> in Mice.","Downregulator"
"In the present study, we identified <e1>amprenavir</e1>, a widely used HIV PI, as a potent <e2>PXR</e2>-selective agonist.","Agonist"
"Anti-diabetic Activity of <e1>Swertiamarin</e1> is due to an Active Metabolite, Gentianine, that Upregulates <e2>PPAR-γ</e2> Gene Expression in 3T3-L1 cells.","Not"
"<e1>Swertiamarin</e1> treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-γ and <e2>GLUT-4</e2>; however, there was a significant increase in the mRNA expression of adiponectin.","Not"
"Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, <e1>Gentianine</e1>, that Upregulates <e2>PPAR-γ</e2> Gene Expression in 3T3-L1 cells.","Upregulator"
"<e1>Swertiamarin</e1> treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-γ and GLUT-4; however, there was a significant increase in the mRNA expression of <e2>adiponectin</e2>.","Upregulator"
"On the other hand, treatment with <e1>gentianine</e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of <e2>PPAR-γ</e2>, GLUT-4 and adiponectin.","Upregulator"
"On the other hand, treatment with <e1>gentianine</e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-γ, <e2>GLUT-4</e2> and adiponectin.","Upregulator"
"On the other hand, treatment with <e1>gentianine</e1> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-γ, GLUT-4 and <e2>adiponectin</e2>.","Upregulator"
"<e1>Jaspamide</e1> also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the <e2>Kv11.1</e2> (hERG) channel was minimally affected.","Not"
"<e1>Jaspamide</e1> also inhibited other channels including Cav1.2, Cav3.2, and HCN2; however, the Kv11.1 (<e2>hERG</e2>) channel was minimally affected.","Not"
"The effects of <e1>jaspamide</e1> on human cardiomyocyte function and <e2>cardiac ion channel</e2> activity.","Regulator"
"<e1>Jaspamide</e1> also inhibited other channels including <e2>Cav1.2</e2>, Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.","Downregulator"
"<e1>Jaspamide</e1> also inhibited other channels including Cav1.2, <e2>Cav3.2</e2>, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.","Downregulator"
"<e1>Jaspamide</e1> also inhibited other channels including Cav1.2, Cav3.2, and <e2>HCN2</e2>; however, the Kv11.1 (hERG) channel was minimally affected.","Downregulator"
"<e1>Carvedilol</e1> modulates the expression of <e2>hypoxia-inducible factor-1alpha</e2> and vascular endothelial growth factor in a rat model of volume-overload heart failure.","Regulator"
"<e1>Carvedilol</e1> modulates the expression of hypoxia-inducible factor-1alpha and <e2>vascular endothelial growth factor</e2> in a rat model of volume-overload heart failure.","Regulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and <e2>NGF-beta</e2> to the baseline values.","Upregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of <e2>HIF-1alpha</e2>, VEGF, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF</e2>, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>BNP</e2>, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of <e2>HIF-1alpha</e2>, VEGF, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF</e2>, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>BNP</e2>, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of <e2>HIF-1alpha</e2>, VEGF, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF</e2>, BNP, and NGF-beta to the baseline values.","Downregulator"
"These effects were fully counteracted by dietary <e1>phenolics</e1> which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of <e2>p66Shc</e2> signalling molecule.","Downregulator"
"The deduced amino acid sequence showed significant identity to plant and mammalian <e2>serine racemases</e2> and contained conserved pyridoxal 5-phosphate (<e1>PLP</e1>)-binding lysine and PLP-interacting amino acid residues.","Part_of"
"The deduced <e1>amino acid</e1> sequence showed significant identity to plant and mammalian <e2>serine racemases</e2> and contained conserved pyridoxal 5-phosphate (PLP)-binding lysine and PLP-interacting amino acid residues.","Part_of"
"In this study, we cloned and sequenced a cDNA encoding a <e2>serine racemase</e2> from barley which contained an open reading frame encoding 337 <e1>amino acid</e1> residues.","Part_of"
"The deduced <e1>amino acid</e1> sequence showed significant identity to plant and mammalian <e2>serine racemases</e2> and contained conserved pyridoxal 5-phosphate (PLP)-binding lysine and PLP-interacting amino acid residues.","Part_of"
"The deduced amino acid sequence showed significant identity to plant and mammalian <e2>serine racemases</e2> and contained conserved <e1>pyridoxal 5-phosphate</e1> (PLP)-binding lysine and PLP-interacting amino acid residues.","Part_of"
"The deduced amino acid sequence showed significant identity to plant and mammalian <e2>serine racemases</e2> and contained conserved pyridoxal 5-phosphate (<e1>PLP</e1>)-binding lysine and PLP-interacting amino acid residues.","Part_of"
"The deduced amino acid sequence showed significant identity to plant and mammalian <e2>serine racemases</e2> and contained conserved pyridoxal 5-phosphate (PLP)-binding <e1>lysine</e1> and PLP-interacting amino acid residues.","Part_of"
"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not <e1>ATP</e1>, whereas mammalian <e2>serine racemase</e2> activity is increased by ATP.","Upregulator"
"The deduced amino acid sequence showed significant identity to plant and mammalian <e2>serine racemase</e2>s and contained conserved pyridoxal 5-phosphate (<e1>PLP</e1>)-binding lysine and PLP-interacting amino acid residues.","Cofactor"
"The enzyme requires PLP and divalent cations such as <e1>Ca(2+)</e1>, Mg(2+), or Mn(2+), but not ATP, whereas mammalian <e2>serine racemase</e2> activity is increased by ATP.","Cofactor"
"The enzyme requires PLP and divalent cations such as Ca(2+), <e1>Mg(2+)</e1>, or Mn(2+), but not ATP, whereas mammalian <e2>serine racemase</e2> activity is increased by ATP.","Cofactor"
"The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or <e1>Mn(2+)</e1>, but not ATP, whereas mammalian <e2>serine racemase</e2> activity is increased by ATP.","Cofactor"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (<e1>milrinone</e1>, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-<e2>phosphodiesterase</e2> activity.","Not"
"Blockade of PDE1 (<e1>8-methoxymethyl-3-isobutyl-1-methylxanthine</e1>, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-<e2>phosphodiesterase</e2> activity.","Not"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [<e1>erythro-9-(2-hydroxy-3-nonyl)adenine</e1>, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-<e2>phosphodiesterase</e2> activity.","Not"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [<e1>4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one</e1>], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-<e2>phosphodiesterase</e2> activity.","Not"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (<e1>zaprinast</e1>, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-<e2>phosphodiesterase</e2> activity.","Not"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [<e1>BRL-50481</e1> (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-<e2>phosphodiesterase</e2> activity.","Not"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (<e1>5-nitro-2,N,N-trimethylbenzenesulfonamide</e1>), 10 microM] did not alter renal ecto-<e2>phosphodiesterase</e2> activity.","Not"
"Administration of a concentration (100 microM) of <e1>dipyridamole</e1> that blocks <e2>PDE8</e2> inhibited ecto-phosphodiesterase activity (by 44%).","Not"
"Administration of a concentration (100 microM) of <e1>dipyridamole</e1> that blocks PDE8 inhibited ecto-<e2>phosphodiesterase</e2> activity (by 44%).","Not"
"Administration of a concentration (100 microM) of <e1>dipyridamole</e1> that blocks PDE8 inhibited ecto-<e2>phosphodiesterase</e2> activity (by 44%).","Downregulator"
"A broad-spectrum <e2>phosphodiesterase</e2> (PDE) inhibitor (<e1>1,3-isobutyl-1-methylxanthine</e1>, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.","Downregulator"
"A broad-spectrum phosphodiesterase (<e2>PDE</e2>) inhibitor (<e1>1,3-isobutyl-1-methylxanthine</e1>, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.","Downregulator"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], <e2>PDE3</e2> (<e1>milrinone</e1>, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Blockade of <e2>PDE1</e2> (<e1>8-methoxymethyl-3-isobutyl-1-methylxanthine</e1>, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), <e2>PDE2</e2> [<e1>erythro-9-(2-hydroxy-3-nonyl)adenine</e1>, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), <e2>PDE4</e2> (Ro 20-1724 [<e1>4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one</e1>], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), <e2>PDE5</e2> and PDE6 (<e1>zaprinast</e1>, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and <e2>PDE6</e2> (<e1>zaprinast</e1>, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and <e2>PDE7</e2> [<e1>BRL-50481</e1> (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and <e2>PDE7</e2> [BRL-50481 (<e1>5-nitro-2,N,N-trimethylbenzenesulfonamide</e1>), 10 microM] did not alter renal ecto-phosphodiesterase activity.","Downregulator"
"Administration of a concentration (100 microM) of <e1>dipyridamole</e1> that blocks <e2>PDE8</e2> inhibited ecto-phosphodiesterase activity (by 44%).","Downregulator"
"Administration of a concentration (100 microM) of <e1>dipyridamole</e1> that blocks PDE8 inhibited ecto-<e2>phosphodiesterase</e2> activity (by 44%).","Downregulator"
"However, a lower concentration of <e1>dipyridamole</e1> (3 microM) that blocks <e2>PDE9</e2>, PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.","Downregulator"
"However, a lower concentration of <e1>dipyridamole</e1> (3 microM) that blocks PDE9, <e2>PDE10</e2>, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.","Downregulator"
"However, a lower concentration of <e1>dipyridamole</e1> (3 microM) that blocks PDE9, PDE10, and <e2>PDE11</e2>, but not PDE8, did not inhibit ecto-phosphodiesterase activity.","Downregulator"
"In kidneys, stimulation of adenylyl cyclase causes egress of c<e1>AMP</e1>, conversion of cAMP to AMP by ecto-<e2>phosphodiesterase</e2>, and metabolism of AMP to adenosine by ecto-5'-nucleotidase.","Substrate"
"In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to <e1>adenosine</e1> by <e2>ecto-5'-nucleotidase</e2>.","Substrate"
"In kidneys, stimulation of adenylyl cyclase causes egress of <e1>cAMP</e1>, conversion of cAMP to AMP by ecto-<e2>phosphodiesterase</e2>, and metabolism of AMP to adenosine by ecto-5'-nucleotidase.","Substrate"
"In kidneys, stimulation of adenylyl cyclase causes egress of c<e1>AMP</e1>, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by <e2>ecto-5'-nucleotidase</e2>.","Substrate"
"The potential for <e1>ketoconazole</e1>, the archetypal strong inhibitor of <e2>CYP3A4</e2>, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.","Downregulator"
"The potential for <e1>ketoconazole</e1>, the archetypal strong inhibitor of <e2>CYP3A4</e2>, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.","Downregulator"
"<e1>Ambrisentan</e1> is an <e2>endothelin type A (ET(A))-selective receptor</e2> antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.","Antagonist"
"<e1>Ambrisentan</e1> is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by <e2>CYP3A4</e2>.","Substrate"
"Although <e2>thioredoxin reductase</e2> (TRR) inhibitors (<e1>aurothioglucose</e1> and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.","Downregulator"
"Although thioredoxin reductase (<e2>TRR</e2>) inhibitors (<e1>aurothioglucose</e1> and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.","Downregulator"
"Although <e2>thioredoxin reductase</e2> (TRR) inhibitors (aurothioglucose and <e1>Sb(III)</e1>) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.","Downregulator"
"Although thioredoxin reductase (<e2>TRR</e2>) inhibitors (aurothioglucose and <e1>Sb(III)</e1>) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.","Downregulator"
"Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect <e2>methyltransferase</e2> inhibitor periodate-oxidized <e1>adenosine</e1> was without effect.","Downregulator"
"Although <e2>glutathione S-transferase omega 1</e2> (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze <e1>DMAs(V)</e1> reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.","Substrate"
"Although glutathione S-transferase omega 1 (GSTO1) and <e2>arsenic methyltransferase</e2> have been shown or thought to catalyze <e1>DMAs(V)</e1> reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.","Substrate"
"The <e2>kinase</e2> activity of EGFR was little inhibited by <e1>TT-B</e1> in a cell-free system.","Downregulator"
"<e1>TT-B</e1> and anti-epidermal growth factor receptor (anti-<e2>EGFR</e2>) were antagonistic to each other in inhibiting the cell cycle progression of SC-6 from G0/G1 to S, suggesting that the two compounds share the same target, EGFR.","Downregulator"
"Thus, <e1>sorafenib</e1> may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of <e2>Raf</e2> and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling).","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and <e2>Kit</e2>), which play key roles in tumor progression and angiogenesis.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (<e2>VEGFR</e2>-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (<e2>PDGFR</e2>-beta and Kit), which play key roles in tumor progression and angiogenesis.","Downregulator"
"<e1>Sorafenib</e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and <e2>tyrosine kinases</e2> VEGFR/PDGFR in tumor vasculature.","Downregulator"
"<e1>Sorafenib</e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases <e2>VEGFR</e2>/PDGFR in tumor vasculature.","Downregulator"
"<e1>Sorafenib</e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/<e2>PDGFR</e2> in tumor vasculature.","Downregulator"
"<e1>Sorafenib</e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets <e2>RAF</e2>/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"<e1>Sorafenib</e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/<e2>MEK</e2>/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"<e1>Sorafenib</e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/<e2>ERK</e2> pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (<e1>BAY 43-9006</e1>, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and <e2>tyrosine kinases</e2> VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (<e1>BAY 43-9006</e1>, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases <e2>VEGFR</e2>/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (<e1>BAY 43-9006</e1>, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/<e2>PDGFR</e2> in tumor vasculature.","Downregulator"
"Sorafenib (<e1>BAY 43-9006</e1>, Nexavar), a dual-action inhibitor that targets <e2>RAF</e2>/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (<e1>BAY 43-9006</e1>, Nexavar), a dual-action inhibitor that targets RAF/<e2>MEK</e2>/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (<e1>BAY 43-9006</e1>, Nexavar), a dual-action inhibitor that targets RAF/MEK/<e2>ERK</e2> pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (BAY 43-9006, <e1>Nexavar</e1>), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and <e2>tyrosine kinases</e2> VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (BAY 43-9006, <e1>Nexavar</e1>), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases <e2>VEGFR</e2>/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (BAY 43-9006, <e1>Nexavar</e1>), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/<e2>PDGFR</e2> in tumor vasculature.","Downregulator"
"Sorafenib (BAY 43-9006, <e1>Nexavar</e1>), a dual-action inhibitor that targets <e2>RAF</e2>/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (BAY 43-9006, <e1>Nexavar</e1>), a dual-action inhibitor that targets RAF/<e2>MEK</e2>/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Sorafenib (BAY 43-9006, <e1>Nexavar</e1>), a dual-action inhibitor that targets RAF/MEK/<e2>ERK</e2> pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the <e2>vascular endothelial growth factor receptor</e2> family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (<e2>VEGFR-2</e2> and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and <e2>VEGFR-3</e2>) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and <e2>platelet-derived growth factor receptor</e2> family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (<e2>PDGFR-beta</e2> and Kit), which play key roles in tumor progression and angiogenesis.","Downregulator"
"Further characterization of <e1>sorafenib</e1> revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and <e2>Kit</e2>), which play key roles in tumor progression and angiogenesis.","Downregulator"
"A novel class of <e1>biaryl urea</e1> that inhibits <e2>C-RAF</e2> kinase was discovered using a combination of medicinal and combinatorial chemistry approaches.","Downregulator"
"A novel class of <e1>biaryl urea</e1> that inhibits C-RAF <e2>kinase</e2> was discovered using a combination of medicinal and combinatorial chemistry approaches.","Downregulator"
"<e1>Sorafenib</e1> (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine <e2>kinase</e2>s VEGFR/PDGFR in tumor vasculature.","Downregulator"
"<e1>Sorafenib</e1> inhibited the kinase activity of both <e2>C-RAF</e2> and B-RAF (wild type and V600E mutant).","Downregulator"
"<e1>Sorafenib</e1> inhibited the kinase activity of both C-RAF and <e2>B-RAF</e2> (wild type and V600E mutant).","Downregulator"
"<e1>Sorafenib</e1> inhibited the kinase activity of both C-RAF and B-RAF (wild type and <e2>V600E</e2> mutant).","Downregulator"
"In randomized controlled trials, bisphosphonates (pamidronate and zoledronic acid) and selective <e2>estrogen receptor</e2> modulators (raloxifene and <e1>toremifene</e1>) increased bone mineral density in GnRH agonist-treated men.","Regulator"
"In randomized controlled trials, bisphosphonates (pamidronate and zoledronic acid) and selective <e2>estrogen receptor</e2> modulators (<e1>raloxifene</e1> and toremifene) increased bone mineral density in GnRH agonist-treated men.","Regulator"
"The latter is the first in vivo open-ring metabolite of <e1>rapamycin</e1> that does not affect <e2>mTOR</e2>.","Regulator"
"We found that in vitro <e1>rapamycin</e1> also regulates the <e2>proteasome</e2>, an essential intracellular protease of the ubiquitin-proteasome pathway.","Regulator"
"We found that in vitro <e1>rapamycin</e1> also regulates the proteasome, an essential intracellular protease of the <e2>ubiquitin</e2>-proteasome pathway.","Regulator"
"We found that in vitro <e1>rapamycin</e1> also regulates the <e2>proteasome</e2>, an essential intracellular protease of the ubiquitin-proteasome pathway.","Regulator"
"We found that in vitro <e1>rapamycin</e1> also regulates the <e2>proteasome</e2>, an essential intracellular protease of the ubiquitin-proteasome pathway.","Regulator"
"<e1>Rapamycin</e1> inhibits <e2>proteinase</e2> and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.","Downregulator"
"<e1>Rapamycin</e1> inhibits proteinase and selected <e2>peptidase</e2> activities of the catalytic core proteasome at low micromolar concentrations.","Downregulator"
"<e1>Rapamycin</e1> allosterically inhibits the <e2>proteasome</e2>.","Downregulator"
"We found that in vitro <e1>rapamycin</e1> also regulates the <e2>proteasome</e2>, an essential intracellular protease of the ubiquitin-proteasome pathway.","Modulator"
"We found that in vitro <e1>rapamycin</e1> also regulates the <e2>proteasome</e2>, an essential intracellular protease of the ubiquitin-proteasome pathway.","Modulator"
"<e1>Rapamycin</e1> allosterically inhibits the <e2>proteasome</e2>.","Modulator"
"<e1>Rapamycin</e1> is a canonical allosteric inhibitor of the <e2>mTOR</e2> kinase with immunosuppressive and pro-apoptotic activities.","Modulator"
"<e1>Rapamycin</e1> is a canonical allosteric inhibitor of the mTOR <e2>kinase</e2> with immunosuppressive and pro-apoptotic activities.","Modulator"
"<e1>MELANOTAN</e1> (NDP-MSH) binds the <e2>MC1 receptor</e2> to significantly increase the eumelanin content of human skin cells.","Regulator"
"MELANOTAN (<e1>NDP-MSH</e1>) binds the <e2>MC1 receptor</e2> to significantly increase the eumelanin content of human skin cells.","Regulator"
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <e1>chloramine T</e1> (CT), to destroy <e2>plasmatic PAI-1</e2> and alpha2-antiplasmin.","Downregulator"
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor <e1>chloramine T</e1> (CT), to destroy plasmatic PAI-1 and alpha2-anti<e2>plasmin</e2>.","Downregulator"
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<e1>CT</e1>), to destroy <e2>plasmatic PAI-1</e2> and alpha2-antiplasmin.","Downregulator"
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T (<e1>CT</e1>), to destroy plasmatic PAI-1 and alpha2-anti<e2>plasmin</e2>.","Downregulator"
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the <e1>singlet oxygen</e1> (1O2) donor chloramine T (CT), to destroy <e2>plasmatic PAI-1</e2> and alpha2-antiplasmin.","Downregulator"
"Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (<e1>1O2</e1>) donor chloramine T (CT), to destroy <e2>plasmatic PAI-1</e2> and alpha2-antiplasmin.","Downregulator"
"After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M <e1>arginine</e1>, pH 8.7, and oxidized with 50 microL of 20 mM CT. For determination of <e2>plasmin</e2> activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).","Substrate"
"For determination of [<e2>PA</e2>+Pli]-activity, <e1>arginine</e1> was added after this incubation.","Substrate"
"For determination of [PA+<e2>Pli</e2>]-activity, <e1>arginine</e1> was added after this incubation.","Substrate"
"The immunosuppressive effects of T3 SCI were caused by <e1>NE</e1> acting at <e2>beta2-adrenergic receptors</e2> (beta2AR) and could be reversed using beta2AR blockers.","Regulator"
"The immunosuppressive effects of T3 SCI were caused by <e1>NE</e1> acting at beta2-adrenergic receptors (<e2>beta2AR</e2>) and could be reversed using beta2AR blockers.","Regulator"
"This study also investigated the effect of <e1>zuclopenthixol</e1> on cortical and hippocampal monoaminergic neurotransmitters' levels together with acetylcholinesterase enzyme (<e2>AChE</e2>) activity, both of which are known to be important in control of cognitive function.","Not"
"This study also investigated the effect of <e1>zuclopenthixol</e1> on cortical and hippocampal monoaminergic neurotransmitters' levels together with <e2>acetylcholinesterase</e2> enzyme (AChE) activity, both of which are known to be important in control of cognitive function.","Regulator"
"This study also investigated the effect of <e1>zuclopenthixol</e1> on cortical and hippocampal monoaminergic neurotransmitters' levels together with acetylcholinesterase enzyme (<e2>AChE</e2>) activity, both of which are known to be important in control of cognitive function.","Regulator"
"Potent and selective: The unique nature of the <e1>ATP</e1> binding pocket structure of <e2>Pim</e2> family protein kinases (PKs) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub-nanomolar affinity.","Regulator"
"Potent and selective: The unique nature of the <e1>ATP</e1> binding pocket structure of Pim family <e2>protein kinases</e2> (PKs) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub-nanomolar affinity.","Regulator"
"Potent and selective: The unique nature of the <e1>ATP</e1> binding pocket structure of Pim family protein kinases (<e2>PKs</e2>) was used for the development of bisubstrate inhibitors and a fluorescent probe with sub-nanomolar affinity.","Regulator"
"<e2>KCNK1</e2>, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after <e1>phenobarbital</e1> treatment.","Upregulator"
"KCNK1, a member of the family of two-pore <e2>K(+) ion channels</e2>, is specifically induced in the livers of male mice after <e1>phenobarbital</e1> treatment.","Upregulator"
"<e2>KCNK1</e2>, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after <e1>phenobarbital</e1> treatment.","Upregulator"
"Upon activation by <e1>phenobarbital</e1>, <e2>nuclear receptor</e2> CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter.","Upregulator"
"Nuclear receptor <e2>CAR</e2> specifically activates the two-pore K+ channel Kcnk1 gene in male mouse livers, which attenuates <e1>phenobarbital</e1>-induced hepatic hyperplasia.","Upregulator"
"<e2>KCNK1</e2>, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after <e1>phenobarbital</e1> treatment.","Upregulator"
"Nuclear receptor CAR specifically activates the two-pore K+ channel <e2>Kcnk1</e2> gene in male mouse livers, which attenuates <e1>phenobarbital</e1>-induced hepatic hyperplasia.","Upregulator"
"<e1>Dexamethasone</e1> probes <e2>glucocorticoid receptor</e2> (GR) function, while prednisolone probes both GR and mineralocorticoid receptor (MR) function.","Regulator"
"<e1>Dexamethasone</e1> probes glucocorticoid receptor (<e2>GR</e2>) function, while prednisolone probes both GR and mineralocorticoid receptor (MR) function.","Regulator"
"Dexamethasone probes glucocorticoid receptor (<e2>GR</e2>) function, while <e1>prednisolone</e1> probes both GR and mineralocorticoid receptor (MR) function.","Regulator"
"Dexamethasone probes glucocorticoid receptor (GR) function, while <e1>prednisolone</e1> probes both GR and <e2>mineralocorticoid receptor</e2> (MR) function.","Regulator"
"Dexamethasone probes glucocorticoid receptor (GR) function, while <e1>prednisolone</e1> probes both GR and mineralocorticoid receptor (<e2>MR</e2>) function.","Regulator"
"Dexamethasone probes glucocorticoid receptor (GR) function, while <e1>prednisolone</e1> probes both GR and mineralocorticoid receptor (<e2>MR</e2>) function.","Regulator"
"Our previous results showed that <e1>methylphenidate</e1> treatment in adolescent SHR enhanced cocaine self-administration during adulthood, and alterations in <e2>DAT</e2> function in prefrontal cortex play a role in this response.","Not"
"Our previous results showed that <e1>methylphenidate</e1> treatment in adolescent SHR enhanced cocaine self-administration during adulthood, and alterations in <e2>DAT</e2> function in prefrontal cortex play a role in this response.","Regulator"
"Our previous results showed that <e1>methylphenidate</e1> treatment in adolescent SHR enhanced cocaine self-administration during adulthood, and alterations in <e2>DAT</e2> function in prefrontal cortex play a role in this response.","Regulator"
"Our previous results showed that <e1>methylphenidate</e1> treatment in adolescent SHR enhanced cocaine self-administration during adulthood, and alterations in <e2>DAT</e2> function in prefrontal cortex play a role in this response.","Regulator"
"<e1>Methylphenidate</e1>, an inhibitor of dopamine and norepinephrine transporters (<e2>DAT</e2> and NET, respectively), is a standard treatment for ADHD.","Upregulator"
"Our previous results showed that <e1>methylphenidate</e1> treatment in adolescent SHR enhanced cocaine self-administration during adulthood, and alterations in <e2>DAT</e2> function in prefrontal cortex play a role in this response.","Upregulator"
"<e1>Methylphenidate</e1>, an inhibitor of <e2>dopamine and norepinephrine transporters</e2> (DAT and NET, respectively), is a standard treatment for ADHD.","Downregulator"
"<e1>Methylphenidate</e1>, an inhibitor of dopamine and norepinephrine transporters (<e2>DAT</e2> and NET, respectively), is a standard treatment for ADHD.","Downregulator"
"<e1>Methylphenidate</e1>, an inhibitor of dopamine and norepinephrine transporters (DAT and <e2>NET</e2>, respectively), is a standard treatment for ADHD.","Downregulator"
"<e1>Methylphenidate</e1>, an inhibitor of dopamine and norepinephrine transporters (<e2>DAT</e2> and NET, respectively), is a standard treatment for ADHD.","Downregulator"
"Our previous results showed that <e1>methylphenidate</e1> treatment in adolescent SHR enhanced cocaine self-administration during adulthood, and alterations in <e2>DAT</e2> function in prefrontal cortex play a role in this response.","Downregulator"
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit cyclooxygenase-2 (<e2>COX-2</e2>).","Downregulator"
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (<e2>COX</e2>-1) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).","Downregulator"
"The effects of meloxicam were compared with those of <e1>diclofenac</e1>, a nonselective <e2>COX</e2> inhibitor.","Downregulator"
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (<e2>COX-1</e2>) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).","Downregulator"
"METHODS: <e2>COX-1</e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg <e1>diclofenac</e1> and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).","Downregulator"
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (<e2>COX-1</e2>) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).","Downregulator"
"METHODS: <e2>COX-1</e2> inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg <e1>diclofenac</e1> and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).","Downregulator"
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit <e2>cyclooxygenase-2</e2> (COX-2).","Downregulator"
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit cyclooxygenase-2 (<e2>COX-2</e2>).","Downregulator"
"OBJECTIVE: To evaluate the extent of <e2>human cyclooxygenase-1</e2> (COX-1) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).","Downregulator"
"OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (<e2>COX-1</e2>) inhibition by <e1>meloxicam</e1>, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of <e2>VEGF</e2> and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of VEGF and <e2>MMP-9</e2> through Akt pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of <e2>VEGF</e2> and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of VEGF and <e2>MMP-9</e2> through Akt pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of <e2>VEGF</e2> and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Western blotting demonstrated that <e1>DMBT</e1> effectively suppressed the expression of VEGF, <e2>p-VEGFR-2</e2>, p-EGFR, and p-Akt.","Downregulator"
"Western blotting demonstrated that <e1>DMBT</e1> effectively suppressed the expression of VEGF, p-VEGFR-2, <e2>p-EGFR</e2>, and p-Akt.","Downregulator"
"Western blotting demonstrated that <e1>DMBT</e1> effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and <e2>p-Akt</e2>.","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of VEGF and <e2>MMP-9</e2> through Akt pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of VEGF and MMP-9 through <e2>Akt</e2> pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Inhibition of angiogenesis and invasion by <e1>DMBT</e1> is mediated by downregulation of VEGF and MMP-9 through <e2>Akt</e2> pathway in MDA-MB-231 breast cancer cells.","Downregulator"
"Expression of L-type pyruvate kinase (<e2>L-PK</e2>) is upregulated in the liver by dietary <e1>carbohydrate</e1>.","Upregulator"
"Expression of <e2>L-type pyruvate kinase</e2> (L-PK) is upregulated in the liver by dietary <e1>carbohydrate</e1>.","Upregulator"
"To investigate the possibility that <e1>felbamate</e1>'s favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant <e2>NMDA receptors</e2> composed of the NR1a subunit and various NR2 subunits.","Downregulator"
"To investigate the possibility that <e1>felbamate</e1>'s favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the <e2>NR1a</e2> subunit and various NR2 subunits.","Downregulator"
"To investigate the possibility that <e1>felbamate</e1>'s favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various <e2>NR2</e2> subunits.","Downregulator"
"<e1>Felbamate</e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the <e2>rat NR1a</e2> subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).","Downregulator"
"<e1>Felbamate</e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the <e2>NR2A</e2>, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).","Downregulator"
"<e1>Felbamate</e1> block of recombinant N-methyl-D-aspartate receptors: selectivity for the <e2>NR2B</e2> subunit.","Downregulator"
"<e1>Felbamate</e1> produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or <e2>NR2C</e2> subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).","Downregulator"
"<e1>Felbamate</e1> block of recombinant <e2>N-methyl-D-aspartate receptors</e2>: selectivity for the NR2B subunit.","Downregulator"
"<e1>Felbamate</e1> block of recombinant N-methyl-D-aspartate receptors: selectivity for the <e2>NR2B</e2> subunit.","Downregulator"
"To investigate the possibility that <e1>felbamate</e1>'s favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant <e2>NMDA receptors</e2> composed of the NR1a subunit and various NR2 subunits.","Downregulator"
"The higher affinity of <e1>felbamate</e1> block of NMDA receptors containing the <e2>NR2B</e2> subunit could be accounted for by more rapid association and slower dissociation from these sites.","Downregulator"
"To investigate the possibility that <e1>felbamate</e1>'s favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant <e2>NMDA receptors</e2> composed of the NR1a subunit and various NR2 subunits.","Downregulator"
"To investigate the possibility that <e1>felbamate</e1>'s favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the <e2>NR1a</e2> subunit and various NR2 subunits.","Downregulator"
"The higher affinity of <e1>felbamate</e1> block of NMDA receptors containing the <e2>NR2B</e2> subunit could be accounted for by more rapid association and slower dissociation from these sites.","Downregulator"
"The anticonvulsant <e1>felbamate</e1> blocks <e2>N-methyl-D-asparate (NMDA) receptors</e2> but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.","Downregulator"
"The anticonvulsant <e1>felbamate</e1> blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other <e2>NMDA receptor</e2> antagonists.","Antagonist"
"The anticonvulsant <e1>felbamate</e1> blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other <e2>NMDA receptor</e2> antagonists.","Antagonist"
"Baseline <e1>cortisol</e1> (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), <e2>ACTH</e2>, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated.","Substrate"
"Baseline <e1>cortisol</e1> (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), <e2>ACTH</e2>, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated.","Substrate"
"Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), <e2>ACTH</e2>, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), <e1>delta cortisol</e1> (ΔCor), delta DHEA-S (ΔDHEA-S) responses were evaluated.","Substrate"
"Baseline cortisol (Cor0), DHEA-S (DHEA-S0), cortisol binding globulin (CBG), <e2>ACTH</e2>, calculated free cortisol (by Coolen's equation = CFC), free cortisol index (FCI), 60-min cortisol (Cor60), and DHEA-S (DHEA-S60), delta cortisol (ΔCor), <e1>delta DHEA</e1>-S (ΔDHEA-S) responses were evaluated.","Substrate"
"U50, 488H caused a significant down-regulation of the <e2>hkor</e2>, although <e1>etorphine</e1> did not.","Not"
"Neither <e1>U50,488H</e1> nor etorphine caused down-regulation of the <e2>rat kappa-opioid receptor</e2>.","Not"
"Neither U50,488H nor <e1>etorphine</e1> caused down-regulation of the <e2>rat kappa-opioid receptor</e2>.","Not"
"<e1>U50, 488H</e1> caused a significant down-regulation of the <e2>hkor</e2>, although etorphine did not.","Downregulator"
"Previously, we showed that the human kappa-opioid receptor (<e2>hkor</e2>) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>U50,488H</e1> treatment.","Downregulator"
"U50, 488H caused a significant down-regulation of the <e2>hkor</e2>, although <e1>etorphine</e1> did not.","Downregulator"
"Expression of the dominant negative mutants <e2>rab5A</e2>-N133I or rab7-N125I blunted <e1>U50,488H</e1>-induced down-regulation.","Downregulator"
"Expression of the dominant negative mutants rab5A-<e2>N133I</e2> or rab7-N125I blunted <e1>U50,488H</e1>-induced down-regulation.","Downregulator"
"Expression of the dominant negative mutants rab5A-N133I or <e2>rab7</e2>-N125I blunted <e1>U50,488H</e1>-induced down-regulation.","Downregulator"
"Expression of the dominant negative mutants rab5A-N133I or rab7-<e2>N125I</e2> blunted <e1>U50,488H</e1>-induced down-regulation.","Downregulator"
"Previously, we showed that the human kappa-opioid receptor (<e2>hkor</e2>) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>U50,488H</e1> treatment.","Downregulator"
"Previously, we showed that the human kappa-opioid receptor (<e2>hkor</e2>) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>U50,488H</e1> treatment.","Downregulator"
"Previously, we showed that the <e2>human kappa-opioid receptor</e2> (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>U50,488H</e1> treatment.","Downregulator"
"Previously, we showed that the human kappa-opioid receptor (<e2>hkor</e2>) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged <e1>U50,488H</e1> treatment.","Downregulator"
"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or <e2>proteasome</e2> inhibitors (proteasome inhibitor I, <e1>MG-132</e1>, or lactacystin) decreased the extent of U50,488H-induced down-regulation.","Downregulator"
"Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or <e2>proteasome</e2> inhibitors (proteasome inhibitor I, MG-132, or <e1>lactacystin</e1>) decreased the extent of U50,488H-induced down-regulation.","Downregulator"
"We postulate that <e1>vescalagin</e1> is an active component in PWFE that may alleviate the <e2>insulin</e2> resistance in mouse hepatocytes.","Regulator"
"In HepG2 cells, GCs induced a decreased expression of <e2>FXR</e2> and SHP, and inhibited the regulatory effect of <e1>GW4064</e1> on FXR-target genes.","Regulator"
"In HepG2 cells, GCs induced a decreased expression of <e2>FXR</e2> and SHP, and inhibited the regulatory effect of <e1>GW4064</e1> on FXR-target genes.","Upregulator"
"In HepG2 cells, GCs induced a decreased expression of FXR and <e2>SHP</e2>, and inhibited the regulatory effect of <e1>GW4064</e1> on FXR-target genes.","Upregulator"
"In Alexander cells, only when they were transfected with FXR+RXR, <e1>GW4064</e1> caused up-regulation of SHP and <e2>OSTβ</e2>, and a down-regulation of CYP27A1.","Upregulator"
"In Alexander cells, only when they were transfected with FXR+RXR, <e1>GW4064</e1> caused up-regulation of SHP and OSTβ, and a down-regulation of <e2>CYP27A1</e2>.","Downregulator"
"This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-κB complex containing a form of <e2>p65</e2> phosphorylated on <e1>Ser</e1>536, did not change.","Part_of"
"Despite normal binding, autoactivation of mutants <e2>D22G</e2> and K23_I24insIDK was not stimulated by <e1>calcium</e1>.","Not"
"Despite normal binding, autoactivation of mutants D22G and <e2>K23_I24insIDK</e2> was not stimulated by <e1>calcium</e1>.","Not"
"The <e2>tetra-aspartate motif</e2> in the trypsinogen activation peptide binds <e1>calcium</e1> (KD ~1.6 mM), which stimulates autoactivation.","Regulator"
"<e2>Opioid receptors</e2> are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as <e1>morphine</e1> and fentanyl as well as endogenous opioid peptides enkephalins and endorphins.","Regulator"
"<e2>Opioid receptors</e2> are the membrane proteins that mediate the pain-relieving effect of opioid drugs, such as morphine and <e1>fentanyl</e1> as well as endogenous opioid peptides enkephalins and endorphins.","Regulator"
"The exposure of highly toxic <e1>aconitine</e1> does not significantly impact the activity and expression of <e2>cytochrome P450 3A</e2> in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone.","Not"
"Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on <e2>CYP3A</e2> using the probe <e1>buspirone</e1> in rats.","Regulator"
"Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on <e2>CYP3A</e2> using the probe <e1>buspirone</e1> in rats.","Regulator"
"The CBC physically associates with these complexes to recruit them during transcription and mediates phosphorylation at <e1>Ser</e1>-2 of the C-terminal domain (CTD) of <e2>RNA polymerase II</e2>.","Part_of"
"The <e1>C</e1>BC physically associates with these complexes to recruit them during transcription and mediates phosphorylation at Ser-2 of the C-terminal domain (CTD) of <e2>RNA polymerase II</e2>.","Part_of"
"In contrast, <e1>2, 4-dioxo-5-acetamido-6-phenylhexanoic acid</e1>, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both <e2>PAM</e2> and dopamine-beta-hydroxylase.","Regulator"
"In contrast, <e1>2, 4-dioxo-5-acetamido-6-phenylhexanoic acid</e1>, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and <e2>dopamine-beta-hydroxylase</e2>.","Regulator"
"Kinetic parameters for <e2>PAM</e2> inactivation by 4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and <e1>4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid</e1> were obtained by using both the conventional dilution assay method and the more complex progress curve method.","Downregulator"
"In contrast, <e1>2, 4-dioxo-5-acetamido-6-phenylhexanoic acid</e1>, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both <e2>PAM</e2> and dopamine-beta-hydroxylase.","Downregulator"
"In contrast, <e1>2, 4-dioxo-5-acetamido-6-phenylhexanoic acid</e1>, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and <e2>dopamine-beta-hydroxylase</e2>.","Downregulator"
"Kinetic parameters for <e2>PAM</e2> inactivation by <e1>4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid</e1> were obtained by using both the conventional dilution assay method and the more complex progress curve method.","Downregulator"
"In contrast, their effects on <e2>MRP2</e2> varied with two (V-4, V-6) inhibiting E217βG transport (IC50's 2.0, 9.2 μM), two (V-3, III-1) stimulating transport (>2-fold), while <e1>CGP</e1> I-5 had no effect.","Not"
"Five classes of chalcogenopyrylium dyes (<e1>CGPs</e1>) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217βG) (a prototypical <e2>MRP</e2> substrate) into MRP-enriched inside-out membrane vesicles.","Regulator"
"<e1>Chalcogenopyrylium</e1> Dyes as Differential Modulators of Organic Anion Transport by <e2>MRP1</e2>, MRP2 and MRP4.","Regulator"
"<e1>Chalcogenopyrylium</e1> Dyes as Differential Modulators of Organic Anion Transport by MRP1, <e2>MRP2</e2> and MRP4.","Regulator"
"<e1>Chalcogenopyrylium</e1> Dyes as Differential Modulators of Organic Anion Transport by MRP1, MRP2 and <e2>MRP4</e2>.","Regulator"
"This study is the first to identify Class V CGPs with their distinctive <e1>methine</e1> or trimethine linkage between two disubstituted pyrylium moieties as a particularly potent class of <e2>MRP</e2> modulators and also show that within this core structure, differences in the electronegativity associated with a chalcogen atom can be the sole determinant of whether a compound will stimulate or inhibit MRP2.","Regulator"
"This study is the first to identify Class V CGPs with their distinctive methine or <e1>trimethine</e1> linkage between two disubstituted pyrylium moieties as a particularly potent class of <e2>MRP</e2> modulators and also show that within this core structure, differences in the electronegativity associated with a chalcogen atom can be the sole determinant of whether a compound will stimulate or inhibit MRP2.","Regulator"
"Chalcogeno<e1>pyrylium</e1> Dyes as Differential Modulators of Organic Anion Transport by <e2>MRP</e2>1, MRP2 and MRP4.","Regulator"
"Five classes of <e1>chalcogenopyrylium</e1> dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217βG) (a prototypical <e2>MRP</e2> substrate) into MRP-enriched inside-out membrane vesicles.","Regulator"
"Sixteen of 34 <e1>CGPs</e1> inhibited <e2>MRP1</e2>-mediated E217βG uptake by >50% (IC50's 0.7-7.6 μM).","Downregulator"
"Sixteen of 34 <e1>CGPs</e1> inhibited <e2>MRP1</e2>-mediated E217βG uptake by >50% (IC50's 0.7-7.6 μM).","Downregulator"
"These five <e1>CGPs</e1> also inhibited [(3)H]E217βG uptake by <e2>MRP4</e2>.","Downregulator"
"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of <e1>[(3)H]estradiol glucuronide</e1> (E217βG) (a prototypical <e2>MRP</e2> substrate) into MRP-enriched inside-out membrane vesicles.","Substrate"
"Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (<e1>E217βG</e1>) (a prototypical <e2>MRP</e2> substrate) into MRP-enriched inside-out membrane vesicles.","Substrate"
"Sixteen of 34 CGPs inhibited <e2>MRP1</e2>-mediated <e1>E217βG</e1> uptake by >50% (IC50's 0.7-7.6 μM).","Substrate"
"Of 9 CGPs with IC50's ≤2 μM, two belonged to Class I, two to Class III and five to Class V. When tested in the intact cells, only 4 of 16 CGPs (at 10 μM) inhibited <e2>MRP1</e2>-mediated <e1>calcein</e1> efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.","Substrate"
"These five CGPs also inhibited <e1>[(3)H]E217βG</e1> uptake by <e2>MRP4</e2>.","Substrate"
"The cellular prion protein PrP(<e1>C</e1>) consists of two domains--a flexible N-terminal domain, which participates in copper and zinc regulation, and a largely helical C-terminal domain that converts to β sheet in the course of prion disease.","Part_of"
"The cellular prion protein <e2>PrP(C)</e2> consists of two domains--a flexible <e1>N</e1>-terminal domain, which participates in copper and zinc regulation, and a largely helical C-terminal domain that converts to β sheet in the course of prion disease.","Part_of"
"The cellular prion protein PrP(<e1>C</e1>) consists of two domains--a flexible N-terminal domain, which participates in copper and zinc regulation, and a largely helical C-terminal domain that converts to β sheet in the course of prion disease.","Part_of"
"The cellular <e2>prion protein PrP(C)</e2> consists of two domains--a flexible <e1>N</e1>-terminal domain, which participates in copper and zinc regulation, and a largely helical C-terminal domain that converts to β sheet in the course of prion disease.","Part_of"
"The cellular <e2>prion protein PrP(C)</e2> consists of two domains--a flexible N-terminal domain, which participates in <e1>copper</e1> and zinc regulation, and a largely helical C-terminal domain that converts to β sheet in the course of prion disease.","Regulator"
"The cellular <e2>prion protein PrP(C)</e2> consists of two domains--a flexible N-terminal domain, which participates in copper and <e1>zinc</e1> regulation, and a largely helical C-terminal domain that converts to β sheet in the course of prion disease.","Regulator"
"Here, we identify a <e1>Zn²⁺</e1>-driven N-terminal to C-terminal tertiary interaction in <e2>PrP(C)</e2>.","Regulator"
"<e1>Zinc</e1> drives a tertiary fold in the <e2>prion protein</e2> with familial disease mutation sites at the interface.","Regulator"
"Using the viral mimic <e1>polyinosinic:polycytidylic acid</e1> and the <e2>IFN</e2>α/β antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced STAT1 activation and expression of CXCL10.","Regulator"
"Using the viral mimic <e1>polyinosinic:polycytidylic acid</e1> and the IFNα/β antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote <e2>IL-22</e2>-induced STAT1 activation and expression of CXCL10.","Regulator"
"Using the viral mimic <e1>polyinosinic:polycytidylic acid</e1> and the IFNα/β antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced <e2>STAT1</e2> activation and expression of CXCL10.","Regulator"
"Using the viral mimic <e1>polyinosinic:polycytidylic acid</e1> and the IFNα/β antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced STAT1 activation and expression of <e2>CXCL10</e2>.","Regulator"
"Using the viral mimic <e1>polyinosinic:polycytidylic acid</e1> and the <e2>IFNα/β</e2> antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced STAT1 activation and expression of CXCL10.","Cofactor"
"Since <e1>gemfibrozil</e1> is known to activate peroxisome proliferator-activated receptor-alpha (<e2>PPAR-alpha</e2>), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.","Not"
"Inhibition of human iNOS promoter-driven luciferase activity by <e1>gemfibrozil</e1> in <e2>cytokine</e2>-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS.","Not"
"Since <e1>gemfibrozil</e1> is known to activate <e2>peroxisome proliferator-activated receptor-alpha</e2> (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.","Upregulator"
"Since <e1>gemfibrozil</e1> is known to activate peroxisome proliferator-activated receptor-alpha (<e2>PPAR-alpha</e2>), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.","Upregulator"
"Since <e1>gemfibrozil</e1> is known to activate peroxisome proliferator-activated receptor-alpha (<e2>PPAR-alpha</e2>), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.","Upregulator"
"<e1>Gemfibrozil</e1> induced <e2>peroxisome proliferator-responsive element</e2> (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.","Upregulator"
"<e1>Gemfibrozil</e1> induced peroxisome proliferator-responsive element (<e2>PPRE</e2>)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.","Upregulator"
"Similar to <e1>gemfibrozil</e1>, clofibrate, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"<e1>Gemfibrozil</e1>, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of <e2>inducible nitric-oxide synthase</e2> (iNOS) in human U373MG astroglial cells and primary astrocytes.","Downregulator"
"<e1>Gemfibrozil</e1>, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (<e2>iNOS</e2>) in human U373MG astroglial cells and primary astrocytes.","Downregulator"
"Similar to <e1>gemfibrozil</e1>, clofibrate, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"Similar to gemfibrozil, <e1>clofibrate</e1>, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"Similar to gemfibrozil, clo<e1>fibrate</e1>, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"Inhibition of <e2>human iNOS promoter</e2>-driven luciferase activity by <e1>gemfibrozil</e1> in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS.","Downregulator"
"Similar to <e1>gemfibrozil</e1>, clofibrate, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"Similar to <e1>gemfibrozil</e1>, clofibrate, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"Similar to <e1>gemfibrozil</e1>, clofibrate, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"<e1>Gemfibrozil</e1>, a lipid-lowering drug, inhibits the induction of <e2>nitric-oxide synthase</e2> in human astrocytes.","Downregulator"
"<e1>Gemfibrozil</e1>, a lipid-lowering drug, inhibited <e2>cytokine</e2>-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.","Downregulator"
"The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (<e2>NF-kappaB</e2>), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of <e1>gemfibrozil</e1> on the activation of these transcription factors.","Downregulator"
"The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (<e2>AP-1</e2>), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of <e1>gemfibrozil</e1> on the activation of these transcription factors.","Downregulator"
"The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (<e2>C/EBPbeta</e2>); therefore, we investigated the effect of <e1>gemfibrozil</e1> on the activation of these transcription factors.","Downregulator"
"Similar to <e1>gemfibrozil</e1>, clofibrate, another fibrate drug, also inhibited the expression of <e2>iNOS</e2>.","Downregulator"
"The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (<e2>NF-kappaB</e2>), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of <e1>gemfibrozil</e1> on the activation of these transcription factors.","Downregulator"
"The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (<e2>AP-1</e2>), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of <e1>gemfibrozil</e1> on the activation of these transcription factors.","Downregulator"
"The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (<e2>C/EBPbeta</e2>); therefore, we investigated the effect of <e1>gemfibrozil</e1> on the activation of these transcription factors.","Downregulator"
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of <e1>NO</e1> and the expression of <e2>inducible nitric-oxide synthase</e2> (iNOS) in human U373MG astroglial cells and primary astrocytes.","Substrate"
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of <e1>NO</e1> and the expression of inducible nitric-oxide synthase (<e2>iNOS</e2>) in human U373MG astroglial cells and primary astrocytes.","Substrate"
"Gemfibrozil, a lipid-lowering drug, inhibits the induction of <e1>nitric-oxide</e1> synthase in human astrocytes.","Substrate"
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible <e1>nitric-oxide</e1> synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.","Substrate"
"Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible <e1>nitric-oxide</e1> synthase (<e2>iNOS</e2>) in human U373MG astroglial cells and primary astrocytes.","Substrate"
"<e1>Dexmedetomidine</e1> was effective in blocking these sympathomimetic actions of cocaine even in all 7 subjects who were homozygous for the Del322-325 polymorphism in the <e2>alpha2C AR</e2>, a loss-of-function mutation that is highly enriched in blacks.","Regulator"
"CONCLUSIONS: The data advance the novel hypothesis that central sympatholysis with <e1>dexmedetomidine</e1> constitutes a highly effective countermeasure for cocaine's sympathomimetic actions on the human cardiovascular system, even in individuals carrying the <e2>alpha2C</e2>Del322-325 polymorphism.","Regulator"
"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting <e2>alpha2 adrenergic receptor</e2> (AR) agonist (<e1>dexmedetomidine</e1>).","Agonist"
"OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (<e2>AR</e2>) agonist (<e1>dexmedetomidine</e1>).","Agonist"
"We investigated the effect of the clinically used nitrates nitroglycerin (<e1>NTG</e1>), isosorbide dinitrate (ISDN), and sodium nitroprusside (SNP) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Not"
"We investigated the effect of the clinically used nitrates nitroglycerin (NTG), isosorbide dinitrate (<e1>ISDN</e1>), and sodium nitroprusside (SNP) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Not"
"<e1>SNP</e1> inhibits the accumulation of HIF-1alpha, the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or <e2>soluble guanylate cyclase</e2>.","Not"
"The inhibitory effect of <e1>sodium nitroprusside</e1> on HIF-1 activation is not dependent on nitric oxide-<e2>soluble guanylyl cyclase</e2> pathway.","Not"
"We investigated the effect of the clinically used nitrates nitroglycerin (NTG), isosorbide dinitrate (ISDN), and sodium nitroprusside (<e1>SNP</e1>) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Regulator"
"We investigated the effect of the clinically used nitrates <e1>nitroglycerin</e1> (NTG), isosorbide dinitrate (ISDN), and sodium nitroprusside (SNP) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Regulator"
"We investigated the effect of the clinically used nitrates nitroglycerin (<e1>NTG</e1>), isosorbide dinitrate (ISDN), and sodium nitroprusside (SNP) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Regulator"
"We investigated the effect of the clinically used nitrates nitroglycerin (NTG), <e1>isosorbide dinitrate</e1> (ISDN), and sodium nitroprusside (SNP) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Regulator"
"We investigated the effect of the clinically used nitrates nitroglycerin (NTG), isosorbide dinitrate (<e1>ISDN</e1>), and sodium nitroprusside (SNP) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Regulator"
"The inhibitory effect of <e1>sodium nitroprusside</e1> on <e2>HIF-1</e2> activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.","Regulator"
"<e1>SNP</e1> inhibits the accumulation of <e2>HIF-1alpha</e2>, the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","Downregulator"
"We investigated the effect of the clinically used nitrates nitroglycerin (NTG), isosorbide dinitrate (ISDN), and sodium nitroprusside (<e1>SNP</e1>) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Downregulator"
"<e1>SNP</e1> inhibits the accumulation of <e2>HIF-1alpha</e2>, the regulatory subunit of HIF-1, and the transcriptional activation of HIF-1alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.","Downregulator"
"We investigated the effect of the clinically used nitrates nitroglycerin (NTG), isosorbide dinitrate (ISDN), and sodium nitroprusside (<e1>SNP</e1>) on <e2>HIF-1</e2>-mediated transcriptional responses to hypoxia.","Downregulator"
"The inhibitory effect of <e1>sodium nitroprusside</e1> on <e2>HIF-1</e2> activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway.","Downregulator"
"CONCLUSIONS: Our results show that <e1>indomethacin</e1>, a known cyclooxygenase (<e2>COX</e2>) inhibitor, is also an activator of CA.","Regulator"
"CONCLUSIONS: Our results show that <e1>indomethacin</e1>, a known cyclooxygenase (<e2>COX</e2>) inhibitor, is also an activator of CA.","Regulator"
"<e1>Indomethacin</e1> completely antagonizes <e2>CA</e2> activity, i.e.","Upregulator"
"<e1>Indomethacin</e1> completely antagonizes <e2>CA</e2> activity, i.e.","Upregulator"
"<e1>Indomethacin</e1> activates <e2>carbonic anhydrase</e2> and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.","Upregulator"
"<e1>Indomethacin</e1> activates <e2>carbonic anhydrase</e2> and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.","Upregulator"
"OBJECTIVES: In this paper we investigated the effect of <e1>indomethacin</e1>, acetazolamide and their combination in vitro and in vivo on carbonic anhydrase (<e2>CA</e2>) isozymes.","Upregulator"
"OBJECTIVES: In this paper we investigated the effect of <e1>indomethacin</e1>, acetazolamide and their combination in vitro and in vivo on carbonic anhydrase (<e2>CA</e2>) isozymes.","Upregulator"
"OBJECTIVES: In this paper we investigated the effect of <e1>indomethacin</e1>, acetazolamide and their combination in vitro and in vivo on carbonic anhydrase (<e2>CA</e2>) isozymes.","Upregulator"
"<e1>Acetazolamide</e1>, a specific inhibitor of <e2>CA</e2>, reduces the activity of CA I and CA II from red cells.","Downregulator"
"<e1>Acetazolamide</e1>, a specific inhibitor of CA, reduces the activity of <e2>CA I</e2> and CA II from red cells.","Downregulator"
"<e1>Acetazolamide</e1>, a specific inhibitor of CA, reduces the activity of CA I and <e2>CA II</e2> from red cells.","Downregulator"
"OBJECTIVES: In this paper we investigated the effect of indomethacin, <e1>acetazolamide</e1> and their combination in vitro and in vivo on carbonic anhydrase (<e2>CA</e2>) isozymes.","Downregulator"
"OBJECTIVES: In this paper we investigated the effect of indomethacin, <e1>acetazolamide</e1> and their combination in vitro and in vivo on carbonic anhydrase (<e2>CA</e2>) isozymes.","Downregulator"
"Indomethacin activates <e2>carbonic anhydrase</e2> and antagonizes the effect of the specific carbonic anhydrase inhibitor <e1>acetazolamide</e1>, by a direct mechanism of action.","Downregulator"
"Indomethacin activates <e2>carbonic anhydrase</e2> and antagonizes the effect of the specific carbonic anhydrase inhibitor <e1>acetazolamide</e1>, by a direct mechanism of action.","Downregulator"
"CONCLUSIONS: Our results show that <e1>indomethacin</e1>, a known <e2>cyclooxygenase</e2> (COX) inhibitor, is also an activator of CA.","Downregulator"
"CONCLUSIONS: Our results show that <e1>indomethacin</e1>, a known cyclooxygenase (<e2>COX</e2>) inhibitor, is also an activator of CA.","Downregulator"
"OBJECTIVES: In this paper we investigated the effect of indomethacin, <e1>acetazolamide</e1> and their combination in vitro and in vivo on carbonic anhydrase (<e2>CA</e2>) isozymes.","Downregulator"
"These compounds are competitive and, in a few cases, non-competitive inhibitors for <e2>AChE</e2>, the most potent being compound (14), though three-fold less active than <e1>tacrine</e1>.","Downregulator"
"The acetylcholinesterase (<e2>AChE</e2>) and butyrylcholinesterase (BuChE) inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines</e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase</e2> (BuChE) inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines</e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The <e2>acetylcholinesterase</e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines</e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE</e2>) inhibitory activities of a series of <e1>pyrano[2,3-b]quinolines</e1> (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The <e2>BuChE</e2> inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than <e1>tacrine</e1>.","Downregulator"
"The acetylcholinesterase (<e2>AChE</e2>) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines</e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase</e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines</e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The <e2>acetylcholinesterase</e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines</e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE</e2>) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), <e1>[1,8]naphthyridines</e1> (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (<e2>AChE</e2>) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines</e1> (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase</e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines</e1> (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The <e2>acetylcholinesterase</e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines</e1> (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE</e2>) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), <e1>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines</e1> (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (<e2>AChE</e2>) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine</e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase</e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine</e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The <e2>acetylcholinesterase</e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine</e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE</e2>) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine</e1> (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (<e2>AChE</e2>) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline</e1> (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase</e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline</e1> (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The <e2>acetylcholinesterase</e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline</e1> (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE</e2>) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), <e1>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline</e1> (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.","Downregulator"
"The acetylcholinesterase (<e2>AChE</e2>) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine</e1> (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and <e2>butyrylcholinesterase</e2> (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine</e1> (16) are described.","Downregulator"
"The <e2>acetylcholinesterase</e2> (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine</e1> (16) are described.","Downregulator"
"The acetylcholinesterase (AChE) and butyrylcholinesterase (<e2>BuChE</e2>) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ <e1>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine</e1> (16) are described.","Downregulator"
"<e1>Juglone</e1>, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of <e2>AR</e2> expression in human prostate cancer LNCaP cells.","Downregulator"
"Moreover, we found that <e1>juglone</e1> significantly inhibited the expression levels of <e2>androgen receptor</e2> (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Downregulator"
"Moreover, we found that <e1>juglone</e1> significantly inhibited the expression levels of androgen receptor (<e2>AR</e2>) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Downregulator"
"Moreover, we found that <e1>juglone</e1> significantly inhibited the expression levels of androgen receptor (AR) and <e2>prostate-specific antigen</e2> (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Downregulator"
"Moreover, we found that <e1>juglone</e1> significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (<e2>PSA</e2>) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Downregulator"
"Moreover, we found that <e1>juglone</e1> significantly inhibited the expression levels of androgen receptor (<e2>AR</e2>) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Downregulator"
"Moreover, we found that <e1>juglone</e1> significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen (<e2>PSA</e2>) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Downregulator"
"Moreover, we found that <e1>juglone</e1> significantly inhibited the expression levels of androgen receptor (<e2>AR</e2>) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT).","Downregulator"
"The efficacy of <e1>astemizole</e1>, a new, long acting, oral <e2>histamine H1-receptor</e2> antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.","Antagonist"
"<e1>Astemizole</e1>, a potent <e2>histamine H1-receptor</e2> antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.","Antagonist"
"<e1>Tacrine</e1>, the first of the <e2>cholinesterase</e2> inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.","Downregulator"
"Other <e2>cholinesterase</e2> inhibitors, including <e1>rivastigmine</e1>, with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced.","Downregulator"
"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA</e1>), a concentration that selectively inhibits the NHE isoforms <e2>NHE1</e2> and NHE2, but not NHE3, did not affect DBS.","Downregulator"
"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA</e1>), a concentration that selectively inhibits the NHE isoforms NHE1 and <e2>NHE2</e2>, but not NHE3, did not affect DBS.","Downregulator"
"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA</e1>), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not <e2>NHE3</e2>, did not affect DBS.","Downregulator"
"Moreover, <e1>S1611</e1> and S3226, both specific inhibitors of <e2>NHE3</e2> only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.","Downregulator"
"Moreover, S1611 and <e1>S3226</e1>, both specific inhibitors of <e2>NHE3</e2> only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.","Downregulator"
"Nevertheless, coperfusion with 0.1 and 0.3 mM <e1>5-nitro-2-(3-phenylpropylamino) benzoic acid</e1>, which inhibits the <e2>cystic fibrosis transmembrane conductor regulator</e2> (CFTR), dose dependently inhibited S3226-induced DBS.","Downregulator"
"Nevertheless, coperfusion with 0.1 and 0.3 mM <e1>5-nitro-2-(3-phenylpropylamino) benzoic acid</e1>, which inhibits the cystic fibrosis transmembrane conductor regulator (<e2>CFTR</e2>), dose dependently inhibited S3226-induced DBS.","Downregulator"
"<e1>5-(N,N-dimethyl)-amiloride</e1> (50 microM; DMA), a concentration that selectively inhibits the <e2>NHE</e2> isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.","Downregulator"
"<e1>5-(N,N-dimethyl)-amiloride</e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms <e2>NHE1</e2> and NHE2, but not NHE3, did not affect DBS.","Downregulator"
"<e1>5-(N,N-dimethyl)-amiloride</e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and <e2>NHE2</e2>, but not NHE3, did not affect DBS.","Downregulator"
"<e1>5-(N,N-dimethyl)-amiloride</e1> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not <e2>NHE3</e2>, did not affect DBS.","Downregulator"
"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA</e1>), a concentration that selectively inhibits the <e2>NHE</e2> isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.","Downregulator"
"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA</e1>), a concentration that selectively inhibits the NHE isoforms <e2>NHE1</e2> and NHE2, but not NHE3, did not affect DBS.","Downregulator"
"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA</e1>), a concentration that selectively inhibits the NHE isoforms NHE1 and <e2>NHE2</e2>, but not NHE3, did not affect DBS.","Downregulator"
"5-(N,N-dimethyl)-amiloride (50 microM; <e1>DMA</e1>), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not <e2>NHE3</e2>, did not affect DBS.","Downregulator"
"In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-<e1>HCO3</e1>- cotransporter activation, or intracellular HCO3- formation by <e2>carbonic anhydrase</e2> was not involved.","Substrate"
"Few targets like epidermal growth factor receptor (EGFR) mutations and <e2>anaplastic lymphoma kinase</e2> (ALK) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and <e1>crizotinib</e1>, respectively.","Regulator"
"Few targets like epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (<e2>ALK</e2>) gene rearrangements have successfully been targeted with EGFR tyrosine kinase inhibitors (TKIs) and <e1>crizotinib</e1>, respectively.","Regulator"
"Dabrafenib is a <e2>BRAF</e2> (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the <e1>valine</e1> 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma.","Part_of"
"Dabrafenib is a <e2>BRAF</e2> (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to <e1>glutamic acid</e1> substitution (BRAF(V600E)), which is commonly found in metastatic melanoma.","Part_of"
"Mechanisms limiting distribution of the <e2>threonine-protein kinase B-RaF</e2>(V600E) inhibitor <e1>dabrafenib</e1> to the brain: implications for the treatment of melanoma brain metastases.","Downregulator"
"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(<e2>V600E</e2>) inhibitor <e1>dabrafenib</e1> to the brain: implications for the treatment of melanoma brain metastases.","Downregulator"
"Further, compared with <e1>vemurafenib</e1>, another <e2>BRAF</e2>(V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose.","Downregulator"
"Further, compared with <e1>vemurafenib</e1>, another BRAF(<e2>V600E</e2>) inhibitor, dabrafenib showed greater brain penetration with a similar dose.","Downregulator"
"Thus, the objective of the current study was to evaluate the brain distribution of <e1>dabrafenib</e1> in mice, and to see whether active efflux by P-glycoprotein (<e2>P-gp</e2>) and breast cancer resistance protein (BCRP) restricts its delivery across the blood-brain barrier (BBB).","Substrate"
"Thus, the objective of the current study was to evaluate the brain distribution of <e1>dabrafenib</e1> in mice, and to see whether active efflux by P-glycoprotein (P-gp) and breast cancer resistance protein (<e2>BCRP</e2>) restricts its delivery across the blood-brain barrier (BBB).","Substrate"
"Since the original discovery of <e1>azoles</e1> analogs as <e2>PXR</e2> antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.","Antagonist"
"Since the original discovery of <e1>azoles</e1> analogs as <e2>PXR</e2> antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.","Antagonist"
"Since the original discovery of <e1>azoles</e1> analogs as <e2>PXR</e2> antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.","Antagonist"
"Activation of endogenous <e2>somatostatin receptor subtype 2</e2> (sst2) by <e1>somatostatin-14</e1> or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.","Upregulator"
"Activation of endogenous somatostatin receptor subtype 2 (<e2>sst2</e2>) by <e1>somatostatin-14</e1> or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect.","Upregulator"
"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected <e2>rat D2 dopamine receptors</e2> (rD2(long)) by <e1>quinpirole</e1> had no effect.","Upregulator"
"Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors (<e2>rD2</e2>(long)) by <e1>quinpirole</e1> had no effect.","Upregulator"
"In contrast, in the same system, <e1>N</e1>-type currents, formed from transiently transfected alpha(1B)/alpha(2)delta-1/beta(3), showed strong <e2>G-protein</e2>-mediated inhibition.","Downregulator"
"Inhibition of lysosomes or proteasomes by co-treatment with antofine and their respective specific inhibitors, <e1>NH4Cl</e1> or MG132, partially inhibited the antofine-induced decrease in <e2>Cx43</e2> protein levels, but did not inhibit the antofine-induced inhibition of GJIC.","Regulator"
"Inhibition of lysosomes or proteasomes by co-treatment with antofine and their respective specific inhibitors, NH4Cl or <e1>MG132</e1>, partially inhibited the antofine-induced decrease in <e2>Cx43</e2> protein levels, but did not inhibit the antofine-induced inhibition of GJIC.","Regulator"
"<e1>Antofine</e1>-induced <e2>connexin43</e2> gap junction disassembly in rat astrocytes involves protein kinase Cβ.","Regulator"
"<e1>Antofine</e1>-induced connexin43 gap junction disassembly in rat astrocytes involves <e2>protein kinase Cβ</e2>.","Regulator"
"Levels of <e2>Cx43</e2> protein were also decreased in a dose- and time-dependent manner following <e1>antofine</e1> treatment.","Regulator"
"Moreover, co-treatment with <e1>antofine</e1> and a specific <e2>PKCβ</e2> inhibitor prevented endocytosis of gap junctions, downregulation of Cx43, and inhibition of GJIC.","Upregulator"
"Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator <e1>BAPTA-AM</e1> prevented downregulation of <e2>Cx43</e2> and inhibition of GJIC.","Upregulator"
"Levels of <e2>Cx43</e2> protein were also decreased in a dose- and time-dependent manner following <e1>antofine</e1> treatment.","Downregulator"
"Levels of <e2>Cx43</e2> protein were also decreased in a dose- and time-dependent manner following <e1>antofine</e1> treatment.","Downregulator"
"Levels of <e2>Cx43</e2> protein were also decreased in a dose- and time-dependent manner following <e1>antofine</e1> treatment.","Downregulator"
"In the present study, the ability of different concentrations of <e1>torasemide</e1> to modify <e2>angiotensin II</e2> (Ang II)-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.","Regulator"
"In the present study, the ability of different concentrations of <e1>torasemide</e1> to modify angiotensin II (<e2>Ang II</e2>)-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.","Regulator"
"<e1>Torasemide</e1> inhibits <e2>angiotensin II</e2>-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.","Downregulator"
"In the present study, the ability of different concentrations of <e1>torasemide</e1> to modify angiotensin II (<e2>Ang II</e2>)-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.","Downregulator"
"In the present study, the ability of different concentrations of <e1>torasemide</e1> to modify angiotensin II (<e2>Ang II</e2>)-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.","Downregulator"
"In the present study, the ability of different concentrations of <e1>torasemide</e1> to modify angiotensin II (<e2>Ang II</e2>)-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.","Downregulator"
"In the present study, the ability of different concentrations of <e1>torasemide</e1> to modify angiotensin II (<e2>Ang II</e2>)-induced vascular responses was examined, with the use of an organ bath system, in endothelium-denuded aortic rings from spontaneously hypertensive rats.","Downregulator"
"The twigs of Cudrania tricuspidata were found to show strong <e2>tyrosinase</e2> inhibitory activity, and further detailed component analysis resulted in the isolation of a new flavanol glucoside, (2S,3S)-2,3-<e1>trans-dihydromorin</e1>-7-O-β-d-glucoside (1), plus twenty-seven known compounds (2-28).","Downregulator"
"Among the isolated compounds, trans-dihydromorin (8), <e1>oxyresveratrol</e1> (9), and steppogenin (12) were found to exhibit significant <e2>tyrosinase</e2> inhibition activities.","Downregulator"
"Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and <e1>steppogenin</e1> (12) were found to exhibit significant <e2>tyrosinase</e2> inhibition activities.","Downregulator"
"The modulation of <e2>high-voltage-activated (HVA) Ca2+ channels</e2> by the prostaglandin E series (PGE1 and <e1>PGE2</e1>) was studied in the paratracheal ganglion cells.","Regulator"
"The modulation of <e2>high-voltage-activated (HVA) Ca2+ channels</e2> by the <e1>prostaglandin E</e1> series (PGE1 and PGE2) was studied in the paratracheal ganglion cells.","Regulator"
"<e1>PGE1</e1> and PGE2 also inhibited the remaining ICa in a saturating concentration of nifedipine, omega-conotoxin-GVIA and omega-conotoxin-MVIIC, suggesting that <e2>R-type Ca2+ channels</e2> are involved.","Regulator"
"PGE1 and <e1>PGE2</e1> also inhibited the remaining ICa in a saturating concentration of nifedipine, omega-conotoxin-GVIA and omega-conotoxin-MVIIC, suggesting that <e2>R-type Ca2+ channels</e2> are involved.","Regulator"
"The modulation of <e2>high-voltage-activated (HVA) Ca2+ channels</e2> by the prostaglandin E series (<e1>PGE1</e1> and PGE2) was studied in the paratracheal ganglion cells.","Regulator"
"The <e1>prostaglandin E</e1> series modulates <e2>high-voltage-activated calcium channels</e2> probably through the EP3 receptor in rat paratracheal ganglia.","Regulator"
"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the <e1>PGE1</e1>- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the <e2>EP3 receptor</e2>.","Regulator"
"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or <e1>PGE2</e1>-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the <e2>EP3 receptor</e2>.","Regulator"
"The <e1>prostaglandin E</e1> series modulates high-voltage-activated calcium channels probably through the <e2>EP3 receptor</e2> in rat paratracheal ganglia.","Regulator"
"SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the <e1>PGE1</e1>- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the <e2>EP3 receptor</e2>.","Regulator"
"It was concluded that <e1>PGE1</e1> selectively reduces both N- and R-type Ca2+ currents by activating a <e2>G-protein</e2> probably through the EP3 receptor in paratracheal ganglion cells.","Upregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <e1>17-phenyl-trinor-PGE2</e1> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, <e1>STA2</e1> (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of <e1>thromboxane A2</e1>), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <e1>sulprostone</e1> (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <e1>sulprostone</e1> (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-<e1>PGE2</e1> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, <e1>PGE1</e1>>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, <e1>STA2</e1> (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <e1>17-phenyl-trinor-PGE2</e1> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, <e1>PGE1</e1>>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-<e1>PGE2</e1> (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit <e2>HVA Ca2+ channels</e2> was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Downregulator"
"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the <e2>protein kinase C</e2> (PKC) inhibitor <e1>chelerythrine</e1> blocked the action of PMA.","Downregulator"
"The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C (<e2>PKC</e2>) inhibitor <e1>chelerythrine</e1> blocked the action of PMA.","Downregulator"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), <e1>17-phenyl-trinor-PGE2</e1> (an <e2>EP1</e2>-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Agonist"
"Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and <e1>sulprostone</e1> (an <e2>EP3</e2>-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2.","Agonist"
"<e1>SC-51089</e1> (10(-5) M), a selective <e2>EP1-receptor</e2> antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor.","Antagonist"
"Inhibition of <e2>MCP-1</e2> and MIP-2 transcription and translation by <e1>mimosine</e1> in muscle tissue infected with the parasite Trichinella spiralis.","Regulator"
"Inhibition of MCP-1 and <e2>MIP-2</e2> transcription and translation by <e1>mimosine</e1> in muscle tissue infected with the parasite Trichinella spiralis.","Regulator"
"Inhibition of <e2>MCP-1</e2> and MIP-2 transcription and translation by <e1>mimosine</e1> in muscle tissue infected with the parasite Trichinella spiralis.","Downregulator"
"Inhibition of MCP-1 and <e2>MIP-2</e2> transcription and translation by <e1>mimosine</e1> in muscle tissue infected with the parasite Trichinella spiralis.","Downregulator"
"Inhibition of <e2>MCP-1</e2> and MIP-2 transcription and translation by <e1>mimosine</e1> in muscle tissue infected with the parasite Trichinella spiralis.","Downregulator"
"Inhibition of MCP-1 and <e2>MIP-2</e2> transcription and translation by <e1>mimosine</e1> in muscle tissue infected with the parasite Trichinella spiralis.","Downregulator"
"This is described in a case study of the expedited review and approval of <e1>peramivir</e1>, a novel <e2>neuraminidase</e2> inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009.","Downregulator"
"The influence of sex, ethnicity, and <e2>CYP2B6</e2> genotype on <e1>bupropion</e1> metabolism as an index of hepatic CYP2B6 activity in humans.","Substrate"
"The influence of sex, ethnicity, and <e2>CYP2B6</e2> genotype on <e1>bupropion</e1> metabolism as an index of hepatic CYP2B6 activity in humans.","Substrate"
"The influence of sex, ethnicity, and <e2>CYP2B6</e2> genotype on <e1>bupropion</e1> metabolism as an index of hepatic CYP2B6 activity in humans.","Substrate"
"The influence of sex, ethnicity, and <e2>CYP2B6</e2> genotype on <e1>bupropion</e1> metabolism as an index of hepatic CYP2B6 activity in humans.","Substrate"
"To identify important covariates associated with interindividual variation in <e2>CYP2B6</e2> activity in vivo, we evaluated these effects in healthy volunteers using bupropion (<e1>Wellbutrin SR</e1> GlaxoSmithKline, Research Triangle Park, NC) as a CYP2B6 probe substrate.","Substrate"
"The influence of sex, ethnicity, and <e2>CYP2B6</e2> genotype on <e1>bupropion</e1> metabolism as an index of hepatic CYP2B6 activity in humans.","Substrate"
"Forskolin did not affect the relaxant response to UK14,304, suggesting that <e1>cAMP</e1> is not involved in the coupling of <e2>alpha-2 adrenoceptors</e2> to nitric oxide-induced vascular relaxation.","Not"
"Ka values in nM for <e1>rauwolscine</e1> (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the <e2>alpha-2D adrenoceptor</e2> subtype.","Regulator"
"Ka values in nM for rauwolscine (19), <e1>WB-4101</e1> (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the <e2>alpha-2D adrenoceptor</e2> subtype.","Regulator"
"Ka values in nM for rauwolscine (19), WB-4101 (265), <e1>SKF-104078</e1> (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the <e2>alpha-2D adrenoceptor</e2> subtype.","Regulator"
"Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), <e1>spiroxatrine</e1> (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the <e2>alpha-2D adrenoceptor</e2> subtype.","Regulator"
"Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and <e1>prazosin</e1> (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the <e2>alpha-2D adrenoceptor</e2> subtype.","Regulator"
"Ka values for <e1>rauwolscine</e1> and WB-4101, drugs distinguishing the alpha-2D from the <e2>alpha-2A adrenoceptor</e2> subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries.","Regulator"
"Ka values for rauwolscine and <e1>WB-4101</e1>, drugs distinguishing the alpha-2D from the <e2>alpha-2A adrenoceptor</e2> subtype, were significantly higher in blocking relaxation of rat arteries compared with pig arteries, suggesting the alpha-2D adrenoceptor subtype mediates NO-induced relaxation in rat arteries.","Regulator"
"The identification of the <e1>succinate</e1> receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists.","Agonist"
"The identification of the <e1>succinate</e1> receptor <e2>SUCNR1</e2> in platelets is of particular interest, because physiologically relevant concentrations of succinate were shown to potentiate the effect of low doses of a variety of platelet agonists.","Agonist"
"<e1>Neostigmine</e1> enhances excitatory parasympathetic activity by competing with acetylcholine for attachment to <e2>acetylcholinesterase</e2> at sites of cholinergic transmission and enhancing cholinergic action.","Regulator"
"Neostigmine enhances excitatory parasympathetic activity by competing with <e1>acetylcholine</e1> for attachment to <e2>acetylcholinesterase</e2> at sites of cholinergic transmission and enhancing cholinergic action.","Regulator"
"Apoptosis initiation of <e1>β-ionone</e1> in SGC-7901 gastric carcinoma cancer cells via a <e2>PI3K</e2>-AKT pathway.","Regulator"
"Apoptosis initiation of <e1>β-ionone</e1> in SGC-7901 gastric carcinoma cancer cells via a PI3K-<e2>AKT</e2> pathway.","Regulator"
"To investigate the effects of <e1>β-ionone</e1> on apoptosis initiation and its possible mechanisms of action, we qualified cell apoptosis, proteins related to apoptosis and a <e2>phosphatidylinositol 3-kinase</e2> (PI3K)-AKT pathway in human gastric adenocarcinoma cancer SGC-7901 cells.","Regulator"
"Apoptosis initiation of <e1>β-ionone</e1> in SGC-7901 gastric carcinoma cancer cells via a <e2>PI3K</e2>-AKT pathway.","Regulator"
"Apoptosis initiation of <e1>β-ionone</e1> in SGC-7901 gastric carcinoma cancer cells via a PI3K-<e2>AKT</e2> pathway.","Regulator"
"Apoptosis initiation of <e1>β-ionone</e1> in SGC-7901 gastric carcinoma cancer cells via a <e2>PI3K</e2>-AKT pathway.","Regulator"
"Apoptosis initiation of <e1>β-ionone</e1> in SGC-7901 gastric carcinoma cancer cells via a PI3K-<e2>AKT</e2> pathway.","Regulator"
"The results demonstrated that <e1>β-ionone</e1>-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with β-ionone (25, 50, 100 and 200 μmol/L) for 24 h. β-ionone was also shown to induce the expression of cleaved-<e2>caspase-3</e2> and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.","Upregulator"
"The results demonstrated that <e1>β-ionone</e1>-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with β-ionone (25, 50, 100 and 200 μmol/L) for 24 h. β-ionone was also shown to induce the expression of cleaved-caspase-3 and inhibit <e2>bcl-2</e2> expression in SGC-7901 cells in a dose-dependent manner.","Downregulator"
"The significantly decreased levels of <e2>p-PI3K</e2> and p-AKT expression were observed in SGC-7901 cells after <e1>β-ionone</e1> treatments in a time- and dose-dependent manner (P < 0.01).","Downregulator"
"The significantly decreased levels of p-PI3K and <e2>p-AKT</e2> expression were observed in SGC-7901 cells after <e1>β-ionone</e1> treatments in a time- and dose-dependent manner (P < 0.01).","Downregulator"
"<e1>Eprosartan</e1> acts at vascular <e2>AT(1) receptors</e2> (postsynaptically) and at presynaptic AT(1) receptors, where it inhibits sympathetically stimulated noradrenaline release.","Regulator"
"<e1>Eprosartan</e1> acts at vascular <e2>AT(1) receptors</e2> (postsynaptically) and at presynaptic AT(1) receptors, where it inhibits sympathetically stimulated noradrenaline release.","Regulator"
"However, <e2>AII</e2> receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P. Within the class of AII blockers, <e1>eprosartan</e1> differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action.","Downregulator"
"In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the <e2>ACE</e2> inhibitor <e1>enalapril</e1>, and has significantly lower side effects.","Downregulator"
"Reductive detoxification of <e1>arylhydroxylamine</e1> carcinogens by human <e2>NADH cytochrome b5 reductase</e2> and cytochrome b5.","Substrate"
"On the basis of our findings with structurally similar <e1>arylhydroxylamine</e1> metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (<e2>b5R</e2>) and cytochrome b5 (cyt b5).","Substrate"
"Reductive detoxification of <e1>arylhydroxylamine</e1> carcinogens by human NADH <e2>cytochrome b5</e2> reductase and cytochrome b5.","Substrate"
"On the basis of our findings with structurally similar <e1>arylhydroxylamine</e1> metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of arylhydroxylamine carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (<e2>cyt b5</e2>).","Substrate"
"We found that reduction of the carcinogenic <e1>hydroxylamines</e1> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R</e2> and cyt b5.","Substrate"
"We found that reduction of the carcinogenic <e1>hydroxylamines</e1> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5</e2>.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the <e1>aromatic amine</e1> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R</e2> and cyt b5.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the <e1>aromatic amine</e1> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5</e2>.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <e1>4-aminobiphenyl</e1> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R</e2> and cyt b5.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine <e1>4-aminobiphenyl</e1> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5</e2>.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<e1>4-ABP</e1>; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R</e2> and cyt b5.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<e1>4-ABP</e1>; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5</e2>.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <e1>heterocyclic amine</e1> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R</e2> and cyt b5.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the <e1>heterocyclic amine</e1> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5</e2>.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <e1>2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine</e1> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R</e2> and cyt b5.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine <e1>2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine</e1> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5</e2>.","Substrate"
"Reductive detoxification of <e1>arylhydroxylamine</e1> carcinogens by human NADH <e2>cytochrome b5</e2> reductase and cytochrome b5.","Substrate"
"Reductive detoxification of <e1>arylhydroxylamine</e1> carcinogens by <e2>human NADH cytochrome b5 reductase</e2> and cytochrome b5.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<e1>PhIP</e1>; found in grilled meats) was indeed catalyzed by a purified system containing only <e2>human b5R</e2> and cyt b5.","Substrate"
"We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<e1>PhIP</e1>; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and <e2>cyt b5</e2>.","Substrate"
"Polyclonal antisera to either <e2>b5R</e2> or cyt b5 significantly inhibited <e1>N-hydroxy-4-aminobiphenyl</e1> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).","Substrate"
"Polyclonal antisera to either b5R or <e2>cyt b5</e2> significantly inhibited <e1>N-hydroxy-4-aminobiphenyl</e1> (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).","Substrate"
"Polyclonal antisera to either <e2>b5R</e2> or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl (<e1>NHOH-4-ABP</e1>) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).","Substrate"
"Polyclonal antisera to either b5R or <e2>cyt b5</e2> significantly inhibited N-hydroxy-4-aminobiphenyl (<e1>NHOH-4-ABP</e1>) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).","Substrate"
"An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, <e1>p-aminobenzamidine</e1> (p-ABZ) and proflavin binding to the catalytic site of two proteolyzed forms of <e2>alpha-thrombin</e2>, i.e.","Regulator"
"An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine (<e1>p-ABZ</e1>) and proflavin binding to the catalytic site of two proteolyzed forms of <e2>alpha-thrombin</e2>, i.e.","Regulator"
"An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine (p-ABZ) and <e1>proflavin</e1> binding to the catalytic site of two proteolyzed forms of <e2>alpha-thrombin</e2>, i.e.","Regulator"
"An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, <e1>p-aminobenzamidine</e1> (p-ABZ) and proflavin binding to the catalytic site of two proteolyzed forms of alpha-<e2>thrombin</e2>, i.e.","Regulator"
"A phenomenological analysis of thermodynamic data showed that the amide substrates and <e1>p-ABZ</e1> interactions with <e2>zeta-thrombin</e2> were respectively, associated with a chemical compensation (i.e.","Regulator"
"Clinical effects of pranlukast, an oral <e1>leukotriene</e1> receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.","Regulator"
"Pranlukast is a new, orally active, selective inhibitor of <e2>CysLt1</e2> <e1>leukotriene</e1> receptor.","Regulator"
"Clinical effects of pranlukast, an oral <e1>leukotriene</e1> receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.","Regulator"
"<e1>Pranlukast</e1> is a new, orally active, selective inhibitor of <e2>CysLt1</e2> leukotriene receptor.","Downregulator"
"<e1>Pranlukast</e1> is a new, orally active, selective inhibitor of CysLt1 <e2>leukotriene receptor</e2>.","Downregulator"
"Clinical effects of <e1>pranlukast</e1>, an oral <e2>leukotriene receptor</e2> antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.","Antagonist"
"Binding sites for <e2>hERG</e2> blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix (Thr-623, <e1>Ser</e1>-624, Val-625).","Part_of"
"Binding sites for <e2>hERG</e2> blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix (Thr-623, Ser-624, <e1>Val</e1>-625).","Part_of"
"Binding sites for <e2>hERG</e2> blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (<e1>Tyr</e1>-652, Phe-656) and residues in the pore helix (Thr-623, Ser-624, Val-625).","Part_of"
"Binding sites for <e2>hERG</e2> blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, <e1>Phe</e1>-656) and residues in the pore helix (Thr-623, Ser-624, Val-625).","Part_of"
"Binding sites for <e2>hERG</e2> blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix (<e1>Thr</e1>-623, Ser-624, Val-625).","Part_of"
"Drug binding interactions in the inner cavity of <e2>HERG</e2> channels: molecular insights from structure-activity relationships of <e1>clofilium</e1> and ibutilide analogs.","Regulator"
"Drug binding interactions in the inner cavity of <e2>HERG</e2> channels: molecular insights from structure-activity relationships of clofilium and <e1>ibutilide</e1> analogs.","Regulator"
"In contrast, analogs with different para-substituents on the <e1>phenyl</e1> ring had significantly different potencies for wild-type <e2>hERG</e2> block.","Regulator"
"We used mutagenesis of these residues, combined with an investigation of <e2>hERG</e2> block by close analogs of <e1>clofilium</e1> and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions.","Downregulator"
"We used mutagenesis of these residues, combined with an investigation of <e2>hERG</e2> block by close analogs of clofilium and <e1>ibutilide</e1>, to assess how specific alterations in drug structure affected potency and binding interactions.","Downregulator"
"There was also an increase in <e2>c-kit</e2>, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, <e2>Trio</e2>, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, Trio, <e2>Rho-A</e2>, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, Trio, Rho-A, <e2>Rac-3</e2>, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, <e2>Notch-4</e2>, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, <e2>Dvl-2</e2>, Ezrin, beta catenin and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, <e2>Ezrin</e2>, beta catenin and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, <e2>beta catenin</e2> and mutant p53 protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant <e2>p53</e2> protein expression in the <e1>parathion</e1>-treated cells.","Upregulator"
"<e1>Parathion</e1> is a <e2>cholinesterase</e2> inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses.","Downregulator"
"Both forms of the enzyme reacted with a rabbit antibody raised to the <e1>amino</e1>-terminal peptide of the liver enzyme, suggesting that <e2>phosphodiester alpha-GlcNAcase</e2> is a type I membrane-spanning glycoprotein with its amino terminus in the lumen of the Golgi apparatus.","Part_of"
"Both forms of the enzyme reacted with a rabbit antibody raised to the <e1>amino</e1>-terminal peptide of the liver enzyme, suggesting that phosphodiester alpha-GlcNAcase is a <e2>type I membrane-spanning glycoprotein</e2> with its amino terminus in the lumen of the Golgi apparatus.","Part_of"
"<e2>N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase</e2> (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the <e1>mannose 6-phosphate</e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.","Substrate"
"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (<e2>EC 3.1.4.45</e2>; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the <e1>mannose 6-phosphate</e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.","Substrate"
"N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; <e2>phosphodiester alpha-GlcNAcase</e2>) catalyzes the second step in the synthesis of the <e1>mannose 6-phosphate</e1> determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.","Substrate"
"The purified <e2>phosphodiester alpha-GlcNAcase</e2> has a specific activity of 498 micromol of <e1>[3H]GlcNAc-alpha-phosphomannose-alpha-methyl</e1> cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.","Substrate"
"The purified <e2>phosphodiester alpha-GlcNAcase</e2> has a specific activity of 498 micromol of <e1>[3H]GlcNAc-alpha-phosphomannose-alpha-methyl</e1> cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.","Substrate"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the <e2>matrix metalloproteinases</e2>-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Regulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the <e2>tissue inhibitors of matrix metalloproteinases</e2> (MMP-TIMP) system.","Regulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (<e2>MMP</e2>-TIMP) system.","Regulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-<e2>TIM</e2>P) system.","Regulator"
"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), <e2>lactic dehydrogenase</e2> (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high <e1>glucose</e1> (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Regulator"
"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (<e2>LDH</e2>), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high <e1>glucose</e1> (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Regulator"
"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), <e2>superoxide dismutase</e2> (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high <e1>glucose</e1> (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Regulator"
"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (<e2>SOD</e2>), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high <e1>glucose</e1> (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Regulator"
"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and <e2>catalase</e2> (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high <e1>glucose</e1> (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Regulator"
"In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (<e2>CAT</e2>)) in human umbilical vein endothelial cells (HUVECs) damaged by high <e1>glucose</e1> (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Regulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), <e2>lactic dehydrogenase</e2> (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Downregulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (<e2>LDH</e2>), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Downregulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), <e2>superoxide dismutase</e2> (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Downregulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (<e2>SOD</e2>), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Downregulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and <e2>catalase</e2> (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Downregulator"
"In the in vitro assay, <e1>kinsenoside</e1> (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (<e2>CAT</e2>)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.","Downregulator"
"The vascular protective effects of <e1>kinsenoside</e1> were speculated to be attributed to oxidative stress inhibition and the reduction of <e2>nuclear factor kappa B</e2> (NF-κB) mRNA expression levels in high glucose conditions.","Downregulator"
"The vascular protective effects of <e1>kinsenoside</e1> were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (<e2>NF-κB</e2>) mRNA expression levels in high glucose conditions.","Downregulator"
"<e1>8-pCPT-2'-O-Me-cAMP-AM</e1> alone (5 μM) did not stimulate <e2>insulin</e2> secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+).","Not"
"Potentiation of sulfonylurea action by an <e2>EPAC</e2>-selective <e1>cAMP</e1> analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx.","Regulator"
"We examined the ability of the <e2>EPAC</e2>-selective cAMP analog <e1>8-pCPT-2'-O-Me-cAMP-AM</e1> to potentiate the action of these drugs and the mechanism that might account for it.","Regulator"
"Both tolbutamide and <e1>gliclazide</e1> stimulated <e2>phospholipase C</e2> activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.","Upregulator"
"Both <e1>tolbutamide</e1> and gliclazide stimulated <e2>phospholipase C</e2> activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.","Upregulator"
"Both tolbutamide and <e1>gliclazide</e1> stimulated <e2>phospholipase C</e2> activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin.","Upregulator"
"Both tolbutamide and <e1>gliclazide</e1> stimulated phospholipase C activity; however, only gliclazide did so independently of its activity at <e2>K(ATP) channels</e2>, and this activity was partially inhibited by pertussis toxin.","Upregulator"
"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>insulin</e2> secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor <e1>bisindolylmaleimide I</e1> (1 μM).","Upregulator"
"<e1>Tolbutamide</e1> and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating <e2>insulin</e2> secretion in pancreatic beta cells.","Upregulator"
"<e2>Insulin</e2> secretion stimulated by both 200 μM <e1>tolbutamide</e1> and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.","Upregulator"
"<e2>Insulin</e2> secretion stimulated by both 200 μM tolbutamide and 20 μM <e1>gliclazide</e1>, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.","Upregulator"
"<e2>Insulin</e2> secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by <e1>8-pCPT-2'-O-Me-cAMP-AM</e1> at concentrations ≥2 μM in INS-1 cells.","Upregulator"
"<e1>8-pCPT-2'-O-Me-cAMP-AM</e1> alone (5 μM) did not stimulate <e2>insulin</e2> secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (2-APB) or the removal of extracellular Ca(2+).","Upregulator"
"8-pCPT-2'-O-Me-cAMP-AM potentiation of <e2>insulin</e2> secretion stimulated by <e1>tolbutamide</e1> was markedly inhibited by 2-APB (25 μM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 μM).","Upregulator"
"<e2>Insulin</e2> secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by <e1>thapsigargin</e1> (1 μM) or the L-type Ca(2+) channel blocker nicardipine (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.","Downregulator"
"<e2>Insulin</e2> secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the L-type Ca(2+) channel blocker <e1>nicardipine</e1> (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.","Downregulator"
"8-pCPT-2'-O-Me-cAMP-AM alone (5 μM) did not stimulate <e2>insulin</e2> secretion, but did increase intracellular Ca(2+) concentration significantly, and this activity was inhibited by 25 μM 2-aminoethoxydiphenylborate (<e1>2-APB</e1>) or the removal of extracellular Ca(2+).","Downregulator"
"8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 μM) and enhanced by the <e2>PKC</e2> inhibitor <e1>bisindolylmaleimide I</e1> (1 μM).","Downregulator"
"<e1>Tolbutamide</e1> and gliclazide block the <e2>K(ATP) channel</e2> K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.","Downregulator"
"<e1>Tolbutamide</e1> and gliclazide block the K(ATP) channel <e2>K(ir)6.2</e2>/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.","Downregulator"
"<e1>Tolbutamide</e1> and gliclazide block the K(ATP) channel K(ir)6.2/<e2>Sur1</e2>, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells.","Downregulator"
"Insulin secretion stimulated by both 200 μM tolbutamide and 20 μM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 μM) or the <e2>L-type Ca(2+) channel</e2> blocker <e1>nicardipine</e1> (2 μM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations ≥2 μM in INS-1 cells.","Downregulator"
"<e1>2-Deoxyglucose</e1> increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of <e2>TSC1</e2> bound to TSC2.","Not"
"Phosphorylation of <e2>AMPK</e2> at <e1>Thr</e1>172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to 2-deoxyglucose.","Part_of"
"The objective of this study was to examine the effect of AMP-activated protein kinase (<e2>AMPK</e2>) activation by <e1>2-deoxyglucose</e1> on protein synthesis and the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway in bovine mammary epithelial cells.","Upregulator"
"Phosphorylation of ER-stress marker <e2>eIF2α</e2> was also increased but only at 30 min of <e1>2-deoxyglucose</e1> exposure.","Upregulator"
"<e1>2-Deoxyglucose</e1> increased phosphorylation of tuberous sclerosis complex 2 (<e2>TSC2</e2>) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2.","Upregulator"
"<e1>2-Deoxyglucose</e1> increased phosphorylation of <e2>tuberous sclerosis complex 2</e2> (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2.","Upregulator"
"<e1>2-Deoxyglucose</e1> increased phosphorylation of tuberous sclerosis complex 2 (<e2>TSC2</e2>) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2.","Upregulator"
"<e1>2-Deoxyglucose</e1> increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on <e2>AMPK</e2> consensus sites but did not change the amount of TSC1 bound to TSC2.","Upregulator"
"<e1>Conivaptan</e1> is a nonpeptide dual <e2>V1a/V2 AVP receptor</e2> antagonist.","Antagonist"
"<e1>Conivaptan</e1>: a dual <e2>vasopressin receptor v1a/v2</e2> antagonist [corrected].","Antagonist"
"<e1>Histamine</e1> and asthma: an appraisal based on specific <e2>H1-receptor</e2> antagonism.","Regulator"
"<e2>H1-receptor</e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>histamine</e1> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.","Agonist"
"<e2>H1-receptor</e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>histamine</e1> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.","Agonist"
"<e2>H1-receptor</e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>histamine</e1> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.","Agonist"
"<e2>H1-receptor</e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>histamine</e1> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.","Agonist"
"<e2>H1-receptor</e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>histamine</e1> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.","Agonist"
"<e2>H1-receptor</e2> antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which <e1>histamine</e1> is considered to be of pathogenic importance and conversely to help elucidate the role of histamine in disease, through an evaluation of their influence on disease expression.","Agonist"
"<e2>Cholesterol esterase</e2> (CE) induced surface erosion of poly(ethylene carbonate) (<e1>PEC</e1>) and drug release from PEC under mild physiological environment was investigated.","Substrate"
"Cholesterol esterase (<e2>CE</e2>) induced surface erosion of poly(ethylene carbonate) (<e1>PEC</e1>) and drug release from PEC under mild physiological environment was investigated.","Substrate"
"<e2>Cholesterol esterase</e2> (CE) induced surface erosion of <e1>poly(ethylene carbonate)</e1> (PEC) and drug release from PEC under mild physiological environment was investigated.","Substrate"
"Cholesterol esterase (<e2>CE</e2>) induced surface erosion of <e1>poly(ethylene carbonate)</e1> (PEC) and drug release from PEC under mild physiological environment was investigated.","Substrate"
"Islet morphology was examined and <e2>insulin</e2> secretion and <e1>glucose</e1> oxidation were measured in isolated islets.","Regulator"
"Islet morphology was examined and <e2>insulin</e2> secretion and <e1>glucose</e1> oxidation were measured in isolated islets.","Regulator"
"Insulin secretion was studied after oral and intravenous administration of glucose and <e2>glucagon</e2> secretion after intravenous <e1>arginine</e1>.","Upregulator"
"Islet morphology was examined and <e2>insulin</e2> secretion and <e1>glucose</e1> oxidation were measured in isolated islets.","Upregulator"
"<e2>PIP5K1B</e2> encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>phosphatidylinositol-4,5-bisphosphate</e1> [PI(4,5)P2].","Substrate"
"PIP5K1B encodes <e2>phosphatidylinositol 4-phosphate 5-kinase β type I</e2> (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>phosphatidylinositol-4,5-bisphosphate</e1> [PI(4,5)P2].","Substrate"
"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (<e2>pip5k1β</e2>), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate <e1>phosphatidylinositol-4,5-bisphosphate</e1> [PI(4,5)P2].","Substrate"
"<e2>PIP5K1B</e2> encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>PI(4,5)P2</e1>].","Substrate"
"PIP5K1B encodes <e2>phosphatidylinositol 4-phosphate 5-kinase β type I</e2> (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>PI(4,5)P2</e1>].","Substrate"
"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (<e2>pip5k1β</e2>), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>PI(4,5)P2</e1>].","Substrate"
"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (<e2>pip5k1β</e2>), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [<e1>PI(4,5)P2</e1>].","Substrate"
"<e2>PIP5K1B</e2> encodes <e1>phosphatidylinositol 4-phosphate</e1> 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].","Substrate"
"PIP5K1B encodes <e1>phosphatidylinositol 4-phosphate</e1> 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].","Substrate"
"PIP5K1B encodes <e1>phosphatidylinositol 4-phosphate</e1> 5-kinase β type I (<e2>pip5k1β</e2>), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].","Substrate"
"<e2>PIP5K1B</e2> encodes phosphatidylinositol 4-phosphate 5-kinase β type I (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>PI(4)P</e1>] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].","Substrate"
"PIP5K1B encodes <e2>phosphatidylinositol 4-phosphate 5-kinase β type I</e2> (pip5k1β), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>PI(4)P</e1>] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].","Substrate"
"PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase β type I (<e2>pip5k1β</e2>), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [<e1>PI(4)P</e1>] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].","Substrate"
"<e2>Regucalcin</e2> (RGN/SMP30) was originally discovered in 1978 as a unique <e1>calcium</e1>-binding protein that does not contain the EF-hand motif of calcium-binding domain.","Regulator"
"Regucalcin (<e2>RGN</e2>/SMP30) was originally discovered in 1978 as a unique <e1>calcium</e1>-binding protein that does not contain the EF-hand motif of calcium-binding domain.","Regulator"
"Regucalcin (RGN/<e2>SMP30</e2>) was originally discovered in 1978 as a unique <e1>calcium</e1>-binding protein that does not contain the EF-hand motif of calcium-binding domain.","Regulator"
"The expression of <e2>regucalcin</e2> is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by <e1>streptozotocin</e1> administration in vivo.","Downregulator"
"<e2>AMPK</e2> activators <e1>metformin</e1> and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.","Upregulator"
"<e2>AMPK</e2> activators metformin and <e1>AICAR</e1> partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.","Upregulator"
"The in vivo effects of the non-steroid anti-inflammatory drug (NSAID) amtolmetin guacyl, a pro-drug of the NSAID tolmetin, on lipid peroxidation, glutathione levels and activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase) in rat gastric mucosa, colon mucosa and liver, were compared with the effects of non-selective (indomethacin, diclofenac) and <e2>COX-2</e2> selective (<e1>celecoxib</e1>) NSAIDs.","Regulator"
"<e1>Indomethacin</e1> treatment led to an increase in lipid peroxidation, <e2>glutathione peroxidase</e2> and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.","Upregulator"
"<e1>Indomethacin</e1> treatment led to an increase in lipid peroxidation, glutathione peroxidase and <e2>glucose-6-phosphate dehydrogenase</e2> activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.","Upregulator"
"<e1>Indomethacin</e1> treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in <e2>catalase</e2> activity and glutathione levels in gastric mucosa.","Downregulator"
"Diclofenac-β-d-glucuronide, <e1>clopidogrel-β-d-glucuronide</e1>, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit <e2>hCES2</e2>.","Not"
"Diclofenac-β-d-glucuronide, clopidogrel-β-d-glucuronide, <e1>ibuprofen-β-d-glucuronide</e1>, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit <e2>hCES2</e2>.","Not"
"Diclofenac-β-d-glucuronide, clopidogrel-β-d-glucuronide, ibuprofen-β-d-glucuronide, <e1>(R)-naproxen-β-d-glucuronide</e1>, and (S)-naproxen-β-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit <e2>hCES2</e2>.","Not"
"Diclofenac-β-d-glucuronide, clopidogrel-β-d-glucuronide, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and <e1>(S)-naproxen-β-d-glucuronide</e1> selectively inhibited hCES1, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit <e2>hCES2</e2>.","Not"
"<e1>Valproate-β-d-glucuronide</e1> and CGP 47292-β-d-glucuronide did not inhibit either <e2>hCES</e2>.","Not"
"Valproate-β-d-glucuronide and <e1>CGP 47292-β-d-glucuronide</e1> did not inhibit either <e2>hCES</e2>.","Not"
"Time-dependent inactivation of <e2>hCES1</e2> by <e1>diclofenac-β-d-glucuronide</e1> was not observed.","Not"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>hCES1</e2>) and 2 (hCES2).","Not"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>hCES2</e2>).","Not"
"<e1>Diclofenac-β-d-glucuronide</e1>, clopidogrel-β-d-glucuronide, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit <e2>hCES2</e2>.","Not"
"Diclofenac-β-d-glucuronide, <e1>clopidogrel-β-d-glucuronide</e1>, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited <e2>hCES1</e2>, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.","Downregulator"
"Diclofenac-β-d-glucuronide, clopidogrel-β-d-glucuronide, <e1>ibuprofen-β-d-glucuronide</e1>, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited <e2>hCES1</e2>, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.","Downregulator"
"Diclofenac-β-d-glucuronide, clopidogrel-β-d-glucuronide, ibuprofen-β-d-glucuronide, <e1>(R)-naproxen-β-d-glucuronide</e1>, and (S)-naproxen-β-d-glucuronide selectively inhibited <e2>hCES1</e2>, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.","Downregulator"
"Diclofenac-β-d-glucuronide, clopidogrel-β-d-glucuronide, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and <e1>(S)-naproxen-β-d-glucuronide</e1> selectively inhibited <e2>hCES1</e2>, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.","Downregulator"
"Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to <e1>acyl glucuronides</e1> due to the potential inhibition of <e2>hCESs</e2>.","Downregulator"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of <e2>human carboxylesterases 1</e2> (hCES1) and 2 (hCES2).","Downregulator"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>hCES1</e2>) and 2 (hCES2).","Downregulator"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>hCES2</e2>).","Downregulator"
"Reversible inhibition of <e2>human carboxylesterases</e2> by <e1>acyl glucuronides</e1>.","Downregulator"
"<e1>Diclofenac-β-d-glucuronide</e1>, clopidogrel-β-d-glucuronide, ibuprofen-β-d-glucuronide, (R)-naproxen-β-d-glucuronide, and (S)-naproxen-β-d-glucuronide selectively inhibited <e2>hCES1</e2>, with Ki values of 4.32 ± 0.47, 24.8 ± 4.2, 355 ± 38, 468 ± 21, 707 ± 64 µM, respectively, but did not significantly inhibit hCES2.","Downregulator"
"<e2>Carboxylesterases</e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting <e1>alcohols</e1>, amines, and thiols, respectively.","Substrate"
"<e2>Uridine 5'-diphosphate- glucuronosyltransferases</e2> are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to <e1>acyl glucuronides</e1>, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.","Substrate"
"Reversible inhibition of human <e2>carboxylesterases</e2> by <e1>acyl glucuronides</e1>.","Substrate"
"<e2>Uridine 5'-diphosphate- glucuronosyltransferases</e2> are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to <e1>acyl glucuronides</e1>, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.","Substrate"
"<e2>Carboxylesterases</e2> hydrolyze esters, amides, and thioesters to produce <e1>carboxylic acids</e1> and resulting alcohols, amines, and thiols, respectively.","Substrate"
"<e2>Carboxylesterases</e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, <e1>amines</e1>, and thiols, respectively.","Substrate"
"<e2>Carboxylesterases</e2> hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and <e1>thiols</e1>, respectively.","Substrate"
"<e2>Uridine 5'-diphosphate- glucuronosyltransferases</e2> are colocalized with carboxylesterases and have the potential to further metabolize <e1>carboxylic acids</e1> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.","Substrate"
"Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with <e2>carboxylesterases</e2> and have the potential to further metabolize <e1>carboxylic acids</e1> to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.","Substrate"
"<e2>Carboxylesterases</e2> hydrolyze <e1>esters</e1>, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.","Substrate"
"<e2>Carboxylesterases</e2> hydrolyze esters, <e1>amides</e1>, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.","Substrate"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of <e2>human carboxylesterases 1</e2> (hCES1) and 2 (hCES2).","Substrate"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>hCES1</e2>) and 2 (hCES2).","Substrate"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>hCES2</e2>).","Substrate"
"<e2>Carboxylesterases</e2> hydrolyze esters, amides, and <e1>thioesters</e1> to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.","Substrate"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (<e2>hCES1</e2>) and 2 (hCES2).","Substrate"
"Objective: This study explores the ability of <e1>acyl glucuronides</e1> to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (<e2>hCES2</e2>).","Substrate"
"<e2>NF-κB</e2>-associated mechanisms underlying the response of embryonic cells to <e1>Doxorubicin</e1>.","Regulator"
"Therefore, we tried to assess the involvement of the <e2>p65</e2> subunit of NF-κB in the embryonic response to the anti-cancer drug Doxorubicin (<e1>DOX</e1>).","Downregulator"
"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of <e2>caspase 3</e2> and release of cytochrome c to the cytosol induced by <e1>DZN</e1>.","Upregulator"
"<e1>Crocin</e1> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of <e2>caspase 3</e2> and release of cytochrome c to the cytosol induced by DZN.","Upregulator"
"RESULTS: <e1>DZN</e1> induced histophatological damages and elevated the level of cardiac marker <e2>CK-MB</e2>.","Upregulator"
"Crocin (25 and 50mg/kg) or <e1>vitamin E</e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of <e2>caspase 3</e2> and release of cytochrome c to the cytosol induced by DZN.","Upregulator"
"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of <e2>cytochrome c</e2> to the cytosol induced by <e1>DZN</e1>.","Upregulator"
"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>Bax</e2>/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <e1>DZN</e1>.","Upregulator"
"<e1>Crocin</e1> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of <e2>cytochrome c</e2> to the cytosol induced by DZN.","Downregulator"
"Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/<e2>Bcl2</e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by <e1>DZN</e1>.","Downregulator"
"<e1>Crocin</e1> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and <e2>CK-MB</e2>, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.","Downregulator"
"<e1>Crocin</e1> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>Bax</e2>/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.","Downregulator"
"<e1>Crocin</e1> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/<e2>Bcl2</e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.","Downregulator"
"Crocin (25 and 50mg/kg) or <e1>vitamin E</e1> improved histopathological damages, decreased MDA and <e2>CK-MB</e2>, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.","Downregulator"
"Crocin (25 and 50mg/kg) or <e1>vitamin E</e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of <e2>Bax</e2>/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.","Downregulator"
"Crocin (25 and 50mg/kg) or <e1>vitamin E</e1> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/<e2>Bcl2</e2> ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.","Downregulator"
"This effect requires cold-induced, TRPA-1-mediated <e1>calcium</e1> influx and a calcium-sensitive <e2>PKC</e2> that signals to the transcription factor DAF-16/FOXO.","Regulator"
"Effect of <e1>fenoterol</e1>-induced constitutive <e2>beta(2)-adrenoceptor</e2> activity on contractile receptor function in airway smooth muscle.","Upregulator"
"Effect of <e1>fenoterol</e1>-induced constitutive <e2>beta(2)-adrenoceptor</e2> activity on contractile receptor function in airway smooth muscle.","Upregulator"
"Effect of <e1>fenoterol</e1>-induced constitutive <e2>beta(2)-adrenoceptor</e2> activity on contractile receptor function in airway smooth muscle.","Upregulator"
"Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full <e2>muscarinic receptor</e2> agonist methacholine, the partial muscarinic receptor agonist <e1>4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium</e1> (McN-A-343) and histamine.","Agonist"
"In the present study, we investigated the effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on <e2>muscarinic receptor</e2> agonist- and <e1>histamine</e1>-induced bovine tracheal smooth muscle contractions.","Agonist"
"Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full <e2>muscarinic receptor</e2> agonist <e1>methacholine</e1>, the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine.","Agonist"
"In conclusion, fenoterol-induced constitutive <e2>beta(2)-adrenoceptor</e2> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist <e1>timolol</e1>.","Agonist"
"In addition, <e1>BGG</e1>-mediated inhibition of AR prevented LPS-induced activation of <e2>JNK</e2> and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis.","Downregulator"
"In addition, <e1>BGG</e1>-mediated inhibition of AR prevented LPS-induced activation of JNK and <e2>p38</e2> and lowered ROS levels, which could inhibit LPS-induced apoptosis.","Downregulator"
"<e1>Beta-glucogallin</e1> reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of <e2>aldose reductase</e2> in murine macrophages and ocular tissues.","Downregulator"
"<e1>Beta-glucogallin</e1> (BGG), a recently described <e2>AR</e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).","Downregulator"
"Beta-glucogallin (<e1>BGG</e1>), a recently described <e2>AR</e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).","Downregulator"
"Beta-glucogallin (<e1>BGG</e1>), a recently described <e2>AR</e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).","Downregulator"
"Beta-glucogallin (<e1>BGG</e1>), a recently described <e2>AR</e2> inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis).","Downregulator"
"<e2>Aldose reductase</e2> (AR) catalyzes the reduction of toxic lipid aldehydes to their <e1>alcohol</e1> products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).","Substrate"
"Aldose reductase (<e2>AR</e2>) catalyzes the reduction of toxic lipid aldehydes to their <e1>alcohol</e1> products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).","Substrate"
"<e2>Aldose reductase</e2> (AR) catalyzes the reduction of toxic lipid <e1>aldehydes</e1> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).","Substrate"
"Aldose reductase (<e2>AR</e2>) catalyzes the reduction of toxic lipid <e1>aldehydes</e1> to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS).","Substrate"
"Differential phosphoproteome of the striatum from <e2>pleiotrophin</e2> knockout and midkine knockout mice treated with <e1>amphetamine</e1>: Correlations with amphetamine-induced neurotoxicity.","Regulator"
"The neurotrophic factors pleiotrophin (<e2>PTN</e2>) and midkine (MK) have been shown to modulate <e1>amphetamine</e1>-induced neurotoxicity.","Regulator"
"Differential phosphoproteome of the striatum from pleiotrophin knockout and <e2>midkine</e2> knockout mice treated with <e1>amphetamine</e1>: Correlations with amphetamine-induced neurotoxicity.","Regulator"
"The neurotrophic factors pleiotrophin (PTN) and midkine (<e2>MK</e2>) have been shown to modulate <e1>amphetamine</e1>-induced neurotoxicity.","Regulator"
"The neurotrophic factors pleiotrophin (<e2>PTN</e2>) and midkine (MK) have been shown to modulate <e1>amphetamine</e1>-induced neurotoxicity.","Regulator"
"The neurotrophic factors pleiotrophin (PTN) and midkine (<e2>MK</e2>) have been shown to modulate <e1>amphetamine</e1>-induced neurotoxicity.","Regulator"
"Exogenous C2-<e1>ceramide</e1> activates c-fos serum response element via <e2>Rac</e2>-dependent signalling pathway.","Regulator"
"Exogenous <e1>C2-ceramide</e1> activates c-fos serum response element via <e2>Rac</e2>-dependent signalling pathway.","Regulator"
"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (<e2>cPLA2</e2>) oligonucleotide repressed the <e1>C2-ceramide</e1>-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus.","Regulator"
"In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (<e2>cPLA2</e2>) oligonucleotide repressed the <e1>C2-ceramide</e1>-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus.","Regulator"
"Exogenous <e1>C2-ceramide</e1> activates c-fos serum response element via <e2>Rac</e2>-dependent signalling pathway.","Regulator"
"Exogenous C2-<e1>ceramide</e1> activates c-fos serum response element via <e2>Rac</e2>-dependent signalling pathway.","Regulator"
"Treatment of Rat-2 fibroblast cells with <e1>C2-ceramide</e1> caused the stimulation of <e2>c-fos SRE</e2>-dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis.","Upregulator"
"To understand the signal transduction pathway of <e1>ceramide</e1> to the nucleus, in the present study, we examined whether C2-ceramide, a cell permeable ceramide, activates c-fos serum response element (<e2>SRE</e2>).","Upregulator"
"To understand the signal transduction pathway of ceramide to the nucleus, in the present study, we examined whether <e1>C2-ceramide</e1>, a cell permeable ceramide, activates c-fos serum response element (<e2>SRE</e2>).","Upregulator"
"Exogenous <e1>C2-ceramide</e1> activates <e2>c-fos serum response element</e2> via Rac-dependent signalling pathway.","Upregulator"
"To understand the signal transduction pathway of ceramide to the nucleus, in the present study, we examined whether <e1>C2-ceramide</e1>, a cell permeable ceramide, activates c-fos serum response element (<e2>SRE</e2>).","Upregulator"
"In a further study to analyse the downstream mediator of Rac in the <e1>ceramide</e1>-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of <e2>phospholipase A2</e2>, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the C2-ceramide-induced SRE activation selectively, implying a critical role of cPLA2 in C2-ceramide-induced signalling to nucleus.","Upregulator"
"Consistent with these results, the translocation of cPLA2 protein as well as the release of <e1>arachidonic acid</e1>, a principal product of <e2>phospholipase A2</e2>, was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner.","Substrate"
"<e1>Melatonin</e1> and N-acetyl-5-hydroxytryptamine (N-acetyl-5-HT), a ligand of <e2>MT3</e2> biding site, also had no impairment on the performance, per se.","Regulator"
"Melatonin and <e1>N-acetyl-5-hydroxytryptamine</e1> (N-acetyl-5-HT), a ligand of <e2>MT3</e2> biding site, also had no impairment on the performance, per se.","Regulator"
"Melatonin and N-acetyl-5-hydroxytryptamine (<e1>N-acetyl-5-HT</e1>), a ligand of <e2>MT3</e2> biding site, also had no impairment on the performance, per se.","Regulator"
"Effect of <e1>ramelteon</e1> (TAK-375), a selective <e2>MT1/MT2 receptor</e2> agonist, on motor performance in mice.","Agonist"
"Effect of ramelteon (<e1>TAK-375</e1>), a selective <e2>MT1/MT2 receptor</e2> agonist, on motor performance in mice.","Agonist"
"Effect of <e1>ramelteon</e1> (TAK-375), a selective <e2>MT1/MT2 receptor</e2> agonist, on motor performance in mice.","Agonist"
"Effect of ramelteon (<e1>TAK-375</e1>), a selective <e2>MT1/MT2 receptor</e2> agonist, on motor performance in mice.","Agonist"
"Effect of <e1>(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide</e1> (ramelteon, TAK-375), a selective <e2>MT1/MT2 receptor</e2> agonist, on motor coordination was studied using rota-rod performance in mice.","Agonist"
"This paper aims to review briefly the literature on the <e1>5-HT</e1> hypothesis of depression with a major focus on the possible role of <e2>SERT</e2> in this disorder, while highlighting how recent data are more oriented on dimensional rather than nosological involvement of this structure in different conditions spanning from normality to pathology.","Regulator"
"Our previous work, built on the early pioneering multikinase inhibitor <e1>LY294002</e1>, resulted in the only <e2>PI3K</e2> vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.","Downregulator"
"Our previous work, built on the early pioneering multikinase inhibitor <e1>LY294002</e1>, resulted in the only <e2>PI3K</e2> vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.","Downregulator"
"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only <e2>PI3K</e2> vascular-targeted PI3K inhibitor prodrug, <e1>SF1126</e1>, which has now completed Phase I clinical trials.","Downregulator"
"Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only <e2>PI3K</e2> vascular-targeted PI3K inhibitor prodrug, <e1>SF1126</e1>, which has now completed Phase I clinical trials.","Downregulator"
"Synthesis and cancer stem cell-based activity of substituted <e1>5-morpholino-7H-thieno[3,2-b]pyran-7-one</e1>s designed as next generation <e2>PI3K</e2> inhibitors.","Downregulator"
"Synthesis and cancer stem cell-based activity of substituted <e1>5-morpholino-7H-thieno[3,2-b]pyran-7-one</e1>s designed as next generation <e2>PI3K</e2> inhibitors.","Downregulator"
"Synthesis and cancer stem cell-based activity of substituted <e1>5-morpholino-7H-thieno[3,2-b]pyran-7-ones</e1> designed as next generation <e2>PI3K</e2> inhibitors.","Downregulator"
"<e1>Fingolimod</e1> (FTY720), a synthetic <e2>sphingosine phosphate receptor</e2> modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials.","Regulator"
"Fingolimod (<e1>FTY720</e1>), a synthetic <e2>sphingosine phosphate receptor</e2> modulator that reduces the recirculation of lymphocytes to blood and peripheral tissues including inflammatory lesions and graft sites is undergoing phase III trials.","Regulator"
"CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.<e1>FK778</e1>, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, <e2>dihydroorotic acid dehydrogenase</e2>, and receptor-associated tyrosine kinases has completed phase II trials.","Regulator"
"CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.<e1>FK778</e1>, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and <e2>receptor-associated tyrosine kinases</e2> has completed phase II trials.","Regulator"
"CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic <e1>malononitrilamide</e1> that targets the critical enzyme of the de novo pyrimidine synthesis, <e2>dihydroorotic acid dehydrogenase</e2>, and receptor-associated tyrosine kinases has completed phase II trials.","Regulator"
"CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic <e1>malononitrilamide</e1> that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and <e2>receptor-associated tyrosine kinases</e2> has completed phase II trials.","Regulator"
"<e1>CP-690550</e1>, a <e2>JAK3</e2> inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials.","Downregulator"
"The activation appears to be due to an increase of <e2>GAD</e2> affinity for its cofactor, pyridoxal phosphate (<e1>PLP</e1>).","Regulator"
"The activation appears to be due to an increase of <e2>GAD</e2> affinity for its cofactor, <e1>pyridoxal phosphate</e1> (PLP).","Regulator"
"The activation appears to be due to an increase of <e2>GAD</e2> affinity for its cofactor, pyridoxal phosphate (<e1>PLP</e1>).","Regulator"
"The activation appears to be due to an increase of <e2>GAD</e2> affinity for its cofactor, pyridoxal phosphate (<e1>PLP</e1>).","Regulator"
"The activation appears to be due to an increase of <e2>GAD</e2> affinity for its cofactor, <e1>pyridoxal phosphate</e1> (PLP).","Cofactor"
"The activation appears to be due to an increase of <e2>GAD</e2> affinity for its cofactor, pyridoxal phosphate (<e1>PLP</e1>).","Cofactor"
"Firstly, the V(max) of <e2>GAD</e2> was increased when ApoCaM was present whereas the affinity for the substrate, <e1>glutamate</e1>, was not affected.","Substrate"
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>sodium hydrosulphide</e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in <e2>SP</e2> concentration and expression of PPT-A and NK1-R in acinar cells.","Upregulator"
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>sodium hydrosulphide</e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of <e2>PPT-A</e2> and NK1-R in acinar cells.","Upregulator"
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, <e1>sodium hydrosulphide</e1> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and <e2>NK1-R</e2> in acinar cells.","Upregulator"
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>NaHS</e1>), (10, 50 and 100 muM), that resulted in a significant increase in <e2>SP</e2> concentration and expression of PPT-A and NK1-R in acinar cells.","Upregulator"
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>NaHS</e1>), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of <e2>PPT-A</e2> and NK1-R in acinar cells.","Upregulator"
"To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<e1>NaHS</e1>), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and <e2>NK1-R</e2> in acinar cells.","Upregulator"
"<e1>Caerulein</e1> increased the levels of H(2)S and <e2>CSE</e2> mRNA expression while CBS mRNA expression was decreased.","Upregulator"
"Furthermore, <e2>substance P</e2> (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein</e1>-treated acinar cells.","Upregulator"
"Furthermore, substance P (<e2>SP</e2>) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein</e1>-treated acinar cells.","Upregulator"
"Furthermore, substance P (<e2>SP</e2>) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein</e1>-treated acinar cells.","Upregulator"
"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (<e2>preprotachykinin-A</e2>, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein</e1>-treated acinar cells.","Upregulator"
"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, <e2>PPT-A</e2>) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein</e1>-treated acinar cells.","Upregulator"
"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and <e2>neurokinin-1 receptor</e2> (NK-1R), the primary receptor for SP, are increased in secretagogue <e1>caerulein</e1>-treated acinar cells.","Upregulator"
"Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (<e2>NK-1R</e2>), the primary receptor for SP, are increased in secretagogue <e1>caerulein</e1>-treated acinar cells.","Upregulator"
"<e1>Caerulein</e1> increased the levels of H(2)S and CSE mRNA expression while <e2>CBS</e2> mRNA expression was decreased.","Downregulator"
"Inhibition of endogenous production of <e1>H(2)S</e1> by PAG significantly suppressed <e2>SP</e2> concentration, PPT-A expression and NK1-R expression in the acini.","Downregulator"
"Inhibition of endogenous production of <e1>H(2)S</e1> by PAG significantly suppressed SP concentration, <e2>PPT-A</e2> expression and NK1-R expression in the acini.","Downregulator"
"Inhibition of endogenous production of <e1>H(2)S</e1> by PAG significantly suppressed SP concentration, PPT-A expression and <e2>NK1-R</e2> expression in the acini.","Downregulator"
"In addition, cells pre-treated with <e1>DL-propargylglycine</e1> (PAG, 3 mM), a <e2>CSE</e2> inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.","Downregulator"
"In addition, cells pre-treated with DL-propargylglycine (<e1>PAG</e1>, 3 mM), a <e2>CSE</e2> inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.","Downregulator"
"Inhibition of endogenous production of <e1>H(2)S</e1> by PAG significantly suppressed <e2>SP</e2> concentration, PPT-A expression and NK1-R expression in the acini.","Substrate"
"These results suggest that the pro-inflammatory effect of <e1>H(2)S</e1> may be mediated by SP-<e2>NK-1R</e2> related pathway in mouse pancreatic acinar cells.","Substrate"
"Hydrogen sulphide (<e1>H(2)S</e1>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS).","Substrate"
"Hydrogen sulphide (<e1>H(2)S</e1>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase</e2> (CBS).","Substrate"
"Hydrogen sulphide (<e1>H(2)S</e1>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS</e2>).","Substrate"
"Hydrogen sulphide (<e1>H(2)S</e1>) is synthesized from L-cysteine via the action of <e2>cystathionine-gamma-lyase</e2> (CSE) and cystathionine-beta-synthase (CBS).","Substrate"
"Hydrogen sulphide (<e1>H(2)S</e1>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS).","Substrate"
"Hydrogen sulphide (<e1>H(2)S</e1>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS</e2>).","Substrate"
"<e1>Hydrogen sulphide</e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS).","Substrate"
"<e1>Hydrogen sulphide</e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase</e2> (CBS).","Substrate"
"<e1>Hydrogen sulphide</e1> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS</e2>).","Substrate"
"<e1>Hydrogen sulphide</e1> (H(2)S) is synthesized from L-cysteine via the action of <e2>cystathionine-gamma-lyase</e2> (CSE) and cystathionine-beta-synthase (CBS).","Substrate"
"Hydrogen sulphide (<e1>H(2)S</e1>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS).","Substrate"
"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine</e1> via the action of cystathionine-gamma-lyase (<e2>CSE</e2>) and cystathionine-beta-synthase (CBS).","Substrate"
"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine</e1> via the action of cystathionine-gamma-lyase (CSE) and <e2>cystathionine-beta-synthase</e2> (CBS).","Substrate"
"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine</e1> via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (<e2>CBS</e2>).","Substrate"
"Hydrogen sulphide (H(2)S) is synthesized from <e1>L-cysteine</e1> via the action of <e2>cystathionine-gamma-lyase</e2> (CSE) and cystathionine-beta-synthase (CBS).","Substrate"
"The results showed that administration of <e1>AlCl3</e1> resulted in a significant elevation in the levels of AchE activity, <e2>CRP</e2>, NF-κB, and MCP-1 accompanied with a significant depletion in the Ach level.","Upregulator"
"The results showed that administration of <e1>AlCl3</e1> resulted in a significant elevation in the levels of AchE activity, CRP, <e2>NF-κB</e2>, and MCP-1 accompanied with a significant depletion in the Ach level.","Upregulator"
"The results showed that administration of <e1>AlCl3</e1> resulted in a significant elevation in the levels of AchE activity, CRP, NF-κB, and <e2>MCP-1</e2> accompanied with a significant depletion in the Ach level.","Upregulator"
"The results showed that administration of <e1>AlCl3</e1> resulted in a significant elevation in the levels of <e2>AchE</e2> activity, CRP, NF-κB, and MCP-1 accompanied with a significant depletion in the Ach level.","Upregulator"
"6-DHSG was metabolised by GSH to form a GSH conjugate (<e1>GS-6-DHSG</e1>) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of <e2>glutathione-S-transferase</e2> (GST).","Substrate"
"6-DHSG was metabolised by GSH to form a GSH conjugate (<e1>GS-6-DHSG</e1>) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (<e2>GST</e2>).","Substrate"
"<e1>6-DHSG</e1> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of <e2>glutathione-S-transferase</e2> (GST).","Substrate"
"<e1>6-DHSG</e1> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase (<e2>GST</e2>).","Substrate"
"The concentration response to <e1>levcromakalim</e1> (LEVC), a <e2>K(ATP) channel</e2> opener, was significantly shifted to the left in the inflamed smooth-muscle cells.","Upregulator"
"The concentration response to levcromakalim (<e1>LEVC</e1>), a <e2>K(ATP) channel</e2> opener, was significantly shifted to the left in the inflamed smooth-muscle cells.","Upregulator"
"Sulfhydration of <e2>sulfonylurea receptor 2B</e2> (SUR2B) was induced by <e1>NaHS</e1> and colonic inflammation.","Upregulator"
"Sulfhydration of sulfonylurea receptor 2B (<e2>SUR2B</e2>) was induced by <e1>NaHS</e1> and colonic inflammation.","Upregulator"
"<e1>Hydrogen sulfide</e1> as an allosteric modulator of <e2>ATP-sensitive potassium channels</e2> in colonic inflammation.","Modulator"
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>sotalol</e1> or ibutilide in patients with a mutation in the <e2>IKr</e2>-coding gene KCNH2 (HERG).","Downregulator"
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>sotalol</e1> or ibutilide in patients with a mutation in the IKr-coding gene <e2>KCNH2</e2> (HERG).","Downregulator"
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., <e1>sotalol</e1> or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (<e2>HERG</e2>).","Downregulator"
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>ibutilide</e1> in patients with a mutation in the <e2>IKr</e2>-coding gene KCNH2 (HERG).","Downregulator"
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>ibutilide</e1> in patients with a mutation in the IKr-coding gene <e2>KCNH2</e2> (HERG).","Downregulator"
"Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or <e1>ibutilide</e1> in patients with a mutation in the IKr-coding gene KCNH2 (<e2>HERG</e2>).","Downregulator"
"The nonsteroidal antiandrogen <e1>RU 23908</e1> ( Anandron ) weakly interacts with the prostatic cytosolic <e2>androgen receptor</e2> and shows a fast dissociation rate.","Not"
"The nonsteroidal antiandrogen RU 23908 ( <e1>Anandron</e1> ) weakly interacts with the prostatic cytosolic <e2>androgen receptor</e2> and shows a fast dissociation rate.","Not"
"Although inhibition of <e2>LH</e2> release can be achieved by <e1>estrogen</e1> and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.","Downregulator"
"Although inhibition of <e2>LH</e2> release can be achieved by estrogen and <e1>progestins</e1>, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.","Downregulator"
"<e1>Glycylsarcosine</e1> coadministration could inhibit the uptake of cefadroxil in <e2>PEPT2</e2>(+/+) mice (p < 0.01) but not PEPT2(-/-) mice.","Not"
"<e1>Glycylsarcosine</e1> coadministration could inhibit the uptake of cefadroxil in <e2>PEPT2</e2>(+/+) mice (p < 0.01) but not PEPT2(-/-) mice.","Regulator"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"Mechanisms of <e1>cefadroxil</e1> uptake in the choroid plexus: studies in wild-type and <e2>PEPT2</e2> knockout mice.","Substrate"
"The choroid plexus uptake of <e1>[(3)H]cefadroxil</e1> was studied in <e2>peptide transporter 2</e2> (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.","Substrate"
"The choroid plexus uptake of <e1>[(3)H]cefadroxil</e1> was studied in peptide transporter 2 (<e2>PEPT2</e2>) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.","Substrate"
"In the <e1>IB-MECA</e1> group, <e2>α-amylase</e2> activity was decreased with statistically high significance compared to group I.","Downregulator"
"The effects of the <e2>adenosine A3 receptor</e2> agonist <e1>IB-MECA</e1> on sodium taurocholate-induced experimental acute pancreatitis.","Agonist"
"The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the <e2>adenosine A3 receptor</e2> agonist IB-MECA <e1>(1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide</e1> at a dose of 0.75 mg/kg b.w.","Agonist"
"The effects of the <e2>adenosine A3 receptor</e2> agonist <e1>IB-MECA</e1> on sodium taurocholate-induced experimental acute pancreatitis.","Agonist"
"The effects of the adenosine <e2>A3 receptor</e2> agonist <e1>IB-MECA</e1> on sodium taurocholate-induced experimental acute pancreatitis.","Agonist"
"We describe the discovery of several <e1>pyrrolopyrazines</e1> as potent and selective <e2>Syk</e2> inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.","Downregulator"
"<e1>Pyrrolopyrazines</e1> as Selective <e2>Spleen Tyrosine Kinase</e2> Inhibitors.","Downregulator"
"The <e2>microtubule</e2> binding affinities of a series of synthetic <e1>taxanes</e1> have been measured with the aims of dissecting individual group contributions and obtaining a rationale for the design of novel compounds with the ability to overcome drug resistance.","Regulator"
"Insight into the structural basis for this improvement was gained with molecular modeling and NMR data obtained for <e2>microtubule</e2>-bound <e1>docetaxel</e1>.","Regulator"
"<e1>Taxanes</e1> with affinities for <e2>microtubules</e2> well above their affinities for P-glycoprotein are shown not to be affected by multidrug resistance.","Regulator"
"<e1>Taxanes</e1> with affinities for microtubules well above their affinities for <e2>P-glycoprotein</e2> are shown not to be affected by multidrug resistance.","Regulator"
"Optimization of taxane binding to <e2>microtubules</e2>: binding affinity dissection and incremental construction of a high-affinity analog of <e1>paclitaxel</e1>.","Regulator"
"Optimization of <e1>taxane</e1> binding to <e2>microtubules</e2>: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel.","Regulator"
"<e1>Ozone</e1> plus PM(2.5) exposure, however, induced <e2>CRP</e2>, IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.","Upregulator"
"<e1>Ozone</e1> plus PM(2.5) exposure, however, induced CRP, <e2>IL-6</e2>, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.","Upregulator"
"<e1>Ozone</e1> plus PM(2.5) exposure, however, induced CRP, IL-6, <e2>CK</e2>, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.","Upregulator"
"<e1>Ozone</e1> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, <e2>LDH</e2> and MDA increase, SOD and HRV decrease significantly in a dose-response way.","Upregulator"
"<e1>Ozone</e1> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, <e2>SOD</e2> and HRV decrease significantly in a dose-response way.","Downregulator"
"<e1>Flavopiridol</e1>, a <e2>cyclin-dependent kinase</e2> inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660].","Downregulator"
"In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent <e2>CDK2</e2> inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of <e1>flavopiridol</e1>.","Downregulator"
"<e1>Flavopiridol</e1> inhibits <e2>CDK</e2> with an IC50 value of 0.4 mM [285707].","Downregulator"
"Some of these derivatives showed good inhibitory potency against two <e2>human CA</e2> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and <e1>methazolamide</e1>.","Downregulator"
"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, <e2>CA I</e2>, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and <e1>methazolamide</e1>.","Downregulator"
"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and <e2>CA II</e2>, of the same order of magnitude as the clinically used drugs acetazolamide and <e1>methazolamide</e1>.","Downregulator"
"<e2>Carbonic anhydrase</e2> inhibitors: <e1>aromatic and heterocyclic sulfonamides</e1> incorporating adamantyl moieties with strong anticonvulsant activity.","Downregulator"
"<e2>Carbonic anhydrase</e2> inhibitors: aromatic and heterocyclic sulfonamides incorporating <e1>adamantyl</e1> moieties with strong anticonvulsant activity.","Downregulator"
"Some of these derivatives showed good inhibitory potency against two <e2>human CA</e2> isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs <e1>acetazolamide</e1> and methazolamide.","Downregulator"
"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, <e2>CA I</e2>, and CA II, of the same order of magnitude as the clinically used drugs <e1>acetazolamide</e1> and methazolamide.","Downregulator"
"Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and <e2>CA II</e2>, of the same order of magnitude as the clinically used drugs <e1>acetazolamide</e1> and methazolamide.","Downregulator"
"A hybrid cDNA was created by fusing a human cDNA for <e1>amino acids</e1> 1-101 of <e2>GAD67</e2> to a human cDNA for amino acids 96-585 of GAD65; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to mammalian brain GAD with diabetes sera.","Part_of"
"A hybrid cDNA was created by fusing a human cDNA for <e1>amino acids</e1> 1-101 of GAD67 to a human cDNA for amino acids 96-585 of <e2>GAD65</e2>; the recombinant (r) protein was expressed in yeast and was shown to have equivalent immunoreactivity to mammalian brain GAD with diabetes sera.","Part_of"
"BACKGROUND AND AIMS: <e2>Glutamic acid decarboxylase</e2> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to <e1>gamma-aminobutyric acid</e1> (GABA).","Substrate"
"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GAD</e2>, EC 4.1.1.15) catalyses the conversion of glutamate to <e1>gamma-aminobutyric acid</e1> (GABA).","Substrate"
"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>EC 4.1.1.15</e2>) catalyses the conversion of glutamate to <e1>gamma-aminobutyric acid</e1> (GABA).","Substrate"
"BACKGROUND AND AIMS: <e2>Glutamic acid decarboxylase</e2> (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>GABA</e1>).","Substrate"
"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GAD</e2>, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>GABA</e1>).","Substrate"
"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>EC 4.1.1.15</e2>) catalyses the conversion of glutamate to gamma-aminobutyric acid (<e1>GABA</e1>).","Substrate"
"BACKGROUND AND AIMS: <e2>Glutamic acid decarboxylase</e2> (GAD, EC 4.1.1.15) catalyses the conversion of <e1>glutamate</e1> to gamma-aminobutyric acid (GABA).","Substrate"
"BACKGROUND AND AIMS: Glutamic acid decarboxylase (<e2>GAD</e2>, EC 4.1.1.15) catalyses the conversion of <e1>glutamate</e1> to gamma-aminobutyric acid (GABA).","Substrate"
"BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD, <e2>EC 4.1.1.15</e2>) catalyses the conversion of <e1>glutamate</e1> to gamma-aminobutyric acid (GABA).","Substrate"
"FCEO significantly inhibited <e1>nitric oxide</e1> (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of <e2>inducible nitric oxide synthase</e2> (iNOS) and cyclooxygenase (COX)-2, respectively.","Downregulator"
"FCEO significantly inhibited <e1>nitric oxide</e1> (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (<e2>iNOS</e2>) and cyclooxygenase (COX)-2, respectively.","Downregulator"
"FCEO significantly inhibited nitric oxide (<e1>NO</e1>) and prostaglandin E2 (PGE2) by suppressing the protein expression of <e2>inducible nitric oxide synthase</e2> (iNOS) and cyclooxygenase (COX)-2, respectively.","Downregulator"
"FCEO significantly inhibited nitric oxide (<e1>NO</e1>) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (<e2>iNOS</e2>) and cyclooxygenase (COX)-2, respectively.","Downregulator"
"FCEO significantly inhibited nitric oxide (NO) and <e1>prostaglandin E2</e1> (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and <e2>cyclooxygenase (COX)-2</e2>, respectively.","Downregulator"
"FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (<e1>PGE2</e1>) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and <e2>cyclooxygenase (COX)-2</e2>, respectively.","Downregulator"
"In human blood, the tested glucocorticoids beclomethasone, <e1>dexamethasone</e1> and fluticasone inhibited the LPS induced <e2>TNF</e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","Regulator"
"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and <e1>milrinone</e1>, reduced the <e2>GM-CSF</e2> release in a concentration dependent manner.","Downregulator"
"<e1>Amrinone</e1> and milrinone, selective PDE3 inhibitors, suppressed <e2>TNF</e2> secretion to a lesser extent.","Downregulator"
"Amrinone and <e1>milrinone</e1>, selective PDE3 inhibitors, suppressed <e2>TNF</e2> secretion to a lesser extent.","Downregulator"
"In human blood, the tested glucocorticoids <e1>beclomethasone</e1>, dexamethasone and fluticasone inhibited the LPS induced <e2>TNF</e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","Downregulator"
"In human blood, the tested glucocorticoids beclomethasone, <e1>dexamethasone</e1> and fluticasone inhibited the LPS induced <e2>TNF</e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","Downregulator"
"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and <e1>fluticasone</e1> inhibited the LPS induced <e2>TNF</e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","Downregulator"
"The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors <e1>amrinone</e1> and milrinone, reduced the <e2>GM-CSF</e2> release in a concentration dependent manner.","Downregulator"
"The selective <e2>PDE 4</e2> inhibitors, and to a certain extent the PDE3 inhibitors amrinone and <e1>milrinone</e1>, reduced the GM-CSF release in a concentration dependent manner.","Downregulator"
"Amrinone and <e1>milrinone</e1>, selective <e2>PDE3</e2> inhibitors, suppressed TNF secretion to a lesser extent.","Downregulator"
"<e1>Amrinone</e1> and milrinone, selective <e2>PDE3</e2> inhibitors, suppressed TNF secretion to a lesser extent.","Downregulator"
"Amrinone and <e1>milrinone</e1>, selective <e2>PDE3</e2> inhibitors, suppressed TNF secretion to a lesser extent.","Downregulator"
"The effects of <e1>theophylline</e1> (unspecific <e2>PDE</e2> inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.","Downregulator"
"The effects of theophylline (unspecific PDE inhibitor), <e1>vinpocetine</e1> (<e2>PDE1</e2> inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.","Downregulator"
"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the <e2>PDE5</e2> inhibitors <e1>zaprinast</e1> and E 4021 were weak.","Downregulator"
"The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the <e2>PDE5</e2> inhibitors zaprinast and <e1>E 4021</e1> were weak.","Downregulator"
"In human blood, the tested glucocorticoids <e1>beclomethasone</e1>, dexamethasone and fluticasone inhibited the LPS induced <e2>TNF</e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","Downregulator"
"In human blood, the tested glucocorticoids beclomethasone, <e1>dexamethasone</e1> and fluticasone inhibited the LPS induced <e2>TNF</e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","Downregulator"
"In human blood, the tested glucocorticoids beclomethasone, dexamethasone and <e1>fluticasone</e1> inhibited the LPS induced <e2>TNF</e2> release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.","Downregulator"
"The selective <e2>PDE 4</e2> inhibitors, and to a certain extent the PDE3 inhibitors <e1>amrinone</e1> and milrinone, reduced the GM-CSF release in a concentration dependent manner.","Downregulator"
"The selective PDE 4 inhibitors, and to a certain extent the <e2>PDE3</e2> inhibitors <e1>amrinone</e1> and milrinone, reduced the GM-CSF release in a concentration dependent manner.","Downregulator"
"Taken together, our results suggested that <e1>Rg1</e1> protected against Aβ25-35-induced apoptosis at least in part by two complementary <e2>GR</e2>-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.","Regulator"
"Taken together, our results suggested that <e1>Rg1</e1> protected against Aβ25-35-induced apoptosis at least in part by two complementary <e2>GR</e2>-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1α initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.","Regulator"
"Activating glucocorticoid receptor-<e2>ERK</e2> signaling pathway contributes to ginsenoside <e1>Rg1</e1> protection against β-amyloid peptide-induced human endothelial cells apoptosis.","Regulator"
"Activating glucocorticoid receptor-<e2>ERK</e2> signaling pathway contributes to ginsenoside <e1>Rg1</e1> protection against β-amyloid peptide-induced human endothelial cells apoptosis.","Upregulator"
"Activating <e2>glucocorticoid receptor</e2>-ERK signaling pathway contributes to <e1>ginsenoside Rg1</e1> protection against β-amyloid peptide-induced human endothelial cells apoptosis.","Upregulator"
"Activating glucocorticoid receptor-<e2>ERK</e2> signaling pathway contributes to <e1>ginsenoside Rg1</e1> protection against β-amyloid peptide-induced human endothelial cells apoptosis.","Upregulator"
"<e1>Rg1</e1> attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting <e2>HIF-1α</e2> expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.","Downregulator"
"<e1>Rg1</e1> attenuated the Aβ25-35-associated mitochondrial apoptotic events, accompanied by inhibiting <e2>HIF-1α</e2> expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.","Downregulator"
"<e1>Rg1</e1> attenuated the <e2>Aβ25-35</e2>-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.","Downregulator"
"Activating glucocorticoid receptor-ERK signaling pathway contributes to <e1>ginsenoside Rg1</e1> protection against <e2>β-amyloid peptide</e2>-induced human endothelial cells apoptosis.","Downregulator"
"<e1>Rg1</e1> attenuated the <e2>Aβ25-35</e2>-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.","Downregulator"
"<e1>Rg1</e1> attenuated the <e2>Aβ25-35</e2>-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1α expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.","Downregulator"
"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or <e2>p-ERK</e2> inhibitor <e1>U0126</e1> rather than estrogen receptor α antagonist ICI 82,780.","Downregulator"
"These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than <e2>estrogen receptor α</e2> antagonist <e1>ICI 82,780</e1>.","Antagonist"
"These protective effects were abolished by <e2>glucocorticoid receptor</e2> (GR) antagonist <e1>RU486</e1> or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780.","Antagonist"
"These protective effects were abolished by glucocorticoid receptor (<e2>GR</e2>) antagonist <e1>RU486</e1> or p-ERK inhibitor U0126 rather than estrogen receptor α antagonist ICI 82,780.","Antagonist"
"On study day 1, <e1>candoxatril</e1> acutely increased plasma <e2>ANP</e2> levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures.","Upregulator"
"On study day 1, <e1>candoxatril</e1> acutely increased plasma <e2>ANP</e2> levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures.","Upregulator"
"<e1>Candoxatril</e1> is a novel, orally active inhibitor of <e2>neutral endopeptidase</e2> EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP).","Downregulator"
"<e1>Candoxatril</e1> is a novel, orally active inhibitor of neutral endopeptidase <e2>EC 3.4.24.11</e2>, the enzyme that degrades atrial natriuretic peptide (ANP).","Downregulator"
"Effectiveness of <e2>endopeptidase</e2> inhibition (<e1>candoxatril</e1>) in congestive heart failure.","Downregulator"
"Longer <e2>HSD11B2</e2> CA-repeat in impaired <e1>glucose</e1> tolerance and type 2 diabetes.","Regulator"
"<e2>Type 2 11β-hydroxysteroid dehydrogenase</e2> encoded by the HSD11B2 gene converts <e1>cortisol</e1> to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.","Substrate"
"Type 2 11β-hydroxysteroid dehydrogenase encoded by the <e2>HSD11B2</e2> gene converts <e1>cortisol</e1> to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.","Substrate"
"<e2>Type 2 11β-hydroxysteroid dehydrogenase</e2> encoded by the HSD11B2 gene converts cortisol to inactive <e1>cortisone</e1>, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.","Substrate"
"Type 2 11β-hydroxysteroid dehydrogenase encoded by the <e2>HSD11B2</e2> gene converts cortisol to inactive <e1>cortisone</e1>, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.","Substrate"
"The <e2>alpha(1)-adrenoceptor</e2> antagonist, <e1>tamsulosin</e1>, is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors.","Antagonist"
"The alpha(1)-adrenoceptor antagonist, <e1>tamsulosin</e1>, is selective for <e2>alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors</e2>.","Antagonist"
"In conclusion, these results suggested that <e1>pioglitazone</e1> protected against cisplatin- induced nephrotoxicity through its interaction with <e2>PPAR-γ</e2> receptors and antioxidant effects.","Regulator"
"The obtained results showed that <e1>pioglitazone</e1> improved the renal function, structural changes, renal malondialdehyde (MDA), <e2>tumor necrosis factor alpha</e2> (TNF-α), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats.","Upregulator"
"The obtained results showed that <e1>pioglitazone</e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (<e2>TNF-α</e2>), nuclear factor kappa B (NF-κB) genes expression in cisplatin injected rats.","Upregulator"
"The obtained results showed that <e1>pioglitazone</e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), <e2>nuclear factor kappa B</e2> (NF-κB) genes expression in cisplatin injected rats.","Upregulator"
"The obtained results showed that <e1>pioglitazone</e1> improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (<e2>NF-κB</e2>) genes expression in cisplatin injected rats.","Upregulator"
"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), <e2>tumor necrosis factor alpha</e2> (TNF-α), nuclear factor kappa B (NF-κB) genes expression in <e1>cisplatin</e1> injected rats.","Downregulator"
"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (<e2>TNF-α</e2>), nuclear factor kappa B (NF-κB) genes expression in <e1>cisplatin</e1> injected rats.","Downregulator"
"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), <e2>nuclear factor kappa B</e2> (NF-κB) genes expression in <e1>cisplatin</e1> injected rats.","Downregulator"
"The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (<e2>NF-κB</e2>) genes expression in <e1>cisplatin</e1> injected rats.","Downregulator"
"The affinities of <e1>dfbp</e1> and dfbp-o for the regulatory domain of <e2>cTnC</e2> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of <e2>cTnC</e2> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of <e2>cTnC</e2> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of <e1>dfbp</e1> and dfbp-o for the regulatory domain of <e2>cTnC</e2> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"<e1>Dfbp-o</e1> also increased the affinity of <e2>cTnI</e2> for cTnC.","Regulator"
"<e1>Dfbp-o</e1> also increased the affinity of cTnI for <e2>cTnC</e2>.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of <e2>cTnC</e2> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of cTnC were measured in the absence and presence of <e2>cTnI</e2> by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of <e2>cTnC</e2> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of cTnC were measured in the absence and presence of <e2>cTnI</e2> by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of cTnC were measured in the absence and presence of <e2>cTnI</e2> by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The affinities of dfbp and <e1>dfbp-o</e1> for the regulatory domain of <e2>cTnC</e2> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.","Regulator"
"The Ca(2+)-sensitizer, <e1>levosimendan</e1>, targets <e2>cTnC</e2>; however, detailed understanding of its mechanism has been obscured by its instability.","Regulator"
"The <e1>Ca(2+)</e1> dependent interaction between <e2>troponin I</e2> (cTnI) and troponin C (cTnC) triggers contraction in heart muscle.","Regulator"
"The <e1>Ca(2+)</e1> dependent interaction between troponin I (<e2>cTnI</e2>) and troponin C (cTnC) triggers contraction in heart muscle.","Regulator"
"The <e1>Ca(2+)</e1> dependent interaction between troponin I (cTnI) and <e2>troponin C</e2> (cTnC) triggers contraction in heart muscle.","Regulator"
"The <e1>Ca(2+)</e1> dependent interaction between troponin I (cTnI) and troponin C (<e2>cTnC</e2>) triggers contraction in heart muscle.","Regulator"
"The Ca(2+)-sensitizer, <e1>levosimendan</e1>, targets <e2>cTnC</e2>; however, detailed understanding of its mechanism has been obscured by its instability.","Regulator"
"The structural and functional data reveal that the <e1>levosimendan</e1> class of Ca(2+)-sensitizers work by binding to the regulatory domain of cTnC and stabilizing the pivotal cTnC-<e2>cTnI</e2> regulatory unit via a network of hydrophobic and electrostatic interactions, in contrast to the destabilizing effects of antagonists such as W7 at the same interface.","Regulator"
"Combining in vivo and in vitro findings, we identified nine <e2>AhR</e2> agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including <e1>leflunomide</e1>, flutamide, and nimodipine.","Agonist"
"Combining in vivo and in vitro findings, we identified nine <e2>AhR</e2> agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, <e1>flutamide</e1>, and nimodipine.","Agonist"
"Combining in vivo and in vitro findings, we identified nine <e2>AhR</e2> agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and <e1>nimodipine</e1>.","Agonist"
"No mutations in the <e1>serotonin</e1> related <e2>TPH1</e2> and HTR1B genes in patients with monogenic sclerosing bone disorders.","Regulator"
"Inhibition of ERK1/2 with <e1>U0126</e1> induces apoptosis but fails to activate <e2>JNK</e2> phosphorylation or down-regulate beta-catenin protein expression.","Not"
"Inhibition of ERK1/2 with <e1>U0126</e1> induces apoptosis but fails to activate JNK phosphorylation or down-regulate <e2>beta-catenin</e2> protein expression.","Not"
"<e1>Sulindac</e1> independently modulates extracellular signal-regulated kinase 1/2 and <e2>cyclic GMP-dependent protein kinase</e2> signaling pathways.","Regulator"
"The purpose of this study was to determine if <e2>PKG</e2>, ERK1/2, JNK, and beta-catenin are independent targets for <e1>sulindac</e1> in vitro.","Regulator"
"Inhibition of ERK1/2 with <e1>U0126</e1> induces apoptosis but fails to activate <e2>JNK</e2> phosphorylation or down-regulate beta-catenin protein expression.","Upregulator"
"Pharmacologic activation of PKG with <e1>YC-1</e1> increases <e2>JNK</e2> phosphorylation and induces apoptosis in colon cancer cells without modulating ERK1/2 phosphorylation or beta-catenin protein expression.","Upregulator"
"The purpose of this study was to determine if PKG, ERK1/2, <e2>JNK</e2>, and beta-catenin are independent targets for <e1>sulindac</e1> in vitro.","Upregulator"
"<e1>Sulindac</e1> independently modulates extracellular signal-regulated kinase 1/2 and <e2>cyclic GMP-dependent protein kinase</e2> signaling pathways.","Upregulator"
"<e1>Sulindac</e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (<e2>PKG</e2>); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.","Upregulator"
"Inhibition of ERK1/2 with <e1>U0126</e1> induces apoptosis but fails to activate JNK phosphorylation or down-regulate <e2>beta-catenin</e2> protein expression.","Downregulator"
"Pharmacologic activation of PKG with <e1>YC-1</e1> increases JNK phosphorylation and induces apoptosis in colon cancer cells without modulating ERK1/2 phosphorylation or <e2>beta-catenin</e2> protein expression.","Downregulator"
"The purpose of this study was to determine if PKG, ERK1/2, JNK, and <e2>beta-catenin</e2> are independent targets for <e1>sulindac</e1> in vitro.","Downregulator"
"<e1>Sulindac</e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease <e2>beta-catenin</e2> protein expression at times and doses consistent with apoptosis.","Downregulator"
"<e1>Sulindac</e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate <e2>c-jun NH2-terminal kinase</e2> (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.","Downregulator"
"<e1>Sulindac</e1> metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (<e2>JNK</e2>); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis.","Downregulator"
"A series of 2-carbonyl analogues of the muscarinic antagonist <e1>diphenidol</e1> bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the <e2>M2</e2> and M3 muscarinic receptor subtypes was evaluated by functional tests.","Antagonist"
"A series of 2-carbonyl analogues of the muscarinic antagonist <e1>diphenidol</e1> bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the <e2>M2 and M3 muscarinic receptor</e2> subtypes was evaluated by functional tests.","Antagonist"
"Synthesis and antagonistic activity at <e2>muscarinic receptor</e2> subtypes of some 2-carbonyl derivatives of <e1>diphenidol</e1>.","Antagonist"
"Synthesis and antagonistic activity at <e2>muscarinic receptor</e2> subtypes of some <e1>2-carbonyl</e1> derivatives of diphenidol.","Antagonist"
"Additionally, <e2>AIF</e2> levels in the cytosol decreased due to EGTA but not due to <e1>calpeptin</e1>.","Not"
"<e1>ALD</e1> increased calpain expression and <e2>caspase-3</e2> activity and promoted Bid cleavage.","Upregulator"
"<e1>ALD</e1> increased calpain expression and <e2>caspase-3</e2> activity and promoted Bid cleavage.","Upregulator"
"In this study, aldosterone (<e1>ALD</e1>)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>calpain</e2> signaling were clarified.","Upregulator"
"In this study, aldosterone (<e1>ALD</e1>)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>calpain</e2> signaling were clarified.","Upregulator"
"Activation of an apoptotic signal transduction pathway involved in the upregulation of <e2>calpain</e2> and apoptosis-inducing factor in <e1>aldosterone</e1>-induced primary cultured cardiomyocytes.","Upregulator"
"Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and <e2>apoptosis-inducing factor</e2> in <e1>aldosterone</e1>-induced primary cultured cardiomyocytes.","Upregulator"
"In this study, aldosterone (<e1>ALD</e1>)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>calpain</e2> signaling were clarified.","Upregulator"
"The upregulation of calpain, <e2>tBid</e2> and caspase-3 activity were further inhibited by treatment with EGTA in the presence of <e1>ALD</e1>.","Upregulator"
"In this study, aldosterone (<e1>ALD</e1>)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of <e2>calpain</e2> signaling were clarified.","Upregulator"
"Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of <e1>ALD</e1> but reversed the ALD-induced increase of calpain and <e2>AIF</e2> levels.","Upregulator"
"Activation of an apoptotic signal transduction pathway involved in the upregulation of <e2>calpain</e2> and apoptosis-inducing factor in <e1>aldosterone</e1>-induced primary cultured cardiomyocytes.","Upregulator"
"The upregulation of <e2>calpain</e2>, tBid and caspase-3 activity were further inhibited by treatment with <e1>EGTA</e1> in the presence of ALD.","Downregulator"
"The upregulation of calpain, <e2>tBid</e2> and caspase-3 activity were further inhibited by treatment with <e1>EGTA</e1> in the presence of ALD.","Downregulator"
"Additionally, <e2>AIF</e2> levels in the cytosol decreased due to <e1>EGTA</e1> but not due to calpeptin.","Downregulator"
"Furthermore, treatment with <e1>spironoclactone</e1> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of <e2>calpain</e2> and AIF levels.","Downregulator"
"Furthermore, treatment with <e1>spironoclactone</e1> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and <e2>AIF</e2> levels.","Downregulator"
"The upregulation of calpain, tBid and <e2>caspase-3</e2> activity were further inhibited by treatment with <e1>EGTA</e1> in the presence of ALD.","Downregulator"
"<e1>Loperamide</e1>, an opiate analog, differently modifies the <e2>adrenocorticotropin</e2> responses to corticotropin-releasing hormone and lysine vasopressin in patients with Addison's disease.","Regulator"
"In this work, the interactions between <e1>loperamide</e1> and two <e2>ACTH</e2> secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease.","Regulator"
"In this work, the interactions between <e1>loperamide</e1> and two <e2>ACTH</e2> secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease.","Regulator"
"<e1>Loperamide</e1>, an opiate analog, differently modifies the adrenocorticotropin responses to corticotropin-releasing hormone and <e2>lysine vasopressin</e2> in patients with Addison's disease.","Regulator"
"<e1>Loperamide</e1>, an opiate analog, differently modifies the adrenocorticotropin responses to <e2>corticotropin-releasing hormone</e2> and lysine vasopressin in patients with Addison's disease.","Regulator"
"In this work, the interactions between <e1>loperamide</e1> and two ACTH secretagogues, lysine vasopressin (<e2>LVP</e2>) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease.","Regulator"
"In this work, the interactions between <e1>loperamide</e1> and two ACTH secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (<e2>CRH</e2>), were investigated in patients with Addison's disease.","Regulator"
"In this work, the interactions between <e1>loperamide</e1> and two ACTH secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (<e2>CRH</e2>), were investigated in patients with Addison's disease.","Downregulator"
"In this work, the interactions between <e1>loperamide</e1> and two <e2>ACTH</e2> secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease.","Downregulator"
"<e1>Loperamide</e1> is a peripheral opiate agonist able to inhibit <e2>ACTH</e2> secretion.","Downregulator"
"In this work, the interactions between <e1>loperamide</e1> and two <e2>ACTH</e2> secretagogues, lysine vasopressin (LVP) and corticotropin-releasing hormone (CRH), were investigated in patients with Addison's disease.","Downregulator"
"In animals, the <e1>R-enantiomer of timolol</e1> causes a significant reduction in intraocular pressure but had only 1/80 the activity of the S-enantiomer at <e2>extraocular receptors</e2>.","Regulator"
"<e1>CCl(4)</e1> administration triggered inflammatory response in mice livers by activating <e2>nuclear factor-kappaB</e2> (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2).","Upregulator"
"<e1>CCl(4)</e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (<e2>NF-κB</e2>), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (COX-2).","Upregulator"
"<e1>CCl(4)</e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of <e2>tumor necrosis factor-alpha</e2> (TNF-α) and cyclooxygenase-2 (COX-2).","Upregulator"
"<e1>CCl(4)</e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (<e2>TNF-α</e2>) and cyclooxygenase-2 (COX-2).","Upregulator"
"<e1>CCl(4)</e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and <e2>cyclooxygenase-2</e2> (COX-2).","Upregulator"
"<e1>CCl(4)</e1> administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-κB), which coincided with the induction of tumor necrosis factor-alpha (TNF-α) and cyclooxygenase-2 (<e2>COX-2</e2>).","Upregulator"
"<e1>CCl(4)</e1> intoxication caused hepatic necrosis and increased serum <e2>ALT</e2> activity.","Upregulator"
"Furthermore, RA significantly inhibited the <e1>CCl(4)</e1>-induced apoptosis, which was evident from decreased cleavage of <e2>caspase-3</e2>.","Downregulator"
"Pre-clinical pharmacology of <e1>zolmitriptan</e1> (Zomig; formerly 311C90), a centrally and peripherally acting <e2>5HT1B/1D</e2> agonist for migraine.","Regulator"
"These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that <e1>zolmitriptan</e1> blocks elevations of <e2>calcitonin-gene-related peptide</e2> in jugular venous blood during electrical stimulation of the trigeminal ganglion.","Downregulator"
"Zolmitriptan (Zomig; formerly <e1>311C90</e1>) is a novel <e2>5-hydroxytryptamine (5HT)1B/1D</e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.","Agonist"
"Pre-clinical pharmacology of <e1>zolmitriptan</e1> (Zomig; formerly 311C90), a centrally and peripherally acting <e2>5HT1B/1D</e2> agonist for migraine.","Agonist"
"<e1>Zolmitriptan</e1> (Zomig; formerly 311C90) is a novel <e2>5-hydroxytryptamine (5HT)1B/1D</e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.","Agonist"
"Pre-clinical pharmacology of zolmitriptan (<e1>Zomig</e1>; formerly 311C90), a centrally and peripherally acting <e2>5HT1B/1D</e2> agonist for migraine.","Agonist"
"Pre-clinical pharmacology of zolmitriptan (Zomig; formerly <e1>311C90</e1>), a centrally and peripherally acting <e2>5HT1B/1D</e2> agonist for migraine.","Agonist"
"Zolmitriptan (<e1>Zomig</e1>; formerly 311C90) is a novel <e2>5-hydroxytryptamine (5HT)1B/1D</e2> receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.","Agonist"
"It has been reported that oligomeric <e1>procyanidins</e1> of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and <e2>insulin</e2>-potentiating activities.","Upregulator"
"They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with <e2>rhArg</e2>, to <e1>citrulline</e1>, which is converted back to arginine via ASS.","Substrate"
"They all expressed ASS, but not <e1>ornithine</e1> transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.","Substrate"
"They all expressed ASS, but not <e1>ornithine</e1> transcarbamylase (<e2>OTC</e2>), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.","Substrate"
"Pegylated recombinant human arginase (<e2>rhArg</e2>-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through <e1>arginine</e1> depletion.","Substrate"
"Hepatocellular carcinoma (HCC) is believed to be auxotrophic for <e1>arginine</e1> through the lack of expression of argininosuccinate synthetase (<e2>ASS</e2>).","Substrate"
"Pegylated recombinant human arginase (<e2>rhArg</e2>-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through <e1>arginine</e1> depletion.","Substrate"
"Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to <e1>arginine</e1> depletion with <e2>arginine-depleting enzymes</e2>.","Substrate"
"The effect of sumatriptan, but not of <e1>LY 344864</e1>, was prevented by pretreatment with the antagonist SDZ 21-009, which displays high affinity for <e2>rat 5-HT1B</e2> receptors.","Not"
"To establish the relative importance of these subtypes, we compared the effects of <e1>sumatriptan</e1> with those of a selective 5-HT1F receptor agonist (LY 344864) on <e2>c-fos</e2> protein expression in the trigeminal nucleus caudalis.","Regulator"
"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (<e1>LY 344864</e1>) on <e2>c-fos</e2> protein expression in the trigeminal nucleus caudalis.","Regulator"
"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective <e2>5-HT1F</e2> receptor agonist (<e1>LY 344864</e1>) on c-fos protein expression in the trigeminal nucleus caudalis.","Regulator"
"The effect of <e1>sumatriptan</e1>, but not of LY 344864, was prevented by pretreatment with the antagonist SDZ 21-009, which displays high affinity for rat <e2>5-HT1B</e2> receptors.","Regulator"
"The effect of <e1>sumatriptan</e1>, but not of LY 344864, was prevented by pretreatment with the antagonist SDZ 21-009, which displays high affinity for <e2>rat 5-HT1B</e2> receptors.","Regulator"
"<e2>c-fos</e2> expression was induced in urethane-anaesthetized rats by intracisternal <e1>capsaicin</e1> administration.","Upregulator"
"<e2>c-fos</e2> expression was induced in urethane-anaesthetized rats by intracisternal <e1>capsaicin</e1> administration.","Upregulator"
"<e1>Sumatriptan</e1> and LY 344864 decreased the number of capsaicin-induced <e2>c-fos</e2>-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).","Downregulator"
"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective 5-HT1F receptor agonist (<e1>LY 344864</e1>) on <e2>c-fos</e2> protein expression in the trigeminal nucleus caudalis.","Downregulator"
"To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective <e2>5-HT1F</e2> receptor agonist (<e1>LY 344864</e1>) on c-fos protein expression in the trigeminal nucleus caudalis.","Agonist"
"The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist <e1>SDZ 21-009</e1>, which displays high affinity for <e2>rat 5-HT1B</e2> receptors.","Antagonist"
"Involvement of <e2>EP1</e2> and EP2 receptors in the regulation of the Na,K-ATPase by <e1>prostaglandins</e1> in MDCK cells.","Regulator"
"Involvement of EP1 and <e2>EP2 receptors</e2> in the regulation of the Na,K-ATPase by <e1>prostaglandins</e1> in MDCK cells.","Regulator"
"Involvement of EP1 and EP2 receptors in the regulation of the <e2>Na,K-ATPase</e2> by <e1>prostaglandins</e1> in MDCK cells.","Regulator"
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of <e2>EP1 receptors</e2> in the <e1>PGE1</e1> mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.","Regulator"
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of <e2>EP1 receptors</e2> in the <e1>PGE1</e1> mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.","Regulator"
"In MDCK cells, which model distal tubule cells, the transcription of the <e2>Na,K-ATPase beta</e2>1 subunit is regulated by <e1>PGE1</e1> and PGE2.","Upregulator"
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of <e2>Na,K-ATPase beta</e2> subunit gene transcription includes the stimulatory effect of <e1>17-phenyl trinor PGE2</e1>, as well as the inhibitory effects of SC-51089.","Upregulator"
"In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of <e2>Na,K-ATPase beta</e2> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of <e1>SC-51089</e1>.","Downregulator"
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the <e2>PKC</e2>I vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, <e1>thapsigargin</e1>, as well as the calmodulin antagonists W7 and W13.","Downregulator"
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the <e2>PKC</e2>I vector (encoding the PKC inhibitory domain), the PKC inhibitor <e1>Go 6976</e1>, thapsigargin, as well as the calmodulin antagonists W7 and W13.","Downregulator"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist <e1>17-phenyl trinor PGE2</e1>, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).","Agonist"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist <e1>17-phenyl trinor PGE2</e1>, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).","Agonist"
"The involvement of EP1 and <e2>EP2 receptors</e2> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist <e1>butaprost</e1> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).","Agonist"
"The involvement of EP1 and <e2>EP2</e2> receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist <e1>butaprost</e1> (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).","Agonist"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>SC-51089</e1> (EP1 specific) and AH 6809 (EP1 and EP2 specific).","Agonist"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>SC-51089</e1> (EP1 specific) and AH 6809 (EP1 and EP2 specific).","Agonist"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists <e1>SC-51089</e1> (EP1 specific) and AH 6809 (EP1 and EP2 specific).","Agonist"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809</e1> (EP1 and EP2 specific).","Agonist"
"The involvement of EP1 and <e2>EP2 receptors</e2> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809</e1> (EP1 and EP2 specific).","Agonist"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809</e1> (EP1 and EP2 specific).","Agonist"
"The involvement of EP1 and <e2>EP2</e2> receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809</e1> (EP1 and EP2 specific).","Agonist"
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <e2>calmodulin</e2> antagonists <e1>W7</e1> and W13.","Antagonist"
"Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the <e2>calmodulin</e2> antagonists W7 and <e1>W13</e1>.","Antagonist"
"The involvement of <e2>EP1</e2> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809</e1> (EP1 and EP2 specific).","Antagonist"
"The involvement of EP1 and <e2>EP2</e2> receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and <e1>AH 6809</e1> (EP1 and EP2 specific).","Antagonist"
"The effects of <e1>amphetamine</e1> (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter <e2>DAT</e2> or the vesicular transporter for monoamine storage, VMAT2.","Regulator"
"The effects of <e1>amphetamine</e1> (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, <e2>VMAT2</e2>.","Regulator"
"The effects of amphetamine (<e1>AMPH</e1>) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter <e2>DAT</e2> or the vesicular transporter for monoamine storage, VMAT2.","Regulator"
"The effects of amphetamine (<e1>AMPH</e1>) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, <e2>VMAT2</e2>.","Regulator"
"The effects of amphetamine (AMPH) and <e1>cocaine</e1> (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter <e2>DAT</e2> or the vesicular transporter for monoamine storage, VMAT2.","Regulator"
"The effects of amphetamine (AMPH) and <e1>cocaine</e1> (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, <e2>VMAT2</e2>.","Regulator"
"The effects of amphetamine (AMPH) and cocaine (<e1>COC</e1>), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter <e2>DAT</e2> or the vesicular transporter for monoamine storage, VMAT2.","Regulator"
"The effects of amphetamine (AMPH) and cocaine (<e1>COC</e1>), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, <e2>VMAT2</e2>.","Regulator"
"The effects of amphetamine (<e1>AMPH</e1>) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter <e2>DAT</e2> or the vesicular transporter for monoamine storage, VMAT2.","Regulator"
"The effects of amphetamine (AMPH) and cocaine (<e1>COC</e1>), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter <e2>DAT</e2> or the vesicular transporter for monoamine storage, VMAT2.","Regulator"
"Spiro heterocycles as potential inhibitors of <e2>SIRT1</e2>: Pd/C-mediated synthesis of novel <e1>N-indolylmethyl spiroindoline-3,2'-quinazolines</e1>.","Downregulator"
"Novel <e1>N-indolylmethyl substituted spiroindoline-3,2'-quinazolines</e1> were designed as potential inhibitiors of <e2>SIRT1</e2>.","Downregulator"
"The action of <e1>15d-PGJ2</e1> does not appear to involve its nuclear receptor <e2>peroxisome proliferator-activated receptor gamma</e2> (PPARgamma) because troglitazone, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.","Not"
"The action of <e1>15d-PGJ2</e1> does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (<e2>PPARgamma</e2>) because troglitazone, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.","Not"
"The action of 15d-PGJ2 does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) because <e1>troglitazone</e1>, a specific ligand of PPARgamma, was unable to inhibit <e2>iNOS</e2> induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.","Not"
"The action of 15d-PGJ2 does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (<e2>PPAR</e2>gamma) because <e1>troglitazone</e1>, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.","Not"
"The action of <e1>15d-PGJ2</e1> does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (<e2>PPAR</e2>gamma) because troglitazone, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.","Not"
"<e1>15d-PGJ2</e1> did not block nuclear translocation or DNA-binding activity of the transcription factor <e2>NFkappaB</e2>, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.","Not"
"The action of 15d-PGJ2 does not appear to involve its nuclear receptor peroxisome proliferator-activated receptor gamma (<e2>PPARgamma</e2>) because <e1>troglitazone</e1>, a specific ligand of PPARgamma, was unable to inhibit iNOS induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent promoter in the absence of cotransfected PPARgamma.","Regulator"
"<e1>15d-PGJ2</e1> did not block nuclear translocation or DNA-binding activity of the transcription factor <e2>NFkappaB</e2>, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.","Regulator"
"Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of <e2>inducible nitric-oxide synthase</e2> by <e1>15-deoxy-Delta12,14-prostaglandin J2</e1>.","Downregulator"
"In activated microglia, <e1>15d-PGJ2</e1> suppressed <e2>iNOS</e2> promoter activity, iNOS mRNA, and protein levels.","Downregulator"
"<e1>Cyclopentenone prostaglandins</e1> suppress activation of microglia: down-regulation of <e2>inducible nitric-oxide synthase</e2> by 15-deoxy-Delta12,14-prostaglandin J2.","Downregulator"
"<e1>Cyclopentenone prostaglandins</e1> were potent inhibitors of <e2>iNOS</e2> induction and were more effective than their precursors, prostaglandins E2 and D2.","Downregulator"
"Cyclopentenone prostaglandins were potent inhibitors of <e2>iNOS</e2> induction and were more effective than their precursors, <e1>prostaglandins E2 and D2</e1>.","Downregulator"
"In activated microglia, <e1>15d-PGJ2</e1> suppressed <e2>iNOS promoter</e2> activity, iNOS mRNA, and protein levels.","Downregulator"
"<e1>15d-PGJ2</e1> did not block nuclear translocation or DNA-binding activity of the transcription factor <e2>NFkappaB</e2>, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptional activity in the nucleus.","Downregulator"
"In activated microglia, <e1>15d-PGJ2</e1> suppressed <e2>iNOS</e2> promoter activity, iNOS mRNA, and protein levels.","Downregulator"
"Changes in coagulation and fibrinolysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine <e1>oleate</e1> (EO), by means of serial determination of plasma fibrinopeptide A (<e2>FPA</e2>) and fibrinopeptide B beta 15-42 (B beta 15-42).","Regulator"
"In vitro studies, however, revealed that EO inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or <e1>benzyl alcohol</e1> exhibited procoagulant activity in <e2>FPA</e2> formation in vitro.","Regulator"
"The activation may be accelerated by an acute inflammatory process provoked by <e1>oleate</e1>, which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma <e2>fibrinogen</e2> level which was observed in all during the period.","Upregulator"
"Changes in coagulation and <e2>fibrin</e2>olysis were investigated in 20 patients with oesophageal varices, who underwent endoscopic injection sclerotherapy (EIS) with 5 per cent ethanolamine oleate (<e1>EO</e1>), by means of serial determination of plasma fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (B beta 15-42).","Downregulator"
"OBJECTIVE: Celecoxib and <e1>rofecoxib</e1> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the <e2>cyclo-oxygenase-2</e2> (COX-2) isoenzyme at therapeutic concentrations.","Downregulator"
"OBJECTIVE: Celecoxib and <e1>rofecoxib</e1> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (<e2>COX-2</e2>) isoenzyme at therapeutic concentrations.","Downregulator"
"This study was conducted in order to understand the association between acute renal failure and the two <e2>COX-2</e2> inhibitors <e1>celecoxib</e1> and rofecoxib.","Downregulator"
"OBJECTIVE: Celecoxib and <e1>rofecoxib</e1> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (<e2>COX-2</e2>) isoenzyme at therapeutic concentrations.","Downregulator"
"OBJECTIVE: <e1>Celecoxib</e1> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the <e2>cyclo-oxygenase-2</e2> (COX-2) isoenzyme at therapeutic concentrations.","Downregulator"
"OBJECTIVE: <e1>Celecoxib</e1> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 (<e2>COX-2</e2>) isoenzyme at therapeutic concentrations.","Downregulator"
"The affinity estimate for <e1>prazosin</e1> on human prostate was lower than the corresponding binding affinity determined at <e2>alpha 1A adrenoceptors</e2> and RS 17053 was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned human alpha 1A adrenoceptors.","Regulator"
"<e1>(+)-Tamsulosin</e1>, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Regulator"
"The affinity estimate for prazosin on human prostate was lower than the corresponding binding affinity determined at alpha 1A adrenoceptors and <e1>RS 17053</e1> was a very weak antagonist on human prostate (pA2 = 6.0) relative to the high affinity (pKi = 8.6) determined at cloned <e2>human alpha 1A adrenoceptors</e2>.","Regulator"
"The <e1>quinazoline</e1> antagonists, prazosin, doxazosin and alfuzosin displayed high affinity but were non selective for the three cloned <e2>human alpha 1 adrenoceptors</e2>.","Regulator"
"(+)-Tamsulosin, <e1>(-)-tamsulosin</e1>, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Regulator"
"The quinazoline antagonists, <e1>prazosin</e1>, doxazosin and alfuzosin displayed high affinity but were non selective for the three cloned <e2>human alpha 1 adrenoceptors</e2>.","Regulator"
"The quinazoline antagonists, prazosin, <e1>doxazosin</e1> and alfuzosin displayed high affinity but were non selective for the three cloned <e2>human alpha 1 adrenoceptors</e2>.","Regulator"
"The quinazoline antagonists, prazosin, doxazosin and <e1>alfuzosin</e1> displayed high affinity but were non selective for the three cloned <e2>human alpha 1 adrenoceptors</e2>.","Regulator"
"<e1>RS 17053</e1> showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to alpha 1B (pKi = 7.3) and <e2>alpha 1D</e2> (pKi = 7.1) subtypes.","Regulator"
"<e1>RS 17053</e1> showed high affinity and selectivity for <e2>alpha 1A adrenoceptors</e2> (pKi 8.6) relative to alpha 1B (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes.","Regulator"
"<e1>RS 17053</e1> showed high affinity and selectivity for alpha 1A adrenoceptors (pKi 8.6) relative to <e2>alpha 1B</e2> (pKi = 7.3) and alpha 1D (pKi = 7.1) subtypes.","Regulator"
"(+)-Tamsulosin, (-)-tamsulosin, <e1>SL 89,0591</e1>, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Regulator"
"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, <e1>Rec 15/2739</e1>, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Regulator"
"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, <e1>SNAP 1069</e1> and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Regulator"
"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and <e1>RS 17053</e1> appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Regulator"
"The profile of a range of <e2>alpha 1 adrenoceptor</e2> antagonists was determined in vitro against cloned human alpha 1A, alpha 1B and alpha 1D adrenoceptors and against <e1>noradrenaline</e1>-mediated contractions of rat aorta and human prostate.","Regulator"
"<e1>Indoramin</e1> and SNAP 1069 showed selectivity for alpha 1A and alpha 1B adrenoceptors relative to the <e2>alpha 1D subtype</e2>.","Regulator"
"Indoramin and <e1>SNAP 1069</e1> showed selectivity for alpha 1A and alpha 1B adrenoceptors relative to the <e2>alpha 1D subtype</e2>.","Regulator"
"<e1>Rec 15/2739</e1>, WB 4101, SL 89,0591, (+)- and (-)- tamsulosin showed selectivity for alpha 1A and alpha 1D adrenoceptors relative to the <e2>alpha 1B subtype</e2>.","Regulator"
"Rec 15/2739, <e1>WB 4101</e1>, SL 89,0591, (+)- and (-)- tamsulosin showed selectivity for alpha 1A and alpha 1D adrenoceptors relative to the <e2>alpha 1B subtype</e2>.","Regulator"
"Rec 15/2739, WB 4101, <e1>SL 89,0591</e1>, (+)- and (-)- tamsulosin showed selectivity for alpha 1A and alpha 1D adrenoceptors relative to the <e2>alpha 1B subtype</e2>.","Regulator"
"Rec 15/2739, WB 4101, SL 89,0591, <e1>(+)- and (-)- tamsulosin</e1> showed selectivity for alpha 1A and alpha 1D adrenoceptors relative to the <e2>alpha 1B subtype</e2>.","Regulator"
"<e1>(+)-Tamsulosin</e1>, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Antagonist"
"(+)-Tamsulosin, <e1>(-)-tamsulosin</e1>, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Antagonist"
"(+)-Tamsulosin, (-)-tamsulosin, <e1>SL 89,0591</e1>, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Antagonist"
"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, <e1>Rec 15/2739</e1>, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Antagonist"
"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, <e1>SNAP 1069</e1> and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Antagonist"
"(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and <e1>RS 17053</e1> appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned <e2>human alpha 1D adrenoceptors</e2>.","Antagonist"
"In functional experiments, <e1>risperidone</e1> is selective, not for the B, but for the A subtype of <e2>alpha 1-adrenoceptors</e2>.","Not"
"<e1>Prazosin</e1> was found to be unselective; 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101), 5-methyl-urapidil, indoramin and (+)-niguldipine were confirmed as selective for the <e2>alpha 1A-adrenoceptor</e2>, whereas spiperone was weakly alpha 1B-selective.","Not"
"However, at <e2>guinea-pig and mouse splenic alpha 1B-adrenoceptors</e2>, the affinity values of <e1>risperidone</e1> were 10-fold lower than those of prazosin.","Regulator"
"However, at <e2>guinea-pig and mouse splenic alpha 1B-adrenoceptors</e2>, the affinity values of risperidone were 10-fold lower than those of <e1>prazosin</e1>.","Regulator"
"Risperidone was equipotent to <e1>prazosin</e1> at <e2>alpha 1A-adrenoceptors</e2> in rat vas deferens and kidney.","Regulator"
"In functional experiments, <e1>risperidone</e1> is selective, not for the B, but for the A subtype of <e2>alpha 1-adrenoceptors</e2>.","Regulator"
"Prazosin was found to be unselective; <e1>2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane</e1> (WB 4101), 5-methyl-urapidil, indoramin and (+)-niguldipine were confirmed as selective for the <e2>alpha 1A-adrenoceptor</e2>, whereas spiperone was weakly alpha 1B-selective.","Regulator"
"Prazosin was found to be unselective; 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (<e1>WB 4101</e1>), 5-methyl-urapidil, indoramin and (+)-niguldipine were confirmed as selective for the <e2>alpha 1A-adrenoceptor</e2>, whereas spiperone was weakly alpha 1B-selective.","Regulator"
"Prazosin was found to be unselective; 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101), <e1>5-methyl-urapidil</e1>, indoramin and (+)-niguldipine were confirmed as selective for the <e2>alpha 1A-adrenoceptor</e2>, whereas spiperone was weakly alpha 1B-selective.","Regulator"
"Prazosin was found to be unselective; 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101), 5-methyl-urapidil, <e1>indoramin</e1> and (+)-niguldipine were confirmed as selective for the <e2>alpha 1A-adrenoceptor</e2>, whereas spiperone was weakly alpha 1B-selective.","Regulator"
"Prazosin was found to be unselective; 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101), 5-methyl-urapidil, indoramin and <e1>(+)-niguldipine</e1> were confirmed as selective for the <e2>alpha 1A-adrenoceptor</e2>, whereas spiperone was weakly alpha 1B-selective.","Regulator"
"<e1>Risperidone</e1> was equipotent to prazosin at <e2>alpha 1A-adrenoceptors</e2> in rat vas deferens and kidney.","Regulator"
"The potency of the antipsychotic drug, <e1>risperidone</e1>, to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and <e2>alpha 1B-adrenoceptor</e2>-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.","Antagonist"
"In functional experiments, <e1>risperidone</e1> is selective, not for the B, but for the A subtype of <e2>alpha 1-adrenoceptor</e2>s.","Antagonist"
"The potency of the antipsychotic drug, <e1>risperidone</e1>, to antagonize <e2>alpha 1A-adrenoceptor</e2>-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.","Antagonist"
"In this article, the action of <e1>dasatinib</e1> (BMS-354825) is contrasted with that of imatinib, a <e2>kinase</e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.","Downregulator"
"In this article, the action of dasatinib (<e1>BMS-354825</e1>) is contrasted with that of imatinib, a <e2>kinase</e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.","Downregulator"
"In this article, the action of dasatinib (BMS-354825) is contrasted with that of <e1>imatinib</e1>, a <e2>kinase</e2> inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders.","Downregulator"
"The work of Chen and colleagues shows that <e1>dasatinib</e1> is a particularly potent inhibitor of <e2>PDGFR</e2> and that the compound also targets Src kinase.","Downregulator"
"The work of Chen and colleagues shows that <e1>dasatinib</e1> is a particularly potent inhibitor of PDGFR and that the compound also targets <e2>Src kinase</e2>.","Downregulator"
"In another experiment, <e1>cyanopindolol</e1>, an antagonist of the <e2>serotonin terminal autoreceptor</e2>, also prolonged the clearance of 5-HT from the CA3 region.","Antagonist"
"From these data, it is inferred that both the <e2>SERT</e2> and NET contribute to the active clearance of exogenously applied <e1>5-HT</e1> in the dentate gyrus.","Substrate"
"From these data, it is inferred that both the SERT and <e2>NET</e2> contribute to the active clearance of exogenously applied <e1>5-HT</e1> in the dentate gyrus.","Substrate"
"These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of <e1>5-HT</e1> uptake through an effect on the <e2>serotonin transporter</e2>.","Substrate"
"These and other data have generated a working hypothesis that activation of the terminal <e2>serotonin autoreceptor</e2> enhances the kinetics of <e1>5-HT</e1> uptake through an effect on the serotonin transporter.","Substrate"
"These results suggest that the beneficial effect of <e1>minaprine</e1> on cycloheximide-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems (<e2>5-HT2 receptors</e2>).","Regulator"
"These results suggest that the beneficial effect of minaprine on <e1>cycloheximide</e1>-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems (<e2>5-HT2 receptors</e2>).","Regulator"
"The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a <e2>5-HT1A</e2>-selective agonist, <e1>8-hydroxy-2-(di-n-propylamino)tetralin</e1>, was inactive.","Agonist"
"The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective <e2>5-HT2</e2> antagonist, <e1>ritanserin</e1>.","Antagonist"
"Even though the activities of <e2>MAT</e2> and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and <e1>S-adenosylhomocysteine</e1> increased (113%, p<0.001) in the dwarf mice.","Substrate"
"Even though the activities of MAT and <e2>GNMT</e2> were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and <e1>S-adenosylhomocysteine</e1> increased (113%, p<0.001) in the dwarf mice.","Substrate"
"Even though the activities of <e2>MAT</e2> and GNMT were elevated, the concentration of liver <e1>S-adenosylmethionine</e1> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.","Substrate"
"Even though the activities of MAT and <e2>GNMT</e2> were elevated, the concentration of liver <e1>S-adenosylmethionine</e1> was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.","Substrate"
"RESULTS: In vivo, loss and recovery of the righting reflex required similar times after intraperitoneal injection of <e1>etomidate</e1> in wild-type and in <e2>alpha2A-receptor</e2>-deficient mice, indicating that the hypnotic effect of etomidate in mice does not require the alpha2A-receptor subtype.","Not"
"METHODS: Sedative and cardiovascular responses to <e1>etomidate</e1> and the alpha2-agonist, dexmedetomidine, were determined in mice deficient in <e2>alpha2-receptor</e2> subtypes.","Regulator"
"Inhibition of binding of the alpha2-receptor antagonist [3H]RX821002 to recombinant <e2>alpha2-receptors</e2> by <e1>etomidate</e1> was tested in human embryonic kidney (HEK293) cells in vitro.","Regulator"
"In membranes from HEK293 cells transfected with alpha2-receptors, <e1>etomidate</e1> inhibited binding of the alpha2-antagonist, [3H]RX821002, with higher potency from alpha2B- and alpha2C-receptors than from <e2>alpha2A-receptors</e2> (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).","Regulator"
"METHODS: Sedative and cardiovascular responses to <e1>etomidate</e1> and the alpha2-agonist, dexmedetomidine, were determined in mice deficient in <e2>alpha2-receptor</e2> subtypes.","Regulator"
"RESULTS: In vivo, loss and recovery of the righting reflex required similar times after intraperitoneal injection of <e1>etomidate</e1> in wild-type and in <e2>alpha2A-receptor</e2>-deficient mice, indicating that the hypnotic effect of etomidate in mice does not require the alpha2A-receptor subtype.","Regulator"
"Inhibition of binding of the alpha2-receptor antagonist [3H]RX821002 to recombinant <e2>alpha2-receptors</e2> by <e1>etomidate</e1> was tested in human embryonic kidney (HEK293) cells in vitro.","Regulator"
"In membranes from HEK293 cells transfected with alpha2-receptors, <e1>etomidate</e1> inhibited binding of the alpha2-antagonist, [3H]RX821002, with higher potency from <e2>alpha2B- and alpha2C-receptors</e2> than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).","Regulator"
"In <e2>alpha2B-receptor</e2>-expressing HEK293 cells, <e1>etomidate</e1> rapidly increased phosphorylation of the extracellular signal-related kinases ERK1/2.","Regulator"
"In <e2>alpha2B-receptor</e2>-expressing HEK293 cells, <e1>etomidate</e1> rapidly increased phosphorylation of the extracellular signal-related kinases ERK1/2.","Regulator"
"The current study was performed to elucidate the possible interaction of <e1>etomidate</e1> with <e2>alpha2-adrenoceptors</e2> in mice lacking individual alpha2-adrenoceptor subtypes (alpha2-KO).","Regulator"
"BACKGROUND: The intravenous anesthetic <e1>etomidate</e1> exhibits structural similarities to specific <e2>alpha2-adrenoceptor</e2> agonists of the type such as dexmedetomidine.","Regulator"
"Activation of <e2>alpha 2B-adrenoceptors</e2> mediates the cardiovascular effects of <e1>etomidate</e1>.","Upregulator"
"In alpha2B-receptor-expressing HEK293 cells, <e1>etomidate</e1> rapidly increased phosphorylation of the <e2>extracellular signal-related kinases</e2> ERK1/2.","Upregulator"
"In alpha2B-receptor-expressing HEK293 cells, <e1>etomidate</e1> rapidly increased phosphorylation of the extracellular signal-related kinases <e2>ERK1/2</e2>.","Upregulator"
"METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist, <e1>dexmedetomidine</e1>, were determined in mice deficient in <e2>alpha2-receptor</e2> subtypes.","Agonist"
"BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific <e2>alpha2-adrenoceptor</e2> agonists of the type such as <e1>dexmedetomidine</e1>.","Agonist"
"The current study was performed to elucidate the possible interaction of <e1>etomidate</e1> with <e2>alpha2-adrenoceptors</e2> in mice lacking individual alpha2-adrenoceptor subtypes (alpha2-KO).","Agonist"
"Inhibition of binding of the <e2>alpha2-receptor</e2> antagonist <e1>[3H]RX821002</e1> to recombinant alpha2-receptors by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.","Antagonist"
"Inhibition of binding of the alpha2-receptor antagonist <e1>[3H]RX821002</e1> to recombinant <e2>alpha2-receptors</e2> by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.","Antagonist"
"Inhibition of binding of the alpha2-receptor antagonist <e1>[3H]RX821002</e1> to recombinant <e2>alpha2-receptors</e2> by etomidate was tested in human embryonic kidney (HEK293) cells in vitro.","Antagonist"
"In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist, <e1>[3H]RX821002</e1>, with higher potency from alpha2B- and alpha2C-receptors than from <e2>alpha2A-receptors</e2> (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm).","Antagonist"
"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>SiO(2)</e1> NPs, the messenger RNA level of apoptotic genes (<e2>caspase-3</e2> and caspase-9) were upregulated in a dose-dependent manner.","Upregulator"
"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>SiO(2)</e1> NPs, the messenger RNA level of apoptotic genes (caspase-3 and <e2>caspase-9</e2>) were upregulated in a dose-dependent manner.","Upregulator"
"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>SiO(2)</e1> NPs, the messenger RNA level of apoptotic genes (<e2>caspase-3</e2> and caspase-9) were upregulated in a dose-dependent manner.","Upregulator"
"Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to <e1>SiO(2)</e1> NPs, the messenger RNA level of apoptotic genes (caspase-3 and <e2>caspase-9</e2>) were upregulated in a dose-dependent manner.","Upregulator"
"<e1>ThioTEPA</e1> (<e2>CYP2B6</e2> inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.","Downregulator"
"ThioTEPA (CYP2B6 inhibitor, 25 μM) and the monoclonal antibody against CYP2B6 but not <e1>troleandomycin</e1> (<e2>CYP3A4</e2> inhibitor, 25 μM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.","Downregulator"
"The intrinsic clearance for both <e1>ketamine</e1> enantiomers by the high affinity enzyme in HLMs with <e2>CYP2B6*1</e2>/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.","Substrate"
"The <e2>CYP2B6*6</e2> Allele Significantly Alters the N-demethylation of <e1>Ketamine</e1> Enantiomers In Vitro.","Substrate"
"<e1>Ketamine</e1> is primarily metabolized to norketamine by hepatic <e2>cytochrome P450 (CYP) 2B6</e2> and CYP3A4-mediated N-demethylation.","Substrate"
"<e1>Ketamine</e1> is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and <e2>CYP3A4</e2>-mediated N-demethylation.","Substrate"
"The <e2>CYP2B6</e2>*6 allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in <e1>ketamine</e1> metabolism.","Substrate"
"The <e2>CYP2B6*6</e2> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in <e1>ketamine</e1> metabolism.","Substrate"
"The <e2>CYP2B6*6</e2> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in <e1>ketamine</e1> metabolism.","Substrate"
"The <e2>CYP2B6*6</e2> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in <e1>ketamine</e1> metabolism.","Substrate"
"We examined the specificity and initial sites of recruitment of Arf-dependent adaptors (AP-1 and GGAs) in response to the Golgi or endosomal localization of specific cargo proteins (furin, mannose-6-phosphate receptor (M6PR) and M6PR lacking a <e1>C</e1>-terminal domain <e2>M6PRΔC</e2>).","Part_of"
"PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the <e2>aromatase</e2> inhibitor, <e1>testolactone</e1>, and resulting changes in semen parameters.","Downregulator"
"We evaluated the effect of <e1>anastrozole</e1>, a more selective <e2>aromatase</e2> inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios.","Downregulator"
"The results show that CYP2E1 inhibits <e2>CYP2B4</e2>-mediated metabolism of benzphetamine (<e1>BNZ</e1>) with a K(i) of 0.04 µM.","Regulator"
"The results show that CYP2E1 inhibits <e2>CYP2B4</e2>-mediated metabolism of <e1>benzphetamine</e1> (BNZ) with a K(i) of 0.04 µM.","Substrate"
"The results show that CYP2E1 inhibits <e2>CYP2B4</e2>-mediated metabolism of benzphetamine (<e1>BNZ</e1>) with a K(i) of 0.04 µM.","Substrate"
"However, CYP2B4 is not an inhibitor of <e2>CYP2E1</e2>-mediated <e1>p-nitrophenol</e1> hydroxylation.","Substrate"
"Probing for a hydrophobic a binding register in <e2>prostate-specific membrane antigen</e2> with <e1>phenylalkylphosphonamidates</e1>.","Regulator"
"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of <e2>PSMA</e2> a series of <e1>phenylalkylphosphonamidate</e1> derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against PSMA.","Downregulator"
"To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of <e2>PSMA</e2> a series of phenylalkylphosphonamidate derivatives of <e1>glutamic acid</e1> were synthesized and evaluated for their inhibitory potencies against PSMA.","Downregulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, <e2>Bcl-2</e2>).","Regulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, <e2>Bax</e2>) and cell-survival molecules (AKT, Bcl-2).","Regulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, <e2>Bcl-2</e2>).","Regulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (<e2>AKT</e2>, Bcl-2).","Upregulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, <e2>Bcl-2</e2>).","Upregulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, <e2>Bcl-2</e2>).","Upregulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), p53, procaspase 3, cleaved caspase 3, <e2>Bax</e2>) and cell-survival molecules (AKT, Bcl-2).","Upregulator"
"The objective of the current study was to determine whether a low-dose subchronic <e1>DEX</e1> treatment (100 μg/kg for 8 consecutive days) exerts long-term effects on apoptosis in the adult rat prefrontal cortex (PFC) by examining the expression of cell death-promoting molecules (poly (ADP-ribose) polymerase (PARP), <e2>p53</e2>, procaspase 3, cleaved caspase 3, Bax) and cell-survival molecules (AKT, Bcl-2).","Downregulator"
"The <e2>IL-2</e2>/gamma(c) interface itself exhibits the smallest buried surface and the fewest <e1>hydrogen</e1> bonds in the complex, which is consistent with its promiscuous use in other cytokine receptor complexes.","Part_of"
"Antitumor activity of <e1>sorafenib</e1> in <e2>FLT3</e2>-driven leukemic cells.","Downregulator"
"Antitumor activity of <e1>sorafenib</e1> in <e2>FLT3</e2>-driven leukemic cells.","Downregulator"
"Antitumor activity of <e1>sorafenib</e1> in <e2>FLT3</e2>-driven leukemic cells.","Downregulator"
"Antitumor activity of <e1>sorafenib</e1> in <e2>FLT3</e2>-driven leukemic cells.","Downregulator"
"We show that sorafenib (<e1>BAY 43-9006</e1>, Nexavar) potently inhibits <e2>FLT3</e2> enzymatic and signaling activities.","Downregulator"
"We show that sorafenib (BAY 43-9006, <e1>Nexavar</e1>) potently inhibits <e2>FLT3</e2> enzymatic and signaling activities.","Downregulator"
"Antitumor activity of <e1>sorafenib</e1> in <e2>FLT3</e2>-driven leukemic cells.","Downregulator"
"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, <e1>sorafenib</e1> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as <e2>extracellular signal-regulated kinase1/2</e2> and Stat5 phosphorylation.","Downregulator"
"In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, <e1>sorafenib</e1> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and <e2>Stat5</e2> phosphorylation.","Downregulator"
"Antitumor activity of <e1>sorafenib</e1> in <e2>FLT3</e2>-driven leukemic cells.","Downregulator"
"Antitumor activity of <e1>sorafenib</e1> in <e2>FLT3</e2>-driven leukemic cells.","Downregulator"
"<e1>DBDCT</e1> induced the release of <e2>cytochrome c</e2> from the mitochondria to the cytosol and the generation of reactive oxygen species.","Regulator"
"PC12 cell apoptosis induced by <e1>DBDCT</e1> was confirmed by annexin V/propidium iodide staining, and characterized by cleavage of <e2>caspase-9</e2> and caspase-3 proteins.","Regulator"
"PC12 cell apoptosis induced by <e1>DBDCT</e1> was confirmed by annexin V/propidium iodide staining, and characterized by cleavage of caspase-9 and <e2>caspase-3</e2> proteins.","Regulator"
"PC12 cell apoptosis induced by <e1>DBDCT</e1> was confirmed by annexin V/propidium iodide staining, and characterized by cleavage of <e2>caspase-9</e2> and caspase-3 proteins.","Regulator"
"PC12 cell apoptosis induced by <e1>DBDCT</e1> was confirmed by annexin V/propidium iodide staining, and characterized by cleavage of caspase-9 and <e2>caspase-3</e2> proteins.","Regulator"
"<e1>DBDCT</e1> also caused the phosphorylation of <e2>JNK</e2> and p38(MAPK).","Upregulator"
"<e1>DBDCT</e1> also caused the phosphorylation of JNK and <e2>p38</e2>(MAPK).","Upregulator"
"<e1>DBDCT</e1> also caused the phosphorylation of JNK and p38(<e2>MAPK</e2>).","Upregulator"
"<e1>DBDCT</e1> up-regulated the expression of <e2>Bax</e2>, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2.","Upregulator"
"<e1>DBDCT</e1> up-regulated the expression of Bax, down-regulated the expression of <e2>Bcl-2</e2>, and significantly increased the ratio of Bax/Bcl-2.","Upregulator"
"<e1>DBDCT</e1> up-regulated the expression of <e2>Bax</e2>, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2.","Upregulator"
"<e1>DBDCT</e1> up-regulated the expression of Bax, down-regulated the expression of <e2>Bcl-2</e2>, and significantly increased the ratio of Bax/Bcl-2.","Downregulator"
"<e1>Aliskiren</e1> represents the first in a novel class of <e2>renin</e2> inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.","Downregulator"
"This led to the discovery of <e1>aliskiren</e1>, a highly potent and selective inhibitor of <e2>human renin</e2> in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.","Downregulator"
"Structure-based design of <e1>aliskiren</e1>, a novel orally effective <e2>renin</e2> inhibitor.","Downregulator"
"Structure-based design of <e1>aliskiren</e1>, a novel orally effective <e2>renin</e2> inhibitor.","Downregulator"
"The x-ray co-crystal structure of LeuRS showed that a <e1>C</e1>-terminal extension of about 60 amino acids forms a discrete domain, which is unique among the <e2>LeuRSs</e2> and interacts with the corner of the L-shaped tRNALeu.","Part_of"
"The x-ray co-crystal structure of LeuRS showed that a C-terminal extension of about 60 <e1>amino acids</e1> forms a discrete domain, which is unique among the <e2>LeuRSs</e2> and interacts with the corner of the L-shaped tRNALeu.","Part_of"
"Interestingly, deletion of the entire <e2>yeast mitochondrial LeuRS</e2> <e1>C</e1>-terminal domain enhanced its aminoacylation and amino acid editing activities.","Part_of"
"Interestingly, deletion of the entire <e2>yeast mitochondrial LeuRS</e2> C-terminal domain enhanced its aminoacylation and <e1>amino acid</e1> editing activities.","Part_of"
"In striking contrast, deletion of the corresponding <e1>C</e1>-terminal domain of <e2>Escherichia coli LeuRS</e2> abolished aminoacylation of tRNALeu and also amino acid editing of mischarged tRNA molecules.","Part_of"
"Functional divergence of a unique <e1>C</e1>-terminal domain of <e2>leucyl-tRNA synthetase</e2> to accommodate its splicing and aminoacylation roles.","Part_of"
"Functional divergence of a unique C-terminal domain of <e1>leucyl</e1>-tRNA synthetase to accommodate its splicing and aminoacylation roles.","Part_of"
"<e1>Leucyl</e1>-tRNA synthetase (LeuRS) performs dual essential roles in group I intron RNA splicing as well as protein synthesis within the yeast mitochondria.","Part_of"
"In striking contrast, deletion of the corresponding C-terminal domain of <e2>Escherichia coli LeuRS</e2> abolished aminoacylation of tRNALeu and also <e1>amino acid</e1> editing of mischarged tRNA molecules.","Part_of"
"Interestingly, deletion of the entire <e2>yeast mitochondrial LeuRS</e2> <e1>C</e1>-terminal domain enhanced its aminoacylation and amino acid editing activities.","Part_of"
"Herein, we determined that a fiveamino acid <e1>C</e1>-terminal deletion of <e2>LeuRS</e2>, which does not complement a null strain, can form a ternary complex with the bI4 intron and its maturase splicing partner.","Part_of"
"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the <e2>VEGFR</e2> tyrosine kinase inhibitors sunitinib and/or <e1>sorafenib</e1>.","Downregulator"
"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR <e2>tyrosine kinase</e2> inhibitors sunitinib and/or <e1>sorafenib</e1>.","Downregulator"
"<e1>Everolimus</e1> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of <e2>mTOR</e2> (mammalian target of rapamycin) to reach the oncology clinic.","Downregulator"
"<e1>Everolimus</e1> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (<e2>mammalian target of rapamycin</e2>) to reach the oncology clinic.","Downregulator"
"Everolimus (<e1>RAD001</e1>, Afinitor((R)) Novartis) is the first oral inhibitor of <e2>mTOR</e2> (mammalian target of rapamycin) to reach the oncology clinic.","Downregulator"
"Everolimus (<e1>RAD001</e1>, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR (<e2>mammalian target of rapamycin</e2>) to reach the oncology clinic.","Downregulator"
"Everolimus (RAD001, <e1>Afinitor((R)) Novartis</e1>) is the first oral inhibitor of <e2>mTOR</e2> (mammalian target of rapamycin) to reach the oncology clinic.","Downregulator"
"Everolimus (RAD001, <e1>Afinitor((R)) Novartis</e1>) is the first oral inhibitor of mTOR (<e2>mammalian target of rapamycin</e2>) to reach the oncology clinic.","Downregulator"
"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the <e2>VEGFR</e2> tyrosine kinase inhibitors <e1>sunitinib</e1> and/or sorafenib.","Downregulator"
"A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR <e2>tyrosine kinase</e2> inhibitors <e1>sunitinib</e1> and/or sorafenib.","Downregulator"
"Recent studies highlight the capacity of <e1>sucralfate</e1> to bind <e2>basic fibroblast growth factor</e2> (bFGF) and deliver it in high concentration to the ulcer.","Regulator"
"Recent studies highlight the capacity of <e1>sucralfate</e1> to bind basic fibroblast growth factor (<e2>bFGF</e2>) and deliver it in high concentration to the ulcer.","Regulator"
"Synthesis and structure-activity relationship of <e1>pyripyropene A</e1> derivatives as potent and selective <e2>acyl-CoA:cholesterol acyltransferase 2</e2> (ACAT2) inhibitors: Part 2.","Downregulator"
"Synthesis and structure-activity relationship of <e1>pyripyropene A</e1> derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (<e2>ACAT2</e2>) inhibitors: Part 2.","Downregulator"
"<e1>Adrenaline</e1> via <e2>alpha 2-adrenoceptors</e2> inhibited the Ca2+ currents by about 50%.","Regulator"
"In membranes of control but not of pertussis toxin-treated cells, <e1>adrenaline</e1> via <e2>alpha 2-adrenoceptors</e2> stimulated incorporation of the photo-reactive GTP analog [alpha-32P]GTP azidoanilide into pertussis toxin substrates comigrating with the alpha-subunits of Gi2, Go2, and the not further identified Go subtype.","Regulator"
"These <e2>G-proteins</e2> are likely to be involved in the <e1>adrenaline</e1>-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the adrenaline-induced inhibition of insulin secretion.","Regulator"
"Since voltage-dependent Ca2+ currents play a key role in <e2>insulin</e2> secretion, we examined whether <e1>adrenaline</e1> modulates voltage-dependent Ca2+ currents of the rat insulinoma cell line, RINm5F.","Downregulator"
"<e1>Somatostatin</e1> which also inhibits <e2>insulin</e2> secretion was less efficient (inhibition by 20%).","Downregulator"
"<e1>Adrenaline</e1> inhibits <e2>insulin</e2> secretion via pertussis toxin-sensitive mechanisms.","Downregulator"
"Since voltage-dependent Ca2+ currents play a key role in <e2>insulin</e2> secretion, we examined whether <e1>adrenaline</e1> modulates voltage-dependent Ca2+ currents of the rat insulinoma cell line, RINm5F.","Downregulator"
"In contrast to adrenaline and <e1>somatostatin</e1>, galanin, another inhibitor of <e2>insulin</e2> secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.","Downregulator"
"We had previously reported a <e1>fluorescein</e1> conjugate that was shown (by confocal microscopy imaging of DS-red-labelled cortical neurons) to bind specifically to <e2>GluN2B</e2>.","Regulator"
"Synthesis and in Vitro Characterisation of <e1>Ifenprodil</e1>-Based Fluorescein Conjugates as <e2>GluN1</e2>/GluN2B N-Methyl-D-aspartate Receptor Antagonists.","Antagonist"
"Synthesis and in Vitro Characterisation of <e1>Ifenprodil</e1>-Based Fluorescein Conjugates as GluN1/<e2>GluN2B</e2> N-Methyl-D-aspartate Receptor Antagonists.","Antagonist"
"Synthesis and in Vitro Characterisation of <e1>Ifenprodil</e1>-Based Fluorescein Conjugates as GluN1/GluN2B <e2>N-Methyl-D-aspartate Receptor</e2> Antagonists.","Antagonist"
"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>Fluorescein</e1> Conjugates as <e2>GluN1</e2>/GluN2B N-Methyl-D-aspartate Receptor Antagonists.","Antagonist"
"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>Fluorescein</e1> Conjugates as GluN1/<e2>GluN2B</e2> N-Methyl-D-aspartate Receptor Antagonists.","Antagonist"
"Synthesis and in Vitro Characterisation of Ifenprodil-Based <e1>Fluorescein</e1> Conjugates as GluN1/GluN2B <e2>N-Methyl-D-aspartate Receptor</e2> Antagonists.","Antagonist"
"<e1>Ifenprodil</e1>, known as the <e2>GluNR2B</e2> antagonist of reference, was chosen as the template for the elaboration of probes.","Antagonist"
"<e1>C</e1>onformational epitopes on the diabetes autoantigen <e2>GAD65</e2> identified by peptide phage display and molecular modeling.","Part_of"
"Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing <e1>amino acids</e1>, and the surface of the <e2>GAD65 PLP-binding domain</e2> surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these amino acids.","Part_of"
"Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing <e1>amino acids</e1>, and the surface of the <e2>GAD65 PLP-binding domain</e2> surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these amino acids.","Part_of"
"Mutation of <e2>Ser-530 to Ala</e2> or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key <e1>lumiracoxib</e1> analogs.","Not"
"Mutation of Ser-530 to Ala or <e2>Val-349 to Ala or Leu</e2> abolished the potent inhibition observed with wild-type human COX-2 and key <e1>lumiracoxib</e1> analogs.","Not"
"Using standard assays, <e1>lumiracoxib</e1> was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified human <e2>COX-2</e2>.","Regulator"
"The chemical identity and position of the substituents on the lower <e1>aniline</e1> ring were important in determining the potency and extent of COX inhibition as well as <e2>COX-2</e2> selectivity.","Regulator"
"Interestingly, a <e2>Val-349 to Ile</e2> mutant was inhibited with equal potency to human COX-2 with <e1>2,6-dichloro</e1>-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.","Downregulator"
"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>human COX-2</e2> with <e1>2,6-dichloro</e1>-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.","Downregulator"
"Interestingly, a <e2>Val-349 to Ile</e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, <e1>2,6-dimethyl</e1>-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.","Downregulator"
"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>human COX-2</e2> with 2,6-dichloro-, <e1>2,6-dimethyl</e1>-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.","Downregulator"
"Interestingly, a <e2>Val-349 to Ile</e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or <e1>2-chloro-6-methyl</e1>-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.","Downregulator"
"Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to <e2>human COX-2</e2> with 2,6-dichloro-, 2,6-dimethyl-, or <e1>2-chloro-6-methyl</e1>-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.","Downregulator"
"Interestingly, a <e2>Val-349 to Ile</e2> mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of <e1>lumiracoxib</e1>, actually showed an increase in potency.","Downregulator"
"Using standard assays, <e1>lumiracoxib</e1> was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified <e2>human COX-2</e2>.","Downregulator"
"Taken together with a recent crystal structure of a <e1>lumiracoxib</e1>-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant <e2>COX-2s</e2> by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition.","Downregulator"
"Using standard assays, <e1>lumiracoxib</e1> was found to be a poor inhibitor of purified <e2>ovine COX-1</e2> and a relatively weak inhibitor of purified human COX-2.","Downregulator"
"Using standard assays, <e1>lumiracoxib</e1> was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified <e2>human COX-2</e2>.","Downregulator"
"Using standard assays, <e1>lumiracoxib</e1> was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified <e2>human COX-2</e2>.","Downregulator"
"Lumiracoxib is the first example of a marketed <e2>COX-2</e2> inhibitor of the <e1>arylacetic acid</e1> class, and it is reported to be the most selective COXIB in vivo.","Downregulator"
"<e1>Lumiracoxib</e1> is the first example of a marketed <e2>COX-2</e2> inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo.","Downregulator"
"Inhibition studies demonstrated that the <e1>methyl</e1> group on the phenylacetic acid ring is required for <e2>COX-2</e2> selectivity.","Downregulator"
"Inhibition studies demonstrated that the methyl group on the <e1>phenylacetic acid</e1> ring is required for <e2>COX-2</e2> selectivity.","Downregulator"
"Molecular determinants for the selective inhibition of <e2>cyclooxygenase-2</e2> by <e1>lumiracoxib</e1>.","Downregulator"
"The chemical identity and position of the substituents on the lower <e1>aniline</e1> ring were important in determining the potency and extent of <e2>COX</e2> inhibition as well as COX-2 selectivity.","Downregulator"
"Using standard assays, <e1>lumiracoxib</e1> was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified <e2>human COX-2</e2>.","Downregulator"
"In this sample of neuroleptic-refractory schizophrenic patients, <e1>olanzapine</e1> and clozapine showed a different pattern of occupancy of <e2>D2-like receptor</e2> despite a common lack of extrapyramidal side-effects.","Regulator"
"In this sample of neuroleptic-refractory schizophrenic patients, olanzapine and <e1>clozapine</e1> showed a different pattern of occupancy of <e2>D2-like receptor</e2> despite a common lack of extrapyramidal side-effects.","Regulator"
"The <e2>neuronal vesicular monoamine transporter</e2> (VMAT2) is the target molecule of action of some psychostimulants, such as <e1>methamphetamine</e1> and 3,4-methylenedioxymethamphetamine (MDMA).","Regulator"
"The neuronal vesicular monoamine transporter (<e2>VMAT2</e2>) is the target molecule of action of some psychostimulants, such as <e1>methamphetamine</e1> and 3,4-methylenedioxymethamphetamine (MDMA).","Regulator"
"The <e2>neuronal vesicular monoamine transporter</e2> (VMAT2) is the target molecule of action of some psychostimulants, such as methamphetamine and <e1>3,4-methylenedioxymethamphetamine</e1> (MDMA).","Regulator"
"The neuronal vesicular monoamine transporter (<e2>VMAT2</e2>) is the target molecule of action of some psychostimulants, such as methamphetamine and <e1>3,4-methylenedioxymethamphetamine</e1> (MDMA).","Regulator"
"The <e2>neuronal vesicular monoamine transporter</e2> (VMAT2) is the target molecule of action of some psychostimulants, such as methamphetamine and 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>).","Regulator"
"The neuronal vesicular monoamine transporter (<e2>VMAT2</e2>) is the target molecule of action of some psychostimulants, such as methamphetamine and 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>).","Regulator"
"Moreover, kinetic analysis revealed that inhibition by <e1>reserpine</e1>, a typical <e2>VMAT2</e2> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine.","Downregulator"
"Moreover, kinetic analysis revealed that inhibition by <e1>reserpine</e1>, a typical <e2>VMAT2</e2> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine.","Downregulator"
"These results suggest that <e1>fluoxetine</e1> inhibited the activity of <e2>VMAT2</e2> by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2.","Downregulator"
"These results suggest that <e1>fluoxetine</e1> inhibited the activity of <e2>VMAT2</e2> by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2.","Downregulator"
"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on <e2>VMAT2</e2> activity by measuring adenosine triphosphate-dependent [(3)H]<e1>dopamine</e1> uptake into synaptic vesicles prepared from rat striatum.","Substrate"
"The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on <e2>VMAT2</e2> activity by measuring adenosine triphosphate-dependent <e1>[(3)H]dopamine</e1> uptake into synaptic vesicles prepared from rat striatum.","Substrate"
"<e1>Cisapride</e1> was found to bind the <e2>human ether-a-go-go-related gene (HERG) potassium channel</e2>, which provides a plausible mechanism for QTc interval prolongation/arrhythmia.","Regulator"
"Other QTc interval-prolonging/arrhythmic drugs that also bind to <e2>HERG</e2> provided an analogy for <e1>cisapride</e1> causing QTc interval prolongation/arrhythmia via this mechanism.","Regulator"
"In this study, we examined whether <e1>betaxolol</e1> and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (<e2>Na(+) channel</e2>) in rat cerebrocortical synaptosomes.","Regulator"
"In this study, we examined whether <e1>betaxolol</e1> and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the <e2>voltage-sensitive sodium channel</e2> (Na(+) channel) in rat cerebrocortical synaptosomes.","Regulator"
"In this study, we examined whether <e1>betaxolol</e1> and other beta-adrenoceptor antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (<e2>Na(+) channel</e2>) in rat cerebrocortical synaptosomes.","Regulator"
"<e1>Betaxolol</e1> inhibited specific [(3)H]-batrachotoxinin-A 20-alpha-benzoate ([(3)H]-BTX-B) binding to <e2>neurotoxin site 2</e2> in a concentration-dependent manner with an IC(50) value of 9.8 microM.","Regulator"
"Betaxolol inhibited specific <e1>[(3)H]-batrachotoxinin-A 20-alpha-benzoate</e1> ([(3)H]-BTX-B) binding to <e2>neurotoxin site 2</e2> in a concentration-dependent manner with an IC(50) value of 9.8 microM.","Regulator"
"Betaxolol inhibited specific [(3)H]-batrachotoxinin-A 20-alpha-benzoate (<e1>[(3)H]-BTX-B</e1>) binding to <e2>neurotoxin site 2</e2> in a concentration-dependent manner with an IC(50) value of 9.8 microM.","Regulator"
"None of the drugs caused a significant inhibition of <e1>[(3)H]-saxitoxin</e1> binding to <e2>neurotoxin receptor site 1</e2>, even at concentrations as high as 250 microM.","Regulator"
"<e1>Betaxolol</e1>, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with <e2>Na(+) channels</e2>: comparison with other beta-adrenoceptor antagonists.","Regulator"
"In this study, we examined whether <e1>betaxolol</e1> and other <e2>beta-adrenoceptor</e2> antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.","Antagonist"
"<e1>Betaxolol</e1>, a <e2>beta(1)-adrenoceptor</e2> antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.","Antagonist"
"Comparison of all the <e2>beta-adrenoceptor</e2> antagonists tested revealed a potency order of <e1>propranolol</e1>>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.","Antagonist"
"In this study, we examined whether <e1>betaxolol</e1> and other <e2>beta-adrenoceptor</e2> antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes.","Antagonist"
"Comparison of all the <e2>beta-adrenoceptor</e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately <e1>levobetaxolol</e1>>levobunolol approximately carteolol>/=timolol>atenolol.","Antagonist"
"Comparison of all the <e2>beta-adrenoceptor</e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol><e1>levobunolol</e1> approximately carteolol>/=timolol>atenolol.","Antagonist"
"Comparison of all the <e2>beta-adrenoceptor</e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately <e1>carteolol</e1>>/=timolol>atenolol.","Antagonist"
"Comparison of all the <e2>beta-adrenoceptor</e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=<e1>timolol</e1>>atenolol.","Antagonist"
"Comparison of all the <e2>beta-adrenoceptor</e2> antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol><e1>atenolol</e1>.","Antagonist"
"<e1>Betaxolol</e1>, a <e2>beta(1)-adrenoceptor</e2> antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.","Antagonist"
"<e1>Betaxolol</e1>, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other <e2>beta-adrenoceptor</e2> antagonists.","Antagonist"
"The results demonstrated that intracerebral infusions of <e1>LTD4</e1> (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of Aβ1-40 and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (<e2>APP</e2>).","Regulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (<e2>CysLT(1)R</e2>) and NF-κB p65 in the hippocampus and cortex.","Regulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and <e2>NF-κB</e2> p65 in the hippocampus and cortex.","Regulator"
"<e1>Leukotriene D4</e1> induces cognitive impairment through enhancement of <e2>CysLT₁ R</e2>-mediated amyloid-β generation in mice.","Upregulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (<e2>CysLT(1)R</e2>) and NF-κB p65 in the hippocampus and cortex.","Upregulator"
"<e1>Leukotriene D4</e1> induces cognitive impairment through enhancement of CysLT₁ R-mediated <e2>amyloid-β</e2> generation in mice.","Upregulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (<e2>CysLT(1)R</e2>) and NF-κB p65 in the hippocampus and cortex.","Upregulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and <e2>NF-κB</e2> p65 in the hippocampus and cortex.","Upregulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-κB <e2>p65</e2> in the hippocampus and cortex.","Upregulator"
"These results suggest that <e1>LTD4</e1> increases <e2>Aβ peptide</e2> burden via activation of CysLT(1)R, which further affects APP levels and activity of β- and γ-secretases via the NF-κB pathway.","Upregulator"
"The results demonstrated that intracerebral infusions of <e1>LTD4</e1> (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of <e2>Aβ1-40</e2> and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (APP).","Upregulator"
"The results demonstrated that intracerebral infusions of <e1>LTD4</e1> (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of Aβ1-40 and <e2>Aβ1-42</e2> in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (APP).","Upregulator"
"The results demonstrated that intracerebral infusions of <e1>LTD4</e1> (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of Aβ1-40 and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of <e2>amyloid precursor protein</e2> (APP).","Upregulator"
"The results demonstrated that intracerebral infusions of <e1>LTD4</e1> (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of Aβ1-40 and Aβ1-42 in the hippocampus and cortex through increased activity of β- and γ-secretases accompanied with increased expression of amyloid precursor protein (<e2>APP</e2>).","Upregulator"
"<e1>LTD4</e1> also induced expression of <e2>cysteinyl leukotriene receptor 1</e2> (CysLT(1)R) and NF-κB p65 in the hippocampus and cortex.","Upregulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (<e2>CysLT(1)R</e2>) and NF-κB p65 in the hippocampus and cortex.","Upregulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and <e2>NF-κB</e2> p65 in the hippocampus and cortex.","Upregulator"
"<e1>LTD4</e1> also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-κB <e2>p65</e2> in the hippocampus and cortex.","Upregulator"
"Pretreatment with <e1>pranlukast</e1> (1.5 ng/mouse, intracerebroventricularly), a <e2>CysLT(1)R</e2> antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.","Downregulator"
"Moreover, LTD4-induced increases in CysLT(1)R and <e2>NF-κB</e2> p65 in the brain were also attenuated by <e1>pranlukast</e1>.","Downregulator"
"Moreover, LTD4-induced increases in CysLT(1)R and NF-κB <e2>p65</e2> in the brain were also attenuated by <e1>pranlukast</e1>.","Downregulator"
"Pretreatment with <e1>pranlukast</e1> (1.5 ng/mouse, intracerebroventricularly), a <e2>CysLT(1)R</e2> antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.","Antagonist"
"Predicting cardiomyopathic phenotypes by altering <e1>Ca2+</e1> affinity of <e2>cardiac troponin C</e2>.
Cardiac diseases associated with mutations in troponin subunits include hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and restrictive cardiomyopathy (RCM).","Regulator"
"Steady-state fluorescence was utilized to assess <e1>Ca(2+)</e1> affinity in isolated <e2>cardiac (c)TnCs</e2> containing F27W and did not necessarily mirror the fiber Ca(2+) sensitivity.","Regulator"
"Steady-state fluorescence was utilized to assess <e1>Ca(2+)</e1> affinity in isolated cardiac (c)TnCs containing <e2>F27W</e2> and did not necessarily mirror the fiber Ca(2+) sensitivity.","Regulator"
"Steady-state fluorescence was utilized to assess <e1>Ca(2+)</e1> affinity in isolated <e2>cardiac (c)TnCs</e2> containing F27W and did not necessarily mirror the fiber Ca(2+) sensitivity.","Regulator"
"Circular dichroism of mutant <e2>cTnCs</e2> revealed a trend where increased alpha-helical content correlated with increased <e1>Ca(2+)</e1> sensitivity in skinned fibers and vice versa.","Regulator"
"Circular dichroism of mutant <e2>cTnC</e2>s revealed a trend where increased alpha-helical content correlated with increased <e1>Ca(2+)</e1> sensitivity in skinned fibers and vice versa.","Regulator"
"Circular dichroism of mutant <e2>cTnC</e2>s revealed a trend where increased alpha-helical content correlated with increased <e1>Ca(2+)</e1> sensitivity in skinned fibers and vice versa.","Regulator"
"Circular dichroism of mutant <e2>cTnC</e2>s revealed a trend where increased alpha-helical content correlated with increased <e1>Ca(2+)</e1> sensitivity in skinned fibers and vice versa.","Regulator"
"Circular dichroism of mutant <e2>cTnC</e2>s revealed a trend where increased alpha-helical content correlated with increased <e1>Ca(2+)</e1> sensitivity in skinned fibers and vice versa.","Regulator"
"Mutations in the <e1>Ca(2+)</e1> sensor, <e2>troponin C</e2> (TnC), were generated to increase/decrease the Ca(2+) sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.","Regulator"
"Mutations in the <e1>Ca(2+)</e1> sensor, troponin C (<e2>TnC</e2>), were generated to increase/decrease the Ca(2+) sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.","Regulator"
"Mutations in the <e1>Ca(2+)</e1> sensor, <e2>troponin C</e2> (TnC), were generated to increase/decrease the Ca(2+) sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.","Regulator"
"Mutations in the <e1>Ca(2+)</e1> sensor, troponin C (<e2>TnC</e2>), were generated to increase/decrease the Ca(2+) sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.","Regulator"
"In addition, <e1>escitalopram</e1> has negligible effects on <e2>cytochrome P450</e2> drug-metabolising enzymes in vitro, suggesting a low potential for drug-drug interactions.","Not"
"Preclinical studies demonstrate that the therapeutic activity of citalopram resides in the S-isomer and that <e1>escitalopram</e1> binds with high affinity to the <e2>human serotonin transporter</e2>.","Regulator"
"Computational modeling showed the direct interaction of the <e1>carboxylic acid</e1> moiety of statins with the catalytic site of <e2>HDAC2</e2>.","Regulator"
"<e1>Statins</e1> increase <e2>p21</e2> through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.","Upregulator"
"<e1>Statins</e1> increase p21 through inhibition of histone deacetylase activity and release of promoter-associated <e2>HDAC1/2</e2>.","Upregulator"
"<e1>Statins</e1> are <e2>3-hydroxy-3-methylglutaryl-CoA reductase</e2> inhibitors broadly used for the control of hypercholesterolemia.","Downregulator"
"In the subsequent enzymatic assay, it was shown that <e1>lovastatin</e1> inhibited <e2>HDAC2</e2> activity competitively with a K(i) value of 31.6 micromol/L.","Downregulator"
"<e1>Statins</e1> increase p21 through inhibition of <e2>histone deacetylase</e2> activity and release of promoter-associated HDAC1/2.","Downregulator"
"<e1>Imatinib</e1> was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on <e2>interleukin 1alpha</e2> (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.","Not"
"<e1>Imatinib</e1> was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (<e2>IL-1alpha</e2>) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.","Not"
"<e1>Imatinib</e1> was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and <e2>receptor activator of nuclear factor kappa B ligand</e2> (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.","Not"
"<e1>Imatinib</e1> was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (<e2>RANKL</e2>)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.","Not"
"Recent studies have reported that <e1>imatinib</e1> mesylate, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (<e2>M-CSF</e2>) receptor, c-FMS.","Downregulator"
"Recent studies have reported that <e1>imatinib</e1> mesylate, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, <e2>c-FMS</e2>.","Downregulator"
"Recent studies have reported that <e1>imatinib mesylate</e1>, a kinase inhibitor that targets the intracellular <e2>tyrosine kinase</e2> BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.","Downregulator"
"Recent studies have reported that <e1>imatinib mesylate</e1>, a kinase inhibitor that targets the intracellular tyrosine kinase <e2>BCR</e2>-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.","Downregulator"
"Recent studies have reported that <e1>imatinib mesylate</e1>, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-<e2>ABL</e2> and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.","Downregulator"
"Recent studies have reported that <e1>imatinib mesylate</e1>, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the <e2>platelet derived growth factor (PDGF) receptor</e2>, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.","Downregulator"
"Recent studies have reported that <e1>imatinib mesylate</e1>, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the <e2>macrophage colony stimulating factor (M-CSF) receptor</e2>, c-FMS.","Downregulator"
"Recent studies have reported that <e1>imatinib mesylate</e1>, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, <e2>c-FMS</e2>.","Downregulator"
"Recent studies have reported that <e1>imatinib mesylate</e1>, a <e2>kinase</e2> inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.","Downregulator"
"Recent studies have reported that <e1>imatinib</e1> mesylate, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, <e2>c-FMS</e2>.","Downregulator"
"<e1>Imatinib</e1> was also found to inhibit <e2>M-CSF</e2>-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.","Downregulator"
"<e1>Imatinib</e1> was also found to inhibit <e2>M-CSF</e2>-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.","Downregulator"
"Structural basis for LFA-1 inhibition upon <e1>lovastatin</e1> binding to the <e2>CD11a I-domain</e2>.","Regulator"
"We report here that <e1>lovastatin</e1>, a drug clinically used for lowering cholesterol levels, inhibits the interaction of <e2>human LFA-1</e2> with its counter-receptor intercellular adhesion molecule-1.","Downregulator"
"We report here that <e1>lovastatin</e1>, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor <e2>intercellular adhesion molecule-1</e2>.","Downregulator"
"Structural basis for <e2>LFA-1</e2> inhibition upon <e1>lovastatin</e1> binding to the CD11a I-domain.","Downregulator"
"Particularly, the effects of <e1>doxycycline</e1> used as a non selective <e2>MMP</e2> inhibitor in experimental and clinical studies will be discussed.","Downregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"Time-dependent changes in hepatic and intestinal induction of <e2>cytochrome P450 3A</e2> after administration of <e1>dexamethasone</e1> to rats.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>cytochrome P450 3A</e2> (CYP3A) in rats using <e1>dexamethasone 21-phosphate</e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using <e1>dexamethasone 21-phosphate</e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using <e1>dexamethasone 21-phosphate</e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>cytochrome P450 3A</e2> (CYP3A) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam</e1> (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>MDZ</e1>) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Upregulator"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using <e1>dexamethasone 21-phosphate</e1> (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Substrate"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (<e1>DEX-P</e1>) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.","Substrate"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal <e2>cytochrome P450 3A</e2> (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam</e1> (MDZ) as an inducer and a substrate to CYP3A, respectively.","Substrate"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam</e1> (MDZ) as an inducer and a substrate to CYP3A, respectively.","Substrate"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (DEX-P) and <e1>midazolam</e1> (MDZ) as an inducer and a substrate to CYP3A, respectively.","Substrate"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>MDZ</e1>) as an inducer and a substrate to CYP3A, respectively.","Substrate"
"We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (<e2>CYP3A</e2>) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (<e1>MDZ</e1>) as an inducer and a substrate to CYP3A, respectively.","Substrate"
"Serotonin transporter (<e2>SERT</e2>) has been associated with drugs of abuse like d-methamphetamine (<e1>METH</e1>).","Regulator"
"<e2>Serotonin transporter</e2> (SERT) has been associated with drugs of abuse like <e1>d-methamphetamine</e1> (METH).","Regulator"
"Serotonin transporter (<e2>SERT</e2>) has been associated with drugs of abuse like <e1>d-methamphetamine</e1> (METH).","Regulator"
"Serotonin transporter (<e2>SERT</e2>) has been associated with drugs of abuse like d-methamphetamine (<e1>METH</e1>).","Regulator"
"A comparative autoradiography study of the relationship between the binding pattern of <e2>SERT</e2> in autoshaping new untrained vs. trained treated (METH, <e1>FLX</e1>, or both) animals was made.","Regulator"
"<e2>Serotonin transporter</e2> (SERT) has been associated with drugs of abuse like d-methamphetamine (<e1>METH</e1>).","Regulator"
"Serotonin transporter (<e2>SERT</e2>) has been associated with drugs of abuse like d-methamphetamine (<e1>METH</e1>).","Regulator"
"Serotonin transporter (<e2>SERT</e2>) has been associated with drugs of abuse like d-methamphetamine (<e1>METH</e1>).","Regulator"
"We previously reported that the enzyme <e1>lactate</e1> dehydrogenase (<e2>LDH</e2>) has increased activity and gene expression in placentas from preeclamptic pregnancies [Tsoi SCM, Zheng J, Xu F, Kay HH.","Substrate"
"<e2>LDH</e2> is responsible for <e1>pyruvate</e1> conversion to lactate through glycolysis.","Substrate"
"PURPOSE: <e1>Dasatinib</e1> (BMS-354825), a potent oral multi-targeted <e2>kinase</e2> inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.","Downregulator"
"PURPOSE: <e1>Dasatinib</e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against <e2>SRC</e2> and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.","Downregulator"
"PURPOSE: <e1>Dasatinib</e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR</e2>-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.","Downregulator"
"PURPOSE: <e1>Dasatinib</e1> (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL</e2>, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib</e1> (BMS-354825): a potent oral multi-targeted <e2>kinase</e2> inhibitor against SRC and BCR-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib</e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against <e2>SRC</e2> and BCR-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib</e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR</e2>-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of <e1>dasatinib</e1> (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL</e2>.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted <e2>kinase</e2> inhibitor against SRC and BCR-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted kinase inhibitor against <e2>SRC</e2> and BCR-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR</e2>-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL</e2>.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted <e2>kinase</e2> inhibitor against SRC and BCR-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted kinase inhibitor against <e2>SRC</e2> and BCR-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted kinase inhibitor against SRC and <e2>BCR</e2>-ABL.","Downregulator"
"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (<e1>BMS-354825</e1>): a potent oral multi-targeted kinase inhibitor against SRC and BCR-<e2>ABL</e2>.","Downregulator"
"<e1>BMY 7378</e1> displayed high affinity for cloned <e2>human alpha 1D-adrenoceptors</e2> (pKi = 8.2 +/- 0.10) and was selective over alpha 1A (pKi = 6.2 +/- 0.10) and alpha 1B subtypes (6.7 +/- 0.11).","Regulator"
"WB 4101, <e1>benoxathian</e1> and phentolamine displayed high affinity for <e2>alpha 1A and alpha 1D adrenoceptors</e2> compared to the alpha 1B subtype.","Regulator"
"WB 4101, benoxathian and <e1>phentolamine</e1> displayed high affinity for <e2>alpha 1A and alpha 1D adrenoceptors</e2> compared to the alpha 1B subtype.","Regulator"
"<e1>Spiperone</e1> displayed high affinity and selectivity for <e2>alpha 1B adrenoceptors</e2> (pKi 8.8 +/- 0.16).","Regulator"
"The affinities of a number of alpha 1-adrenoceptor antagonists were determined by displacement of <e1>[3H]-prazosin</e1> binding from cloned <e2>human alpha 1A-adrenoceptors</e2> (previously designated cloned alpha 1c subtype), alpha 1B alpha 1D and rat alpha 1D-adrenoceptors, stably expressed in rat-1 fibroblasts.","Regulator"
"The affinities of a number of alpha 1-adrenoceptor antagonists were determined by displacement of <e1>[3H]-prazosin</e1> binding from cloned human alpha 1A-adrenoceptors (previously designated cloned alpha 1c subtype), alpha 1B alpha 1D and <e2>rat alpha 1D-adrenoceptors</e2>, stably expressed in rat-1 fibroblasts.","Regulator"
"The affinities of a number of <e2>alpha 1-adrenoceptor</e2> antagonists were determined by displacement of <e1>[3H]-prazosin</e1> binding from cloned human alpha 1A-adrenoceptors (previously designated cloned alpha 1c subtype), alpha 1B alpha 1D and rat alpha 1D-adrenoceptors, stably expressed in rat-1 fibroblasts.","Regulator"
"<e1>5-Methyl-urapidil</e1> was selective for cloned <e2>alpha 1A adrenoceptors</e2>.","Regulator"
"Characterization of an <e2>alpha 1D-adrenoceptor</e2> mediating the contractile response of rat aorta to <e1>noradrenaline</e1>.","Regulator"
"The results of this study suggest that <e1>noradrenaline</e1> predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an <e2>alphalD-adrenoceptor</e2>.","Upregulator"
"An increase in the <e1>ADP</e1>/ATP ratio opens <e2>K(ATP) channels</e2>, leading to membrane hyperpolarization.","Upregulator"
"An increase in the ADP/<e1>ATP</e1> ratio opens <e2>K(ATP) channels</e2>, leading to membrane hyperpolarization.","Upregulator"
"Comparison of the effect of <e1>rofecoxib</e1> (a <e2>cyclooxygenase 2</e2> inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.","Downregulator"
"Comparison of the effect of <e1>rofecoxib</e1> (a <e2>cyclooxygenase 2</e2> inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.","Downregulator"
"<e1>[-]-Huperzine A</e1> ([-]-Hup A), is a naturally occurring potent reversible <e2>AChE</e2> inhibitor that penetrates the blood-brain barrier.","Downregulator"
"[-]-Huperzine A (<e1>[-]-Hup A</e1>), is a naturally occurring potent reversible <e2>AChE</e2> inhibitor that penetrates the blood-brain barrier.","Downregulator"
"The synthetic stereoisomer, <e1>[+]-Hup A</e1>, is less toxic due to poor <e2>AChE</e2> inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.","Downregulator"
"In the present study, the exposure of melanoma cells to <e1>vinblastine</e1> was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both <e2>cytochrome c</e2> and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase.","Regulator"
"In the present study, the exposure of melanoma cells to <e1>vinblastine</e1> was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and <e2>apoptosis inducing factor</e2>, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase.","Regulator"
"In the present study, the exposure of melanoma cells to <e1>vinblastine</e1> was found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of <e2>Poly (ADP-ribose)-Polymerase</e2>.","Regulator"
"<e1>Vinblastine</e1>-induced apoptosis of melanoma cells is mediated by <e2>Ras homologous A protein</e2> (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms.","Regulator"
"<e1>Vinblastine</e1>-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (<e2>Rho A</e2>) via mitochondrial and non-mitochondrial-dependent mechanisms.","Regulator"
"In addition, <e1>vinblastine</e1> induces the DNA-binding activities of the transcription factor <e2>NF-κB</e2>, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.","Upregulator"
"In addition, <e1>vinblastine</e1> induces the DNA-binding activities of the transcription factor NF-κB, <e2>HSF1</e2>, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.","Upregulator"
"In addition, <e1>vinblastine</e1> induces the DNA-binding activities of the transcription factor NF-κB, HSF1, <e2>AP-1</e2>, and ATF-2, together with the expression of HSP70 and Bax proteins.","Upregulator"
"In addition, <e1>vinblastine</e1> induces the DNA-binding activities of the transcription factor NF-κB, HSF1, AP-1, and <e2>ATF-2</e2>, together with the expression of HSP70 and Bax proteins.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of <e2>Ras homologous protein A</e2>, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of <e2>apoptosis signal-regulating kinase 1</e2>, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, <e2>c-jun-N-terminal kinase</e2>, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, <e2>p38</e2>, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, <e2>inhibitor of kappaBα</e2> (IκBα) kinase, and inositol requiring enzyme 1α.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (<e2>IκBα</e2>) kinase, and inositol requiring enzyme 1α.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating <e2>kinase</e2> 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and inositol requiring enzyme 1α.","Upregulator"
"Also, <e1>vinblastine</e1> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBα (IκBα) kinase, and <e2>inositol requiring enzyme 1α</e2>.","Upregulator"
"In addition, <e1>vinblastine</e1> induces the DNA-binding activities of the transcription factor NF-κB, HSF1, AP-1, and ATF-2, together with the expression of <e2>HSP70</e2> and Bax proteins.","Upregulator"
"In addition, <e1>vinblastine</e1> induces the DNA-binding activities of the transcription factor NF-κB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and <e2>Bax</e2> proteins.","Upregulator"
"The deduced <e1>amino acid</e1> sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other <e2>PDE</e2> families.","Part_of"
"The deduced amino acid sequence contains 779 <e1>amino acids</e1>, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other <e2>PDE</e2> families.","Part_of"
"The deduced <e1>amino</e1> acid sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other <e2>PDE</e2> families.","Part_of"
"The deduced <e1>amino acid</e1> sequence contains 779 amino acids, including a putative cGMP binding sequence in the amino-terminal portion of the molecule and a catalytic domain that is 16-47% identical in amino acid sequence to those of other <e2>PDE</e2> families.","Part_of"
"Of the <e2>PDE</e2> inhibitors tested, <e1>dipyridamole</e1> was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively.","Downregulator"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both <e1>cAMP</e1> and cGMP (<e2>PDE</e2>10A).","Substrate"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and <e1>cGMP</e1> (<e2>PDE</e2>10A).","Substrate"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both <e1>cAMP</e1> and cGMP (<e2>PDE10A</e2>).","Substrate"
"Cloning and characterization of a novel <e2>human phosphodiesterase</e2> that hydrolyzes both <e1>cAMP</e1> and cGMP (PDE10A).","Substrate"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and <e1>cGMP</e1> (<e2>PDE10A</e2>).","Substrate"
"Cloning and characterization of a novel <e2>human phosphodiesterase</e2> that hydrolyzes both cAMP and <e1>cGMP</e1> (PDE10A).","Substrate"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both <e1>cAMP</e1> and cGMP (<e2>PDE10A</e2>).","Substrate"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and <e1>cGMP</e1> (<e2>PDE10A</e2>).","Substrate"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and <e1>cGMP</e1> (<e2>PDE10A</e2>).","Substrate"
"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both <e1>cAMP</e1> and cGMP (<e2>PDE10A</e2>).","Substrate"
"Effects of <e1>5-aza-2'-deoxycytidine</e1> on <e2>fetal hemoglobin</e2> levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.","Regulator"
"We examined if subcutaneous <e1>decitabine</e1> could increase <e2>HbF</e2> levels and improve SSD pathophysiology without cytotoxicity.","Upregulator"
"Weekly subcutaneous <e1>decitabine</e1> produces cumulative increases in HbF and total <e2>hemoglobin</e2> through a noncytotoxic mechanism of action.","Upregulator"
"We examined if subcutaneous <e1>decitabine</e1> could increase <e2>HbF</e2> levels and improve SSD pathophysiology without cytotoxicity.","Upregulator"
"The <e1>cytosine</e1> analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting <e2>DNA methyltransferase</e2>.","Downregulator"
"The cytosine analog <e1>5-aza-2'-deoxycytidine</e1> (decitabine) hypomethylates DNA by inhibiting <e2>DNA methyltransferase</e2>.","Downregulator"
"The cytosine analog 5-aza-2'-deoxycytidine (<e1>decitabine</e1>) hypomethylates DNA by inhibiting <e2>DNA methyltransferase</e2>.","Downregulator"
"Interestingly, <e2>Nox4</e2> activity is also stimulated by reducing agents that possibly act by reducing the disulfide bridge (<e1>Cys</e1>226, Cys270) located in the extracellular E-loop of Nox4.","Part_of"
"Interestingly, <e2>Nox4</e2> activity is also stimulated by reducing agents that possibly act by reducing the disulfide bridge (<e1>Cys</e1>226, Cys270) located in the extracellular E-loop of Nox4.","Part_of"
"<e1>Quinone</e1> compounds regulate the level of ROS production by the <e2>NADPH oxidase</e2> Nox4.","Regulator"
"<e1>Quinone</e1> compounds regulate the level of ROS production by the NADPH oxidase <e2>Nox4</e2>.","Regulator"
"Such model of <e2>Nox4</e2> activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which <e1>quinones</e1> and Nox4 are implicated.","Upregulator"
"<e2>Nox4</e2> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>quinone</e1> derivatives could modulate this activity.","Upregulator"
"Nox4 <e2>oxidase</e2> activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>quinone</e1> derivatives could modulate this activity.","Upregulator"
"<e2>Nox4</e2> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>quinone</e1> derivatives could modulate this activity.","Upregulator"
"In fact, we demonstrated a significant stimulation of <e2>Nox4</e2> activity by 4 quinone derivatives (<e1>AA-861</e1>, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines.","Upregulator"
"In fact, we demonstrated a significant stimulation of <e2>Nox4</e2> activity by 4 quinone derivatives (AA-861, <e1>tBuBHQ</e1>, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines.","Upregulator"
"In fact, we demonstrated a significant stimulation of <e2>Nox4</e2> activity by 4 quinone derivatives (AA-861, tBuBHQ, <e1>tBuBQ</e1>, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines.","Upregulator"
"In fact, we demonstrated a significant stimulation of <e2>Nox4</e2> activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and <e1>duroquinone</e1>) observed in 3 different cellular models, HEK293E, T-REx™, and chondrocyte cell lines.","Upregulator"
"<e2>Nox4</e2> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>quinone</e1> derivatives could modulate this activity.","Upregulator"
"Nox4 <e2>oxidase</e2> activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific <e1>quinone</e1> derivatives could modulate this activity.","Upregulator"
"Although the inhibition of <e2>cyclooxygenases</e2> by <e1>aspirin</e1>, which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined.","Regulator"
"In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of <e1>aspirin</e1> to acetylate the <e2>tumor suppressor protein p53</e2>.","Upregulator"
"Although the inhibition of <e2>cyclooxygenases</e2> by <e1>aspirin</e1>, which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined.","Downregulator"
"<e1>Camptothecin</e1> (CPT), a <e2>topoisomerase (Top) I</e2>-targeting drug that stabilizes Top1-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.","Regulator"
"<e1>Camptothecin</e1> (CPT), a topoisomerase (Top) I-targeting drug that stabilizes <e2>Top1</e2>-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.","Regulator"
"Camptothecin (<e1>CPT</e1>), a <e2>topoisomerase (Top) I</e2>-targeting drug that stabilizes Top1-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.","Regulator"
"Camptothecin (<e1>CPT</e1>), a topoisomerase (Top) I-targeting drug that stabilizes <e2>Top1</e2>-DNA covalent adducts, can induce S-phase-specific cytotoxicity due to the arrest of progressing replication forks.","Regulator"
"In this study, we have identified <e2>topoisomerase IIβ</e2> (Top2β) as a specific determinant for <e1>CPT</e1> sensitivity, but not for many other cytotoxic agents, in non-S-phase cells.","Regulator"
"In this study, we have identified topoisomerase IIβ (<e2>Top2β</e2>) as a specific determinant for <e1>CPT</e1> sensitivity, but not for many other cytotoxic agents, in non-S-phase cells.","Regulator"
"Altogether, our findings support a model in which Top2β deficiency promotes <e1>CPT</e1>-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and <e2>p53</e2> accumulation.","Upregulator"
"To explore the molecular basis for <e1>CPT</e1> hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the <e2>RNA polymerase II large subunit</e2> (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells.","Downregulator"
"To explore the molecular basis for <e1>CPT</e1> hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (<e2>RNAP LS</e2>) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells.","Downregulator"
"To explore the molecular basis for <e1>CPT</e1> hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (<e2>RNAP LS</e2>) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells.","Downregulator"
"To explore the molecular basis for <e1>CPT</e1> hypersensitivity in Top2β-deficient cells, we found that upon CPT exposure, the RNA polymerase II large subunit (<e2>RNAP LS</e2>) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2β-deficient cells.","Downregulator"
"Second, <e1>ICRF-187</e1>, a <e2>Top2</e2> catalytic inhibitor known to deplete Top2β, specifically sensitized MEFs to CPT.","Downregulator"
"Second, <e1>ICRF-187</e1>, a Top2 catalytic inhibitor known to deplete <e2>Top2β</e2>, specifically sensitized MEFs to CPT.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and <e1>t-butyl</e1>) exhibiting different pharmacological potencies.","Not"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and <e1>t-butyl</e1>) exhibiting different pharmacological potencies.","Not"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, <e2>caldesmon kinase</e2> and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and <e1>t-butyl</e1>) exhibiting different pharmacological potencies.","Not"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, <e2>caldesmon kinase</e2> and myosin light chain kinase) of the dihydropyridine <e1>Ca2+</e1> channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin light chain kinase</e2>) of the dihydropyridine <e1>Ca2+</e1> channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine <e1>Ca2+</e1> channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, <e2>caldesmon kinase</e2> and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin light chain kinase</e2>) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"Effects of <e1>felodipine</e1> (a dihydropyridine calcium channel blocker) and analogues on <e2>calmodulin-dependent enzymes</e2>.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, <e2>caldesmon kinase</e2> and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin light chain kinase</e2>) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three <e2>calmodulin-dependent enzymes</e2> (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, <e2>caldesmon kinase</e2> and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and <e1>t-butyl</e1>) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin light chain kinase</e2>) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and <e1>t-butyl</e1>) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three <e2>calmodulin-dependent enzymes</e2> (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and <e1>t-butyl</e1>) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and <e1>t-butyl</e1>) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP <e2>phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"Effects of <e1>felodipine</e1> (a dihydropyridine calcium channel blocker) and analogues on <e2>calmodulin</e2>-dependent enzymes.","Regulator"
"Finally, the effects of <e1>felodipine</e1> and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated <e2>Mg2+-ATPase</e2> activity of myosin and the assembly of myosin filaments.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Regulator"
"Effects of felodipine (a <e1>dihydropyridine</e1> calcium channel blocker) and analogues on <e2>calmodulin-dependent enzymes</e2>.","Regulator"
"Felodipine and the <e1>p-chloro</e1> analogue inhibited the actin-activated <e2>Mg2+-ATPase</e2> activity of smooth muscle myosin (IC50 = 25.1 microM).","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine <e2>Ca2+ channel</e2> blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"Finally, the effects of <e1>felodipine</e1> and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated <e2>Mg2+-ATPase</e2> activity of myosin and the assembly of myosin filaments.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"Felodipine and the <e1>p-chloro</e1> analogue inhibited the actin-activated <e2>Mg2+-ATPase</e2> activity of smooth muscle myosin (IC50 = 25.1 microM).","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin</e2> light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"Effects of <e1>felodipine</e1> (a dihydropyridine calcium channel blocker) and analogues on <e2>calmodulin-dependent enzymes</e2>.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"<e1>Felodipine</e1> and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of <e2>cAMP phosphodiesterase</e2> as well as the calmodulin-stimulated activity.","Downregulator"
"<e1>Felodipine</e1> and the p-chloro analogue inhibited the basal (Ca2+/<e2>calmodulin</e2>-independent) activity of cAMP phosphodiesterase as well as the calmodulin-stimulated activity.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three <e2>calmodulin</e2>-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (<e2>cAMP phosphodiesterase</e2>, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"<e1>Felodipine</e1> and the p-chloro analogue inhibited Ca2+/calmodulin-dependent <e2>caldesmon kinase</e2> with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, <e2>caldesmon kinase</e2> and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin light chain kinase</e2>) of the dihydropyridine Ca2+ channel blocker <e1>felodipine</e1> and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"Effects of <e1>felodipine</e1> (a dihydropyridine <e2>calcium channel</e2> blocker) and analogues on calmodulin-dependent enzymes.","Downregulator"
"Effects of felodipine (a <e1>dihydropyridine</e1> <e2>calcium channel</e2> blocker) and analogues on calmodulin-dependent enzymes.","Downregulator"
"We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and <e2>myosin light chain kinase</e2>) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (<e1>p-chloro</e1>, oxidized and t-butyl) exhibiting different pharmacological potencies.","Downregulator"
"<e1>Felodipine</e1> and the p-chloro analogue inhibited the actin-activated <e2>Mg2+-ATPase</e2> activity of smooth muscle myosin (IC50 = 25.1 microM).","Downregulator"
"<e1>Felodipine</e1> and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle <e2>myosin</e2> (IC50 = 25.1 microM).","Downregulator"
"We report rapid ENaCγ translocation to the plasma membrane after 30min <e1>aldosterone</e1> treatment in polarized M1 cortical collecting duct cells, which was significantly impaired in <e2>PKD1</e2> shRNA-mediated knockdown cells.","Regulator"
"PKD1 and <e2>PI4KIIIβ</e2> localize to the TGN, and <e1>aldosterone</e1> induced an interaction between PKD1 and PI4KIIIβ following aldosterone treatment.","Regulator"
"<e1>Aldosterone</e1>-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via <e2>protein kinase D1</e2>-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.","Regulator"
"<e1>Aldosterone</e1>-induced ENaC and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-<e2>phosphatidylinositol 4-kinaseIIIβ</e2> trans Golgi signalling in M1 cortical collecting duct cells.","Regulator"
"<e1>Aldosterone</e1> regulates Na(+) transport in the distal nephron through multiple mechanisms that include the transcriptional control of epithelial <e2>sodium channel</e2> (ENaC) and Na(+)/K(+)-ATPase subunits.","Regulator"
"<e1>Aldosterone</e1>-induced <e2>ENaC</e2> and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.","Regulator"
"<e1>Aldosterone</e1>-induced ENaC and basal <e2>Na(+)/K(+)-ATPase</e2> trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.","Regulator"
"<e1>Aldosterone</e1> also induces the rapid phosphorylation of <e2>Protein Kinase D1</e2> (PKD1).","Upregulator"
"<e1>Aldosterone</e1> also induces the rapid phosphorylation of Protein Kinase D1 (<e2>PKD1</e2>).","Upregulator"
"<e1>Aldosterone</e1>-induced <e2>ENaC</e2> and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.","Upregulator"
"<e1>Aldosterone</e1>-induced ENaC and basal <e2>Na(+)/K(+)-ATPase</e2> trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIIIβ trans Golgi signalling in M1 cortical collecting duct cells.","Upregulator"
"The role of <e2>5-HT(1A)</e2> and 5-HT(1B/1D) receptors on the modulation of acute <e1>fluoxetine</e1>-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol.","Regulator"
"The role of <e2>5-HT(1A)</e2> and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of <e1>(+/-)pindolol</e1>.","Antagonist"
"The role of <e2>5-HT(1A)</e2> and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)<e1>pindolol</e1>.","Antagonist"
"The role of <e2>5-HT(1A)</e2> and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of <e1>(+/-)pindolol</e1>.","Antagonist"
"In the present study, we compared the pharmacology of (+/-)pindolol, <e1>WAY-100635</e1> (a <e2>5-HT(1A)</e2> antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.","Antagonist"
"In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and <e1>isamoltane</e1> (a <e2>5-HT(1B)</e2> antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.","Antagonist"
"Local LC <e1>citalopram</e1> effect was abolished by LC presence of the <e2>5-HT3</e2> receptor antagonist MDL72222 (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM).","Regulator"
"Local LC <e1>citalopram</e1> effect was abolished by LC presence of the <e2>5-HT3</e2> receptor antagonist MDL72222 (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM).","Regulator"
"In the local presence into the LC of the <e2>α2-adrenoceptor</e2> antagonist <e1>RS79948</e1> (1 μM), systemic citalopram increased NA in the LC (Emax = 157 ± 25 %) and PFC (Emax = 175 ± 24 %).","Antagonist"
"Local LC citalopram effect was abolished by LC presence of the <e2>5-HT3</e2> receptor antagonist <e1>MDL72222</e1> (1 μM) but not the 5-HT1/2 receptor antagonist methiothepin (1 μM).","Antagonist"
"Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1 μM) but not the <e2>5-HT1/2</e2> receptor antagonist <e1>methiothepin</e1> (1 μM).","Antagonist"
"alpha(1)-Adrenoceptor antagonists were tested against the <e1>phenylephrine</e1> (<e2>alpha(1)-adrenoceptor</e2> agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.","Agonist"
"alpha(1)-Adrenoceptor antagonists were tested against the <e1>phenylephrine</e1> (<e2>alpha(1)-adrenoceptor</e2> agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.","Agonist"
"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective <e2>alpha(1A)-adrenoceptor</e2> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the <e1>phenylephrine</e1>-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","Agonist"
"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <e2>alpha(1D)-adrenoceptor</e2> antagonist) competitively antagonized the <e1>phenylephrine</e1>-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","Agonist"
"alpha(1)-Adrenoceptor antagonists were tested against the <e1>phenylephrine</e1> (<e2>alpha(1)-adrenoceptor</e2> agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.","Agonist"
"<e1>Noradrenaline</e1> and phenylephrine (<e2>alpha(1)-adrenoceptor</e2> agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.","Agonist"
"<e1>Prazosin</e1> (nonselective <e2>alpha(1)-adrenoceptor</e2> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","Antagonist"
"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), <e1>silodosin</e1> (selective <e2>alpha(1A)-adrenoceptor</e2> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","Antagonist"
"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and <e1>BMY-7378</e1> (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective <e2>alpha(1D)-adrenoceptor</e2> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","Antagonist"
"Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (<e1>8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride</e1>) (selective <e2>alpha(1D)-adrenoceptor</e2> antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).","Antagonist"
"<e1>BDZs</e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs</e2>), which could contribute to reduced neuronal excitability.","Not"
"Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (<e2>I1150A</e2>) did not affect <e1>diazepam</e1> potency.","Downregulator"
"<e1>BDZs</e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCC</e2>s), which could contribute to reduced neuronal excitability.","Downregulator"
"The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, <e1>pentobarbital</e1>, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3 <e2>L-VGCCs</e2> expressed with beta(3) and alpha(2)delta-1 in HEK293T cells.","Downregulator"
"BDZs and other positive GABA(A)R modulators, including <e1>barbiturates</e1>, ethanol, and neurosteroids, can also inhibit <e2>L-type voltage-gated calcium channels</e2> (L-VGCCs), which could contribute to reduced neuronal excitability.","Downregulator"
"BDZs and other positive GABA(A)R modulators, including <e1>barbiturates</e1>, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs</e2>), which could contribute to reduced neuronal excitability.","Downregulator"
"BDZs and other positive GABA(A)R modulators, including barbiturates, <e1>ethanol</e1>, and neurosteroids, can also inhibit <e2>L-type voltage-gated calcium channels</e2> (L-VGCCs), which could contribute to reduced neuronal excitability.","Downregulator"
"BDZs and other positive GABA(A)R modulators, including barbiturates, <e1>ethanol</e1>, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs</e2>), which could contribute to reduced neuronal excitability.","Downregulator"
"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and <e1>neurosteroids</e1>, can also inhibit <e2>L-type voltage-gated calcium channels</e2> (L-VGCCs), which could contribute to reduced neuronal excitability.","Downregulator"
"BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and <e1>neurosteroids</e1>, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs</e2>), which could contribute to reduced neuronal excitability.","Downregulator"
"The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, <e1>pentobarbital</e1>, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and <e2>Ca(v)1.3</e2> L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells.","Downregulator"
"The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, <e1>pentobarbital</e1>, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal <e2>Ca(v)1.2</e2> and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells.","Downregulator"
"<e2>Ca(v)1.3</e2> channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to <e1>dihydropyridine</e1> (DHP) L-VGCC antagonists.","Downregulator"
"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than <e2>Ca(v)1.2</e2> channels, similar to <e1>dihydropyridine</e1> (DHP) L-VGCC antagonists.","Downregulator"
"<e2>Ca(v)1.3</e2> channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (<e1>DHP</e1>) L-VGCC antagonists.","Downregulator"
"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than <e2>Ca(v)1.2</e2> channels, similar to dihydropyridine (<e1>DHP</e1>) L-VGCC antagonists.","Downregulator"
"The current studies assessed the effects of <e1>BDZs</e1> (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal <e2>Ca(v)1.2</e2> and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells.","Downregulator"
"The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, <e1>pentobarbital</e1>, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal <e2>Ca(v)1.2</e2> and Ca(v)1.3 L-VGCCs expressed with beta(3) and alpha(2)delta-1 in HEK293T cells.","Downregulator"
"<e1>BDZs</e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit <e2>L-type voltage-gated calcium channels</e2> (L-VGCCs), which could contribute to reduced neuronal excitability.","Downregulator"
"<e1>BDZs</e1> and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (<e2>L-VGCCs</e2>), which could contribute to reduced neuronal excitability.","Downregulator"
"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to <e1>dihydropyridine</e1> (DHP) <e2>L-VGCC</e2> antagonists.","Antagonist"
"Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (<e1>DHP</e1>) <e2>L-VGCC</e2> antagonists.","Antagonist"
"Benzodiazepines (<e1>BDZs</e1>) depress neuronal excitability via positive allosteric modulation of inhibitory <e2>GABA(A) receptors</e2> (GABA(A)R).","Modulator"
"Benzodiazepines (<e1>BDZs</e1>) depress neuronal excitability via positive allosteric modulation of inhibitory GABA(A) receptors (<e2>GABA(A)R</e2>).","Modulator"
"<e1>Benzodiazepines</e1> (BDZs) depress neuronal excitability via positive allosteric modulation of inhibitory <e2>GABA(A) receptors</e2> (GABA(A)R).","Modulator"
"<e1>Benzodiazepines</e1> (BDZs) depress neuronal excitability via positive allosteric modulation of inhibitory GABA(A) receptors (<e2>GABA(A)R</e2>).","Modulator"
"BDZs and other positive <e2>GABA(A)R</e2> modulators, including <e1>barbiturates</e1>, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability.","Modulator"
"BDZs and other positive <e2>GABA(A)R</e2> modulators, including barbiturates, <e1>ethanol</e1>, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability.","Modulator"
"BDZs and other positive <e2>GABA(A)R</e2> modulators, including barbiturates, ethanol, and <e1>neurosteroids</e1>, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability.","Modulator"
"Benzodiazepines (<e1>BDZs</e1>) depress neuronal excitability via positive allosteric modulation of inhibitory GABA(A) receptors (<e2>GABA(A)R</e2>).","Modulator"
"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>5HHMF</e1>) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>iNOS</e2>) in BV2 microglia.","Regulator"
"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>5HHMF</e1>) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>iNOS</e2>) in BV2 microglia.","Regulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (HO-1) expression via <e2>nuclear factor-erythroid 2-related factor 2</e2> (Nrf2) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>Nrf2</e2>) activation.","Upregulator"
"In addition, <e1>cobalt protoporphyrin</e1> (CoPP), a specific <e2>HO-1</e2> inducer, predominantly suppressed LPS-induced NO production.","Upregulator"
"In addition, cobalt protoporphyrin (<e1>CoPP</e1>), a specific <e2>HO-1</e2> inducer, predominantly suppressed LPS-induced NO production.","Upregulator"
"<e1>5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone</e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and <e2>Nrf-2</e2>-dependent heme oxygenase-1 induction.","Upregulator"
"<e1>5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone</e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-κB suppression and Nrf-2-dependent <e2>heme oxygenase-1</e2> induction.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>Nrf2</e2>) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>Nrf2</e2>) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (<e2>HO-1</e2>) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances <e2>heme oxygenase-1</e2> (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (<e2>HO-1</e2>) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (<e2>HO-1</e2>) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>Nrf2</e2>) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>Nrf2</e2>) activation.","Upregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (<e2>Nrf2</e2>) activation.","Upregulator"
"In addition, 5HHMF blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (<e2>NF-κB</e2>) subunits, namely p65 and p50, which are important molecules involved in the regulation of i<e1>NO</e1>S expression.","Downregulator"
"Further, 5HHMF increased specific DNA-binding activity of <e2>Nrf2</e2>, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced <e1>NO</e1> inhibition, which was followed by suppression of HO-1 activity.","Downregulator"
"In addition, cobalt protoporphyrin (CoPP), a specific <e2>HO-1</e2> inducer, predominantly suppressed LPS-induced <e1>NO</e1> production.","Downregulator"
"In addition, cobalt protoporphyrin (CoPP), a specific <e2>HO-1</e2> inducer, predominantly suppressed LPS-induced <e1>NO</e1> production.","Downregulator"
"In addition, <e1>5HHMF</e1> blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of <e2>nuclear factor-κB</e2> (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.","Downregulator"
"In addition, <e1>5HHMF</e1> blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (<e2>NF-κB</e2>) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.","Downregulator"
"In addition, <e1>5HHMF</e1> blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely <e2>p65</e2> and p50, which are important molecules involved in the regulation of iNOS expression.","Downregulator"
"In addition, <e1>5HHMF</e1> blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and <e2>p50</e2>, which are important molecules involved in the regulation of iNOS expression.","Downregulator"
"In this study, we found that <e1>5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone</e1> (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of <e2>inducible NO synthase</e2> (iNOS) in BV2 microglia.","Downregulator"
"In this study, we found that <e1>5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone</e1> (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>iNOS</e2>) in BV2 microglia.","Downregulator"
"<e1>Pyrrolidine dithiocarbamate</e1> (PDTC), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced <e2>iNOS</e2> expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity.","Downregulator"
"Pyrrolidine dithiocarbamate (<e1>PDTC</e1>), a specific NF-κB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced <e2>iNOS</e2> expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity.","Downregulator"
"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>5HHMF</e1>) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>iNOS</e2>) in BV2 microglia.","Downregulator"
"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>5HHMF</e1>) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of <e2>inducible NO synthase</e2> (iNOS) in BV2 microglia.","Downregulator"
"In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (<e1>5HHMF</e1>) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (<e2>iNOS</e2>) in BV2 microglia.","Downregulator"
"In addition, <e1>5HHMF</e1> blocked LPS-induced phosphorylation of <e2>IκB</e2>, resulting in suppression of the nuclear translocation of nuclear factor-κB (NF-κB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.","Downregulator"
"<e1>Pyrrolidine dithiocarbamate</e1> (PDTC), a specific <e2>NF-κB</e2> inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity.","Downregulator"
"Pyrrolidine dithiocarbamate (<e1>PDTC</e1>), a specific <e2>NF-κB</e2> inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-κB activity.","Downregulator"
"In addition, <e1>5HHMF</e1> blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (<e2>NF-κB</e2>) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.","Downregulator"
"<e1>5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone</e1> inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via <e2>NF-κB</e2> suppression and Nrf-2-dependent heme oxygenase-1 induction.","Downregulator"
"In contrast, <e1>zinc protoporphyrin</e1> (ZnPP), a specific <e2>HO-1</e2> inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.","Downregulator"
"In contrast, zinc protoporphyrin (<e1>ZnPP</e1>), a specific <e2>HO-1</e2> inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.","Downregulator"
"Thus, we found that <e1>5HHMF</e1> enhances heme oxygenase-1 (<e2>HO-1</e2>) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.","Downregulator"
"In addition, <e1>5HHMF</e1> blocked LPS-induced phosphorylation of IκB, resulting in suppression of the nuclear translocation of nuclear factor-κB (<e2>NF-κB</e2>) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.","Downregulator"
"Synthesis and antitumor activity of <e1>1,3,4-oxadiazole</e1> possessing 1,4-benzodioxan moiety as a novel class of potent <e2>methionine aminopeptidase type II</e2> inhibitors.","Downregulator"
"Synthesis and antitumor activity of 1,3,4-oxadiazole possessing <e1>1,4-benzodioxan</e1> moiety as a novel class of potent <e2>methionine aminopeptidase type II</e2> inhibitors.","Downregulator"
"One of the <e2>CB2</e2> agonists, <e1>N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine</e1> (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.","Agonist"
"Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted <e1>1,3,5-triazine</e1>s as <e2>CB2</e2> agonists.","Agonist"
"Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of <e1>2,4,6-trisubstituted 1,3,5-triazines</e1> as <e2>CB2</e2> agonists.","Agonist"
"Purified <e2>PAOh1</e2>/SMO oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize <e1>spermidine</e1>.","Not"
"Purified PAOh1/<e2>SMO</e2> oxidizes both spermine (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize <e1>spermidine</e1>.","Not"
"Properties of purified recombinant human <e1>polyamine</e1> oxidase, <e2>PAOh1</e2>/SMO.","Not"
"Properties of purified recombinant human <e1>polyamine</e1> oxidase, PAOh1/<e2>SMO</e2>.","Not"
"Purified <e2>PAOh1</e2>/SMO oxidizes both <e1>spermine</e1> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.","Substrate"
"Purified PAOh1/<e2>SMO</e2> oxidizes both <e1>spermine</e1> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.","Substrate"
"Purified <e2>PAOh1</e2>/SMO oxidizes both spermine (K(m)=1.6 microM) and <e1>N(1)-acetylspermine</e1> (K(m)=51 microM), but does not oxidize spermidine.","Substrate"
"Purified PAOh1/<e2>SMO</e2> oxidizes both spermine (K(m)=1.6 microM) and <e1>N(1)-acetylspermine</e1> (K(m)=51 microM), but does not oxidize spermidine.","Substrate"
"Purified <e2>PAOh1</e2>/SMO oxidizes both <e1>spermine</e1> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.","Substrate"
"Purified PAOh1/<e2>SMO</e2> oxidizes both <e1>spermine</e1> (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.","Substrate"
"The discovery of an inducible <e2>oxidase</e2> whose apparent substrate preference is <e1>spermine</e1> indicates that polyamine catabolism is more complex than that originally proposed.","Substrate"
"), an analogue of <e1>okadaic acid</e1> lacking activity against <e2>protein phosphatases</e2>, did not affect the antinociceptive effect of morphine.","Not"
"Neither <e1>okadaic acid</e1> nor cantharidin (1-10000 nM) displaced [3H]naloxone from its specific binding sites, which indicates that they do not interact at the <e2>opioid receptor</e2> level.","Not"
"Neither okadaic acid nor <e1>cantharidin</e1> (1-10000 nM) displaced [3H]naloxone from its specific binding sites, which indicates that they do not interact at the <e2>opioid receptor</e2> level.","Not"
"Neither okadaic acid nor cantharidin (1-10000 nM) displaced <e1>[3H]naloxone</e1> from its specific binding sites, which indicates that they do not interact at the <e2>opioid receptor</e2> level.","Not"
"These results suggest that the activation of <e2>type 2A serine/threonine protein phosphatases</e2> may play a role in the antinociceptive effect of <e1>morphine</e1>, and that PP1 might counterbalace this activity.","Regulator"
"administration of very low doses of <e1>okadaic acid</e1> (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit <e2>PP2A</e2>, produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).","Downregulator"
"administration of very low doses of okadaic acid (0.001-1 pg/mouse) and <e1>cantharidin</e1> (0.001-1 ng/mouse), which inhibit <e2>PP2A</e2>, produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).","Downregulator"
"), which also block <e2>PP1</e2>, and <e1>calyculin-A</e1> (0.1 fg/mouse-1 ng/mouse, i.c.v.","Downregulator"
"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid</e1>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid</e1>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid</e1>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as <e1>p-hydroxybenzoic acid</e1>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"<e1>Phenols</e1> like the ones investigated here possess a <e2>CA</e2> inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.","Downregulator"
"Phenols like the ones investigated here possess a <e2>CA</e2> inhibition mechanism distinct of that of the <e1>sulfonamides</e1>/sulfamates used clinically or the coumarins.","Downregulator"
"Phenols like the ones investigated here possess a <e2>CA</e2> inhibition mechanism distinct of that of the sulfonamides/<e1>sulfamates</e1> used clinically or the coumarins.","Downregulator"
"Phenols like the ones investigated here possess a <e2>CA</e2> inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the <e1>coumarins</e1>.","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid</e1>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid</e1>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid</e1>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, <e1>p-coumaric acid</e1>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid</e1>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid</e1>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid</e1>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, <e1>caffeic acid</e1>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"Inhibition of <e2>mammalian isoforms I-XIV</e2> with a series of natural product <e1>polyphenols</e1> and phenolic acids.","Downregulator"
"Inhibition of <e2>mammalian isoforms I-XIV</e2> with a series of natural product polyphenols and <e1>phenolic acids</e1>.","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid</e1>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid</e1>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid</e1>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, <e1>ferulic acid</e1>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"A series of <e1>phenolic acids</e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of <e1>phenolic acids</e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of <e1>phenolic acids</e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of <e1>phenolic acids</e1> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid</e1>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid</e1>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid</e1>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, <e1>gallic acid</e1>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid</e1>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid</e1>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid</e1>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, <e1>syringic acid</e1>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin</e1>, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin</e1>, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin</e1>, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, <e1>quercetin</e1>, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid</e1>, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid</e1>, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid</e1>, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and <e1>ellagic acid</e1>, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"A series of <e1>phenol</e1>ic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the <e2>metalloenzyme</e2> carbonic anhydrase (CA, EC 4.2.1.1).","Downregulator"
"A series of <e1>phenol</e1>ic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme <e2>carbonic anhydrase</e2> (CA, EC 4.2.1.1).","Downregulator"
"A series of <e1>phenol</e1>ic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1).","Downregulator"
"A series of <e1>phenol</e1>ic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>).","Downregulator"
"Comparison with the <e2>rSDH</e2>-(PLP-OMS) holo-enzyme reveals a large structural difference in active sites caused by the artifical <e1>O-methylserine</e1>.","Regulator"
"<e2>L-serine dehydratase</e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield <e1>pyruvate</e1> or 2-oxobutyrate.","Substrate"
"L-serine dehydratase (<e2>SDH</e2>), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield <e1>pyruvate</e1> or 2-oxobutyrate.","Substrate"
"<e2>L-serine dehydratase</e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or <e1>2-oxobutyrate</e1>.","Substrate"
"L-serine dehydratase (<e2>SDH</e2>), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or <e1>2-oxobutyrate</e1>.","Substrate"
"<e1>L-serine</e1> dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate.","Substrate"
"<e1>L-serine</e1> dehydratase (<e2>SDH</e2>), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate.","Substrate"
"<e2>L-serine dehydratase</e2> (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <e1>L-threonine</e1> to yield pyruvate or 2-oxobutyrate.","Substrate"
"L-serine dehydratase (<e2>SDH</e2>), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and <e1>L-threonine</e1> to yield pyruvate or 2-oxobutyrate.","Substrate"
"Synthesis and evaluation of <e1>carbamoylmethylene</e1> linked prodrugs of BMS-582949, a clinical <e2>p38α</e2> inhibitor.","Downregulator"
"Synthesis and evaluation of carbamoylmethylene linked prodrugs of <e1>BMS-582949</e1>, a clinical <e2>p38α</e2> inhibitor.","Downregulator"
"Synthesis and evaluation of <e1>carbamoylmethylene</e1> linked prodrugs of BMS-582949, a clinical <e2>p38α</e2> inhibitor.","Downregulator"
"Synthesis and evaluation of carbamoylmethylene linked prodrugs of <e1>BMS-582949</e1>, a clinical <e2>p38α</e2> inhibitor.","Downregulator"
"AIM: To study the changes in the expression and phosphorylation of cAMP response element binding protein (<e2>CREB</e2>) in the rat nucleus accumbens after chronic <e1>ethanol</e1> intake and its withdrawal.","Not"
"AIM: To study the changes in the expression and phosphorylation of cAMP response element binding protein (<e2>CREB</e2>) in the rat nucleus accumbens after chronic <e1>ethanol</e1> intake and its withdrawal.","Not"
"<e1>Naloxone</e1> (alone) treatment of rats had no effect on the levels of CREB and <e2>p-CREB</e2> protein in the nucleus accumbens.","Not"
"<e1>Naloxone</e1> (alone) treatment of rats had no effect on the levels of <e2>CREB</e2> and p-CREB protein in the nucleus accumbens.","Not"
"AIM: To study the changes in the expression and phosphorylation of cAMP response element binding protein (<e2>CREB</e2>) in the rat nucleus accumbens after chronic <e1>ethanol</e1> intake and its withdrawal.","Regulator"
"Changes of phosphorylation of <e2>cAMP response element binding protein</e2> in rat nucleus accumbens after chronic <e1>ethanol</e1> intake: naloxone reversal.","Regulator"
"Changes of phosphorylation of <e2>cAMP response element binding protein</e2> in rat nucleus accumbens after chronic <e1>ethanol</e1> intake: naloxone reversal.","Regulator"
"Changes of phosphorylation of <e2>cAMP response element binding protein</e2> in rat nucleus accumbens after chronic ethanol intake: <e1>naloxone</e1> reversal.","Regulator"
"Changes of phosphorylation of <e2>cAMP response element binding protein</e2> in rat nucleus accumbens after chronic <e1>ethanol</e1> intake: naloxone reversal.","Regulator"
"However, when <e1>naloxone</e1> was administered concurrently with ethanol treatment, it antagonized the down-regulation of p-<e2>CREB</e2> protein in the nucleus accumbens (142 %) of rats exposed to ethanol.","Upregulator"
"AIM: To study the changes in the expression and phosphorylation of cAMP response element binding protein (<e2>CREB</e2>) in the rat nucleus accumbens after chronic <e1>ethanol</e1> intake and its withdrawal.","Downregulator"
"RESULTS: Ethanol given to rats in drinking water decreased the level of <e2>p-CREB</e2> protein in the nucleus accumbens (-75 %) at the time of exposure to <e1>ethanol</e1>.","Downregulator"
"RESULTS: Ethanol given to rats in drinking water decreased the level of <e2>p-CREB</e2> protein in the nucleus accumbens (-75 %) at the time of exposure to <e1>ethanol</e1>.","Downregulator"
"RESULTS: Ethanol given to rats in drinking water decreased the level of <e2>p-CREB</e2> protein in the nucleus accumbens (-75 %) at the time of exposure to <e1>ethanol</e1>.","Downregulator"
"RESULTS: Ethanol given to rats in drinking water decreased the level of <e2>p-CREB</e2> protein in the nucleus accumbens (-75 %) at the time of exposure to <e1>ethanol</e1>.","Downregulator"
"RESULTS: <e1>Ethanol</e1> given to rats in drinking water decreased the level of <e2>p-CREB</e2> protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol.","Downregulator"
"Adenosine, an enzymatic ATP degradation product, acts at prejunctional A1 <e1>adenosine</e1> receptors (<e2>A1Rs</e2>) to inhibit NE release.","Not"
"Adenosine, an enzymatic ATP degradation product, acts at prejunctional A1 <e1>adenosine</e1> receptors (<e2>A1Rs</e2>) to inhibit NE release.","Regulator"
"<e1>Adenosine</e1>, an enzymatic ATP degradation product, acts at prejunctional <e2>A1 adenosine receptors</e2> (A1Rs) to inhibit NE release.","Regulator"
"The <e2>A2A adenosine receptor</e2> agonist CGS21680 (<e1>C23H29N7O6.HCl.xH2O</e1>) (0.001-0.1 μM) did not alter NE oxidation currents.","Agonist"
"Adenosine and N(6)-cyclopentyl-adenosine (<e1>CPA</e1>, <e2>A1R</e2> agonist) constricted MVs but not MAs.","Agonist"
"<e1>Adenosine</e1>, an enzymatic ATP degradation product, acts at prejunctional A1 adenosine receptors (<e2>A1R</e2>s) to inhibit NE release.","Agonist"
"Adenosine and <e1>N(6)-cyclopentyl-adenosine</e1> (CPA, <e2>A1R</e2> agonist) constricted MVs but not MAs.","Agonist"
"The <e2>A2A adenosine receptor</e2> agonist <e1>CGS21680</e1> (C23H29N7O6.HCl.xH2O) (0.001-0.1 μM) did not alter NE oxidation currents.","Agonist"
"<e1>Pasireotide</e1> (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via <e2>somatostatin receptors</e2> to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.","Regulator"
"Pasireotide (<e1>Signifor</e1>(®)) is a new subcutaneous somatostatin analogue that acts via <e2>somatostatin receptors</e2> to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.","Regulator"
"<e1>Pasireotide</e1> has a receptor binding profile that is distinct from that of other somatostatin analogues, binding with high affinity to <e2>somatostatin receptor subtype 5</e2>, which is strongly over expressed in corticotroph adenoma cells.","Regulator"
"<e1>Pasireotide</e1> (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of <e2>corticotropin</e2> from the pituitary adenoma in patients with Cushing's disease.","Downregulator"
"Pasireotide (<e1>Signifor</e1>(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of <e2>corticotropin</e2> from the pituitary adenoma in patients with Cushing's disease.","Downregulator"
"<e1>SB365</e1>, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the <e2>AKT</e2>/mTOR signalling pathway.","Regulator"
"<e1>SB365</e1>, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/<e2>mTOR</e2> signalling pathway.","Regulator"
"SB365, <e1>Pulsatilla saponin D</e1> suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the <e2>AKT</e2>/mTOR signalling pathway.","Regulator"
"SB365, <e1>Pulsatilla saponin D</e1> suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/<e2>mTOR</e2> signalling pathway.","Regulator"
"Also, <e1>SB365</e1> showed anti-angiogenic activity by decreasing the expression of <e2>HIF-1α</e2> and VEGF.","Downregulator"
"Also, <e1>SB365</e1> showed anti-angiogenic activity by decreasing the expression of HIF-1α and <e2>VEGF</e2>.","Downregulator"
"<e1>SB365</e1>, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the <e2>AKT</e2>/mTOR signalling pathway.","Downregulator"
"<e1>SB365</e1>, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/<e2>mTOR</e2> signalling pathway.","Downregulator"
"<e1>SB365</e1>, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the <e2>AKT</e2>/mTOR signalling pathway.","Downregulator"
"<e1>SB365</e1>, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/<e2>mTOR</e2> signalling pathway.","Downregulator"
"Then the cells were treated with various concentrations of apoE3, <e2>lactoferrin</e2> and bovine serum albumin with or without 100 microg/ml of <e1>GMC</e1>, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined.","Not"
"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum <e2>albumin</e2> with or without 100 microg/ml of <e1>GMC</e1>, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined.","Not"
"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in <e2>SGLT1</e2> activity induced by gentamicin C.
Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular <e1>aminoglycoside</e1> accumulation.","Downregulator"
"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in <e2>SGLT1</e2> activity induced by <e1>gentamicin C</e1>.
Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation.","Downregulator"
"In this study, using a model of gentamicin C (<e1>GMC</e1>)-induced reduction in <e2>SGLT1</e2> activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.","Downregulator"
"In this study, using a model of gentamicin C (<e1>GMC</e1>)-induced reduction in <e2>SGLT1</e2> activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.","Downregulator"
"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in <e2>SGLT1</e2> activity induced by <e1>gentamicin C</e1>.
Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation.","Downregulator"
"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the <e2>SGLT1</e2>-dependent <e1>methyl alpha-D-glucopyranoside</e1> (AMG) uptake and levels of SGLT1 expression were determined.","Substrate"
"Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the <e2>SGLT1</e2>-dependent methyl alpha-D-glucopyranoside (<e1>AMG</e1>) uptake and levels of SGLT1 expression were determined.","Substrate"
"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C.
Megalin, a family of <e2>endocytic receptors</e2> related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular <e1>aminoglycoside</e1> accumulation.","Substrate"
"Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C.
Megalin, a family of endocytic receptors related to the <e2>low-density lipoprotein (LDL) receptor</e2>, is a major pathway for proximal tubular <e1>aminoglycoside</e1> accumulation.","Substrate"
"Actions of <e1>nizatidine</e1>, a selective <e2>histamine H2-receptor</e2> antagonist, on gastric acid secretion in dogs, rats and frogs.","Antagonist"
"<e1>Nizatidine</e1> (LY139037), a selective <e2>histamine H2-receptor</e2> antagonist, is a potent inhibitor of gastric acid secretion.","Antagonist"
"Nizatidine (<e1>LY139037</e1>), a selective <e2>histamine H2-receptor</e2> antagonist, is a potent inhibitor of gastric acid secretion.","Antagonist"
"Based on these suggestions, the rational redesign of <e1>furanopyrimidine</e1> 24 (clog P=7.41; <e2>Aurora A</e2> IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of quinazoline 67 (clog P=5.28; Aurora A IC(50) =25 nM; HCT-116 IC(50) =23 nM).","Downregulator"
"Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog P=7.41; <e2>Aurora A</e2> IC(50) =43 nM; HCT-116 IC(50) =400 nM) led to the identification of <e1>quinazoline</e1> 67 (clog P=5.28; Aurora A IC(50) =25 nM; HCT-116 IC(50) =23 nM).","Downregulator"
"Three different 3D-QSAR models were built and validated by using a set of 66 <e1>pyrazole</e1> (Model I) and furanopyrimidine (Model II) compounds with IC(50) values toward <e2>Aurora kinase A</e2> ranging from 33 nM to 10.5 μM.","Downregulator"
"Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (Model I) and <e1>furanopyrimidine</e1> (Model II) compounds with IC(50) values toward <e2>Aurora kinase A</e2> ranging from 33 nM to 10.5 μM.","Downregulator"
"3D-QSAR-assisted drug design: identification of a potent <e1>quinazoline</e1>-based <e2>Aurora kinase</e2> inhibitor.","Downregulator"
"Thus prolonged activation of NMDA receptors in hippocampal neurons reduced <e2>GABAR δ subunit</e2> expression through <e1>Ca2+</e1> entry and at least in part by ERK1/2 activation.","Downregulator"
"Chelation of calcium ions by BAPTA-AM or blockade of <e2>ERK1/2</e2> activation by <e1>UO126</e1> also prevented the NMDA effects.","Downregulator"
"In this report, we demonstrate the utility of reversed-phase protein chromatography and FT-ICR mass spectrometry in analyzing CCNU (<e1>lomustine</e1>, 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea, MW: 233.7Da) modification of <e2>stathmin</e2>.","Regulator"
"In this report, we demonstrate the utility of reversed-phase protein chromatography and FT-ICR mass spectrometry in analyzing CCNU (lomustine, <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea</e1>, MW: 233.7Da) modification of <e2>stathmin</e2>.","Regulator"
"Amitriptyline, but not any other <e1>tricyclic</e1> or selective serotonin reuptake inhibitor antidepressants, promotes <e2>TrkA</e2> autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.","Not"
"We report here that <e1>amitriptyline</e1>, an antidepressant drug, directly binds <e2>TrkA</e2> and TrkB and triggers their dimerization and activation.","Regulator"
"We report here that <e1>amitriptyline</e1>, an antidepressant drug, directly binds TrkA and <e2>TrkB</e2> and triggers their dimerization and activation.","Regulator"
"<e1>Amitriptyline</e1> is a <e2>TrkA</e2> and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Regulator"
"<e1>Amitriptyline</e1> is a TrkA and <e2>TrkB</e2> receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Regulator"
"We report here that <e1>amitriptyline</e1>, an antidepressant drug, directly binds <e2>TrkA</e2> and TrkB and triggers their dimerization and activation.","Regulator"
"<e1>Amitriptyline</e1> is a <e2>TrkA</e2> and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Regulator"
"<e1>Amitriptyline</e1> is a TrkA and <e2>TrkB</e2> receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Regulator"
"<e1>Amitriptyline</e1> is a <e2>TrkA</e2> and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Regulator"
"<e1>Amitriptyline</e1> is a TrkA and <e2>TrkB</e2> receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Regulator"
"We report here that <e1>amitriptyline</e1>, an antidepressant drug, directly binds <e2>TrkA</e2> and TrkB and triggers their dimerization and activation.","Regulator"
"<e1>Amitriptyline</e1> is a <e2>TrkA</e2> and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Upregulator"
"We report here that <e1>amitriptyline</e1>, an antidepressant drug, directly binds TrkA and <e2>TrkB</e2> and triggers their dimerization and activation.","Agonist"
"We report here that <e1>amitriptyline</e1>, an antidepressant drug, directly binds <e2>TrkA</e2> and TrkB and triggers their dimerization and activation.","Agonist"
"<e1>Amitriptyline</e1> is a <e2>TrkA</e2> and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Agonist"
"<e1>Amitriptyline</e1> is a TrkA and <e2>TrkB</e2> receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.","Agonist"
"The expression of the <e1>NH2</e1> terminally truncated <e2>ErbB2</e2> receptor (p95ErbB2) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185ErbB2.","Part_of"
"The expression of the <e1>NH2</e1> terminally truncated ErbB2 receptor (<e2>p95ErbB2</e2>) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185ErbB2.","Part_of"
"Truncated ErbB2 receptor (<e2>p95ErbB2</e2>) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Regulator"
"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with <e2>ErbB3</e2> yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Regulator"
"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>GW572016</e1> resulted in the inhibition of downstream phospho-<e2>Erk1/2</e2>, phospho-AKT, and cyclin D steady-state protein levels.","Downregulator"
"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>GW572016</e1> resulted in the inhibition of downstream phospho-Erk1/2, phospho-<e2>AKT</e2>, and cyclin D steady-state protein levels.","Downregulator"
"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>GW572016</e1> resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and <e2>cyclin D</e2> steady-state protein levels.","Downregulator"
"Truncated ErbB2 receptor (<e2>p95ErbB2</e2>) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Downregulator"
"Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by <e1>GW572016</e1> resulted in the inhibition of downstream phospho-Erk1/2, phospho-<e2>AKT</e2>, and cyclin D steady-state protein levels.","Downregulator"
"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual <e2>EGFR</e2>/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Downregulator"
"Truncated <e2>ErbB2</e2> receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Downregulator"
"<e1>GW572016</e1>, a reversible small molecule inhibitor of EGFR and ErbB2 <e2>tyrosine kinases</e2>, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.","Downregulator"
"Truncated ErbB2 receptor (<e2>p95ErbB2</e2>) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Downregulator"
"Truncated ErbB2 receptor (<e2>p95ErbB2</e2>) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Downregulator"
"Inhibition of p95ErbB2, <e2>p185ErbB2</e2>, and EGFR phosphorylation by <e1>GW572016</e1> resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.","Downregulator"
"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual <e2>EGFR</e2>/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Downregulator"
"Truncated <e2>ErbB2</e2> receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor <e1>GW572016</e1>.","Downregulator"
"To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of <e1>sulindac</e1> on <e2>14-3-3epsilon</e2> protein expression in colorectal cancer cells.","Regulator"
"Overexpression of PPARdelta by adenoviral transfer rescued <e2>14-3-3epsilon</e2> proteins from elimination by sulindac or <e1>indomethacin</e1>.","Regulator"
"To determine the role of 14-3-3 in colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of <e1>sulindac</e1> on <e2>14-3-3epsilon protein</e2> expression in colorectal cancer cells.","Regulator"
"<e1>Sulindac sulfide</e1> inhibited <e2>PPARdelta</e2> protein expression and PPARdelta transcriptional activity.","Downregulator"
"<e1>Sulindac sulfide</e1> inhibited <e2>PPARdelta</e2> protein expression and PPARdelta transcriptional activity.","Downregulator"
"<e1>Sulindac sulfide</e1> inhibited <e2>14-3-3epsilon proteins</e2> in HT-29 and DLD-1 cells in a time- and concentration-dependent manner.","Downregulator"
"<e1>Indomethacin</e1> and SC-236, a selective <e2>cyclooxygenase-2</e2> (COX-2) inhibitor, exerted a similar effect as sulindac.","Downregulator"
"<e1>Indomethacin</e1> and SC-236, a selective cyclooxygenase-2 (<e2>COX-2</e2>) inhibitor, exerted a similar effect as sulindac.","Downregulator"
"Indomethacin and <e1>SC-236</e1>, a selective <e2>cyclooxygenase-2</e2> (COX-2) inhibitor, exerted a similar effect as sulindac.","Downregulator"
"Indomethacin and <e1>SC-236</e1>, a selective cyclooxygenase-2 (<e2>COX-2</e2>) inhibitor, exerted a similar effect as sulindac.","Downregulator"
"The role of drug metabolism in <e1>gemcitabine</e1> cytotoxicity was examined with inhibitors of deoxycytidine kinase (<e2>dCK</e2>), 5'-nucleotidase, and cytidine deaminase, whereas the role of pemetrexed targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.","Regulator"
"The effect of <e1>gemcitabine</e1> and pemetrexed on <e2>Akt</e2> phosphorylation was investigated with enzyme-linked immunosorbent assay, whereas quantitative polymerase chain reaction (PCR) was used to study target gene-expression profiles and its modulation by each drug.","Regulator"
"The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (<e2>dCK</e2>), 5'-nucleotidase, and cytidine deaminase, whereas the role of <e1>pemetrexed</e1> targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.","Upregulator"
"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed</e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the <e2>human nucleoside equilibrative transporter 1</e2> (hENT1) in all cell lines.","Upregulator"
"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed</e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (<e2>hENT1</e2>) in all cell lines.","Upregulator"
"The role of drug metabolism in gemcitabine cytotoxicity was examined with inhibitors of deoxycytidine kinase (<e2>dCK</e2>), 5'-nucleotidase, and cytidine deaminase, whereas the role of <e1>pemetrexed</e1> targets, thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) in drug chemosensitivity was analyzed in cytotoxicity rescue studies.","Upregulator"
"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed</e1> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (<e2>hENT1</e2>) in all cell lines.","Upregulator"
"Synergistic cytotoxicity was demonstrated, and <e1>pemetrexed</e1> significantly decreased the amount of <e2>phosphorylated Akt</e2>, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.","Downregulator"
"The effect of <e1>gemcitabine</e1> and pemetrexed on <e2>Akt</e2> phosphorylation was investigated with enzyme-linked immunosorbent assay, whereas quantitative polymerase chain reaction (PCR) was used to study target gene-expression profiles and its modulation by each drug.","Downregulator"
"The effect of gemcitabine and <e1>pemetrexed</e1> on <e2>Akt</e2> phosphorylation was investigated with enzyme-linked immunosorbent assay, whereas quantitative polymerase chain reaction (PCR) was used to study target gene-expression profiles and its modulation by each drug.","Downregulator"
"<e1>Kynurenic acid</e1> (KA) is an endogenous <e2>glutamate receptor</e2> antagonist at the level of the different ionotropic glutamate receptors.","Antagonist"
"<e1>Kynurenic acid</e1> (KA) is an endogenous glutamate receptor antagonist at the level of the different <e2>ionotropic glutamate receptors</e2>.","Antagonist"
"Kynurenic acid (<e1>KA</e1>) is an endogenous <e2>glutamate receptor</e2> antagonist at the level of the different ionotropic glutamate receptors.","Antagonist"
"Kynurenic acid (<e1>KA</e1>) is an endogenous glutamate receptor antagonist at the level of the different <e2>ionotropic glutamate receptors</e2>.","Antagonist"
"One of the enzymes responsible for the production of <e1>KA</e1>, <e2>kynurenine aminotransferase I</e2> (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of <e1>KA</e1>, kynurenine aminotransferase I (<e2>KATI</e2>), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of KA, <e2>kynurenine aminotransferase I</e2> (KATI), also catalyses the reversible transamination of <e1>glutamine</e1> to oxoglutaramic acid (GTK, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (<e2>KATI</e2>), also catalyses the reversible transamination of <e1>glutamine</e1> to oxoglutaramic acid (GTK, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of <e1>glutamine</e1> to oxoglutaramic acid (<e2>GTK</e2>, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of KA, <e2>kynurenine aminotransferase I</e2> (KATI), also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid</e1> (GTK, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (<e2>KATI</e2>), also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid</e1> (GTK, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid</e1> (<e2>GTK</e2>, EC 2.6.1.15).","Substrate"
"One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to <e1>oxoglutaramic acid</e1> (GTK, <e2>EC 2.6.1.15</e2>).","Substrate"
"In this paper the effect of shRNA LRRK2 knock-down on <e1>Mn</e1> toxicity was examined in control and <e2>DAT</e2> transfected HEK293 cells.","Regulator"
"In this paper the effect of shRNA LRRK2 knock-down on <e1>Mn</e1> toxicity was examined in control and <e2>DAT</e2> transfected HEK293 cells.","Regulator"
"Combined treatment of <e1>Mn</e1> and DA further augments cell toxicity, ROS production and <e2>JNK</e2> phosphorylation in LRRK2 deficient cells compared to controls.","Upregulator"
"Although the treatment with MSG increased <e2>IRS-1</e2> <e1>tyrosine</e1> phosphorylation (pIRS-1) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.","Part_of"
"Swim training of monosodium L-glutamate-obese mice improves the impaired <e2>insulin receptor</e2> <e1>tyrosine</e1> phosphorylation in pancreatic islets.","Part_of"
"Although the treatment with MSG increased <e2>IRS-1</e2> <e1>tyrosine</e1> phosphorylation (pIRS-1) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.","Part_of"
"The results showed that <e2>IR</e2> <e1>tyrosine</e1> phosphorylation (pIR) was reduced by 42 % in MSG-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Part_of"
"The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (<e2>IR</e2>) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from <e1>MSG</e1>-obese mice submitted to or not submitted to swim training.","Regulator"
"The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 (<e2>IRS-1</e2>) signalling in pancreatic islets from <e1>MSG</e1>-obese mice submitted to or not submitted to swim training.","Regulator"
"The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 (<e2>IRS-1</e2>) signalling in pancreatic islets from <e1>MSG</e1>-obese mice submitted to or not submitted to swim training.","Regulator"
"The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (IR) and insulin receptor substrate-1 (<e2>IRS-1</e2>) signalling in pancreatic islets from <e1>MSG</e1>-obese mice submitted to or not submitted to swim training.","Regulator"
"The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (<e2>IR</e2>) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from <e1>MSG</e1>-obese mice submitted to or not submitted to swim training.","Regulator"
"The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (<e2>IR</e2>) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from <e1>MSG</e1>-obese mice submitted to or not submitted to swim training.","Regulator"
"The goal of the present study was to investigate changes on glucose homoeostasis and of the insulin receptor (<e2>IR</e2>) and insulin receptor substrate-1 (IRS-1) signalling in pancreatic islets from <e1>MSG</e1>-obese mice submitted to or not submitted to swim training.","Regulator"
"Although the treatment with <e1>MSG</e1> increased IRS-1 tyrosine phosphorylation (<e2>pIRS-1</e2>) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.","Upregulator"
"Although the treatment with <e1>MSG</e1> increased IRS-1 tyrosine phosphorylation (<e2>pIRS-1</e2>) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.","Upregulator"
"Although the treatment with <e1>MSG</e1> increased IRS-1 tyrosine phosphorylation (<e2>pIRS-1</e2>) by 96 % (MSG, 17.02 ± 0.6; control, 8.7 ± 0.2 a.u.","Upregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"The results showed that IR tyrosine phosphorylation (<e2>pIR</e2>) was reduced by 42 % in <e1>MSG</e1>-obese mice (MSG, 6.7 ± 0.2 arbitrary units (a.u.","Downregulator"
"With the use of <e1>sildenafil</e1>, it has been clearly, clinically demonstrated that the selective inhibition of <e2>PDE5</e2> is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.","Downregulator"
"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of <e1>sildenafil</e1> (Viagra, Pfizer) - the first approved selective <e2>PDE</e2> inhibitor for the treatment of ED.","Downregulator"
"Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (<e1>Viagra</e1>, Pfizer) - the first approved selective <e2>PDE</e2> inhibitor for the treatment of ED.","Downregulator"
"<e1>Sildenafil</e1> is inhibitory of <e2>PDE5</e2> at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.","Downregulator"
"<e1>Sildenafil</e1> is inhibitory of <e2>PDE</e2>5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.","Downregulator"
"<e1>Sildenafil</e1> is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (<e2>PDE6</e2>), which produces visual changes through the retinal rods.","Downregulator"
"The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of <e2>PDE5</e2> that breaks down <e1>cGMP</e1>, the key pathway for the production of erectile function in humans.","Substrate"
"The <e2>cAspAT</e2> TZD-responsive site was restricted to a single <e1>AGGACA</e1> hexanucleotide located at -381 to -376 bp whose mutation impaired the specific RORalpha binding.","Part_of"
"The <e2>cAspAT</e2> TZD-responsive site was restricted to a single AGGACA <e1>hexanucleotide</e1> located at -381 to -376 bp whose mutation impaired the specific RORalpha binding.","Part_of"
"The cAspAT <e1>TZD</e1>-responsive site was restricted to a single AGGACA hexanucleotide located at -381 to -376 bp whose mutation impaired the specific <e2>RORalpha</e2> binding.","Regulator"
"Nevertheless, <e2>PPARgamma</e2> is indirectly necessary for both cAspAT basal expression and <e1>TZD</e1> responsiveness because they are, respectively, diminished and abolished by ectopic overexpression of a dominant negative PPARgamma.","Regulator"
"Nevertheless, <e2>PPARgamma</e2> is indirectly necessary for both cAspAT basal expression and <e1>TZD</e1> responsiveness because they are, respectively, diminished and abolished by ectopic overexpression of a dominant negative PPARgamma.","Regulator"
"<e2>cAspAT</e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (<e1>TZD</e1>) rosiglitazone.","Regulator"
"<e2>Cytosolic aspartate aminotransferase</e2>, a new partner in adipocyte glyceroneogenesis and an atypical target of <e1>thiazolidinedione</e1>.","Regulator"
"<e2>cAspAT</e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the <e1>thiazolidinedione</e1> (TZD) rosiglitazone.","Upregulator"
"<e2>cAspAT</e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (<e1>TZD</e1>) rosiglitazone.","Upregulator"
"<e2>cAspAT</e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) <e1>rosiglitazone</e1>.","Upregulator"
"<e2>RORalpha</e2> ectopic expression activated the cAspAT gene transcription in absence of <e1>rosiglitazone</e1>, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes.","Upregulator"
"<e2>cAspAT</e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) <e1>rosiglitazone</e1>.","Upregulator"
"The cAspAT <e1>TZD</e1>-responsive site was restricted to a single AGGACA hexanucleotide located at -381 to -376 bp whose mutation impaired the specific <e2>RORalpha</e2> binding.","Upregulator"
"<e2>cAspAT</e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (<e1>TZD</e1>) rosiglitazone.","Upregulator"
"<e2>cAspAT</e2> activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (<e1>TZD</e1>) rosiglitazone.","Upregulator"
"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>navitoclax</e1>, a selective inhibitor of both <e2>BCL-2</e2> and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.","Downregulator"
"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>navitoclax</e1>, a selective inhibitor of both BCL-2 and <e2>BCL-2-like 1</e2> (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.","Downregulator"
"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>navitoclax</e1>, a selective inhibitor of both BCL-2 and BCL-2-like 1 (<e2>BCL-X(L)</e2>), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.","Downregulator"
"The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of <e1>navitoclax</e1>, a selective inhibitor of both <e2>BCL-2</e2> and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.","Downregulator"
"<e1>ABT-199</e1>, a potent and selective <e2>BCL-2</e2> inhibitor, achieves antitumor activity while sparing platelets.","Downregulator"
"<e1>ABT-199</e1>, a potent and selective <e2>BCL-2</e2> inhibitor, achieves antitumor activity while sparing platelets.","Downregulator"
"<e1>Nicotine</e1> does not account for the CSE stimulation of <e2>VEGF</e2> in HFL-1.","Not"
"Suppression of TβR1 by the pharmacological inhibitor (<e1>SB431542</e1>) markedly reduced <e2>VEGF</e2> release by HFL-1 in response to CSE and this effect was confirmed by TβR1 siRNA.","Downregulator"
"Suppression of <e2>TβR1</e2> by the pharmacological inhibitor (<e1>SB431542</e1>) markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by TβR1 siRNA.","Downregulator"
"Previous work has extensively characterized a common allosteric site on <e2>mGlu5</e2>, termed the <e1>MPEP</e1> (2-Methyl-6-(phenylethynyl)pyridine) binding site.","Part_of"
"Previous work has extensively characterized a common allosteric site on <e2>mGlu5</e2>, termed the MPEP (<e1>2-Methyl-6-(phenylethynyl)pyridine</e1>) binding site.","Part_of"
"However, one <e2>mGlu5</e2> PAM, <e1>CPPHA</e1> (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on mGlu5.","Regulator"
"However, one <e2>mGlu5</e2> PAM, CPPHA (<e1>N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide</e1>), interacts with a separate allosteric site on mGlu5.","Regulator"
"Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious <e2>mGlu5</e2> PAM from the CPPHA series termed <e1>NCFP</e1> (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).","Regulator"
"Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious <e2>mGlu5</e2> PAM from the CPPHA series termed <e1>NCFP</e1> (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).","Regulator"
"Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious <e2>mGlu5</e2> PAM from the CPPHA series termed <e1>NCFP</e1> (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).","Regulator"
"However, one <e2>mGlu5</e2> PAM, <e1>CPPHA</e1> (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on mGlu5.","Regulator"
"Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious <e2>mGlu5</e2> PAM from the CPPHA series termed <e1>NCFP</e1> (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).","Upregulator"
"However, one <e2>mGlu5</e2> PAM, <e1>CPPHA</e1> (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on mGlu5.","Modulator"
"However, one <e2>mGlu5</e2> PAM, CPPHA (<e1>N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide</e1>), interacts with a separate allosteric site on mGlu5.","Modulator"
"However, one <e2>mGlu5</e2> PAM, <e1>CPPHA</e1> (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on mGlu5.","Modulator"
"Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious <e2>mGlu5</e2> PAM from the CPPHA series termed <e1>NCFP</e1> (N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide).","Modulator"
"Using cell-based assays and brain slice preparations, we characterized the interaction of a potent and efficacious <e2>mGlu5</e2> PAM from the CPPHA series termed NCFP (<e1>N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide</e1>).","Modulator"
"However, one <e2>mGlu5</e2> PAM, <e1>CPPHA</e1> (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on mGlu5.","Modulator"
"We report herein the location of the binding site for the inhaled anesthetic halothane at the <e1>amino acid</e1> residue level of resolution in the ligand binding cavity in a prototypical G protein-coupled receptor, bovine <e2>rhodopsin</e2>.","Part_of"
"We report herein the location of the binding site for the inhaled anesthetic halothane at the <e1>amino acid</e1> residue level of resolution in the ligand binding cavity in a prototypical <e2>G protein-coupled receptor</e2>, bovine rhodopsin.","Part_of"
"We report herein the location of the binding site for the inhaled anesthetic halothane at the <e1>amino acid</e1> residue level of resolution in the ligand binding cavity in a prototypical G protein-coupled receptor, <e2>bovine rhodopsin</e2>.","Part_of"
"We report herein the location of the binding site for the inhaled anesthetic <e1>halothane</e1> at the amino acid residue level of resolution in the ligand binding cavity in a prototypical G protein-coupled receptor, <e2>bovine rhodopsin</e2>.","Regulator"
"Tryptophan fluorescence quenching and direct photoaffinity labeling with <e1>[(14)C]halothane</e1> suggested an interhelical location of halothane with a stoichiometry of 1 (halothane/<e2>rhodopsin</e2> molar ratio).","Regulator"
"We report herein the location of the binding site for the inhaled anesthetic <e1>halothane</e1> at the amino acid residue level of resolution in the ligand binding cavity in a prototypical <e2>G protein-coupled receptor</e2>, bovine rhodopsin.","Regulator"
"Using the alpha1 and alpha2-adrenoceptor antagonists, prazosin and idazoxane, we also demonstrate the role of the <e2>alpha-adrenoceptors</e2> in the augmentation of <e1>venlafaxine</e1>-induced changes.","Regulator"
"Effects of <e1>venlafaxine</e1> on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via <e2>5-HT1A</e2> receptor antagonism.","Regulator"
"Combination treatment with the selective <e2>5-HT1A</e2> antagonist <e1>WAY100635</e1> produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.","Antagonist"
"The beta-adrenergic/<e2>5-HT1A</e2> receptor antagonist <e1>(+/-)pindolol</e1> and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.","Antagonist"
"However, <e1>topiramate</e1> at low concentrations causes slow inhibition of <e2>GluR5</e2> kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.","Downregulator"
"However, <e1>topiramate</e1> at low concentrations causes slow inhibition of GluR5 <e2>kainate receptor</e2>-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.","Downregulator"
"However, <e1>topiramate</e1> at low concentrations causes slow inhibition of <e2>GluR5</e2> kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.","Downregulator"
"However, <e1>topiramate</e1> at low concentrations causes slow inhibition of GluR5 <e2>kainate receptor</e2>-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.","Downregulator"
"The selective <e2>GluR5</e2> kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist <e1>LY293558</e1>.","Antagonist"
"The selective GluR5 <e2>kainate receptor</e2> agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 kainate receptor antagonist <e1>LY293558</e1>.","Antagonist"
"The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by <e1>glutathione</e1> conjugate formation catalyzed by <e2>glutathione S-transferases</e2>.","Substrate"
"<e2>Multidrug resistance-associated proteins</e2> are involved in the transport of the <e1>glutathione</e1> conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells.","Substrate"
"Inhibition studies revealed that the <e2>multidrug resistance-associated proteins</e2> (ABCCs) are involved in the transport of <e1>BPDE glutathione</e1> conjugates.","Substrate"
"Inhibition studies revealed that the multidrug resistance-associated proteins (<e2>ABCCs</e2>) are involved in the transport of <e1>BPDE glutathione</e1> conjugates.","Substrate"
"Stable <e2>ABCC1</e2>, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <e1>BPDE glutathione</e1> conjugates.","Substrate"
"Stable ABCC1, <e2>ABCC2</e2> and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <e1>BPDE glutathione</e1> conjugates.","Substrate"
"Stable <e2>ABCC1</e2>, ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <e1>BPDE glutathione</e1> conjugates.","Substrate"
"Stable ABCC1, <e2>ABCC2</e2> and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and ABCC2 the apical excretion of <e1>BPDE glutathione</e1> conjugates.","Substrate"
"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean <e1>isoflavone</e1> increased gene expression of <e2>heme oxygenase-1</e2> (HO-1), a major antioxidative stress enzyme.","Upregulator"
"Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean <e1>isoflavone</e1> increased gene expression of heme oxygenase-1 (<e2>HO-1</e2>), a major antioxidative stress enzyme.","Upregulator"
"Comparison of <e2>cyclooxygenase</e2> inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and <e1>bromfenac sodium</e1>.","Regulator"
"OBJECTIVE: To compare the cyclooxygenase (<e2>COX</e2>) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and <e1>bromfenac sodium</e1> (bromfenac).","Regulator"
"RESULTS: <e1>Ketorolac</e1> was six times more active against <e2>COX-1</e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Regulator"
"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than <e2>COX-2</e2> (IC(50) = 0.12 microM) while <e1>bromfenac</e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Regulator"
"RESULTS: Ketorolac was six times more active against <e2>COX-1</e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while <e1>bromfenac</e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Regulator"
"Comparison of <e2>cyclooxygenase</e2> inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and <e1>bromfenac</e1> sodium.","Regulator"
"OBJECTIVE: To compare the cyclooxygenase (<e2>COX</e2>) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and <e1>bromfenac</e1> sodium (bromfenac).","Regulator"
"RESULTS: <e1>Ketorolac</e1> was six times more active against <e2>COX-1</e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Regulator"
"RESULTS: <e1>Ketorolac</e1> was six times more active against COX-1 (IC(50) = 0.02 microM) than <e2>COX-2</e2> (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Regulator"
"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than <e2>COX-2</e2> (IC(50) = 0.12 microM) while <e1>bromfenac</e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Regulator"
"RESULTS: Ketorolac was six times more active against <e2>COX-1</e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while <e1>bromfenac</e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Regulator"
"Comparison of <e2>cyclooxygenase</e2> inhibitory activity and ocular anti-inflammatory effects of <e1>ketorolac tromethamine</e1> and bromfenac sodium.","Regulator"
"OBJECTIVE: To compare the cyclooxygenase (<e2>COX</e2>) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) <e1>ketorolac tromethamine</e1> (ketorolac) and bromfenac sodium (bromfenac).","Regulator"
"Comparison of <e2>cyclooxygenase</e2> inhibitory activity and ocular anti-inflammatory effects of <e1>ketorolac</e1> tromethamine and bromfenac sodium.","Regulator"
"OBJECTIVE: To compare the cyclooxygenase (<e2>COX</e2>) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) <e1>ketorolac</e1> tromethamine (ketorolac) and bromfenac sodium (bromfenac).","Regulator"
"RESULTS: <e1>Ketorolac</e1> was six times more active against COX-1 (IC(50) = 0.02 microM) than <e2>COX-2</e2> (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Downregulator"
"RESULTS: <e1>Ketorolac</e1> was six times more active against <e2>COX-1</e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Downregulator"
"RESULTS: Ketorolac was six times more active against <e2>COX-1</e2> (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while <e1>bromfenac</e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Downregulator"
"RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than <e2>COX-2</e2> (IC(50) = 0.12 microM) while <e1>bromfenac</e1> was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM).","Downregulator"
"Comparison of <e2>cyclooxygenase</e2> inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and <e1>bromfenac sodium</e1>.","Downregulator"
"Comparison of <e2>cyclooxygenase</e2> inhibitory activity and ocular anti-inflammatory effects of <e1>ketorolac tromethamine</e1> and bromfenac sodium.","Downregulator"
"METHODS: <e2>Cyclooxygenase</e2> activity and selectivity was determined in vitro by measuring <e1>prostaglandin E(2)</e1> (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.","Substrate"
"METHODS: <e2>Cyclooxygenase</e2> activity and selectivity was determined in vitro by measuring prostaglandin E(2) (<e1>PGE(2)</e1>) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.","Substrate"
"<e1>PGE(2)</e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four <e2>prostanoid receptors EP(1)</e2> through EP(4).","Regulator"
"<e1>PGE(2)</e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through <e2>EP(4)</e2>.","Regulator"
"<e2>EP(1)</e2> and EP(3) receptor antagonists <e1>ONO-8713</e1> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.","Antagonist"
"EP(1) and <e2>EP(3) receptor</e2> antagonists <e1>ONO-8713</e1> and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.","Antagonist"
"<e2>EP(1)</e2> and EP(3) receptor antagonists ONO-8713 and <e1>ONO-AE3-240</e1>, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.","Antagonist"
"EP(1) and <e2>EP(3) receptor</e2> antagonists ONO-8713 and <e1>ONO-AE3-240</e1>, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.","Antagonist"
"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <e2>EP(4)</e2> antagonists <e1>ONO-AE3-208</e1> and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.","Antagonist"
"EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the <e2>EP(4)</e2> antagonists ONO-AE3-208 and <e1>AH 23848</e1>, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.","Antagonist"
"Tumor-growth-promoting <e2>cyclooxygenase-2</e2> <e1>prostaglandin E2</e1> pathway provides medulloblastoma therapeutic targets.","Substrate"
"<e1>PGE(2)</e1> is synthesized from arachidonic acid by <e2>cyclooxygenases</e2> (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"<e1>PGE(2)</e1> is synthesized from arachidonic acid by cyclooxygenases (<e2>COX</e2>) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"<e1>PGE(2)</e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and <e2>prostaglandin E synthases</e2> (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"<e1>PGE(2)</e1> is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases (<e2>PGES</e2>) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"PGE(2) is synthesized from <e1>arachidonic acid</e1> by <e2>cyclooxygenases</e2> (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"PGE(2) is synthesized from <e1>arachidonic acid</e1> by cyclooxygenases (<e2>COX</e2>) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"PGE(2) is synthesized from <e1>arachidonic acid</e1> by cyclooxygenases (COX) and <e2>prostaglandin E synthases</e2> (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"PGE(2) is synthesized from <e1>arachidonic acid</e1> by cyclooxygenases (COX) and prostaglandin E synthases (<e2>PGES</e2>) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4).","Substrate"
"The pharmacologic properties of <e1>fluticasone propionate</e1>-including high lipophilicity, high selectivity and affinity for the <e2>glucocorticoid receptor</e2>, low systemic absorption, and rapid metabolism and clearance-combine to give fluticasone propionate a high therapeutic index.","Regulator"
"Inhibitors of <e2>PDE4</e2> (<e1>rolipram</e1>; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.","Downregulator"
"Inhibitors of PDE4 (rolipram; 0.1-10 microM) and <e2>PDE3</e2> (<e1>cilostazol</e1>; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.","Downregulator"
"Inhibitor of <e2>cGMP-specific PDE5</e2> (<e1>zaprinast</e1>; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.","Downregulator"
"Increasing lutein with high fat (6%) or <e1>EPA</e1> (15 micromol/L EPA) increased <e2>PPARgamma</e2> and RXRalpha mRNA levels.","Regulator"
"Two experiments were conducted to investigate the effect of lutein and fat or eicosapentaenoic acid (<e1>EPA</e1>) interaction on inducible nitric oxide synthase (iNOS), PPARs alpha, beta, and gamma, and retinoic acid X receptor (<e2>RXR</e2>) alpha and gamma mRNA levels.","Regulator"
"Lutein and <e1>eicosapentaenoic acid</e1> interact to modify iNOS mRNA levels through the <e2>PPARgamma</e2>/RXR pathway in chickens and HD11 cell lines.","Regulator"
"Lutein and <e1>eicosapentaenoic acid</e1> interact to modify iNOS mRNA levels through the PPARgamma/<e2>RXR</e2> pathway in chickens and HD11 cell lines.","Regulator"
"Two experiments were conducted to investigate the effect of lutein and fat or eicosapentaenoic acid (<e1>EPA</e1>) interaction on inducible nitric oxide synthase (<e2>iNOS</e2>), PPARs alpha, beta, and gamma, and retinoic acid X receptor (RXR) alpha and gamma mRNA levels.","Regulator"
"Lutein and <e1>eicosapentaenoic acid</e1> interact to modify <e2>iNOS</e2> mRNA levels through the PPARgamma/RXR pathway in chickens and HD11 cell lines.","Regulator"
"<e1>GW9662</e1>, a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced <e2>iNOS</e2> mRNA downregulation in HD11 cells.","Upregulator"
"<e1>GW9662</e1>, a <e2>PPARgamma</e2> antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells.","Antagonist"
"Occupancy of dopamine D(1), D (2) and <e2>serotonin (2A) receptors</e2> in schizophrenic patients treated with <e1>flupentixol</e1> in comparison with risperidone and haloperidol.","Regulator"
"Occupancy of dopamine D(1), D (2) and <e2>serotonin (2A) receptors</e2> in schizophrenic patients treated with flupentixol in comparison with <e1>risperidone</e1> and haloperidol.","Regulator"
"Occupancy of dopamine D(1), D (2) and <e2>serotonin (2A) receptors</e2> in schizophrenic patients treated with flupentixol in comparison with risperidone and <e1>haloperidol</e1>.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), D(1) and <e2>5-HT(2A)</e2> receptors and recently, FLX showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with <e1>flupentixol</e1>'s interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"Occupancy of dopamine <e2>D(1)</e2>, D (2) and serotonin (2A) receptors in schizophrenic patients treated with <e1>flupentixol</e1> in comparison with risperidone and haloperidol.","Regulator"
"In vitro data show comparable affinity to <e2>dopamine D(2)</e2>, D(1) and 5-HT(2A) receptors and recently, <e1>FLX</e1> showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), <e2>D(1)</e2> and 5-HT(2A) receptors and recently, <e1>FLX</e1> showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), D(1) and <e2>5-HT(2A) receptors</e2> and recently, <e1>FLX</e1> showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), D(1) and <e2>5-HT(2A)</e2> receptors and recently, <e1>FLX</e1> showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, <e1>FLX</e1> showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or <e2>D(1) receptors</e2>.","Regulator"
"In vitro data show comparable affinity to <e2>dopamine D(2)</e2>, D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to <e1>risperidone</e1> in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"Occupancy of dopamine <e2>D(1)</e2>, D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with <e1>risperidone</e1> and haloperidol.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), D(1) and <e2>5-HT(2A) receptors</e2> and recently, FLX showed to be not inferior to <e1>risperidone</e1> in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), D(1) and <e2>5-HT(2A)</e2> receptors and recently, FLX showed to be not inferior to <e1>risperidone</e1> in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.","Regulator"
"In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to <e1>risperidone</e1> in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or <e2>D(1) receptors</e2>.","Regulator"
"We hypothesized that the <e1>HED</e1> compounds would be most potent at the <e2>norepinephrine transporter</e2> (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.","Downregulator"
"We hypothesized that the <e1>HED</e1> compounds would be most potent at the norepinephrine transporter (<e2>NET</e2>) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.","Downregulator"
"Stereospecific inhibition of <e2>monoamine uptake transporters</e2> by <e1>meta-hydroxyephedrine</e1> isomers.","Downregulator"
"To extend structure-activity analyses of binding sites within <e2>monoamine transporters</e2> and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the <e1>HED</e1> compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of <e2>Dickkopfs</e2> (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Not"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (<e2>Dkks</e2>), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Not"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (<e2>Rspo2</e2> and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and <e2>Rspo3</e2>) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"Thus, the <e1>TCDD</e1>-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (<e2>Dkk1</e2> and Dkk2) of the pathway.","Downregulator"
"Thus, the <e1>TCDD</e1>-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and <e2>Dkk2</e2>) of the pathway.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of <e2>Lgr5</e2>, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a <e2>RSPO receptor</e2> that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of <e2>R-spondins</e2> (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (<e2>Rspo2</e2> and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and <e2>Rspo3</e2>) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of <e2>Lef1</e2>, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, <e2>Tcf1</e2>, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and <e2>Wif1</e2>, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"<e1>TCDD</e1> inhibition of canonical <e2>wnt</e2> signaling disrupts prostatic bud formation in mouse urogenital sinus.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical <e2>Wnt</e2> signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical <e2>Wnt</e2> signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical <e2>Wnt</e2> signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In support of the hypothesis that <e1>TCDD</e1> decreases canonical <e2>Wnt</e2> signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.","Downregulator"
"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and <e1>EETs</e1> markedly suppressed Ang II-induced inflammatory <e2>cytokine</e2> expression.","Downregulator"
"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and <e1>EETs</e1> markedly suppressed <e2>Ang II</e2>-induced inflammatory cytokine expression.","Downregulator"
"In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and <e1>EETs</e1> markedly suppressed <e2>Ang II</e2>-induced inflammatory cytokine expression.","Downregulator"
"<e2>Cytochrome P450 epoxygenase 2J2</e2> (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (<e1>EETs</e1>), which possess various beneficial effects on the cardiovascular system.","Substrate"
"<e2>CYP2J2</e2> overexpression increases <e1>EETs</e1> and protects against angiotensin II-induced abdominal aortic aneurysm in mice.","Substrate"
"<e2>CYP2J2</e2> overexpression increases <e1>EETs</e1> and protects against angiotensin II-induced abdominal aortic aneurysm in mice.","Substrate"
"<e2>Cytochrome P450 epoxygenase 2J2</e2> (CYP2J2) metabolizes arachidonic acids to form <e1>epoxyeicosatrienoic acids</e1> (EETs), which possess various beneficial effects on the cardiovascular system.","Substrate"
"Cytochrome P450 epoxygenase 2J2 (<e2>CYP2J2</e2>) metabolizes arachidonic acids to form <e1>epoxyeicosatrienoic acids</e1> (EETs), which possess various beneficial effects on the cardiovascular system.","Substrate"
"<e2>Cytochrome P450 epoxygenase 2J2</e2> (CYP2J2) metabolizes <e1>arachidonic acids</e1> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system.","Substrate"
"Cytochrome P450 epoxygenase 2J2 (<e2>CYP2J2</e2>) metabolizes <e1>arachidonic acids</e1> to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system.","Substrate"
"This study was aimed to compare the in vitro effects of 3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one (C21H2HOSe; <e1>organoselenium</e1>) and sodium selenate (inorganic Se) on adenosine deaminase (<e2>ADA</e2>) activity, cell viability, lipid peroxidation, scavenger of nitric oxide (NO) and nonprotein thiols (NP-SH) content in the cerebral cortex slices of the young rats.","Downregulator"
"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with <e1>aflatoxin B(1)</e1> decreased the frequencies of SCE and the malondialdehyde level and increased amount of <e2>superoxide dismutase</e2>, glutathione and glutathione peroxidase which were decreased by aflatoxin.","Upregulator"
"Cotreatments of 5, 10 and 20 µg/mL concentrations of MEP with <e1>aflatoxin</e1> B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and <e2>glutathione peroxidase</e2> which were decreased by aflatoxin.","Downregulator"
"<e1>Cobalt chloride</e1>, a typical HIF activator, induced the gene expression of <e2>CAR</e2>-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.","Regulator"
"<e1>Phenobarbital</e1> (PB), a typical CAR activator, increased the gene expression of <e2>HIF</e2>-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.","Regulator"
"<e1>Cobalt chloride</e1>, a typical HIF activator, induced the gene expression of <e2>CAR</e2>-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.","Regulator"
"<e1>Cobalt chloride</e1>, a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the <e2>PB-responsive enhancer module</e2>-mediated transactivation in the mouse liver.","Regulator"
"<e1>Phenobarbital</e1> (PB), a typical <e2>CAR</e2> activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.","Upregulator"
"<e1>Cobalt chloride</e1>, a typical <e2>HIF</e2> activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.","Upregulator"
"<e1>Phenobarbital</e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including <e2>erythropoietin</e2>, heme oxygenase-1 and vascular endothelial growth factor-a.","Upregulator"
"<e1>Phenobarbital</e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, <e2>heme oxygenase-1</e2> and vascular endothelial growth factor-a.","Upregulator"
"<e1>Phenobarbital</e1> (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and <e2>vascular endothelial growth factor-a</e2>.","Upregulator"
"<e1>Cobalt chloride</e1>, a typical HIF activator, induced the gene expression of CAR-target genes, including <e2>cyp2b9</e2> and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.","Upregulator"
"<e1>Cobalt chloride</e1>, a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and <e2>cyp2b10</e2>, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.","Upregulator"
"The beta subunit has been cloned and shown to lower the K(m) of <e2>methionine adenosyltransferase II alpha2</e2> (the MAT2A product) for methionine and to render the enzyme more susceptible to <e1>S-adenosylmethionine</e1> inhibition.","Downregulator"
"BACKGROUND & AIMS: Of the 2 genes (MAT1A, <e2>MAT2A</e2>) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>S-adenosylmethionine</e1>, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.","Downregulator"
"BACKGROUND & AIMS: Of the 2 genes (<e2>MAT1A</e2>, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>S-adenosylmethionine</e1>, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.","Substrate"
"BACKGROUND & AIMS: Of the 2 genes (<e2>MAT1A</e2>, MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>S-adenosylmethionine</e1>, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.","Substrate"
"BACKGROUND & AIMS: Of the 2 genes (MAT1A, <e2>MAT2A</e2>) encoding methionine adenosyltransferase, the enzyme that synthesizes <e1>S-adenosylmethionine</e1>, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.","Substrate"
"BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding <e2>methionine adenosyltransferase</e2>, the enzyme that synthesizes <e1>S-adenosylmethionine</e1>, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.","Substrate"
"The beta subunit has been cloned and shown to lower the K(m) of <e1>methionine</e1> adenosyltransferase II alpha2 (the MAT2A product) for methionine and to render the enzyme more susceptible to S-adenosylmethionine inhibition.","Substrate"
"BACKGROUND & AIMS: Of the 2 genes (MAT1A, <e2>MAT2A</e2>) encoding <e1>methionine</e1> adenosyltransferase, the enzyme that synthesizes S-adenosylmethionine, MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues.","Substrate"
"<e2>GABA type A receptors</e2> (GABA(A)-R) are important for <e1>ethanol</e1> actions and it is of interest to link individual subunits with specific ethanol behaviors.","Regulator"
"GABA type A receptors (<e2>GABA(A)-R</e2>) are important for <e1>ethanol</e1> actions and it is of interest to link individual subunits with specific ethanol behaviors.","Regulator"
"All together, they indicate that aversive property of <e1>ethanol</e1> is dependent on ethanol action on <e2>α2-containing GABA(A)-R</e2>. Deletion of the α2-subunit led to faster recovery whereas absence of the α3-subunit slowed recovery from ethanol-induced incoordination (rotarod).","Regulator"
"Linking <e2>GABA(A) receptor</e2> subunits to <e1>alcohol</e1>-induced conditioned taste aversion and recovery from acute alcohol intoxication.","Regulator"
"In the <e1>resveratrol</e1>+As(2)O(3) group, activities of <e2>superoxide dismutase</e2>, catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.","Regulator"
"In the <e1>resveratrol</e1>+As(2)O(3) group, activities of superoxide dismutase, <e2>catalase</e2> in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.","Regulator"
"In the resveratrol+<e1>As(2)O(3)</e1> group, activities of <e2>superoxide dismutase</e2>, catalase in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.","Regulator"
"In the resveratrol+<e1>As(2)O(3)</e1> group, activities of superoxide dismutase, <e2>catalase</e2> in serum and GSH/GSSG were significantly increased, histopathological effects were reduced, and arsenic accumulation markedly decreased in the liver, compared with the As(2)O(3)-treated group.","Regulator"
"A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of vitamin D measurement, <e2>LDL</e2> and HDL cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between <e1>25-OHD</e1> and the risk of progression to IFG and diabetes.","Regulator"
"A multivariable model adjusted for age, sex, population group, immigrant status, BMI, season of vitamin D measurement, LDL and <e2>HDL</e2> cholesterol, triglycerides, estimated glomerular filtration rate, history of hypertension or cardiovascular disease, Charlson comorbidity index, smoking, and socioeconomic status revealed an inverse association between <e1>25-OHD</e1> and the risk of progression to IFG and diabetes.","Regulator"
"The <e2>CB1</e2> and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated <e1>CP 55,940</e1> binding in both mutants.","Not"
"The CB1 and <e2>CB2</e2> second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated <e1>CP 55,940</e1> binding in both mutants.","Not"
"The antagonist <e1>SR 141716A</e1> has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral <e2>CB2</e2> receptor, making it an excellent tool for probing receptor structure-activity relationships.","Not"
"The replacement of the conserved <e1>cysteine</e1> residues in e2 of <e2>CB2</e2> by serine also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm.","Part_of"
"The replacement of the conserved cysteine residues in e2 of <e2>CB2</e2> by <e1>serine</e1> also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm.","Part_of"
"Structural features of the central cannabinoid <e2>CB1</e2> receptor involved in the binding of the specific CB1 antagonist <e1>SR 141716A</e1>.","Regulator"
"Structural features of the central cannabinoid <e2>CB1</e2> receptor involved in the binding of the specific CB1 antagonist <e1>SR 141716A</e1>.","Regulator"
"The <e2>e2 domain</e2> thus plays some role in <e1>CP 55,940</e1> binding but none in SR 141716A recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.","Regulator"
"The <e2>e2 domain</e2> thus plays some role in CP 55,940 binding but none in <e1>SR 141716A</e1> recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.","Regulator"
"Structural features of the central cannabinoid <e2>CB1</e2> receptor involved in the binding of the specific CB1 antagonist <e1>SR 141716A</e1>.","Regulator"
"The antagonist <e1>SR 141716A</e1> has a high specificity for the central CB1 <e2>cannabinoid receptor</e2> and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships.","Regulator"
"Structural features of the central cannabinoid <e2>CB1</e2> receptor involved in the binding of the specific CB1 antagonist <e1>SR 141716A</e1>.","Regulator"
"Structural features of the central cannabinoid <e2>CB1</e2> receptor involved in the binding of the specific CB1 antagonist <e1>SR 141716A</e1>.","Antagonist"
"Drosophila GABA-gated <e2>chloride channel</e2>: modified [3H]EBOB binding site associated with <e1>Ala</e1>-->Ser or Gly mutants of Rdl subunit.","Part_of"
"Drosophila GABA-gated <e2>chloride channel</e2>: modified [3H]EBOB binding site associated with Ala-->Ser or <e1>Gly</e1> mutants of Rdl subunit.","Part_of"
"Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302--><e1>Ser</e1> replacement in the <e2>Rdl GABA receptor</e2> subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement.","Part_of"
"Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an <e1>Ala</e1>302-->Ser replacement in the <e2>Rdl GABA receptor</e2> subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement.","Part_of"
"Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302--><e1>Ser</e1> replacement in the <e2>Rdl GABA receptor</e2> subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement.","Part_of"
"Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the <e2>Rdl GABA receptor</e2> subunit and in D. simulans to an homologous Ala-->Ser or <e1>Gly</e1> replacement.","Part_of"
"Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala-->Ser or <e1>Gly</e1> mutants of <e2>Rdl</e2> subunit.","Part_of"
"Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with <e1>Ala</e1>-->Ser or Gly mutants of <e2>Rdl</e2> subunit.","Part_of"
"Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala--><e1>Ser</e1> or Gly mutants of <e2>Rdl</e2> subunit.","Part_of"
"The non-competitive blocker site of the <e2>GABA-gated chloride ion channel</e2> in normal susceptible strains of Drosophila melanogaster and simulans binds <e1>4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate</e1> ([3H]EBOB) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein.","Regulator"
"The non-competitive blocker site of the <e2>GABA-gated chloride ion channel</e2> in normal susceptible strains of Drosophila melanogaster and simulans binds 4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate (<e1>[3H]EBOB</e1>) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein.","Regulator"
"<e2>Drosophila GABA-gated chloride channel</e2>: modified <e1>[3H]EBOB</e1> binding site associated with Ala-->Ser or Gly mutants of Rdl subunit.","Regulator"
"The channel activators <e1>avermectin</e1> and moxidectin usually retain their inhibitory potency in the <e2>Rdl</e2> subunit mutants.","Downregulator"
"The channel activators avermectin and <e1>moxidectin</e1> usually retain their inhibitory potency in the <e2>Rdl</e2> subunit mutants.","Downregulator"
"Monodemethylated <e1>mifepristone</e1> bound to <e2>rabbit thymic GR</e2> with higher affinity than monodemethylated CDB-2914 or CDB-4124.","Regulator"
"Monodemethylated mifepristone bound to <e2>rabbit thymic GR</e2> with higher affinity than monodemethylated <e1>CDB-2914</e1> or CDB-4124.","Regulator"
"In vitro antiprogestational/antiglucocorticoid activity and progestin and <e2>glucocorticoid receptor</e2> binding of the putative metabolites and synthetic derivatives of <e1>CDB-2914</e1>, CDB-4124, and mifepristone.","Regulator"
"In vitro antiprogestational/antiglucocorticoid activity and progestin and <e2>glucocorticoid receptor</e2> binding of the putative metabolites and synthetic derivatives of CDB-2914, <e1>CDB-4124</e1>, and mifepristone.","Regulator"
"In vitro antiprogestational/antiglucocorticoid activity and progestin and <e2>glucocorticoid receptor</e2> binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and <e1>mifepristone</e1>.","Regulator"
"Monodemethylated mifepristone bound to <e2>rabbit thymic GR</e2> with higher affinity than monodemethylated CDB-2914 or <e1>CDB-4124</e1>.","Regulator"
"In vitro antiprogestational/anti<e2>glucocorticoid</e2> activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and <e1>mifepristone</e1>.","Agonist"
"5-Fluorouracil (<e1>5-FU</e1>), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"5-Fluorouracil (<e1>5-FU</e1>), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"<e1>5-Fluorouracil</e1> (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"<e1>5-Fluorouracil</e1> (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>F3(d)Thd</e1>) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>F3(d)Thd</e1>) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"5-Fluorouracil (5-FU), <e1>5-fluoro-2'-deoxyuridine</e1> (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"5-Fluorouracil (5-FU), <e1>5-fluoro-2'-deoxyuridine</e1> (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (<e1>FdUrd</e1>) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (<e1>FdUrd</e1>) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and <e1>5-trifluorothymidine</e1> (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and <e1>5-trifluorothymidine</e1> (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>F3(d)Thd</e1>) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (<e1>F3(d)Thd</e1>) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"The failure of the myometrium to respond to <e1>ritodrine</e1> (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and <e2>beta 2-adrenergic receptor</e2> concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls.","Downregulator"
"Antiarrhythmic effects of <e1>(-)-epicatechin-3-gallate</e1>, a novel <e2>sodium channel</e2> agonist in cultured neonatal rat ventricular myocytes.","Agonist"
"Liver choline dehydrogenase and kidney <e2>betaine-homocysteine methyltransferase</e2> expression are not affected by <e1>methionine</e1> or choline intake in growing rats.","Not"
"Liver <e2>choline dehydrogenase</e2> and kidney betaine-homocysteine methyltransferase expression are not affected by <e1>methionine</e1> or choline intake in growing rats.","Not"
"Liver <e1>choline</e1> dehydrogenase and kidney <e2>betaine-homocysteine methyltransferase</e2> expression are not affected by methionine or choline intake in growing rats.","Not"
"Liver <e1>choline</e1> dehydrogenase and kidney betaine-homocysteine methyltransferase expression are not affected by methionine or choline intake in growing rats.","Not"
"<e2>BHMT</e2> is expressed at high levels in rat liver and its expression is regulated by dietary <e1>Met</e1> and choline.","Regulator"
"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<e2>BHMT</e2>) are 2 enzymes involved in <e1>choline</e1> oxidation.","Regulator"
"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<e2>BHMT</e2>) are 2 enzymes involved in <e1>choline</e1> oxidation.","Upregulator"
"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<e2>BHMT</e2>) are 2 enzymes involved in <e1>choline</e1> oxidation.","Upregulator"
"<e2>BHMT</e2> is expressed at high levels in rat liver and its expression is regulated by dietary <e1>Met</e1> and choline.","Upregulator"
"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<e2>BHMT</e2>) are 2 enzymes involved in <e1>choline</e1> oxidation.","Upregulator"
"<e2>Choline dehydrogenase</e2> (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <e1>choline</e1> oxidation.","Substrate"
"Choline dehydrogenase (<e2>CHDH</e2>) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in <e1>choline</e1> oxidation.","Substrate"
"Liver <e1>choline</e1> dehydrogenase and kidney <e2>betaine-homocysteine methyltransferase</e2> expression are not affected by methionine or choline intake in growing rats.","Substrate"
"Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<e2>BHMT</e2>) are 2 enzymes involved in <e1>choline</e1> oxidation.","Substrate"
"Identification of a new interaction mode between the Src homology 2 (SH2) domain of <e1>C</e1>-terminal Src kinase (Csk) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG).","Part_of"
"Identification of a new interaction mode between the Src homology 2 (SH2) domain of <e1>C</e1>-terminal Src kinase (<e2>Csk</e2>) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG).","Part_of"
"This structure, together with biochemical experiments, revealed the existence of a novel binding region in addition to the canonical <e1>phosphotyrosine</e1>-314 binding site of <e2>Cbp</e2>.","Part_of"
"Identification of a new interaction mode between the Src homology 2 (SH2) domain of <e1>C</e1>-terminal Src kinase (Csk) and Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid microdomains (PAG).","Part_of"
"<e1>BPA</e1> induced sex-specific altered DNA methylation in specific CpG pairs in the <e2>calsequestrin 2</e2> CpG island.","Regulator"
"<e2>DNA methyltransferase 3a</e2> expression was increased in all <e1>BPA</e1> males and BPA 0.5 females and reduced in BPA 200 females.","Upregulator"
"<e2>DNA methyltransferase 3a</e2> expression was increased in all <e1>BPA</e1> males and BPA 0.5 females and reduced in BPA 200 females.","Upregulator"
"<e2>DNA methyltransferase 3a</e2> expression was increased in all <e1>BPA</e1> males and BPA 0.5 females and reduced in BPA 200 females.","Downregulator"
"The <e1>calcium</e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (<e2>PLB</e2>), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.","Substrate"
"The <e1>calcium</e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), <e2>phospho-PLB</e2>, and calsequestrin 2 are important for contraction and relaxation.","Substrate"
"The <e1>calcium</e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and <e2>calsequestrin 2</e2> are important for contraction and relaxation.","Substrate"
"The <e1>calcium</e1> homeostasis proteins <e2>sarcoendoplasmic reticulum ATPase 2a</e2> (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.","Substrate"
"The <e1>calcium</e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (<e2>SERCA2a</e2>), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.","Substrate"
"The <e1>calcium</e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), <e2>sodium calcium exchanger-1</e2>, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.","Substrate"
"The <e1>calcium</e1> homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, <e2>phospholamban</e2> (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.","Substrate"
"<e1>Wogonoside</e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the <e2>extracellular signal-regulated kinase</e2> (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.","Regulator"
"<e1>Wogonoside</e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and <e2>p38</e2> involved mitogen-activated protein kinase (MAPK) signaling pathway.","Regulator"
"<e1>Wogonoside</e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (<e2>ERK1/2</e2>) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.","Regulator"
"<e1>Wogonoside</e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved <e2>mitogen-activated protein kinase</e2> (MAPK) signaling pathway.","Regulator"
"<e1>Wogonoside</e1> induces autophagy in MDA-MB-231 cells by regulating <e2>MAPK</e2>-mTOR pathway.","Regulator"
"<e1>Wogonoside</e1> induces autophagy in MDA-MB-231 cells by regulating <e2>MAPK</e2>-mTOR pathway.","Regulator"
"<e1>Wogonoside</e1> induces autophagy in MDA-MB-231 cells by regulating MAPK-<e2>mTOR</e2> pathway.","Regulator"
"Taken together, these results suggest that <e1>wogonoside</e1> partially inhibits MDA-MB-231 cell growth by inducing autophagy through the <e2>MAPK</e2>-mTOR pathway and may be a promising anti-tumor agent.","Regulator"
"Taken together, these results suggest that <e1>wogonoside</e1> partially inhibits MDA-MB-231 cell growth by inducing autophagy through the MAPK-<e2>mTOR</e2> pathway and may be a promising anti-tumor agent.","Regulator"
"We report that <e1>wogonoside</e1> triggered the formation of <e2>microtubule-associated protein-light chain 3</e2> (MAP-LC3) positive autophagosomes and the accumulation of acidic vesicular and autolysosomes in MDA-MB-231 cells.","Regulator"
"We report that <e1>wogonoside</e1> triggered the formation of microtubule-associated protein-light chain 3 (<e2>MAP-LC3</e2>) positive autophagosomes and the accumulation of acidic vesicular and autolysosomes in MDA-MB-231 cells.","Regulator"
"The results showed that <e1>wogonoside</e1> promotes the expression of <e2>LC3-II</e2> and Beclin-1.","Upregulator"
"The results showed that <e1>wogonoside</e1> promotes the expression of LC3-II and <e2>Beclin-1</e2>.","Upregulator"
"<e1>Wogonoside</e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and <e2>p70-S6 kinase</e2> (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.","Downregulator"
"<e1>Wogonoside</e1> also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (<e2>p70S6K)</e2> by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.","Downregulator"
"<e1>Wogonoside</e1> also suppressed the activation of <e2>mammalian target of rapamycin</e2> (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.","Downregulator"
"<e1>Wogonoside</e1> induces autophagy in MDA-MB-231 cells by regulating MAPK-<e2>mTOR</e2> pathway.","Downregulator"
"The <e2>mitochondrial respiratory chain complex IV</e2> (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <e1>oxygen</e1>, yielding water.","Substrate"
"The mitochondrial respiratory chain complex IV (<e2>cytochrome c oxidase</e2>) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular <e1>oxygen</e1>, yielding water.","Substrate"
"Here we report the <e1>amino acid</e1> sequence of the <e2>bovine oxytocin-neurophysin I (OT-NpI) precursor</e2> which was derived from sequence analysis of the cloned cDNA.","Part_of"
"Deduced <e1>amino acid</e1> sequence from the <e2>bovine oxytocin-neurophysin I precursor</e2> cDNA.","Part_of"
"We examined the effects of <e1>anthocyanidins</e1> (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Not"
"We examined the effects of <e1>anthocyanidins</e1> (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Not"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of antho<e1>cyanidin</e1>s (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the <e2>aryl hydrocarbon receptor</e2> (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of antho<e1>cyanidin</e1>s (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of antho<e1>cyanidin</e1>s (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, <e1>delphinidin</e1>, malvidin, peonidin, petunidin, pelargonidin) on the <e2>aryl hydrocarbon receptor</e2> (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, <e1>delphinidin</e1>, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, <e1>delphinidin</e1>, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, <e1>malvidin</e1>, peonidin, petunidin, pelargonidin) on the <e2>aryl hydrocarbon receptor</e2> (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, <e1>malvidin</e1>, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, <e1>malvidin</e1>, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, <e1>peonidin</e1>, petunidin, pelargonidin) on the <e2>aryl hydrocarbon receptor</e2> (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, <e1>peonidin</e1>, petunidin, pelargonidin) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, <e1>peonidin</e1>, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, <e1>petunidin</e1>, pelargonidin) on the <e2>aryl hydrocarbon receptor</e2> (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, <e1>petunidin</e1>, pelargonidin) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, <e1>petunidin</e1>, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the <e2>aryl hydrocarbon receptor</e2> (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"<e1>Pelargonidin</e1> activates the AhR and induces <e2>CYP1A1</e2> in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.","Regulator"
"We examined the effects of <e1>anthocyanidins</e1> (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the <e2>aryl hydrocarbon receptor</e2> (AhR)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of <e1>anthocyanidins</e1> (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"We examined the effects of <e1>anthocyanidins</e1> (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Regulator"
"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM <e1>2,3,7,8-tetrachlorodibenzodioxin</e1> (TCDD), the most potent activator of <e2>AhR</e2>.","Upregulator"
"Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>TCDD</e1>), the most potent activator of <e2>AhR</e2>.","Upregulator"
"<e1>Pelargonidin</e1> activates the <e2>AhR</e2> and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.","Upregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Upregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Upregulator"
"Similarly, pelargonidin induced the expression of <e2>CYP1A1</e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM <e1>2,3,7,8-tetrachlorodibenzodioxin</e1> (TCDD), the most potent activator of AhR.","Upregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Upregulator"
"CYP1A1 and <e2>CYP1A2</e2> mRNAs were also increased by <e1>pelargonidin</e1> in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.","Upregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (<e2>AhR</e2>)-CYP1A1 signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Upregulator"
"Similarly, pelargonidin induced the expression of <e2>CYP1A1</e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>TCDD</e1>), the most potent activator of AhR.","Upregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Upregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Upregulator"
"Similarly, pelargonidin induced the expression of <e2>CYP1A1</e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>TCDD</e1>), the most potent activator of AhR.","Upregulator"
"CYP1A1 and <e2>CYP1A2</e2> mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of <e1>TCDD</e1> potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.","Upregulator"
"Similarly, pelargonidin induced the expression of <e2>CYP1A1</e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>TCDD</e1>), the most potent activator of AhR.","Upregulator"
"Similarly, pelargonidin induced the expression of <e2>CYP1A1</e2> mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (<e1>TCDD</e1>), the most potent activator of AhR.","Upregulator"
"We examined the effects of anthocyanidins (cyanidin, <e1>delphinidin</e1>, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Downregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Downregulator"
"We examined the effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, <e1>pelargonidin</e1>) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Downregulator"
"We examined the effects of anthocyanidins (cyanidin, <e1>delphinidin</e1>, malvidin, peonidin, petunidin, pelargonidin) on the aryl hydrocarbon receptor (AhR)-<e2>CYP1A1</e2> signaling pathway in human hepatocytes, hepatic HepG2 and intestinal LS174T cancer cells.","Downregulator"
"Cloning and expression of a novel <e2>serotonin receptor</e2> with high affinity for <e1>tricyclic</e1> psychotropic drugs.","Regulator"
"The inhibition of <e1>[125I]LSD</e1> binding by other serotonergic agonists and antagonists revealed a pharmacological profile that does not correlate with that of any previously described <e2>serotonin receptor</e2> subtype.","Regulator"
"In HEK-293 cells stably transfected with this receptor, <e1>serotonin</e1> elicits a potent stimulation of <e2>adenylyl cyclase</e2> activity, which is blocked by antipsychotic and antidepressant drugs.","Upregulator"
"A head-to-head comparison between <e2>insulin</e2> detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma <e1>glucose</e1> improved with insulin detemir without an increased incidence of hypoglycaemia.","Upregulator"
"BACKGROUND: Delta(6)-Desaturase (<e2>FADS2</e2>) is the rate-limiting step in the polyunsaturated fatty acid (<e1>PUFA</e1>) biosynthetic pathway.","Substrate"
"OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of <e2>FADS2</e2> affects the PUFA biosynthetic pathway and consequently modifies the effect of <e1>alpha-linolenic acid</e1> (ALA) on myocardial infarction (MI).","Substrate"
"OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of <e2>FADS2</e2> affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (<e1>ALA</e1>) on myocardial infarction (MI).","Substrate"
"We topically applied the <e2>nitric oxide synthase</e2> (NOS) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a <e1>cilazapril</e1> diet.","Regulator"
"We evaluated the effects of <e2>angiotensin II</e2> and an angiotensin-converting enzyme inhibitor (<e1>cilazapril</e1>) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.","Downregulator"
"We evaluated the effects of angiotensin II and an <e2>angiotensin-converting enzyme</e2> inhibitor (<e1>cilazapril</e1>) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.","Downregulator"
"We topically applied the nitric oxide synthase (<e2>NOS</e2>) inhibitor, <e1>NG-nitro-L-arginine</e1>, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.","Downregulator"
"We topically applied the <e2>nitric oxide synthase</e2> (NOS) inhibitor, <e1>NG-nitro-L-arginine</e1>, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.","Downregulator"
"The R(-) and S(+) isomers of MDMA were significantly less efficacious at the <e2>5-HT2A</e2> receptor as compared to MDA; <e1>S(+)MDMA</e1> had no effect.","Not"
"The <e1>R(-) and S(+) isomers of MDMA</e1> were significantly less efficacious at the <e2>5-HT2A</e2> receptor as compared to MDA; S(+)MDMA had no effect.","Not"
"Effect of the R(-) and S(+) isomers of MDA and <e1>MDMA</e1> on phosphatidyl inositol turnover in cultured cells expressing <e2>5-HT2A</e2> or 5-HT2C receptors.","Regulator"
"Effect of the R(-) and S(+) isomers of MDA and <e1>MDMA</e1> on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or <e2>5-HT2C</e2> receptors.","Regulator"
"Effect of the R(-) and S(+) isomers of <e1>MDA</e1> and MDMA on phosphatidyl inositol turnover in cultured cells expressing <e2>5-HT2A</e2> or 5-HT2C receptors.","Regulator"
"Effect of the R(-) and S(+) isomers of <e1>MDA</e1> and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or <e2>5-HT2C</e2> receptors.","Regulator"
"Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing <e1>5-HT</e1>2A or 5-HT2C receptors.","Regulator"
"Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing <e1>5-HT</e1>2A or <e2>5-HT2C</e2> receptors.","Regulator"
"Effect of the R(-) and S(+) isomers of <e1>MDA</e1> and MDMA on phosphatidyl inositol turnover in cultured cells expressing <e2>5-HT2A</e2> or 5-HT2C receptors.","Regulator"
"At the <e2>5-HT2C</e2> receptor, both <e1>R(-) and S(+)MDA</e1> were equipotent at stimulating PI hydrolysis, with the S(+) isomer of MDMA being more efficacious at the 5-HT2C receptor compared with the R(-) isomer.","Regulator"
"At the <e2>5-HT2C</e2> receptor, both R(-) and S(+)MDA were equipotent at stimulating PI hydrolysis, with the <e1>S(+) isomer of MDMA</e1> being more efficacious at the 5-HT2C receptor compared with the R(-) isomer.","Regulator"
"Effect of the R(-) and S(+) isomers of <e1>MDA</e1> and MDMA on phosphatidyl inositol turnover in cultured cells expressing <e2>5-HT2A</e2> or 5-HT2C receptors.","Regulator"
"The isomers of MDA produced a concentration dependent increase in phosphatidyl inositol (PI) hydrolysis at the <e2>5-HT2A</e2> receptors, with the <e1>R(-) isomer of MDA</e1> being more potent than the S(+) at the 5-HT2A receptor.","Regulator"
"ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates <e2>Stat3</e2> in <e1>tyrosine</e1>, allowing its dimerization.","Part_of"
"Also, ROS from NADPH oxidase favors ERK1/2 activation that phosphorylates <e2>Stat3</e2> in <e1>serine</e1>, resulting in a compensatory or adaptive survival response such as production of metallothionein-II in short Cd exposure times.","Part_of"
"Also, ROS from NADPH oxidase favors ERK1/2 activation that phosphorylates Stat3 in serine, resulting in a compensatory or adaptive survival response such as production of <e2>metallothionein-II</e2> in short <e1>Cd</e1> exposure times.","Regulator"
"<e1>Cadmium</e1> activates <e2>NADPH oxidase</e2>.","Upregulator"
"However, after 12h <e1>CdCl2</e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in <e2>p53</e2> activation and the pro-apoptotic protein Bax.","Upregulator"
"However, after 12h <e1>CdCl2</e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein <e2>Bax</e2>.","Upregulator"
"However, after 12h <e1>CdCl2</e1> treatment, cell viability diminished in 50%, accompanied by a drastic decrease of <e2>metallothionein-II</e2> production, and an increase in p53 activation and the pro-apoptotic protein Bax.","Downregulator"
"CONCLUSION: The peptide sequences containing <e1>Tyr</e1>, Phe conservative residues identified in this study can bind to cell surface <e2>IL-2Ralpha</e2>.","Regulator"
"CONCLUSION: The peptide sequences containing Tyr, <e1>Phe</e1> conservative residues identified in this study can bind to cell surface <e2>IL-2Ralpha</e2>.","Regulator"
"Ginseng total saponins, <e1>ginsenoside</e1>s Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma <e2>IL-6</e2> level.","Not"
"Ginsenosides Rb2, Rd and Rg1 significantly decreased nor<e1>epinephrine</e1> and/or epinephrine-induced increase of <e2>IL-6</e2> level in macrophage cell line (RAW 264.7).","Upregulator"
"Ginsenosides Rb2, Rd and Rg1 significantly decreased <e1>norepinephrine</e1> and/or epinephrine-induced increase of <e2>IL-6</e2> level in macrophage cell line (RAW 264.7).","Upregulator"
"Ginsenosides Rb2, Rd and Rg1 significantly decreased nor<e1>epinephrine</e1> and/or epinephrine-induced increase of <e2>IL-6</e2> level in macrophage cell line (RAW 264.7).","Upregulator"
"Ginsenosides Rb2, Rd and Rg1 significantly decreased <e1>norepinephrine</e1> and/or epinephrine-induced increase of <e2>IL-6</e2> level in macrophage cell line (RAW 264.7).","Upregulator"
"The inhibitory effect of <e1>ginseng saponins</e1> on the stress-induced plasma <e2>interleukin-6</e2> level in mice.","Downregulator"
"The effect of ginseng <e1>saponins</e1> on plasma interleukin-6 (<e2>IL-6</e2>) in non-stressed and immobilization-stressed mice were investigated.","Downregulator"
"Ginseng total saponins, <e1>ginsenosides Rb2, Rg1 and Rd</e1> administered intraperitoneally attenuated the immobilization stress-induced increase in plasma <e2>IL-6</e2> level.","Downregulator"
"<e1>Ginsenosides Rb2, Rd and Rg1</e1> significantly decreased norepinephrine and/or epinephrine-induced increase of <e2>IL-6</e2> level in macrophage cell line (RAW 264.7).","Downregulator"
"The effect of <e1>ginseng saponins</e1> on plasma interleukin-6 (<e2>IL-6</e2>) in non-stressed and immobilization-stressed mice were investigated.","Downregulator"
"The effect of <e1>ginseng saponins</e1> on plasma interleukin-6 (<e2>IL-6</e2>) in non-stressed and immobilization-stressed mice were investigated.","Downregulator"
"In large, well designed phase III trials in patients with type 2 diabetes mellitus, <e1>sitagliptin</e1> 100 or 200mg once daily alone or in combination with other antihyperglycaemics was associated with significant improvements relative to placebo in overall glycaemic control and indices for <e2>insulin</e2> response and beta-cell function.","Regulator"
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>HbA(1c)</e2> to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to <e1>glipizide</e1> when added to metformin.","Regulator"
"Improvements from baseline in mean <e2>glycosylated haemoglobin</e2> (HbA(1c)) were significantly greater with <e1>sitagliptin</e1> monotherapy than with placebo in patients with type 2 diabetes.","Upregulator"
"Improvements from baseline in mean glycosylated haemoglobin (<e2>HbA(1c)</e2>) were significantly greater with <e1>sitagliptin</e1> monotherapy than with placebo in patients with type 2 diabetes.","Upregulator"
"Improvements from baseline in mean glycosylated haemoglobin (<e2>HbA(1c)</e2>) were significantly greater with <e1>sitagliptin</e1> monotherapy than with placebo in patients with type 2 diabetes.","Upregulator"
"<e1>Sitagliptin</e1>, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the <e2>incretin hormones</e2> glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.","Upregulator"
"<e1>Sitagliptin</e1>, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones <e2>glucagon-like peptide-1</e2> and glucose-dependent insulinotropic polypeptide.","Upregulator"
"<e1>Sitagliptin</e1>, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and <e2>glucose-dependent insulinotropic polypeptide</e2>.","Upregulator"
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>HbA(1c)</e2> to a significantly greater extent than placebo when added to <e1>metformin</e1> or pioglitazone and was noninferior to glipizide when added to metformin.","Upregulator"
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>HbA(1c)</e2> to a significantly greater extent than placebo when added to metformin or <e1>pioglitazone</e1> and was noninferior to glipizide when added to metformin.","Upregulator"
"As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved <e2>HbA(1c)</e2> to a significantly greater extent than placebo when added to <e1>metformin</e1> or pioglitazone and was noninferior to glipizide when added to metformin.","Downregulator"
"<e1>Sitagliptin</e1>, an oral dipeptidyl peptidase-4 (<e2>DPP-4</e2>) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.","Downregulator"
"<e1>Sitagliptin</e1>, an oral <e2>dipeptidyl peptidase-4</e2> (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.","Downregulator"
"<e1>Sitagliptin</e1>, an oral dipeptidyl peptidase-4 (<e2>DPP-4</e2>) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.","Downregulator"
"In addition, pretreatment with <e1>Z-Val-Ala-Asp-fluoromethylketone</e1> (Z-VAD-fmk), a broad spectrum of <e2>caspase</e2> inhibitor, could not rescue apoptotic cells from ClpP toxicity.","Downregulator"
"In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone (<e1>Z-VAD-fmk</e1>), a broad spectrum of <e2>caspase</e2> inhibitor, could not rescue apoptotic cells from ClpP toxicity.","Downregulator"
"Along with weight loss, <e1>orlistat</e1> also favourably affects blood pressure and glucose and <e2>insulin</e2> levels in obese individuals and in obese type 2 diabetic patients.","Regulator"
"In the long term, <e1>orlistat</e1> has been shown to be more effective than placebo in reducing body weight and serum total and <e2>low-density lipoprotein</e2> cholesterol levels.","Downregulator"
"<e1>Orlistat</e1> is a new inhibitor of <e2>pancreatic lipase</e2> enzyme.","Downregulator"
"<e1>Genistin</e1> decreased <e2>myosin light chain kinase</e2> (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.","Downregulator"
"<e1>Genistin</e1> decreased myosin light chain kinase (<e2>MLCK</e2>) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.","Downregulator"
"<e1>Genistin</e1> decreased myosin light chain kinase (<e2>MLCK</e2>) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.","Downregulator"
"Genistin decreased myosin light chain kinase (<e2>MLCK</e2>) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the <e1>genistin</e1>-induced inhibitory effects.","Downregulator"
"<e1>Genistin</e1> decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-<e2>ATPase</e2> activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.","Downregulator"
"Genistin decreased myosin light chain kinase (<e2>MLCK</e2>) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the <e1>genistin</e1>-induced inhibitory effects.","Downregulator"
"The expression pattern of <e2>Sim2</e2> and Drebrin correspond to 50mmol/L <e1>glucose</e1> (hyperglycaemia) was also found in primary cultured neurons.","Regulator"
"The expression pattern of Sim2 and <e2>Drebrin</e2> correspond to 50mmol/L <e1>glucose</e1> (hyperglycaemia) was also found in primary cultured neurons.","Regulator"
"Moreover, <e1>curcumin</e1> alleviated <e2>Sim2</e2> expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia.","Upregulator"
"Moreover, <e1>curcumin</e1> alleviated Sim2 expression, and reversely raised <e2>Drebrin</e2> expression in neurons treated with hyperglycaemia.","Upregulator"
"It was found that expression of <e2>Sim2</e2> protein in cortical neurons was increased in <e1>streptozotocin</e1>-induced diabetes mellitus rat model.","Upregulator"
"Polymorphisms in dopamine transporter (<e2>SLC6A3</e2>) are associated with stimulant effects of <e1>D-amphetamine</e1>: an exploratory pharmacogenetic study using healthy volunteers.","Upregulator"
"Polymorphisms in <e2>dopamine transporter</e2> (SLC6A3) are associated with stimulant effects of <e1>D-amphetamine</e1>: an exploratory pharmacogenetic study using healthy volunteers.","Upregulator"
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by <e1>cyclopiazonic acid</e1> (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial <e2>SERCA</e2> pump.","Downregulator"
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid (<e1>CPA</e1>), which promotes store-operated Ca(2+) entry by inhibiting the endothelial <e2>SERCA</e2> pump.","Downregulator"
"Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the <e2>NADPH oxidase</e2> inhibitor <e1>apocynin</e1>.","Downregulator"
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <e2>G protein-coupled receptor</e2> agonist <e1>acetylcholine</e1> (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.","Agonist"
"Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the <e2>G protein-coupled receptor</e2> agonist acetylcholine (<e1>ACh</e1>) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump.","Agonist"
"Potentiation was prevented by catalase, the catalase/<e1>superoxide</e1> dismutase mimetic manganese porphyrin and the <e2>NADPH oxidase</e2> inhibitor apocynin.","Substrate"
"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin</e1> biosynthesis such as <e2>l-phenylalanine ammonia-lyase</e2> (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX).","Substrate"
"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin</e1> biosynthesis such as l-phenylalanine ammonia-lyase (<e2>PAL</e2>) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX).","Substrate"
"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin</e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and <e2>chalcone synthase</e2> (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX).","Substrate"
"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin</e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (<e2>CHS</e2>), and an antioxidant enzyme such as ascorbate peroxidase (APX).","Substrate"
"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin</e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as <e2>ascorbate peroxidase</e2> (APX).","Substrate"
"We isolated partial cDNAs that codified for enzymes implicated in the <e1>anthocyanin</e1> biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (<e2>APX</e2>).","Substrate"
"The fact that <e1>acetaminophen</e1> acts functionally as a selective <e2>COX-2</e2> inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.","Downregulator"
"In vitro, <e1>acetaminophen</e1> elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for <e2>COX-1</e2>; IC(50)=25.8 micromol/L for COX-2).","Downregulator"
"The fact that <e1>acetaminophen</e1> acts functionally as a selective <e2>COX-2</e2> inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.","Downregulator"
"<e1>Acetaminophen</e1> plasma concentrations remained above the in vitro IC(50) for <e2>COX-2</e2> for at least 5 h postadministration.","Downregulator"
"<e1>Acetaminophen</e1> (paracetamol) is a selective <e2>cyclooxygenase-2</e2> inhibitor in man.","Downregulator"
"Acetaminophen (<e1>paracetamol</e1>) is a selective <e2>cyclooxygenase-2</e2> inhibitor in man.","Downregulator"
"In vitro, <e1>acetaminophen</e1> elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for <e2>COX-1</e2>; IC(50)=25.8 micromol/L for COX-2).","Downregulator"
"The fact that <e1>acetaminophen</e1> acts functionally as a selective <e2>COX-2</e2> inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.","Downregulator"
"The fact that <e1>acetaminophen</e1> acts functionally as a selective <e2>COX-2</e2> inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.","Downregulator"
"The fact that <e1>acetaminophen</e1> acts functionally as a selective <e2>COX-2</e2> inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.","Downregulator"
"The fact that <e1>acetaminophen</e1> acts functionally as a selective <e2>COX-2</e2> inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.","Downregulator"
"The fact that <e1>acetaminophen</e1> acts functionally as a selective <e2>COX</e2>-2 inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.","Downregulator"
"Coagulation-induced <e1>thromboxane B(2)</e1> and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of <e2>COX-1</e2> and COX-2 activity.","Substrate"
"Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced <e1>prostaglandin E(2)</e1> were measured ex vivo and in vitro in human whole blood as indices of COX-1 and <e2>COX-2</e2> activity.","Substrate"
"In the interaction of <e1>GAL</e1> and CAR, <e2>AChE</e2> inhibition was stronger but without any statistical significance.","Downregulator"
"OBJECTIVES: The alkaloid <e1>galantamine</e1> (GAL), which exhibits a combined <e2>anticholinesterase</e2> and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.","Downregulator"
"OBJECTIVES: The alkaloid galantamine (<e1>GAL</e1>), which exhibits a combined <e2>anticholinesterase</e2> and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.","Downregulator"
"In the interaction of <e1>GAL</e1> and CAR, <e2>AChE</e2> inhibition was stronger but without any statistical significance.","Downregulator"
"<e1>NaAsO(2)</e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the <e2>heavy subunit of neurofilament</e2>, microtubule-associated protein 2, or actin.","Not"
"<e1>NaAsO(2)</e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, <e2>microtubule-associated protein 2</e2>, or actin.","Not"
"<e1>NaAsO(2)</e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or <e2>actin</e2>.","Not"
"In this study, we performed live imaging analyses of Neuro-2a cells expressing SCAT3, a <e2>caspase-3</e2> cleavage peptide sequence linking two fluorescent proteins; enhanced cyan fluorescence protein (ECFP) and Venus, to determine whether sodium arsenite (<e1>NaAsO(2)</e1>; 0, 1, 5, or 10 μM) affects both neurite outgrowth and/or induces apoptosis with the same doses and in the same cell cultures.","Not"
"<e1>NaAsO(2)</e1> increased the mRNA levels of the <e2>light and medium subunits of neurofilament</e2> and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.","Upregulator"
"<e1>NaAsO(2)</e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of <e2>tau</e2> and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.","Downregulator"
"<e1>NaAsO(2)</e1> increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and <e2>tubulin</e2> in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin.","Downregulator"
"The interaction of <e1>naloxone estrone azine</e1> (N-EH) with various <e2>opioid receptor</e2> types was studied in vitro.","Regulator"
"The interaction of naloxone estrone azine (<e1>N-EH</e1>) with various <e2>opioid receptor</e2> types was studied in vitro.","Regulator"
"A <e1>naloxone-steroid hybrid azine</e1> with selective and long-acting opioid antagonism at <e2>delta receptors</e2> in vitro.","Antagonist"
"In this report, we show that the hypolipidemic agent <e1>atorvastatin</e1> is a competitive inhibitor of <e2>porcine DPP-IV</e2> in vitro, with K(i)=57.8+/-2.3 microM.","Downregulator"
"Inhibition of dipeptidyl peptidase-IV (<e2>DPP-IV</e2>) by <e1>atorvastatin</e1>.","Downregulator"
"Inhibition of <e2>dipeptidyl peptidase-IV</e2> (DPP-IV) by <e1>atorvastatin</e1>.","Downregulator"
"Inhibition of dipeptidyl peptidase-IV (<e2>DPP-IV</e2>) by <e1>atorvastatin</e1>.","Downregulator"
"In addition, we found that <e1>neoechinulin A</e1> significantly suppressed the production of neurotoxic inflammatory mediator <e2>tumour necrosis factor-α</e2> (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.","Downregulator"
"In addition, we found that <e1>neoechinulin A</e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (<e2>TNF-α</e2>), interleukin-1β (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.","Downregulator"
"In addition, we found that <e1>neoechinulin A</e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), <e2>interleukin-1β</e2> (IL-1β), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.","Downregulator"
"In addition, we found that <e1>neoechinulin A</e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (<e2>IL-1β</e2>), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.","Downregulator"
"In addition, we found that <e1>neoechinulin A</e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), <e2>interleukin-6</e2> (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.","Downregulator"
"In addition, we found that <e1>neoechinulin A</e1> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (<e2>IL-6</e2>), and prostaglandin E2 (PGE2) in activated BV-2 cells.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of <e2>nuclear factor-κB</e2> (NF-κB) p65 and p50 subunits.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (<e2>NF-κB</e2>) p65 and p50 subunits.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) <e2>p65</e2> and p50 subunits.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and <e2>p50</e2> subunits.","Downregulator"
"<e1>Neoechinulin A</e1> suppresses <e2>amyloid-β</e2> oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of <e2>mitogen-activated protein kinase</e2> (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (<e2>MAPK</e2>) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule <e2>p38</e2>, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, <e2>apoptosis signal-regulating kinase 1</e2> (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits.","Downregulator"
"The molecular mechanism studies suggested that <e1>neoechinulin A</e1> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (<e2>ASK-1</e2>) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits.","Downregulator"
"In this study, focus was given to evaluate the ability of <e1>neoechinulin A</e1>, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric <e2>amyloid-β 1-42</e2> (Aβ42).","Downregulator"
"In this study, focus was given to evaluate the ability of <e1>neoechinulin A</e1>, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-β 1-42 (<e2>Aβ42</e2>).","Downregulator"
"In this study, focus was given to evaluate the ability of neoechinulin A, an <e1>indole</e1> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric <e2>amyloid-β 1-42</e2> (Aβ42).","Downregulator"
"In this study, focus was given to evaluate the ability of neoechinulin A, an <e1>indole</e1> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-β 1-42 (<e2>Aβ42</e2>).","Downregulator"
"<e1>Neoechinulin A</e1> treatment significantly inhibited the generation of reactive oxygen and nitrogen species in <e2>Aβ42</e2>-activated BV-2 microglia cells.","Downregulator"
"<e1>Epi</e1> increased the activity of the human WNT6 promoter through <e2>Cav1</e2>-dependent binding of β-catenin to the proximal WNT6 promoter.","Regulator"
"<e1>Epi</e1> increased the activity of the human WNT6 promoter through Cav1-dependent binding of <e2>β-catenin</e2> to the proximal WNT6 promoter.","Regulator"
"<e1>Epi</e1> increased the activity of the <e2>human WNT6 promoter</e2> through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.","Upregulator"
"<e1>Epi</e1> increased the activity of the human <e2>WNT6 promoter</e2> through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.","Upregulator"
"<e2>WNT6</e2> knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (<e1>Epi</e1>) and doxorubicin (Dox).","Upregulator"
"<e1>Epi</e1> increased both WNT6/<e2>Wnt6</e2> and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).","Upregulator"
"<e1>Epi</e1> increased the activity of the human WNT6 promoter through <e2>Cav1</e2>-dependent binding of β-catenin to the proximal WNT6 promoter.","Upregulator"
"<e2>WNT6</e2> knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the <e1>anthracycline</e1> chemotherapeutics epirubicin (Epi) and doxorubicin (Dox).","Upregulator"
"These results showed that WNT6 and <e2>Cav1</e2> are upregulated by chemotherapeutics and enhance the resistance of GC cells to <e1>anthracycline</e1> drugs.","Upregulator"
"In concert with these results, we highlighted that the secretion of pro-inflammatory <e2>cytokine</e2> and NF-κB activation induced by TCDD can be mediated by elevation of [<e1>Ca(2+)</e1>]i in HAPI microglial cells.","Regulator"
"However, <e1>Ca(2+)</e1> blockers also obviously attenuated <e2>NF-κB</e2> activation and transnuclear transport induced by TCDD.","Regulator"
"Further, <e1>TCDD</e1> exposure could induce phosphorylation- and ubiquitination-dependent degradation of <e2>IкBα</e2>, and the translocation of NF-κB p65 from the cytosol to the nucleus in this microglial cell line.","Upregulator"
"Further, <e1>TCDD</e1> exposure could induce phosphorylation- and ubiquitination-dependent degradation of IкBα, and the translocation of <e2>NF-κB</e2> p65 from the cytosol to the nucleus in this microglial cell line.","Upregulator"
"Further, <e1>TCDD</e1> exposure could induce phosphorylation- and ubiquitination-dependent degradation of IкBα, and the translocation of <e2>NF-κB</e2> p65 from the cytosol to the nucleus in this microglial cell line.","Upregulator"
"In concert with these results, we highlighted that the secretion of pro-inflammatory <e2>cytokine</e2> and NF-κB activation induced by <e1>TCDD</e1> can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.","Upregulator"
"Further, <e1>TCDD</e1> exposure could induce phosphorylation- and ubiquitination-dependent degradation of IкBα, and the translocation of <e2>NF-κB</e2> p65 from the cytosol to the nucleus in this microglial cell line.","Upregulator"
"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that <e1>TCDD</e1> up-regulated the expression and secretion of <e2>tumor necrosis factor-alpha</e2> (TNF-α) in a time-dependent manner in cultured HAPI microglial cells.","Upregulator"
"In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that <e1>TCDD</e1> up-regulated the expression and secretion of tumor necrosis factor-alpha (<e2>TNF-α</e2>) in a time-dependent manner in cultured HAPI microglial cells.","Upregulator"
"<e1>TCDD</e1> also caused a fast (within 30min as judged by the increase in its mRNA level) activation of <e2>cytosolic phospholipase A2</e2> (cPLA2).","Upregulator"
"<e1>TCDD</e1> also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 (<e2>cPLA2</e2>).","Upregulator"
"This initial action was accompanied by up-regulation of <e2>cyclooxygenase-2</e2> (COX-2), an important inflammation marker within 1h after <e1>TCDD</e1> treatment.","Upregulator"
"This initial action was accompanied by up-regulation of cyclooxygenase-2 (<e2>COX-2</e2>), an important inflammation marker within 1h after <e1>TCDD</e1> treatment.","Upregulator"
"Further, <e1>TCDD</e1> exposure could induce phosphorylation- and ubiquitination-dependent degradation of IкBα, and the translocation of <e2>NF-κB</e2> p65 from the cytosol to the nucleus in this microglial cell line.","Upregulator"
"<e1>Eprosartan</e1> acts at vascular <e2>AT1 receptors</e2> (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release.","Regulator"
"<e1>Eprosartan</e1> acts at vascular <e2>AT1 receptors</e2> (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release.","Regulator"
"The ARB <e1>eprosartan</e1> is a nonbiphenyl nontetrazole <e2>angiotensin II type 1 receptor</e2> (AT1) antagonist, which acts to decrease total peripheral resistance.","Antagonist"
"The ARB <e1>eprosartan</e1> is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (<e2>AT1</e2>) antagonist, which acts to decrease total peripheral resistance.","Antagonist"
"Combined concentration-ratio analysis demonstrated that <e1>tamsulosin</e1>, which does not discriminate between <e2>alpha 1A</e2>- and alpha 1L-adrenoceptors, and RS-17053 competed for binding at the same site in the SMA.","Regulator"
"Combined concentration-ratio analysis demonstrated that <e1>tamsulosin</e1>, which does not discriminate between alpha 1A- and <e2>alpha 1L-adrenoceptors</e2>, and RS-17053 competed for binding at the same site in the SMA.","Regulator"
"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective <e2>alpha 1A</e2>-adrenoceptor antagonist <e1>RS-17053</e1> against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.","Regulator"
"Combined concentration-ratio analysis demonstrated that tamsulosin, which does not discriminate between alpha 1A- and <e2>alpha 1L-adrenoceptors</e2>, and <e1>RS-17053</e1> competed for binding at the same site in the SMA.","Regulator"
"<e1>Prazosin</e1> antagonized all agonists with a low potency (pA2: 8.29-8.80) indicating the involvement of <e2>alpha 1L</e2>-rather than alpha 1A-adrenoceptors.","Regulator"
"<e1>Prazosin</e1> antagonized all agonists with a low potency (pA2: 8.29-8.80) indicating the involvement of alpha 1L-rather than <e2>alpha 1A-adrenoceptors</e2>.","Regulator"
"To illuminate the controversy on <e2>alpha 1A</e2>- or alpha 1L-adrenoceptor involvement in <e1>noradrenaline</e1>-mediated contractions of rat small mesenteric artery (SMA), we have studied the effects of subtype-selective alpha 1-adrenoceptor agonists and antagonists under different experimental conditions.","Regulator"
"To illuminate the controversy on alpha 1A- or <e2>alpha 1L-adrenoceptor</e2> involvement in <e1>noradrenaline</e1>-mediated contractions of rat small mesenteric artery (SMA), we have studied the effects of subtype-selective alpha 1-adrenoceptor agonists and antagonists under different experimental conditions.","Regulator"
"Selective protection of a putative <e2>alpha 1A-adrenoceptor</e2> population against the irreversible action of <e1>phenoxybenzamine</e1> also failed to increase the potency of RS-17053 (pA2 = 8.25 +/- 0.06 against A61603).","Regulator"
"To illuminate the controversy on alpha 1A- or alpha 1L-adrenoceptor involvement in <e1>noradrenaline</e1>-mediated contractions of rat small mesenteric artery (SMA), we have studied the effects of subtype-selective <e2>alpha 1-adrenoceptor</e2> agonists and antagonists under different experimental conditions.","Regulator"
"To illuminate the controversy on alpha 1A- or <e2>alpha 1L-adrenoceptor</e2> involvement in <e1>noradrenaline</e1>-mediated contractions of rat small mesenteric artery (SMA), we have studied the effects of subtype-selective alpha 1-adrenoceptor agonists and antagonists under different experimental conditions.","Regulator"
"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective <e2>alpha 1A-adrenoceptor</e2> antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist <e1>A-61603</e1> (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.","Agonist"
"The putative <e2>alpha 1L-adrenoceptor</e2> antagonist <e1>JTH-601</e1>, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.","Antagonist"
"The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the <e2>alpha 1B-adrenoceptor</e2> antagonist <e1>chloroethylclonidine</e1> (10 microM) antagonized noradrenaline-induced contractions of SMA.","Antagonist"
"The potency of the selective <e2>alpha 1D-adrenoceptor</e2> antagonist <e1>BMY 7378</e1> against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.","Antagonist"
"The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective <e2>alpha 1A-adrenoceptor</e2> antagonist <e1>RS-17053</e1> against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.","Antagonist"
"Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <e2>dopamine D1 receptor</e2> antagonist <e1>SCH 39166</e1> ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).","Antagonist"
"Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the <e2>dopamine D1 receptor</e2> antagonist SCH 39166 (<e1>(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine</e1>) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).","Antagonist"
"Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the <e2>dopamine D2 receptor</e2> antagonist <e1>raclopride</e1> (both at 0.003-0.03 mg/kg).","Antagonist"
"<e1>Carvedilol</e1> reduced the risk of death or heart failure in patients with above-median levels of <e2>N-BNP</e2> or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value.","Downregulator"
"<e1>Carvedilol</e1> reduced the risk of death or heart failure in patients with above-median levels of N-BNP or <e2>adrenomedullin</e2>, or both, to rates not significantly different from those observed in patients with levels below the median value.","Downregulator"
"<e1>Carvedilol</e1> reduced the risk of death or heart failure in patients with above-median levels of <e2>N-BNP</e2> or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value.","Downregulator"
"<e1>Carvedilol</e1> reduced the risk of death or heart failure in patients with above-median levels of N-BNP or <e2>adrenomedullin</e2>, or both, to rates not significantly different from those observed in patients with levels below the median value.","Downregulator"
"The inhibition of phosphoinositide 3-kinase using <e1>Ly294002</e1> augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of <e2>Sp1</e2> and cyclin D1.","Not"
"The inhibition of phosphoinositide 3-kinase using <e1>Ly294002</e1> augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and <e2>cyclin D1</e2>.","Not"
"In combination with <e1>clofarabine</e1>, the ability of resveratrol to reduce the contents of <e2>Sp1</e2> and its target gene products was also evident in a time- and dose-dependent experiment.","Downregulator"
"In combination with clofarabine, the ability of <e1>resveratrol</e1> to reduce the contents of <e2>Sp1</e2> and its target gene products was also evident in a time- and dose-dependent experiment.","Downregulator"
"In combination with <e1>clofarabine</e1>, the ability of resveratrol to reduce the contents of <e2>Sp1</e2> and its target gene products was also evident in a time- and dose-dependent experiment.","Downregulator"
"In combination with clofarabine, the ability of <e1>resveratrol</e1> to reduce the contents of <e2>Sp1</e2> and its target gene products was also evident in a time- and dose-dependent experiment.","Downregulator"
"The inhibition of phosphoinositide 3-kinase using <e1>Ly294002</e1> augmented a decrease in the <e2>p21</e2> level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.","Downregulator"
"Taken together, the data provide evidence that the synergistic antiproliferative effect of <e1>resveratrol</e1> and clofarabine is linked to the inhibition of <e2>Akt</e2> and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","Downregulator"
"In combination with clofarabine, the ability of <e1>resveratrol</e1> to reduce the contents of <e2>Sp1</e2> and its target gene products was also evident in a time- and dose-dependent experiment.","Downregulator"
"Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and <e1>clofarabine</e1> is linked to the inhibition of <e2>Akt</e2> and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.","Downregulator"
"In combination with <e1>clofarabine</e1>, the ability of resveratrol to reduce the contents of <e2>Sp1</e2> and its target gene products was also evident in a time- and dose-dependent experiment.","Downregulator"
"The inhibition of <e2>phosphoinositide 3-kinase</e2> using <e1>Ly294002</e1> augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.","Downregulator"
"<e1>Phillyrin</e1> strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating <e2>sterol regulatory element-binding protein-1c</e2> (SREBP-1c) activation.","Regulator"
"<e1>Phillyrin</e1> strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c (<e2>SREBP-1c</e2>) activation.","Regulator"
"Moreover, use of the pharmacological AMP-activated protein kinase (<e2>AMPK</e2>) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in <e1>phillyrin</e1>-treated cells.","Upregulator"
"Finally, we found that liver kinase B1 (<e2>LKB1</e2>) phosphorylation is required for the <e1>phillyrin</e1>-enhanced activation of AMPK in HepG2 hepatocytes.","Upregulator"
"Moreover, use of the pharmacological AMP-activated protein kinase (<e2>AMPK</e2>) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in <e1>phillyrin</e1>-treated cells.","Upregulator"
"<e1>Phillyrin</e1> attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of <e2>LKB1</e2>/AMP-activated protein kinase-dependent signalling.","Upregulator"
"<e1>Phillyrin</e1> attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/<e2>AMP-activated protein kinase</e2>-dependent signalling.","Upregulator"
"Moreover, use of the pharmacological AMP-activated protein kinase (<e2>AMPK</e2>) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in <e1>phillyrin</e1>-treated cells.","Upregulator"
"Phillyrin strongly inhibited high <e1>glucose</e1>-induced <e2>fatty acid synthase</e2> (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.","Upregulator"
"Phillyrin strongly inhibited high <e1>glucose</e1>-induced fatty acid synthase (<e2>FAS</e2>) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.","Upregulator"
"Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing <e2>SREBP-1c</e2> expression in <e1>phillyrin</e1>-treated cells.","Downregulator"
"These results indicate that <e1>phillyrin</e1> prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and <e2>FAS</e2> through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.","Downregulator"
"<e1>Phillyrin</e1> strongly inhibited high glucose-induced <e2>fatty acid synthase</e2> (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.","Downregulator"
"<e1>Phillyrin</e1> strongly inhibited high glucose-induced fatty acid synthase (<e2>FAS</e2>) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.","Downregulator"
"Moreover, use of the pharmacological <e2>AMP-activated protein kinase</e2> (AMPK) inhibitor <e1>compound C</e1> revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.","Downregulator"
"Moreover, use of the pharmacological AMP-activated protein kinase (<e2>AMPK</e2>) inhibitor <e1>compound C</e1> revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.","Downregulator"
"Moreover, use of the pharmacological AMP-activated protein kinase (<e2>AMPK</e2>) inhibitor <e1>compound C</e1> revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.","Downregulator"
"To significantly improve the pharmacological properties of the drug, a pegylated form of <e2>IFNalpha(2a)</e2> was developed (<e1>PEG</e1>ASYS).","Part_of"
"This 40 kDa PEG-conjugated <e2>IFNalpha(2a)</e2> ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a <e1>lysine</e1> side-chain of IFNalpha(2a).","Part_of"
"While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of <e2>AKT-1</e2>, it increased phosphorylation at <e1>Ser</e1>517/Ser473.","Part_of"
"While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of <e2>AKT-1</e2>, it increased phosphorylation at <e1>Ser</e1>517/Ser473.","Part_of"
"A series of <e1>benzenesulfonamides</e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"A series of <e1>benzenesulfonamides</e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>ScCA</e2>.","Downregulator"
"A series of <e1>benzenesulfonamides</e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the <e2>β-carbonic anhydrase</e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"A series of <e1>benzenesulfonamides</e1> incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"A series of benzenesulfonamides incorporating <e1>cyanoacrylamide</e1> moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"A series of benzenesulfonamides incorporating <e1>cyanoacrylamide</e1> moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>ScCA</e2>.","Downregulator"
"Benzenesulfonamides incorporating <e1>cyanoacrylamide</e1> moieties strongly inhibit Saccharomyces cerevisiae <e2>β-carbonic anhydrase</e2>.","Downregulator"
"A series of benzenesulfonamides incorporating <e1>cyanoacrylamide</e1> moieties (tyrphostine analogs) were assayed as inhibitors of the β-carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine</e1> analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, <e2>EC 4.2.1.1</e2>) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine</e1> analogs) were assayed as inhibitors of the β-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, <e2>ScCA</e2>.","Downregulator"
"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine</e1> analogs) were assayed as inhibitors of the <e2>β-carbonic anhydrase</e2> (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"A series of benzenesulfonamides incorporating cyanoacrylamide moieties (<e1>tyrphostine</e1> analogs) were assayed as inhibitors of the β-carbonic anhydrase (<e2>CA</e2>, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.","Downregulator"
"<e1>Benzenesulfonamides</e1> incorporating cyanoacrylamide moieties strongly inhibit <e2>Saccharomyces cerevisiae β-carbonic anhydrase</e2>.","Downregulator"
"Benzenesulfonamides incorporating <e1>cyanoacrylamide</e1> moieties strongly inhibit <e2>Saccharomyces cerevisiae β-carbonic anhydrase</e2>.","Downregulator"
"The mRNA levels of <e2>microphthalmia-associated transcription factor</e2> (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>artemisinic acid</e1> treatment.","Downregulator"
"The mRNA levels of microphthalmia-associated transcription factor (<e2>MITF</e2>) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>artemisinic acid</e1> treatment.","Downregulator"
"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes <e2>tyrosinase</e2>, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by <e1>artemisinic acid</e1> treatment.","Downregulator"
"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, <e2>tyrosinase-related protein (TRP)-1</e2>, and TRP-2 were reduced by <e1>artemisinic acid</e1> treatment.","Downregulator"
"The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and <e2>TRP-2</e2> were reduced by <e1>artemisinic acid</e1> treatment.","Downregulator"
"Additionally, the mRNA levels of melanogenesis-related genes (<e2>c-KIT</e2>, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>artemisinic acid</e1>.","Downregulator"
"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, <e2>stem cell factor</e2> (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>artemisinic acid</e1>.","Downregulator"
"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (<e2>SCF</e2>), and macrophage migration inhibitory factor (MIF)) were down-regulated by <e1>artemisinic acid</e1>.","Downregulator"
"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and <e2>macrophage migration inhibitory factor</e2> (MIF)) were down-regulated by <e1>artemisinic acid</e1>.","Downregulator"
"Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (<e2>MIF</e2>)) were down-regulated by <e1>artemisinic acid</e1>.","Downregulator"
"Moreover, attempts to elucidate a possible mechanism underlying the <e1>artemisinic acid</e1>-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the <e2>hydroxymethylglutaryl CoA (HMG CoA) reductase</e2> gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene.","Downregulator"
"Moreover, attempts to elucidate a possible mechanism underlying the <e1>artemisinic acid</e1>-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the <e2>CCAAT/enhancer-binding protein (C/EBP) α</e2> gene.","Downregulator"
"<e1>Artemisinic acid</e1> inhibits melanogenesis through downregulation of C/EBP α-dependent expression of <e2>HMG-CoA reductase</e2> gene.","Downregulator"
"Taken together, these findings indicate that the inhibition of melanogenesis by <e1>artemisinic acid</e1> occurs through reduced expression of the <e2>HMG CoA reductase</e2> gene, which is mediated by C/EBP α inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.","Downregulator"
"Furthermore, cAMP production and <e2>protein kinase A</e2> (PKA) activity were suppressed by <e1>artemisinic acid</e1>.","Downregulator"
"Furthermore, cAMP production and protein kinase A (<e2>PKA</e2>) activity were suppressed by <e1>artemisinic acid</e1>.","Downregulator"
"<e1>Artemisinic acid</e1> inhibits melanogenesis through downregulation of <e2>C/EBP α</e2>-dependent expression of HMG-CoA reductase gene.","Downregulator"
"Taken together, these findings indicate that the inhibition of melanogenesis by <e1>artemisinic acid</e1> occurs through reduced expression of the HMG CoA reductase gene, which is mediated by <e2>C/EBP α</e2> inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.","Downregulator"
"<e1>Norethisterone</e1> metabolites modulate the <e2>uteroglobin</e2> and progesterone receptor gene expression in prepubertal rabbits.","Regulator"
"<e1>Norethisterone</e1> metabolites modulate the uteroglobin and <e2>progesterone receptor</e2> gene expression in prepubertal rabbits.","Regulator"
"The effects of these metabolites on the expression of <e2>uteroglobin</e2> (UG) and progesterone receptor (PR) genes, both regulated by <e1>progesterone (P4)</e1>, were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.","Regulator"
"The effects of these metabolites on the expression of uteroglobin (<e2>UG</e2>) and progesterone receptor (PR) genes, both regulated by <e1>progesterone (P4)</e1>, were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.","Regulator"
"The effects of these metabolites on the expression of uteroglobin (UG) and <e2>progesterone receptor</e2> (PR) genes, both regulated by <e1>progesterone (P4)</e1>, were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.","Regulator"
"The effects of these metabolites on the expression of uteroglobin (UG) and progesterone receptor (<e2>PR</e2>) genes, both regulated by <e1>progesterone (P4)</e1>, were evaluated in the uterus of prepubertal female rabbits that were simultaneously treated with P4 (1.0 mg) for 5 consecutive days.","Regulator"
"Both <e1>5 alpha-NET</e1> and 3 beta,5 alpha-NET blocked the <e2>PR</e2> down-regulation induced by P4 as assessed by Western and Northern blot methods.","Upregulator"
"Both 5 alpha-NET and <e1>3 beta,5 alpha-NET</e1> blocked the <e2>PR</e2> down-regulation induced by P4 as assessed by Western and Northern blot methods.","Upregulator"
"Both <e1>5 alpha-NET</e1> and 3 beta,5 alpha-NET blocked the <e2>PR</e2> down-regulation induced by P4 as assessed by Western and Northern blot methods.","Upregulator"
"As determined by Western and Northern blot analyses, <e1>5 alpha-NET</e1> inhibited the P4-induced <e2>UG</e2> gene expression in a dose-dependent manner.","Downregulator"
"The estrogenic agent <e1>3 beta,5 alpha-NET</e1> and estradiol at a dose of 1.0 mg also inhibited the <e2>UG</e2> gene expression induced by P4.","Downregulator"
"The estrogenic agent 3 beta,5 alpha-NET and <e1>estradiol</e1> at a dose of 1.0 mg also inhibited the <e2>UG</e2> gene expression induced by P4.","Downregulator"
"As determined by Western and Northern blot analyses, <e1>5 alpha-NET</e1> inhibited the P4-induced <e2>UG</e2> gene expression in a dose-dependent manner.","Downregulator"
"The estrogenic agent <e1>3 beta,5 alpha-NET</e1> and estradiol at a dose of 1.0 mg also inhibited the <e2>UG</e2> gene expression induced by P4.","Downregulator"
"Both 5 alpha-NET and <e1>3 beta,5 alpha-NET</e1> blocked the <e2>PR</e2> down-regulation induced by P4 as assessed by Western and Northern blot methods.","Downregulator"
"As determined by Western and Northern blot analyses, 5 alpha-<e1>NET</e1> inhibited the P4-induced <e2>UG</e2> gene expression in a dose-dependent manner.","Downregulator"
"Both 5 alpha-<e1>NET</e1> and 3 beta,5 alpha-NET blocked the <e2>PR</e2> down-regulation induced by P4 as assessed by Western and Northern blot methods.","Downregulator"
"<e1>Dioscin</e1>-induced autophagy mitigates cell apoptosis through modulation of <e2>PI3K</e2>/Akt and ERK and JNK signaling pathways in human lung cancer cell lines.","Regulator"
"<e1>Dioscin</e1>-induced autophagy mitigates cell apoptosis through modulation of PI3K/<e2>Akt</e2> and ERK and JNK signaling pathways in human lung cancer cell lines.","Regulator"
"<e1>Dioscin</e1>-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and <e2>ERK</e2> and JNK signaling pathways in human lung cancer cell lines.","Regulator"
"<e1>Dioscin</e1>-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and ERK and <e2>JNK</e2> signaling pathways in human lung cancer cell lines.","Regulator"
"<e1>Dioscin</e1>-induced autophagy via <e2>ERK1/2</e2> and JNK1/2 pathways may provide a protective mechanism for cell survival against dioscin-induced apoptosis to act as a cytoprotective reaction.","Regulator"
"<e1>Dioscin</e1>-induced autophagy via ERK1/2 and <e2>JNK1/2</e2> pathways may provide a protective mechanism for cell survival against dioscin-induced apoptosis to act as a cytoprotective reaction.","Regulator"
"Treatment of A549 and H1299 cells with <e1>dioscin</e1> caused a dose-dependent increase in <e2>ERK1/2</e2> and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.","Regulator"
"Treatment of A549 and H1299 cells with <e1>dioscin</e1> caused a dose-dependent increase in ERK1/2 and <e2>JNK1/2</e2> activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.","Regulator"
"Meanwhile, autophagy was detected as early as 12 h after an exposure to low-dose <e1>dioscin</e1>, as indicated by an up-regulated expression of <e2>LC3-II</e2> and beclin-1 proteins.","Upregulator"
"Meanwhile, autophagy was detected as early as 12 h after an exposure to low-dose <e1>dioscin</e1>, as indicated by an up-regulated expression of LC3-II and <e2>beclin-1</e2> proteins.","Upregulator"
"Treatment of A549 and H1299 cells with <e1>dioscin</e1> caused a dose-dependent increase in ERK1/2 and <e2>JNK1/2</e2> activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.","Upregulator"
"Treatment of A549 and H1299 cells with <e1>dioscin</e1> caused a dose-dependent increase in <e2>ERK1/2</e2> and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.","Upregulator"
"Treatment of A549 and H1299 cells with <e1>dioscin</e1> caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased <e2>PI3K</e2> expression and decreased phosphorylation of Akt and mTOR.","Downregulator"
"Treatment of A549 and H1299 cells with <e1>dioscin</e1> caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of <e2>Akt</e2> and mTOR.","Downregulator"
"Treatment of A549 and H1299 cells with <e1>dioscin</e1> caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and <e2>mTOR</e2>.","Downregulator"
"Our results showed that <e1>2-hydroxy-3-methylanthraquinone</e1> decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased p-p38MAPK, but did not affect expressions of <e2>p-JNK1/2</e2> in U937 cells.","Not"
"<e1>2-Hydroxy-3-methylanthraquinone</e1> from Hedyotis diffusa Willd induces apoptosis in human leukemic U937 cells through modulation of <e2>MAPK</e2> pathways.","Regulator"
"Our results showed that <e1>2-hydroxy-3-methylanthraquinone</e1> decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased <e2>p-p38MAPK</e2>, but did not affect expressions of p-JNK1/2 in U937 cells.","Upregulator"
"Our results showed that <e1>2-hydroxy-3-methylanthraquinone</e1> decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased <e2>p-p38MAPK</e2>, but did not affect expressions of p-JNK1/2 in U937 cells.","Upregulator"
"Moreover, treatment of U937 cells with <e1>2-hydroxy-3-methylanthraquinone</e1> resulted in activation of <e2>caspase-3</e2>.","Upregulator"
"Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or <e1>SB203580</e1> (<e2>p-p38MAPK</e2> inhibitor), decreased apoptosis in U937 cells.","Downregulator"
"In addition a deletion in one of the alleles of the <e2>deoxycytidine kinase</e2> was detected in the <e1>fludarabine</e1>-resistant line.","Regulator"
"<e2>Ribonucleotide reductase</e2> activity was found to be strongly increased in the <e1>gemcitabine</e1>-selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line.","Upregulator"
"Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and <e2>purine nucleoside phosphorylase</e2> was increased in the <e1>2-chlorodeoxyadenosine</e1>-selected line.","Upregulator"
"A new series of N2-substituted-<e1>5-(p-toluenesulfonylamino)phthalimide</e1> analogues as <e2>α-glucosidase</e2> inhibitors.","Downregulator"
"Several members of a new family of non-sugar-type <e2>α-glycosidase</e2> inhibitors, bearing a <e1>5-(p-toluenesulfonylamino)phthalimide</e1> moiety and various substituent at the N2 position, were synthesized and their activities were investigated.","Downregulator"
"A new series of <e1>N2-substituted-5-(p-toluenesulfonylamino)phthalimide</e1> analogues as <e2>α-glucosidase</e2> inhibitors.","Downregulator"
"The lysosomal inhibitor <e1>chloroquine</e1> significantly increased <e2>RCAN1</e2> accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition.","Upregulator"
"In addition to CYP2B6, <e1>anisomycin</e1> co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not <e2>CYP3A4</e2> or UDP-glucuronosyltransferase 1A1 mRNAs.","Not"
"In addition to CYP2B6, <e1>anisomycin</e1> co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or <e2>UDP-glucuronosyltransferase 1A1</e2> mRNAs.","Not"
"Here, we have now found that activation of p38 MAPK by <e1>anisomycin</e1> potentiated induction of CYP2B6 mRNA by <e2>CAR</e2> ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Regulator"
"Here, we have now found that activation of <e2>p38</e2> MAPK by <e1>anisomycin</e1> potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Upregulator"
"Here, we have now found that activation of p38 <e2>MAPK</e2> by <e1>anisomycin</e1> potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Upregulator"
"Here, we have now found that activation of p38 MAPK by <e1>anisomycin</e1> potentiated induction of <e2>CYP2B6</e2> mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Upregulator"
"Here, we have now found that activation of p38 MAPK by <e1>anisomycin</e1> potentiated induction of <e2>CYP2B6</e2> mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Upregulator"
"Here, we have now found that activation of p38 MAPK by <e1>anisomycin</e1> potentiated induction of <e2>CYP2B6</e2> mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.","Upregulator"
"In addition to CYP2B6, <e1>anisomycin</e1> co-treatment potentiated an increase in <e2>CYP2A7</e2> and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.","Upregulator"
"In addition to CYP2B6, <e1>anisomycin</e1> co-treatment potentiated an increase in CYP2A7 and <e2>CYP2C9</e2> mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.","Upregulator"
"No effects were observed when <e1>fenclozic acid</e1> was assessed for <e2>P450</e2>-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.","Not"
"No effects were observed when <e1>fenclozic acid</e1> was assessed for <e2>P450</e2>-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.","Not"
"No effects were observed when <e1>fenclozic acid</e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major <e2>human cytochrome P450</e2> enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.","Downregulator"
"No effects were observed when <e1>fenclozic acid</e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary <e2>efflux transporters</e2> BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.","Downregulator"
"No effects were observed when <e1>fenclozic acid</e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters <e2>BSEP</e2> and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.","Downregulator"
"No effects were observed when <e1>fenclozic acid</e1> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and <e2>MRP2</e2> or mitochondrial toxicity to THLE or HepG2 cells.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and <e2>IRF3</e2>, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed <e2>TLR4</e2>-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"IRF3 activation induced by MyD88-independent signaling components, <e2>TRIF</e2> and TBK1, was also downregulated by <e1>auranofin</e1>.","Downregulator"
"IRF3 activation induced by MyD88-independent signaling components, TRIF and <e2>TBK1</e2>, was also downregulated by <e1>auranofin</e1>.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed <e2>TLR4</e2>-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of <e2>COX-2</e2>, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed TLR4-mediated activation of transcription factors, <e2>NF-kappaB</e2> and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"<e1>Auranofin</e1>, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of <e2>TLR4</e2>.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed <e2>TLR4</e2>-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed <e2>TLR4</e2>-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed <e2>TLR4</e2>-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed TLR4-mediated activation of transcription factors, <e2>NF-kappaB</e2> and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed TLR4-mediated activation of transcription factors, NF-kappaB and <e2>IRF3</e2>, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Our results demonstrated that <e1>auranofin</e1> suppressed <e2>TLR4</e2>-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.","Downregulator"
"Using biotinylated FGF-2 and <e2>FGF-7</e2> (KGF) as probes, we have identified specific interactions between FGFs and heparan <e1>sulfate</e1>s in human tissues.","Not"
"Using biotinylated FGF-2 and FGF-7 (KGF) as probes, we have identified specific interactions between <e2>FGFs</e2> and heparan <e1>sulfates</e1> in human tissues.","Regulator"
"Using biotinylated FGF-2 and FGF-7 (KGF) as probes, we have identified specific interactions between <e2>FGFs</e2> and heparan <e1>sulfates</e1> in human tissues.","Regulator"
"Using biotinylated <e2>FGF-2</e2> and FGF-7 (KGF) as probes, we have identified specific interactions between FGFs and heparan <e1>sulfate</e1>s in human tissues.","Regulator"
"<e2>FGF</e2>s signal through transmembrane receptor tyrosine kinases, but heparan <e1>sulfate</e1> is also required for signaling by members of the FGF family.","Regulator"
"<e1>Vandetanib</e1> (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and <e2>epidermal growth-factor receptors</e2>.","Downregulator"
"<e1>Vandetanib</e1> (Caprelsa(®), AstraZeneca) is a once-daily oral <e2>tyrosine kinase</e2> inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.","Downregulator"
"<e1>Vandetanib</e1> (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by <e2>growth-factor receptor tyrosine kinase</e2> RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.","Downregulator"
"<e1>Vandetanib</e1> (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase <e2>RET</e2> (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.","Downregulator"
"Vandetanib (<e1>Caprelsa</e1>(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and <e2>epidermal growth-factor receptors</e2>.","Downregulator"
"Vandetanib (<e1>Caprelsa</e1>(®), AstraZeneca) is a once-daily oral <e2>tyrosine kinase</e2> inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.","Downregulator"
"One exception is <e1>tranexamic acid</e1> (TXA), which, as a lysine mimetic, inhibits binding of <e2>plasminogen</e2> to fibrin.","Downregulator"
"One exception is <e1>tranexamic acid</e1> (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to <e2>fibrin</e2>.","Downregulator"
"One exception is tranexamic acid (<e1>TXA</e1>), which, as a lysine mimetic, inhibits binding of <e2>plasminogen</e2> to fibrin.","Downregulator"
"One exception is tranexamic acid (<e1>TXA</e1>), which, as a lysine mimetic, inhibits binding of plasminogen to <e2>fibrin</e2>.","Downregulator"
"One exception is tranexamic acid (TXA), which, as a <e1>lysine</e1> mimetic, inhibits binding of <e2>plasminogen</e2> to fibrin.","Downregulator"
"One exception is tranexamic acid (TXA), which, as a <e1>lysine</e1> mimetic, inhibits binding of plasminogen to <e2>fibrin</e2>.","Downregulator"
"Coupling this computational technique with a high-quality low-throughput screen identified <e1>5-(4-piperidyl)-3-isoxazolol</e1> (4-PIOL) as a potent <e2>plasminogen</e2> binding inhibitor with the potential for the treatment of various bleeding disorders.","Downregulator"
"Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (<e1>4-PIOL</e1>) as a potent <e2>plasminogen</e2> binding inhibitor with the potential for the treatment of various bleeding disorders.","Downregulator"
"Qualitatively similar but significantly attenuated responses to the <e1>catecholamines</e1> were observed in tissue from ANXA1-null mice, an effect that was not associated with changes in <e2>beta-adrenoceptor</e2> mRNA expression.","Not"
"Epididymal tissue from wild-type mice responded in vitro to <e1>noradrenaline</e1> and isoprenaline with increased glycerol release, reduced <e2>IL-6</e2> release, and increased cAMP accumulation.","Downregulator"
"Epididymal tissue from wild-type mice responded in vitro to noradrenaline and <e1>isoprenaline</e1> with increased glycerol release, reduced <e2>IL-6</e2> release, and increased cAMP accumulation.","Downregulator"
"Phospholipase A2 inhibitors <e1>p-bromophenacyl bromide</e1> and arachidonyl trifluoromethyl ketone suppressed <e2>interleukin-2</e2> (IL-2) expression in murine primary splenocytes.","Regulator"
"Phospholipase A2 inhibitors <e1>p-bromophenacyl bromide</e1> and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Regulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on <e2>interleukin-2</e2> (IL-2) expression in murine primary splenocytes.","Regulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Regulator"
"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone</e1> suppressed <e2>interleukin-2</e2> (IL-2) expression in murine primary splenocytes.","Regulator"
"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone</e1> suppressed interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Regulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on <e2>interleukin-2</e2> (IL-2) expression in murine primary splenocytes.","Regulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Regulator"
"<e2>Phospholipase A2</e2> inhibitors <e1>p-bromophenacyl bromide</e1> and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.","Upregulator"
"Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed <e1>phorbol 12-myristate 13-acetate</e1> plus ionomycin-induced <e2>IL-2</e2> secretion in a concentration-dependent manner.","Upregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Phospholipase A2 inhibitors <e1>p-bromophenacyl bromide</e1> and arachidonyl trifluoromethyl ketone suppressed <e2>interleukin-2</e2> (IL-2) expression in murine primary splenocytes.","Downregulator"
"Phospholipase A2 inhibitors <e1>p-bromophenacyl bromide</e1> and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone</e1> suppressed <e2>interleukin-2</e2> (IL-2) expression in murine primary splenocytes.","Downregulator"
"Phospholipase A2 inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone</e1> suppressed interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of PLA2 inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (<e2>IL-2</e2>) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"<e2>Phospholipase A2</e2> inhibitors p-bromophenacyl bromide and <e1>arachidonyl trifluoromethyl ketone</e1> suppressed interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors <e1>p-bromophenacyl bromide</e1> (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors p-bromophenacyl bromide (<e1>BPB</e1>) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors p-bromophenacyl bromide (BPB) and <e1>arachidonyl trifluoromethyl ketone</e1> (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"Therefore, the objective of the present study was to investigate the effects of <e2>PLA2</e2> inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone (<e1>AACOCF3</e1>) on interleukin-2 (IL-2) expression in murine primary splenocytes.","Downregulator"
"The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and <e1>imatinib</e1>, a selective <e2>tyrosine kinase</e2> inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST.","Downregulator"
"<e1>Thiazolidinediones</e1> (TZDs) are <e2>insulin</e2> sensitizers used for treatment of diabetes.","Regulator"
"<e1>TZD</e1>s also inhibited <e2>alkaline phosphatase</e2> activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).","Regulator"
"<e1>TZD</e1>s also inhibited alkaline phosphatase activity (58-75%, p<0.046) and <e2>osteocalcin</e2> production (52-75%, p<0.031).","Regulator"
"Thiazolidinediones (<e1>TZDs</e1>) are <e2>insulin</e2> sensitizers used for treatment of diabetes.","Regulator"
"Thiazolidinediones (<e1>TZD</e1>s) affect osteoblast viability and biomarkers independently of the TZD effects on <e2>aromatase</e2>.","Regulator"
"<e1>TZDs</e1> also inhibited <e2>alkaline phosphatase</e2> activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).","Downregulator"
"<e1>TZDs</e1> also inhibited alkaline phosphatase activity (58-75%, p<0.046) and <e2>osteocalcin</e2> production (52-75%, p<0.031).","Downregulator"
"Thiazolidinediones (<e1>TZD</e1>s) affect osteoblast viability and biomarkers independently of the TZD effects on <e2>aromatase</e2>.","Downregulator"
"Thiazolidinediones (<e1>TZDs</e1>) affect osteoblast viability and biomarkers independently of the TZD effects on <e2>aromatase</e2>.","Downregulator"
"Thiazolidinediones (<e1>TZD</e1>s) affect osteoblast viability and biomarkers independently of the TZD effects on <e2>aromatase</e2>.","Downregulator"
"We have previously reported that TZDs reduce <e1>estrogen</e1> synthesis by inhibiting <e2>aromatase</e2> activity in human granulosa cells (HGC).","Substrate"
"Several <e2>purinergic receptors</e2> have been described on platelets; P2X (1), a calcium channel, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by <e1>clopidogrel</e1>.","Not"
"Several purinergic receptors have been described on platelets; <e2>P2X (1)</e2>, a calcium channel, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by <e1>clopidogrel</e1>.","Not"
"Several purinergic receptors have been described on platelets; P2X (1), a <e2>calcium channel</e2>, and P2Y1 a Gq-coupled seven-transmembrane domain receptor, have been found not to be antagonized by <e1>clopidogrel</e1>.","Not"
"<e2>P2Y1</e2>2, a new platelet ADP receptor, target of <e1>clopidogrel</e1>.","Not"
"Several purinergic receptors have been described on platelets; P2X (1), a calcium channel, and P2Y1 a <e2>Gq-coupled seven-transmembrane domain receptor</e2>, have been found not to be antagonized by <e1>clopidogrel</e1>.","Not"
"These results demonstrate that this receptor corresponds to the previously called ""<e2>P2t</e2>"" platelet receptor and show that the active metabolite of <e1>clopidogrel</e1> binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of ADP on platelets.","Regulator"
"These results demonstrate that this receptor corresponds to the previously called ""P2t"" <e2>platelet receptor</e2> and show that the active metabolite of <e1>clopidogrel</e1> binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of ADP on platelets.","Regulator"
"These results demonstrate that this receptor corresponds to the previously called ""<e2>P2t</e2>"" platelet receptor and show that the active metabolite of clopidogrel binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of <e1>ADP</e1> on platelets.","Regulator"
"These results demonstrate that this receptor corresponds to the previously called ""P2t"" <e2>platelet receptor</e2> and show that the active metabolite of clopidogrel binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of <e1>ADP</e1> on platelets.","Regulator"
"The antiaggregating effect of <e1>clopidogrel</e1> is attributed to an irreversible inhibition of ADP binding to a <e2>purinergic receptor</e2> present at the platelet surface.","Regulator"
"The antiaggregating effect of clopidogrel is attributed to an irreversible inhibition of <e1>ADP</e1> binding to a <e2>purinergic receptor</e2> present at the platelet surface.","Regulator"
"<e2>P2Y12</e2>, a new platelet ADP receptor, target of <e1>clopidogrel</e1>.","Regulator"
"P2Y12, a new platelet <e2>ADP receptor</e2>, target of <e1>clopidogrel</e1>.","Regulator"
"We show for the first time that a single <e1>amino acid</e1> is able to determine the substrate specificity of <e2>CrAT</e2> and COT.","Part_of"
"We show for the first time that a single <e1>amino acid</e1> is able to determine the substrate specificity of CrAT and <e2>COT</e2>.","Part_of"
"Carnitine acetyltransferases (<e2>CrAT</e2>) catalyze the reversible conversion of acetyl-CoA and carnitine to <e1>acetylcarnitine</e1> and free CoA.","Substrate"
"The <e2>M564G</e2> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, <e1>acetyl-CoA</e1>.","Substrate"
"Carnitine acetyltransferases (<e2>CrAT</e2>) catalyze the reversible conversion of <e1>acetyl-CoA</e1> and carnitine to acetylcarnitine and free CoA.","Substrate"
"Carnitine acetyltransferases (<e2>CrAT</e2>) catalyze the reversible conversion of <e1>acetyl-CoA</e1> and carnitine to acetylcarnitine and free CoA.","Substrate"
"The M564G mutated <e2>CrAT</e2> showed higher activity toward longer chain <e1>acyl-CoAs</e1>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <e2>carnitine octanoyltransferase</e2> (COT) decreased activity toward its natural substrates, medium- and long-chain <e1>acyl-CoAs</e1>, and increased activity toward short-chain acyl-CoAs.","Substrate"
"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<e2>COT</e2>) decreased activity toward its natural substrates, medium- and long-chain <e1>acyl-CoAs</e1>, and increased activity toward short-chain acyl-CoAs.","Substrate"
"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in <e2>carnitine octanoyltransferase</e2> (COT) decreased activity toward its natural substrates, medium- and long-chain <e1>acyl-CoAs</e1>, and increased activity toward short-chain acyl-CoAs.","Substrate"
"In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase (<e2>COT</e2>) decreased activity toward its natural substrates, medium- and long-chain <e1>acyl-CoAs</e1>, and increased activity toward short-chain acyl-CoAs.","Substrate"
"The M564G mutated <e2>CrAT</e2> showed higher activity toward longer chain <e1>acyl-CoAs</e1>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"Carnitine acetyltransferases (<e2>CrAT</e2>) catalyze the reversible conversion of <e1>acetyl-CoA</e1> and carnitine to acetylcarnitine and free CoA.","Substrate"
"Carnitine acetyltransferases (<e2>CrAT</e2>) catalyze the reversible conversion of acetyl-CoA and <e1>carnitine</e1> to acetylcarnitine and free CoA.","Substrate"
"The <e2>M564G</e2> mutated CrAT showed higher activity toward longer chain <e1>acyl-CoAs</e1>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"The M564G mutated <e2>CrAT</e2> showed higher activity toward longer chain <e1>acyl-CoAs</e1>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"The M564G mutated <e2>CrAT</e2> showed higher activity toward longer chain <e1>acyl-CoAs</e1>: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"The <e2>M564G</e2> mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward <e1>myristoyl-CoA</e1> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"The M564G mutated <e2>CrAT</e2> showed higher activity toward longer chain acyl-CoAs: activity toward <e1>myristoyl-CoA</e1> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"The M564G mutated <e2>CrAT</e2> showed higher activity toward longer chain acyl-CoAs: activity toward <e1>myristoyl-CoA</e1> was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.","Substrate"
"<e2>Carnitine acetyltransferases</e2> (CrAT) catalyze the reversible conversion of <e1>acetyl-CoA</e1> and carnitine to acetylcarnitine and free CoA.","Substrate"
"<e2>Carnitine acetyltransferases</e2> (CrAT) catalyze the reversible conversion of acetyl-CoA and <e1>carnitine</e1> to acetylcarnitine and free CoA.","Substrate"
"<e2>Carnitine acetyltransferases</e2> (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to <e1>acetylcarnitine</e1> and free CoA.","Substrate"
"The high-affinity binding of <e1>L-noradrenaline</e1> to <e2>phenylalanine hydroxylase</e2>, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline.","Regulator"
"The high-affinity binding of <e1>L-noradrenaline</e1> to <e2>phenylalanine hydroxylase</e2>, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline.","Regulator"
"The high-affinity binding of <e1>L-noradrenaline</e1> to <e2>phenylalanine hydroxylase</e2>, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline.","Regulator"
"Cooperative homotropic interaction of <e1>L-noradrenaline</e1> with the catalytic site of <e2>phenylalanine 4-monooxygenase</e2>.","Regulator"
"The high-affinity of <e1>catecholamines</e1> to <e2>phenylalanine hydroxylase</e2> is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.","Regulator"
"The high-affinity of <e1>catecholamines</e1> to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme <e2>tyrosine hydroxylase</e2>, which is purified as a stable catecholamine-Fe(III) complex.","Regulator"
"Catecholamines (<e1>adrenaline</e1>, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase</e2>, EC 1.14.16.1).","Downregulator"
"Catecholamines (<e1>adrenaline</e1>, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1</e2>).","Downregulator"
"Cooperative homotropic interaction of L-nor<e1>adrenaline</e1> with the catalytic site of <e2>phenylalanine 4-monooxygenase</e2>.","Downregulator"
"Catecholamines (adrenaline, <e1>noradrenaline</e1> and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase</e2>, EC 1.14.16.1).","Downregulator"
"Catecholamines (adrenaline, <e1>noradrenaline</e1> and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1</e2>).","Downregulator"
"Cooperative homotropic interaction of L-<e1>noradrenaline</e1> with the catalytic site of <e2>phenylalanine 4-monooxygenase</e2>.","Downregulator"
"Catecholamines (adrenaline, noradrenaline and <e1>dopamine</e1>) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase</e2>, EC 1.14.16.1).","Downregulator"
"Catecholamines (adrenaline, noradrenaline and <e1>dopamine</e1>) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1</e2>).","Downregulator"
"Catecholamines (adrenaline, noradrenaline and <e1>dopamine</e1>) are potent inhibitors of <e2>phenylalanine 4-monooxygenase</e2> (phenylalanine hydroxylase, EC 1.14.16.1).","Downregulator"
"<e1>Catecholamines</e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (<e2>phenylalanine hydroxylase</e2>, EC 1.14.16.1).","Downregulator"
"<e1>Catecholamines</e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, <e2>EC 1.14.16.1</e2>).","Downregulator"
"<e1>Catecholamines</e1> (adrenaline, noradrenaline and dopamine) are potent inhibitors of <e2>phenylalanine 4-monooxygenase</e2> (phenylalanine hydroxylase, EC 1.14.16.1).","Downregulator"
"<e2>Kisspeptin</e2> is a 54-<e1>amino acid</e1> peptide which is encoded by the KiSS-1 gene and activates the G protein-coupled receptor GPR54.","Part_of"
"Central and peripheral administration of <e2>kisspeptin</e2> stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a <e1>gonadotrophin releasing hormone</e1> (GnRH) antagonist abolishes this effect.","Downregulator"
"Central and peripheral administration of <e2>kisspeptin</e2> stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone (<e1>GnRH</e1>) antagonist abolishes this effect.","Downregulator"
"Moreover, in rat hepatoma H4-II-E cells, the esterified-<e1>BM</e1> failed to induce <e2>tyrosine aminotransferase</e2>, which is regulated by GR-mediated transactivation activity.","Not"
"Species-specific differences in the <e2>glucocorticoid receptor</e2> transactivation function upon binding with <e1>betamethasone-esters</e1>.","Regulator"
"Dexamethasone (DEX), betamethasone (<e1>BM</e1>), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or <e2>rat GR</e2>.","Agonist"
"Dexamethasone (<e1>DEX</e1>), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or <e2>rat GR</e2>.","Agonist"
"Dexamethasone (DEX), betamethasone (<e1>BM</e1>), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or rat <e2>GR</e2>.","Agonist"
"Dexamethasone (DEX), betamethasone (<e1>BM</e1>), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or <e2>rat GR</e2>.","Agonist"
"<e1>Dexamethasone</e1> (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR</e2>.","Agonist"
"Dexamethasone (<e1>DEX</e1>), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR</e2>.","Agonist"
"Dexamethasone (DEX), <e1>betamethasone</e1> (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR</e2>.","Agonist"
"Dexamethasone (DEX), betamethasone (<e1>BM</e1>), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either <e2>human or rat GR</e2>.","Agonist"
"Dexamethasone (DEX), betamethasone (<e1>BM</e1>), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either human or <e2>rat GR</e2>.","Agonist"
"Insulin-like growth factor (IGF)-binding protein (IGFBP)-related proteins (<e2>IGFBP-rPs</e2>) are newly described <e1>cysteine</e1>-rich proteins that share significant aminoterminal structural similarity with the conventional IGFBPs and are involved in a diversity of biological functions, including growth regulation.","Part_of"
"<e2>Insulin-like growth factor (IGF)-binding protein (IGFBP)-related proteins</e2> (IGFBP-rPs) are newly described <e1>cysteine</e1>-rich proteins that share significant aminoterminal structural similarity with the conventional IGFBPs and are involved in a diversity of biological functions, including growth regulation.","Part_of"
"Moreover, <e2>IGFBP-rP2</e2> noticeably increased in response to TGF-beta1 and <e1>all-trans retinoic acid</e1> (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.","Upregulator"
"Moreover, <e2>IGFBP-rP2</e2> noticeably increased in response to TGF-beta1 and all-trans retinoic acid (<e1>atRA</e1>) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.","Upregulator"
"Although the data collected on <e2>IGFBP-rP3</e2> in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by <e1>atRA</e1>.","Downregulator"
"On the basis of <e2>FIP1L1</e2>-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the tyrosine kinase inhibitor <e1>imatinib mesylate</e1> (Glivec) would be effective.","Regulator"
"On the basis of FIP1L1-<e2>PDGFRa</e2> fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the tyrosine kinase inhibitor <e1>imatinib mesylate</e1> (Glivec) would be effective.","Regulator"
"On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the <e2>tyrosine kinase</e2> inhibitor <e1>imatinib mesylate</e1> (Glivec) would be effective.","Downregulator"
"Transport by <e2>OATP1B1</e2> and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>quercetin</e1> derivatives.","Regulator"
"Transport by OATP1B1 and <e2>OATP1B3</e2> enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>quercetin</e1> derivatives.","Regulator"
"<e1>Flavonoids</e1> such as green tea catechins and quercetin glycosides have been shown to modulate the function of some <e2>OATPs</e2>.","Regulator"
"Flavonoids such as green tea <e1>catechins</e1> and quercetin glycosides have been shown to modulate the function of some <e2>OATPs</e2>.","Regulator"
"Flavonoids such as green tea catechins and <e1>quercetin glycosides</e1> have been shown to modulate the function of some <e2>OATPs</e2>.","Regulator"
"Uptake of the radiolabeled model substrates <e1>estradiol 17β-glucuronide</e1>, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1</e2> or OATP1B3.","Substrate"
"Uptake of the radiolabeled model substrates <e1>estradiol 17β-glucuronide</e1>, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3</e2>.","Substrate"
"Uptake of the radiolabeled model substrates estradiol 17β-glucuronide, <e1>estrone 3-sulfate</e1>, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1</e2> or OATP1B3.","Substrate"
"Uptake of the radiolabeled model substrates estradiol 17β-glucuronide, <e1>estrone 3-sulfate</e1>, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3</e2>.","Substrate"
"Uptake of the radiolabeled model substrates estradiol 17β-glucuronide, estrone 3-sulfate, and <e1>dehydroepiandrosterone sulfate</e1> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1</e2> or OATP1B3.","Substrate"
"Uptake of the radiolabeled model substrates estradiol 17β-glucuronide, estrone 3-sulfate, and <e1>dehydroepiandrosterone sulfate</e1> (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3</e2>.","Substrate"
"Uptake of the radiolabeled model substrates estradiol 17β-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<e1>DHEAS</e1>) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either <e2>OATP1B1</e2> or OATP1B3.","Substrate"
"Uptake of the radiolabeled model substrates estradiol 17β-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (<e1>DHEAS</e1>) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3</e2>.","Substrate"
"Uptake of the radiolabeled model substrates <e1>estradiol 17β-glucuronide</e1>, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3</e2>.","Substrate"
"Uptake of the radiolabeled model substrates <e1>estradiol 17β-glucuronide</e1>, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or <e2>OATP1B3</e2>.","Substrate"
"Transport by <e2>OATP1B1</e2> and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>quercetin</e1> derivatives.","Substrate"
"Transport by OATP1B1 and <e2>OATP1B3</e2> enhances the cytotoxicity of epigallocatechin 3-O-gallate and several <e1>quercetin</e1> derivatives.","Substrate"
"Transport by <e2>OATP1B1</e2> and OATP1B3 enhances the cytotoxicity of <e1>epigallocatechin 3-O-gallate</e1> and several quercetin derivatives.","Substrate"
"Transport by OATP1B1 and <e2>OATP1B3</e2> enhances the cytotoxicity of <e1>epigallocatechin 3-O-gallate</e1> and several quercetin derivatives.","Substrate"
"Transport by <e2>OATP</e2>1B1 and OATP1B3 enhances the cytotoxicity of <e1>epigallocatechin 3-O-gallate</e1> and several quercetin derivatives.","Substrate"
"Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (<e1>EGCG</e1>) and most of compounds 1-6 killed preferentially <e2>OATP</e2>-expressing CHO cells.","Substrate"
"<e1>EGCG</e1>, 1, and 3 were the most potent cytotoxic compounds, with EGCG and 3 selectively killing <e2>OATP1B3</e2>-expressing cells.","Substrate"
"Results demonstrate that predominantly FUT7, and to a lesser extent FUT4, forms the selectin-ligand at the <e1>N</e1> terminus of leukocyte <e2>P-selectin glycoprotein ligand-1</e2> (PSGL-1) in humans and mice.","Part_of"
"Preliminary evidence suggests that <e1>ergotamine</e1> may not occupy striatal <e2>dopamine D2-receptors</e2> to a large extent and thus may not cross the blood brain barrier in large quantities.","Not"
"<e2>Dopamine D2-receptor</e2> imaging with <e1>123I-iodobenzamide</e1> SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?","Regulator"
"Two migraine patients were studied by in vivo SPECT using the <e2>dopamine D2-receptor</e2> specific radioligand <e1>123I-3-iodo-6-methoxybenzamide</e1> (123I-IBZM) during ergotamine abuse and after withdrawal.","Regulator"
"Two migraine patients were studied by in vivo SPECT using the <e2>dopamine D2-receptor</e2> specific radioligand 123I-3-iodo-6-methoxybenzamide (<e1>123I-IBZM</e1>) during ergotamine abuse and after withdrawal.","Regulator"
"<e2>Dopamine D2-receptor</e2> imaging with 123I-iodobenzamide SPECT in migraine patients abusing <e1>ergotamine</e1>: does ergotamine cross the blood brain barrier?","Regulator"
"Two migraine patients were studied by in vivo SPECT using the <e2>dopamine D2-receptor</e2> specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during <e1>ergotamine</e1> abuse and after withdrawal.","Regulator"
"<e1>Reboxetine</e1>, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the <e2>human norepinephrine transporter</e2>.","Regulator"
"<e1>Reboxetine</e1>, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the <e2>human norepinephrine transporter</e2>.","Downregulator"
"Degradation of MAC13243 and studies of the interaction of resulting <e1>thiourea</e1> compounds with the lipoprotein targeting chaperone <e2>LolA</e2>.","Regulator"
"Taken together, we conclude that the <e1>thiourea</e1> series of compounds share a similar cellular mechanism that includes interaction with LolA in addition to the well-characterized target <e2>MreB</e2>.","Regulator"
"Degradation of MAC13243 and studies of the interaction of resulting <e1>thiourea</e1> compounds with the lipoprotein targeting chaperone <e2>LolA</e2>.","Regulator"
"Degradation of <e1>MAC13243</e1> and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone <e2>LolA</e2>.","Regulator"
"Degradation of MAC13243 and studies of the interaction of resulting <e1>thiourea</e1> compounds with the lipoprotein targeting <e2>chaperone</e2> LolA.","Regulator"
"Degradation of MAC13243 and studies of the interaction of resulting <e1>thiourea</e1> compounds with the lipoprotein targeting chaperone <e2>LolA</e2>.","Regulator"
"Degradation of MAC13243 and studies of the interaction of resulting <e1>thiourea</e1> compounds with the <e2>lipoprotein</e2> targeting chaperone LolA.","Regulator"
"We previously employed a chemical genomic strategy to identify a novel small molecule, <e1>MAC13243</e1>, as a likely inhibitor of the <e2>bacterial lipoprotein</e2> targeting chaperone, LolA.","Downregulator"
"Degradation of <e1>MAC13243</e1> and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting <e2>chaperone</e2> LolA.","Downregulator"
"Degradation of <e1>MAC13243</e1> and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone <e2>LolA</e2>.","Downregulator"
"<e1>Tamsulosin</e1>, which has high affinity for alpha1aAR and alpha1dAR subtypes but not for <e2>alpha1bAR</e2>, shows efficacy similar to the nonsubtype selective agents terazosin and doxazosin.","Not"
"<e1>Tamsulosin</e1>, which has high affinity for <e2>alpha1aAR</e2> and alpha1dAR subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and doxazosin.","Regulator"
"<e1>Tamsulosin</e1>, which has high affinity for alpha1aAR and <e2>alpha1dAR</e2> subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and doxazosin.","Regulator"
"Tamsulosin, which has high affinity for <e2>alpha1aAR</e2> and alpha1dAR subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and <e1>doxazosin</e1>.","Regulator"
"Tamsulosin, which has high affinity for alpha1aAR and <e2>alpha1dAR</e2> subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents terazosin and <e1>doxazosin</e1>.","Regulator"
"Tamsulosin, which has high affinity for <e2>alpha1aAR</e2> and alpha1dAR subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents <e1>terazosin</e1> and doxazosin.","Regulator"
"Tamsulosin, which has high affinity for alpha1aAR and <e2>alpha1dAR</e2> subtypes but not for alpha1bAR, shows efficacy similar to the nonsubtype selective agents <e1>terazosin</e1> and doxazosin.","Regulator"
"Tamsulosin, which has high affinity for alpha1aAR and alpha1dAR subtypes but not for <e2>alpha1bAR</e2>, shows efficacy similar to the nonsubtype selective agents <e1>terazosin</e1> and doxazosin.","Regulator"
"Tamsulosin, which has high affinity for alpha1aAR and alpha1dAR subtypes but not for <e2>alpha1bAR</e2>, shows efficacy similar to the nonsubtype selective agents terazosin and <e1>doxazosin</e1>.","Regulator"
"Our results showed that low dose <e1>BPA</e1> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of <e2>Oct4</e2> and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein.","Upregulator"
"Our results showed that low dose <e1>BPA</e1> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and <e2>Nanog</e2> proteins, while only BPA could downregulate the expression of E-cadherin protein.","Upregulator"
"Our results showed that low dose <e1>BPA</e1> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only BPA could downregulate the expression of <e2>E-cadherin</e2> protein.","Downregulator"
"To this end, 158N murine oligodendrocytes were treated with <e1>7KC</e1> or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of <e2>Akt</e2> and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation.","Regulator"
"To this end, 158N murine oligodendrocytes were treated with <e1>7KC</e1> or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and <e2>GSK3</e2>, mitochondrial depolarization involving Mcl-1, and caspase-3 activation.","Regulator"
"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>7βOHC</e1> inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of <e2>Akt</e2> and GSK3, mitochondrial depolarization involving Mcl-1, and caspase-3 activation.","Regulator"
"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>7βOHC</e1> inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and <e2>GSK3</e2>, mitochondrial depolarization involving Mcl-1, and caspase-3 activation.","Regulator"
"Thus, in 158N cells, the ability of <e1>oxysterols</e1> to trigger a mode of cell death by apoptosis involving <e2>GSK-3</e2> and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.","Upregulator"
"Thus, in 158N cells, the ability of <e1>oxysterols</e1> to trigger a mode of cell death by apoptosis involving GSK-3 and <e2>caspase-3</e2> activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.","Upregulator"
"To this end, 158N murine oligodendrocytes were treated with <e1>7KC</e1> or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving <e2>Mcl-1</e2>, and caspase-3 activation.","Upregulator"
"To this end, 158N murine oligodendrocytes were treated with <e1>7KC</e1> or 7βOHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and <e2>caspase-3</e2> activation.","Upregulator"
"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>7βOHC</e1> inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving <e2>Mcl-1</e2>, and caspase-3 activation.","Upregulator"
"To this end, 158N murine oligodendrocytes were treated with 7KC or <e1>7βOHC</e1> inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and <e2>caspase-3</e2> activation.","Upregulator"
"METHOD: The authors conducted a PET study to evaluate <e2>D(2)</e2> occupancy (using <e1>[(11)C]raclopride</e1>) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range.","Regulator"
"METHOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and <e2>5-HT(2)</e2> occupancy (using <e1>[(18)F]setoperone</e1>) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range.","Regulator"
"METHOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and <e2>5-HT(2)</e2> occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of <e1>ziprasidone</e1>, which reflected the recommended dose range.","Regulator"
"The estimated plasma <e1>ziprasidone</e1> concentration associated with 50% maximal 5-HT(2) receptor occupancy was almost four times lower than that for <e2>D(2) receptor</e2> occupancy.","Regulator"
"OBJECTIVE: <e1>Ziprasidone</e1> is an atypical antipsychotic drug that shows a higher affinity for serotonin <e2>5-HT(2) receptors</e2> compared with dopamine D(2) receptors in vitro.","Regulator"
"OBJECTIVE: <e1>Ziprasidone</e1> is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT(2) receptors compared with <e2>dopamine D(2) receptors</e2> in vitro.","Regulator"
"METHOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and <e2>5-HT(2)</e2> occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of <e1>ziprasidone</e1>, which reflected the recommended dose range.","Regulator"
"The estimated plasma <e1>ziprasidone</e1> concentration associated with 50% maximal 5-HT(2) receptor occupancy was almost four times lower than that for <e2>D(2) receptor</e2> occupancy.","Regulator"
"The estimated plasma <e1>ziprasidone</e1> concentration associated with 50% maximal 5-HT(2) receptor occupancy was almost four times lower than that for <e2>D(2) receptor</e2> occupancy.","Regulator"
"The relatively high <e2>D(2) receptor</e2> occupancy, even at trough plasma levels, suggests that ziprasidone is more similar to <e1>risperidone</e1> and olanzapine in receptor occupancy profile than to clozapine and quetiapine.","Regulator"
"The relatively high <e2>D(2) receptor</e2> occupancy, even at trough plasma levels, suggests that ziprasidone is more similar to risperidone and olanzapine in receptor occupancy profile than to <e1>clozapine</e1> and quetiapine.","Regulator"
"The relatively high <e2>D(2) receptor</e2> occupancy, even at trough plasma levels, suggests that ziprasidone is more similar to risperidone and olanzapine in receptor occupancy profile than to clozapine and <e1>quetiapine</e1>.","Regulator"
"Similarly, pretreatment with <e1>sulindac sulfide</e1> blocks the ability of EGF to induce <e2>ERK1/2</e2> and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Not"
"Similarly, pretreatment with <e1>sulindac sulfide</e1> blocks the ability of EGF to induce <e2>ERK1/2</e2> and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Not"
"<e1>Sulindac sulfide</e1> inhibits epidermal growth factor-induced phosphorylation of <e2>extracellular-regulated kinase 1/2</e2> and Bad in human colon cancer cells.","Regulator"
"Similarly, pretreatment with <e1>sulindac sulfide</e1> blocks the ability of EGF to induce <e2>ERK1/2</e2> and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Regulator"
"Similarly, pretreatment with <e1>sulindac sulfide</e1> blocks the ability of EGF to induce <e2>ERK1/2</e2> and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Regulator"
"<e1>Sulindac</e1> metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit <e2>ERK1/2</e2> phosphorylation in human colon cancer cells.","Downregulator"
"Similarly, pretreatment with <e1>sulindac sulfide</e1> blocks the ability of EGF to induce ERK1/2 and <e2>Bad</e2> phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Downregulator"
"Similarly, pretreatment with <e1>sulindac</e1> sulfide blocks the ability of EGF to induce <e2>ERK1/2</e2> and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Downregulator"
"EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with <e1>U0126</e1>, a selective <e2>MAP kinase kinase (MKK)1/2</e2> inhibitor.","Downregulator"
"<e2>EGF</e2>-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with <e1>U0126</e1>, a selective MAP kinase kinase (MKK)1/2 inhibitor.","Downregulator"
"EGF-stimulated phosphorylation of <e2>ERK</e2> and Bad is blocked by pretreatment with <e1>U0126</e1>, a selective MAP kinase kinase (MKK)1/2 inhibitor.","Downregulator"
"EGF-stimulated phosphorylation of ERK and <e2>Bad</e2> is blocked by pretreatment with <e1>U0126</e1>, a selective MAP kinase kinase (MKK)1/2 inhibitor.","Downregulator"
"Similarly, pretreatment with <e1>sulindac sulfide</e1> blocks the ability of <e2>EGF</e2> to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Downregulator"
"Similarly, pretreatment with <e1>sulindac sulfide</e1> blocks the ability of EGF to induce ERK1/2 and <e2>Bad</e2> phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.","Downregulator"
"The ability of <e1>sulindac</e1> to block ERK1/2 signaling by the <e2>EGF receptor</e2> may account for at least part of its potent growth-inhibitory effects against cancer cells.","Downregulator"
"<e1>Sulindac</e1> and selective <e2>cyclooxygenase (COX)-2</e2> inhibitors cause regression of colonic polyps in familial polyposis patients.","Downregulator"
"<e1>Sulindac sulfide</e1> inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and <e2>Bad</e2> in human colon cancer cells.","Downregulator"
"<e1>Sulindac sulfide</e1> inhibits <e2>epidermal growth factor</e2>-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.","Downregulator"
"After inflammation was established mice were dosed with the <e2>H4R</e2> antagonist, <e1>JNJ 7777120</e1>, or anti-IL-13 antibody for comparison.","Antagonist"
"The activity of polymerases containing mutations known to confer resistance to <e1>foscarnet</e1> (<e2>V715M</e2>, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Not"
"The activity of polymerases containing mutations known to confer resistance to <e1>foscarnet</e1> (V715M, <e2>T700A</e2> and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Not"
"The activity of polymerases containing mutations known to confer resistance to <e1>foscarnet</e1> (V715M, T700A and <e2>N495K</e2>) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Not"
"The activity of <e2>polymerases</e2> containing mutations known to confer resistance to <e1>foscarnet</e1> (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Downregulator"
"The activity of polymerases containing mutations known to confer resistance to <e1>foscarnet</e1> (<e2>V715M</e2>, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Downregulator"
"The activity of polymerases containing mutations known to confer resistance to <e1>foscarnet</e1> (V715M, <e2>T700A</e2> and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Downregulator"
"The activity of polymerases containing mutations known to confer resistance to <e1>foscarnet</e1> (V715M, T700A and <e2>N495K</e2>) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Downregulator"
"The activity of <e2>polymerases</e2> containing mutations known to confer resistance to <e1>foscarnet</e1> (V715M, T700A and N495K) was inhibited by concentrations of foscarnet eight to 14 times higher than those required to inhibit wild-type polymerases.","Downregulator"
"Development and validation of a non-radioactive <e2>DNA polymerase</e2> assay for studying cytomegalovirus resistance to <e1>foscarnet</e1>.","Downregulator"
"Absorption and secretion of <e1>fluoride</e1> increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a <e2>F(-)/OH(-) antiporter</e2>.","Substrate"
"Absorption and secretion of <e1>fluoride</e1> increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a <e2>F(-)/H(+) cotransporter</e2> or a F(-)/OH(-) antiporter.","Substrate"
"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<e1>SCH 900229</e1>), a potent, <e2>PS1</e2>-selective γ-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease.","Downregulator"
"An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<e1>SCH 900229</e1>), a potent, PS1-selective <e2>γ-secretase</e2> inhibitor and clinical candidate for the treatment of Alzheimer's disease.","Downregulator"
"Structure activity relationship studies of <e1>tricyclic bispyran sulfone</e1> <e2>γ-secretase</e2> inhibitors.","Downregulator"
"In contrast, an <e1>NH(2)</e1>-terminal deletion mutant of <e2>K8</e2> promoted the formation of intracellular aggregates even in the absence of K18 overexpression.","Part_of"
"Culture of HepG2 cells with <e1>griseofulvin</e1> has now been shown to induce both the formation of intracellular aggregates containing <e2>K18</e2> as well as an increase in the abundance of K18 mRNA.","Upregulator"
"Culture of HepG2 cells with <e1>griseofulvin</e1> has now been shown to induce both the formation of intracellular aggregates containing <e2>K18</e2> as well as an increase in the abundance of K18 mRNA.","Upregulator"
"To determine whether 3,4-methylenedioxymethamphetamine (MDMA)-induced reductions in <e2>SERT</e2> density could be related to such a mechanism, <e1>p-chlorophenylalanine</e1> or MDMA was administered to rats, and brain serotonin and SERT density were measured.","Regulator"
"To determine whether 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>)-induced reductions in <e2>SERT</e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.","Regulator"
"To determine whether 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>)-induced reductions in <e2>SERT</e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.","Downregulator"
"MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on <e1>serotonin</e1> transporter densities.","Downregulator"
"Low levels of <e1>serotonin</e1> may reduce the density of the serotonin transporter (<e2>SERT</e2>) by either increasing trafficking or reducing synthesis; a ""neuroadaptive response"".","Downregulator"
"To determine whether <e1>3,4-methylenedioxymethamphetamine</e1> (MDMA)-induced reductions in <e2>SERT</e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.","Downregulator"
"To determine whether 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>)-induced reductions in <e2>SERT</e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.","Downregulator"
"To determine whether 3,4-methylenedioxymethamphetamine (<e1>MDMA</e1>)-induced reductions in <e2>SERT</e2> density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and SERT density were measured.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and <e2>IL-27</e2> expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/<e2>NF-κB</e2> signaling pathway and IL-27 expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and <e2>IL-27</e2> expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the <e2>TLR4</e2>/NF-κB signaling pathway and IL-27 expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/<e2>NF-κB</e2> signaling pathway and IL-27 expression.","Downregulator"
"Compared with the untreated colitis group, the <e1>curcumin</e1>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-κB mRNA, IL-27 mRNA, TLR4 protein, NF-κB <e2>p65</e2> protein, and IL-27 p28 protein (p < 0.05).","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and <e2>IL-27</e2> expression.","Downregulator"
"Compared with the untreated colitis group, the <e1>curcumin</e1>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-κB mRNA, IL-27 mRNA, TLR4 protein, NF-κB p65 protein, and IL-27 <e2>p28</e2> protein (p < 0.05).","Downregulator"
"<e1>Curcumin</e1> improves TNBS-induced colitis in rats by inhibiting <e2>IL-27</e2> expression via the TLR4/NF-κB signaling pathway.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the <e2>TLR4</e2>/NF-κB signaling pathway and IL-27 expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/<e2>NF-κB</e2> signaling pathway and IL-27 expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and <e2>IL-27</e2> expression.","Downregulator"
"There was no significant difference in <e2>TLR4</e2>, NF-κB, and IL-27 mRNA and proteins between curcumin-treated and <e1>sulfasalazine</e1>-treated groups.","Downregulator"
"There was no significant difference in TLR4, <e2>NF-κB</e2>, and IL-27 mRNA and proteins between curcumin-treated and <e1>sulfasalazine</e1>-treated groups.","Downregulator"
"There was no significant difference in TLR4, NF-κB, and <e2>IL-27</e2> mRNA and proteins between curcumin-treated and <e1>sulfasalazine</e1>-treated groups.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-κB signaling pathway and <e2>IL-27</e2> expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the <e2>TLR4</e2>/NF-κB signaling pathway and IL-27 expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/<e2>NF-κB</e2> signaling pathway and IL-27 expression.","Downregulator"
"Compared with the untreated colitis group, the <e1>curcumin</e1>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, <e2>myeloperoxidase</e2> activity, and expressions of NF-κB mRNA, IL-27 mRNA, TLR4 protein, NF-κB p65 protein, and IL-27 p28 protein (p < 0.05).","Downregulator"
"<e1>Curcumin</e1> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the <e2>TLR4</e2>/NF-κB signaling pathway.","Downregulator"
"<e1>Curcumin</e1> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/<e2>NF-κB</e2> signaling pathway.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the <e2>TLR4</e2>/NF-κB signaling pathway and IL-27 expression.","Downregulator"
"This study explored whether <e1>curcumin</e1> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/<e2>NF-κB</e2> signaling pathway and IL-27 expression.","Downregulator"
"New data for cattle (Bos taurus) indicates a gene encoding <e2>GnRH-II</e2> decapeptide possessing arginine (codon: CGG) rather than <e1>tryptophan</e1> (TGG) at position three in the mature peptide.","Part_of"
"The updated <e2>bovine type II GnRH receptor</e2> gene sequence revealed inactivation by frame shifts, premature stop codons, and <e1>nucleotide</e1> changes specifying nonconservative replacement of amino acid residues, similar to inactivation of sheep type II GnRH receptor.","Part_of"
"The updated <e2>bovine type II GnRH receptor</e2> gene sequence revealed inactivation by frame shifts, premature stop codons, and nucleotide changes specifying nonconservative replacement of <e1>amino acid</e1> residues, similar to inactivation of sheep type II GnRH receptor.","Part_of"
"New data for cattle (Bos taurus) indicates a gene encoding <e2>GnRH-II</e2> decapeptide possessing <e1>arginine</e1> (codon: CGG) rather than tryptophan (TGG) at position three in the mature peptide.","Part_of"
"New data for cattle (Bos taurus) indicates a gene encoding <e2>GnRH-II</e2> decapeptide possessing arginine (codon: <e1>CGG</e1>) rather than tryptophan (TGG) at position three in the mature peptide.","Part_of"
"New data for cattle (Bos taurus) indicates a gene encoding <e2>GnRH-II</e2> decapeptide possessing arginine (codon: CGG) rather than <e1>tryptophan</e1> (TGG) at position three in the mature peptide.","Part_of"
"New data for cattle (Bos taurus) indicates a gene encoding <e2>GnRH-II</e2> decapeptide possessing arginine (codon: CGG) rather than tryptophan (<e1>TGG</e1>) at position three in the mature peptide.","Part_of"
"Under isotonic conditions, <e1>N-ethylmaleimide</e1> (NEM) produced <e2>KCC</e2> activation and transient cell shrinkage.","Upregulator"
"Under isotonic conditions, N-ethylmaleimide (<e1>NEM</e1>) produced <e2>KCC</e2> activation and transient cell shrinkage.","Upregulator"
"A <e2>KCC</e2> inhibitor-<e1>[(dihydroindenyl)oxy] alkanoic acid</e1> (DIOA)-blocked RVD more in HCEC than RCEC.","Downregulator"
"A <e2>KCC</e2> inhibitor-[(dihydroindenyl)oxy] alkanoic acid (<e1>DIOA</e1>)-blocked RVD more in HCEC than RCEC.","Downregulator"
"The most potent compound, <e1>D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid</e1> (lorglumide, CR 1409), has a great affinity for the pancreatic <e2>CCK receptors</e2> and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.","Regulator"
"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (<e1>lorglumide</e1>, CR 1409), has a great affinity for the pancreatic <e2>CCK receptors</e2> and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.","Regulator"
"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, <e1>CR 1409</e1>), has a great affinity for the pancreatic <e2>CCK receptors</e2> and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.","Regulator"
"<e1>Lorglumide</e1> is therefore a useful pharmacological tool to study the functions of <e2>CCK</e2>.","Regulator"
"Pharmacological properties of <e1>lorglumide</e1> as a member of a new class of <e2>cholecystokinin</e2> antagonists.","Antagonist"
"The most potent compound, <e1>D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid</e1> (lorglumide, CR 1409), has a great affinity for the pancreatic <e2>CCK</e2> receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.","Antagonist"
"Derivatives of <e1>5-(dipentylamino)-5-oxo-pentanoic acid</e1> are a new class of non-peptide cholecystokinin (<e2>CCK</e2>) antagonists.","Antagonist"
"Derivatives of <e1>5-(dipentylamino)-5-oxo-pentanoic acid</e1> are a new class of non-peptide <e2>cholecystokinin</e2> (CCK) antagonists.","Antagonist"
"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (<e1>lorglumide</e1>, CR 1409), has a great affinity for the pancreatic <e2>CCK</e2> receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.","Antagonist"
"The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, <e1>CR 1409</e1>), has a great affinity for the pancreatic <e2>CCK</e2> receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.","Antagonist"
"The most potent in vitro DASI discovered is an <e1>imidazole</e1> derivative with IC50 values against <e2>aromatase</e2> and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively.","Downregulator"
"The most potent in vitro DASI discovered is an <e1>imidazole</e1> derivative with IC50 values against aromatase and <e2>steroid sulfatase</e2> in a JEG-3 cell preparation of 0.2 and 2.5 nM, respectively.","Downregulator"
"The parent <e1>phenol</e1> of this compound inhibits <e2>aromatase</e2> with an IC50 value of 0.028 nM in the same assay.","Downregulator"
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<e1>F</e1>, Cl, Br) derivatives are first-generation dual <e2>aromatase</e2> and sulfatase inhibitors (DASIs).","Downregulator"
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (<e1>F</e1>, Cl, Br) derivatives are first-generation dual aromatase and <e2>sulfatase</e2> inhibitors (DASIs).","Downregulator"
"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual <e2>Aromatase</e2>-Sulfatase Inhibitor <e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</e1>.","Downregulator"
"Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-<e2>Sulfatase</e2> Inhibitor <e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</e1>.","Downregulator"
"<e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</e1> and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual <e2>aromatase</e2> and sulfatase inhibitors (DASIs).","Downregulator"
"<e1>4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</e1> and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and <e2>sulfatase</e2> inhibitors (DASIs).","Downregulator"
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, <e1>Cl</e1>, Br) derivatives are first-generation dual <e2>aromatase</e2> and sulfatase inhibitors (DASIs).","Downregulator"
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, <e1>Cl</e1>, Br) derivatives are first-generation dual aromatase and <e2>sulfatase</e2> inhibitors (DASIs).","Downregulator"
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, <e1>Br</e1>) derivatives are first-generation dual <e2>aromatase</e2> and sulfatase inhibitors (DASIs).","Downregulator"
"4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, <e1>Br</e1>) derivatives are first-generation dual aromatase and <e2>sulfatase</e2> inhibitors (DASIs).","Downregulator"
"As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both <e1>dimethyldiguanide</e1> (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and <e2>insulin</e2> levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay.","Downregulator"
"These findings demonstrate that cinnamon <e1>polyphenols</e1> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of <e2>iNOS</e2>, NF-κB activation.","Downregulator"
"These findings demonstrate that cinnamon <e1>polyphenols</e1> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, <e2>NF-κB</e2> activation.","Downregulator"
"Finally, a third nonadrenergic internal membrane site, labeled by [3H]IDX, was consistent with a <e2>subtype-I2 imidazol(in)e receptor</e2> site (rank order: <e1>cirazoline</e1> > IDX >> amiloride > moxonidine > clonidine).","Regulator"
"Finally, a third nonadrenergic internal membrane site, labeled by [3H]IDX, was consistent with a <e2>subtype-I2 imidazol(in)e receptor</e2> site (rank order: cirazoline > IDX >> <e1>amiloride</e1> > moxonidine > clonidine).","Regulator"
"Finally, a third nonadrenergic internal membrane site, labeled by [3H]IDX, was consistent with a <e2>subtype-I2 imidazol(in)e receptor</e2> site (rank order: cirazoline > IDX >> amiloride > <e1>moxonidine</e1> > clonidine).","Regulator"
"Finally, a third nonadrenergic internal membrane site, labeled by [3H]IDX, was consistent with a <e2>subtype-I2 imidazol(in)e receptor</e2> site (rank order: cirazoline > IDX >> amiloride > moxonidine > <e1>clonidine</e1>).","Regulator"
"Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to <e2>human subtype-I1 imidazol(in)e receptor</e2> sites in the brain stem (rank order: <e1>moxonidine</e1> > clonidine > cirazoline > IDX > amiloride).","Regulator"
"Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to <e2>human subtype-I1 imidazol(in)e receptor</e2> sites in the brain stem (rank order: moxonidine > <e1>clonidine</e1> > cirazoline > IDX > amiloride).","Regulator"
"Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to <e2>human subtype-I1 imidazol(in)e receptor</e2> sites in the brain stem (rank order: moxonidine > clonidine > <e1>cirazoline</e1> > IDX > amiloride).","Regulator"
"Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to <e2>human subtype-I1 imidazol(in)e receptor</e2> sites in the brain stem (rank order: moxonidine > clonidine > cirazoline > <e1>IDX</e1> > amiloride).","Regulator"
"Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to <e2>human subtype-I1 imidazol(in)e receptor</e2> sites in the brain stem (rank order: moxonidine > clonidine > cirazoline > IDX > <e1>amiloride</e1>).","Regulator"
"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to <e1>clonidine</e1> and endogenous clonidine-displacing substance(s), and may serve as markers of <e2>imidazoline receptors</e2> in humans.","Regulator"
"These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to <e1>clonidine</e1> and endogenous clonidine-displacing substance(s), and may serve as markers of <e2>imidazoline receptors</e2> in humans.","Upregulator"
"To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), <e1>corticosterone</e1>-binding <e2>glucocorticoid receptors</e2> (GR) and mineralocorticoid receptors (MR) were also measured.","Regulator"
"To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), <e1>corticosterone</e1>-binding glucocorticoid receptors (<e2>GR</e2>) and mineralocorticoid receptors (MR) were also measured.","Regulator"
"To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), <e1>corticosterone</e1>-binding glucocorticoid receptors (GR) and <e2>mineralocorticoid receptors</e2> (MR) were also measured.","Regulator"
"To control for possible interactions between the expression of the estrogen receptor genes and other learning-related steroid receptors, androgen receptors (AR), <e1>corticosterone</e1>-binding glucocorticoid receptors (GR) and mineralocorticoid receptors (<e2>MR</e2>) were also measured.","Regulator"
"Effects of <e1>ORF 17583</e1>, other <e2>histamine H2-receptor</e2> antagonists and omeprazole on gastric acid secretory states in rats and dogs.","Antagonist"
"Effects of <e1>ORF 17583</e1>, other <e2>histamine H2-receptor</e2> antagonists and omeprazole on gastric acid secretory states in rats and dogs.","Antagonist"
"In the presence of the system L inhibitor BCH, <e1>Na(+)</e1>-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Upregulator"
"In the presence of the system L inhibitor BCH, Na(+)-dependent <e1>l-alanine</e1> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Upregulator"
"In the presence of the system L inhibitor BCH, <e1>Na(+)</e1>-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Upregulator"
"Underexpression of the Na+-dependent neutral <e1>amino acid</e1> transporter <e2>ASCT2</e2> in the spontaneously hypertensive rat kidney.","Upregulator"
"This study examined the inward transport of l-[(14)C]<e1>alanine</e1>, an <e2>ASCT2</e2> preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.","Downregulator"
"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, <e1>serine</e1>, and cysteine, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Downregulator"
"In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and <e1>cysteine</e1>, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Downregulator"
"In the presence of the system L inhibitor BCH, Na(+)-dependent <e1>l-alanine</e1> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Substrate"
"Underexpression of the Na+-dependent neutral <e1>amino acid</e1> transporter <e2>ASCT2</e2> in the spontaneously hypertensive rat kidney.","Substrate"
"In the presence of the system L inhibitor BCH, Na(+)-dependent <e1>l-alanine</e1> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Substrate"
"In conclusion, immortalized SHR and WKY PTE cells take up <e1>l-alanine</e1> mainly through a high-affinity <e2>Na(+)-dependent amino acid transporter</e2>, with functional features of ASCT2 transport.","Substrate"
"In the presence of the system L inhibitor BCH, Na(+)-dependent <e1>l-alanine</e1> uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through <e2>ASCT2</e2>.","Substrate"
"This study examined the inward transport of <e1>l-[(14)C]alanine</e1>, an <e2>ASCT2</e2> preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.","Substrate"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide block <e2>erg3</e2>, a human brain K(+) channel.","Downregulator"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide block erg3, a <e2>human brain K(+) channel</e2>.","Downregulator"
"The antipsychotic drugs sertindole and <e1>pimozide</e1> block <e2>erg3</e2>, a human brain K(+) channel.","Downregulator"
"The antipsychotic drugs sertindole and <e1>pimozide</e1> block erg3, a <e2>human brain K(+) channel</e2>.","Downregulator"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide block <e2>erg3</e2>, a human brain K(+) channel.","Downregulator"
"<e1>Pimozide</e1> blocked <e2>erg3</e2> channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.","Downregulator"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide block <e2>erg3</e2>, a human brain K(+) channel.","Downregulator"
"The antipsychotic drugs sertindole and <e1>pimozide</e1> block <e2>erg3</e2>, a human brain K(+) channel.","Downregulator"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the <e2>cardiac K(+) channel</e2> known as HERG (human ether-a-go-go-related gene; erg1).","Downregulator"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as <e2>HERG</e2> (human ether-a-go-go-related gene; erg1).","Downregulator"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (<e2>human ether-a-go-go-related gene</e2>; erg1).","Downregulator"
"The antipsychotic drugs <e1>sertindole</e1> and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; <e2>erg1</e2>).","Downregulator"
"The antipsychotic drugs sertindole and <e1>pimozide</e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the <e2>cardiac K(+) channel</e2> known as HERG (human ether-a-go-go-related gene; erg1).","Downregulator"
"The antipsychotic drugs sertindole and <e1>pimozide</e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as <e2>HERG</e2> (human ether-a-go-go-related gene; erg1).","Downregulator"
"The antipsychotic drugs sertindole and <e1>pimozide</e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (<e2>human ether-a-go-go-related gene</e2>; erg1).","Downregulator"
"The antipsychotic drugs sertindole and <e1>pimozide</e1> are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; <e2>erg1</e2>).","Downregulator"
"CNTs with linear <e1>poly(ethylene glycol)</e1> amphiphiles trigger the <e2>lectin</e2> pathway of the complement through both L-ficolin and mannan-binding lectin recognition.","Regulator"
"CNTs with linear <e1>poly(ethylene glycol)</e1> amphiphiles trigger the <e2>lectin</e2> pathway of the complement through both L-ficolin and mannan-binding lectin recognition.","Regulator"
"CNTs with linear <e1>poly(ethylene glycol)</e1> amphiphiles trigger the <e2>lectin</e2> pathway of the complement through both L-ficolin and mannan-binding lectin recognition.","Upregulator"
"<e1>Vardenafil</e1> has higher affinity to <e2>phosphodiesterase-5</e2> (PDE5) than sildenafil and lower administered dosage for the treatment of erectile dysfunction.","Regulator"
"<e1>Vardenafil</e1> has higher affinity to phosphodiesterase-5 (<e2>PDE5</e2>) than sildenafil and lower administered dosage for the treatment of erectile dysfunction.","Regulator"
"Reported here is a crystal structure of the fully active and nonmutated <e2>PDE5A1 catalytic domain</e2> in complex with <e1>vardenafil</e1>.","Regulator"
"Reported here is a crystal structure of the fully active and nonmutated <e2>PDE5A1</e2> catalytic domain in complex with <e1>vardenafil</e1>.","Regulator"
"Reported here is a crystal structure of the fully active and nonmutated <e2>PDE5</e2>A1 catalytic domain in complex with <e1>vardenafil</e1>.","Regulator"
"Vardenafil has higher affinity to phosphodiesterase-5 (<e2>PDE5</e2>) than <e1>sildenafil</e1> and lower administered dosage for the treatment of erectile dysfunction.","Regulator"
"Conformational variations of both <e2>phosphodiesterase-5</e2> and inhibitors provide the structural basis for the physiological effects of vardenafil and <e1>sildenafil</e1>.","Regulator"
"Vardenafil has higher affinity to phosphodiesterase-5 (<e2>PDE5</e2>) than <e1>sildenafil</e1> and lower administered dosage for the treatment of erectile dysfunction.","Regulator"
"Reported here is a crystal structure of the fully active and nonmutated <e2>PDE</e2>5A1 catalytic domain in complex with <e1>vardenafil</e1>.","Regulator"
"Conformational variations of both <e2>phosphodiesterase-5</e2> and inhibitors provide the structural basis for the physiological effects of <e1>vardenafil</e1> and sildenafil.","Regulator"
"Conformational variations of both <e2>phosphodiesterase-5</e2> and inhibitors provide the structural basis for the physiological effects of vardenafil and <e1>sildenafil</e1>.","Downregulator"
"Here we found that the anticancer agent <e1>cucurbitacin I</e1>, a <e2>Jak2</e2> inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.","Not"
"<e1>Cucurbitacin I</e1> also failed to affect the activation of <e2>P-Rex1</e2> by heregulin.","Not"
"<e1>Cucurbitacin I</e1> also failed to affect the activation of P-Rex1 by <e2>heregulin</e2>.","Not"
"<e1>Cucurbitacin I</e1> inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of <e2>janus tyrosine kinase 2</e2> and p-rex1.","Not"
"<e1>Cucurbitacin I</e1> inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and <e2>p-rex1</e2>.","Not"
"Subsequent analysis revealed that <e1>cucurbitacin I</e1> strongly activates <e2>RhoA</e2> and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.","Upregulator"
"Subsequent analysis revealed that <e1>cucurbitacin I</e1> strongly activates <e2>Rho</e2>A and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.","Upregulator"
"Subsequent analysis revealed that <e1>cucurbitacin I</e1> strongly activates RhoA and the Rho effector <e2>Rho kinase</e2> (ROCK) in breast cancer cells and induces the formation of stress fibers.","Upregulator"
"Subsequent analysis revealed that <e1>cucurbitacin I</e1> strongly activates RhoA and the Rho effector Rho kinase (<e2>ROCK</e2>) in breast cancer cells and induces the formation of stress fibers.","Upregulator"
"Subsequent analysis revealed that <e1>cucurbitacin I</e1> strongly activates <e2>RhoA</e2> and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.","Upregulator"
"The ROS scavenger <e1>N-acetyl l-cysteine</e1> and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on <e2>Rac1</e2> activation.","Upregulator"
"<e1>Cucurbitacin I</e1> inhibits <e2>rac1</e2> activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.","Downregulator"
"Here we found that the anticancer agent <e1>cucurbitacin I</e1>, a Jak2 inhibitor, reduced the activation of <e2>Rac1</e2> and motility in response to the ErbB3 ligand heregulin in breast cancer cells.","Downregulator"
"Here we found that the anticancer agent <e1>cucurbitacin I</e1>, a Jak2 inhibitor, reduced the activation of <e2>Rac1</e2> and motility in response to the ErbB3 ligand heregulin in breast cancer cells.","Downregulator"
"Here we found that the anticancer agent <e1>cucurbitacin I</e1>, a Jak2 inhibitor, reduced the activation of <e2>Rac1</e2> and motility in response to the ErbB3 ligand heregulin in breast cancer cells.","Downregulator"
"Here we found that the anticancer agent <e1>cucurbitacin I</e1>, a <e2>Jak2</e2> inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.","Downregulator"
"Here we found that the anticancer agent <e1>cucurbitacin I</e1>, a Jak2 inhibitor, reduced the activation of <e2>Rac1</e2> and motility in response to the ErbB3 ligand heregulin in breast cancer cells.","Downregulator"
"Ig module I and the <e1>C</e1>-terminus of <e2>Ig module II</e2>I are dispensable for high-affinity binding of FGF-1, FGF-2, and FGF-7.","Part_of"
"Several site-specific alterations in the <e1>C</e1>-terminus of full-length <e2>FGFR1IIIc</e2>, an isoform that otherwise absolutely rejects FGF-7, resulted in gain of FGF-7 binding.","Part_of"
"Ig module I and the <e1>C</e1>-terminus of <e2>Ig module III</e2> are dispensable for high-affinity binding of FGF-1, FGF-2, and FGF-7.","Part_of"
"These results suggest that a complex of <e2>Ig module II</e2> and heparan <e1>sulfate</e1> is the base common active core of the FGFR ectodomain and that flanking structural domains modify FGF affinity and determine specificity.","Regulator"
"Previously, we reported that a primary heparin or heparan <e1>sulfate</e1> binding site resides in a distinct sequence in <e2>immunoglobulin (Ig)-like module II</e2> of the three modules of FGFR.","Regulator"
"The assembly and activation of oligomeric complexes of FGF, the transmembrane receptor kinase (<e2>FGFR</e2>), and heparan <e1>sulfate</e1> transmit intracellular signals regulating growth and function of cells.","Regulator"
"A receptor binding assay using rat forebrain and spinal cord membrane preparations demonstrated that <e1>[3H]CP-101,606</e1> bound to the brain <e2>NR2B</e2> receptor with a greater extent compared to the spinal cord one.","Regulator"
"Brain but not spinal <e2>NR2B</e2> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist <e1>CP-101,606</e1> in a rat chronic constriction injury model.","Downregulator"
"Brain but not spinal <e2>NR2B</e2> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist <e1>CP-101,606</e1> in a rat chronic constriction injury model.","Antagonist"
"In order to examine the site of action of an NR2B subtype-selective <e2>NMDA</e2> antagonist <e1>CP-101,606</e1>, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.","Antagonist"
"Brain but not spinal <e2>NR2B</e2> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist <e1>CP-101,606</e1> in a rat chronic constriction injury model.","Antagonist"
"Brain but not spinal <e2>NR2B</e2> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist <e1>CP-101,606</e1> in a rat chronic constriction injury model.","Antagonist"
"In contrast, intrathecal injection of a non-selective <e2>NMDA</e2> antagonist, <e1>memantine</e1>, significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.","Antagonist"
"Reserpine-induced ptosis was reversed by <e1>rasagiline</e1> at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as <e2>MAO-B</e2>, but not at MAO-B-selective doses.","Not"
"<e1>Rasagiline</e1> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit <e2>MAO-B</e2> but not MAO-A.","Downregulator"
"<e1>Rasagiline</e1> does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not <e2>MAO-A</e2>.","Downregulator"
"<e1>Rasagiline</e1> [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible <e2>monoamine oxidase</e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.","Downregulator"
"<e1>Rasagiline</e1> [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (<e2>MAO</e2>) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.","Downregulator"
"Rasagiline [N-propargyl-1R(+)-aminoindan; <e1>TVP1012</e1>] is a potent irreversible <e2>monoamine oxidase</e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.","Downregulator"
"Rasagiline [N-propargyl-1R(+)-aminoindan; <e1>TVP1012</e1>] is a potent irreversible monoamine oxidase (<e2>MAO</e2>) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.","Downregulator"
"Reserpine-induced ptosis was reversed by <e1>rasagiline</e1> at doses above 2 mg x kg(-1) i.p., which inhibit <e2>MAO-A</e2> as well as MAO-B, but not at MAO-B-selective doses.","Downregulator"
"Reserpine-induced ptosis was reversed by <e1>rasagiline</e1> at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as <e2>MAO-B</e2>, but not at MAO-B-selective doses.","Downregulator"
"), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both <e2>MAO-A</e2> and MAO-B by <e1>tranylcypromine</e1> together with the monoamine precursors.","Downregulator"
"), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and <e2>MAO-B</e2> by <e1>tranylcypromine</e1> together with the monoamine precursors.","Downregulator"
"), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both <e2>MAO-A</e2> and MAO-B by tranylcypromine together with the <e1>monoamine</e1> precursors.","Downregulator"
"), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and <e2>MAO-B</e2> by tranylcypromine together with the <e1>monoamine</e1> precursors.","Downregulator"
"Rasagiline [<e1>N-propargyl-1R(+)-aminoindan</e1>; TVP1012] is a potent irreversible <e2>monoamine oxidase</e2> (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.","Downregulator"
"Rasagiline [<e1>N-propargyl-1R(+)-aminoindan</e1>; TVP1012] is a potent irreversible monoamine oxidase (<e2>MAO</e2>) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.","Downregulator"
"<e2>Omega class GSTs</e2> have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of <e1>monomethylarsonate</e1>, an intermediate in the pathway of arsenic biotransformation.","Substrate"
"The latter reaction, catalyzed by aspartoacylase (<e2>ASPA</e2>), produces <e1>acetyl</e1> groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.","Part_of"
"The latter reaction, catalyzed by <e2>aspartoacylase</e2> (ASPA), produces <e1>acetyl</e1> groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.","Substrate"
"The latter reaction, catalyzed by aspartoacylase (<e2>ASPA</e2>), produces <e1>acetyl</e1> groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.","Substrate"
"The latter reaction, catalyzed by <e2>aspartoacylase</e2> (ASPA), produces acetyl groups plus <e1>aspartate</e1> and has been proposed to occur in both soluble and membranous subfractions of white matter.","Substrate"
"The latter reaction, catalyzed by aspartoacylase (<e2>ASPA</e2>), produces acetyl groups plus <e1>aspartate</e1> and has been proposed to occur in both soluble and membranous subfractions of white matter.","Substrate"
"<e1>Tamoxifen</e1> does not reduce the incidence of <e2>ER</e2>-negative cancers, nor does it appear to be effective in preventing the appearance of one third of ER-positive cancers.","Not"
"<e1>Tamoxifen</e1> does not reduce the incidence of <e2>ER</e2>-negative cancers, nor does it appear to be effective in preventing the appearance of one third of ER-positive cancers.","Not"
"<e1>Raloxifene</e1> is a selective <e2>ER</e2> modulator with less uterine estrogen agonist activity than tamoxifen, and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer.","Regulator"
"It is not yet clear whether <e1>tamoxifen</e1> can reduce breast cancer incidence in women with BRCA1 and <e2>BRCA2</e2> mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.","Downregulator"
"It is not yet clear whether <e1>tamoxifen</e1> can reduce breast cancer incidence in women with BRCA1 and <e2>BRCA2</e2> mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation.","Downregulator"
"Individuals in whom <e1>tamoxifen</e1>-associated breast cancer risk reduction appears to outweigh risk of serious side-effects include women with prior in situ or estrogen receptor (<e2>ER</e2>)-positive invasive cancer, atypical hyperplasia, and/or women ages 35-49 with a calculated Gail 5-year risk of > or =1.7%, hysterectomized women aged 50 and older with a 5-year Gail risk of > or =2.5%, and nonhysterectomized women aged 50 and older with a 5-year Gail risk of >5.0%.","Modulator"
"The effect of <e1>troglitazone</e1>, an anti-diabetic drug with <e2>insulin</e2>-sensitizing action, on antigen-induced production of leukotriene (LT) B(4), C(4) and E(4) and prostaglandin D(2) (PGD(2)) was examined in dinitrophenol (DNP)-specific immunoglobulin E (IgE)-sensitized RBL-2H3 mast cells following stimulation by the antigen, DNP-conjugated human serum albumin.","Regulator"
"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of <e1>zileuton</e1>, a specific inhibitor of <e2>5-lipoxygenase</e2> (5-LOX) and a clinically used anti-asthmatic drug.","Downregulator"
"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of <e1>zileuton</e1>, a specific inhibitor of 5-lipoxygenase (<e2>5-LOX</e2>) and a clinically used anti-asthmatic drug.","Downregulator"
"Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of <e1>zileuton</e1>, a specific inhibitor of 5-lipoxygenase (<e2>5-LOX</e2>) and a clinically used anti-asthmatic drug.","Downregulator"
"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that <e1>troglitazone</e1> inhibits LT production by direct inhibition of <e2>5-LOX</e2> activity.","Downregulator"
"Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that <e1>troglitazone</e1> inhibits LT production by direct inhibition of <e2>5-LOX</e2> activity.","Downregulator"
"This study showed that the retinol binding protein and the <e2>immunoglobulin A</e2> are lower in children with <e1>vitamin A</e1> deficiency.","Upregulator"
"The positive correlation between <e1>vitamin A</e1> and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during <e2>immunoglobulins A</e2> synthesis.","Upregulator"
"This study showed that the retinol binding protein and the <e2>immunoglobulin A</e2> are lower in children with <e1>vitamin A</e1> deficiency.","Upregulator"
"The positive correlation between <e1>vitamin A</e1> and immunoglobulin A concentrations might be the result of the vitamin A inductive effect during <e2>immunoglobulins A</e2> synthesis.","Upregulator"
"Experimental as well as clinical reports support the hypothesis that <e2>calcium channel</e2> blockers such as <e1>verapamil</e1> may be an appropriate therapeutic approach in LQTS.","Downregulator"
"METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, <e1>veratridine</e1> (0.1 microM), an inhibitor of <e2>sodium channel</e2> inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3.","Downregulator"
"Exogenous <e1>all-trans-retinol</e1>, all-trans-13,14-dihydroretinol, or all-trans-7,8-dihydroretinol led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, <e2>Cyp26A1</e2>, arguing for an active signaling function of dihydroretinoid metabolites in zebrafish.","Regulator"
"Exogenous all-trans-retinol, <e1>all-trans-13,14-dihydroretinol</e1>, or all-trans-7,8-dihydroretinol led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, <e2>Cyp26A1</e2>, arguing for an active signaling function of dihydroretinoid metabolites in zebrafish.","Regulator"
"Exogenous all-trans-retinol, all-trans-13,14-dihydroretinol, or <e1>all-trans-7,8-dihydroretinol</e1> led to the strong induction of the expression of the retinoic acid-metabolizing enzyme, <e2>Cyp26A1</e2>, arguing for an active signaling function of dihydroretinoid metabolites in zebrafish.","Regulator"
"Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and <e1>all-trans-retinoic acid</e1>, which is involved in the regulation of gene expression through the <e2>retinoic acid receptor</e2>.","Regulator"
"Specificity of <e2>zebrafish retinol saturase</e2>: formation of <e1>all-trans-13,14-dihydroretinol</e1> and all-trans-7,8- dihydroretinol.","Substrate"
"Specificity of <e2>zebrafish retinol saturase</e2>: formation of all-trans-13,14-dihydroretinol and <e1>all-trans-7,8- dihydroretinol</e1>.","Substrate"
"Unlike mouse RetSat (mRetSat), <e2>zRetSat A</e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either <e1>all-trans-13,14-dihydroretinol</e1> or all-trans-7,8-dihydroretinol, respectively.","Substrate"
"Unlike mouse RetSat (mRetSat), <e2>zRetSat A</e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or <e1>all-trans-7,8-dihydroretinol</e1>, respectively.","Substrate"
"Unlike mouse RetSat (mRetSat), <e2>zRetSat A</e2> had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of <e1>all-trans-retinol</e1> to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively.","Substrate"
"Specifically, <e1>all-trans-13,14-dihydroretinol</e1> is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by <e2>Cyp26</e2> enzymes.","Substrate"
"<e2>zRetSat A</e2> also saturated the 13-14 or 7-8 double bonds of <e1>all-trans-3,4-didehydroretinol</e1> (vitamin A2), a second endogenous form of vitamin A in zebrafish.","Substrate"
"<e2>zRetSat A</e2> also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (<e1>vitamin A2</e1>), a second endogenous form of vitamin A in zebrafish.","Substrate"
"Estimation of <e1>warfarin</e1> maintenance dose based on VKORC1 (-1639 G>A) and <e2>CYP2C9</e2> genotypes.","Regulator"
"Estimation of <e1>warfarin</e1> maintenance dose based on <e2>VKORC1</e2> (-1639 G>A) and CYP2C9 genotypes.","Regulator"
"Estimation of <e1>warfarin</e1> maintenance dose based on <e2>VKORC1</e2> (-1639 G>A) and CYP2C9 genotypes.","Regulator"
"BACKGROUND: <e2>CYP2C9</e2> polymorphisms are associated with decreased <e1>S-warfarin</e1> clearance and lower maintenance dosage.","Regulator"
"<e1>Rasagiline</e1> is a novel, potent, and irreversible <e2>monoamine oxidase type B</e2> (MAO-B) inhibitor which has been approved for treatment of PD.","Downregulator"
"<e1>Rasagiline</e1> is a novel, potent, and irreversible monoamine oxidase type B (<e2>MAO-B</e2>) inhibitor which has been approved for treatment of PD.","Downregulator"
"<e1>Rasagiline</e1> is a novel, potent, and irreversible monoamine oxidase type B (<e2>MAO-B</e2>) inhibitor which has been approved for treatment of PD.","Downregulator"
"Lithium's effects on <e2>GluR3</e2> desensitization are distinct from the effects of <e1>aniracetam</e1> on desensitization.","Not"
"Specifically, <e1>aniracetam</e1>, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3(<e2>L507Y</e2>) mutant, but has synergistic effects with lithium on wild-type receptors.","Not"
"Lithium modulates desensitization of the <e1>glutamate</e1> receptor subtype gluR3 in Xenopus oocytes.","Regulator"
"Analysis of splice variants and site-directed mutants of the <e1>AMPA</e1> receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Regulator"
"Analysis of splice variants and site-directed mutants of the <e1>AMPA</e1> receptor <e2>GluR3</e2> expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Regulator"
"Analysis of splice variants and site-directed mutants of the <e1>AMPA</e1> receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Regulator"
"Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the <e1>glutamate</e1> binding site blocks desensitization of <e2>AMPA receptors</e2>.","Regulator"
"Lithium modulates desensitization of the <e1>glutamate</e1> receptor subtype gluR3 in Xenopus oocytes.","Regulator"
"Lithium modulates desensitization of the <e1>glutamate</e1> receptor subtype <e2>gluR3</e2> in Xenopus oocytes.","Regulator"
"Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of <e1>AMPA</e1> receptors.","Regulator"
"Additionally, experiments with the non-desensitizing site-directed mutant GluR3(L507Y) (Stern-Bach, Y., Russo, S., Neuman, M. and Rosenmund, C., A point mutation in the glutamate binding site blocks desensitization of <e1>AMPA</e1> receptors.","Regulator"
"<e1>Lithium</e1> modulates desensitization of the <e2>glutamate receptor</e2> subtype gluR3 in Xenopus oocytes.","Regulator"
"<e1>Lithium</e1> modulates desensitization of the glutamate receptor subtype <e2>gluR3</e2> in Xenopus oocytes.","Regulator"
"Lithium's effects on <e2>GluR3</e2> desensitization are distinct from the effects of <e1>aniracetam</e1> on desensitization.","Regulator"
"Specifically, aniracetam, which potentiates wild-type <e2>AMPA receptors</e2>, is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with <e1>lithium</e1> on wild-type receptors.","Regulator"
"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that <e1>lithium</e1> produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on <e2>glutamate receptor</e2> function.","Regulator"
"Analysis of splice variants and site-directed mutants of the AMPA receptor <e2>GluR3</e2> expressed in Xenopus oocytes has shown that <e1>lithium</e1> produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Upregulator"
"Analysis of splice variants and site-directed mutants of the AMPA receptor <e2>GluR3</e2> expressed in Xenopus oocytes has shown that <e1>lithium</e1> produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Upregulator"
"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that <e1>lithium</e1> produces a large potentiation of the <e2>GluR3 flop</e2> splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Upregulator"
"Specifically, <e1>aniracetam</e1>, which potentiates wild-type <e2>AMPA receptors</e2>, is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.","Upregulator"
"Analysis of splice variants and site-directed mutants of the AMPA receptor <e2>GluR3</e2> expressed in Xenopus oocytes has shown that <e1>lithium</e1> produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Upregulator"
"Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3(<e2>L507Y</e2>) mutant, but has synergistic effects with <e1>lithium</e1> on wild-type receptors.","Upregulator"
"Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that <e1>lithium</e1> produces a large potentiation of the <e2>GluR3 flop</e2> splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.","Upregulator"
"We have reported that a deficiency of tetrahydrobiopterin (<e1>BH(4)</e1>), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the <e2>insulin</e2>-resistant state.","Regulator"
"We have reported that a deficiency of tetrahydrobiopterin (<e1>BH(4)</e1>), an active cofactor of endothelial NO synthase (<e2>eNOS</e2>), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Regulator"
"We have reported that a deficiency of tetrahydrobiopterin (<e1>BH(4)</e1>), an active cofactor of endothelial NO synthase (<e2>eNOS</e2>), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Upregulator"
"We have reported that a deficiency of tetrahydrobiopterin (<e1>BH(4)</e1>), an active cofactor of endothelial NO synthase (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the <e2>insulin</e2>-resistant state.","Upregulator"
"Moreover, BH(4) treatment of the <e1>fructose</e1>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>nuclear factor-kappaB</e2> and activating protein-1, which were increased in fructose-fed rats.","Upregulator"
"Moreover, BH(4) treatment of the <e1>fructose</e1>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>activating protein-1</e2>, which were increased in fructose-fed rats.","Upregulator"
"Moreover, BH(4) treatment of the <e1>fructose</e1>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>nuclear factor-kappaB</e2> and activating protein-1, which were increased in fructose-fed rats.","Upregulator"
"Moreover, BH(4) treatment of the <e1>fructose</e1>-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>activating protein-1</e2>, which were increased in fructose-fed rats.","Upregulator"
"Moreover, <e1>BH(4)</e1> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, <e2>nuclear factor-kappaB</e2> and activating protein-1, which were increased in fructose-fed rats.","Downregulator"
"Moreover, <e1>BH(4)</e1> treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and <e2>activating protein-1</e2>, which were increased in fructose-fed rats.","Downregulator"
"We have reported that a deficiency of <e1>tetrahydrobiopterin</e1> (BH(4)), an active cofactor of endothelial NO synthase (<e2>eNOS</e2>), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Cofactor"
"We have reported that a deficiency of <e1>tetrahydrobiopterin</e1> (BH(4)), an active cofactor of endothelial NO synthase (<e2>eNOS</e2>), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Cofactor"
"We have reported that a deficiency of <e1>tetrahydrobiopterin</e1> (BH(4)), an active cofactor of <e2>endothelial NO synthase</e2> (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Cofactor"
"We have reported that a deficiency of tetrahydrobiopterin (<e1>BH(4)</e1>), an active cofactor of endothelial NO synthase (<e2>eNOS</e2>), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Cofactor"
"We have reported that a deficiency of tetrahydrobiopterin (<e1>BH(4)</e1>), an active cofactor of endothelial NO synthase (<e2>eNOS</e2>), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Cofactor"
"We have reported that a deficiency of tetrahydrobiopterin (<e1>BH(4)</e1>), an active cofactor of <e2>endothelial NO synthase</e2> (eNOS), contributes to the endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O(2)(-)) generation in the insulin-resistant state.","Cofactor"
"However, we show that <e2>hCTR1</e2> is not the major entry route of <e1>platinum</e1>-drugs and that the copper transporter is not internalized in response to extracellular drug.","Not"
"A Re-evaluation of the Role of <e2>hCTR1</e2>, the Human High Affinity Cu Transporter in <e1>Pt</e1>-Drug Entry into Human Cells.","Substrate"
"It has been claimed that <e2>hCTR1</e2>, the human high affinity copper transporter, is the major entry pathway for <e1>cDDP</e1> and related drugs via a mechanism that mimics copper.","Substrate"
"It has been claimed that hCTR1, the <e2>human high affinity copper transporter</e2>, is the major entry pathway for <e1>cDDP</e1> and related drugs via a mechanism that mimics copper.","Substrate"
"Using electrophysiologic techniques, the present study assessed the in vivo action of <e1>brexpiprazole</e1> on <e2>serotonin (5-HT) receptor</e2> subtypes 5-HT1A, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors.","Regulator"
"Using electrophysiologic techniques, the present study assessed the in vivo action of <e1>brexpiprazole</e1> on serotonin (5-HT) receptor subtypes <e2>5-HT1A</e2>, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors.","Regulator"
"Using electrophysiologic techniques, the present study assessed the in vivo action of <e1>brexpiprazole</e1> on serotonin (5-HT) receptor subtypes 5-HT1A, <e2>5-HT1B</e2>, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors.","Regulator"
"Using electrophysiologic techniques, the present study assessed the in vivo action of <e1>brexpiprazole</e1> on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and <e2>5-HT2A</e2>; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors.","Regulator"
"Using electrophysiologic techniques, the present study assessed the in vivo action of <e1>brexpiprazole</e1> on serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, and 5-HT2A; <e2>dopamine (DA) D2 autoreceptors</e2>, and alpha1- and alpha2-adrenergic receptors.","Regulator"
"Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, <e1>brexpiprazole</e1> displayed less efficacy at <e2>D2 receptors</e2>.","Downregulator"
"Using electrophysiologic techniques, the present study assessed the in vivo action of <e1>brexpiprazole</e1> on serotonin (5-HT) receptor subtypes <e2>5-HT1A</e2>, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors.","Agonist"
"Using electrophysiologic techniques, the present study assessed the in vivo action of <e1>brexpiprazole</e1> on serotonin (5-HT) receptor subtypes <e2>5-HT1A</e2>, 5-HT1B, and 5-HT2A; dopamine (DA) D2 autoreceptors, and alpha1- and alpha2-adrenergic receptors.","Agonist"
"In addition, the effects on <e2>5-HT1A</e2> autoreceptors in the dorsal raphe nucleus (DRN) and D2 autoreceptors in the ventral tegmental area (VTA) were compared with those of <e1>aripiprazole</e1>, an agent in wide clinical use.","Agonist"
"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <e2>5-HT2A</e2> receptor agonist <e1>DOI</e1> (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.","Agonist"
"In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential <e2>5-HT2A</e2> receptor agonist DOI (<e1>2,5-dimethoxy-4-iodoamphetamine</e1>) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.","Agonist"
"Brexpiprazole reversed the inhibitory effect of the DA agonist <e1>apomorphine</e1> on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on <e2>D2 receptors</e2>.","Agonist"
"In the lateral geniculate nucleus, <e1>brexpiprazole</e1> displayed <e2>alpha1B-adrenoceptor</e2> antagonistic action.","Antagonist"
"For <e2>AII</e2> and ET1, MAP was also increased for the <e1>fenofibrate</e1> group but not in a dose-dependent fashion.","Not"
"For AII and <e2>ET1</e2>, MAP was also increased for the <e1>fenofibrate</e1> group but not in a dose-dependent fashion.","Not"
"Effects of <e1>fenofibrate</e1>, a <e2>PPAR-α</e2> ligand, on the haemodynamics of glycerol-induced renal failure in rats.","Regulator"
"For <e2>AII</e2> and ET1, MAP was also increased for the <e1>fenofibrate</e1> group but not in a dose-dependent fashion.","Upregulator"
"For AII and <e2>ET1</e2>, MAP was also increased for the <e1>fenofibrate</e1> group but not in a dose-dependent fashion.","Upregulator"
"<e1>Glutaraldehyde</e1> crosslinked <e2>albumin</e2> nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.","Part_of"
"Glutaraldehyde crosslinked <e2>albumin</e2> nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to <e1>methionine</e1> residues of albumin and is released in a reductive environment.","Part_of"
"<e2>Albumin</e2> nanoparticles were surface-coated with bifunctional <e1>polyethylene glycol</e1> 3500 (PEG) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor (EGFR).","Part_of"
"<e2>Albumin</e2> nanoparticles were surface-coated with bifunctional polyethylene glycol 3500 (<e1>PEG</e1>) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor (EGFR).","Part_of"
"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a <e2>multikinase</e2> inhibitor <e1>17864</e1> to EGFR overexpressing tumor cells.","Downregulator"
"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a <e2>multikinase</e2> inhibitor <e1>17864</e1> to EGFR overexpressing tumor cells.","Downregulator"
"Endogenously produced asymmetrically methylated <e1>arginine</e1> residues are competitive inhibitors of all three isoforms of <e2>nitric oxide synthase</e2> (NOS).","Downregulator"
"Endogenously produced asymmetrically methylated <e1>arginine</e1> residues are competitive inhibitors of all three isoforms of nitric oxide synthase (<e2>NOS</e2>).","Downregulator"
"The enzyme dimethyl<e1>arginine</e1> dimethylaminohydrolase (DDAH) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines.","Substrate"
"The enzyme dimethyl<e1>arginine</e1> dimethylaminohydrolase (<e2>DDAH</e2>) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines.","Substrate"
"The enzyme di<e1>methylarginine</e1> dimethylaminohydrolase (<e2>DDAH</e2>) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines.","Substrate"
"Structure-based design of novel <e1>dihydroisoquinoline</e1> <e2>BACE-1</e2> inhibitors that do not engage the catalytic aspartates.","Downregulator"
"Structure-based design of novel <e1>dihydroisoquinoline</e1> <e2>BACE-1</e2> inhibitors that do not engage the catalytic aspartates.","Downregulator"
"Furthermore, tPA induced rapid <e1>tyrosine</e1> phosphorylation on the beta subunit of <e2>LRP-1</e2>, which was followed by the activation of Mek1 and its downstream Erk-1 and -2.","Part_of"
"Furthermore, tPA induced rapid <e1>tyrosine</e1> phosphorylation on the beta subunit of <e2>LRP-1</e2>, which was followed by the activation of Mek1 and its downstream Erk-1 and -2.","Part_of"
"Tissue-type plasminogen activator (tPA), a <e1>serine</e1> protease well known for generating plasmin, has been demonstrated to induce <e2>matrix metalloproteinase-9</e2> (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.","Upregulator"
"Tissue-type <e2>plasmin</e2>ogen activator (tPA), a <e1>serine</e1> protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts.","Upregulator"
"Furthermore, tPA induced rapid <e1>tyrosine</e1> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of <e2>Mek1</e2> and its downstream Erk-1 and -2.","Upregulator"
"Furthermore, tPA induced rapid <e1>tyrosine</e1> phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream <e2>Erk-1 and -2</e2>.","Upregulator"
"Furthermore, estrogen responsive genes in fish liver, <e2>ERα</e2> and VTG, are not induced by <e1>CP[c]Ph</e1>, suggesting that the compound has no endocrine disrupting potential.","Not"
"Furthermore, estrogen responsive genes in fish liver, ERα and <e2>VTG</e2>, are not induced by <e1>CP[c]Ph</e1>, suggesting that the compound has no endocrine disrupting potential.","Not"
"Furthermore, <e1>estrogen</e1> responsive genes in fish liver, <e2>ERα</e2> and VTG, are not induced by CP[c]Ph, suggesting that the compound has no endocrine disrupting potential.","Regulator"
"Furthermore, <e1>estrogen</e1> responsive genes in fish liver, ERα and <e2>VTG</e2>, are not induced by CP[c]Ph, suggesting that the compound has no endocrine disrupting potential.","Regulator"
"The data show that <e1>CP[c]Ph</e1> is less potent at inducing <e2>CYP1A</e2> gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.","Upregulator"
"The data show that CP[c]Ph is less potent at inducing <e2>CYP1A</e2> gene expression in rainbow trout than <e1>benzo[a]pyrene</e1> (B[a]P), a well-known Ah-receptor agonist.","Upregulator"
"The data show that CP[c]Ph is less potent at inducing <e2>CYP1A</e2> gene expression in rainbow trout than benzo[a]pyrene (<e1>B[a]P</e1>), a well-known Ah-receptor agonist.","Upregulator"
"The data show that <e1>CP[c]Ph</e1> is less potent at inducing <e2>CYP1A</e2> gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.","Upregulator"
"<e1>CP[c]Ph</e1> has, comparably to B[a]P, a potential to repress expression of <e2>tumor suppressor p53</e2>, in the head kidney of rainbow trout.","Downregulator"
"CP[c]Ph has, comparably to <e1>B[a]P</e1>, a potential to repress expression of <e2>tumor suppressor p53</e2>, in the head kidney of rainbow trout.","Downregulator"
"Mutation of a single <e1>amino acid</e1> residue in the potential <e2>BiP binding site</e2> increased the secretion efficiency of factor VIII by threefold.","Part_of"
"We propose that <e1>Cu(I)</e1> binds the <e2>type-1 copper ion-binding site</e2> in the A1 domain and provides the essential requirement for a stable interaction between the heavy and light chains.","Regulator"
"We propose that <e1>Cu(I)</e1> binds the type-1 copper ion-binding site in the <e2>A1 domain</e2> and provides the essential requirement for a stable interaction between the heavy and light chains.","Regulator"
"Identification of <e1>benzofuran</e1> central cores for the inhibition of <e2>leukotriene A(4) hydrolase</e2>.","Downregulator"
"This paper describes the identification and synthesis of substituted <e1>benzofurans</e1> as <e2>LTH(4)H</e2> inhibitors.","Downregulator"
"<e1>Benzofuran</e1> 28 showed dose responsive target engagement and provides a useful tool to explore a <e2>LTA(4)H</e2> inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).","Downregulator"
"Leukotriene A(4) hydrolase (<e2>LTA(4)H</e2>) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to <e1>LTB(4)</e1>.","Substrate"
"<e2>Leukotriene A(4) hydrolase</e2> (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to <e1>LTB(4)</e1>.","Substrate"
"Leukotriene A(4) hydrolase (<e1>LTA(4)</e1>H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4).","Substrate"
"<e2>Leukotriene A(4) hydrolase</e2> (<e1>LTA(4)</e1>H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to LTB(4).","Substrate"
"<e1>Minocycline</e1> treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well as the appearance of a <e2>calpain</e2> cleaved substrate, a marker of excitotoxic/necrotic cell death.","Regulator"
"<e1>Minocycline</e1> treatment prevents the formation of activated <e2>caspase-3</e2>, a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death.","Downregulator"
"<e2>DAT</e2> occupancy was determined by displacement of <e1>8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane</e1> (FECNT).","Regulator"
"Similar to <e1>cocaine</e1>, other local anesthetics bind to the <e2>dopamine transporter</e2> (DAT) and inhibit DA uptake in rodent and monkey brain.","Regulator"
"Similar to <e1>cocaine</e1>, other local anesthetics bind to the dopamine transporter (<e2>DAT</e2>) and inhibit DA uptake in rodent and monkey brain.","Regulator"
"<e2>DAT</e2> occupancy was determined by displacement of 8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane (<e1>FECNT</e1>).","Regulator"
"The present study examined the reinforcing and <e2>DAT</e2> effects of the local anesthetics <e1>dimethocaine</e1>, procaine and cocaine using in vivo techniques.","Regulator"
"The present study examined the reinforcing and <e2>DAT</e2> effects of the local anesthetics dimethocaine, <e1>procaine</e1> and cocaine using in vivo techniques.","Regulator"
"Similar to cocaine, other local anesthetics bind to the dopamine transporter (<e1>DA</e1>T) and inhibit DA uptake in rodent and monkey brain.","Regulator"
"The present study examined the reinforcing and <e2>DAT</e2> effects of the local anesthetics <e1>dimethocaine</e1>, procaine and cocaine using in vivo techniques.","Regulator"
"The present study examined the reinforcing and <e2>DAT</e2> effects of the local anesthetics dimethocaine, <e1>procaine</e1> and cocaine using in vivo techniques.","Regulator"
"Similar to <e1>cocaine</e1>, other local anesthetics bind to the dopamine transporter (<e2>DAT</e2>) and inhibit DA uptake in rodent and monkey brain.","Regulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO</e2>) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Regulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T</e2>), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Regulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (<e2>ALA-T</e2>).","Regulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO</e2>) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Regulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T</e2>), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Regulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (<e2>ALA-T</e2>).","Regulator"
"The effects of <e1>PLZ</e1> on both amino acids and their <e2>transaminases</e2> were blocked by pre-treatment with the MAO inhibitor tranylcypromine.","Regulator"
"The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the <e2>MAO</e2> inhibitor <e1>tranylcypromine</e1>.","Downregulator"
"The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the <e2>MAO</e2> inhibitor <e1>tranylcypromine</e1>.","Downregulator"
"The effects of PLZ on both amino acids and their <e2>transaminases</e2> were blocked by pre-treatment with the MAO inhibitor <e1>tranylcypromine</e1>.","Downregulator"
"Neurochemical effects of the <e2>monoamine oxidase</e2> inhibitor <e1>phenelzine</e1> on brain GABA and alanine: A comparison with vigabatrin.","Downregulator"
"PURPOSE: To compare <e1>phenelzine</e1> (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO</e2>) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with <e1>vigabatrin</e1> (VIG), an anticonvulsant which elevates brain GABA by inhibition of <e2>GABA transaminase</e2> (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with <e1>vigabatrin</e1> (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T</e2>), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of <e2>GABA transaminase</e2> (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T</e2>), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits <e2>monoamine oxidase</e2> (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO</e2>) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T</e2>), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T</e2>), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO</e2>) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (<e1>PLZ</e1>), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (<e2>ALA-T</e2>).","Downregulator"
"Neurochemical effects of the <e2>monoamine oxidase</e2> inhibitor <e1>phenelzine</e1> on brain GABA and alanine: A comparison with vigabatrin.","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (<e2>GABA-T</e2>), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (<e2>MAO</e2>) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T).","Downregulator"
"PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (<e1>VIG</e1>), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (<e2>ALA-T</e2>).","Downregulator"
"Clinical pharmacology of <e1>enalkiren</e1>, a novel, dipeptide <e2>renin</e2> inhibitor.","Downregulator"
"Clinical pharmacology of enalkiren, a novel, <e1>dipeptide</e1> <e2>renin</e2> inhibitor.","Downregulator"
"<e1>Enalkiren</e1> (A-64662), a potent, dipeptide <e2>renin</e2> inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.","Downregulator"
"<e1>Enalkiren</e1> (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the <e2>human renin</e2> substrate, angiotensinogen.","Downregulator"
"Enalkiren (<e1>A-64662</e1>), a potent, dipeptide <e2>renin</e2> inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.","Downregulator"
"Enalkiren (<e1>A-64662</e1>), a potent, dipeptide renin inhibitor, mimics the transition state of the <e2>human renin</e2> substrate, angiotensinogen.","Downregulator"
"Clinical pharmacology of <e1>enalkiren</e1>, a novel, dipeptide <e2>renin</e2> inhibitor.","Downregulator"
"<e1>Enalkiren</e1> (A-64662), a potent, dipeptide <e2>renin</e2> inhibitor, mimics the transition state of the human renin substrate, angiotensinogen.","Downregulator"
"<e1>Enalkiren</e1> has been shown to produce dose-related suppression of plasma renin activity (PRA) and <e2>angiotensin II</e2> when administered intravenously.","Downregulator"
"Clinical pharmacology of enalkiren, a novel, <e1>dipeptide</e1> <e2>renin</e2> inhibitor.","Downregulator"
"Enalkiren (A-64662), a potent, <e1>dipeptide</e1> renin inhibitor, mimics the transition state of the <e2>human renin</e2> substrate, angiotensinogen.","Downregulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Not"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular <e1>monoamine</e1> transporter-2 (VMAT-2) were assessed.","Part_of"
"Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the <e2>DAT</e2> ligand <e1>WIN35428</e1>, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.","Regulator"
"To determine whether these responses were common to other <e1>amphetamines</e1> of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal <e2>DA transporter</e2> (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other <e1>amphetamines</e1> of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other <e1>amphetamines</e1> of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and <e2>vesicular monoamine transporter-2</e2> (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other <e1>amphetamines</e1> of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 (<e2>VMAT-2</e2>) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of <e1>methylenedioxymethamphetamine</e1> (MDMA) on the plasmalemmal <e2>DA transporter</e2> (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of <e1>methylenedioxymethamphetamine</e1> (MDMA) on the plasmalemmal DA transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of <e1>methylenedioxymethamphetamine</e1> (MDMA) on the plasmalemmal DA transporter (DAT) and <e2>vesicular monoamine transporter-2</e2> (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of <e1>methylenedioxymethamphetamine</e1> (MDMA) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 (<e2>VMAT-2</e2>) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal <e2>DA transporter</e2> (DAT) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (DAT) and <e2>vesicular monoamine transporter-2</e2> (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 (<e2>VMAT-2</e2>) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Regulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (DAT) and vesicular monoamine transporter-2 (<e2>VMAT-2</e2>) were assessed.","Regulator"
"Also in contrast to effects of multiple <e1>METH</e1> injections, 1) MDMA caused little or no decrease in binding of the <e2>DAT</e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.","Regulator"
"Taken together, these results reveal several differences between effects of MDMA and previously reported <e1>METH</e1> on DAT and <e2>VMAT-2</e2>; differences that may underlie the dissimilar neurotoxic profile of these agents.","Regulator"
"Also in contrast to effects of multiple <e1>METH</e1> injections, 1) MDMA caused little or no decrease in binding of the <e2>DAT</e2> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.","Downregulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (<e1>MDMA</e1>) on the plasmalemmal DA transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Downregulator"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal <e1>DA</e1> transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Substrate"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal <e1>DA</e1> transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Substrate"
"To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal <e1>DA</e1> transporter (<e2>DAT</e2>) and vesicular monoamine transporter-2 (VMAT-2) were assessed.","Substrate"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of <e2>CYP2D</e2> and CYP3A, in rats.","Not"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of <e2>CYP2D</e2> and CYP3A, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of CYP2D and <e2>CYP3A</e2>, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of CYP2D and <e2>CYP3A</e2>, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of <e2>CYP2D</e2> and CYP3A, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of CYP2D and <e2>CYP3A</e2>, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of <e2>CYP2D</e2> and CYP3A, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of CYP2D and <e2>CYP3A</e2>, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of <e2>CYP2D</e2> and CYP3A, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of <e1>baicalin</e1> on the metabolism of dextromethorphan, a dual probe of CYP2D and <e2>CYP3A</e2>, in rats.","Downregulator"
"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan</e1>, a dual probe of <e2>CYP2D</e2> and CYP3A, in rats.","Substrate"
"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan</e1>, a dual probe of CYP2D and <e2>CYP3A</e2>, in rats.","Substrate"
"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>DXM</e1>), a dual probe substrate of <e2>CYP2D</e2> and CYP3A, in rats.","Substrate"
"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>DXM</e1>), a dual probe substrate of CYP2D and <e2>CYP3A</e2>, in rats.","Substrate"
"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan</e1>, a dual probe of <e2>CYP2D</e2> and CYP3A, in rats.","Substrate"
"Concentration-dependent inhibitory effects of baicalin on the metabolism of <e1>dextromethorphan</e1>, a dual probe of CYP2D and <e2>CYP3A</e2>, in rats.","Substrate"
"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>DXM</e1>), a dual probe substrate of <e2>CYP2D</e2> and CYP3A, in rats.","Substrate"
"In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (<e1>DXM</e1>), a dual probe substrate of CYP2D and <e2>CYP3A</e2>, in rats.","Substrate"
"Identification of a novel <e1>benzimidazole</e1> derivative as a highly potent <e2>NPY Y5 receptor</e2> antagonist with an anti-obesity profile.","Antagonist"
"We evaluated the clinical effectiveness of <e1>esmolol</e1>, an ultra-short-acting <e2>beta 1-adrenergic receptor</e2> blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT).","Downregulator"
"The centerpiece of the A<e1>N</e1>D gate is a bisected methionyl-tRNA synthetase (<e2>MetRS</e2>) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met).","Part_of"
"<e1>C</e1>ellular protein labeling occurs only upon activation of two different promoters that drive expression of the N- and C-terminal fragments of the bisected <e2>MetRS</e2>.","Part_of"
"The centerpiece of the A<e1>N</e1>D gate is a bisected methionyl-tRNA synthetase (<e2>MetRS</e2>) that charges the Met surrogate azidonorleucine (Anl) to tRNA(Met).","Part_of"
"<e1>C</e1>ellular protein labeling occurs only upon activation of two different promoters that drive expression of the N- and C-terminal fragments of the bisected <e2>MetRS</e2>.","Part_of"
"The beta(2)-adrenoceptor (<e2>beta(2)-AR</e2>) agonists <e1>clenbuterol</e1> and fenoterol have similar beneficial effects in animal models of heart failure.","Agonist"
"The <e2>beta(2)-adrenoceptor</e2> (beta(2)-AR) agonists <e1>clenbuterol</e1> and fenoterol have similar beneficial effects in animal models of heart failure.","Agonist"
"The beta(2)-adrenoceptor (<e2>beta(2)-AR</e2>) agonists clenbuterol and <e1>fenoterol</e1> have similar beneficial effects in animal models of heart failure.","Agonist"
"The <e2>beta(2)-adrenoceptor</e2> (beta(2)-AR) agonists clenbuterol and <e1>fenoterol</e1> have similar beneficial effects in animal models of heart failure.","Agonist"
"<e2>beta(1)-Adrenoceptor</e2> antagonism (10 mg kg(-1) <e1>bisoprolol</e1>) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).","Antagonist"
"The mouse <e2>CYP2J</e2> subfamily includes members that have wide tissue distribution and are active in the metabolism of <e1>arachidonic acid</e1> (AA), linoleic acid (LA), and other lipids and xenobiotics.","Substrate"
"The mouse <e2>CYP2J</e2> subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA), <e1>linoleic acid</e1> (LA), and other lipids and xenobiotics.","Substrate"
"Although dopaminergic neurons within the nigrostriatal pathway appear intact, <e1>Mn</e1>-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the dopamine transporter (<e2>DAT</e2>).","Regulator"
"Although dopaminergic neurons within the nigrostriatal pathway appear intact, <e1>Mn</e1>-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the dopamine transporter (<e2>DAT</e2>).","Regulator"
"Although dopaminergic neurons within the nigrostriatal pathway appear intact, <e1>Mn</e1>-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the dopamine transporter (<e2>DAT</e2>).","Regulator"
"Although dopaminergic neurons within the nigrostriatal pathway appear intact, <e1>Mn</e1>-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the dopamine transporter (<e2>DAT</e2>).","Regulator"
"Although dopaminergic neurons within the nigrostriatal pathway appear intact, <e1>Mn</e1>-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the <e2>dopamine transporter</e2> (DAT).","Regulator"
"Although dopaminergic neurons within the nigrostriatal pathway appear intact, <e1>Mn</e1>-induced irregularities in DA transmission have been observed including decreased amphetamine-induced DA release and loss of the dopamine transporter (<e2>DAT</e2>).","Regulator"
"The model includes 607 of the 773 <e1>amino acids</e1> of <e2>L-CPT I</e2>, and the positions of carnitine, CoA and the palmitoyl group were assigned by superposition and docking analysis.","Part_of"
"<e2>CPT I</e2> (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into <e1>palmitoylcarnitine</e1> in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.","Substrate"
"CPT I (<e2>carnitine palmitoyltransferase I</e2>) catalyses the conversion of palmitoyl-CoA into <e1>palmitoylcarnitine</e1> in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.","Substrate"
"<e2>CPT I</e2> (carnitine palmitoyltransferase I) catalyses the conversion of <e1>palmitoyl-CoA</e1> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.","Substrate"
"CPT I (<e2>carnitine palmitoyltransferase I</e2>) catalyses the conversion of <e1>palmitoyl-CoA</e1> into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria.","Substrate"
"Cholesterol uptake from <e2>lipoproteins</e2>, intracellular vesicle transport and lipid transfer are also modified by <e1>oxysterols</e1>.","Regulator"
"<e1>Oxysterols</e1> interfere with <e2>ERK</e2>, hedgehog and wnt pathways of proliferation and differentiation.","Regulator"
"<e1>Oxysterols</e1> interfere with ERK, <e2>hedgehog</e2> and wnt pathways of proliferation and differentiation.","Regulator"
"<e1>Oxysterols</e1> interfere with ERK, hedgehog and <e2>wnt</e2> pathways of proliferation and differentiation.","Regulator"
"<e1>Cholesterol</e1> uptake from <e2>lipoproteins</e2>, intracellular vesicle transport and lipid transfer are also modified by oxysterols.","Substrate"
"In vivo <e2>HIF</e2>-mediated reductive carboxylation is regulated by <e1>citrate</e1> levels and sensitizes VHL-deficient cells to glutamine deprivation.","Regulator"
"In addition, the new compound <e1>perviridicin B</e1> (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant <e2>NF-κB</e2> (p65) inhibitory activity in an ELISA assay.","Downregulator"
"In addition, the new compound <e1>perviridicin B</e1> (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-κB (<e2>p65</e2>) inhibitory activity in an ELISA assay.","Downregulator"
"In addition, the new compound perviridicin B (2), three known <e1>rocaglate</e1> derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant <e2>NF-κB</e2> (p65) inhibitory activity in an ELISA assay.","Downregulator"
"In addition, the new compound perviridicin B (2), three known <e1>rocaglate</e1> derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-κB (<e2>p65</e2>) inhibitory activity in an ELISA assay.","Downregulator"
"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known <e1>sesquiterpene</e1>, 2-oxaisodauc-5-en-12-al (17), showed significant <e2>NF-κB</e2> (p65) inhibitory activity in an ELISA assay.","Downregulator"
"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known <e1>sesquiterpene</e1>, 2-oxaisodauc-5-en-12-al (17), showed significant NF-κB (<e2>p65</e2>) inhibitory activity in an ELISA assay.","Downregulator"
"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, <e1>2-oxaisodauc-5-en-12-al</e1> (17), showed significant <e2>NF-κB</e2> (p65) inhibitory activity in an ELISA assay.","Downregulator"
"In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, <e1>2-oxaisodauc-5-en-12-al</e1> (17), showed significant NF-κB (<e2>p65</e2>) inhibitory activity in an ELISA assay.","Downregulator"
"In further evaluation, the representative compound <e1>N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide</e1> (3b) exhibited potent pro-apoptotic activity, through <e2>RhoB</e2> activation, in HeLa cells.","Upregulator"
"The <e2>adenosine triphosphate binding cassette (ABC)-transporter</e2> ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs <e1>cisplatin</e1> and paclitaxel.","Not"
"RNA interference-triggered reversal of <e2>ABCC2</e2>-dependent <e1>cisplatin</e1> resistance in human cancer cells.","Not"
"The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (<e2>MRP2</e2>/cMOAT) can mediate resistance against the commonly used anticancer drugs <e1>cisplatin</e1> and paclitaxel.","Not"
"The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/<e2>cMOAT</e2>) can mediate resistance against the commonly used anticancer drugs <e1>cisplatin</e1> and paclitaxel.","Not"
"The <e2>adenosine triphosphate binding cassette (ABC)-transporter</e2> ABCC2 (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and <e1>paclitaxel</e1>.","Not"
"The adenosine triphosphate binding cassette (ABC)-transporter <e2>ABCC2</e2> (MRP2/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and <e1>paclitaxel</e1>.","Not"
"The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (<e2>MRP2</e2>/cMOAT) can mediate resistance against the commonly used anticancer drugs cisplatin and <e1>paclitaxel</e1>.","Not"
"The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/<e2>cMOAT</e2>) can mediate resistance against the commonly used anticancer drugs cisplatin and <e1>paclitaxel</e1>.","Not"
"RNA interference-triggered reversal of <e2>ABCC2</e2>-dependent <e1>cisplatin</e1> resistance in human cancer cells.","Not"
"<e1>Chlorpheniramine</e1> (10 microM), another histamine H1 receptor antagonist without significant <e2>5-HT receptor</e2> binding affinity, did not produce any inhibition of the eNANC contraction.","Not"
"<e1>Epinastine</e1> (100 microM) did not displace the dose-response curve to exogenously applied <e2>substance P</e2> (0.01-10 microM).","Not"
"<e1>Epinastine</e1> (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including <e2>alpha-adrenergic receptors</e2> and various serotonin (5-HT) receptor subtypes.","Regulator"
"<e1>Epinastine</e1> (WAL 801CL) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various <e2>serotonin (5-HT) receptor</e2> subtypes.","Regulator"
"Epinastine (<e1>WAL 801CL</e1>) is an antihistaminic drug with binding affinity at certain other receptors, including <e2>alpha-adrenergic receptors</e2> and various serotonin (5-HT) receptor subtypes.","Regulator"
"Epinastine (<e1>WAL 801CL</e1>) is an antihistaminic drug with binding affinity at certain other receptors, including alpha-adrenergic receptors and various <e2>serotonin (5-HT) receptor</e2> subtypes.","Regulator"
"<e1>Epinastine</e1> (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional <e2>5-HT1-like receptor</e2>.","Regulator"
"Epinastine (<e1>WAL 801CL</e1>) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional <e2>5-HT1-like receptor</e2>.","Regulator"
"These results suggest that <e1>epinastine</e1>, although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional <e2>5-HT1-like receptor</e2>, located to sensory nerves.","Upregulator"
"Pretreatment of the tissues with combined <e2>5-HT1</e2>/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of <e1>epinastine</e1> on the noncholinergic contraction.","Agonist"
"Pretreatment of the tissues with combined <e2>5-HT1</e2>/5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of <e1>epinastine</e1> on the noncholinergic contraction.","Agonist"
"Pretreatment of the tissues with combined 5-HT1/<e2>5-HT2</e2> antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of <e1>epinastine</e1> on the noncholinergic contraction.","Agonist"
"Pretreatment of the tissues with combined <e2>5-HT1</e2>/5-HT2 antagonists, <e1>methysergide</e1> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.","Antagonist"
"Pretreatment of the tissues with combined 5-HT1/<e2>5-HT2</e2> antagonists, <e1>methysergide</e1> (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.","Antagonist"
"Pretreatment of the tissues with combined <e2>5-HT1</e2>/5-HT2 antagonists, methysergide (1 microM) or <e1>methiothepin</e1> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.","Antagonist"
"Pretreatment of the tissues with combined 5-HT1/<e2>5-HT2</e2> antagonists, methysergide (1 microM) or <e1>methiothepin</e1> (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction.","Antagonist"
"Pretreatment with <e1>tropisetron</e1> (1 microM), a <e2>5-HT3</e2> antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.","Antagonist"
"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, <e1>ketanserin</e1> (10 microM), a <e2>5-HT2</e2> antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.","Antagonist"
"Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, <e1>thioperamide</e1> (10 microM), a <e2>histamine H3</e2> antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.","Antagonist"
"<e1>Chlorpheniramine</e1> (10 microM), another <e2>histamine H1 receptor</e2> antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction.","Antagonist"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced <e2>NF-κB</e2> activation that involves degradation of I-κBε and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.","Regulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of I-κBε and nuclear translocation of <e2>c-Rel</e2>/p50 in alveolar epithelial cells.","Regulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of I-κBε and nuclear translocation of c-Rel/<e2>p50</e2> in alveolar epithelial cells.","Regulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of I-κBε and nuclear translocation of <e2>c-Rel</e2>/p50 in alveolar epithelial cells.","Regulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of <e2>I-κBε</e2> and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.","Downregulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of <e2>I-κBε</e2> and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.","Downregulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced NF-κB activation that involves degradation of I-κBε and nuclear translocation of <e2>c-Rel</e2>/p50 in alveolar epithelial cells.","Downregulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced <e2>NF-κB</e2> activation that involves degradation of I-κBε and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.","Downregulator"
"It is possible that <e1>vitamin C</e1>, an antioxidant, may prevent cigarette smoke (CS)-induced <e2>NF-κB</e2> activation that involves degradation of I-κBε and nuclear translocation of c-Rel/p50 in alveolar epithelial cells.","Downregulator"
"<e1>Vitamin C</e1> forestalls cigarette smoke induced <e2>NF-κB</e2> activation in alveolar epithelial cells.","Downregulator"
"Promoter and electromobility shift assays showed that transcriptional activation of NF-κB was significantly reduced by <e1>catalpol</e1> treatment, while <e2>AP-1</e2> was not.","Not"
"<e1>Catalpol</e1> also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of IκBα and the nuclear localization of <e2>NF-κB</e2>.","Downregulator"
"<e1>Catalpol</e1> also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of <e2>IκBα</e2> and the nuclear localization of NF-κB.","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as <e2>monocyte chemotactic protein-1</e2> (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE).","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (<e2>MCP-1</e2>), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE).","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), <e2>tumor necrosis factor-α</e2> (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (RAGE).","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (<e2>TNF-α</e2>), inducible NO synthase (iNOS), and receptor for AGE (RAGE).","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), <e2>inducible NO synthase</e2> (iNOS), and receptor for AGE (RAGE).","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (<e2>iNOS</e2>), and receptor for AGE (RAGE).","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and <e2>receptor for AGE</e2> (RAGE).","Downregulator"
"<e1>Catalpol</e1> reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), inducible NO synthase (iNOS), and receptor for AGE (<e2>RAGE</e2>).","Downregulator"
"Promoter and electromobility shift assays showed that transcriptional activation of <e2>NF-κB</e2> was significantly reduced by <e1>catalpol</e1> treatment, while AP-1 was not.","Downregulator"
"<e1>Catalpol</e1> also suppressed AGE-induced phosphorylation of <e2>mitogen activated protein (MAP) kinases</e2>, degradation of IκBα and the nuclear localization of NF-κB.","Downregulator"
"Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by <e1>catalpol</e1> treatment, through dual action of reducing ROS itself and inhibiting <e2>NADPH oxidase</e2> activity.","Downregulator"
"Promoter and electromobility shift assays showed that transcriptional activation of <e2>NF-κB</e2> was significantly reduced by <e1>catalpol</e1> treatment, while AP-1 was not.","Downregulator"
"<e1>VP-16</e1> induced the release of <e2>IL-8</e2>, and addition of MXF reduced enhanced release and the spontaneous release of VEGF from the cells.","Regulator"
"VP-16 induced the release of <e2>IL-8</e2>, and addition of <e1>MXF</e1> reduced enhanced release and the spontaneous release of VEGF from the cells.","Regulator"
"VP-16 induced the release of IL-8, and addition of <e1>MXF</e1> reduced enhanced release and the spontaneous release of <e2>VEGF</e2> from the cells.","Regulator"
"The aim of this study was to investigate the effects of moxifloxacin (<e1>MXF</e1>) and VP-16 on cellular <e2>topo II</e2> activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells.","Regulator"
"Etoposide (<e1>VP-16</e1>) is a topoisomerase-II (<e2>topo II</e2>) inhibitor chemotherapeutic agent.","Regulator"
"Apoptosis studies (DAPI staining and <e2>caspase 3</e2> activity) showed a marked increase in the presence of <e1>MXF</e1> and VP-16 compared to VP-16 alone.","Upregulator"
"Apoptosis studies (DAPI staining and <e2>caspase 3</e2> activity) showed a marked increase in the presence of MXF and <e1>VP-16</e1> compared to VP-16 alone.","Upregulator"
"Apoptosis studies (DAPI staining and <e2>caspase 3</e2> activity) showed a marked increase in the presence of MXF and <e1>VP-16</e1> compared to VP-16 alone.","Upregulator"
"The aim of this study was to investigate the effects of moxifloxacin (<e1>MXF</e1>) and VP-16 on cellular <e2>topo II</e2> activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells.","Downregulator"
"Etoposide (<e1>VP-16</e1>) is a topoisomerase-II (<e2>topo II</e2>) inhibitor chemotherapeutic agent.","Downregulator"
"<e1>Etoposide</e1> (VP-16) is a <e2>topoisomerase-II</e2> (topo II) inhibitor chemotherapeutic agent.","Downregulator"
"<e1>Etoposide</e1> (VP-16) is a topoisomerase-II (<e2>topo II</e2>) inhibitor chemotherapeutic agent.","Downregulator"
"The aim of this study was to investigate the effects of moxifloxacin (<e1>MXF</e1>) and VP-16 on cellular <e2>topo II</e2> activity in drug-treated cells and evaluate the influence of MXF on the mode of action of VP-16, on proliferation and apoptosis of HT-29 cells.","Downregulator"
"Etoposide (<e1>VP-16</e1>) is a topoisomerase-II (<e2>topo II</e2>) inhibitor chemotherapeutic agent.","Downregulator"
"Etoposide (<e1>VP-16</e1>) is a <e2>topoisomerase-II</e2> (topo II) inhibitor chemotherapeutic agent.","Downregulator"
"Etoposide (<e1>VP-16</e1>) is a topoisomerase-II (<e2>topo II</e2>) inhibitor chemotherapeutic agent.","Downregulator"
"In the present study, we measured the enzyme activity of <e2>thymidine kinase</e2> (TK), thymidine phosphorylase (TP) and thymidilate synthase (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of <e1>TAS-102</e1>.","Regulator"
"Thymidine kinase and <e2>thymidine phosphorylase</e2> level as the main predictive parameter for sensitivity to <e1>TAS-102</e1> in a mouse model.","Regulator"
"<e1>TAS-102</e1> currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of <e2>TS</e2> and incorporation into DNA.","Regulator"
"<e1>TAS-102</e1> currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of <e2>TS</e2> and incorporation into DNA.","Downregulator"
"In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and <e2>thymidilate synthase</e2> (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of <e1>TAS-102</e1>.","Downregulator"
"<e1>TAS-102</e1> currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of <e2>TS</e2> and incorporation into DNA.","Downregulator"
"TAS-102 is a new oral anti-cancer drug preparation, composed of a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-trifluorothymidine (FTD) and 5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione hydrochloride (<e1><e2>TP</e2>I</e1>).","Cofactor"
"Though <e1>FUR</e1> alone obviously induced endoplasmic reticulum stress, this signaling pathway may not contribute to the synergetic anti-proliferative effect as the protein expression of <e2>CHOP</e2> and BIP was similar in FUR alone and combined treatment group.","Regulator"
"Though <e1>FUR</e1> alone obviously induced endoplasmic reticulum stress, this signaling pathway may not contribute to the synergetic anti-proliferative effect as the protein expression of CHOP and <e2>BIP</e2> was similar in FUR alone and combined treatment group.","Regulator"
"<e1>Furanodiene</e1> Presents Synergistic Anti-proliferative Activity With Paclitaxel Via Altering Cell Cycle and <e2>Integrin</e2> Signaling in 95-D Lung Cancer Cells.","Regulator"
"Furanodiene Presents Synergistic Anti-proliferative Activity With <e1>Paclitaxel</e1> Via Altering Cell Cycle and <e2>Integrin</e2> Signaling in 95-D Lung Cancer Cells.","Regulator"
"Because clinical studies investigating interactions between garlic and <e2>human immunodeficiency virus protease</e2> inhibitors <e1>saquinavir</e1> and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.","Downregulator"
"Because clinical studies investigating interactions between garlic and <e2>human immunodeficiency virus protease</e2> inhibitors saquinavir and <e1>ritonavir</e1> have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes.","Downregulator"
"Labetalol and dilevalol (both at > or = 10(-7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to labetalol at 10(-6) M was abolished by <e1>ICI 118,551</e1> which illustrates that the labetalol-induced attenuation is <e2>beta 2-adrenoceptor</e2> mediated.","Regulator"
"Labetalol and dilevalol (both at > or = 10(-7) M) attenuated the spontaneous contractile activity of the rat portal vein and the attenuation to <e1>labetalol</e1> at 10(-6) M was abolished by ICI 118,551 which illustrates that the labetalol-induced attenuation is <e2>beta 2-adrenoceptor</e2> mediated.","Regulator"
"Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the <e1>isoprenaline</e1> responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>beta 1-adrenoceptors</e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.","Agonist"
"<e1>Labetalol</e1> (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>beta 1-adrenoceptors</e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.","Antagonist"
"Labetalol (> or = 3 x 10(-8) M) and <e1>dilevalol</e1> (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>beta 1-adrenoceptors</e2> of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.","Antagonist"
"The isoprenaline attenuation responses of the portal vein were inhibited by <e1>labetalol</e1> and dilevalol (both at > or = 10(-7) M) and the pA2 value for the labetalol at <e2>beta 2-adrenoceptors</e2> was 7.59.","Antagonist"
"It is concluded that <e1>labetalol</e1> and dilevalol are <e2>beta 1-adrenoceptor</e2> selective antagonists.","Antagonist"
"Labetalol (> or = 3 x 10(-8) M) and <e1>dilevalol</e1> (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the <e2>beta 1-adrenoceptor</e2>s of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.","Antagonist"
"[Effect of <e1>mifepristone</e1> on the expression of <e2>progesterone receptor</e2> messenger RNA and protein in uterine leiomyomata].","Regulator"
"OBJECTIVE: To determine the expression of progesterone receptor (<e2>PR</e2>) mRNA and PR protein levels in the myometrium and leiomyomata from untreated and <e1>mifepristone</e1> pretreated women with leiomyoma and to examine the mechanism of mifepristone treatment on uterine leiomyomata.","Regulator"
"OBJECTIVE: To determine the expression of progesterone receptor (PR) mRNA and <e2>PR protein</e2> levels in the myometrium and leiomyomata from untreated and <e1>mifepristone</e1> pretreated women with leiomyoma and to examine the mechanism of mifepristone treatment on uterine leiomyomata.","Regulator"
"METHODS: Expression of <e2>PR mRNA</e2> and PR protein were determined by Northern blot and HAP of single-dose saturated analysis in myometrium and leiomyomata (center and marginal area) from 27 untreated and 6 <e1>mifepristone</e1> pretreated women with leiomyomata.","Regulator"
"OBJECTIVE: To determine the expression of progesterone receptor (PR) mRNA and <e2>PR protein</e2> levels in the myometrium and leiomyomata from untreated and <e1>mifepristone</e1> pretreated women with leiomyoma and to examine the mechanism of mifepristone treatment on uterine leiomyomata.","Regulator"
"[Effect of <e1>mifepristone</e1> on the expression of <e2>progesterone receptor</e2> messenger RNA and protein in uterine leiomyomata].","Regulator"
"METHODS: Expression of <e2>PR mRNA</e2> and PR protein were determined by Northern blot and HAP of single-dose saturated analysis in myometrium and leiomyomata (center and marginal area) from 27 untreated and 6 <e1>mifepristone</e1> pretreated women with leiomyomata.","Downregulator"
"One of the mechanism of <e1>mifepristone</e1> action on decreasing leiomyomata volume may be related to suppression on expression of <e2>PR gene</e2>.","Downregulator"
"Experimental cystathioninuria was induced in rats by administration of the <e2>cystathionine gamma-lyase</e2> inhibitor, <e1>D,L-propargylglycine</e1>.","Downregulator"
"The non-selective <e2>adenosine receptor</e2> antagonist (<e1>caffeine</e1>), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.","Antagonist"
"The non-selective adenosine receptor antagonist (caffeine), and the selective <e2>adenosine A1 receptor</e2> antagonist (<e1>DPCPX</e1>), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.","Antagonist"
"The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of <e1>flumazenil</e1> (5.0 mg/kg) - a <e2>BDZ receptor</e2> antagonist, immediately induced BDZ withdrawal signs in these animals.","Antagonist"
"As is the case with BLTs, <e1>glyburide</e1> increased the apparent affinity of <e2>HDL</e2> binding to SR-BI.","Regulator"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Regulator"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated cholesterol transport by the small molecules <e1>BLT-4</e1> and glyburide.","Downregulator"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated cholesterol transport by the small molecules <e1>BLT-4</e1> and glyburide.","Downregulator"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Downregulator"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Downregulator"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Downregulator"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Downregulator"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Downregulator"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Downregulator"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated cholesterol transport by the small molecules BLT-4 and <e1>glyburide</e1>.","Downregulator"
"The activities of ABCA1 and other <e2>ATP binding cassette superfamily</e2> members are inhibited by the drug <e1>glyburide</e1>, and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs.","Downregulator"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated cholesterol transport by the small molecules <e1>BLT</e1>-4 and glyburide.","Downregulator"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated cholesterol transport by the small molecules <e1>BLT</e1>-4 and glyburide.","Downregulator"
"Here, we show that one BLT, [<e1>1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea</e1>] (BLT-4), blocked <e2>ABCA1</e2>-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).","Downregulator"
"Here, we show that one BLT, [<e1>1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea</e1>] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of <e2>SR-BI</e2> (IC(50) approximately 55-60 microM).","Downregulator"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated <e1>cholesterol</e1> transport by the small molecules BLT-4 and glyburide.","Substrate"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated <e1>cholesterol</e1> transport by the small molecules BLT-4 and glyburide.","Substrate"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated <e1>cholesterol</e1> transport by the small molecules BLT-4 and glyburide.","Substrate"
"<e2>SR-BI</e2> is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of <e1>cholesteryl esters</e1> from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL.","Substrate"
"Cross-inhibition of <e2>SR-BI</e2>- and ABCA1-mediated <e1>cholesterol</e1> transport by the small molecules BLT-4 and glyburide.","Substrate"
"Cross-inhibition of SR-BI- and <e2>ABCA1</e2>-mediated <e1>cholesterol</e1> transport by the small molecules BLT-4 and glyburide.","Substrate"
"The treatment of mice with <e1>Fe-NTA</e1> alone enhances <e2>ornithine decarboxylase</e2> activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls.","Upregulator"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs</e1>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Regulator"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs</e1>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Regulator"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs</e1>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Upregulator"
"<e2>Aldo-keto reductases</e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive <e1>oxygen</e1> species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive <e1>oxygen</e1> species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"<e2>Aldo-keto reductases</e2> (AKRs) metabolize a wide range of substrates, including <e1>polycyclic aromatic hydrocarbons</e1> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including <e1>polycyclic aromatic hydrocarbons</e1> (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"<e2>Aldo-keto reductases</e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs</e1>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs</e1>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"<e2>Aldo-keto reductases</e2> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<e1>o-quinones</e1>) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (<e1>o-quinones</e1>) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"Aldo-keto reductases (<e2>AKRs</e2>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (<e1>PAHs</e1>), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.","Substrate"
"<e1>β-Lapachone</e1> (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through <e2>NAD(P)H:quinone oxidoreductase-1</e2> (NQO1).","Regulator"
"<e1>β-Lapachone</e1> (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 (<e2>NQO1</e2>).","Regulator"
"<e1>β-Lap</e1>achone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through <e2>NAD(P)H:quinone oxidoreductase-1</e2> (NQO1).","Regulator"
"<e1>β-Lap</e1>achone (β-Lap) is a 1,2-orthonaphthoquinone that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 (<e2>NQO1</e2>).","Regulator"
"β-Lapachone (β-Lap) is a <e1>1,2-orthonaphthoquinone</e1> that selectively induces cell death in human cancer cells through <e2>NAD(P)H:quinone oxidoreductase-1</e2> (NQO1).","Regulator"
"β-Lapachone (β-Lap) is a <e1>1,2-orthonaphthoquinone</e1> that selectively induces cell death in human cancer cells through NAD(P)H:quinone oxidoreductase-1 (<e2>NQO1</e2>).","Regulator"
"The pretreatment with 20 mg L(-1) <e1>La(III)</e1> could alleviate the effects of UV-B radiation on the activities of <e2>nitrate reductase</e2>, glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.","Downregulator"
"The pretreatment with 20 mg L(-1) <e1>La(III)</e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, <e2>glutamine synthetase</e2>, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.","Downregulator"
"The pretreatment with 20 mg L(-1) <e1>La(III)</e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, <e2>glutamate synthase</e2>, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings.","Downregulator"
"The pretreatment with 20 mg L(-1) <e1>La(III)</e1> could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and <e2>glutamate dehydrogenase</e2>, promoting amino acid conversion and protein synthesis in soybean seedlings.","Downregulator"
"In competition experiments with <e2>human lung glucocorticoid receptors</e2> we have determined the relative receptor affinities (RRA) of these substances with reference to <e1>dexamethasone</e1> (RRA = 100).","Regulator"
"Based on recent reports that the small molecules, <e1>isatin</e1> and phthalimide, are suitable scaffolds for the design of high potency <e2>monoamine oxidase</e2> (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.","Downregulator"
"Based on recent reports that the small molecules, <e1>isatin</e1> and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (<e2>MAO</e2>) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.","Downregulator"
"Based on recent reports that the small molecules, isatin and <e1>phthalimide</e1>, are suitable scaffolds for the design of high potency <e2>monoamine oxidase</e2> (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.","Downregulator"
"Based on recent reports that the small molecules, isatin and <e1>phthalimide</e1>, are suitable scaffolds for the design of high potency monoamine oxidase (<e2>MAO</e2>) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.","Downregulator"
"In most instances, C6-substituted <e1>phthalides</e1> exhibit <e2>MAO-B</e2> specific inhibition.","Downregulator"
"In most instances, C6-substituted <e1>phthalides</e1> exhibit <e2>MAO</e2>-B specific inhibition.","Downregulator"
"Inhibition of <e2>monoamine oxidase</e2> by <e1>phthalide</e1> analogues.","Downregulator"
"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (<e2>MAO</e2>) inhibitors, the present study examines the MAO inhibitory properties of a series of <e1>phthalide</e1> [2-benzofuran-1(3H)-one] analogues.","Downregulator"
"Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (<e2>MAO</e2>) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [<e1>2-benzofuran-1(3H)-one</e1>] analogues.","Downregulator"
"However, a lid conformation was induced by [<e1>Sar</e1>(1),Gln(2),Ile(8)] <e2>AngII</e2>, a specific analog that binds to the D281A mutant with better affinity than AngII.","Part_of"
"However, a lid conformation was induced by [<e1>Sar</e1>(1),Gln(2),Ile(8)] <e2>AngII</e2>, a specific analog that binds to the D281A mutant with better affinity than AngII.","Part_of"
"However, a lid conformation was induced by [Sar(1),<e1>Gln</e1>(2),Ile(8)] <e2>AngII</e2>, a specific analog that binds to the D281A mutant with better affinity than AngII.","Part_of"
"However, a lid conformation was induced by [Sar(1),<e1>Gln</e1>(2),Ile(8)] <e2>AngII</e2>, a specific analog that binds to the D281A mutant with better affinity than AngII.","Part_of"
"However, a lid conformation was induced by [Sar(1),Gln(2),<e1>Ile</e1>(8)] <e2>AngII</e2>, a specific analog that binds to the D281A mutant with better affinity than AngII.","Part_of"
"However, a lid conformation was induced by [Sar(1),Gln(2),<e1>Ile</e1>(8)] <e2>AngII</e2>, a specific analog that binds to the D281A mutant with better affinity than AngII.","Part_of"
"Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type <e2>AT1R</e2> changed the accessibility of reporter <e1>cysteines</e1>, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2.","Part_of"
"However, a lid conformation was induced by [<e1>Sar</e1>(1),Gln(2),Ile(8)] AngII, a specific analog that binds to the <e2>D281A</e2> mutant with better affinity than AngII.","Regulator"
"However, a lid conformation was induced by [Sar(1),<e1>Gln</e1>(2),Ile(8)] AngII, a specific analog that binds to the <e2>D281A</e2> mutant with better affinity than AngII.","Regulator"
"However, a lid conformation was induced by [Sar(1),Gln(2),<e1>Ile</e1>(8)] AngII, a specific analog that binds to the <e2>D281A</e2> mutant with better affinity than AngII.","Regulator"
"Binding of the agonist angiotensin II (AngII) and inverse agonist <e1>losartan</e1> in wild-type <e2>AT1R</e2> changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific ""lid"" conformations of ECL2.","Agonist"
"<e1>TAS-102</e1> is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit <e2>TS</e2>.","Regulator"
"Numerous studies have suggested that increased <e2>TS</e2> levels are associated closely with resistance to <e1>fluoropyrimidine</e1>-based chemotherapy.","Regulator"
"<e1>TAS-102</e1> is a novel drug containing trifluorothymidine, which is phosphorylated by <e2>TK-1</e2> to its active monophosphated form, that in turn can inhibit TS.","Regulator"
"Numerous studies have suggested that increased <e2>TS</e2> levels are associated closely with resistance to <e1>fluoropyrimidine</e1>-based chemotherapy.","Regulator"
"<e1>TAS-102</e1> is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit <e2>TS</e2>.","Downregulator"
"<e2>Thymidine kinase-1</e2> (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo <e1>pyrimidine</e1> synthesis, respectively.","Substrate"
"Thymidine kinase-1 (<e2>TK-1)</e2> and thymidylate synthase (TS) are key enzymes for salvage and de novo <e1>pyrimidine</e1> synthesis, respectively.","Substrate"
"Immunohistochemical characterization of <e1>pyrimidine</e1> synthetic enzymes, thymidine kinase-1 and <e2>thymidylate synthase</e2>, in various types of cancer.","Substrate"
"Thymidine kinase-1 (TK-1) and thymidylate synthase (<e2>TS</e2>) are key enzymes for salvage and de novo <e1>pyrimidine</e1> synthesis, respectively.","Substrate"
"Immunohistochemical characterization of <e1>pyrimidine</e1> synthetic enzymes, <e2>thymidine kinase-1</e2> and thymidylate synthase, in various types of cancer.","Substrate"
"Immunohistochemical characterization of <e1>pyrimidine</e1> synthetic enzymes, thymidine kinase-1 and <e2>thymidylate synthase</e2>, in various types of cancer.","Substrate"
"Thymidine kinase-1 (TK-1) and thymidylate synthase (<e2>TS</e2>) are key enzymes for salvage and de novo <e1>pyrimidine</e1> synthesis, respectively.","Substrate"
"<e1>TAS-102</e1> is a novel drug containing trifluorothymidine, which is phosphorylated by <e2>TK-1</e2> to its active monophosphated form, that in turn can inhibit TS.","Substrate"
"TAS-102 is a novel drug containing <e1>trifluorothymidine</e1>, which is phosphorylated by <e2>TK-1</e2> to its active monophosphated form, that in turn can inhibit TS.","Substrate"
"The contractions to 5-HT were inhibited by <e1>ketanserin</e1> and alosetron indicating involvement of <e2>5-HT(2A)</e2> and 5-HT(3) receptors, respectively.","Downregulator"
"The contractions to 5-HT were inhibited by ketanserin and <e1>alosetron</e1> indicating involvement of 5-HT(2A) and <e2>5-HT(3)</e2> receptors, respectively.","Downregulator"
"The <e1>keto</e1> and phenolic -OH are major factors that are prominently involved in interaction with <e2>COX-2</e2> active site.","Regulator"
"The keto and <e1>phenolic</e1> -OH are major factors that are prominently involved in interaction with <e2>COX-2</e2> active site.","Regulator"
"The keto and phenolic -<e1>OH</e1> are major factors that are prominently involved in interaction with <e2>COX-2</e2> active site.","Regulator"
"Regarding <e2>urease</e2> inhibition, <e1>n-butanol</e1> was the most potent fraction (IC50: 97 µg/mL).","Downregulator"
"The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective <e2>acetylcholinesterase</e2> reactivator, <e1>1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate</e1> (MMB-4).","Upregulator"
"The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective <e2>acetylcholinesterase</e2> reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate (<e1>MMB-4</e1>).","Upregulator"
"5'-flanking region of <e2>glut3</e2>-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that <e1>(m)CpGs</e1> inhibit glut3 transcription.","Regulator"
"5'-flanking region of <e2>glut3</e2>-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that <e1>(m)CpGs</e1> inhibit glut3 transcription.","Regulator"
"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG (<e1>(m)CpG</e1>) island of the <e2>glut3</e2> gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3).","Regulator"
"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG (<e1>(m)CpG</e1>) island of the <e2>glut3</e2> gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3).","Regulator"
"Methylation-specific PCR and bisulfite sequencing identified methylation of this <e1>CpG</e1> ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in <e2>DNA methyl transferase 3a</e2> concentrations noted with advancing postnatal age (PN14 vs PN3).","Upregulator"
"Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG (<e1>(m)CpG</e1>) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in <e2>DNA methyl transferase 3a</e2> concentrations noted with advancing postnatal age (PN14 vs PN3).","Upregulator"
"5'-flanking region of <e2>glut3</e2>-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that <e1>(m)CpGs</e1> inhibit glut3 transcription.","Downregulator"
"Separate <e1>5-aza-2'-deoxycytidine</e1> pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting <e2>Mecp2</e2> and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.","Downregulator"
"Separate <e1>5-aza-2'-deoxycytidine</e1> pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and <e2>Creb1</e2> separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.","Downregulator"
"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with <e1>trichostatin A</e1> reduced (m)CpG and specific small interference RNAs targeting <e2>Mecp2</e2> and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.","Downregulator"
"Separate 5-aza-2'-deoxycytidine pretreatment or in combination with <e1>trichostatin A</e1> reduced (m)CpG and specific small interference RNAs targeting Mecp2 and <e2>Creb1</e2> separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.","Downregulator"
"<e1>Citalopram</e1>, which is devoid of affinity for the <e2>NET</e2>, exerted a significant reduction of immobility time in the NET-/- mice.","Not"
"Autoradiographic studies showed decreased binding of the beta-adrenergic ligand <e1>[3H]CGP12177</e1> in the cerebral cortex of NET-/- mice, indicating the changes at the level of <e2>beta-adrenergic receptors</e2> similar to those obtained with ADs treatment.","Regulator"
"The binding of <e1>[3H]prazosin</e1> to <e2>alpha1-adrenergic receptors</e2> in the cerebral cortex of NET-/- mice was also decreased, most probably as an adaptive response to the sustained elevation of extracellular NE levels observed in these mice.","Regulator"
"Autoradiographic studies showed decreased binding of the beta-adrenergic ligand [3H]CGP12177 in the cerebral cortex of <e1>NE</e1>T-/- mice, indicating the changes at the level of beta-<e2>adrenergic receptors</e2> similar to those obtained with ADs treatment.","Regulator"
"A pronounced <e2>NET</e2> knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as <e1>reboxetine</e1>, desipramine, and imipramine.","Downregulator"
"A pronounced <e2>NET</e2> knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine, <e1>desipramine</e1>, and imipramine.","Downregulator"
"A pronounced <e2>NET</e2> knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by NET-inhibiting ADs such as reboxetine, desipramine, and <e1>imipramine</e1>.","Downregulator"
"In conclusion, of the seven NSAIDs investigated, <e1>niflumic acid</e1> was the most potent inhibitor of recombinant <e2>UGT1A9</e2> via 4-MUG in a competitive manner.","Downregulator"
"In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant <e2>human UDP-glucuronosyltransferase 1A9</e2>--potent inhibition by <e1>niflumic acid</e1>.","Downregulator"
"Affinities of <e1>venlafaxine</e1> and various reuptake inhibitors for the serotonin and <e2>norepinephrine transporter</e2>s.","Not"
"The selective 5-HT reuptake inhibitors <e1>paroxetine</e1>, indalpine and fluvoxamine displayed a high affinity for the <e2>5-HT transporter</e2>, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.","Regulator"
"The selective 5-HT reuptake inhibitors paroxetine, <e1>indalpine</e1> and fluvoxamine displayed a high affinity for the <e2>5-HT transporter</e2>, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.","Regulator"
"The selective 5-HT reuptake inhibitors paroxetine, indalpine and <e1>fluvoxamine</e1> displayed a high affinity for the <e2>5-HT transporter</e2>, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.","Regulator"
"The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor <e1>desipramine</e1> had a high affinity for the <e2>norepinephrine transporter</e2>.","Regulator"
"Interestingly, <e1>venlafaxine</e1>, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the <e2>5-HT transporter</e2> (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM).","Regulator"
"Mutation analysis of KYNU encoding <e2>kynureninase</e2> of the index case revealed homozygosity for a c.593 A > G substitution leading to a <e1>threonine</e1>-to-alanine (T198A) shift.","Part_of"
"Mutation analysis of KYNU encoding <e2>kynureninase</e2> of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to-<e1>alanine</e1> (T198A) shift.","Part_of"
"<e1>Co-C</e1> bond activation in <e2>methylmalonyl-CoA mutase</e2> by stabilization of the post-homolysis product Co2+ cobalamin.","Part_of"
"showed that when <e1>AdoCbl</e1> is bound to the <e2>MMCM</e2> active site, no enzymatic perturbation of the Co3+ Cbl electronic structure occurs, even in the presence of substrate (analogues).","Regulator"
"Co-C bond activation in <e2>methylmalonyl-CoA mutase</e2> by stabilization of the post-homolysis product Co2+ <e1>cobalamin</e1>.","Cofactor"
"Co-C bond activation in <e2>methylmalonyl-CoA mutase</e2> by stabilization of the post-homolysis product <e1>Co2+</e1> cobalamin.","Cofactor"
"In this work, we utilized magnetic circular dichroism spectroscopy to explore how the electronic structure of the reduced B12 cofactor (i.e., the post-homolysis product <e1>Co2+ Cbl</e1>) is modulated by the enzyme <e2>methylmalonyl-CoA mutase</e2>.","Cofactor"
"Cells exposed to <e1>α-MeDA</e1> showed an increase in intracellular glutathione (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of <e2>γ-glutamylcysteine synthetase</e2> (γ-GCS), revealing a possible transient effect.","Not"
"Cells exposed to <e1>α-MeDA</e1> showed an increase in intracellular glutathione (GSH) levels, which, at the 48 h time-point, was not dependent in the activity increase of γ-glutamylcysteine synthetase (<e2>γ-GCS</e2>), revealing a possible transient effect.","Not"
"<e1>MDMA</e1> catechol metabolites were neurotoxic to SH-SY5Y neurons, leading to <e2>caspase 3</e2>-independent cell death in a concentration- and time-dependent manner.","Regulator"
"MDMA <e1>catechol</e1> metabolites were neurotoxic to SH-SY5Y neurons, leading to <e2>caspase 3</e2>-independent cell death in a concentration- and time-dependent manner.","Regulator"
"Importantly, pre-treatment with buthionine sulfoximine (<e1>BSO</e1>), an inhibitor of <e2>γ-GCS</e2>, prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.","Downregulator"
"Neither the superoxide radical scavenger, tiron, nor the inhibitor of the <e2>dopamine (DA) transporter</e2>, <e1>GBR 12909</e1>, prevented the metabolites' toxicity.","Downregulator"
"Importantly, pre-treatment with <e1>buthionine sulfoximine</e1> (BSO), an inhibitor of <e2>γ-GCS</e2>, prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.","Downregulator"
"<e1>MNU</e1>-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high <e2>MGMT</e2> staining.","Upregulator"
"<e1>MNU</e1>-induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of <e2>E-cadherin</e2>, and high MGMT staining.","Downregulator"
"The treatment with <e1>arsenic</e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (<e2>alanine aminotransferase</e2>, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).","Upregulator"
"The treatment with <e1>arsenic</e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, <e2>aspartate aminotransferase</e2>, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).","Upregulator"
"The treatment with <e1>arsenic</e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, <e2>alkaline phosphatase</e2>, total protein, albumin, bilirubin, cholesterol, urea and creatinine).","Upregulator"
"The treatment with <e1>arsenic</e1> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, <e2>albumin</e2>, bilirubin, cholesterol, urea and creatinine).","Upregulator"
"In preclinical studies, the <e2>mammalian target of rapamycin</e2> (mTOR) in the medial prefrontal cortex and the eukaryotic elongation factor (eEF2) in the hippocampus have been proposed as critical mediators of <e1>ketamine</e1>'s rapid antidepressant actions.","Regulator"
"In preclinical studies, the mammalian target of rapamycin (<e2>mTOR</e2>) in the medial prefrontal cortex and the eukaryotic elongation factor (eEF2) in the hippocampus have been proposed as critical mediators of <e1>ketamine</e1>'s rapid antidepressant actions.","Regulator"
"In preclinical studies, the mammalian target of rapamycin (mTOR) in the medial prefrontal cortex and the <e2>eukaryotic elongation factor</e2> (eEF2) in the hippocampus have been proposed as critical mediators of <e1>ketamine</e1>'s rapid antidepressant actions.","Regulator"
"In preclinical studies, the mammalian target of rapamycin (mTOR) in the medial prefrontal cortex and the eukaryotic elongation factor (<e2>eEF2</e2>) in the hippocampus have been proposed as critical mediators of <e1>ketamine</e1>'s rapid antidepressant actions.","Regulator"
"However, recent clinical studies have shown that a single low-dose injection of <e1>ketamine</e1>, an <e2>N-methyl d-aspartate receptor</e2> (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.","Antagonist"
"However, recent clinical studies have shown that a single low-dose injection of <e1>ketamine</e1>, an N-methyl d-aspartate receptor (<e2>NMDAR</e2>) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.","Antagonist"
"The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic <e2>CYP3A</e2> subfamily-mediated metabolism (21.9% decrease) of <e1>doxorubicin</e1>.","Substrate"
"<e1>Doxorubicin</e1> is mainly excreted into the bile via <e2>P-glycoprotein</e2> (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.","Substrate"
"<e1>Doxorubicin</e1> is mainly excreted into the bile via P-glycoprotein (<e2>P-gp</e2>) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.","Substrate"
"<e1>Doxorubicin</e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and <e2>multidrug resistance-associated protein 2</e2> (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.","Substrate"
"<e1>Doxorubicin</e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (<e2>Mrp2</e2>) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.","Substrate"
"<e1>Doxorubicin</e1> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via <e2>cytochrome P450 (CYP) 3A</e2> subfamily.","Substrate"
"Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of <e2>GSK3β</e2> at inactive form <e1>serine</e1> 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.","Part_of"
"Conversely, AMPK inhibitor <e1>compound C</e1> or GSK3β inhibitor SB216763 blocked the cleavages of <e2>PARP</e2> and caspase 3 induced by ursolic acid in HepG2 cells.","Regulator"
"Conversely, AMPK inhibitor compound C or GSK3β inhibitor <e1>SB216763</e1> blocked the cleavages of <e2>PARP</e2> and caspase 3 induced by ursolic acid in HepG2 cells.","Regulator"
"Furthermore, proteosomal inhibitor <e1>MG132</e1> suppressed AMPK activation, GSK3β phosphorylation, cleaved <e2>PARP</e2> and deceased AEG-1 induced by ursolic acid in HepG2 cells.","Regulator"
"Also, <e1>ursolic acid</e1> enhanced the cleavages of poly-ADP-ribose polymerase (<e2>PARP</e2>) and caspase3, attenuated the expression of astrocyte elevated gene (AEG1) and survivin in HepG2 cells.","Regulator"
"Thus, in the present study, the roles of AMP-activated protein kinase (<e2>AMPK</e2>) and glycogen synthase kinase 3 beta (GSK3β) were examined in <e1>ursolic acid</e1> induced apoptosis in HepG2 hepatocellular carcinoma cells.","Upregulator"
"Interestingly, <e1>ursolic acid</e1> increased the phosphorylation of AMPK and <e2>coenzyme A carboxylase</e2> and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.","Upregulator"
"Thus, in the present study, the roles of AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3 beta (<e2>GSK3β</e2>) were examined in <e1>ursolic acid</e1> induced apoptosis in HepG2 hepatocellular carcinoma cells.","Upregulator"
"Activation of <e2>AMP-activated Protein Kinase</e2> and Phosphorylation of Glycogen Synthase Kinase3 β Mediate <e1>Ursolic Acid</e1> Induced Apoptosis in HepG2 Liver Cancer Cells.","Upregulator"
"Activation of AMP-activated Protein Kinase and Phosphorylation of <e2>Glycogen Synthase Kinase3 β</e2> Mediate <e1>Ursolic Acid</e1> Induced Apoptosis in HepG2 Liver Cancer Cells.","Upregulator"
"Thus, in the present study, the roles of AMP-activated protein kinase (<e2>AMPK</e2>) and glycogen synthase kinase 3 beta (GSK3β) were examined in <e1>ursolic acid</e1> induced apoptosis in HepG2 hepatocellular carcinoma cells.","Upregulator"
"Thus, in the present study, the roles of AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3 beta (<e2>GSK3β</e2>) were examined in <e1>ursolic acid</e1> induced apoptosis in HepG2 hepatocellular carcinoma cells.","Upregulator"
"Thus, in the present study, the roles of AMP-activated protein kinase (<e2>AMPK</e2>) and glycogen synthase kinase 3 beta (GSK3β) were examined in <e1>ursolic acid</e1> induced apoptosis in HepG2 hepatocellular carcinoma cells.","Upregulator"
"Thus, in the present study, the roles of AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3 beta (<e2>GSK3β</e2>) were examined in <e1>ursolic acid</e1> induced apoptosis in HepG2 hepatocellular carcinoma cells.","Upregulator"
"Also, <e1>ursolic acid</e1> enhanced the cleavages of poly-ADP-ribose polymerase (<e2>PARP</e2>) and caspase3, attenuated the expression of astrocyte elevated gene (AEG1) and survivin in HepG2 cells.","Upregulator"
"Conversely, AMPK inhibitor compound C or GSK3β inhibitor SB216763 blocked the cleavages of PARP and <e2>caspase 3</e2> induced by <e1>ursolic acid</e1> in HepG2 cells.","Upregulator"
"Furthermore, proteosomal inhibitor <e1>MG132</e1> suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased <e2>AEG-1</e2> induced by ursolic acid in HepG2 cells.","Upregulator"
"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased <e2>AEG-1</e2> induced by <e1>ursolic acid</e1> in HepG2 cells.","Upregulator"
"Conversely, AMPK inhibitor <e1>compound C</e1> or GSK3β inhibitor SB216763 blocked the cleavages of PARP and <e2>caspase 3</e2> induced by ursolic acid in HepG2 cells.","Downregulator"
"Conversely, AMPK inhibitor compound C or GSK3β inhibitor <e1>SB216763</e1> blocked the cleavages of PARP and <e2>caspase 3</e2> induced by ursolic acid in HepG2 cells.","Downregulator"
"Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3β phosphorylation, cleaved PARP and deceased <e2>AEG-1</e2> induced by <e1>ursolic acid</e1> in HepG2 cells.","Downregulator"
"Interestingly, <e1>ursolic acid</e1> increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of <e2>AKT</e2> and mTOR in HepG2 cells.","Downregulator"
"Interestingly, <e1>ursolic acid</e1> increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3β at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and <e2>mTOR</e2> in HepG2 cells.","Downregulator"
"Conversely, <e2>AMPK</e2> inhibitor <e1>compound C</e1> or GSK3β inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells.","Downregulator"
"Conversely, AMPK inhibitor compound C or <e2>GSK3β</e2> inhibitor <e1>SB216763</e1> blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells.","Downregulator"
"Furthermore, proteosomal inhibitor <e1>MG132</e1> suppressed <e2>AMPK</e2> activation, GSK3β phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells.","Downregulator"
"Furthermore, proteosomal inhibitor <e1>MG132</e1> suppressed AMPK activation, <e2>GSK3β</e2> phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells.","Downregulator"
"Using <e1>paraoxon</e1> as a reference acetylcholinesterase (<e2>AChE</e2>) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Not"
"Using <e1>paraoxon</e1> as a reference acetylcholinesterase (<e2>AChE</e2>) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Not"
"Using <e1>paraoxon</e1> as a reference acetylcholinesterase (<e2>AChE</e2>) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Upregulator"
"Using <e1>paraoxon</e1> as a reference acetylcholinesterase (<e2>AChE</e2>) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Upregulator"
"Using <e1>paraoxon</e1> as a reference acetylcholinesterase (<e2>AChE</e2>) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Downregulator"
"Using <e1>paraoxon</e1> as a reference <e2>acetylcholinesterase</e2> (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Downregulator"
"Using <e1>paraoxon</e1> as a reference acetylcholinesterase (<e2>AChE</e2>) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.","Downregulator"
"Conversely, opioid antagonists such as <e1>naloxone</e1> and naltrexone (which bind to non-selectively <e2>opioid receptors</e2>) have been shown to decrease alcohol consumption under various experimental conditions.","Regulator"
"Conversely, opioid antagonists such as naloxone and <e1>naltrexone</e1> (which bind to non-selectively <e2>opioid receptors</e2>) have been shown to decrease alcohol consumption under various experimental conditions.","Regulator"
"There is, however, much information on the direct (acute and chronic) effects of <e1>alcohol</e1> on the binding properties of <e2>opioid receptors</e2>, as well as modulation of opioid peptide synthesis and secretion (e.g.","Regulator"
"There is, however, much information on the direct (acute and chronic) effects of <e1>alcohol</e1> on the binding properties of opioid receptors, as well as modulation of <e2>opioid peptide</e2> synthesis and secretion (e.g.","Regulator"
"Conversely, opioid antagonists such as naloxone and <e1>naltrexone</e1> (which bind to non-selectively <e2>opioid receptors</e2>) have been shown to decrease alcohol consumption under various experimental conditions.","Upregulator"
"Conversely, opioid antagonists such as <e1>naloxone</e1> and naltrexone (which bind to non-selectively <e2>opioid receptors</e2>) have been shown to decrease alcohol consumption under various experimental conditions.","Antagonist"
"Some Gram-positive bacterial pathogens harbor a gene that encodes a protein (<e2>HNS</e2>, Heme domain of <e1>NO</e1> Synthase-like proteins) with striking sequence identity to the oxygenase domain of mammalian NO synthases (NOS).","Regulator"
"<e1>NO</e1> rebinding in HNS from Staphylococcus aureus (<e2>SA-HNS</e2>) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine.","Regulator"
"<e1>NO</e1> rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (<e2>BA-HNS</e2>) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine.","Regulator"
"The unique properties of HNS make it an excellent model system for probing how the heme environment tunes <e1>NO</e1> dynamics and for comparing it to the endothelial NO synthase heme domain (<e2>eNOS(HD)</e2>) using ultrafast transient spectroscopy.","Regulator"
"Dynamics of <e1>NO</e1> rebinding to the <e2>heme domain of NO synthase-like proteins</e2> from bacterial pathogens.","Regulator"
"<e1>Esmolol</e1>, a unique cardioselective <e2>beta 1-adrenergic receptor</e2> blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy.","Downregulator"
"The active site of the <e2>metalloproteinase domain</e2> has a consensus HEXXHXXGXXHD sequence and a <e1>Met</e1>-turn.","Part_of"
"The two <e1>NH2</e1>-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a <e2>carbonic anhydrase (CA) V</e2> isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.","Part_of"
"The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-<e1>amino acid</e1> putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a <e2>carbonic anhydrase (CA) V</e2> isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.","Part_of"
"The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 <e1>amino acids</e1>, yielding a protein equivalent to a <e2>carbonic anhydrase (CA) V</e2> isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.","Part_of"
"Investigation of a site-specific mutant of <e2>CA V</e2> containing the replacement Tyr64--><e1>His</e1> showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.","Part_of"
"Mouse <e2>CA V</e2> has a <e1>tyrosine</e1> at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway.","Part_of"
"<e2>The carbonic anhydrase V</e2> produced by a vector containing the full coding sequence, which includes a possible <e1>NH2</e1>-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends.","Part_of"
"<e2>The carbonic anhydrase V</e2> produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several <e1>amino</e1>-terminal ends.","Part_of"
"In catalytic properties, mouse <e2>CA V</e2> is closest to CA I; however, in inhibition by <e1>acetazolamide</e1>, ethoxzolamide, and cyanate, CA V is very similar to CA II.","Downregulator"
"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by <e1>acetazolamide</e1>, ethoxzolamide, and cyanate, CA V is very similar to <e2>CA II</e2>.","Downregulator"
"In catalytic properties, mouse <e2>CA V</e2> is closest to CA I; however, in inhibition by acetazolamide, <e1>ethoxzolamide</e1>, and cyanate, CA V is very similar to CA II.","Downregulator"
"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, <e1>ethoxzolamide</e1>, and cyanate, CA V is very similar to <e2>CA II</e2>.","Downregulator"
"In catalytic properties, mouse <e2>CA V</e2> is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and <e1>cyanate</e1>, CA V is very similar to CA II.","Downregulator"
"In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and <e1>cyanate</e1>, CA V is very similar to <e2>CA II</e2>.","Downregulator"
"<e2>AdSS</e2> from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345 <e1>amino acids</e1> long against an average length of 430-457 amino acids for most mesophilic AdSS.","Part_of"
"AdSS from the thermophilic archaea, Methanocaldococcus jannaschii (<e2>MjAdSS</e2>) is 345 <e1>amino acids</e1> long against an average length of 430-457 amino acids for most mesophilic AdSS.","Part_of"
"<e2>AdSS</e2> from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345 <e1>amino acids</e1> long against an average length of 430-457 amino acids for most mesophilic AdSS.","Part_of"
"This short <e2>AdSS</e2> has two large deletions that map to the middle and <e1>C</e1>-terminus of the protein.","Part_of"
"<e1>Phosphate</e1>, a product of the reaction, was found to be a potent inhibitor of <e2>MjAdSS</e2> showing biphasic inhibition of enzyme activity.","Downregulator"
"<e2>Adenylosuccinate synthetase</e2> (AdSS) catalyzes the <e1>Mg2+</e1> dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP.","Cofactor"
"<e2>Adenylosuccinate synthetase</e2> (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form <e1>adenylosuccinate</e1>, in a reaction driven by the hydrolysis of GTP to GDP.","Substrate"
"Adenylosuccinate synthetase (<e2>AdSS</e2>) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form <e1>adenylosuccinate</e1>, in a reaction driven by the hydrolysis of GTP to GDP.","Substrate"
"Adenylosuccinate synthetase (<e2>AdSS</e2>) catalyzes the <e1>Mg2+</e1> dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP.","Substrate"
"Inhibition of <e2>NF-kappa B</e2> by <e1>sodium salicylate</e1> and aspirin.","Downregulator"
"Inhibition of <e2>NF-kappa B</e2> by sodium salicylate and <e1>aspirin</e1>.","Downregulator"
"<e1>Sodium salicylate</e1> and aspirin also inhibited <e2>NF-kappa B</e2>-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","Downregulator"
"<e1>Sodium salicylate</e1> and aspirin also inhibited NF-kappa B-dependent transcription from the <e2>Ig kappa</e2> enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","Downregulator"
"Inhibition of <e2>NF-kappa B</e2> by sodium salicylate and <e1>aspirin</e1>.","Downregulator"
"Sodium salicylate and <e1>aspirin</e1> also inhibited NF-kappa B-dependent transcription from the <e2>Ig kappa</e2> enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.","Downregulator"
"Galanin attenuates <e2>cyclic AMP regulatory element-binding protein</e2> (CREB) phosphorylation induced by chronic <e1>morphine</e1> and naloxone challenge in Cath.a cells and primary striatal cultures.","Upregulator"
"Galanin attenuates cyclic AMP regulatory element-binding protein (<e2>CREB</e2>) phosphorylation induced by chronic <e1>morphine</e1> and naloxone challenge in Cath.a cells and primary striatal cultures.","Upregulator"
"Galanin attenuates <e2>cyclic AMP regulatory element-binding protein</e2> (CREB) phosphorylation induced by chronic morphine and <e1>naloxone</e1> challenge in Cath.a cells and primary striatal cultures.","Upregulator"
"Galanin attenuates cyclic AMP regulatory element-binding protein (<e2>CREB</e2>) phosphorylation induced by chronic morphine and <e1>naloxone</e1> challenge in Cath.a cells and primary striatal cultures.","Upregulator"
"Existing <e2>ion channel</e2> blockers, such as amiodarone, dronedarone, bepridil, aprindine, and <e1>cibenzoline</e1>, have been found to have an NCX inhibitory action.","Downregulator"
"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and <e1>cibenzoline</e1>, have been found to have an <e2>NCX</e2> inhibitory action.","Downregulator"
"The pharmacology of <e2>NCX</e2> inhibitors has been studied extensively since the development of <e1>KB-R7943</e1>, a prototype benzyloxyphenyl NCX inhibitor, in 1996.","Downregulator"
"The pharmacology of <e2>NCX</e2> inhibitors has been studied extensively since the development of KB-R7943, a prototype <e1>benzyloxyphenyl</e1> NCX inhibitor, in 1996.","Downregulator"
"The pharmacology of <e2>NCX</e2> inhibitors has been studied extensively since the development of KB-R7943, a prototype <e1>benzyloxyphenyl</e1> NCX inhibitor, in 1996.","Downregulator"
"Existing <e2>ion channel</e2> blockers, such as <e1>amiodarone</e1>, dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action.","Downregulator"
"Existing ion channel blockers, such as <e1>amiodarone</e1>, dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an <e2>NCX</e2> inhibitory action.","Downregulator"
"Existing <e2>ion channel</e2> blockers, such as amiodarone, <e1>dronedarone</e1>, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action.","Downregulator"
"Existing ion channel blockers, such as amiodarone, <e1>dronedarone</e1>, bepridil, aprindine, and cibenzoline, have been found to have an <e2>NCX</e2> inhibitory action.","Downregulator"
"Existing <e2>ion channel</e2> blockers, such as amiodarone, dronedarone, <e1>bepridil</e1>, aprindine, and cibenzoline, have been found to have an NCX inhibitory action.","Downregulator"
"Existing ion channel blockers, such as amiodarone, dronedarone, <e1>bepridil</e1>, aprindine, and cibenzoline, have been found to have an <e2>NCX</e2> inhibitory action.","Downregulator"
"Existing <e2>ion channel</e2> blockers, such as amiodarone, dronedarone, bepridil, <e1>aprindine</e1>, and cibenzoline, have been found to have an NCX inhibitory action.","Downregulator"
"Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, <e1>aprindine</e1>, and cibenzoline, have been found to have an <e2>NCX</e2> inhibitory action.","Downregulator"
"The Na(+)/<e1>Ca(2+)</e1> exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.","Substrate"
"The Na(+)/<e1>Ca(2+)</e1> exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.","Substrate"
"Efficacy and safety of the <e2>dipeptidyl peptidase-4</e2> inhibitor, <e1>sitagliptin</e1>, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.","Downregulator"
"AIM: To assess the efficacy and safety of a 24-week treatment with <e1>sitagliptin</e1>, a highly selective once-daily oral dipeptidyl peptidase-4 (<e2>DPP-4</e2>) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.","Downregulator"
"Efficacy and safety of the <e2>dipeptidyl peptidase-4</e2> inhibitor, <e1>sitagliptin</e1>, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.","Downregulator"
"<e1>HSYA</e1> treatment also decreased <e2>NF-κB</e2> p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).","Downregulator"
"<e1>HSYA</e1> treatment also decreased NF-κB <e2>p65</e2> nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK).","Downregulator"
"<e1>HSYA</e1> suppressed the expression of TLR-4, <e2>Myd88</e2>, ICAM-1, TNFα, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.","Downregulator"
"<e1>HSYA</e1> suppressed the expression of TLR-4, Myd88, <e2>ICAM-1</e2>, TNFα, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.","Downregulator"
"<e1>HSYA</e1> suppressed the expression of TLR-4, Myd88, ICAM-1, <e2>TNFα</e2>, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.","Downregulator"
"<e1>HSYA</e1> suppressed the expression of TLR-4, Myd88, ICAM-1, TNFα, <e2>IL-1β</e2> and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.","Downregulator"
"<e1>HSYA</e1> suppressed the expression of TLR-4, Myd88, ICAM-1, TNFα, IL-1β and <e2>IL-6</e2> at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.","Downregulator"
"<e1>HSYA</e1> suppressed the expression of <e2>TLR-4</e2>, Myd88, ICAM-1, TNFα, IL-1β and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells.","Downregulator"
"<e1>HSYA</e1> treatment also decreased NF-κB p65 nuclear translocation and inhibited the phosphorylation of <e2>p38</e2> mitogen-activated protein kinase (p38 MAPK).","Downregulator"
"<e1>HSYA</e1> treatment also decreased NF-κB p65 nuclear translocation and inhibited the phosphorylation of p38 <e2>mitogen-activated protein kinase</e2> (p38 MAPK).","Downregulator"
"<e1>HSYA</e1> treatment also decreased NF-κB p65 nuclear translocation and inhibited the phosphorylation of <e2>p38</e2> mitogen-activated protein kinase (p38 MAPK).","Downregulator"
"<e1>HSYA</e1> treatment also decreased NF-κB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 <e2>MAPK</e2>).","Downregulator"
"Synthesis and biological evaluation of <e1>phosphorylated flavonoids</e1> as potent and selective inhibitors of <e2>cholesterol esterase</e2>.","Downregulator"
"A series of <e1>phosphorylated flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (<e2>CEase</e2>) and acetylcholinesterase (AChE).","Downregulator"
"A series of <e1>phosphorylated flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (CEase) and <e2>acetylcholinesterase</e2> (AChE).","Downregulator"
"A series of <e1>phosphorylated flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (<e2>AChE</e2>).","Downregulator"
"A series of phosphorylated <e1>flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (<e2>CEase</e2>) and acetylcholinesterase (AChE).","Downregulator"
"A series of <e1>phosphorylated flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (<e2>CEase</e2>) and acetylcholinesterase (AChE).","Downregulator"
"A series of <e1>phosphorylated flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (<e2>AChE</e2>).","Downregulator"
"A series of <e1>phosphorylated flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase (<e2>AChE</e2>).","Downregulator"
"The structure-activity relationships revealed that the free <e1>hydroxyl</e1> group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of <e2>CEase</e2>.","Downregulator"
"The structure-activity relationships revealed that the free hydroxyl group at position 5 and <e1>phosphate</e1> group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of <e2>CEase</e2>.","Downregulator"
"A series of <e1>phosphorylated flavonoids</e1> were synthesized and investigated in vitro as inhibitors of pancreatic cholesterol esterase (<e2>CEase</e2>) and acetylcholinesterase (AChE).","Downregulator"
"Synthesis and biological evaluation of <e1>phosphorylated flavonoids</e1> as potent and selective inhibitors of <e2>cholesterol esterase</e2>.","Downregulator"
"In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal <e2>c-FOS</e2> mRNA, whereas <e1>mesalamine</e1> had no effect.","Not"
"Colonic <e2>cyclooxygenase-2</e2> and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by <e1>mesalamine</e1>.","Not"
"Colonic cyclooxygenase-2 and <e2>interkeukin-1beta</e2> mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by <e1>mesalamine</e1>.","Not"
"In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal <e2>c-FOS</e2> mRNA, whereas <e1>mesalamine</e1> had no effect.","Not"
"Taken together, these data suggest that <e1>ATB-429</e1> inhibits hypersensitivity induced by CRD in both healthy and postcolitic, allodynic rats by a <e2>K(ATP) channel</e2>-mediated mechanism.","Regulator"
"In healthy rats, <e1>ATB-429</e1> dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal <e2>c-FOS</e2> mRNA, whereas mesalamine had no effect.","Downregulator"
"Colonic <e2>cyclooxygenase-2</e2> and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by <e1>ATB-429</e1>, but not by mesalamine.","Downregulator"
"Colonic cyclooxygenase-2 and <e2>interkeukin-1beta</e2> mRNA and spinal c-FOS mRNA expression were significantly down-regulated by <e1>ATB-429</e1>, but not by mesalamine.","Downregulator"
"In healthy rats, <e1>ATB-429</e1> dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal <e2>c-FOS</e2> mRNA, whereas mesalamine had no effect.","Downregulator"
"ATB-429-induced antinociception was reversed by <e1>glibenclamide</e1>, a <e2>ATP-sensitive K(+) (K(ATP)) channel</e2> inhibitor.","Downregulator"
"In this study, we have synthesized novel <e1>alpha-hydroxyphenylamide</e1> analogues of diphenylhydantoin and examined their ability to inhibit <e2>human Na(V)1.5</e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","Downregulator"
"Block of human NaV1.5 <e2>sodium channels</e2> by novel <e1>alpha-hydroxyphenylamide</e1> analogues of phenytoin.","Downregulator"
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of <e1>diphenylhydantoin</e1> and examined their ability to inhibit <e2>human Na(V)1.5</e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","Downregulator"
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of <e1>diphenylhydantoin</e1> and examined their ability to inhibit human Na(V)1.5 <e2>sodium channels</e2> expressed in Chinese Hamster Ovary (CHO-K1) cells.","Downregulator"
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of <e1>diphenylhydantoin</e1> and examined their ability to inhibit human <e2>Na(V)1.5</e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","Downregulator"
"In comparison to diphenylhydantoin, the novel <e1>chloro</e1>-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of <e2>Na(V)1.5</e2> channels with an IC(50) value of 14.5 microM.","Downregulator"
"In this study, we have synthesized novel <e1>alpha-hydroxyphenylamide</e1> analogues of diphenylhydantoin and examined their ability to inhibit human <e2>Na(V)1.5</e2> sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","Downregulator"
"<e1>Phenytoin</e1> (diphenylhydantoin, DPH) is an established <e2>sodium channel</e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.","Downregulator"
"Block of human NaV1.5 <e2>sodium channels</e2> by novel <e1>alpha-hydroxyphenylamide</e1> analogues of phenytoin.","Downregulator"
"Block of <e2>human NaV1.5</e2> sodium channels by novel <e1>alpha-hydroxyphenylamide</e1> analogues of phenytoin.","Downregulator"
"Block of human NaV1.5 <e2>sodium channels</e2> by novel alpha-hydroxyphenylamide analogues of <e1>phenytoin</e1>.","Downregulator"
"Block of <e2>human NaV1.5</e2> sodium channels by novel alpha-hydroxyphenylamide analogues of <e1>phenytoin</e1>.","Downregulator"
"Phenytoin (<e1>diphenylhydantoin</e1>, DPH) is an established <e2>sodium channel</e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.","Downregulator"
"Phenytoin (diphenylhydantoin, <e1>DPH</e1>) is an established <e2>sodium channel</e2> blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain.","Downregulator"
"Block of human NaV1.5 <e1>sodium</e1> channels by novel alpha-hydroxyphenylamide analogues of phenytoin.","Substrate"
"Voltage-gated sodium (<e1>Na</e1>) channels are a critical component of electrically excitable cells.","Substrate"
"In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit <e2>human Na(V)1.5</e2> <e1>sodium</e1> channels expressed in Chinese Hamster Ovary (CHO-K1) cells.","Substrate"
"Block of human NaV1.5 <e1>sodium</e1> channels by novel alpha-hydroxyphenylamide analogues of phenytoin.","Substrate"
"Block of human NaV1.5 <e1>sodium</e1> channels by novel alpha-hydroxyphenylamide analogues of phenytoin.","Substrate"
"Block of <e2>human NaV1.5</e2> <e1>sodium</e1> channels by novel alpha-hydroxyphenylamide analogues of phenytoin.","Substrate"
"Voltage-gated <e1>sodium</e1> (Na) channels are a critical component of electrically excitable cells.","Substrate"
"Block of human NaV1.5 <e1>sodium</e1> channels by novel alpha-hydroxyphenylamide analogues of phenytoin.","Substrate"
"Effects of a <e1>serotonin</e1> 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans.","Regulator"
"BACKGROUND: <e1>Serotonin</e1> 5-HT(4) receptors are located on enteric cholinergic neurones and may regulate peristalsis.","Regulator"
"METHODS: Part A compared the effects of placebo to four doses of a <e2>5-HT(4)</e2> receptor antagonist (SB-207266) on the <e1>cisapride</e1> mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.","Regulator"
"METHODS: Part A compared the effects of placebo to four doses of a <e2>5-HT(4)</e2> receptor antagonist (SB-207266) on the <e1>cisapride</e1> mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.","Agonist"
"Effects of a <e2>serotonin 5-HT(4) receptor</e2> antagonist <e1>SB-207266</e1> on gastrointestinal motor and sensory function in humans.","Antagonist"
"Effects of a serotonin <e2>5-HT(4)</e2> receptor antagonist <e1>SB-207266</e1> on gastrointestinal motor and sensory function in humans.","Antagonist"
"Effects of a serotonin <e2>5-HT(4)</e2> receptor antagonist <e1>SB-207266</e1> on gastrointestinal motor and sensory function in humans.","Antagonist"
"<e2>SSAT</e2> was found to self-acetylate <e1>lysine</e1>-26 in the presence of AcCoA and absence of substrate, a reaction apparently catalzyed by AcCoA bound in the second channel of the asymmetric dimer.","Part_of"
"Spermidine/spermine N1-acetyltransferase (<e2>SSAT</e2>) is a key enzyme in the control of <e1>polyamine</e1> levels in human cells, as acetylation of spermidine and spermine triggers export or degradation.","Substrate"
"<e2>Spermidine/spermine N1-acetyltransferase</e2> (SSAT) is a key enzyme in the control of <e1>polyamine</e1> levels in human cells, as acetylation of spermidine and spermine triggers export or degradation.","Substrate"
"<e2>Spermidine/spermine N1-acetyltransferase</e2> (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of <e1>spermidine</e1> and spermine triggers export or degradation.","Substrate"
"Spermidine/<e1>spermine</e1> N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and spermine triggers export or degradation.","Substrate"
"Treatment of C57 BL/6 mice with <e1>bleomycin</e1> increased fibroblast viability and <e2>collagen</e2> production and significantly downregulated Nrf2.","Regulator"
"To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate <e2>Nrf2</e2> and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, <e1>caffeic acid phenethyl ester</e1>, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.","Upregulator"
"In a cell-based model, <e1>bleomycin</e1> suppressed Nrf2 activation via <e2>extracellular signal-related kinase</e2> phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion.","Upregulator"
"Treatment of C57 BL/6 mice with <e1>bleomycin</e1> increased fibroblast viability and collagen production and significantly downregulated <e2>Nrf2</e2>.","Upregulator"
"Treatment of C57 BL/6 mice with <e1>bleomycin</e1> increased fibroblast viability and collagen production and significantly downregulated <e2>Nrf2</e2>.","Downregulator"
"Treatment of C57 BL/6 mice with <e1>bleomycin</e1> increased fibroblast viability and collagen production and significantly downregulated <e2>Nrf2</e2>.","Downregulator"
"6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (<e1>TAK-441</e1>) is a potent, selective hedgehog signaling pathway inhibitor that binds to <e2>Smo</e2> and is being developed for the treatment of cancer.","Regulator"
"Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor <e1>TAK-441</e1> for the inhibition of <e2>Gli1</e2> messenger RNA expression and antitumor efficacy in xenografted tumor model mice.","Regulator"
"Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor <e1>TAK-441</e1> for the inhibition of <e2>Gli1</e2> messenger RNA expression and antitumor efficacy in xenografted tumor model mice.","Downregulator"
"Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor <e1>TAK-441</e1> for the inhibition of <e2>Gli1</e2> messenger RNA expression and antitumor efficacy in xenografted tumor model mice.","Downregulator"
"Pharmacokinetic and pharmacodynamic modeling of <e2>hedgehog</e2> inhibitor <e1>TAK-441</e1> for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.","Downregulator"
"Pharmacokinetic and pharmacodynamic modeling of <e2>hedgehog</e2> inhibitor <e1>TAK-441</e1> for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.","Downregulator"
"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a <e2>COX</e2>-1 and COX-2 inhibitor; <e1>exisulind</e1> (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.","Not"
"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a <e2>COX</e2>-1 and COX-2 inhibitor; exisulind (<e1>sulindac sulfone</e1>), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.","Not"
"In this report, we evaluated the growth-inhibitory effects of <e1>sulindac sulfide</e1>, a <e2>COX-1</e2> and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.","Downregulator"
"In this report, we evaluated the growth-inhibitory effects of <e1>sulindac sulfide</e1>, a COX-1 and <e2>COX-2</e2> inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.","Downregulator"
"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and <e1>nordihydroguaiaretic acid</e1> (NDGA), a <e2>lipoxygenase</e2> inhibitor on human lung cancer cell lines.","Downregulator"
"In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (<e1>NDGA</e1>), a <e2>lipoxygenase</e2> inhibitor on human lung cancer cell lines.","Downregulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Regulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Regulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Regulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Regulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Regulator"
"The Ca(2+)-<e2>S100A4</e2>/<e1>prochlorperazine</e1> (PCP) complex exhibits a similar pentameric assembly.","Regulator"
"The Ca(2+)-<e2>S100A4</e2>/prochlorperazine (<e1>PCP</e1>) complex exhibits a similar pentameric assembly.","Regulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Regulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Regulator"
"Together these studies support a unique mode of inhibition in which <e1>phenothiazines</e1> disrupt the <e2>S100A4</e2>/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.","Regulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Upregulator"
"Using a unique biosensor-based assay, <e1>trifluoperazine</e1> (TFP) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Downregulator"
"Using a unique biosensor-based assay, <e1>trifluoperazine</e1> (TFP) was identified as an inhibitor that disrupts the S100A4/<e2>myosin-IIA</e2> interaction.","Downregulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Downregulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the S100A4/<e2>myosin-IIA</e2> interaction.","Downregulator"
"<e1>Phenothiazines</e1> inhibit <e2>S100A4</e2> function by inducing protein oligomerization.","Downregulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Downregulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the S100A4/<e2>myosin-IIA</e2> interaction.","Downregulator"
"Using a unique biosensor-based assay, trifluoperazine (<e1>TFP</e1>) was identified as an inhibitor that disrupts the <e2>S100A4</e2>/myosin-IIA interaction.","Downregulator"
"Together these studies support a unique mode of inhibition in which <e1>phenothiazines</e1> disrupt the <e2>S100A4</e2>/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.","Downregulator"
"Together these studies support a unique mode of inhibition in which <e1>phenothiazines</e1> disrupt the S100A4/<e2>myosin-IIA</e2> interaction by sequestering S100A4 via small molecule-induced oligomerization.","Downregulator"
"Substrates of <e2>IAP</e2> ubiquitin ligases identified with a designed orthogonal E3 ligase, the <e1>N</e1>EDDylator.","Part_of"
"Their deduced amino acid sequences show a high degree of conservation compared with orthologues from other mammalian species, with the notable exception of the <e1>N</e1>-terminus of <e2>ovine M-CPT 1</e2>.","Part_of"
"These differences were also present in <e2>bovine M-CPT 1</e2>, whose <e1>N</e1>-terminal sequence we determined.","Part_of"
"Their deduced amino acid sequences show a high degree of conservation compared with orthologues from other mammalian species, with the notable exception of the <e1>N</e1>-terminus of <e2>ovine M-CPT 1</e2>.","Part_of"
"Eight normal males received single oral doses of <e1>BRL</e1>35135 8 mg (BRL) or the selective <e2>beta 2-adrenoceptor</e2> agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.","Upregulator"
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <e2>beta 2-adrenoceptor</e2> agonist salbutamol 8 mg (<e1>SAL</e1>), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.","Upregulator"
"Cardiac effects of the <e2>beta 3-adrenoceptor</e2> agonist <e1>BRL35135</e1> in man.","Agonist"
"Cardiac effects of the <e2>beta 3-adrenoceptor</e2> agonist <e1>BRL35135</e1> in man.","Agonist"
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <e2>beta 2-adrenoceptor</e2> agonist <e1>salbutamol</e1> 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.","Agonist"
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective <e2>beta 2-adrenoceptor</e2> agonist salbutamol 8 mg (<e1>SAL</e1>), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.","Agonist"
"Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), <e1>bisoprolol</e1> 5 mg (B5) as a selective <e2>beta 1-adrenoceptor</e2> antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.","Antagonist"
"Disruption of contact inhibition, which was induced by toxic <e2>AhR</e2> ligands <e1>2,3,7,8-tetrachlorodibenzo-p-dioxin</e1> (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Regulator"
"Disruption of contact inhibition, which was induced by toxic <e2>AhR</e2> ligands <e1>2,3,7,8-tetrachlorodibenzo-p-dioxin</e1> (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Regulator"
"Disruption of contact inhibition, which was induced by toxic <e2>AhR</e2> ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Regulator"
"Disruption of contact inhibition, which was induced by toxic <e2>AhR</e2> ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Regulator"
"Disruption of contact inhibition, which was induced by toxic <e2>AhR</e2> ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or <e1>polycyclic aromatic hydrocarbons</e1> in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Regulator"
"Disruption of contact inhibition, which was induced by toxic <e2>AhR</e2> ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or <e1>polycyclic aromatic hydrocarbons</e1> in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Regulator"
"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>Cx43</e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Downregulator"
"Disruption of contact inhibition, which was induced by toxic AhR ligands <e1>2,3,7,8-tetrachlorodibenzo-p-dioxin</e1> (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>Cx43</e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Downregulator"
"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>Cx43</e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Downregulator"
"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or <e1>polycyclic aromatic hydrocarbons</e1> in epithelial WB-F344 cells, reduced <e2>Cx43</e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Downregulator"
"Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (<e1>TCDD</e1>) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced <e2>Cx43</e2> protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.","Downregulator"
"The <e1>nucleotide</e1> sequence of <e2>HmTx</e2> contains 649 bp, and the mature protein is predicted to have 131 amino acid residues-104 of which make up the large subunit, and 27 of which make up the small subunit.","Part_of"
"The nucleotide sequence of <e2>HmTx</e2> contains 649 bp, and the mature protein is predicted to have 131 <e1>amino acid</e1> residues-104 of which make up the large subunit, and 27 of which make up the small subunit.","Part_of"
"The 3D-structure of <e2>HmTx</e2> consists of three conserved alpha-helices: h1 (<e1>Lys</e1>24-His34), h2 (Cys59-Asp71), and h3 (Ala80-Phe89).","Part_of"
"The 3D-structure of <e2>HmTx</e2> consists of three conserved alpha-helices: h1 (Lys24-<e1>His</e1>34), h2 (Cys59-Asp71), and h3 (Ala80-Phe89).","Part_of"
"The 3D-structure of <e2>HmTx</e2> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (<e1>Cys</e1>59-Asp71), and h3 (Ala80-Phe89).","Part_of"
"The 3D-structure of <e2>HmTx</e2> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-<e1>Asp</e1>71), and h3 (Ala80-Phe89).","Part_of"
"The 3D-structure of <e2>HmTx</e2> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-Asp71), and h3 (<e1>Ala</e1>80-Phe89).","Part_of"
"The 3D-structure of <e2>HmTx</e2> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-Asp71), and h3 (Ala80-<e1>Phe</e1>89).","Part_of"
"Molecular analysis of these mutants revealed single base pair exchanges in the <e2>ERG1</e2> gene coding for squalene epoxidase, the target of <e1>terbinafine</e1>.","Not"
"Two mutations that were generated by PCR mutagenesis of the ERG1 gene and that conferred <e1>terbinafine</e1> resistance mapped in the same regions of the <e2>Erg1</e2> protein, with one resulting in an L251F exchange and the other resulting in an F433S exchange.","Not"
"Terbinafine resistance was transmitted with the mutated alleles in gene replacement experiments, proving that single <e1>amino acid</e1> substitutions in the <e2>Erg1</e2> protein were sufficient to confer the resistance phenotype.","Part_of"
"Interestingly, all exchanges identified involved <e1>amino acids</e1> which are conserved in the <e2>squalene epoxidases</e2> of yeasts and mammals.","Part_of"
"Terbinafine resistance was transmitted with the mutated alleles in gene replacement experiments, proving that single <e1>amino acid</e1> substitutions in the <e2>Erg1</e2> protein were sufficient to confer the resistance phenotype.","Part_of"
"Molecular analysis of these mutants revealed single base pair exchanges in the <e2>ERG1</e2> gene coding for squalene epoxidase, the target of <e1>terbinafine</e1>.","Regulator"
"The results strongly indicate that these regions are responsible for the interaction of <e2>yeast squalene epoxidase</e2> with <e1>terbinafine</e1>.","Regulator"
"Molecular analysis of these mutants revealed single base pair exchanges in the ERG1 gene coding for <e2>squalene epoxidase</e2>, the target of <e1>terbinafine</e1>.","Regulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to <e1>toluene diisocyanate</e1> (TDI) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Regulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (<e1>TDI</e1>) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Regulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (TDI) and to investigate the effect of <e1>dexamethasone</e1> on the above mentioned allergic parameters.","Regulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to <e1>toluene diisocyanate</e1> (TDI) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Regulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (<e1>TDI</e1>) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Regulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (TDI) and to investigate the effect of <e1>dexamethasone</e1> on the above mentioned allergic parameters.","Regulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (<e1>TDI</e1>) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Upregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (<e1>TDI</e1>) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Upregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (<e1>TDI</e1>) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Upregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (<e1>TDI</e1>) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Upregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (<e1>TDI</e1>) and to investigate the effect of dexamethasone on the above mentioned allergic parameters.","Upregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (TDI) and to investigate the effect of <e1>dexamethasone</e1> on the above mentioned allergic parameters.","Downregulator"
"<e1>Dexamethasone</e1> suppresses histamine synthesis by repressing both transcription and activity of <e2>HDC</e2> in allergic rats.","Downregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (TDI) and to investigate the effect of <e1>dexamethasone</e1> on the above mentioned allergic parameters.","Downregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (TDI) and to investigate the effect of <e1>dexamethasone</e1> on the above mentioned allergic parameters.","Downregulator"
"<e1>Dexamethasone</e1> suppresses histamine synthesis by repressing both transcription and activity of <e2>HDC</e2> in allergic rats.","Downregulator"
"The objectives of the present study were to examine the changes of histamine content, <e2>HDC</e2> activity and HDC mRNA expression in the nasal mucosa of allergy model rats sensitized by the exposure to toluene diisocyanate (TDI) and to investigate the effect of <e1>dexamethasone</e1> on the above mentioned allergic parameters.","Downregulator"
"Dexamethasone suppresses <e1>histamine</e1> synthesis by repressing both transcription and activity of <e2>HDC</e2> in allergic rats.","Substrate"
"BACKGROUND: <e1>Histamine</e1> synthesized by <e2>histidine decarboxylase</e2> (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.","Substrate"
"BACKGROUND: <e1>Histamine</e1> synthesized by histidine decarboxylase (<e2>HDC</e2>) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.","Substrate"
"Dexamethasone suppresses <e1>histamine</e1> synthesis by repressing both transcription and activity of <e2>HDC</e2> in allergic rats.","Substrate"
"Dexamethasone suppresses <e1>histamine</e1> synthesis by repressing both transcription and activity of <e2>HDC</e2> in allergic rats.","Substrate"
"BACKGROUND: Histamine synthesized by <e2>histidine decarboxylase</e2> (HDC) from <e1>L-histidine</e1> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.","Substrate"
"BACKGROUND: Histamine synthesized by histidine decarboxylase (<e2>HDC</e2>) from <e1>L-histidine</e1> is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.","Substrate"
"The purpose of this study is to determine the effects on <e2>insulin</e2> sensitivity of a <e1>carbohydrate</e1>-rich diet (CARB; similar to the Dietary Approaches to Stop Hypertension [DASH] diet), a protein-rich diet (PROT; protein predominantly from plant sources), and an unsaturated fat-rich diet (UNSAT; predominantly monounsaturated).","Regulator"
"The Effects of <e1>Carbohydrate</e1>, Unsaturated Fat, and Protein Intake on Measures of <e2>Insulin</e2> Sensitivity: Results from the OmniHeart Trial.","Regulator"
"The purpose of this study is to determine the effects on <e2>insulin</e2> sensitivity of a <e1>carbohydrate</e1>-rich diet (CARB; similar to the Dietary Approaches to Stop Hypertension [DASH] diet), a protein-rich diet (PROT; protein predominantly from plant sources), and an unsaturated fat-rich diet (UNSAT; predominantly monounsaturated).","Upregulator"
"In this study, we assessed the effects of clopidogrel and clarithromycin, known <e2>CYP2B6</e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic <e1>sibutramine</e1> in conjunction with CYP2B6 polymorphisms in humans.","Regulator"
"In this study, we assessed the effects of clopidogrel and clarithromycin, known <e2>CYP2B6</e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of <e1>racemic sibutramine</e1> in conjunction with CYP2B6 polymorphisms in humans.","Regulator"
"In this study, we assessed the effects of clopidogrel and clarithromycin, known <e2>CYP2B6</e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic <e1>sibutramine</e1> in conjunction with CYP2B6 polymorphisms in humans.","Regulator"
"In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and <e2>CYP3A</e2> inhibitors, respectively, on the enantioselective disposition of racemic <e1>sibutramine</e1> in conjunction with CYP2B6 polymorphisms in humans.","Regulator"
"In this study, we assessed the effects of <e1>clopidogrel</e1> and clarithromycin, known <e2>CYP2B6</e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.","Downregulator"
"In this study, we assessed the effects of <e1>clopidogrel</e1> and clarithromycin, known <e2>CYP2B6</e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.","Downregulator"
"In this study, we assessed the effects of <e1>clopidogrel</e1> and clarithromycin, known CYP2B6 and <e2>CYP3A</e2> inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.","Downregulator"
"In this study, we assessed the effects of clopidogrel and <e1>clarithromycin</e1>, known <e2>CYP2B6</e2> and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.","Downregulator"
"In this study, we assessed the effects of clopidogrel and <e1>clarithromycin</e1>, known CYP2B6 and <e2>CYP3A</e2> inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.","Downregulator"
"OBJECTIVE: We examined the effect of CysLT antagonists (<e1>pranlukast</e1> and MCI-826) on antigen inhalation-induced eosinophilia in peripheral blood and lung, and on <e2>IL-5</e2> activity in serum during late increase of airway resistance (late asthmatic response, LAR) in sensitized guinea-pigs.","Regulator"
"OBJECTIVE: We examined the effect of CysLT antagonists (pranlukast and <e1>MCI-826</e1>) on antigen inhalation-induced eosinophilia in peripheral blood and lung, and on <e2>IL-5</e2> activity in serum during late increase of airway resistance (late asthmatic response, LAR) in sensitized guinea-pigs.","Regulator"
"BACKGROUND: Allergic airway eosinophilia is suppressed by cysteinyl leukotriene (CysLT) receptor (<e2>CysLT1</e2> receptor) antagonists in several species including humans and guinea-pigs, suggesting that <e1>CysLTs</e1> are directly or indirectly involved in induction of the response.","Upregulator"
"OBJECTIVE: We examined the effect of CysLT antagonists (<e1>pranlukast</e1> and MCI-826) on antigen inhalation-induced eosinophilia in peripheral blood and lung, and on <e2>IL-5</e2> activity in serum during late increase of airway resistance (late asthmatic response, LAR) in sensitized guinea-pigs.","Downregulator"
"OBJECTIVE: We examined the effect of CysLT antagonists (pranlukast and <e1>MCI-826</e1>) on antigen inhalation-induced eosinophilia in peripheral blood and lung, and on <e2>IL-5</e2> activity in serum during late increase of airway resistance (late asthmatic response, LAR) in sensitized guinea-pigs.","Downregulator"
"<e1>Meclofenamic acid</e1> and diclofenac, novel templates of <e2>KCNQ2/Q3</e2> potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.","Regulator"
"<e1>Meclofenamic acid</e1> and diclofenac, novel templates of KCNQ2/Q3 <e2>potassium channel</e2> openers, depress cortical neuron activity and exhibit anticonvulsant properties.","Regulator"
"Meclofenamic acid and <e1>diclofenac</e1>, novel templates of <e2>KCNQ2/Q3</e2> potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.","Regulator"
"Meclofenamic acid and <e1>diclofenac</e1>, novel templates of KCNQ2/Q3 <e2>potassium channel</e2> openers, depress cortical neuron activity and exhibit anticonvulsant properties.","Regulator"
"Here, we show that <e1>meclofenamic acid</e1> (meclofenamate) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel <e2>KCNQ2/Q3</e2> channel openers.","Regulator"
"Here, we show that meclofenamic acid (<e1>meclofenamate</e1>) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel <e2>KCNQ2/Q3</e2> channel openers.","Regulator"
"Meclofenamic acid and <e1>diclofenac</e1>, novel templates of <e2>KCNQ2/Q3</e2> potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.","Regulator"
"Meclofenamic acid and <e1>diclofenac</e1>, novel templates of <e2>KCNQ2/Q3</e2> potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.","Upregulator"
"Here, we show that meclofenamic acid (<e1>meclofenamate</e1>) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel <e2>KCNQ2/Q3</e2> channel openers.","Upregulator"
"We investigated the mechanism of action of <e1>atomoxetine</e1> in ADHD by evaluating the interaction of atomoxetine with <e2>monoamine transporters</e2>, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions.","Regulator"
"<e1>Atomoxetine</e1> inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for <e2>NE transporters</e2>.","Regulator"
"We investigated the mechanism of action of <e1>atomoxetine</e1> in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker <e2>Fos</e2> in brain regions.","Regulator"
"We investigated the mechanism of action of <e1>atomoxetine</e1> in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker <e2>Fos</e2> in brain regions.","Regulator"
"The selective <e2>norepinephrine (NE) transporter</e2> inhibitor <e1>atomoxetine</e1> (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).","Downregulator"
"The selective <e2>norepinephrine (NE) transporter</e2> inhibitor a<e1>tomoxetine</e1> (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).","Downregulator"
"The selective <e2>norepinephrine (NE) transporter</e2> inhibitor atomoxetine (formerly called tomoxetine or <e1>LY139603</e1>) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).","Downregulator"
"Local <e1>PGE2</e1> administration prevented the increase of airway <e2>IL-13</e2> and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.","Downregulator"
"Local <e1>PGE2</e1> administration prevented the increase of airway IL-13 and <e2>osteopontin</e2> and kept lung plasmacytoid dendritic cell counts close to baseline.","Downregulator"
"Lung inflammation, <e2>IL-4</e2> production, and airway mast cell activity were also prevented under this early short-term treatment with <e1>PGE2</e1>.","Downregulator"
"The reactivation of brain <e2>AChE</e2> inhibited with tabun demonstrated better activity of new compound <e1>BT-07-4M</e1>, TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.","Upregulator"
"The reactivation of brain <e2>AChE</e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, <e1>TMB-4</e1> and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.","Upregulator"
"The reactivation of brain <e2>AChE</e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and <e1>obidoxime</e1> from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.","Upregulator"
"The reactivation of brain <e2>AChE</e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric <e1>oximes</e1>, and BT-05 and BT-03 possessing asymmetric structure.","Upregulator"
"The reactivation of brain <e2>AChE</e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and <e1>BT-05</e1> and BT-03 possessing asymmetric structure.","Upregulator"
"The reactivation of brain <e2>AChE</e2> inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and <e1>BT-03</e1> possessing asymmetric structure.","Upregulator"
"Reactivators showed different activity in the reactivation of rat brain <e2>AChE</e2> after dichlorvos, <e1>paraoxon</e1> and tabun inhibition.","Upregulator"
"Reactivators showed different activity in the reactivation of rat brain <e2>AChE</e2> after <e1>dichlorvos</e1>, paraoxon and tabun inhibition.","Downregulator"
"Reactivators showed different activity in the reactivation of <e2>rat brain AChE</e2> after <e1>dichlorvos</e1>, paraoxon and tabun inhibition.","Downregulator"
"Reactivators showed different activity in the reactivation of <e2>rat brain AChE</e2> after dichlorvos, <e1>paraoxon</e1> and tabun inhibition.","Downregulator"
"Reactivators showed different activity in the reactivation of <e2>rat brain AChE</e2> after dichlorvos, paraoxon and <e1>tabun</e1> inhibition.","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: <e2>Nav1.5</e2> (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).","Regulator"
"State-dependent <e1>mibefradil</e1> block of <e2>Na+ channel</e2>s.","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: <e2>Nav1.5</e2> (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), <e2>Nav1.4</e2> (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), <e2>Nav1.2</e2> (brain), and Nav1.7 (peripheral nerve).","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and <e2>Nav1.7</e2> (peripheral nerve).","Downregulator"
"<e1>Mibefradil</e1> blocked <e2>Nav1.5</e2> in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization.","Downregulator"
"<e1>Mibefradil</e1> is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and <e2>Na+ channel</e2>s.","Downregulator"
"<e1>Mibefradil</e1> blocked <e2>Nav1.5</e2> in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization.","Downregulator"
"State-dependent <e1>mibefradil</e1> block of <e2>Na+ channels</e2>.","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: <e2>Nav1.5</e2> (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: <e2>Nav1.5</e2> (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).","Downregulator"
"Using whole-cell voltage clamp, we examined <e1>mibefradil</e1> block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), <e2>Nav1.4</e2> (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve).","Downregulator"
"State-dependent <e1>mibefradil</e1> block of <e2>Na+ channels</e2>.","Downregulator"
"<e1>Mibefradil</e1> is a <e2>T-type Ca2+ channel</e2> antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels.","Antagonist"
"<e1>Docetaxel</e1> is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of <e2>bcl-2</e2> inactivation, which induce apoptosis.","Downregulator"
"Docetaxel is a semisynthetic <e1>taxane</e1> that inhibit tumor growth by induction of microtubule stabilization and promotion of <e2>bcl-2</e2> inactivation, which induce apoptosis.","Downregulator"
"Risperidone is metabolized to its active metabolite, <e1>9-hydroxyrisperidone</e1>, mainly by the <e2>cytochrome P450</e2> enzymes CYP2D6 and 3A4.","Substrate"
"Both <e1>risperidone</e1> and 9-hydroxyrisperidone are substrates of <e2>P-glycoprotein</e2> (P-gp), a transport protein involved in drug absorption, distribution, and elimination.","Substrate"
"Both <e1>risperidone</e1> and 9-hydroxyrisperidone are substrates of P-glycoprotein (<e2>P-gp</e2>), a transport protein involved in drug absorption, distribution, and elimination.","Substrate"
"Both risperidone and <e1>9-hydroxyrisperidone</e1> are substrates of <e2>P-glycoprotein</e2> (P-gp), a transport protein involved in drug absorption, distribution, and elimination.","Substrate"
"Both risperidone and <e1>9-hydroxyrisperidone</e1> are substrates of P-glycoprotein (<e2>P-gp</e2>), a transport protein involved in drug absorption, distribution, and elimination.","Substrate"
"<e1>Risperidone</e1> is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the <e2>cytochrome P450</e2> enzymes CYP2D6 and 3A4.","Substrate"
"Spermine was rapidly taken up and metabolized to spermidine and an unknown, possibly acetamidopropanal, by spermidine/<e1>spermine</e1> N(1)-acetyltransferase (<e2>SSAT</e2>) and polyamine oxidase (PAO).","Regulator"
"<e1>SL-11158</e1> inhibited <e2>SSAT</e2> activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine.","Downregulator"
"bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [<e1>BW-1</e1>, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for <e2>PAO</e2>.","Substrate"
"Synthesis and in vitro evaluation of N-Aryl <e1>pyrido-quinazolines</e1> derivatives as potent <e2>EGFR</e2> inhibitors.","Downregulator"
"A series of <e1>pyrido-quinazolines</e1> have been synthesised, characterised and tested for their in vitro EGFR <e2>tyrosine kinase</e2> inhibitory activity.","Downregulator"
"Synthesis and in vitro evaluation of <e1>N-Aryl pyrido-quinazolines</e1> derivatives as potent <e2>EGFR</e2> inhibitors.","Downregulator"
"The functional protein contains 1160 amino acids with a large central <e2>mucin domain</e2>, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluronan-binding motif, and a potential transmembrane domain near the <e1>C</e1>-terminal.","Part_of"
"The functional protein contains 1160 amino acids with a large central mucin domain, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative <e2>hyaluronan-binding motif</e2>, and a potential transmembrane domain near the <e1>C</e1>-terminal.","Part_of"
"SPACRCA<e1>N</e1>, a novel human interphotoreceptor matrix hyaluronan-binding proteoglycan synthesized by photoreceptors and pinealocytes.","Part_of"
"Removal of N- and <e1>O</e1>-linked oligosaccharides reduces the M(r) to approximately 160,000, suggesting that approximately 60% of the mass of <e2>SPACRCAN</e2> is carbohydrate.","Part_of"
"The functional protein contains 1160 <e1>amino acids</e1> with a large central <e2>mucin domain</e2>, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluronan-binding motif, and a potential transmembrane domain near the C-terminal.","Part_of"
"The functional protein contains 1160 <e1>amino acids</e1> with a large central mucin domain, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative <e2>hyaluronan-binding motif</e2>, and a potential transmembrane domain near the C-terminal.","Part_of"
"Exposure to <e1>Cu</e1> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and <e2>interleukin-8</e2> that mirrored our findings from subacute in vivo inhalation studies in mice.","Upregulator"
"Exposure to <e1>Cu</e1> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of <e2>lactate dehydrogenase</e2>, intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice.","Upregulator"
"Unable to reverse ERK1/2 phosphorylation, TXM-CB3 (<e1>NAc-Cys-Pro-Cys amide</e1>) appeared to function in part, through inhibiting <e2>ASK1</e2>-Trx dissociation.","Regulator"
"Unable to reverse ERK1/2 phosphorylation, TXM-CB3 (<e1>NAc-Cys-Pro-Cys amide</e1>) appeared to function in part, through inhibiting ASK1-<e2>Trx</e2> dissociation.","Regulator"
"The TXM peptides were effective in inhibiting <e1>AuF</e1>-induced MAPK, JNK and p38(MAPK) phosphorylation, in correlation with preventing <e2>caspase-3</e2> cleavage and thereby PARP-1 dissociation.","Regulator"
"The TXM peptides were effective in inhibiting <e1>AuF</e1>-induced MAPK, JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby <e2>PARP-1</e2> dissociation.","Regulator"
"The TXM peptides were effective in inhibiting <e1>AuF</e1>-induced <e2>MAPK</e2>, JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.","Upregulator"
"The TXM peptides were effective in inhibiting <e1>AuF</e1>-induced MAPK, <e2>JNK</e2> and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.","Upregulator"
"The TXM peptides were effective in inhibiting <e1>AuF</e1>-induced MAPK, JNK and <e2>p38</e2>(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.","Upregulator"
"The TXM peptides were effective in inhibiting <e1>AuF</e1>-induced <e2>MAPK</e2>, JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.","Upregulator"
"The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting <e2>TrxR</e2> with <e1>auranofin</e1> (AuF).","Downregulator"
"The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting <e2>TrxR</e2> with auranofin (<e1>AuF</e1>).","Downregulator"
"Flecainide block of <e1>Na</e1>(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (<e2>DeltaKPQ</e2>) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","Not"
"Preferential block of late <e1>sodium</e1> current in the <e2>LQT3 DeltaKPQ mutant</e2> by the class I(C) antiarrhythmic flecainide.","Not"
"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three <e1>amino acids</e1> deleted (<e2>DeltaKPQ</e2>) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","Part_of"
"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the <e2>long QT syndrome 3 (LQT3) sodium channel alpha</e2> subunit mutation with three <e1>amino acids</e1> deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","Part_of"
"<e1>Flecainide</e1> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (<e2>DeltaKPQ</e2>) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","Downregulator"
"Preferential block of late sodium current in the LQT3 <e2>DeltaKPQ</e2> mutant by the class I(C) antiarrhythmic <e1>flecainide</e1>.","Downregulator"
"Preferential block of late sodium current in the LQT3 <e2>DeltaKPQ</e2> mutant by the class I(C) antiarrhythmic <e1>flecainide</e1>.","Downregulator"
"<e1>Flecainide</e1> block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the <e2>long QT syndrome 3 (LQT3) sodium channel alpha</e2> subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","Downregulator"
"Preferential block of late sodium current in the <e2>LQT3 DeltaKPQ mutant</e2> by the class I(C) antiarrhythmic <e1>flecainide</e1>.","Downregulator"
"Preferential block of late sodium current in the LQT3 <e2>DeltaKPQ</e2> mutant by the class I(C) antiarrhythmic <e1>flecainide</e1>.","Downregulator"
"Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) <e1>sodium</e1> channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.","Substrate"
"<e2>Opioid receptor</e2> binding affinity and activity were assessed using <e1>[(3)H]-diprenorphine</e1> binding, guanosine-5'-O-(3-[35S]-thio) triphosphate ([(35)S]-GTPγS) binding and isolated guinea-pig ileum.","Regulator"
"<e2>Opioid receptor</e2> binding affinity and activity were assessed using [(3)H]-diprenorphine binding, <e1>guanosine-5'-O-(3-[35S]-thio) triphosphate</e1> ([(35)S]-GTPγS) binding and isolated guinea-pig ileum.","Regulator"
"<e2>Opioid receptor</e2> binding affinity and activity were assessed using [(3)H]-diprenorphine binding, guanosine-5'-O-(3-[35S]-thio) triphosphate (<e1>[(35)S]-GTPγS</e1>) binding and isolated guinea-pig ileum.","Regulator"
"Both <e1>5'-AMN</e1> and 5'-MABN had high affinity for <e2>κ-receptors</e2> (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and μ-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.","Regulator"
"Both 5'-AMN and <e1>5'-MABN</e1> had high affinity for <e2>κ-receptors</e2> (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and μ-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.","Regulator"
"In vivo and in vitro characterization of <e1>naltrindole</e1>-derived ligands at the <e2>κ-opioid receptor</e2>.","Regulator"
"Both <e1>5'-AMN</e1> and 5'-MABN had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and <e2>μ-receptor</e2> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.","Antagonist"
"Both 5'-AMN and <e1>5'-MABN</e1> had high affinity for κ-receptors (K (i) 1.36 ± 0.98 and 0.27 ± 0.08, respectively) and were revealed as potent κ-antagonists (pA(2) 7.43 and 8.18, respectively) and <e2>μ-receptor</e2> antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.","Antagonist"
"Polo-like kinase-2 (<e2>Plk-2</e2>) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of <e1>dihydropteridinone</e1> based Plk-2 inhibitors.","Downregulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of <e2>β-catenin</e2>, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Regulator"
"<e1>Sphingosine-1-phosphate</e1> promotes the nuclear translocation of <e2>β-catenin</e2> and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines.","Regulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of <e2>β-catenin</e2>, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Regulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of <e2>β-catenin</e2>, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Regulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/<e2>T-cell factor</e2> complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Regulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (<e2>PI3K</e2>)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Upregulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/<e2>Akt</e2> signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Upregulator"
"<e1>Sphingosine-1-phosphate</e1> promotes the nuclear translocation of β-catenin and thereby induces <e2>osteoprotegerin</e2> gene expression in osteoblast-like cell lines.","Upregulator"
"<e1>S1P</e1> increased the amount of <e2>osteoprotegerin</e2> at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization.","Upregulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of <e2>β-catenin</e2>, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Upregulator"
"These findings suggest that <e1>S1P</e1> activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of β-catenin in osteoblast-like cells, resulting in the upregulation of <e2>osteoptotegerin</e2> and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.","Upregulator"
"<e1>S1P</e1> increased the amount of osteoprotegerin at both mRNA and protein levels, and increased the activity of <e2>alkaline phosphatase</e2>, leading to the mineralization.","Upregulator"
"<e1>S1P</e1> activated <e2>phosphatidylinositol 3-kinase</e2> (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Upregulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (<e2>PI3K</e2>)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Upregulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/<e2>Akt</e2> signaling, leading to the inhibition of glycogen synthase kinase-3β and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Upregulator"
"<e1>S1P</e1> activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of <e2>glycogen synthase kinase-3β</e2> and the nuclear translocation of β-catenin, followed by the increase of the transcriptional activity by β-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells.","Downregulator"
"<e1>Plerixafor</e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine <e2>stromal cell-derived factor-1</e2> (SDF-1) to its cognate receptor CXCR4.","Downregulator"
"<e1>Plerixafor</e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>SDF-1</e2>) to its cognate receptor CXCR4.","Downregulator"
"<e1>Plerixafor</e1>, a <e2>CXCR4</e2> antagonist for the mobilization of hematopoietic stem cells.","Downregulator"
"<e1>Plerixafor</e1> (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the <e2>chemokine</e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4.","Downregulator"
"Plerixafor (<e1>AMD3100</e1>, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine <e2>stromal cell-derived factor-1</e2> (SDF-1) to its cognate receptor CXCR4.","Downregulator"
"Plerixafor (<e1>AMD3100</e1>, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>SDF-1</e2>) to its cognate receptor CXCR4.","Downregulator"
"Plerixafor (<e1>AMD3100</e1>, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>CXCR4</e2>.","Downregulator"
"Plerixafor (<e1>AMD3100</e1>, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the <e2>chemokine</e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4.","Downregulator"
"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam</e1> molecule that antagonizes the binding of the chemokine <e2>stromal cell-derived factor-1</e2> (SDF-1) to its cognate receptor CXCR4.","Downregulator"
"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam</e1> molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (<e2>SDF-1</e2>) to its cognate receptor CXCR4.","Downregulator"
"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam</e1> molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor <e2>CXCR4</e2>.","Downregulator"
"Plerixafor (AMD3100, Genzyme Corporation) is a <e1>bicyclam</e1> molecule that antagonizes the binding of the <e2>chemokine</e2> stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4.","Downregulator"
"<e1>Plerixafor</e1>, a <e2>CXCR4</e2> antagonist for the mobilization of hematopoietic stem cells.","Antagonist"
"Both insulin and cAMP-promoting agents activated <e2>β-cat</e2> <e1>Ser</e1>675 phosphorylation, which was attenuated by IPA3 or protein kinase A inhibition, respectively.","Part_of"
"Insulin stimulated <e2>Pak1</e2> activation through increasing its <e1>Thr</e1>423 phosphorylation in gut gcg-expressing cell lines, associated with increased gcg mRNA levels.","Part_of"
"This stimulation was attenuated by the <e2>Pak</e2> inhibitor <e1>2,2'-dihydroxy-1,1'-dinaphthyldisulfide</e1> (IPA3) or dominant-negative Pak1.","Downregulator"
"This stimulation was attenuated by the <e2>Pak</e2> inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide (<e1>IPA3</e1>) or dominant-negative Pak1.","Downregulator"
"Chronic insulin (24 h) activates NHE3 through the classic <e2>phosphatidylinositol 3-kinase</e2>-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor <e1>wortmannin</e1> or a dominant-negative SGK1.","Downregulator"
"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (<e2>PI3K</e2>-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor <e1>wortmannin</e1> or a dominant-negative SGK1.","Downregulator"
"Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (<e2>PI3K</e2>-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor <e1>wortmannin</e1> or a dominant-negative SGK1.","Downregulator"
"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, <e2>BDNF</e2> and ChAT that was eliminated by <e1>olanzapine</e1> treatment.","Not"
"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>ChAT</e2> that was eliminated by <e1>olanzapine</e1> treatment.","Not"
"The effects of adulthood olanzapine treatment on cognitive performance and <e2>neurotrophic factor</e2> content in male and female rats neonatally treated with <e1>quinpirole</e1>.","Regulator"
"Results showed that neonatal <e1>quinpirole</e1> treatment induced <e2>D2</e2> priming that was eliminated by olanzapine treatment.","Upregulator"
"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal <e2>NGF</e2>, BDNF and ChAT that was eliminated by <e1>olanzapine</e1> treatment.","Upregulator"
"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, <e2>BDNF</e2> and ChAT that was eliminated by <e1>olanzapine</e1> treatment.","Upregulator"
"Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>ChAT</e2> that was eliminated by <e1>olanzapine</e1> treatment.","Upregulator"
"Dopamine <e2>D2</e2> receptor priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before <e1>olanzapine</e1> was administered as well as after olanzapine treatment and behavioural testing were complete.","Downregulator"
"Brain tissue analyses revealed that neonatal <e1>quinpirole</e1> treatment produced a significant decrease in hippocampal <e2>NGF</e2>, BDNF and ChAT that was eliminated by olanzapine treatment.","Downregulator"
"Brain tissue analyses revealed that neonatal <e1>quinpirole</e1> treatment produced a significant decrease in hippocampal NGF, <e2>BDNF</e2> and ChAT that was eliminated by olanzapine treatment.","Downregulator"
"Brain tissue analyses revealed that neonatal <e1>quinpirole</e1> treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>ChAT</e2> that was eliminated by olanzapine treatment.","Downregulator"
"Brain tissue analyses revealed that neonatal <e1>quinpirole</e1> treatment produced a significant decrease in hippocampal NGF, <e2>BDNF</e2> and ChAT that was eliminated by olanzapine treatment.","Downregulator"
"Brain tissue analyses revealed that neonatal <e1>quinpirole</e1> treatment produced a significant decrease in hippocampal NGF, BDNF and <e2>ChAT</e2> that was eliminated by olanzapine treatment.","Downregulator"
"Dopamine <e2>D2 receptor</e2> priming was verified through a yawning behavioural test, a D2 receptor-mediated event, before <e1>olanzapine</e1> was administered as well as after olanzapine treatment and behavioural testing were complete.","Downregulator"
"Here, we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing FST315 to a murine IgG(1) Fc and removing the intrinsic heparan <e1>sulfate</e1>-binding activity of <e2>follistatin</e2>.","Regulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of <e2>p21</e2>(WAF1/CIP1) and p53.","Upregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(<e2>WAF1</e2>/CIP1) and p53.","Upregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/<e2>CIP1</e2>) and p53.","Upregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and <e2>p53</e2>.","Upregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of <e2>cyclin D1</e2>, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, <e2>cyclin E</e2>, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, <e2>cyclin A</e2>, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, <e2>cyclin dependent kinase 2</e2> (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (<e2>CDK2</e2>), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), <e2>CDK4</e2>, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, <e2>c-Myc</e2>, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and <e2>retinoblastoma protein</e2> (pRb), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"<e1>Pinosylvin</e1> inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (<e2>pRb</e2>), and the upregulation of p21(WAF1/CIP1) and p53.","Downregulator"
"Suppression of <e2>Src</e2>/ERK and GSK-3/β-catenin signaling by <e1>pinosylvin</e1> inhibits the growth of human colorectal cancer cells.","Downregulator"
"Suppression of Src/<e2>ERK</e2> and GSK-3/β-catenin signaling by <e1>pinosylvin</e1> inhibits the growth of human colorectal cancer cells.","Downregulator"
"Suppression of Src/ERK and <e2>GSK-3</e2>/β-catenin signaling by <e1>pinosylvin</e1> inhibits the growth of human colorectal cancer cells.","Downregulator"
"Suppression of Src/ERK and GSK-3/<e2>β-catenin</e2> signaling by <e1>pinosylvin</e1> inhibits the growth of human colorectal cancer cells.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in f<e2>ocal adhesion kinase</e2> (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (<e2>FAK</e2>)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/<e2>c-Src</e2>/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/<e2>extracellular signal-regulated kinase</e2> (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (<e2>ERK</e2>) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and <e2>phosphoinositide 3-kinase</e2> (PI3K)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (<e2>PI3K</e2>)/Akt/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/<e2>Akt</e2>/ glycogen synthase kinase 3β (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ <e2>glycogen synthase kinase 3β</e2> (GSK-3β) signaling pathway.","Downregulator"
"<e1>Pinosylvin</e1> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3β (<e2>GSK-3β</e2>) signaling pathway.","Downregulator"
"Suppression of Src/ERK and GSK-3/<e2>β-catenin</e2> signaling by <e1>pinosylvin</e1> inhibits the growth of human colorectal cancer cells.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of <e2>PI3K</e2>/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/<e2>Akt</e2>/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/<e2>GSK-3β</e2> signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.","Downregulator"
"Suppression of Src/ERK and GSK-3/<e2>β-catenin</e2> signaling by <e1>pinosylvin</e1> inhibits the growth of human colorectal cancer cells.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including <e2>BMP4</e2>, ID2, survivin, cyclin D1, MMP7, and c-Myc.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, <e2>ID2</e2>, survivin, cyclin D1, MMP7, and c-Myc.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, <e2>survivin</e2>, cyclin D1, MMP7, and c-Myc.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, <e2>cyclin D1</e2>, MMP7, and c-Myc.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, <e2>MMP7</e2>, and c-Myc.","Downregulator"
"Subsequently, <e1>pinosylvin</e1> suppressed the nuclear translocation of β-catenin, one of downstream molecules of PI3K/Akt/GSK-3β signaling, and these events led to the sequential downregulation of β-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and <e2>c-Myc</e2>.","Downregulator"
"The <e1>acyl esters</e1> could be correlated with expression of <e2>alcohol acyl-transferase EEB1</e2> and the acyl esterase IAH1.","Regulator"
"The <e1>acyl esters</e1> could be correlated with expression of alcohol acyl-transferase EEB1 and the <e2>acyl esterase IAH1</e2>.","Regulator"
"Overall, higher alcohol production was reduced by <e1>ammonium</e1> supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and dehydrogenases of the <e2>Ehrlich pathway</e2>.","Regulator"
"Overall, higher alcohol production was reduced by <e1>ammonium</e1> supplementation, and this can be correlated with a general downregulation of genes encoding <e2>decarboxylases</e2> and dehydrogenases of the Ehrlich pathway.","Downregulator"
"Overall, higher alcohol production was reduced by <e1>ammonium</e1> supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and <e2>dehydrogenases</e2> of the Ehrlich pathway.","Downregulator"
"Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of <e1>nitrooxyalkyl ester and ether</e1> side chain of these molecules within the <e2>COX-2</e2> active site to be assessed.","Regulator"
"<e1>Nitrooxy</e1> derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective <e2>COX-2</e2> inhibitors in in vitro experimental models.","Downregulator"
"Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as <e2>cyclooxygenase-2</e2> inhibiting <e1>nitric oxide</e1> donors.","Downregulator"
"Novel analgesic/anti-inflammatory agents: <e1>1,5-diarylpyrrole nitrooxyalkyl ethers</e1> and related compounds as <e2>cyclooxygenase-2</e2> inhibiting nitric oxide donors.","Downregulator"
"New classes of <e1>pyrrole</e1>-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as <e2>COX-2</e2> selective inhibitors and NO donors were synthesized and are herein reported.","Downregulator"
"New classes of pyrrole-derived <e1>nitrooxyalkyl</e1> inverse esters, carbonates, and ethers (7-10) as <e2>COX-2</e2> selective inhibitors and NO donors were synthesized and are herein reported.","Downregulator"
"New classes of pyrrole-derived nitrooxyalkyl inverse <e1>esters</e1>, carbonates, and ethers (7-10) as <e2>COX-2</e2> selective inhibitors and NO donors were synthesized and are herein reported.","Downregulator"
"New classes of pyrrole-derived nitrooxyalkyl inverse esters, <e1>carbonates</e1>, and ethers (7-10) as <e2>COX-2</e2> selective inhibitors and NO donors were synthesized and are herein reported.","Downregulator"
"New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and <e1>ethers</e1> (7-10) as <e2>COX-2</e2> selective inhibitors and NO donors were synthesized and are herein reported.","Downregulator"
"<e1>Eprosartan</e1> is not metabolized by <e2>cytochrome P450</e2> enzymes and therefore has a low potential for metabolic drug interactions, which may be of importance when treating the elderly and patients on multiple drugs.","Not"
"Angiotensin II receptor antagonists block <e1>angiotensin</e1> II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature.","Regulator"
"<e1>Eprosartan</e1> acts not only at vascular <e2>AT1</e2> receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated noradrenaline release.","Regulator"
"<e1>Eprosartan</e1> acts not only at vascular <e2>AT1</e2> receptors but also at presynaptic AT1 receptors, causing inhibition of sympathetically stimulated noradrenaline release.","Regulator"
"The clinical profile of the <e2>angiotensin II receptor</e2> blocker <e1>eprosartan</e1>.","Downregulator"
"In clinical trials <e1>eprosartan</e1> has proven to be at least as effective as the <e2>ACE</e2> inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects.","Downregulator"
"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>silymarin</e1> resulted in significantly increased activities of <e2>ethylmorphine-N-demethylase</e2> and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group.","Upregulator"
"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>silymarin</e1> resulted in significantly increased activities of ethylmorphine-N-demethylase and <e2>aniline 4-hydroxylase</e2> activity and cytochrome P450, compared to the CCl4 only group.","Upregulator"
"In the CCl4 hepatotoxicity model, pre-treatment with PSM or <e1>silymarin</e1> resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and <e2>cytochrome P450</e2>, compared to the CCl4 only group.","Upregulator"
"In the <e1>CCl4</e1> hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of <e2>ethylmorphine-N-demethylase</e2> and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group.","Upregulator"
"In the <e1>CCl4</e1> hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and <e2>aniline 4-hydroxylase</e2> activity and cytochrome P450, compared to the CCl4 only group.","Upregulator"
"In the <e1>CCl4</e1> hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and <e2>cytochrome P450</e2>, compared to the CCl4 only group.","Upregulator"
"A significant decrease of <e2>aspartate aminotransferase</e2>, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4</e1> and PC administration alone.","Downregulator"
"A significant decrease of aspartate aminotransferase, <e2>alanine aminotransferase</e2>, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4</e1> and PC administration alone.","Downregulator"
"A significant decrease of aspartate aminotransferase, alanine aminotransferase, <e2>lactate dehydrogenase</e2> (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4</e1> and PC administration alone.","Downregulator"
"A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (<e2>LDH</e2>) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after <e1>CCl4</e1> and PC administration alone.","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, <e1>kuraridin</e1> ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase</e2> (DGAT).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, <e1>kuraridin</e1> ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), <e1>kurarinol</e1> ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase</e2> (DGAT).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), <e1>kurarinol</e1> ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"These data suggest that the <e1>lavandulyl</e1> side chain and the position of the hydroxy group are important for high <e2>DGAT</e2> inhibitory activity.","Downregulator"
"These data suggest that the lavandulyl side chain and the position of the <e1>hydroxy</e1> group are important for high <e2>DGAT</e2> inhibitory activity.","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), <e1>kushenol H</e1> ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase</e2> (DGAT).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), <e1>kushenol H</e1> ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and <e1>kushenol K</e1> ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase</e2> (DGAT).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and <e1>kushenol K</e1> ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"In vitro inhibition of <e2>diacylglycerol acyltransferase</e2> by <e1>prenylflavonoids</e1> from Sophora flavescens.","Downregulator"
"Four prenylflavonoids, <e1>kurarinone</e1> ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase</e2> (DGAT).","Downregulator"
"Four prenylflavonoids, <e1>kurarinone</e1> ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"Four prenyl<e1>flavonoids</e1>, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a <e1>chalcone</e1> of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on <e2>diacylglycerol acyltransferase</e2> (DGAT).","Downregulator"
"Four prenylflavonoids, kurarinone ( 1), a <e1>chalcone</e1> of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"In vitro inhibition of <e2>diacylglycerol acyltransferase</e2> by <e1>prenylflavonoids</e1> from Sophora flavescens.","Downregulator"
"Four <e1>prenylflavonoids</e1>, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (<e2>DGAT</e2>).","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>1400W dihydrochloride</e1> (1400W), a selective inhibitor of iNOS, decreased the expression of <e2>E-selectin</e2>, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, <e2>VEGF</e2>, and iNOS induced by reIL-4, while <e1>1400W dihydrochloride</e1> (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while <e1>1400W dihydrochloride</e1> (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>1400W</e1> dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of <e2>E-selectin</e2>, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, <e2>VEGF</e2>, and iNOS induced by reIL-4, while <e1>1400W</e1> dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while <e1>1400W</e1> dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (<e1>DXM</e1>) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of <e2>E-selectin</e2>, VEGF, and iNOS.","Downregulator"
"Dexamethasone (<e1>DXM</e1>) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while <e1>1400W</e1> dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of <e2>E-selectin</e2>, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while <e1>1400W</e1> dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"<e1>Dexamethasone</e1> (DXM) decreased the expression of <e2>CXCL-8</e2>, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"<e1>Dexamethasone</e1> (DXM) decreased the expression of CXCL-8, <e2>VEGF</e2>, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"<e1>Dexamethasone</e1> (DXM) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (<e1>DXM</e1>) decreased the expression of <e2>CXCL-8</e2>, VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (<e1>DXM</e1>) decreased the expression of CXCL-8, <e2>VEGF</e2>, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (<e1>DXM</e1>) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while <e1>1400W dihydrochloride</e1> (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and <e2>iNOS</e2> induced by reIL-4, while <e1>1400W</e1> dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS.","Downregulator"
"To address this issue and taking into account that effects of synthetic <e1>progestins</e1> are not only referable to action through the <e2>progesterone receptor</e2> but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity.","Not"
"To address this issue and taking into account that effects of synthetic <e1>progestins</e1> are not only referable to action through the progesterone receptor but may also be mediated by other <e2>steroid receptors</e2>, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity.","Regulator"
"The beneficial role of <e1>17beta-estradiol</e1> on blood pressure, cardiac hypertrophy, vascular <e2>osteopontin</e2> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate.","Upregulator"
"The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular <e2>osteopontin</e2> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of <e1>medroxyprogesterone acetate</e1>.","Downregulator"
"Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the <e2>GluN1</e2>/GluN2B <e1>amino</e1> terminal domain dimer by an induced-fit mechanism.","Part_of"
"Interestingly, recent crystallographic evidence identified that ifenprodil, unlike zinc, binds at the interface of the GluN1/<e2>GluN2B</e2> <e1>amino</e1> terminal domain dimer by an induced-fit mechanism.","Part_of"
"Interestingly, recent crystallographic evidence identified that <e1>ifenprodil,</e1> unlike zinc, binds at the interface of the <e2>GluN1</e2>/GluN2B amino terminal domain dimer by an induced-fit mechanism.","Regulator"
"Interestingly, recent crystallographic evidence identified that <e1>ifenprodil,</e1> unlike zinc, binds at the interface of the GluN1/<e2>GluN2B</e2> amino terminal domain dimer by an induced-fit mechanism.","Regulator"
"Effect of <e1>ifenprodil</e1> on <e2>GluN1</e2>/GluN2B N-methyl-D-aspartate receptor gating.","Regulator"
"Effect of <e1>ifenprodil</e1> on GluN1/<e2>GluN2B</e2> N-methyl-D-aspartate receptor gating.","Regulator"
"Interestingly, recent crystallographic evidence identified that ifenprodil, unlike <e1>zinc</e1>, binds at the interface of the <e2>GluN1</e2>/GluN2B amino terminal domain dimer by an induced-fit mechanism.","Regulator"
"We found distinct differences in the action of ifenprodil at GluN1/GluN2B in comparison with previous studies on the effect of <e1>zinc</e1> on GluN1/<e2>GluN2A</e2> gating, which may arise due to their unique binding sites.","Regulator"
"Effect of <e1>ifenprodil</e1> on <e2>GluN1</e2>/GluN2B N-methyl-D-aspartate receptor gating.","Downregulator"
"Effect of <e1>ifenprodil</e1> on GluN1/<e2>GluN2B</e2> N-methyl-D-aspartate receptor gating.","Downregulator"
"<e1>Ifenprodil</e1> is an allosteric inhibitor of <e2>GluN1</e2>/GluN2B N-methyl-D-aspartate receptors.","Modulator"
"<e1>Ifenprodil</e1> is an allosteric inhibitor of GluN1/<e2>GluN2B</e2> N-methyl-D-aspartate receptors.","Modulator"
"<e1>Ifenprodil</e1> is an allosteric inhibitor of GluN1/GluN2B <e2>N-methyl-D-aspartate receptors</e2>.","Modulator"
"High <e1>glucose</e1> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates <e2>mTOR</e2>.","Upregulator"
"High <e1>glucose</e1> (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates <e2>tuberin</e2> and activates mTOR.","Downregulator"
"Inhibition of mTOR by low dose <e1>rapamycin</e1> decreases HG-induced <e2>Nox4</e2> and Nox1, NADPH oxidase activity and podocyte apoptosis.","Downregulator"
"Inhibition of mTOR by low dose <e1>rapamycin</e1> decreases HG-induced Nox4 and <e2>Nox1</e2>, NADPH oxidase activity and podocyte apoptosis.","Downregulator"
"Pharmacological doses of the <e2>mTOR</e2> inhibitor <e1>rapamycin</e1> reduce albuminura in diabetes.","Downregulator"
"High <e1>glucose</e1> (HG) induces apoptosis of podocytes, inhibits <e2>AMPK</e2> activation, inactivates tuberin and activates mTOR.","Downregulator"
"Pharmacological doses of the <e2>mTOR</e2> inhibitor <e1>rapamycin</e1> reduce albuminura in diabetes.","Downregulator"
"Inhibition of mTOR by low dose <e1>rapamycin</e1> decreases HG-induced Nox4 and Nox1, <e2>NADPH oxidase</e2> activity and podocyte apoptosis.","Downregulator"
"Pharmacological doses of the <e2>mTOR</e2> inhibitor <e1>rapamycin</e1> reduce albuminura in diabetes.","Downregulator"
"Two beta(2)-agonists, <e1>formoterol</e1> and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>beta(2)-adrenoceptor</e2> selectivity.","Regulator"
"Two beta(2)-agonists, formoterol and <e1>salmeterol</e1>, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>beta(2)-adrenoceptor</e2> selectivity.","Regulator"
"A dose of 25 microg kg(-1) day(-1) of <e1>formoterol</e1> elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar <e2>beta-adrenoceptor</e2> downregulation.","Downregulator"
"A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than <e1>salmeterol</e1>, but resulted in similar <e2>beta-adrenoceptor</e2> downregulation.","Downregulator"
"Two beta(2)-agonists, <e1>formoterol</e1> and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>beta(2)-adrenoceptor</e2> selectivity.","Agonist"
"Two beta(2)-agonists, formoterol and <e1>salmeterol</e1>, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater <e2>beta(2)-adrenoceptor</e2> selectivity.","Agonist"
"Systemic administration of <e2>beta2-adrenoceptor</e2> agonists, <e1>formoterol</e1> and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.","Agonist"
"Systemic administration of <e2>beta2-adrenoceptor</e2> agonists, formoterol and <e1>salmeterol</e1>, elicit skeletal muscle hypertrophy in rats at micromolar doses.","Agonist"
"<e1>Acarbose</e1>, an <e2>alpha-glucosidase</e2> inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia.","Downregulator"
"Clinical utility of <e1>acarbose</e1>, an <e2>alpha-glucosidase</e2> inhibitor in cardiometabolic disorders.","Downregulator"
"The values of mean corpuscular <e2>hemoglobin</e2> concentration and mean corpuscular hemoglobin increased in the <e1>STX</e1> group.","Upregulator"
"The values of mean corpuscular <e2>hemoglobin</e2> concentration and mean corpuscular hemoglobin increased in the <e1>STX</e1> group.","Upregulator"
"First, we showed that intracerebroventricular administration of <e1>glucose</e1> in rats increases <e2>DBI</e2> expression in hypothalamic glial-like tanycytes.","Upregulator"
"The dimeric <e1>C</e1>-terminal deletion mutant (Delta473-528) of <e2>hTH1</e2> also showed negative cooperativity of H4biopterin binding (h = 0.4).","Part_of"
"On phosphorylation of Ser40 by <e2>protein kinase A</e2>, the affinity for <e1>H4biopterin</e1> increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).","Regulator"
"<e2>Tyrosine hydroxylase</e2> binds <e1>tetrahydrobiopterin</e1> cofactor with negative cooperativity, as shown by kinetic analyses and surface plasmon resonance detection.","Regulator"
"The dimeric C-terminal deletion mutant (Delta473-528) of <e2>hTH1</e2> also showed negative cooperativity of <e1>H4biopterin</e1> binding (h = 0.4).","Regulator"
"Infrared spectroscopic studies revealed a reduced thermal stability both of the apo-and the holo-<e2>hTH1</e2> on binding of H4biopterin and <e1>Lerythro-dihydrobiopterin</e1> (H2biopterin).","Regulator"
"Infrared spectroscopic studies revealed a reduced thermal stability both of the apo-and the holo-<e2>hTH1</e2> on binding of H4biopterin and Lerythro-dihydrobiopterin (<e1>H2biopterin</e1>).","Regulator"
"The dimeric C-terminal deletion mutant (Delta473-528) of h<e2>TH</e2>1 also showed negative cooperativity of <e1>H4biopterin</e1> binding (h = 0.4).","Regulator"
"The dimeric C-terminal deletion mutant (Delta473-528) of <e2>hTH1</e2> also showed negative cooperativity of <e1>H4biopterin</e1> binding (h = 0.4).","Regulator"
"On phosphorylation of <e1>Ser40</e1> by <e2>protein kinase A</e2>, the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03).","Substrate"
"<e1>Valdecoxib</e1> is a potent and specific inhibitor of <e2>cyclooxygenase-2</e2>, which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain.","Downregulator"
"Disposition of a specific <e2>cyclooxygenase-2</e2> inhibitor, <e1>valdecoxib</e1>, in human.","Downregulator"
"In addition, <e1>Silibinin</e1> caused an increase in <e2>p53</e2> and p21 protein level as well as mRNA levels.","Upregulator"
"In addition, <e1>Silibinin</e1> caused an increase in p53 and <e2>p21</e2> protein level as well as mRNA levels.","Upregulator"
"In mechanistic studies, <e1>Silibinin</e1> decreased the protein level of <e2>p34cdc2</e2>, which might be the possible molecular mechanism of Silibinin efficacy on the growth inhibition in SGC-7901 cells.","Downregulator"
"Western blot analyses showed significant effects of <e1>Pb</e1> exposure on <e2>DNMT1</e2>, DNMT3a, and MeCP2 expression, with effects often seen at the lowest level of exposure and modified by sex and developmental window of Pb exposure.","Regulator"
"Western blot analyses showed significant effects of <e1>Pb</e1> exposure on DNMT1, <e2>DNMT3a</e2>, and MeCP2 expression, with effects often seen at the lowest level of exposure and modified by sex and developmental window of Pb exposure.","Regulator"
"Western blot analyses showed significant effects of <e1>Pb</e1> exposure on DNMT1, DNMT3a, and <e2>MeCP2</e2> expression, with effects often seen at the lowest level of exposure and modified by sex and developmental window of Pb exposure.","Regulator"
"Since DNA methylation is regulated by <e2>DNA methyltransferases</e2> and methyl cytosine-binding proteins, this study assessed the extent to which developmental <e1>Pb</e1> exposure might affect expression of these proteins in the hippocampus.","Regulator"
"Since DNA methylation is regulated by DNA methyltransferases and <e2>methyl cytosine-binding proteins</e2>, this study assessed the extent to which developmental <e1>Pb</e1> exposure might affect expression of these proteins in the hippocampus.","Regulator"
"The interaction between <e2>mGluR1</e2> and the calcium channel <e1>C</e1>av₂.₁ preserves coupling in the presence of long Homer proteins.","Part_of"
"This localization is in turn dependent on the Homer family of scaffolding proteins which bind to a small motif on the distal <e1>C</e1>-termini of <e2>mGluR1 and 5</e2>, localize the receptors near the PSD, strengthen coupling to post-synaptic effectors and simultaneously uncouple the mGluRs from extra-synaptic effectors such as voltage dependent ion channels.","Part_of"
"The alpha class human GSTA4-4 enzyme (<e2>hGSTA4</e2>-4) has a particularly high catalytic efficiency toward <e1>4-HNE</e1> conjugation.","Not"
"The alpha class human GSTA4-4 enzyme (<e2>hGSTA4</e2>-4) has a particularly high catalytic efficiency toward <e1>4-HNE</e1> conjugation.","Not"
"4-Hydroxynonenal (<e1>4-HNE</e1>) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GST</e2>) isoforms.","Substrate"
"4-Hydroxynonenal (<e1>4-HNE</e1>) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <e2>glutathione S-transferase</e2> (GST) isoforms.","Substrate"
"4-Hydroxynonenal (<e1>4-HNE</e1>) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GST</e2>) isoforms.","Substrate"
"The alpha class human GSTA4-4 enzyme (<e2>hGSTA4</e2>-4) has a particularly high catalytic efficiency toward <e1>4-HNE</e1> conjugation.","Substrate"
"<e1>4-Hydroxynonenal</e1> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several <e2>glutathione S-transferase</e2> (GST) isoforms.","Substrate"
"<e1>4-Hydroxynonenal</e1> (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GST</e2>) isoforms.","Substrate"
"The alpha class <e2>human GSTA4-4</e2> enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward <e1>4-HNE</e1> conjugation.","Substrate"
"The alpha class human GSTA4-4 enzyme (<e2>hGSTA4-4</e2>) has a particularly high catalytic efficiency toward <e1>4-HNE</e1> conjugation.","Substrate"
"4-Hydroxynonenal (4-HNE) is a mutagenic <e1>alpha,beta-unsaturated aldehyde</e1> produced during oxidative injury that is conjugated by several <e2>glutathione S-transferase</e2> (GST) isoforms.","Substrate"
"4-Hydroxynonenal (4-HNE) is a mutagenic <e1>alpha,beta-unsaturated aldehyde</e1> produced during oxidative injury that is conjugated by several glutathione S-transferase (<e2>GST</e2>) isoforms.","Substrate"
"HepG2 cells transfected with an hGSTA4 vector construct exhibited high steady-state hGSTA4 mRNA, high GST-<e1>4-HNE</e1> catalytic activities, but lower basal glutathione (GSH) concentrations relative to insert-free vector (control) cells.","Substrate"
"The alpha class human GSTA4-4 enzyme (<e2>hGSTA4</e2>-4) has a particularly high catalytic efficiency toward <e1>4-HNE</e1> conjugation.","Substrate"
"The alpha class human GSTA4-4 enzyme (<e2>hGSTA4</e2>-4) has a particularly high catalytic efficiency toward <e1>4-HNE</e1> conjugation.","Substrate"
"db/db mice treated with <e1>DRF 2655</e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes <e2>carnitine palmitoyltransferase</e2> and carnitine acetyltransferase, respectively.","Upregulator"
"db/db mice treated with <e1>DRF 2655</e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and <e2>carnitine acetyltransferase</e2>, respectively.","Upregulator"
"db/db mice treated with <e1>DRF 2655</e1> showed 5- and 3.6-fold inhibition in <e2>phosphoenolpyruvate carboxykinase</e2> and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.","Downregulator"
"db/db mice treated with <e1>DRF 2655</e1> showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and <e2>glucose 6-phosphatase</e2> activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.","Downregulator"
"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655</e1>, a peroxisome proliferator-activated receptor alpha (<e2>PPARalpha</e2>) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.","Agonist"
"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655</e1>, a peroxisome proliferator-activated receptor alpha (PPARalpha) and <e2>PPARgamma</e2> agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.","Agonist"
"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655</e1>, a peroxisome proliferator-activated receptor alpha (PPARalpha) and <e2>PPARgamma</e2> agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.","Agonist"
"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655</e1>, a <e2>peroxisome proliferator-activated receptor alpha</e2> (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.","Agonist"
"OBJECTIVE: Preclinical evaluation of <e1>DRF 2655</e1>, a peroxisome proliferator-activated receptor alpha (<e2>PPARalpha</e2>) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.","Agonist"
"<e1>Indomethacin</e1> inhibited both <e2>hCOX-1</e2> and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.","Downregulator"
"<e1>Indomethacin</e1> inhibited both hCOX-1 and <e2>hCOX-2</e2>, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.","Downregulator"
"Indomethacin inhibited both hCOX-1 and <e2>hCOX-2</e2>, whereas <e1>NS-398</e1> and Dup-697 selectively inhibited hCOX-2.","Downregulator"
"Indomethacin inhibited both hCOX-1 and <e2>hCOX-2</e2>, whereas NS-398 and <e1>Dup-697</e1> selectively inhibited hCOX-2.","Downregulator"
"Indomethacin inhibited both hCOX-1 and <e2>hCOX-2</e2>, whereas <e1>NS-398</e1> and Dup-697 selectively inhibited hCOX-2.","Downregulator"
"Indomethacin inhibited both hCOX-1 and <e2>hCOX-2</e2>, whereas NS-398 and <e1>Dup-697</e1> selectively inhibited hCOX-2.","Downregulator"
"Both NS-398 and Dup-697 exhibited time-dependent inactivation of <e2>hCOX-2</e2>, as did <e1>indomethacin</e1> on both enzymes.","Downregulator"
"The competitive inhibitor of <e2>hCOX-1</e2>, <e1>mefenamic acid</e1>, also displayed competitive inhibition of hCOX-2.","Downregulator"
"The competitive inhibitor of hCOX-1, <e1>mefenamic acid</e1>, also displayed competitive inhibition of <e2>hCOX-2</e2>.","Downregulator"
"The enzyme <e2>cyclo-oxygenase</e2> catalyses the oxygenation of arachidonic acid, leading to the formation of <e1>prostaglandins</e1>.","Substrate"
"The enzyme <e2>cyclo-oxygenase</e2> catalyses the oxygenation of <e1>arachidonic acid</e1>, leading to the formation of prostaglandins.","Substrate"
"<e2>hCOX-1</e2> had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for <e1>arachidonate</e1> and Vmax.","Substrate"
"of 1500 nmol of O2/nmol of enzyme, whereas <e2>hCOX-2</e2> had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for <e1>arachidonate</e1> and a Vmax.","Substrate"
"In the present study, we determined the dose-response effects of doxycycline and <e1>minocycline</e1> on cerebral <e2>MMP-9</e2> using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain.","Regulator"
"In the present study, we determined the dose-response effects of <e1>doxycycline</e1> and minocycline on cerebral <e2>MMP-9</e2> using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain.","Downregulator"
"<e1>Minocycline</e1> showed more potent inhibition on <e2>MMP-9</e2> mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day.","Downregulator"
"In the present study, we determined the dose-response effects of <e1>doxycycline</e1> and minocycline on cerebral <e2>MMP-9</e2> using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain.","Downregulator"
"We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the <e2>MMP-9</e2> inhibition by <e1>tetracyclines</e1>.","Downregulator"
"In the present study, we determined the dose-response effects of doxycycline and <e1>minocycline</e1> on cerebral <e2>MMP-9</e2> using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain.","Downregulator"
"In the present study, we determined the dose-response effects of <e1>doxycycline</e1> and minocycline on cerebral <e2>MMP-9</e2> using our mouse model with VEGF focal hyperstimulation delivered with adenoviral vector (AdVEGF) in the brain.","Downregulator"
"We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the <e2>MMP-9</e2> inhibition by <e1>tetracyclines</e1>.","Downregulator"
"<e1>Doxycycline</e1> was shown to decrease cerebral <e2>MMP-9</e2> activities and angiogenesis induced by vascular endothelial growth factor (VEGF).","Downregulator"
"<e1>Doxycycline</e1> was shown to decrease cerebral MMP-9 activities and angiogenesis induced by <e2>vascular endothelial growth factor</e2> (VEGF).","Downregulator"
"<e1>Doxycycline</e1> was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (<e2>VEGF</e2>).","Downregulator"
"The ratio between the GDC/<e2>SHMT</e2> and C1-THF synthase/SHMT pathways of <e1>Ser</e1> synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.","Substrate"
"The ratio between the GDC/<e2>SHMT</e2> and C1-THF synthase/SHMT pathways of <e1>Ser</e1> synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.","Substrate"
"The ratio between the GDC/<e2>SHMT</e2> and C1-THF synthase/SHMT pathways of <e1>Ser</e1> synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.","Substrate"
"We concluded that <e2>FDH</e2> has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to <e1>CO(2)</e1> by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis.","Substrate"
"The ratio between the <e2>GDC</e2>/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from <e1>[alpha-(13)C]Gly</e1> and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.","Substrate"
"The ratio between the GDC/SHMT and <e2>C1-THF synthase</e2>/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and <e1>[(13)C]formate</e1>, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e1>glycine</e1> decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e1>glycine</e1> decarboxylase complex (<e2>GDC</e2>, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e1>glycine</e1> decarboxylase complex (GDC, <e2>EC 2.1.1.10</e2>) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e1>glycine</e1> decarboxylase complex (GDC, EC 2.1.1.10) and <e2>serine hydroxymethyltransferase</e2> (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e1>glycine</e1> decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<e2>SHMT</e2>, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e1>glycine</e1> decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <e2>EC 2.1.2.1</e2>) with glycine (Gly) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the <e2>glycine decarboxylase complex</e2> (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>Gly</e1>) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (<e2>GDC</e2>, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>Gly</e1>) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, <e2>EC 2.1.1.10</e2>) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (<e1>Gly</e1>) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and <e2>serine hydroxymethyltransferase</e2> (SHMT, EC 2.1.2.1) with glycine (<e1>Gly</e1>) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (<e2>SHMT</e2>, EC 2.1.2.1) with glycine (<e1>Gly</e1>) as one-carbon (1-C) source.","Substrate"
"One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, <e2>EC 2.1.2.1</e2>) with glycine (<e1>Gly</e1>) as one-carbon (1-C) source.","Substrate"
"An alternative THF-dependent pathway involves the <e2>C1-THF synthase</e2>/SHMT activities with <e1>formate</e1> as 1-C source.","Substrate"
"An alternative THF-dependent pathway involves the C1-THF synthase/<e2>SHMT</e2> activities with <e1>formate</e1> as 1-C source.","Substrate"
"Firstly, transgenic plants overexpressing <e1>formate</e1> dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism.","Substrate"
"Firstly, transgenic plants overexpressing <e1>formate</e1> dehydrogenase (<e2>FDH</e2>, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism.","Substrate"
"Firstly, transgenic plants overexpressing <e1>formate</e1> dehydrogenase (FDH, <e2>EC 1.2.1.2</e2>) were used to continue our previous studies on the function of FDH in formate metabolism.","Substrate"
"Firstly, transgenic plants overexpressing <e1>formate</e1> dehydrogenase (<e2>FDH</e2>, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism.","Substrate"
"Firstly, transgenic plants overexpressing <e1>formate</e1> dehydrogenase (<e2>FDH</e2>, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism.","Substrate"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (<e1>SoRI-9804</e1>), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), <e1>N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine</e1> (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (<e1>SoRI-20040</e1>), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and <e1>N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine</e1> (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (<e1>SoRI-20041</e1>) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited <e1>[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester</e1> (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (<e1>RTI-55</e1>) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of <e1>[(125)I]RTI-55</e1> from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited <e1>[(3)H]dopamine</e1> uptake.","Regulator"
"<e1>N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine</e1> (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (<e1>SoRI-20041</e1>) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the <e2>DAT</e2>, and partially inhibited [(3)H]dopamine uptake.","Regulator"
"<e2>beta2AR</e2> density measured with [3H]dihydroalprenolol (<e1>[3H]DHA</e1>) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.","Regulator"
"<e2>beta2AR</e2> density measured with [3H]dihydroalprenolol (<e1>[3H]DHA</e1>) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.","Regulator"
"Agonist competition assays with [3H]DHA showed the following rank order of potency: <e1>isoproterenol</e1>>epinephrine> norepinephrine, consistent with <e2>beta2AR</e2> interaction.","Regulator"
"Agonist competition assays with [3H]DHA showed the following rank order of potency: isoproterenol><e1>epinephrine</e1>> norepinephrine, consistent with <e2>beta2AR</e2> interaction.","Regulator"
"Agonist competition assays with [3H]DHA showed the following rank order of potency: isoproterenol>epinephrine> <e1>norepinephrine</e1>, consistent with <e2>beta2AR</e2> interaction.","Regulator"
"<e2>beta2AR</e2> density measured with <e1>[3H]dihydroalprenolol</e1> ([3H]DHA) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.","Regulator"
"<e2>beta2AR</e2> density measured with [3H]dihydroalprenolol (<e1>[3H]DHA</e1>) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.","Regulator"
"Agonist competition assays with [3H]DHA showed the following rank order of potency: <e1>isoproterenol</e1>>epinephrine> norepinephrine, consistent with <e2>beta2AR</e2> interaction.","Regulator"
"BACKGROUND: <e1>Rivastigmine</e1> is a carbamate drug designed to inhibit both <e2>acetylcholinesterase</e2> and butyrylcholinesterase by reversibly covalently bonding to these enzymes.","Downregulator"
"BACKGROUND: <e1>Rivastigmine</e1> is a carbamate drug designed to inhibit both acetylcholinesterase and <e2>butyrylcholinesterase</e2> by reversibly covalently bonding to these enzymes.","Downregulator"
"BACKGROUND: Rivastigmine is a <e1>carbamate</e1> drug designed to inhibit both <e2>acetylcholinesterase</e2> and butyrylcholinesterase by reversibly covalently bonding to these enzymes.","Downregulator"
"BACKGROUND: Rivastigmine is a <e1>carbamate</e1> drug designed to inhibit both acetylcholinesterase and <e2>butyrylcholinesterase</e2> by reversibly covalently bonding to these enzymes.","Downregulator"
"The therapeutic potential of allosteric ligands for free <e1>fatty acid</e1> sensitive <e2>GPCRs</e2>.","Regulator"
"The therapeutic potential of allosteric ligands for free <e1>fatty acid</e1> sensitive <e2>GPCRs</e2>.","Regulator"
"Glioma cell sensitivity to <e1>topotecan</e1>: the role of <e2>p53</e2> and topotecan-induced DNA damage.","Not"
"Glioma cell sensitivity to <e1>topotecan</e1>: the role of <e2>p53</e2> and topotecan-induced DNA damage.","Regulator"
"High p53 protein levels, but not genetic or functional p53 status, were associated with increased <e1>topotecan</e1>-induced DNA/<e2>topoisomerase I</e2> complex formation.","Regulator"
"High p53 protein levels, but not genetic or functional p53 status, were associated with increased <e1>topotecan</e1>-induced DNA/<e2>topoisomerase I</e2> complex formation.","Regulator"
"Glioma cell sensitivity to <e1>topotecan</e1>: the role of <e2>p53</e2> and topotecan-induced DNA damage.","Upregulator"
"<e1>Topotecan</e1> is a <e2>topoisomerase I</e2> inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.","Downregulator"
"<e1>Amiloride</e1> is a specific inhibitor of uPA but does not inhibit <e2>tPA</e2>.","Not"
"Significant differences were observed in a different region (loop B93-B101), that we identified as binding site of <e1>amiloride</e1> to the <e2>tissue plasminogen activator</e2> (tPA).","Regulator"
"Significant differences were observed in a different region (loop B93-B101), that we identified as binding site of <e1>amiloride</e1> to the tissue plasminogen activator (<e2>tPA</e2>).","Regulator"
"By theoretical calculations we have determined most probable structure of <e1>amiloride</e1>/<e2>uPAs</e2> complexes.","Regulator"
"Binding site of <e1>amiloride</e1> to <e2>urokinase plasminogen activator</e2> depends on species.","Regulator"
"<e1>Amiloride</e1> is a specific inhibitor of <e2>uPA</e2> but does not inhibit tPA.","Downregulator"
"The inhibitory effect of <e2>endothelin-1</e2> on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist <e1>RES 701-1</e1>, by indomethacin, or by glibenclamide.","Regulator"
"The inhibitory effect of <e2>endothelin-1</e2> on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by <e1>indomethacin</e1>, or by glibenclamide.","Regulator"
"The inhibitory effect of <e2>endothelin-1</e2> on the contraction induced by 5-HT is abolished by deendothelialization, by the endothelin ET(B) receptor antagonist RES 701-1, by indomethacin, or by <e1>glibenclamide</e1>.","Regulator"
"The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the <e2>endothelin ET(B) receptor</e2> antagonist <e1>RES 701-1</e1>, by indomethacin, or by glibenclamide.","Antagonist"
"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <e2>thromboxane A2 receptor</e2> antagonists <e1>GR32191</e1> and ridogrel.","Antagonist"
"The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the <e2>thromboxane A2 receptor</e2> antagonists GR32191 and <e1>ridogrel</e1>.","Antagonist"
"It remains to be fully elucidated whether use of <e1>metformin</e1>, an <e2>insulin</e2> sensitizer, and/or sulfonylureas, insulin secretagogues, affect cancer incidence in subjects with T2DM.","Regulator"
"It remains to be fully elucidated whether use of metformin, an <e2>insulin</e2> sensitizer, and/or <e1>sulfonylureas</e1>, insulin secretagogues, affect cancer incidence in subjects with T2DM.","Regulator"
"A novel class of <e1>quinoxalines</e1> has been discovered as antagonists of the <e2>IgG</e2>:FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.","Antagonist"
"A novel class of <e1>quinoxalines</e1> has been discovered as antagonists of the IgG:<e2>FcRn</e2> protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.","Antagonist"
"<e1>Agmatine</e1>, locally synthesized, is an endogenous agonist at imidazoline receptors, a noncatecholamine ligand at <e2>alpha 2-adrenergic receptors</e2> and may act as a neurotransmitter.","Regulator"
"<e1>Clonidine</e1>, an antihypertensive drug, binds to <e2>alpha 2-adrenergic and imidazoline receptors</e2>.","Regulator"
"The endogenous ligand for <e2>imidazoline receptors</e2> may be a <e1>clonidine</e1>-displacing substance, a small molecule isolated from bovine brain.","Regulator"
"<e1>Agmatine</e1> binds to <e2>alpha 2-adrenergic and imidazoline receptors</e2> and stimulates release of catecholamines from adrenal chromaffin cells.","Regulator"
"<e1>Agmatine</e1> binds to alpha 2-adrenergic and <e2>imidazoline receptors</e2> and stimulates release of catecholamines from adrenal chromaffin cells.","Agonist"
"(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (<e1>GSK2251052</e1>) is a novel boron-containing antibiotic that inhibits <e2>bacterial leucyl tRNA synthetase</e2>, and that has been in development for the treatment of serious Gram-negative infections.","Downregulator"
"<e1>(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole</e1> (GSK2251052) is a novel boron-containing antibiotic that inhibits <e2>bacterial leucyl tRNA synthetase</e2>, and that has been in development for the treatment of serious Gram-negative infections.","Downregulator"
"A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor <e1>4-methylpyrazole</e1> provided strong evidence that <e2>alcohol dehydrogenase</e2>, potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.","Downregulator"
"In addition, ATM7 potentiates <e1>3,4-methylenedioxy-N-methylamphetamine</e1> (MDMA, ""Ecstasy"")-induced reversed transport by <e2>SERT</e2>.","Regulator"
"In addition, ATM7 potentiates 3,4-methylenedioxy-N-methylamphetamine (<e1>MDMA</e1>, ""Ecstasy"")-induced reversed transport by <e2>SERT</e2>.","Regulator"
"Serotonin transporters (<e2>SERT</e2>) play an essential role in the termination and regulation of <e1>serotonin</e1> signaling in the brain.","Substrate"
"Serotonin transporters (<e2>SERT</e2>) play an essential role in the termination and regulation of <e1>serotonin</e1> signaling in the brain.","Substrate"
"Serotonin transporters (<e2>SERT</e2>) play an essential role in the termination and regulation of <e1>serotonin</e1> signaling in the brain.","Substrate"
"Notably, the introduction of the F723A mutation greatly enhanced the <e1>gefitinib</e1> sensitivity of the wild-type <e2>EGFR</e2> in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.","Undefined"
"In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers <e1>gefitinib</e1> resistance on the <e2>G719S</e2> mutant.","Not"
"The <e1>Met</e1>790 side chain of the <e2>G719S</e2>/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.","Part_of"
"The <e1>Met</e1>790 side chain of the G719S/<e2>T790M</e2> double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.","Part_of"
"In the <e2>L858R</e2> mutant structure, the active-site cleft is expanded by the repositioning of <e1>Phe</e1>723 within the P-loop.","Part_of"
"In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers <e1>gefitinib</e1> resistance on the <e2>G719S</e2> mutant.","Regulator"
"In this study, our biochemical analyses revealed that the introduction of the <e2>T790M</e2> mutation confers <e1>gefitinib</e1> resistance on the G719S mutant.","Regulator"
"The T790M mutation increases the <e1>ATP</e1> affinity of the <e2>G719S</e2> mutant, explaining the acquired drug resistance of the double mutant.","Regulator"
"Notably, the introduction of the <e2>F723A</e2> mutation greatly enhanced the <e1>gefitinib</e1> sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.","Regulator"
"They display sensitivity to <e2>TK</e2> inhibitors, including <e1>gefitinib</e1> and erlotinib.","Downregulator"
"They display sensitivity to <e2>TK</e2> inhibitors, including gefitinib and <e1>erlotinib</e1>.","Downregulator"
"Among the [Fe-S] cluster biosynthetic proteins are included a <e1>pyridoxal phosphate</e1>-dependent enzyme (<e2>NifS</e2>) that is involved in the activation of sulphur from l-cysteine, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.","Cofactor"
"Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (<e2>NifS</e2>) that is involved in the activation of sulphur from <e1>l-cysteine</e1>, and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.","Substrate"
"The protein is formed by an <e1>N</e1>-terminal helicase-like domain, a C-terminal DNA polymerase domain, and a large central domain that spans between the two.","Part_of"
"The protein is formed by an N-terminal helicase-like domain, a <e1>C</e1>-terminal DNA polymerase domain, and a large central domain that spans between the two.","Part_of"
"Impaired in vivo binding of <e2>MeCP2</e2> to chromatin in the absence of its D<e1>N</e1>A methyl-binding domain.","Part_of"
"Impaired in vivo binding of <e2>MeCP2</e2> to chromatin in the absence of its D<e1>N</e1>A methyl-binding domain.","Part_of"
"Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the <e1>amiloride</e1>-sensitive epithelial sodium channel (ENaC).","Regulator"
"Thus far, PHA1 has been attributed to mutations affecting the mineralocorticoid receptor or any of the three subunits assembling the <e1>amiloride</e1>-sensitive epithelial sodium channel (<e2>ENaC</e2>).","Regulator"
"In vivo genotoxicity of <e1>methyleugenol</e1> in <e2>gpt</e2> delta transgenic rats following medium-term exposure.","Regulator"
"In this study, a <e2>gpt</e2> delta transgenic rat model was used to clarify whether genotoxic mechanisms are involved in <e1>MEG</e1>-induced hepatocarcinogenesis following medium-term exposure.","Regulator"
"In addition, the number and area of <e2>glutathione S-transferase placental form</e2> (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg <e1>MEG</e1> compared with the control animals.","Upregulator"
"In addition, the number and area of glutathione S-transferase placental form (<e2>GST-P</e2>) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg <e1>MEG</e1> compared with the control animals.","Upregulator"
"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and <e2>proliferating cell nuclear antigen</e2> (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg <e1>MEG</e1> compared with the control animals.","Upregulator"
"In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (<e2>PCNA</e2>) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg <e1>MEG</e1> compared with the control animals.","Upregulator"
"Chronic consumption of <e1>alcohol</e1> also stimulated abrupt increases in pro-inflammatory cytokines such as <e2>nuclear factor (NF)-κB</e2>, tumor necrosis factor (TNF)-α and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.","Upregulator"
"Chronic consumption of <e1>alcohol</e1> also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-κB, <e2>tumor necrosis factor (TNF)-α</e2> and interleukin (IL)-1β in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.","Upregulator"
"Chronic consumption of <e1>alcohol</e1> also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-κB, tumor necrosis factor (TNF)-α and <e2>interleukin (IL)-1β</e2> in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.","Upregulator"
"Consumption of <e1>alcohol</e1> for 8weeks induced severe liver damage with increases in prognostic indicators such as <e2>aspartate transaminase</e2>, alanine transaminase in serum whereas co-administration of CNF suppressed their increases.","Upregulator"
"Consumption of <e1>alcohol</e1> for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase, <e2>alanine transaminase</e2> in serum whereas co-administration of CNF suppressed their increases.","Upregulator"
"Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including <e2>insulin</e2> resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (<e1>EPA</e1>) and docosahexaenoic acid (DHA).","Upregulator"
"Notably, <e1>17-HDHA</e1> treatment reduced adipose tissue expression of inflammatory cytokines, increased <e2>adiponectin</e2> expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.","Upregulator"
"Notably, <e1>17-HDHA</e1> treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to <e2>insulin</e2> sensitivity in obese mice.","Upregulator"
"Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including <e2>insulin</e2> resistance and type 2 diabetes.Chronic inflammation may be a consequence of a failure to actively resolve inflammation,and could result from a lack of local specialized pro-resolving lipid mediators (SPM) such as resolvins and protectins, which derive from the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (<e1>DHA</e1>).","Upregulator"
"Notably, <e1>17-HDHA</e1> treatment reduced adipose tissue expression of inflammatory <e2>cytokines</e2>, increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.","Downregulator"
"The glycogen synthase kinase-3β/<e2>nuclear factor-kappa B</e2> pathway is involved in <e1>cinobufagin</e1>-induced apoptosis in cultured osteosarcoma cells.","Regulator"
"The <e2>glycogen synthase kinase-3β</e2>/nuclear factor-kappa B pathway is involved in <e1>cinobufagin</e1>-induced apoptosis in cultured osteosarcoma cells.","Regulator"
"Furthermore, we validated the inhibition of <e2>GSK-3β</e2>/NF-κB signaling following <e1>cinobufagin</e1> treatment.","Regulator"
"Furthermore, we validated the inhibition of GSK-3β/<e2>NF-κB</e2> signaling following <e1>cinobufagin</e1> treatment.","Regulator"
"Furthermore, we validated the inhibition of <e2>GSK-3β</e2>/NF-κB signaling following <e1>cinobufagin</e1> treatment.","Upregulator"
"Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-<e2>PARP</e2> that are induced by <e1>cinobufagin</e1> treatment.","Upregulator"
"Transduction with constitutively active forms of GSK-3β could protect against the downregulation of p65 and upregulation of cleaved-<e2>PARP</e2> that are induced by <e1>cinobufagin</e1> treatment.","Upregulator"
"However, combined treatment with cinobufagin and <e1>SB216367</e1> resulted in a significant reduction in p65 and an increase in cleaved-<e2>PARP</e2> in U2OS cells.","Upregulator"
"Furthermore, we validated the inhibition of <e2>GSK-3β</e2>/NF-κB signaling following <e1>cinobufagin</e1> treatment.","Downregulator"
"Furthermore, we validated the inhibition of GSK-3β/<e2>NF-κB</e2> signaling following <e1>cinobufagin</e1> treatment.","Downregulator"
"Western blots showed a decrease in nuclear <e2>p65</e2> protein expression after exposure to different concentrations of <e1>cinobufagin</e1>, while the phosphorylation of GSK-3β was simultaneously increased.","Downregulator"
"Western blots showed a decrease in nuclear <e2>p65</e2> protein expression after exposure to different concentrations of <e1>cinobufagin</e1>, while the phosphorylation of GSK-3β was simultaneously increased.","Downregulator"
"Western blots showed a decrease in nuclear <e2>p65</e2> protein expression after exposure to different concentrations of <e1>cinobufagin</e1>, while the phosphorylation of GSK-3β was simultaneously increased.","Downregulator"
"However, combined treatment with cinobufagin and <e1>SB216367</e1> resulted in a significant reduction in <e2>p65</e2> and an increase in cleaved-PARP in U2OS cells.","Downregulator"
"<e1>Arsenic</e1> activates <e2>endothelin-1</e2> Gi protein-coupled receptor signaling to inhibit stem cell differentiation in adipogenesis.","Regulator"
"We hypothesized that <e1>As(III)</e1> signals through the Pertussis toxin (Ptx) sensitive, Gi protein-coupled receptor (<e2>GPCR</e2>) to impair adipogenesis, as previously demonstrated for its stimulation of vascular oxidant generation, angiogenesis, and remodeling.","Regulator"
"Factor Xa or catalytically inactive <e1>5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-Gly-Arg-(DEGR)-chloromethylketone</e1>-<e2>factor Xa</e2> bound indistinguishably to HUVEC and EPR-1 transfectants, and inhibited equally well the binding of 125I-factor Xa to these cells.","Part_of"
"Factor Xa or catalytically inactive 5-dimethylaminonaphthalene-1sulfonyl (dansyl) Glu-<e1>Gly</e1>-Arg-(DEGR)-chloromethylketone-<e2>factor X</e2>a bound indistinguishably to HUVEC and EPR-1 transfectants, and inhibited equally well the binding of 125I-factor Xa to these cells.","Part_of"
"The major ingredient of ginger, <e1>[6]-gingerol</e1>, could inhibit <e2>angiotensin II type 1 receptor</e2> activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.","Downregulator"
"<e1>[6]-Gingerol</e1> derived from Zingiber officinale Roscoe (ginger) was identified as a novel <e2>angiotensin II type 1 receptor</e2> antagonist, with an IC50 value of 8.173 µM.","Antagonist"
"<e1>[6]-gingerol</e1>: a novel <e2>AT₁</e2> antagonist for the treatment of cardiovascular disease.","Antagonist"
"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of <e2>phenylalanine hydroxylase</e2>: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas <e1>N(5)-formyl</e1>- and N(5)-acetyl H(4)biopterin had no effect.","Not"
"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of <e2>phenylalanine hydroxylase</e2>: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and <e1>N(5)-acetyl H(4)biopterin</e1> had no effect.","Not"
"As compared with <e1>N(5)-methyl H(4)biopterin</e1>, N(5)-formyl H(4)biopterin bound with twice the capacity but stimulated <e2>nitric oxide synthase</e2> to a lesser extent.","Regulator"
"As compared with N(5)-methyl H(4)biopterin, <e1>N(5)-formyl H(4)biopterin</e1> bound with twice the capacity but stimulated <e2>nitric oxide synthase</e2> to a lesser extent.","Regulator"
"Here we compared the action of <e1>N(5)</e1>-substituted derivatives on recombinant <e2>rat neuronal nitric oxide synthase</e2> with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.","Regulator"
"Here we compared the action of <e1>N(5)</e1>-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on <e2>dihydropteridine reductase</e2> (EC 1.6.99.7) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.","Regulator"
"Here we compared the action of <e1>N(5)</e1>-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (<e2>EC 1.6.99.7</e2>) and phenylalanine hydroxylase (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.","Regulator"
"Here we compared the action of <e1>N(5)</e1>-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and <e2>phenylalanine hydroxylase</e2> (EC 1.14.16.1),the well-studied classical H(4)biopterin-dependent reactions.","Regulator"
"Here we compared the action of <e1>N(5)</e1>-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and phenylalanine hydroxylase (<e2>EC 1.14.16.1</e2>),the well-studied classical H(4)biopterin-dependent reactions.","Regulator"
"Contrasting effects of <e1>N5-substituted tetrahydrobiopterin</e1> derivatives on phenylalanine hydroxylase, <e2>dihydropteridine reductase</e2> and nitric oxide synthase.","Regulator"
"Contrasting effects of <e1>N5-substituted tetrahydrobiopterin</e1> derivatives on phenylalanine hydroxylase, dihydropteridine reductase and <e2>nitric oxide synthase</e2>.","Regulator"
"Contrasting effects of <e1>N5-substituted tetrahydrobiopterin</e1> derivatives on <e2>phenylalanine hydroxylase</e2>, dihydropteridine reductase and nitric oxide synthase.","Regulator"
"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of <e2>phenylalanine hydroxylase</e2>: <e1>N(5)-methyl</e1>- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.","Downregulator"
"N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of <e2>phenylalanine hydroxylase</e2>: N(5)-methyl- and <e1>N(5)-hydroxymethyl H(4)biopterin</e1> inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.","Downregulator"
"Here we compared the action of N(5)-substituted derivatives on recombinant rat neuronal nitric oxide synthase with their effects on dihydropteridine reductase (EC 1.6.99.7) and <e2>phenylalanine hydroxylase</e2> (EC 1.14.16.1),the well-studied classical <e1>H(4)biopterin</e1>-dependent reactions.","Downregulator"
"Tetrahydrobiopterin [(6R)-5,6,7,8-tetrahydro-L-biopterin, <e1>H(4)biopterin</e1>] is one of several cofactors of <e2>nitric oxide synthase</e2>s (EC 1.14.13.39).","Cofactor"
"<e1>Tetrahydrobiopterin</e1> [(6R)-5,6,7,8-tetrahydro-L-biopterin, H(4)biopterin] is one of several cofactors of <e2>nitric oxide synthases</e2> (EC 1.14.13.39).","Cofactor"
"<e1>Tetrahydrobiopterin</e1> [(6R)-5,6,7,8-tetrahydro-L-biopterin, H(4)biopterin] is one of several cofactors of nitric oxide synthases (<e2>EC 1.14.13.39</e2>).","Cofactor"
"Tetrahydrobiopterin [(6R)-5,6,7,8-tetrahydro-L-biopterin, <e1>H(4)biopterin</e1>] is one of several cofactors of <e2>nitric oxide synthase</e2>s (EC 1.14.13.39).","Cofactor"
"Tetrahydrobiopterin [<e1>(6R)-5,6,7,8-tetrahydro-L-biopterin</e1>, H(4)biopterin] is one of several cofactors of <e2>nitric oxide synthases</e2> (EC 1.14.13.39).","Cofactor"
"Tetrahydrobiopterin [(6R)-5,6,7,8-tetrahydro-L-biopterin, <e1>H(4)biopterin</e1>] is one of several cofactors of <e2>nitric oxide synthases</e2> (EC 1.14.13.39).","Cofactor"
"<e1>N(5)-Substituted H(4)biopterin</e1> derivatives were not oxidized to products serving as substrates for <e2>dihydropteridine reductase</e2> and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect.","Substrate"
"OBJE<e1>C</e1>TIVE: Vesicular monoamine transporter 1 (<e2>VMAT-1</e2>) mRNA and protein were examined (1) to determine whether adult mouse brain expresses full-length VMAT-1 mRNA that can be translated to functional transporter protein and (2) to compare immunoreactive VMAT-1 proteins in brain and adrenal.","Part_of"
"Vesicular monoamine transporter-1 (<e2>VMAT-1</e2>) mR<e1>N</e1>A and immunoreactive proteins in mouse brain.","Part_of"
"The <e1>C</e1>-terminal antibodies detected both proteins in extracts of mouse medulla/pons, cortex, hypothalamus, and cerebellum but only the 73 kD protein and higher molecular weight immunoreactive proteins in mouse adrenal and rat PC12 cells, which are positive controls for <e2>rodent VMAT-1</e2>.","Part_of"
"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by <e1>tetrabenazine</e1>, which has a high affinity for <e2>VMAT-2</e2>.","Regulator"
"Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the <e2>VMAT</e2> inhibitor <e1>reserpine</e1> and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.","Downregulator"
"Mutations of another voltage-gated chloride channel, CLC-Kb, are associated with a form of Bartter's syndrome, whereas other forms of Bartter's syndrome are caused by mutations in the <e1>bumetanide</e1>-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel, ROMK.","Regulator"
"Finally, mutations of the <e1>thiazide</e1>-sensitive sodium-chloride cotransporter (NCCT) are associated with Gitelman's syndrome.","Regulator"
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of <e2>NOS</e2>, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Not"
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor <e1>N(omega)-hydroxy-nor-L-arginine</e1> (Nor-NOHA) on the activity of <e2>NOS</e2>, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Regulator"
"To determine whether <e2>arginases</e2> modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor <e1>N(omega)-hydroxy-nor-L-arginine</e1> (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Regulator"
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor <e1>N(omega)-hydroxy-nor-L-arginine</e1> (Nor-NOHA) on the activity of NOS, arginases, and <e2>L-arginine transporter</e2> and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Regulator"
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of <e2>NOS</e2>, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Regulator"
"To determine whether <e2>arginases</e2> modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Regulator"
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of NOS, arginases, and <e2>L-arginine transporter</e2> and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Regulator"
"To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of <e2>NOS</e2>, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Upregulator"
"Mitochondrial <e2>arginase</e2> II modulates nitric-oxide synthesis through nonfreely exchangeable <e1>L-arginine</e1> pools in human endothelial cells.","Upregulator"
"To determine whether <e2>arginase</e2>s modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor <e1>N(omega)-hydroxy-nor-L-arginine</e1> (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Downregulator"
"To determine whether <e2>arginase</e2>s modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Downregulator"
"To determine whether <e2>arginase</e2>s modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Downregulator"
"To determine whether <e2>arginase</e2>s modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (<e1>Nor-NOHA</e1>) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Downregulator"
"Reduced synthesis of nitric oxide (<e1>NO</e1>) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and mitochondrial <e2>arginase II</e2>.","Substrate"
"Reduced synthesis of <e1>nitric oxide</e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of <e2>constitutive nitric-oxide synthase</e2> (NOS) and cytosolic arginase I and mitochondrial arginase II.","Substrate"
"Reduced synthesis of <e1>nitric oxide</e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (<e2>NOS</e2>) and cytosolic arginase I and mitochondrial arginase II.","Substrate"
"Reduced synthesis of <e1>nitric oxide</e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <e2>arginase I</e2> and mitochondrial arginase II.","Substrate"
"Reduced synthesis of <e1>nitric oxide</e1> (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>mitochondrial arginase II</e2>.","Substrate"
"To determine whether <e2>arginases</e2> modulate the endothelial <e1>NO</e1> synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs).","Substrate"
"Reduced synthesis of nitric oxide (<e1>NO</e1>) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of <e2>constitutive nitric-oxide synthase</e2> (NOS) and cytosolic arginase I and mitochondrial arginase II.","Substrate"
"Reduced synthesis of nitric oxide (<e1>NO</e1>) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (<e2>NOS</e2>) and cytosolic arginase I and mitochondrial arginase II.","Substrate"
"Reduced synthesis of nitric oxide (<e1>NO</e1>) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic <e2>arginase I</e2> and mitochondrial arginase II.","Substrate"
"Reduced synthesis of nitric oxide (<e1>NO</e1>) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>mitochondrial arginase II</e2>.","Substrate"
"<e2>Mitochondrial arginase II</e2> modulates <e1>nitric-oxide</e1> synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells.","Substrate"
"<e2>Mitochondrial arginase II</e2> modulates nitric-oxide synthesis through nonfreely exchangeable <e1>L-arginine</e1> pools in human endothelial cells.","Substrate"
"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>L-arginine</e1>, the common substrate of <e2>constitutive nitric-oxide synthase</e2> (NOS) and cytosolic arginase I and mitochondrial arginase II.","Substrate"
"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>L-arginine</e1>, the common substrate of constitutive nitric-oxide synthase (<e2>NOS</e2>) and cytosolic arginase I and mitochondrial arginase II.","Substrate"
"Mitochondrial <e2>arginase I</e2>I modulates nitric-oxide synthesis through nonfreely exchangeable <e1>L-arginine</e1> pools in human endothelial cells.","Substrate"
"Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of <e1>L-arginine</e1>, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and <e2>mitochondrial arginase II</e2>.","Substrate"
"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and <e1>RSD1235</e1>, a novel mixed <e2>ion channel</e2> blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3.","Downregulator"
"However, pretreatment with agents that block late I(Na), like <e1>lidocaine</e1>, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays <e2>Na channel</e2> inactivation and amplifies late I(Na) greatly, mimicking LQT3.","Downregulator"
"However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and <e1>RSD1235</e1>, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays <e2>Na channel</e2> inactivation and amplifies late I(Na) greatly, mimicking LQT3.","Downregulator"
"Addition of <e1>putrescine</e1> restored the induction of apoptosis as indicated by an increase in the number of detached cells and <e2>caspase 3</e2> activity.","Not"
"The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that <e1>polyamines</e1> might be involved in the <e2>caspase</e2> activating signal cascade.","Upregulator"
"Addition of <e1>putrescine</e1> restored the induction of apoptosis as indicated by an increase in the number of detached cells and <e2>caspase 3</e2> activity.","Upregulator"
"Depletion of putrescine, spermidine, and spermine by <e1>DL-alpha-difluoromethylornithine</e1> (DFMO), a specific inhibitor of <e2>ornithine decarboxylase</e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Downregulator"
"Depletion of putrescine, spermidine, and spermine by <e1>DL-alpha-difluoromethylornithine</e1> (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC</e2>) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Downregulator"
"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<e1>DFMO</e1>), a specific inhibitor of <e2>ornithine decarboxylase</e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Downregulator"
"Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<e1>DFMO</e1>), a specific inhibitor of ornithine decarboxylase (<e2>ODC</e2>) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Downregulator"
"Inhibition of <e2>S-adenosylmethionine decarboxylase</e2> by a specific inhibitor [<e1>diethylglyoxal bis-(guanylhydrazone)</e1>; DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.","Downregulator"
"Inhibition of <e2>S-adenosylmethionine decarboxylase</e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); <e1>DEGBG</e1>] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.","Downregulator"
"Depletion of <e1>putrescine</e1>, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>ornithine decarboxylase</e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Substrate"
"Depletion of <e1>putrescine</e1>, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC</e2>) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Substrate"
"Depletion of putrescine, <e1>spermidine</e1>, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>ornithine decarboxylase</e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Substrate"
"Depletion of putrescine, <e1>spermidine</e1>, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC</e2>) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Substrate"
"Depletion of putrescine, spermidine, and <e1>spermine</e1> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of <e2>ornithine decarboxylase</e2> (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Substrate"
"Depletion of putrescine, spermidine, and <e1>spermine</e1> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase (<e2>ODC</e2>) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.","Substrate"
"Inhibition of <e2>S-adenosylmethionine decarboxylase</e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of <e1>spermidine</e1> and spermine with a significant accumulation of putrescine and induction of ODC.","Substrate"
"Inhibition of <e2>S-adenosylmethionine decarboxylase</e2> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and <e1>spermine</e1> with a significant accumulation of putrescine and induction of ODC.","Substrate"
"Serum <e1>carvedilol</e1> concentration and its relation to change in plasma <e2>brain natriuretic peptide</e2> level in the treatment of heart failure: a preliminary study.","Regulator"
"OBJECTIVE: To examine the influence of <e1>carvedilol</e1> dose and concentration in serum on plasma brain natriuretic peptide (<e2>BNP</e2>), a measure of heart failure progression.","Regulator"
"OBJECTIVE: To examine the influence of <e1>carvedilol</e1> dose and concentration in serum on plasma brain natriuretic peptide (<e2>BNP</e2>), a measure of heart failure progression.","Regulator"
"Serum <e1>carvedilol</e1> concentration and its relation to change in plasma <e2>brain natriuretic peptide</e2> level in the treatment of heart failure: a preliminary study.","Regulator"
"OBJECTIVE: To examine the influence of <e1>carvedilol</e1> dose and concentration in serum on plasma brain natriuretic peptide (<e2>BNP</e2>), a measure of heart failure progression.","Downregulator"
"OBJECTIVE: To examine the influence of <e1>carvedilol</e1> dose and concentration in serum on plasma brain natriuretic peptide (<e2>BNP</e2>), a measure of heart failure progression.","Downregulator"
"Two mechanisms of action have been identified for <e1>A77 1726</e1>: inhibition of <e2>dihydroorotate dehydrogenase</e2> (DHODH) and inhibition of tyrosine kinases.","Downregulator"
"Two mechanisms of action have been identified for <e1>A77 1726</e1>: inhibition of dihydroorotate dehydrogenase (<e2>DHODH</e2>) and inhibition of tyrosine kinases.","Downregulator"
"Two mechanisms of action have been identified for <e1>A77 1726</e1>: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of <e2>tyrosine kinases</e2>.","Downregulator"
"Two mechanisms of action have been identified for <e1>A77 1726</e1>: inhibition of dihydroorotate dehydrogenase (<e2>DHODH</e2>) and inhibition of tyrosine kinases.","Downregulator"
"Two mechanisms of action have been identified for <e1>A77 1726</e1>: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of <e2>tyrosine kinases</e2>.","Downregulator"
"By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding <e2>gamma-glutamyl kinase</e2>, which resulted in a single <e1>amino acid</e1> replacement; Asp (GAC) at position 154 was replaced by Asn (AAC).","Part_of"
"By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding <e2>gamma-glutamyl kinase</e2>, which resulted in a single amino acid replacement; <e1>Asp</e1> (GAC) at position 154 was replaced by Asn (AAC).","Part_of"
"By introducing the mutant-derived genomic library into a non-L-proline-utilizing strain, the mutant was found to carry an allele of the wild-type PRO1 gene encoding <e2>gamma-glutamyl kinase</e2>, which resulted in a single amino acid replacement; Asp (GAC) at position 154 was replaced by <e1>Asn</e1> (AAC).","Part_of"
"<e1>L-proline</e1> accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding <e2>gamma-glutamyl kinase</e2>.","Substrate"
"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <e2>gamma-glutamyl phosphate reductase</e2>, both of which catalyze the first two steps of <e1>L-proline</e1> synthesis from L-glutamate and which together may form a complex in vivo.","Substrate"
"<e1>L-proline</e1> accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding <e2>gamma-glutamyl kinase</e2>.","Substrate"
"<e1>L-proline</e1> accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding <e2>gamma-glutamyl kinase</e2>.","Substrate"
"<e1>L-proline</e1> accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding <e2>gamma-glutamyl kinase</e2>.","Substrate"
"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <e2>gamma-glutamyl phosphate reductase</e2>, both of which catalyze the first two steps of <e1>L-proline</e1> synthesis from L-glutamate and which together may form a complex in vivo.","Substrate"
"Interestingly, the allele of PRO1 was shown to enhance the activities of <e2>gamma-glutamyl kinase</e2> and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from <e1>L-glutamate</e1> and which together may form a complex in vivo.","Substrate"
"Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and <e2>gamma-glutamyl phosphate reductase</e2>, both of which catalyze the first two steps of L-proline synthesis from <e1>L-glutamate</e1> and which together may form a complex in vivo.","Substrate"
"While none of the <e1>phenethylamides</e1> (n = 2) were active, most of the anilides (n = 0) turned out to moderately or strongly inhibit <e2>17β-HSD2</e2>.","Not"
"We report here the optimization of <e2>human 17β-HSD2</e2> inhibitors in the <e1>2,5-thiophene amide</e1> class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group.","Downregulator"
"While none of the phenethylamides (n = 2) were active, most of the <e1>anilides</e1> (n = 0) turned out to moderately or strongly inhibit <e2>17β-HSD2</e2>.","Downregulator"
"Structural optimization of <e1>2,5-thiophene amides</e1> as highly potent and selective <e2>17β-hydroxysteroid dehydrogenase type 2</e2> inhibitors for the treatment of osteoporosis.","Downregulator"
"<e1>Theophylline</e1> exposure resulted in a sustained increase in mRNA expression for CysS and PDE3A, but <e2>PDE4D</e2> gene expression was unchanged.","Not"
"This study examined the effect of <e1>theophylline</e1> on the gene expression of secretory proteins and <e2>phosphodiesterases</e2> in the submaxillary gland.","Regulator"
"<e1>Theophylline</e1> exposure resulted in a sustained increase in mRNA expression for <e2>CysS</e2> and PDE3A, but PDE4D gene expression was unchanged.","Upregulator"
"<e1>Theophylline</e1> exposure resulted in a sustained increase in mRNA expression for CysS and <e2>PDE3A</e2>, but PDE4D gene expression was unchanged.","Upregulator"
"Multiple exposure to <e1>theophylline</e1>, a phosphodiesterase (<e2>PDE</e2>) inhibitor, induces acinar hypertrophy in the salivary gland.","Downregulator"
"Multiple exposure to <e1>theophylline</e1>, a <e2>phosphodiesterase</e2> (PDE) inhibitor, induces acinar hypertrophy in the salivary gland.","Downregulator"
"There was a significant overlap (42 genes) between the 3 and 30 ppb differentially expressed gene lists, with two of these genes (<e2>CYP17A1</e2> and SAMHD1) present in all three <e1>atrazine</e1> treatments.","Regulator"
"There was a significant overlap (42 genes) between the 3 and 30 ppb differentially expressed gene lists, with two of these genes (CYP17A1 and <e2>SAMHD1</e2>) present in all three <e1>atrazine</e1> treatments.","Regulator"
"Terbutaline (Bricanyl) and its prodrug <e1>Bambuterol</e1> (Bambec) are highly potent <e2>beta(2)-adrenoceptor</e2> agonists often used in asthma patients.","Agonist"
"Terbutaline (Bricanyl) and its prodrug Bambuterol (<e1>Bambec</e1>) are highly potent <e2>beta(2)-adrenoceptor</e2> agonists often used in asthma patients.","Agonist"
"<e1>Terbutaline</e1> (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent <e2>beta(2)-adrenoceptor</e2> agonists often used in asthma patients.","Agonist"
"Terbutaline (<e1>Bricanyl</e1>) and its prodrug Bambuterol (Bambec) are highly potent <e2>beta(2)-adrenoceptor</e2> agonists often used in asthma patients.","Agonist"
"The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of <e1>inositol phosphates</e1> that are induced via <e2>alpha 1-adrenoceptors</e2> was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.","Not"
"The influence of (+/-)-tamsulosin, a selective <e2>alpha 1A-adrenoceptor</e2> antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand <e1>oxymetazoline</e1> in the rabbit ventricular myocardium.","Regulator"
"Phenylephrine elicited a concentration-dependent positive inotropic effect via <e2>alpha 1-adrenoceptors</e2> in the presence of either <e1>(+/-)-bupranolol</e1> or S(-)-timolol.","Regulator"
"Phenylephrine elicited a concentration-dependent positive inotropic effect via <e2>alpha 1-adrenoceptors</e2> in the presence of either (+/-)-bupranolol or <e1>S(-)-timolol</e1>.","Regulator"
"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of <e2>alpha 1B-adrenoceptors</e2> by treatment with <e1>chlorethylclonidine</e1>, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.","Downregulator"
"<e1>Phenylephrine</e1> elicited a concentration-dependent positive inotropic effect via <e2>alpha 1-adrenoceptors</e2> in the presence of either (+/-)-bupranolol or S(-)-timolol.","Agonist"
"The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via <e2>alpha 1-adrenoceptors</e2> was studied in comparison with that of another alpha 1A-adrenoceptor ligand <e1>oxymetazoline</e1> in the rabbit ventricular myocardium.","Agonist"
"(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of <e1>phenylephrine</e1> even after inactivation of <e2>alpha 1B-adrenoceptors</e2> by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.","Agonist"
"<e1>(+/-)-tamsulosin</e1>, an <e2>alpha 1A-adrenoceptor</e2> antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.","Antagonist"
"The influence of <e1>(+/-)-tamsulosin</e1>, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via <e2>alpha 1-adrenoceptors</e2> was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.","Antagonist"
"<e1>(+/-)-Tamsulosin</e1> effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of <e2>alpha 1B-adrenoceptors</e2> by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.","Antagonist"
"<e1>(+/-)-tamsulosin</e1>, an <e2>alpha 1A-adrenoceptor</e2> antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.","Antagonist"
"<e1>(+/-)-Tamsulosin</e1>, over the range of concentrations at which it antagonized the positive inotropic effect mediated by <e2>alpha 1-adrenoceptors</e2>, did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.","Antagonist"
"Furthermore, PTE treatment directly inhibited the phosphorylation of <e2>JAK2</e2> at <e1>Tyr</e1> 1007 and the downstream activation of STAT3.","Part_of"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of <e2>JAK2</e2>/STAT3 and apoptosis-related signaling pathways on the activity of PTE.","Regulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of JAK2/<e2>STAT3</e2> and apoptosis-related signaling pathways on the activity of PTE.","Regulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of <e2>JAK2</e2>/STAT3 and apoptosis-related signaling pathways on the activity of PTE.","Regulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of JAK2/<e2>STAT3</e2> and apoptosis-related signaling pathways on the activity of PTE.","Regulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of <e2>JAK2</e2>/STAT3 and apoptosis-related signaling pathways on the activity of PTE.","Regulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of JAK2/<e2>STAT3</e2> and apoptosis-related signaling pathways on the activity of PTE.","Regulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (<e2>Bax</e2>, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.","Upregulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, <e2>Bak</e2>, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.","Upregulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic <e2>Cytochrome c</e2>, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.","Upregulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved <e2>Caspase3</e2>) and cyclin-dependent kinase inhibitors such as p21 and p27.","Upregulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as <e2>p21</e2> and p27.","Upregulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and <e2>p27</e2>.","Upregulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of JAK2/<e2>STAT3</e2> and apoptosis-related signaling pathways on the activity of PTE.","Downregulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of JAK2/<e2>STAT3</e2> and apoptosis-related signaling pathways on the activity of PTE.","Downregulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins <e2>Bcl-xL</e2> and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.","Downregulator"
"<e1>PTE</e1> also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and <e2>Mcl-1</e2>, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.","Downregulator"
"<e1>Pterostilbene</e1> exerts antitumor activity against human osteosarcoma cells by inhibiting the <e2>JAK2</e2>/STAT3 signaling pathway.","Downregulator"
"<e1>Pterostilbene</e1> exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/<e2>STAT3</e2> signaling pathway.","Downregulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of <e2>JAK2</e2>/STAT3 and apoptosis-related signaling pathways on the activity of PTE.","Downregulator"
"PTE, used in combination with a known <e2>JAK2</e2>/STAT3 inhibitor, <e1>AG490</e1>, further decreased the viability of osteosarcoma cells.","Downregulator"
"PTE, used in combination with a known JAK2/<e2>STAT3</e2> inhibitor, <e1>AG490</e1>, further decreased the viability of osteosarcoma cells.","Downregulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of <e2>JAK2</e2>/STAT3 and apoptosis-related signaling pathways on the activity of PTE.","Downregulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of JAK2/<e2>STAT3</e2> and apoptosis-related signaling pathways on the activity of PTE.","Downregulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of <e2>JAK2</e2>/STAT3 and apoptosis-related signaling pathways on the activity of PTE.","Downregulator"
"In this study, we assessed the antitumor activity of <e1>PTE</e1> against human osteosarcoma cells and explored the role of JAK2/<e2>STAT3</e2> and apoptosis-related signaling pathways on the activity of PTE.","Downregulator"
"Furthermore, <e1>sinapic acid</e1> reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of type I <e2>collagen</e2> mRNA and histological analysis of collagen in liver tissue.","Regulator"
"Furthermore, <e1>sinapic acid</e1> reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of <e2>type I collagen</e2> mRNA and histological analysis of collagen in liver tissue.","Downregulator"
"Additionally, the expression of hepatic fibrosis-related factors such as <e2>α-smooth muscle actin</e2> and transforming growth factor-β1 (TGF-β1), were reduced in rats treated with <e1>sinapic acid</e1>.","Downregulator"
"Additionally, the expression of hepatic fibrosis-related factors such as α-smooth muscle actin and <e2>transforming growth factor-β1</e2> (TGF-β1), were reduced in rats treated with <e1>sinapic acid</e1>.","Downregulator"
"Additionally, the expression of hepatic fibrosis-related factors such as α-smooth muscle actin and transforming growth factor-β1 (<e2>TGF-β1</e2>), were reduced in rats treated with <e1>sinapic acid</e1>.","Downregulator"
"Additionally, the expression of hepatic fibrosis-related factors such as α-smooth muscle actin and transforming growth factor-β1 (<e2>TGF-β1</e2>), were reduced in rats treated with <e1>sinapic acid</e1>.","Downregulator"
"FINDINGS: Compared with other ARBs, <e1>candesartan</e1> demonstrates the strongest binding affinity to the <e2>angiotensin II type 1 receptor</e2>.","Regulator"
"Clinical trials have demonstrated that <e1>candesartan</e1> is well tolerated in combination with diuretics or <e2>calcium channel</e2> blockers (CCBs), making it a suitable treatment option for patients whose hypertension is not adequately controlled by monotherapy.","Cofactor"
"These results support the hypothesis that apoplastic <e1>amino acids</e1> acting through heteromeric <e2>GLR3.2</e2>/GLR3.4 channels affect lateral root development via Ca(2+) signaling in the phloem.","Part_of"
"These results support the hypothesis that apoplastic <e1>amino acids</e1> acting through heteromeric GLR3.2/<e2>GLR3.4</e2> channels affect lateral root development via Ca(2+) signaling in the phloem.","Part_of"
"The <e2>Ves a 1</e2> structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛSer/α-helix structural motif, which contains the <e1>Gly</e1>-X-Ser-X-Gly consensus sequence.","Part_of"
"The <e2>Ves a 1</e2> structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛ<e1>Ser</e1>/α-helix structural motif, which contains the Gly-X-Ser-X-Gly consensus sequence.","Part_of"
"The <e2>Ves a 1</e2> structure, which is composed of seven α-helixes and eleven β-strands, contains the β-strand/ɛSer/α-helix structural motif, which contains the <e1>Gly</e1>-X-Ser-X-Gly consensus sequence.","Part_of"
"Moreover, the observed insertion of <e1>proline</e1> into the lid domain of the <e2>Ves a 1</e2> structure is rare.","Part_of"
"We therefore propose that this <e1>proline</e1> residue might be involved in the stability and activity of <e2>Ves a 1s</e2>.","Part_of"
"The cDNAs of the full-length version of <e2>Ves a 1s</e2> revealed that the Ves a 1 gene consists of a 1005-bp ORF, which encodes 334 <e1>amino acid</e1> residues, and 67- and 227-bp 5' and 3' UTRs, respectively.","Part_of"
"The cDNAs of the full-length version of <e2>Ves a 1</e2>s revealed that the Ves a 1 gene consists of a 1005-bp ORF, which encodes 334 <e1>amino acid</e1> residues, and 67- and 227-bp 5' and 3' UTRs, respectively.","Part_of"
"<e1>Thalidomide</e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of <e2>COX-1</e2>, in MCF-7 and HL-60.","Not"
"We also studied the effects of <e1>thalidomide</e1> on <e2>COX-1</e2>, COX-2 or bcl-2 expression, TNFalpha, VEGF, GSH and cytochrome c in these cells.","Regulator"
"We evaluated the effects of <e1>thalidomide</e1> on the growth of human tumor cells expressing (MCF-7 and HL-60) or not expressing (HeLa and K562) <e2>COX-2</e2> in vitro.","Regulator"
"We also studied the effects of <e1>thalidomide</e1> on COX-1, COX-2 or <e2>bcl-2</e2> expression, TNFalpha, VEGF, GSH and cytochrome c in these cells.","Regulator"
"We also studied the effects of <e1>thalidomide</e1> on COX-1, COX-2 or bcl-2 expression, <e2>TNFalpha</e2>, VEGF, GSH and cytochrome c in these cells.","Regulator"
"We also studied the effects of <e1>thalidomide</e1> on COX-1, COX-2 or bcl-2 expression, TNFalpha, <e2>VEGF</e2>, GSH and cytochrome c in these cells.","Regulator"
"We also studied the effects of <e1>thalidomide</e1> on COX-1, COX-2 or bcl-2 expression, TNFalpha, VEGF, GSH and <e2>cytochrome c</e2> in these cells.","Regulator"
"We also studied the effects of <e1>thalidomide</e1> on <e2>COX-1</e2>, COX-2 or bcl-2 expression, TNFalpha, VEGF, GSH and cytochrome c in these cells.","Regulator"
"We evaluated the effects of <e1>thalidomide</e1> on the growth of human tumor cells expressing (MCF-7 and HL-60) or not expressing (HeLa and K562) <e2>COX-2</e2> in vitro.","Regulator"
"<e1>Thalidomide</e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased <e2>cytochrome c</e2>, but had no effect on that of COX-1, in MCF-7 and HL-60.","Upregulator"
"<e1>Thalidomide</e1> inhibits growth of tumors through <e2>COX-2</e2> degradation independent of antiangiogenesis.","Downregulator"
"<e1>Thalidomide</e1> reduced COX-2 expression accompanied by a decrease of <e2>bcl-2</e2> protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.","Downregulator"
"<e1>Thalidomide</e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, <e2>TNFalpha</e2>, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.","Downregulator"
"<e1>Thalidomide</e1> reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, <e2>VEGF</e2>, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60.","Downregulator"
"<e1>Thalidomide</e1> inhibits growth of tumors through <e2>COX-2</e2> degradation independent of antiangiogenesis.","Downregulator"
"We evaluated the effects of <e1>thalidomide</e1> on the growth of human tumor cells expressing (MCF-7 and HL-60) or not expressing (HeLa and K562) <e2>COX-2</e2> in vitro.","Downregulator"
"It is also concluded that <e1>pyrethroid</e1> group of insecticide may cause hematological, biochemical, <e2>cytokine</e2> disturbances and possible mutagenic damage to the tissues.","Regulator"
"Results: The administration of <e1>prallethrin</e1> 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, <e2>hemoglobin</e2>, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of CK, γ-GT, SOD, NO, MDA, AFP, IL-2, and TNFα were recorded.","Upregulator"
"Results: The administration of <e1>prallethrin</e1> 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, <e2>hemoglobin</e2>, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72 h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48 h to return to normal after 72 h. Significant increases in the levels of CK, γ-GT, SOD, NO, MDA, AFP, IL-2, and TNFα were recorded.","Upregulator"
"We show that <e1>CIQ</e1> does not bind to the amino-terminal domain of the <e2>NMDA receptor</e2> and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or ion channel pore.","Not"
"We show that <e1>CIQ</e1> does not bind to the amino-terminal domain of the NMDA receptor and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or <e2>ion channel</e2> pore.","Not"
"We show that CIQ does not bind to the <e1>amino</e1>-terminal domain of the <e2>NMDA receptor</e2> and does not share structural determinants with modulators acting at the agonist-binding domain dimer interface or ion channel pore.","Part_of"
"Molecular modeling of the <e2>kinase domain</e2> of mutant c-Kit (V654A) and AXL showed no binding to <e1>IM</e1> but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor.","Not"
"Further, the two <e1>IM</e1> resistant GIST patients express AXL and not <e2>c-Kit</e2>, seen by immunohistochemistry (IHC).","Not"
"Molecular modeling of the kinase domain of mutant c-Kit (<e2>V654A</e2>) and AXL showed no binding to <e1>IM</e1> but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor.","Not"
"Instead, GIST-R cells have acquired <e1>IM</e1> resistance by overexpressing the oncogenic receptor tyrosine kinase - <e2>AXL</e2> - in a 'kinase switch'.","Not"
"Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor <e1>tyrosine</e1> kinase - <e2>AXL</e2> - in a 'kinase switch'.","Part_of"
"Molecular modeling of the <e2>kinase domain</e2> of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to <e1>MP470</e1>, a novel c-Kit/AXL kinase inhibitor.","Regulator"
"Molecular modeling of the kinase domain of mutant <e2>c-Kit</e2> (V654A) and AXL showed no binding to IM but efficient binding to <e1>MP470</e1>, a novel c-Kit/AXL kinase inhibitor.","Regulator"
"Molecular modeling of the kinase domain of mutant c-Kit (<e2>V654A</e2>) and AXL showed no binding to IM but efficient binding to <e1>MP470</e1>, a novel c-Kit/AXL kinase inhibitor.","Regulator"
"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and <e2>AXL</e2> showed no binding to IM but efficient binding to <e1>MP470</e1>, a novel c-Kit/AXL kinase inhibitor.","Regulator"
"A novel <e2>tyrosine kinase</e2> switch is a mechanism of <e1>imatinib</e1> resistance in gastrointestinal stromal tumors.","Regulator"
"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two <e1>IM</e1> resistant GIST patients demonstrated that <e2>KIT</e2> is downregulated implying a major role in IM resistance.","Downregulator"
"Gene expression profiling (GEP) of GIST-S, GIST-R cells and two <e1>IM</e1> resistant GIST patients demonstrated that <e2>KIT</e2> is downregulated implying a major role in IM resistance.","Downregulator"
"Molecular modeling of the kinase domain of mutant <e2>c-Kit</e2> (V654A) and AXL showed no binding to IM but efficient binding to <e1>MP470</e1>, a novel c-Kit/AXL kinase inhibitor.","Downregulator"
"Molecular modeling of the kinase domain of mutant c-Kit (V654A) and <e2>AXL</e2> showed no binding to IM but efficient binding to <e1>MP470</e1>, a novel c-Kit/AXL kinase inhibitor.","Downregulator"
"Molecular modeling of the <e2>kinase</e2> domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to <e1>MP470</e1>, a novel c-Kit/AXL kinase inhibitor.","Downregulator"
"INTRODUCTION: In this study, we examined the effects of the <e2>alpha-glucosidase</e2> inhibitors acarbose and <e1>voglibose</e1> on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.","Downregulator"
"INTRODUCTION: In this study, we examined the effects of the <e2>alpha-glucosidase</e2> inhibitors <e1>acarbose</e1> and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.","Downregulator"
"INTRODUCTION: In this study, we examined the effects of the <e2>alpha-glucosidase</e2> inhibitors acarbose and voglibose on postprandial plasma <e1>glucose</e1> and serum triglyceride levels in patients with type 2 diabetes mellitus.","Downregulator"
"Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [<e1>Nle</e1>(4), D-Phe(7)]<e2>α-melanocyte-stimulating hormone</e2> (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.","Part_of"
"Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [<e1>Nle</e1>(4), D-Phe(7)]α-melanocyte-stimulating hormone (NDP-<e2>α-MSH</e2>) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.","Part_of"
"Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4), <e1>D-Phe</e1>(7)]<e2>α-melanocyte-stimulating hormone</e2> (NDP-α-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.","Part_of"
"Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4), <e1>D-Phe</e1>(7)]α-melanocyte-stimulating hormone (NDP-<e2>α-MSH</e2>) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-α levels; these effects of NDP-α-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.","Part_of"
"Blockade of <e2>JAK</e2> and ERK pathways with <e1>AG490</e1> and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH.","Downregulator"
"Blockade of JAK and <e2>ERK</e2> pathways with AG490 and <e1>U0126</e1>, respectively, abrogated the myocardial infarct size reduction by NDP-α-MSH.","Downregulator"
"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the <e2>5-LOX</e2> inhibitor <e1>REV 5901</e1>; and the 5-LOX activating protein (FLAP) inhibitor MK-886.","Downregulator"
"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the <e2>5-LOX activating protein</e2> (FLAP) inhibitor <e1>MK-886</e1>.","Downregulator"
"They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (<e2>FLAP</e2>) inhibitor <e1>MK-886</e1>.","Downregulator"
"They included the COX-1 inhibitor indomethacin; the <e2>COX-2</e2> inhibitor <e1>NS-398</e1>; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.","Downregulator"
"They included the <e2>COX-1</e2> inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor <e1>ibuprofen</e1>; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.","Downregulator"
"They included the COX-1 inhibitor indomethacin; the <e2>COX-2</e2> inhibitor NS-398; the mixed COX-1/COX-2 inhibitor <e1>ibuprofen</e1>; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.","Downregulator"
"The <e2>COX</e2> pathway generates inflammatory <e1>prostaglandins</e1>, while the 5-LOX pathway generates inflammatory leukotrienes.","Substrate"
"The COX pathway generates inflammatory prostaglandins, while the <e2>5-LOX</e2> pathway generates inflammatory <e1>leukotrienes</e1>.","Substrate"
"Additionally, <e1>MPTP</e1> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, <e2>cytochrome C</e2> translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.","Regulator"
"To evaluate the neuroprotective effect of CRE, we measured striatal dopamine, movement ability, tyrosine hydroxylase (<e2>TH</e2>) immunoreactivity, and apoptosis-related protein expression levels after treatment of CRE either with or without 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<e1>MPTP</e1>) in ovariectomized female mice.","Regulator"
"Additionally, <e1>MPTP</e1> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in <e2>Bax</e2> expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.","Upregulator"
"Additionally, <e1>MPTP</e1> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-<e2>caspase-3</e2> expression, whereas these were inhibited by CRE or EB treatment.","Upregulator"
"Additionally, <e1>MPTP</e1> significantly down-regulated <e2>Bcl-2</e2> expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.","Downregulator"
"The baseline HbA1c and <e2>glycated albumin</e2> levels were identified as factors that predicted the response to add-on therapy with <e1>sitagliptin</e1>.","Regulator"
"The hemoglobin A1c (<e2>HbA1c</e2>) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with <e1>sitagliptin</e1> (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001).","Regulator"
"The <e2>hemoglobin A1c</e2> (HbA1c) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with <e1>sitagliptin</e1> (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001).","Upregulator"
"The hemoglobin A1c (<e2>HbA1c</e2>) of all patients improved significantly from 8.1±1.2% to 7.6±1.1% after 12 weeks of add-on therapy with <e1>sitagliptin</e1> (p<0.01), and the insulin dosage was reduced from 27.3±15.8 U/day to 24.5±16.5 U/day (p<0.001).","Upregulator"
"Add-on therapy with the <e2>DPP-4</e2> inhibitor <e1>sitagliptin</e1> improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.","Downregulator"
"To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of GPx1, <e2>MsrA</e2> and MsrB1, as well as GPx activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by <e1>sodium selenite</e1> and barricade function of blood-retinal barrier (BRB) were investigated.","Regulator"
"To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of GPx1, MsrA and <e2>MsrB1</e2>, as well as GPx activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by <e1>sodium selenite</e1> and barricade function of blood-retinal barrier (BRB) were investigated.","Regulator"
"To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of <e2>GPx1</e2>, MsrA and MsrB1, as well as GPx activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by <e1>sodium selenite</e1> and barricade function of blood-retinal barrier (BRB) were investigated.","Regulator"
"To clarify the cause of age differences on selenite cataract formation in rats, mRNA expression of <e2>GPx</e2>1, MsrA and MsrB1, as well as GPx activity in Wistar rat lens at different ages were assayed, level of lipid peroxidation, extent of lens damage induced by <e1>sodium selenite</e1> and barricade function of blood-retinal barrier (BRB) were investigated.","Regulator"
"In the present study, we have evaluated possible participation of <e2>monocarboxylate transporters</e2> (MCTs) responsible for the bidirectional membrane transport of <e1>pyruvate</e1> in the cytoprotective property in osteoblasts.","Substrate"
"In the present study, we have evaluated possible participation of monocarboxylate transporters (<e2>MCTs</e2>) responsible for the bidirectional membrane transport of <e1>pyruvate</e1> in the cytoprotective property in osteoblasts.","Substrate"
"Bioinformatic analyses of several vertebrate genomes were undertaken using known <e2>ALDH2</e2> and ALDH1B1 <e1>amino acid</e1> sequences.","Part_of"
"Bioinformatic analyses of several vertebrate genomes were undertaken using known ALDH2 and <e2>ALDH1B1</e2> <e1>amino acid</e1> sequences.","Part_of"
"<e2>Mammalian ALDH1B1</e2>, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing <e1>acetaldehyde</e1> but has a tissue distribution and pattern of activity distinct from that of ALDH2.","Substrate"
"Vertebrate <e2>ALDH2</e2> genes encode mitochondrial enzymes capable of metabolizing <e1>acetaldehyde</e1> and other biological aldehydes in the body.","Substrate"
"Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>COX</e2>) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while <e1>sodium salicylate</e1>, hardly active on COX by itself, is well tolerated by these patients.","Not"
"Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>COX</e2>) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium <e1>salicylate</e1>, hardly active on COX by itself, is well tolerated by these patients.","Regulator"
"However, salicylate moiety appears to interfere with <e1>aspirin</e1> inhibitory action on platelets and vascular <e2>COX</e2>.","Downregulator"
"<e1>Aspirin</e1> (ASA) and other non-steroidal anti-inflammatory drugs, which are <e2>cyclooxygenase</e2> (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.","Downregulator"
"<e1>Aspirin</e1> (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>COX</e2>) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.","Downregulator"
"Aspirin (<e1>ASA</e1>) and other non-steroidal anti-inflammatory drugs, which are <e2>cyclooxygenase</e2> (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.","Downregulator"
"Aspirin (<e1>ASA</e1>) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (<e2>COX</e2>) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.","Downregulator"
"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between <e1>salicylate</e1> and ASA on <e2>cyclo-oxygenase</e2> locus in the respiratory tract in ASA-intolerant patients.","Downregulator"
"Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and <e1>ASA</e1> on <e2>cyclo-oxygenase</e2> locus in the respiratory tract in ASA-intolerant patients.","Downregulator"
"<e1>Minocycline</e1> inhibits <e2>cytochrome c</e2> release and delays progression of amyotrophic lateral sclerosis in mice.","Downregulator"
"We find that <e1>minocycline</e1> inhibits mitochondrial permeability-transition-mediated <e2>cytochrome c</e2> release.","Downregulator"
"<e1>Minocycline</e1> inhibits <e2>cytochrome c</e2> release and delays progression of amyotrophic lateral sclerosis in mice.","Downregulator"
"Here we studied the effects of the recently developed <e2>monoacylglycerol lipase</e2> inhibitor <e1>JZL184</e1> on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses.","Downregulator"
"Among these differentially expressed lncRNAs, the greatest change was noted for <e2>uc002mbe.2</e2>, which had more than 300 folds induction upon <e1>TSA</e1> treatment.","Regulator"
"Among these differentially expressed lncRNAs, the greatest change was noted for <e2>uc002mbe.2</e2>, which had more than 300 folds induction upon <e1>TSA</e1> treatment.","Upregulator"
"Among these differentially expressed lncRNAs, the greatest change was noted for <e2>uc002mbe.2</e2>, which had more than 300 folds induction upon <e1>TSA</e1> treatment.","Upregulator"
"Among these differentially expressed lncRNAs, the greatest change was noted for <e2>uc002mbe.2</e2>, which had more than 300 folds induction upon <e1>TSA</e1> treatment.","Upregulator"
"Considerable attention has focused on the antitumor effect of <e2>histone deacetylase</e2> inhibitor (<e1>Trichostatin A</e1>, TSA) as well as the coding gene expression-induced apoptosis of cancer cells.","Downregulator"
"Considerable attention has focused on the antitumor effect of <e2>histone deacetylase</e2> inhibitor (Trichostatin A, <e1>TSA</e1>) as well as the coding gene expression-induced apoptosis of cancer cells.","Downregulator"
"The <e1>mannose 6-phosphate</e1>-binding sites of M6P/<e2>IGF2R</e2> determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.","Part_of"
"The M6P (<e1>mannose 6-phosphate</e1>)/IGF2R (<e2>insulin-like growth factor II receptor</e2>) interacts with a variety of factors that impinge on tumour invasion and metastasis.","Part_of"
"The mannose 6-phosphate-binding sites of <e1>M6P</e1>/<e2>IGF2R</e2> determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.","Part_of"
"The <e1>M6P</e1> (mannose 6-phosphate)/IGF2R (<e2>insulin-like growth factor II receptor</e2>) interacts with a variety of factors that impinge on tumour invasion and metastasis.","Part_of"
"The mannose 6-phosphate-binding sites of <e1>M6P</e1>/<e2>IGF2R</e2> determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.","Regulator"
"The <e1>mannose 6-phosphate</e1>-binding sites of M6P/<e2>IGF2R</e2> determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.","Regulator"
"The mannose 6-phosphate-binding sites of <e1>M6P</e1>/<e2>IGF2R</e2> determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.","Regulator"
"<e1>Orlistat</e1> treatment also results in modest improvements in total cholesterol, <e2>low-density lipoprotein</e2>, blood pressure, and fasting glucose and insulin concentrations.","Upregulator"
"<e1>Orlistat</e1> treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and <e2>insulin</e2> concentrations.","Upregulator"
"<e1>Orlistat</e1>, a new <e2>lipase</e2> inhibitor for the management of obesity.","Downregulator"
"Other agents, such as <e1>methimazole</e1> and sodium iodide, which influence thyroid cell function, do not directly interfere with the expression of <e2>M/TPO-Ag</e2>.","Not"
"Other agents, such as methimazole and <e1>sodium iodide</e1>, which influence thyroid cell function, do not directly interfere with the expression of <e2>M/TPO-Ag</e2>.","Not"
"Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen (M/<e2>TPO</e2>-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular <e1>cAMP</e1> accumulation and protein synthesis.","Upregulator"
"Evidence has accumulated in the last few years that the expression of the <e2>microsomal/peroxidase antigen</e2> (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular <e1>cAMP</e1> accumulation and protein synthesis.","Upregulator"
"Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen (<e2>M/TPO-Ag</e2>) in thyroid cells is induced by TSH, through pathways which involve intracellular <e1>cAMP</e1> accumulation and protein synthesis.","Upregulator"
"<e2>Saccharomyces cerevisiae τ55</e2>, a subunit of the R<e1>N</e1>A polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal histidine phosphatase domain (τ55-HPD) whose catalytic activity and cellular function is poorly understood.","Part_of"
"<e2>Saccharomyces cerevisiae τ55</e2>, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal <e1>histidine</e1> phosphatase domain (τ55-HPD) whose catalytic activity and cellular function is poorly understood.","Part_of"
"In the present study, we aimed at examining the effect of <e1>1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole</e1>, a synthetic small molecular compound also named Fc11a-2, for the treatment of dextran sulfate sodium (DSS)-induced experimental colitis in mice via targeting <e2>NLRP3</e2> inflammasome.","Regulator"
"In the present study, we aimed at examining the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small molecular compound also named <e1>Fc11a-2</e1>, for the treatment of dextran sulfate sodium (DSS)-induced experimental colitis in mice via targeting <e2>NLRP3</e2> inflammasome.","Regulator"
"The mechanism of action of <e1>Fc11a-2</e1> was related to the inhibition of the cleavage of <e2>pro-caspase-1</e2>, pro-IL-1β and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.","Downregulator"
"The mechanism of action of <e1>Fc11a-2</e1> was related to the inhibition of the cleavage of pro-caspase-1, <e2>pro-IL-1β</e2> and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.","Downregulator"
"The mechanism of action of <e1>Fc11a-2</e1> was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1β and <e2>pro-IL-18</e2> which in turn suppressed the activation of NLRP3 inflammasome.","Downregulator"
"Moreover, protein and mRNA levels of DSS-induced proinflammatory <e2>cytokines</e2> in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by <e1>Fc11a-2</e1>.","Downregulator"
"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including <e2>TNF-α</e2>, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by <e1>Fc11a-2</e1>.","Downregulator"
"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, <e2>IL-1β</e2>, IL-18, IL-17A and IFN-γ, were markedly suppressed by <e1>Fc11a-2</e1>.","Downregulator"
"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, IL-1β, <e2>IL-18</e2>, IL-17A and IFN-γ, were markedly suppressed by <e1>Fc11a-2</e1>.","Downregulator"
"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, IL-1β, IL-18, <e2>IL-17A</e2> and IFN-γ, were markedly suppressed by <e1>Fc11a-2</e1>.","Downregulator"
"Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, IL-1β, IL-18, IL-17A and <e2>IFN-γ</e2>, were markedly suppressed by <e1>Fc11a-2</e1>.","Downregulator"
"A novel <e1>benzo[d]imidazole</e1> derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of <e2>NLRP3</e2> inflammasome.","Downregulator"
"Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of <e2>caspase-1</e2> in peritoneal macrophages were detected in <e1>Fc11a</e1>-2-treated mice.","Downregulator"
"In the present study, we aimed at examining the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small molecular compound also named <e1>Fc11a-2</e1>, for the treatment of dextran sulfate sodium (DSS)-induced experimental colitis in mice via targeting <e2>NLRP3</e2> inflammasome.","Downregulator"
"In the present study, we aimed at examining the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small molecular compound also named <e1>Fc11a-2</e1>, for the treatment of dextran sulfate sodium (DSS)-induced experimental colitis in mice via targeting <e2>NLRP3</e2> inflammasome.","Downregulator"
"In addition, the disease activity index, histopathologic scores and <e2>myeloperoxidase</e2> activity were also significantly reduced by <e1>Fc11a-2</e1> treatment.","Downregulator"
"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH</e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker <e2>tyrosine hydroxylase</e2> (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.","Upregulator"
"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH</e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (<e2>TH</e2>), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.","Upregulator"
"In hippocampal dentate gyrus, <e1>MPH</e1>-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of <e2>neural cell adhesion molecule</e2>).","Upregulator"
"In hippocampal dentate gyrus, <e1>MPH</e1>-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-<e2>NCAM</e2> (polysialylated form of neural cell adhesion molecule).","Upregulator"
"In medial striatum, TH-ir decreased by 21%, and in hypothalamus <e2>neuropeptide Y</e2>-ir increased by 10% in <e1>MPH</e1>-exposed rats.","Upregulator"
"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH</e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less <e2>norepinephrine transporter</e2> (NET)-ir density.","Downregulator"
"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH</e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (<e2>NET</e2>)-ir density.","Downregulator"
"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH</e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (<e2>NET</e2>)-ir density.","Downregulator"
"At PND35, the medial prefrontal cortex (mPFC) of rats given <e1>MPH</e1> showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (<e2>TH</e2>), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.","Downregulator"
